uid	srcuid	trguid	srcname	srctype	trgname	trgtype	trgval	type	pmids	nls
12833	20228	17369	DYSF	Protein	IL6	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
 1310	20228	 7836	DYSF	Protein	CD55	mRNA	-1	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
13907	20228	 1706	DYSF	Protein	RAB2A	mRNA	-1	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
15036	20228	  136	DYSF	Protein	SERPINB1	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
16790	20228	20225	DYSF	Protein	Lyz1	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
16846	20228	 5958	DYSF	Protein	POSTN	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
16947	20228	19193	DYSF	Protein	MT2A	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
18067	20228	16946	DYSF	Protein	H2-Eb1	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
19706	20228	16486	DYSF	Protein	SPP1	mRNA	1	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
22909	20228	17263	DYSF	Protein	CD68	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
22977	20228	 4678	DYSF	Protein	ERRFI1	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
24558	20228	 2720	DYSF	Protein	TAGLN	mRNA	-1	-1	12471055	Table 3. Genes differentially expressed in LGMD2B muscles (DYSF mutant) upregulated
24672	20228	17249	DYSF	Protein	LRP10	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
24986	20228	 2737	DYSF	Protein	AP4S1	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
25222	20228	 6391	DYSF	Protein	VLDLR	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
 2671	20228	 8126	DYSF	Protein	S100B	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
 2808	20228	15988	DYSF	Protein	CASP1	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
28611	20228	 3297	DYSF	Protein	TIMP1	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
30078	20228	 6134	DYSF	Protein	GEM	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
35839	20228	14144	DYSF	Protein	TIMP4	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
37315	20228	  404	DYSF	Protein	Tgtp1	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
37603	20228	 7838	DYSF	Protein	NEDD4L	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
38187	20228	 7421	DYSF	Protein	Ccl9	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
38356	20228	 1872	DYSF	Protein	BTG2	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
38946	20228	12898	DYSF	Protein	UGDH	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
38961	20228	14125	DYSF	Protein	RAB6A	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
39285	20228	13309	DYSF	Protein	LITAF	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
40005	20228	13078	DYSF	Protein	NCF2	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
42057	20228	13115	DYSF	Protein	EGR1	mRNA	-1	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
42191	20228	14895	DYSF	Protein	S100A8	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
42605	20228	 2610	DYSF	Protein	GPCPD1	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
43534	20228	12814	DYSF	Protein	H2-Aa	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
43947	20228	 4591	DYSF	Protein	S100A4	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
44467	20228	13271	DYSF	Protein	CCL2	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
45012	20228	 8381	DYSF	Protein	MYL4	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
45694	20228	 8412	DYSF	Protein	LGALS1	mRNA	0	-1	12471055	Table 3. Genes differentially expressed in LGMD2B muscles (DYSF mutant) upregulated
46247	20228	12457	DYSF	Protein	CCRL2	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
47695	20228	19779	DYSF	Protein	DPT	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
48055	20228	11629	DYSF	Protein	FOS	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
48781	20228	17731	DYSF	Protein	DCN	mRNA	-1	-1	12471055	Table 3. Genes differentially expressed in LGMD2B muscles (DYSF mutant) upregulated
50040	20228	 1696	DYSF	Protein	TNFAIP6	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
50629	20228	14463	DYSF	Protein	Ccl12	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
51237	20228	12304	DYSF	Protein	SIX2	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
51420	20228	  501	DYSF	Protein	BCAT2	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
52442	20228	 3824	DYSF	Protein	CTSS	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
54159	20228	15639	DYSF	Protein	ANKRD1	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
54402	20228	 8846	DYSF	Protein	FGL2	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
58282	20228	13063	DYSF	Protein	Serpina1b	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
 5930	20228	 1713	DYSF	Protein	MYOG	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
61752	20228	 7962	DYSF	Protein	RRAD	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
62014	20228	 2608	DYSF	Protein	HBB	mRNA	1	-1	12471055	Table 3. Genes differentially expressed in LGMD2B muscles (DYSF mutant) upregulated
63970	20228	 5950	DYSF	Protein	CCL7	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
66077	20228	 9520	DYSF	Protein	NEU2	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
  864	20228	19752	DYSF	Protein	H2-DMa	mRNA	0	1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
 9463	20228	18412	DYSF	Protein	PLA2G12A	mRNA	0	-1	15811552	The SJL mouse is a model for human dysferlinopathy (limb-girdle muscular dystrophy type 2B and Miyoshi myopathy). We used cDNA microarrays to compare the expression profiles of 10,012 genes in control and SJL quadriceps femoris muscles in order to find genes involved in the degeneration and regeneration process and in dysferlinps functional network. Many genes involved in the process of muscle regeneration are observed to be up-regulated in SJL mice, including cardiac ankyrin repeated protein (CARP), Neuraminidase 2, interleukin-6, insulin-like growth factor-2 and osteopontin. We found the upregulation of S100 calcium binding proteins, neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) with C2 domain, and intracellular protein traffic associated proteins (Rab6 and Rab2). These proteins have the potential to interact with dysferlin. We must reveal some other molecules which may work with dysferlin in order to clarify the pathological network of dysferlinopathy. This process may lead to future improvements in the therapy for human dysferlinopathy.
11697	 9696	11709	RXR Family	Protein	UCP2	mRNA	0	1	10548525	_ Ariadne: Activation of RXR, the partner of PPARgamma, in the presence of rosiglitazone, increased further p85alpha PI-3K and UCP2 mRNA levels and produced a significant augmentation of Glut 4 expression. [Regulation]
  196	 9696	16874	RXR Family	Protein	PIK3R1	mRNA	0	1	10548525	_ Ariadne: Activation of RXR, the partner of PPARgamma, in the presence of rosiglitazone, increased further p85alpha PI-3K and UCP2 mRNA levels and produced a significant augmentation of Glut 4 expression. [Regulation]
 2480	 9696	17889	RXR Family	Protein	SLC2A4	mRNA	1	1	10548525	_ Ariadne: Activation of RXR, the partner of PPARgamma, in the presence of rosiglitazone, increased further p85alpha PI-3K and UCP2 mRNA levels and produced a significant augmentation of Glut 4 expression. [Regulation]
21917	 6046	 3995	paclitaxel	Compound	ESR1	mRNA	-1	1	15012603	treatment of MCF-7 cells with taxol resulted in induction of estrogen receptor-alpha (ER alpha) gene transcription with a subsequent increase in ER alpha mRNA
28310	 6046	10956	paclitaxel	Compound	TNFRSF10B	mRNA	0	1	14500373	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.
42110	 6046	13115	paclitaxel	Compound	EGR1	mRNA	-1	1	 9520464	Ariadne: Taxol  preferentially induced the expression of mRNA for TNFalpha, COX-2, ATF-4, and  Krox-24. [Expression]
46622	 6046	 4208	paclitaxel	Compound	TNFRSF10A	mRNA	0	1	14500373	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.
49113	 6046	 2802	paclitaxel	Compound	BRD2	mRNA	0	-1	15274316	paclitaxel induced the down-regulation of mRNA NAT expression in T24 cells
20551	 7340	 3284	SFTPA1	Protein	NKX2-1	mRNA	0	1	10867648	Therefore, SP-A signals through PI3 kinase to increase SP-B transcription in type II pneumocytes by enhancing TTF-1 and HNF-3 activation of the SP-B promoter.
 2208	 7340	 5419	SFTPA1	Protein	TNF	mRNA	0	-1	10801802	SP-A can inhibit smooth LPS-induced tumor  necrosis factor alpha expression by alveolar macrophages.
 2409	 7340	 2512	SFTPA1	Protein	IL2RA	mRNA	0	1	12055204	SP-A induced a  significant CD25 expression ( p < 0.01, n = 3) that was 70% of the LPS response  (Fig. 2 ).
 2763	 7340	  908	SFTPA1	Protein	MMP9	mRNA	0	1	12842807	SP-A induced the expression of MMP-9 in both cell types, the effect was time and dose dependent, and MMP-9 was released in its zymogen form.
27809	 7340	 2395	SFTPA1	Protein	EP300	mRNA	0	1	11713256	Because SRC-1 appears to act together with CBP/p300 to induce SP-A promoter activity, these findings suggest that PKA-mediated phosphorylation may enhance TTF-1 transcriptional activity by facilitating recruitment of CBP and SRC-1 to the SP-A promoter.
 3700	 7340	 5902	SFTPA1	Protein	CREBBP	mRNA	0	1	11713256	In transient transfections, CBP and SRC-1 acted synergistically with TTF-1 to increase SP-A promoter activity.
38805	 7340	10290	SFTPA1	Protein	FOXM1	mRNA	1	1	10867648	Therefore, SP-A signals through PI3 kinase to increase SP-B transcription in type II pneumocytes by enhancing TTF-1 and HNF-3 activation of the SP-B promoter.
39548	 7340	15221	SFTPA1	Protein	EN1	mRNA	0	-1	10625644	Transfection of a construct expressing GATA-6- engrailed fusion protein inhibited basal expression of the SP-A/chloramphenicol acetyltransferase construct in MLE-15 cells.
  476	 7340	11404	SFTPA1	Protein	CSF2	mRNA	0	1	10679099	A third potential mechanism by which GM-CSF might influence host responses to P. carinii is through effects on the expression of SP-A and SP-D.
10008	 5226	 4597	glucocorticoid	Compound	UBE2C	mRNA	1	1	15826934	Table 1. Known transcripts increased by dexamethasone
10616	 5226	 4100	glucocorticoid	Compound	SERPINB5	mRNA	0	-1	17016446	Importantly, the activation of GR resulted in normalized expression of PC markers hepsin, AMACR, and maspin. The structural analysis of hepsin and AMACR promoters provided the mechanistic rationale for PC marker downregulation by glucocorticoids via inhibition of specific TFs.
11264	 5226	19608	glucocorticoid	Compound	LEP	mRNA	0	1	12020765	Leptin expression can be induced by obesity, insulin, TNF-a and glucocorticoids and is negatively regulated by fasting, b-adrenergic agonists and thiazolidinediones
13669	 5226	 1438	glucocorticoid	Compound	VEGFA	mRNA	0	-1	17062674	Our previous study has shown that glucocorticoids inhibit tumor angiogenesis possibly by down-regulation of vascular endothelial growth factor (VEGF) and interleukin 8.
13861	 5226	17250	glucocorticoid	Compound	PTGS2	mRNA	0	1	17901074	Glucocorticoids (GCs) are well-known anti-inflammatory drugs inhibiting prostaglandin production. Paradoxically, GCs are reported to stimulate cytosolic phosphoplipase A2 group IVA (PLA2G4A) and prostaglandin-endoperoxide synthase 2 (PTGS2) expression in human amnion fibroblasts.
17844	 5226	 7655	glucocorticoid	Compound	CD163	mRNA	0	1	11854028	The CD163 expression is induced by interleukin-6, interleukin-10 and glucocorticoids.
20866	 5226	19071	glucocorticoid	Compound	IL2	mRNA	0	-1	11397794	glucocorticoid-induced inhibition of interleukin-2 mRNA expression
22583	 5226	15547	glucocorticoid	Compound	GLUL	mRNA	0	1	11014214	glucocorticoids stimulate glutamine synthase production by Tpit/F1 cells.
24135	 5226	 9515	glucocorticoid	Compound	ENC1	mRNA	0	1	12393265	Additionally, a gene recently described in human brain, NRP/B (nuclear restricted protein in brain) that associates with p110Rb in induction of neuronal differentiation and a new truncated transcript of the tenascin-X gene family, are also shown to be up-regulated by glucocorticoids.
25207	 5226	13133	glucocorticoid	Compound	TCEAL1	mRNA	0	1	12897156	estrogen agonists inhibit glucocorticoid induction of p21 mRNA and protein levels
 2964	 5226	  884	glucocorticoid	Compound	AZGP1	mRNA	0	1	15714206	Glucocorticoids have been suggested to increase ZAG expression
 3187	 5226	16645	glucocorticoid	Compound	CCND1	mRNA	0	-1	17016446	This was accompanied by upregulation of p21 and p27, down-regulation of cyclin D1 expression and c-Myc phosphorylation.
33500	 5226	13127	glucocorticoid	Compound	FGG	mRNA	0	1	12900415	During an APR, fibrinogen (FBG) genes are coordinately up-regulated by IL-6 and glucocorticoids
35084	 5226	14468	glucocorticoid	Compound	CARTPT	mRNA	0	1	15207912	Changes in Cocaine- and Amphetamine-Regulated Transcript (CART) mRNA levels have been observed in brain as a result of various physiologic stimuli including feeding, drugs of abuse, stress and glucocorticoids, and activators of the cyclic AMP (cAMP) and protein kinase A (PKA) pathway.
35227	 5226	 5296	glucocorticoid	Compound	PLAU	mRNA	1	-1	11841347	The two plasminogen activators are mainly different in the structural determinants located in the noncatalytic regions of the proteins that are responsible for the enzyme binding to various components of the cell surface and of the cell environment. Thus, in the noncatalytic N-terminal region of the tPA molecule there are two additional domains as compared to the uPA molecule: a finger-domain and the second kringle-domain, which are responsible for specific binding to fibrin [24].  Precise timing and location of adequate extracellular proteolysis is provided by multiple mechanisms among which the mechanisms regulating the expression of plasminogen activators and of their inhibitors are especially important. A wide spectrum of hormones, growth factors, and cell environment factors are involved in the regulation of expression of the genes of plasminogen activators and of their inhibitors. The expression of uPA is activated by various inflammatory factors: cytokines [25], growth factors [26], and tumor promotors, such as phorbol-12-myristate-13-acetate [27], whereas antiinflammatory agents, such as glucocorticoids, inhibit the expression of uPA [28].
35257	 5226	 4038	glucocorticoid	Compound	PAH	mRNA	0	1	11675021	expression of human PAH is independent of glucocorticoids and/or cAMP in contrast to the mouse gene
39411	 5226	 5243	glucocorticoid	Compound	SESN1	mRNA	-1	1	15826934	Table 1. Known transcripts increased by dexamethasone
39518	 5226	 7065	glucocorticoid	Compound	HPN	mRNA	0	-1	17016446	Importantly, the activation of GR resulted in normalized expression of PC markers hepsin, AMACR, and maspin. The structural analysis of hepsin and AMACR promoters provided the mechanistic rationale for PC marker downregulation by glucocorticoids via inhibition of specific TFs.
39569	 5226	13744	glucocorticoid	Compound	CDKN1B	mRNA	-1	-1	17016446	This was accompanied by upregulation of p21 and p27, down-regulation of cyclin D1 expression and c-Myc phosphorylation.
39810	 5226	 7769	glucocorticoid	Compound	FOXO1	mRNA	-1	1	15826934	Table 1. Known transcripts increased by dexamethasone
39941	 5226	 6114	glucocorticoid	Compound	NFKBIA	mRNA	1	1	10402163	Glucocorticoids suppress expression of inflammatory genes by binding glucocorticoid receptor with NF-kappaB, and increasing expression of inhibitory protein of NF-kappaB, IkappaBalpha
42857	 5226	 3879	glucocorticoid	Compound	FAS	mRNA	0	1	11145719	CD95 and CD95 ligand (CD95L) were up-regulated in a dose- and time-dependent manner on the cell membrane and also released after treatment with GC
43738	 5226	 7426	glucocorticoid	Compound	SOCS2	mRNA	0	1	10433229	Glucocorticoids blocked GH-induced SOCS-3 expression in cultured hepatocytes, whereas SOCS-2 and CIS expression was potentiated
48517	 5226	 5391	glucocorticoid	Compound	AMACR	mRNA	0	-1	17016446	Importantly, the activation of GR resulted in normalized expression of PC markers hepsin, AMACR, and maspin. The structural analysis of hepsin and AMACR promoters provided the mechanistic rationale for PC marker downregulation by glucocorticoids via inhibition of specific TFs.
50999	 5226	13884	glucocorticoid	Compound	CDKN1A	mRNA	1	1	12790805	glucocorticoids stimulate expression of p57(Kip2)
51500	 5226	15841	glucocorticoid	Compound	FBXO32	mRNA	-1	1	12928036	Expression of MuRF1 and MAFbx is stimulated when the nerve innervating a muscle is cut, thus resulting in paralysis and severe atrophy; these genes are also upregulated by simple immobilization of the muscle, or by treatment with a glucocorticoid, which causes muscle cachexia [11]. More recently, a predictive experiment was performed, in which sepsis-induced atrophy was induced to determine whether this distinct model of atrophy might also increase expression of MuRF1 and MAFbx. Both of these genes were upregulated several-fold during sepsis [72], and this upregulation could be blocked by a pharmacologic inhibitor of glucocorticoids [72].
51678	 5226	  219	glucocorticoid	Compound	FASLG	mRNA	-1	1	11145719	CD95 and CD95 ligand (CD95L) were up-regulated in a dose- and time-dependent manner on the cell membrane and also released after treatment with GC
52993	 5226	19009	glucocorticoid	Compound	TSC22D3	mRNA	1	1	11259387	up
53292	 5226	 6651	glucocorticoid	Compound	CISH	mRNA	0	1	10433229	Glucocorticoids blocked GH-induced SOCS-3 expression in cultured hepatocytes, whereas SOCS-2 and CIS expression was potentiated
54129	 5226	 4258	glucocorticoid	Compound	PLA2G4A	mRNA	0	1	17901074	Glucocorticoids (GCs) are well-known anti-inflammatory drugs inhibiting prostaglandin production. Paradoxically, GCs are reported to stimulate cytosolic phosphoplipase A2 group IVA (PLA2G4A) and prostaglandin-endoperoxide synthase 2 (PTGS2) expression in human amnion fibroblasts.
54270	 5226	  322	glucocorticoid	Compound	GADD45G	mRNA	1	1	15826934	Table 1. Known transcripts increased by dexamethasone
55387	 5226	12303	glucocorticoid	Compound	SOCS3	mRNA	0	-1	10433229	Glucocorticoids blocked GH-induced SOCS-3 expression in cultured hepatocytes, whereas SOCS-2 and CIS expression was potentiated
55869	 5226	 5857	glucocorticoid	Compound	BHLHE40	mRNA	0	-1	15970569	From full text table 4: Reagents regulating expression of the BHLHB2 and BHLHB3 genes
59733	 5226	 5494	glucocorticoid	Compound	LPIN1	mRNA	0	1	18362392	Here we identify glucocorticoids as the stimulus for the induction of lipin-1 expression in differentiating adipocytes, and characterize a glucocorticoid response element (GRE) in the Lpin1 promoter. The Lpin1 GRE binds to the glucocorticoid receptor and leads to transcriptional activation in adipocytes and hepatocytes, as demonstrated by reporter gene transcription, electrophoretic mobility shift, and chromatin immunoprecipitation assays.
59922	 5226	13264	glucocorticoid	Compound	TRIM63	mRNA	-1	1	12928036	Expression of MuRF1 and MAFbx is stimulated when the nerve innervating a muscle is cut, thus resulting in paralysis and severe atrophy; these genes are also upregulated by simple immobilization of the muscle, or by treatment with a glucocorticoid, which causes muscle cachexia [11]. More recently, a predictive experiment was performed, in which sepsis-induced atrophy was induced to determine whether this distinct model of atrophy might also increase expression of MuRF1 and MAFbx. Both of these genes were upregulated several-fold during sepsis [72], and this upregulation could be blocked by a pharmacologic inhibitor of glucocorticoids [72].
60022	 5226	12976	glucocorticoid	Compound	IL8	mRNA	0	-1	17062674	Our previous study has shown that glucocorticoids inhibit tumor angiogenesis possibly by down-regulation of vascular endothelial growth factor (VEGF) and interleukin 8.
61337	 5226	12385	glucocorticoid	Compound	BCKDHB	mRNA	0	1	11287331	acidification or glucocorticoids increase the maximal activity and subunit mRNA levels of branched chain alpha-ketoacid dehydrogenase [BCKAD] in various cell types dexamethasone concurrently stimulated E2 subunit promoter activity and reduced the binding of nuclear factor-kappaB to a site in the E2 promoter thus acidification and glucocorticoids independently enhance BCKAD subunit gene expression, and the glucocorticoid repsonse in the E2 subunit involves interference with NF-kappaB, which may act as a transrepressor
62421	 5226	11013	glucocorticoid	Compound	IBSP	mRNA	0	1	11459848	_ Ariadne: As BSP expression is increased by glucocorticoids ( 18 ),  hormones that support the differentiation of osteoblasts, it was postulated  that the molecule is involved in the anabolic phase of bone remodeling ( 19 ).
62901	 5226	 4641	glucocorticoid	Compound	GPNMB	mRNA	0	-1	15763343	Dexamethasone and lipopolysaccharide decreased osteoactivin expression in cultured mononuclear phagocytes
64365	 5226	 6353	glucocorticoid	Compound	IRS2	mRNA	0	1	17711920	In human adipocytes, pretreatment with GC induced a dose-dependent [1.0 (control); 1.2 +/- 0.1 (50 nm); 2.2 +/- 0.2 (250 nm), P < 0.01 vs. control; 3.4 +/- 0.2 (1000 nm), P < 0.001 vs. control] and time-dependent [1.0 (1 h); 3.2 +/- 2.0 (6 h); 9.1 +/- 5.9 (24 h), P < 0.05 vs. 1 h; 4.5 +/- 2.2 (48 h)] increase in insulin-stimulated protein kinase B/akt phosphorylation. In addition, whereas insulin receptor substrate (IRS)-1 protein expression did not change, IRS-1 tyrosine phosphorylation increased.Furthermore, GC induced IRS-2 mRNA expression (2.8-fold; P < 0.05) and increased insulin-stimulated glucose uptake [1.0 (control) 1.8 +/- 0.1 (insulin) vs. 2.8 +/- 0.2 (insulin + GC); P < 0.05].
 6547	 5226	 5374	glucocorticoid	Compound	MXD4	mRNA	-1	1	15826934	Table 1. Known transcripts increased by dexamethasone
65914	 5226	 2631	glucocorticoid	Compound	PPARGC1A	mRNA	0	1	11557972	PGC-1 is induced synergistically in primary liver cultures by cyclic AMP and glucocorticoids.
 9764	 5226	 2215	glucocorticoid	Compound	TNFRSF18	mRNA	0	1	16155000	Glucocorticoid-induced tumor necrosis factor receptor
11057	 5530	15610	S100A6	Protein	CDH6	mRNA	0	-1	11830547	Table1: Down-regulation by progesterone (fold) Gene   PRA   PRB  Fibronectin   None   2.8 Integrin a3   None   2.8 Integrin B1   None   >10 Integrin B3   8   5.6 Cadherin 6  6   8 Differences between the PR isoforms were evident: in general, PRB had a greater inhibitory effect on cellular adhesion molecule expression compared with PRA. Only PRB significantly inhibited the expression of fibronectin and the integrins 3 and B1, but both PR isoforms inhibited cadherin 6 and integrin B3.
 2111	 5530	18630	S100A6	Protein	ITGB3	mRNA	0	-1	11830547	Table1: Down-regulation by progesterone (fold) Gene   PRA   PRB  Fibronectin   None   2.8 Integrin a3   None   2.8 Integrin B1   None   >10 Integrin B3   8   5.6 Cadherin 6  6   8 Differences between the PR isoforms were evident: in general, PRB had a greater inhibitory effect on cellular adhesion molecule expression compared with PRA. Only PRB significantly inhibited the expression of fibronectin and the integrins 3 and B1, but both PR isoforms inhibited cadherin 6 and integrin B3.
50992	 5530	13884	S100A6	Protein	CDKN1A	mRNA	1	1	12473170	Activated PRs would recruit a series of important regulatory proteins, which can serve as coactivators or corepressors, such as SRC-1, SRC-2 and SRC-3, CBP/p300 and others. Evidence of a direct PR activation by the protein kinase A pathway was provided by Edwards et al. [21] in the T-47D cell line. Recently, Jacobsen et al. [22] studied ligand-independent activation of the PRA, which resulted in increased expression of several genes, among them prolactin receptors.
52050	 5530	 1634	S100A6	Protein	NEDD9	mRNA	0	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
52992	 5530	19009	S100A6	Protein	TSC22D3	mRNA	1	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
10759	12018	 8674	zebularine	Compound	SLC3A1	mRNA	-1	1	15150099	See Table 6: Microarray and reverse transcription PCR (RT-PCR) comparison. All genes have increased expression in response to Zebularine greater than or equal to 1.5 compared to control.
12821	 4302	17369	Adrb Family	Protein	IL6	mRNA	0	1	12665506	This study was aimed to determine whether beta-adrenergic receptor (beta-AR) stimulated by isoproterenol (ISO) activates signal transducers and activators of transcription (STAT) in mouse heart and, if so, to examine the underlying mechanism. We found that treatment of adult male mice by ISO (15 mg/kg body weight, intraperitoneal) caused a delayed STAT3 activation (at 60-120 min), which was fully abolished by beta-AR antagonist, propranolol. ISO-induced phosphorylation of STAT3 was markedly enhanced by phosphodiesterase inhibitor amrinone, indicating that cAMP is critically involved in beta-AR-mediated STAT3 activation. In addition, beta-AR stimulation significantly increased gene expression of interleukin-6 (IL-6) family of cytokines (IL-6, leukemia inhibitory factor, ciliary neurotrophic factor, and cardiotrophin-1). IL-6 protein levels in serum and mouse myocardium were also significantly increased in response to ISO treatment. In cultured cardiac fibroblasts, IL-6 level was enhanced significantly after ISO (10-6 mol/liter) stimulation for 2 h and then peaked at 12 h, whereas the response of IL-6 in cultured cardiomyocytes to ISO stimulation was not significant, suggesting that ISO-induced increase in IL-6 is primarily from cardiac fibroblasts rather than cardiomyocytes. Most importantly, IL-6 could activate STAT3 in a time-dependent manner in cultured cardiomyocytes, and inhibition of IL-6 level by anti-IL-6-neutralizing antibody clearly attenuated ISO-induced phosphorylation of STAT3 in myocardium. Taken together, these results indicate that beta-AR stimulation leads to a delayed STAT3 activation via an IL-6 family of cytokine-mediated pathway and that cardiac fibroblasts, but not cardiomyocytes, is probably the predominant source of IL-6 in response to ISO stimulation in mouse myocardium.
25451	 4302	 5701	Adrb Family	Protein	ID3	mRNA	0	1	10585876	We here demonstrated that there was a dramatic rise of Id2 and Id3 mRNA levels when 3T3-L1 adipocytes or isolated rat fat cells were exposed to lipolytic and anti-lipogenic agents, forskolin and isoproterenol.
 2966	 4302	  884	Adrb Family	Protein	AZGP1	mRNA	0	1	15714206	In vitro studies using 3T3-L1 adipocytes showed dexamethasone (1.68 microM) to stimulate lipolysis and increase ZAG expression, and both were attenuated by RU38486 (10 microM), anti-ZAG antibody (1 microg ml(-1)), and the beta3-adrenoreceptor (beta3-AR) antagonist SR59230A (10 microM).
36231	 4302	 9322	Adrb Family	Protein	FGF1	mRNA	0	-1	15264218	This mechanism was proved to function in vivo by stimulation of FGF-1 expression in neurons of the cerebral cortex after intracerebral administration of propranolol, an antagonist of adrenergic beta receptors
53078	 4302	16278	Adrb Family	Protein	ID2	mRNA	0	1	10585876	We here demonstrated that there was a dramatic rise of Id2 and Id3 mRNA levels when 3T3-L1 adipocytes or isolated rat fat cells were exposed to lipolytic and anti-lipogenic agents, forskolin and isoproterenol.
55350	 4302	 4481	Adrb Family	Protein	COL5A2	mRNA	1	-1	15479167	Table 1 - Genes regulated  by 1 umol/L isoproterenol (activation of beta adrenoceptors) in A7r5 cells. The differential gene expression values between treatment and control were expressed as an expression ratio and tested by Chen test (95% confidence). Among these genes, we pick out ratio values  1.8 or   0.56 as indicating genes with changed expression.
56471	 4302	  121	Adrb Family	Protein	F2R	mRNA	-1	-1	15479167	Table 1 - Genes regulated  by 1 umol/L isoproterenol (activation of beta adrenoceptors) in A7r5 cells. The differential gene expression values between treatment and control were expressed as an expression ratio and tested by Chen test (95% confidence). Among these genes, we pick out ratio values  1.8 or   0.56 as indicating genes with changed expression.
57941	 4302	 4873	Adrb Family	Protein	LIF	mRNA	0	1	12665506	This study was aimed to determine whether beta-adrenergic receptor (beta-AR) stimulated by isoproterenol (ISO) activates signal transducers and activators of transcription (STAT) in mouse heart and, if so, to examine the underlying mechanism. We found that treatment of adult male mice by ISO (15 mg/kg body weight, intraperitoneal) caused a delayed STAT3 activation (at 60-120 min), which was fully abolished by beta-AR antagonist, propranolol. ISO-induced phosphorylation of STAT3 was markedly enhanced by phosphodiesterase inhibitor amrinone, indicating that cAMP is critically involved in beta-AR-mediated STAT3 activation. In addition, beta-AR stimulation significantly increased gene expression of interleukin-6 (IL-6) family of cytokines (IL-6, leukemia inhibitory factor, ciliary neurotrophic factor, and cardiotrophin-1). IL-6 protein levels in serum and mouse myocardium were also significantly increased in response to ISO treatment. In cultured cardiac fibroblasts, IL-6 level was enhanced significantly after ISO (10-6 mol/liter) stimulation for 2 h and then peaked at 12 h, whereas the response of IL-6 in cultured cardiomyocytes to ISO stimulation was not significant, suggesting that ISO-induced increase in IL-6 is primarily from cardiac fibroblasts rather than cardiomyocytes. Most importantly, IL-6 could activate STAT3 in a time-dependent manner in cultured cardiomyocytes, and inhibition of IL-6 level by anti-IL-6-neutralizing antibody clearly attenuated ISO-induced phosphorylation of STAT3 in myocardium. Taken together, these results indicate that beta-AR stimulation leads to a delayed STAT3 activation via an IL-6 family of cytokine-mediated pathway and that cardiac fibroblasts, but not cardiomyocytes, is probably the predominant source of IL-6 in response to ISO stimulation in mouse myocardium.
61599	 4302	14016	Adrb Family	Protein	CNTF	mRNA	0	1	12665506	This study was aimed to determine whether beta-adrenergic receptor (beta-AR) stimulated by isoproterenol (ISO) activates signal transducers and activators of transcription (STAT) in mouse heart and, if so, to examine the underlying mechanism. We found that treatment of adult male mice by ISO (15 mg/kg body weight, intraperitoneal) caused a delayed STAT3 activation (at 60-120 min), which was fully abolished by beta-AR antagonist, propranolol. ISO-induced phosphorylation of STAT3 was markedly enhanced by phosphodiesterase inhibitor amrinone, indicating that cAMP is critically involved in beta-AR-mediated STAT3 activation. In addition, beta-AR stimulation significantly increased gene expression of interleukin-6 (IL-6) family of cytokines (IL-6, leukemia inhibitory factor, ciliary neurotrophic factor, and cardiotrophin-1). IL-6 protein levels in serum and mouse myocardium were also significantly increased in response to ISO treatment. In cultured cardiac fibroblasts, IL-6 level was enhanced significantly after ISO (10-6 mol/liter) stimulation for 2 h and then peaked at 12 h, whereas the response of IL-6 in cultured cardiomyocytes to ISO stimulation was not significant, suggesting that ISO-induced increase in IL-6 is primarily from cardiac fibroblasts rather than cardiomyocytes. Most importantly, IL-6 could activate STAT3 in a time-dependent manner in cultured cardiomyocytes, and inhibition of IL-6 level by anti-IL-6-neutralizing antibody clearly attenuated ISO-induced phosphorylation of STAT3 in myocardium. Taken together, these results indicate that beta-AR stimulation leads to a delayed STAT3 activation via an IL-6 family of cytokine-mediated pathway and that cardiac fibroblasts, but not cardiomyocytes, is probably the predominant source of IL-6 in response to ISO stimulation in mouse myocardium.
66329	 4302	19218	Adrb Family	Protein	CTF1	mRNA	0	1	12665506	This study was aimed to determine whether beta-adrenergic receptor (beta-AR) stimulated by isoproterenol (ISO) activates signal transducers and activators of transcription (STAT) in mouse heart and, if so, to examine the underlying mechanism. We found that treatment of adult male mice by ISO (15 mg/kg body weight, intraperitoneal) caused a delayed STAT3 activation (at 60-120 min), which was fully abolished by beta-AR antagonist, propranolol. ISO-induced phosphorylation of STAT3 was markedly enhanced by phosphodiesterase inhibitor amrinone, indicating that cAMP is critically involved in beta-AR-mediated STAT3 activation. In addition, beta-AR stimulation significantly increased gene expression of interleukin-6 (IL-6) family of cytokines (IL-6, leukemia inhibitory factor, ciliary neurotrophic factor, and cardiotrophin-1). IL-6 protein levels in serum and mouse myocardium were also significantly increased in response to ISO treatment. In cultured cardiac fibroblasts, IL-6 level was enhanced significantly after ISO (10-6 mol/liter) stimulation for 2 h and then peaked at 12 h, whereas the response of IL-6 in cultured cardiomyocytes to ISO stimulation was not significant, suggesting that ISO-induced increase in IL-6 is primarily from cardiac fibroblasts rather than cardiomyocytes. Most importantly, IL-6 could activate STAT3 in a time-dependent manner in cultured cardiomyocytes, and inhibition of IL-6 level by anti-IL-6-neutralizing antibody clearly attenuated ISO-induced phosphorylation of STAT3 in myocardium. Taken together, these results indicate that beta-AR stimulation leads to a delayed STAT3 activation via an IL-6 family of cytokine-mediated pathway and that cardiac fibroblasts, but not cardiomyocytes, is probably the predominant source of IL-6 in response to ISO stimulation in mouse myocardium.
 7342	 4302	16458	Adrb Family	Protein	UCP1	mRNA	0	1	10938091	beta(3)-AR is required for leptin-mediated regulation of ob mRNA expression in WAT, but is interchangeable with the beta(1)/beta(2)-ARs in mediating leptinps effect on UCP1 mRNA expression in brown adipose tissue
16339	16389	19219	INS	Protein	IER2	mRNA	0	1	15731359	insulin-induced transcription of ATF-3, Pip92, and Insig-1 required MEK-ERK activation
16767	16389	13585	INS	Protein	FADS2	mRNA	0	1	17628011	To address the effects of LXR signaling in human livers, we have used genome-wide expression profiling of primary human hepatocytes cultured at varying physiological concentrations of insulin and treated them with the synthetic LXR agonist GW3965.  85 genes were significantly upregulated and 105 genes were significantly downregulated by insulin and GW3965 treatment, respectively.  38 genes were significantly upregulated and 84 genes were significantly downregulated by insulin alone.  Fold change was 1.5 increase or decrease compared to control.
17307	16389	16992	INS	Protein	SCD	mRNA	0	1	17628011	To address the effects of LXR signaling in human livers, we have used genome-wide expression profiling of primary human hepatocytes cultured at varying physiological concentrations of insulin and treated them with the synthetic LXR agonist GW3965.  85 genes were significantly upregulated and 105 genes were significantly downregulated by insulin and GW3965 treatment, respectively.  38 genes were significantly upregulated and 84 genes were significantly downregulated by insulin alone.  Fold change was 1.5 increase or decrease compared to control.
  194	16389	16874	INS	Protein	PIK3R1	mRNA	0	1	10567366	Insulin acutely up-regulates p85alpha phosphatidylinositol 3-kinase (p85alphaPI 3-K) mRNA levels in human skeletal muscle
21643	16389	 6320	INS	Protein	PGD	mRNA	0	1	17628011	To address the effects of LXR signaling in human livers, we have used genome-wide expression profiling of primary human hepatocytes cultured at varying physiological concentrations of insulin and treated them with the synthetic LXR agonist GW3965.  85 genes were significantly upregulated and 105 genes were significantly downregulated by insulin and GW3965 treatment, respectively.  38 genes were significantly upregulated and 84 genes were significantly downregulated by insulin alone.  Fold change was 1.5 increase or decrease compared to control.
25551	16389	 8993	INS	Protein	EREG	mRNA	0	1	17274952	promoter analysis of HB-EGF and EPI demonstrated that insulin stimulated transcription.
 3069	16389	17401	INS	Protein	HMGCR	mRNA	0	1	17628011	To address the effects of LXR signaling in human livers, we have used genome-wide expression profiling of primary human hepatocytes cultured at varying physiological concentrations of insulin and treated them with the synthetic LXR agonist GW3965.  85 genes were significantly upregulated and 105 genes were significantly downregulated by insulin and GW3965 treatment, respectively.  38 genes were significantly upregulated and 84 genes were significantly downregulated by insulin alone.  Fold change was 1.5 increase or decrease compared to control.
 3154	16389	16645	INS	Protein	CCND1	mRNA	0	1	11337496	Subsequent stimulation with insulin or IGF-I alone failed to induce significant S-phase entry. However, these treatments increased cyclin D1, cyclin E, and p21 gene expression and induced the formation of active Cdk4 complexes but resulted in only minor increases in cyclin E-Cdk2 activity, likely due to recruitment of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/Cip1) into these complexes.
34346	16389	 2401	INS	Protein	LDLR	mRNA	0	1	11679417	The expression of the LDL receptor was also increased by insulin treatment,  as described previously in diabetic rats injected with insulin ( 5 ).
42460	16389	13544	INS	Protein	AGTR1	mRNA	0	1	16675453	For example, Ang II (8), cAMP stimulating agents (9), and estrogens (10, 11) decrease rat AT1AR expression by stimulating rat AT1AR mRNA decay. In contrast, insulin (12), low density lipoprotein (13), and progesterone (11) up-regulate receptor expression by decreasing AT1AR mRNA decay rates. Additionally, rat AT1AR expression is regulated by translational mechanisms via cytosolic proteins that interact with the 5p-UTR of the receptor mRNA (10, 1418).
43737	16389	 7426	INS	Protein	SOCS2	mRNA	0	1	11279166	We demonstrate that insulin induces the expression of SOCS-2 mRNA in the wild type hIR but not in the LA-hIR-overexpressing cells. The induction of SOCS-3 by insulin is reduced but not lost in the LA-hIR cells
44160	16389	 6531	INS	Protein	CCNE1	mRNA	0	1	11337496	Subsequent stimulation with insulin or IGF-I alone failed to induce significant S-phase entry. However, these treatments increased cyclin D1, cyclin E, and p21 gene expression and induced the formation of active Cdk4 complexes but resulted in only minor increases in cyclin E-Cdk2 activity, likely due to recruitment of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/Cip1) into these complexes.
47211	16389	 2052	INS	Protein	ATF3	mRNA	0	1	15731359	insulin-induced transcription of ATF-3, Pip92, and Insig-1 required MEK-ERK activation
51062	16389	13884	INS	Protein	CDKN1A	mRNA	1	1	11337496	Subsequent stimulation with insulin or IGF-I alone failed to induce significant S-phase entry. However, these treatments increased cyclin D1, cyclin E, and p21 gene expression and induced the formation of active Cdk4 complexes but resulted in only minor increases in cyclin E-Cdk2 activity, likely due to recruitment of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/Cip1) into these complexes.
55382	16389	12303	INS	Protein	SOCS3	mRNA	0	1	10821852	Using transfection of COS-7 cells, we show that insulin induction of SOCS-3 is enhanced upon Stat5B expression. Moreover, Stat5B from insulin-stimulated cells binds directly to a Stat element present in the SOCS-3 promoter.
55644	16389	19007	INS	Protein	STAT5B	mRNA	0	1	10821852	Using transfection of COS-7 cells, we show that insulin induction of SOCS-3 is enhanced upon Stat5B expression. Moreover, Stat5B from insulin-stimulated cells binds directly to a Stat element present in the SOCS-3 promoter.
55710	16389	15411	INS	Protein	INSIG1	mRNA	0	1	15731359	insulin-induced transcription of ATF-3, Pip92, and Insig-1 required MEK-ERK activation
55856	16389	 5857	INS	Protein	BHLHE40	mRNA	0	1	15970569	From full text table 4: Reagents regulating expression of the BHLHB2 and BHLHB3 genes
 5648	16389	18424	INS	Protein	DUSP1	mRNA	0	1	12529177	Here the effect of hyperosmolarity (405 mosmol/l) on insulin-induced mitogen-activated protein (MAP) kinase phosphatase (MKP)-1 expression was studied in H4IIE rat hepatoma cells.
59668	16389	 7590	INS	Protein	GCK	mRNA	0	1	17628011	To address the effects of LXR signaling in human livers, we have used genome-wide expression profiling of primary human hepatocytes cultured at varying physiological concentrations of insulin and treated them with the synthetic LXR agonist GW3965.  85 genes were significantly upregulated and 105 genes were significantly downregulated by insulin and GW3965 treatment, respectively.  38 genes were significantly upregulated and 84 genes were significantly downregulated by insulin alone.  Fold change was 1.5 increase or decrease compared to control.
64046	16389	15142	INS	Protein	SDS	mRNA	0	-1	17628011	To address the effects of LXR signaling in human livers, we have used genome-wide expression profiling of primary human hepatocytes cultured at varying physiological concentrations of insulin and treated them with the synthetic LXR agonist GW3965.  85 genes were significantly upregulated and 105 genes were significantly downregulated by insulin and GW3965 treatment, respectively.  38 genes were significantly upregulated and 84 genes were significantly downregulated by insulin alone.  Fold change was 1.5 increase or decrease compared to control.
 6555	16389	 5466	INS	Protein	ACACB	mRNA	0	1	17628011	To address the effects of LXR signaling in human livers, we have used genome-wide expression profiling of primary human hepatocytes cultured at varying physiological concentrations of insulin and treated them with the synthetic LXR agonist GW3965.  85 genes were significantly upregulated and 105 genes were significantly downregulated by insulin and GW3965 treatment, respectively.  38 genes were significantly upregulated and 84 genes were significantly downregulated by insulin alone.  Fold change was 1.5 increase or decrease compared to control.
   70	16389	 9497	INS	Protein	APOA5	mRNA	0	-1	17628011	To address the effects of LXR signaling in human livers, we have used genome-wide expression profiling of primary human hepatocytes cultured at varying physiological concentrations of insulin and treated them with the synthetic LXR agonist GW3965.  85 genes were significantly upregulated and 105 genes were significantly downregulated by insulin and GW3965 treatment, respectively.  38 genes were significantly upregulated and 84 genes were significantly downregulated by insulin alone.  Fold change was 1.5 increase or decrease compared to control.
36559	 3525	 4029	LOC680208	Protein	TLE4	mRNA	-1	1	16807150	See Table 2: Genes up-regulated by IFN-alpha. All changes are greater than or equal to 2.
 4831	 3525	 6386	LOC680208	Protein	HMOX2	mRNA	1	1	16807150	See Table 2: Genes up-regulated by IFN-alpha. All changes are greater than or equal to 2.
44761	 5972	 4862	S1PR1	Protein	PDGFA	mRNA	-1	1	14711826	Modified assertion
63819	 5972	 8819	S1PR1	Protein	PDGFB	mRNA	0	1	14711826	Modified assertion
11149	  236	11640	hyaluronic acid	Compound	TRAF1	mRNA	0	1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
12344	  236	15924	hyaluronic acid	Compound	HDC	mRNA	0	1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
12450	  236	 3889	hyaluronic acid	Compound	CDH5	mRNA	0	-1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
12785	  236	17369	hyaluronic acid	Compound	IL6	mRNA	0	1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
13459	  236	16612	hyaluronic acid	Compound	MMP13	mRNA	0	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
17946	  236	19814	hyaluronic acid	Compound	ELK1	mRNA	0	1	15655247	Elk-1 transactivation activity was significantly stimulated in cells treated with HA (bar b) compared with Elk-1 transcriptional activity in untreated cells (bar a)
18085	  236	  284	hyaluronic acid	Compound	CXCL10	mRNA	0	1	16581825	Hyaluronan (HA) fragments-induce IL-8 and IFN-{gamma}-inducible protein 10 (IP-10) protein and mRNA in human airway epithelial cells.
19898	  236	14849	hyaluronic acid	Compound	TGFB2	mRNA	-1	1	20706656	A microarray analysis performed on the mouse alveolar macrophage cell line (MH-S) generated a list of genes that respond differently to hyaluronan and LPS. For instance, MMP13, TGF-b2, SOCS3, and other genes were induced exclusively by hyaluronan......While some cytokines including TNFa, MCP-1, and RANTES were equally induced by both ligands, others, such as granulocyte macrophage-colony stimulating factor (GMCSF), granulocyte colony-stimulating factor (G-CSF), and IL-1a, were significantly different [88].
 2220	  236	 5419	hyaluronic acid	Compound	TNF	mRNA	0	1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
22513	  236	 4447	hyaluronic acid	Compound	CCNB3	mRNA	0	-1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
23790	  236	 6636	hyaluronic acid	Compound	BCL2L1	mRNA	0	1	19047049	HA binding to CD44 up-regulates p300 expression and its acetyltransferase activity that, in turn, promotes acetylation of beta-catenin and NFkappaB-p65 leading to activation of beta-catenin-associated T-cell factor/lymphocyte enhancer factor transcriptional co-activation and NFkappaB-specific transcriptional up-regulation, respectively. These changes then cause the expression of the MDR1 (P-glycoprotein/P-gp) gene and the anti-apoptotic gene Bcl-x(L) resulting in chemoresistance in MCF-7 cells.
24347	  236	18209	hyaluronic acid	Compound	MMP3	mRNA	0	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
27297	  236	 9781	hyaluronic acid	Compound	TRDN	mRNA	0	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
 2775	  236	  908	hyaluronic acid	Compound	MMP9	mRNA	0	1	12414663	PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation.
 2826	  236	  931	hyaluronic acid	Compound	TP53INP1	mRNA	-1	-1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
32433	  236	20190	hyaluronic acid	Compound	ABCB1	mRNA	0	1	19047049	HA binding to CD44 up-regulates p300 expression and its acetyltransferase activity that, in turn, promotes acetylation of beta-catenin and NFkappaB-p65 leading to activation of beta-catenin-associated T-cell factor/lymphocyte enhancer factor transcriptional co-activation and NFkappaB-specific transcriptional up-regulation, respectively. These changes then cause the expression of the MDR1 (P-glycoprotein/P-gp) gene and the anti-apoptotic gene Bcl-x(L) resulting in chemoresistance in MCF-7 cells.
32498	  236	19410	hyaluronic acid	Compound	CXCL11	mRNA	0	1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
35438	  236	18531	hyaluronic acid	Compound	ICAM1	mRNA	0	1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
36334	  236	 1868	hyaluronic acid	Compound	PDGFC	mRNA	0	-1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
42942	  236	 8368	hyaluronic acid	Compound	CXCL9	mRNA	0	1	12226082	we demonstrate that the synergistic induction of MIG by HA and IFN-gamma occurs at the level of transcription via NF-kappaB.
 4304	  236	19709	hyaluronic acid	Compound	RGS2	mRNA	0	-1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
48601	  236	 6071	hyaluronic acid	Compound	CD79B	mRNA	0	-1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
  489	  236	11404	hyaluronic acid	Compound	CSF2	mRNA	0	1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
 4932	  236	12263	hyaluronic acid	Compound	Clec10a	mRNA	0	-1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
49763	  236	19504	hyaluronic acid	Compound	REST	mRNA	0	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
54074	  236	 5118	hyaluronic acid	Compound	NOS2	mRNA	0	1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
55396	  236	12303	hyaluronic acid	Compound	SOCS3	mRNA	0	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
56169	  236	10811	hyaluronic acid	Compound	FN1	mRNA	-1	-1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
56528	  236	14315	hyaluronic acid	Compound	COL6A2	mRNA	0	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
56930	  236	13743	hyaluronic acid	Compound	TRAF4	mRNA	0	-1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
61443	  236	 2871	hyaluronic acid	Compound	CD28	mRNA	0	-1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
64005	  236	 1792	hyaluronic acid	Compound	FRK	mRNA	0	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
64432	  236	 2077	hyaluronic acid	Compound	GBP1	mRNA	0	1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
 6461	  236	 3862	hyaluronic acid	Compound	SOCS7	mRNA	0	-1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
11028	18431	 8037	MEF2C	Protein	KLF6	mRNA	1	-1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
 1173	18431	18589	MEF2C	Protein	FABP3	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
13335	18431	10696	MEF2C	Protein	JUN	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
14887	18431	14770	MEF2C	Protein	RHOB	mRNA	0	-1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
16255	18431	15838	MEF2C	Protein	PER1	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
16321	18431	 1258	MEF2C	Protein	OSGEPL1	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
17863	18431	18271	MEF2C	Protein	ACTA1	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
18374	18431	14294	MEF2C	Protein	CRYAB	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
23402	18431	 9226	MEF2C	Protein	CITED2	mRNA	1	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
24261	18431	 4420	MEF2C	Protein	TPM3	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
  243	18431	 4377	MEF2C	Protein	MSTN	mRNA	0	1	12242286	The results show that MEF2C enhanced the myostatin promoter activity by threefold (Fig. 5A, panel i) indicating that MEF2C can transactivate the myostatin promoter in C2C12 cells.
25037	18431	11217	MEF2C	Protein	NPPA	mRNA	0	1	15486975	Here, we determine that dHAND also interacts with the myocyte enhancer binding factor-2c (MEF2C) protein, which belongs to MADS-box transcription factors and is essential for heart development. dHAND and MEF2C synergistically activated expression of the atrial naturetic peptide gene (ANP) in transfected HeLa cells. GST-pulldown and immunoprecipitation assay demonstrate that full-length MEF2C protein is able to interact with dHAND in vitro and in vivo, just like MEF2A and bHLH transcription factors MyoD in skeletal muscle cells. In addition, electrophoretic mobility shift assays (EMSAs) demonstrate that MEF2C and dHAND do not influence each otherps DNA binding activity. Using chromatin immunoprecipitation (ChIP) analysis in H9c2 cells we show that dHAND interact with MEF2C to form protein complex and bind A/T sequence in promoter of ANP.
27523	18431	 5070	MEF2C	Protein	HSPB2	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
30425	18431	15099	MEF2C	Protein	ING3	mRNA	0	-1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
34069	18431	16017	MEF2C	Protein	TNNC2	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
34435	18431	12755	MEF2C	Protein	SMYD1	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
37202	18431	 2144	MEF2C	Protein	CPT1B	mRNA	0	1	15356291	synergistic activation of the CPT1beta gene promoter by MEF2C and PPARalpha-RXRalpha
38395	18431	11805	MEF2C	Protein	CSRP3	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
42232	18431	18227	MEF2C	Protein	TNNI1	mRNA	0	1	12857748	_ Ariadne: This report demonstrates  that hMusTRD1alpha1 interacts directly with MEF2C and can prevent MEF2C from  binding to its cognate binding site. [Binding] _ GeneRif: MEF2 activation of the troponin I slow enhancer is repressed by hMusTRD1alpha1 The novel transcription factor hMusTRD1alpha1 (human muscle TFII-I repeat domain-containing protein 1alpha1; previously named MusTRD1; OpMahoney, J. V., Guven, K. L., Lin, J., Joya, J. E., Robinson, C. S., Wade, R. P., and Hardeman, E. C. (1998) Mol. Cell. Biol. 18, 6641-6652) was identified in a yeast one-hybrid screen as a protein that binds within an upstream enhancer-containing region of the skeletal muscle-specific gene, TNNI1 (human troponin I slow; hTnIslow).
46401	18431	 2765	MEF2C	Protein	LDB3	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
47351	18431	14338	MEF2C	Protein	ACTC1	mRNA	0	1	15829506	A dramatic decrease in expression of mRNAs encoding alpha-actin, MLC2a and MLC2v was observed in R58QMLC2vGFP EBs. This event was attributed to a failure of Mef2c to translocate into the nucleus, a Ca(2+)-dependent process.
51255	18431	 1971	MEF2C	Protein	SRPK3	mRNA	0	1	16140986	we performed a microarray analysis using Mef2c-null mouse embryos and identified a novel MEF2-regulated gene encoding a muscle-specific protein kinase, Srpk3,
51555	18431	17867	MEF2C	Protein	ADSSL1	mRNA	0	1	10318837	Finally, we report that several different cardiac transcription factors trans-activate the 1.9HSCAT construct... Adss1 appears to be one of the first target genes identified for the bHLH factors Hand1 and Hand2. the combinations utilizing all of the transcription factors, Nkx 2.5, GATA 4, MEF2C, E12, and Hand1 or Hand2, result in a substantial 35-65-fold enhancement of reporter expression
51935	18431	 1178	MEF2C	Protein	NR4A1	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
54152	18431	15639	MEF2C	Protein	ANKRD1	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
58312	18431	 5913	MEF2C	Protein	CYR61	mRNA	0	-1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
 5935	18431	 1713	MEF2C	Protein	MYOG	mRNA	0	1	10617583	Myogenin expression, and not MyoD, was found to up-regulate MEF2C expression. MEF2A, -B, and -D expression levels were not up-regulated by overexpression of either MyoD or myogenin. To examine whether MEF2C can differentially regulate MyoD or myogenin expression, P19 cell lines overexpressing MEF2C were analyzed. MEF2C induced myogenesis in P19 cells and up-regulated the expression of myogenin with 25-fold greater efficiency than that of MyoD. Therefore, myogenin and MEF2C participate in a regulatory loop in differentiating stem cells.
63318	18431	14311	MEF2C	Protein	ESRRB	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
63763	18431	 8902	MEF2C	Protein	CKB	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
65941	18431	 2631	MEF2C	Protein	PPARGC1A	mRNA	0	1	12764228	Although CREB thus seems to be an important factor in the induction of PGC-1-alpha , the increased effect of CaMKIV in combination with CnA suggests that factors in addition to CREB are likely to be involved in the transcription of the PGC-1-alpha gene in muscle. Because MEF2 and NFAT transcription factors are known targets of CaMKIV and CnA in muscle fiber-type determination, we tested the role of these factors in the control of the PGC-1-alpha  promoter. MEF2C, MEF2D, or NFATc3 alone did not have a significant effect on the function of the 2-kb PGC-1-alpha  promoter (Fig. 2A). However, because MEF2 proteins are known to be coactivated by PGC-1-alpha (7), we also tested these factors in cotransfection experiments. As shown in Fig. 2A, a coactivation by PGC-1-alpha  of both MEF2C and MEF2D, but not NFAT, was observed on the PGC-1-alpha  promoter. These data suggest that PGC-1-alpha might participate in the activation of its own promoter and that the MEF2 proteins may function both in the regulation of PGC-1-alpha  expression and as downstream targets of PGC-1-alpha  coactivation of other muscle-selective genes.
66260	18431	17275	MEF2C	Protein	TM4SF1	mRNA	0	-1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
 6737	18431	10999	MEF2C	Protein	HSPB1	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
 8533	18431	13312	MEF2C	Protein	TOR3A	mRNA	0	1	15706034	We have combined genome-wide transcription factor binding and expression profiling to assemble a regulatory network controlling the myogenic differentiation program in mammalian cells. We identified a cadre of overlapping and distinct targets of the key myogenic regulatory factors (MRFs)--MyoD and myogenin--and Myocyte Enhancer Factor 2 (MEF2). We discovered that MRFs and MEF2 regulate a remarkably extensive array of transcription factor genes that propagate and amplify the signals initiated by MRFs. We found that MRFs play an unexpectedly wide-ranging role in directing the assembly and usage of the neuromuscular junction. Interestingly, these factors also prepare myoblasts to respond to diverse types of stress. Computational analyses identified novel combinations of factors that, depending on the differentiation state, might collaborate with MRFs. Our studies suggest unanticipated biological insights into muscle development and highlight new directions for further studies of genes involved in muscle repair and responses to stress and damage.
   95	18431	 5975	MEF2C	Protein	MYL2	mRNA	0	1	10207035	(ResnetDB) In this in vivo study, overexpressing MEF2 (both MEF2A and MEF2C) enhanced MLC2slow promoter activity in the SOL+ muscles.
33031	 3645	 8503	Interferon	Compound	ITGA11	mRNA	0	1	16697656	Our findings indicated that type I IFNs were able to induce the ITGA-11 mRNA levels in T98G cells.
40747	 3645	 2915	Interferon	Compound	ISG15	mRNA	-1	1	12426315	ISG15 is a ubiquitin-like protein that is induced by interferon and microbial challenge.
52830	 3645	  556	Interferon	Compound	IFI16	mRNA	0	1	15208661	loss of IFN-inducible IFI 16 expression in human fibroblasts allows bypass of cellular senescence.
10662	  168	 3198	polyunsaturated fatty acid	Compound	TFRC	mRNA	-1	-1	11435508	Ariadne: Unsaturated fatty acids suppress interleukin-2  production and transferrin receptor expression by concanavalin A-stimulated rat  lymphocytes.
16774	  168	13585	polyunsaturated fatty acid	Compound	FADS2	mRNA	0	-1	11792729	the hepatic expression of both desaturases was downregulated by dietary PUFA, which were reported to suppress Srebf1c gene expression sustained expression of hepatic nuclear Srebf1c protein in the transgenic mice abolished the PUFA suppression of both desaturases
24931	  168	19864	polyunsaturated fatty acid	Compound	FADS1	mRNA	0	-1	11792729	the hepatic expression of both desaturases was downregulated by dietary PUFA, which were reported to suppress Srebf1c gene expression sustained expression of hepatic nuclear Srebf1c protein in the transgenic mice abolished the PUFA suppression of both desaturases
11233	10723	19608	serum insulin	Compound	LEP	mRNA	0	1	12020765	Leptin expression can be induced by obesity, insulin, TNF-a and glucocorticoids and is negatively regulated by fasting, b-adrenergic agonists and thiazolidinediones
12749	10723	13434	serum insulin	Compound	HIF1A	mRNA	0	1	10463582	We have demonstrated that insulin, IGF-1, IGF-2, EGF, and FGF-2 each induces HIF-1{alpha} expression in cultured cells
13675	10723	 1438	serum insulin	Compound	VEGFA	mRNA	0	1	11571295	injection of insulin and glycated albumin to mice increases VEGF mRNA expression in the eyes insulin and glycated albumin stimulate VEGF mRNA and protein expression in retinal epithelial cells
13943	10723	 5797	serum insulin	Compound	SYNJ2	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
 1405	10723	 6137	serum insulin	Compound	C16orf74	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
16837	10723	16536	serum insulin	Compound	MAK16	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
 1688	10723	  114	serum insulin	Compound	CAPN6	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
16944	10723	19193	serum insulin	Compound	MT2A	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
17051	10723	  413	serum insulin	Compound	SPSB1	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
17683	10723	19562	serum insulin	Compound	ACTR1A	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
17693	10723	 7405	serum insulin	Compound	GNG12	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
17900	10723	 2286	serum insulin	Compound	G6PC	mRNA	0	-1	11742412	Insulin can also influence glucose metabolism indirectly by changes in free fatty acids generated from visceral fat, the so called psingle gatewayp hypothesis64. Because visceral fat is less sensitive to insulin than subcutaneous fat, even after a meal there is little suppression of lipolysis by the hormone in this fat depot. The resulting direct flux of fatty acids derived from these fat cells through the portal vein to the liver can stimulate glucose production, thus providing a signal for both insulin action and insulin resistance in the liver It [insulin] inhibits the transcription of the gene encoding phosphoenolpyruvate carboxylase, the rate-limiting step in gluconeogenesis66. The hormone also decreases transcription of the genes encoding fructose-1,6-bisphosphatase and glucose-6- phosphatase, and increases transcription of glycolytic enzymes such as glucokinase and pyruvate kinase, and lipogenic enzymes such as fatty acid synthase and acetyl-CoA carboxylase.
19927	10723	17834	serum insulin	Compound	CCNG2	mRNA	-1	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
19935	10723	 5757	serum insulin	Compound	ADIPOQ	mRNA	0	1	21062957	In 3T3-L1 and human adipocyte cultures, insulin strongly enhanced adiponectin expression (2-fold) and secretion (3-fold). TNF-a, and not IL-6, strongly opposed the stimulatory effects of insulin
20669	10723	 4942	serum insulin	Compound	BCKDK	mRNA	0	1	12217904	insulin effected a 2fold increase in BCKD kinase protein levels insulin acts to regulate branched-chain amino acid catabolism through stimulation of BCKD kinase expression
21072	10723	17907	serum insulin	Compound	NOP56	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
21084	10723	18920	serum insulin	Compound	VEGFC	mRNA	0	1	11571295	injection of insulin and glycated albumin to mice increases VEGF mRNA expression in the eyes insulin and glycated albumin stimulate VEGF mRNA and protein expression in retinal epithelial cells
21241	10723	15302	serum insulin	Compound	SMC3	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
21259	10723	19465	serum insulin	Compound	C1GALT1C1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
22526	10723	 6168	serum insulin	Compound	TUBB2A	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
23683	10723	 8016	serum insulin	Compound	SLC25A28	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
24042	10723	10086	serum insulin	Compound	SPRED2	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
24260	10723	12409	serum insulin	Compound	TCTA	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
24550	10723	 9992	serum insulin	Compound	MTTP	mRNA	0	-1	12716735	insulin decreases MTP mRNA level mainly through transcriptional regulation in HepG2 cells.
24583	10723	 2720	serum insulin	Compound	TAGLN	mRNA	-1	-1	12031981	Below are the contents of a table from the paper
25072	10723	 4869	serum insulin	Compound	OTC	mRNA	0	-1	16891307	Finally, insulin treatment of human HEPG2 cell lines and HepG2 cells caused repression of PGC1alpha and a concomitant down-regulation of ApoCIII, PEPCK, AldoB, and OTC.
25246	10723	 9693	serum insulin	Compound	TKT	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
25275	10723	 5272	serum insulin	Compound	GCC2	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
25542	10723	 8993	serum insulin	Compound	EREG	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
25707	10723	 9645	serum insulin	Compound	6720489N17Rik	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
25815	10723	19027	serum insulin	Compound	HMOX1	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
25977	10723	10943	serum insulin	Compound	FRMD6	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
26492	10723	11970	serum insulin	Compound	C1orf85	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
27679	10723	16171	serum insulin	Compound	AK3	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
27718	10723	  806	serum insulin	Compound	TAB3	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
27858	10723	 1166	serum insulin	Compound	SLC2A1	mRNA	-1	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
28020	10723	12208	serum insulin	Compound	Ifi202b	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
28120	10723	17708	serum insulin	Compound	FOSL1	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
28233	10723	 7832	serum insulin	Compound	THBS1	mRNA	-1	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
29071	10723	  620	serum insulin	Compound	PHLDA1	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
 2909	10723	 4252	serum insulin	Compound	ABCA1	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
29421	10723	12388	serum insulin	Compound	PKD2	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
29443	10723	17624	serum insulin	Compound	C5orf41	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
29740	10723	  836	serum insulin	Compound	FBXO45	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
30053	10723	13864	serum insulin	Compound	PNPT1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
30151	10723	 7909	serum insulin	Compound	Zfp101	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
 3067	10723	17401	serum insulin	Compound	HMGCR	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
32264	10723	15297	serum insulin	Compound	ALDOB	mRNA	0	-1	16891307	Finally, insulin treatment of human HEPG2 cell lines and HepG2 cells caused repression of PGC1alpha and a concomitant down-regulation of ApoCIII, PEPCK, AldoB, and OTC.
32355	10723	 3118	serum insulin	Compound	ACACA	mRNA	0	1	11742412	Insulin can also influence glucose metabolism indirectly by changes in free fatty acids generated from visceral fat, the so called psingle gatewayp hypothesis64. Because visceral fat is less sensitive to insulin than subcutaneous fat, even after a meal there is little suppression of lipolysis by the hormone in this fat depot. The resulting direct flux of fatty acids derived from these fat cells through the portal vein to the liver can stimulate glucose production, thus providing a signal for both insulin action and insulin resistance in the liver It [insulin] inhibits the transcription of the gene encoding phosphoenolpyruvate carboxylase, the rate-limiting step in gluconeogenesis66. The hormone also decreases transcription of the genes encoding fructose-1,6-bisphosphatase and glucose-6- phosphatase, and increases transcription of glycolytic enzymes such as glucokinase and pyruvate kinase, and lipogenic enzymes such as fatty acid synthase and acetyl-CoA carboxylase.
32894	10723	14012	serum insulin	Compound	SRXN1	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
33053	10723	15107	serum insulin	Compound	SULT1D1P	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
33401	10723	11976	serum insulin	Compound	PDK4	mRNA	0	-1	11812733	Fatty acids caused an increase in the PDK4 message comparable to that induced by WY-14,643. Insulin prevented and reversed the stimulatory effects of dexamethasone on PDK4 gene expression
33678	10723	12902	serum insulin	Compound	SEC16B	mRNA	0	1	12244571	Moreover, the RGPR-p117 mRNA expression in H4-II-E cells was stimulated in the presence of dibutyryl cAMP, PMA, insulin, 17beta-estradiol, or serum in culture medium
33699	10723	 1040	serum insulin	Compound	CD36	mRNA	0	1	15166001	In cardiac myocytes, insulin very rapidly increased the expression of FAT/CD36 protein in a time- and dose-dependent manner
33737	10723	11399	serum insulin	Compound	BZW1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
34208	10723	13000	serum insulin	Compound	EEF2	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
34347	10723	 2401	serum insulin	Compound	LDLR	mRNA	0	1	12716735	both insulin and MAPKerk upregulate LDL-R gene transcription, whereas they both inhibit MTP gene transcription
35220	10723	 1622	serum insulin	Compound	SKIL	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
 3583	10723	16218	serum insulin	Compound	SRR	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
35844	10723	16900	serum insulin	Compound	CDR2	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
36111	10723	18165	serum insulin	Compound	ADRB3	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
 3615	10723	 9855	serum insulin	Compound	DGAT2	mRNA	1	1	12413942	glucose preferentially enhances DGAT1 mRNA expression, whereas insulin specifically increases the level of DGAT2 mRNA.
36312	10723	 3205	serum insulin	Compound	SKP1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
36668	10723	11314	serum insulin	Compound	PCK2	mRNA	-1	-1	11445561	The insulin response sequence (IRS) of the phosphoenolpyruvate carboxykinase (PEPCK) promoter, located within the glucocorticoid response unit, was first characterized by its ability to mediate insulin inhibition when inserted into a thymidine kinase promoter.
36722	10723	 7233	serum insulin	Compound	NOP58	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
36739	10723	 4528	serum insulin	Compound	PKM2	mRNA	0	1	12843653	insulin increased the level of M2-PK mRNA in 3T3-L1 adipocytes in both time- and dose-dependent manners
 3690	10723	 3195	serum insulin	Compound	SARNP	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
37261	10723	 4454	serum insulin	Compound	ZRANB2	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
39358	10723	 3830	serum insulin	Compound	KLHL24	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
40070	10723	13822	serum insulin	Compound	TSPAN5	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
40899	10723	13955	serum insulin	Compound	PPAN	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
40981	10723	 4582	serum insulin	Compound	NOS3	mRNA	1	1	15064952	Insulin induces vasodilatation in human subjects and increases L-arginine transport and NO synthesis in human umbilical vein endothelial cells (HUVEC). Insulin increased L-arginine transport and the mRNA levels for hCAT-1 and hCAT-2B and eNOS expression and activity.
41276	10723	  313	serum insulin	Compound	COX7B	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
42056	10723	13115	serum insulin	Compound	EGR1	mRNA	-1	1	10364249	This induction depends on the activation of mitogen-activated protein (MAP) kinase, and it is phosphatidylinositol 3-kinase-independent, as demonstrated with specific inhibitors for both pathways.
42384	10723	15530	serum insulin	Compound	SLC7A1	mRNA	0	1	15064952	Insulin induces vasodilatation in human subjects and increases L-arginine transport and NO synthesis in human umbilical vein endothelial cells (HUVEC). Insulin increased L-arginine transport and the mRNA levels for hCAT-1 and hCAT-2B and eNOS expression and activity.
42663	10723	11824	serum insulin	Compound	RGL1	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
42926	10723	15885	serum insulin	Compound	ACTB	mRNA	1	1	 1572414	Insulin and the phorbol ester, phorbol 12-myristate 13-acetate, induce beta-actin gene transcription in H4 cells.
44176	10723	10908	serum insulin	Compound	NFIL3	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
44418	10723	13271	serum insulin	Compound	CCL2	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
44485	10723	 5132	serum insulin	Compound	SRSF5	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
44513	10723	15686	serum insulin	Compound	SRP19	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
  450	10723	14844	serum insulin	Compound	ACTG1	mRNA	-1	-1	12031981	Below are the contents of a table from the paper
45559	10723	 8788	serum insulin	Compound	GPAM	mRNA	0	1	12413942	Glucose and insulin are anabolic signals which upregulate the transcriptions of a series of lipogenic enzymes to convert excess carbohydrate into triglycerides for efficient energy storage. These enzymes include ATP-citrate lyase (ACL), acetyl-coenzyme A carboxylase (ACC), fatty acid synthase (FAS), and glycerol-3-phosphate acyltransferase (G3PA).
45616	10723	10049	serum insulin	Compound	CERK	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
45711	10723	 1590	serum insulin	Compound	RSAD2	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
47593	10723	16816	serum insulin	Compound	PTGFR	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
48164	10723	 5868	serum insulin	Compound	B3GALT2	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
 4828	10723	 2431	serum insulin	Compound	GLO1	mRNA	0	1	10564821	A twofold reproducible increase in reporter activity was seen with insulin and ZnCl(2) treatments, indicating a functionally operative insulin response element (IRE) and metal response element (MRE)
48512	10723	15438	serum insulin	Compound	TMEM27	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
48623	10723	19172	serum insulin	Compound	ACLY	mRNA	0	1	12413942	Glucose and insulin are anabolic signals which upregulate the transcriptions of a series of lipogenic enzymes to convert excess carbohydrate into triglycerides for efficient energy storage. These enzymes include ATP-citrate lyase (ACL), acetyl-coenzyme A carboxylase (ACC), fatty acid synthase (FAS), and glycerol-3-phosphate acyltransferase (G3PA).
48905	10723	 5515	serum insulin	Compound	METTL20	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
49514	10723	10600	serum insulin	Compound	CXCL1	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
49814	10723	 4701	serum insulin	Compound	FBP1	mRNA	0	-1	11742412	Insulin can also influence glucose metabolism indirectly by changes in free fatty acids generated from visceral fat, the so called psingle gatewayp hypothesis64. Because visceral fat is less sensitive to insulin than subcutaneous fat, even after a meal there is little suppression of lipolysis by the hormone in this fat depot. The resulting direct flux of fatty acids derived from these fat cells through the portal vein to the liver can stimulate glucose production, thus providing a signal for both insulin action and insulin resistance in the liver It [insulin] inhibits the transcription of the gene encoding phosphoenolpyruvate carboxylase, the rate-limiting step in gluconeogenesis66. The hormone also decreases transcription of the genes encoding fructose-1,6-bisphosphatase and glucose-6- phosphatase, and increases transcription of glycolytic enzymes such as glucokinase and pyruvate kinase, and lipogenic enzymes such as fatty acid synthase and acetyl-CoA carboxylase.
50045	10723	15807	serum insulin	Compound	HLCS	mRNA	0	1	12413942	Glucose and insulin are anabolic signals which upregulate the transcriptions of a series of lipogenic enzymes to convert excess carbohydrate into triglycerides for efficient energy storage. These enzymes include ATP-citrate lyase (ACL), acetyl-coenzyme A carboxylase (ACC), fatty acid synthase (FAS), and glycerol-3-phosphate acyltransferase (G3PA).
50714	10723	13369	serum insulin	Compound	VEGFB	mRNA	0	1	11571295	injection of insulin and glycated albumin to mice increases VEGF mRNA expression in the eyes insulin and glycated albumin stimulate VEGF mRNA and protein expression in retinal epithelial cells
51901	10723	 9496	serum insulin	Compound	C1orf63	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
51983	10723	 4253	serum insulin	Compound	BYSL	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
52015	10723	18084	serum insulin	Compound	SARS	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
52069	10723	 5566	serum insulin	Compound	TUBB6	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
52731	10723	17478	serum insulin	Compound	ADIPOR2	mRNA	0	-1	15123605	Insulin deficiency induced by streptozotocin increased and insulin replenishment reduced the expression of AdipoR1/R2 in vivo. Thus, the expression of AdipoR1/R2 appears to be inversely correlated with plasma insulin levels in vivo
52826	10723	  556	serum insulin	Compound	IFI16	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
52980	10723	 5718	serum insulin	Compound	APOC3	mRNA	0	-1	15546000	It (Apoc3) is predominantly produced in liver, and its hepatic expression is inhibited by insulin
53299	10723	12033	serum insulin	Compound	ALDH3A2	mRNA	0	1	14638678	By employing RNA arbitrarily primed-PCR to search for novel phosphatidylinositol 3-kinase-regulated genes in response to insulin in isolated rat adipocytes, we identified fatty aldehyde dehydrogenase (FALDH), a key component of the detoxification pathway of aldehydes arising from lipid peroxidation events Upon insulin injection, FALDH mRNA expression increased in rat liver and white adipose tissue
 5370	10723	 1837	serum insulin	Compound	CCDC86	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
54263	10723	 5807	serum insulin	Compound	SIX5	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
54336	10723	 4922	serum insulin	Compound	NAB2	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
54380	10723	  991	serum insulin	Compound	INS	mRNA	0	1	11463381	insulin activates the transcription of its own gene and that of the beta cell glucokinase gene (GCK) by different mechanisms
55192	10723	 9791	serum insulin	Compound	SLIRP	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
55385	10723	12303	serum insulin	Compound	SOCS3	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
55713	10723	15411	serum insulin	Compound	INSIG1	mRNA	0	1	15073165	Insulin-induced gene 1 (INSIG-1)
55864	10723	 5857	serum insulin	Compound	BHLHE40	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
56164	10723	10811	serum insulin	Compound	FN1	mRNA	-1	-1	12031981	Below are the contents of a table from the paper
56591	10723	20113	serum insulin	Compound	CP	mRNA	0	1	12029093	IL-6 increased Cp mRNA expression in HepG2 cells by approximately 5-fold. Simultaneous treatment with insulin reduced this stimulation by half. Surprisingly, insulin by itself caused a 2-4-fold induction in Cp mRNA expression. The role of hypoxia-inducible factor-1 in the induction of Cp by insulin was shown by electrophoretic mobility shift assays and by the absence of insulin-stimulated Cp promoter activation in mouse Hepa c4 cells deficient in hypoxia-inducible factor-1 activity.
57714	10723	15323	serum insulin	Compound	Fbxw17	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
58347	10723	12704	serum insulin	Compound	AMOTL2	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
59653	10723	19255	serum insulin	Compound	EGR2	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
59670	10723	 7590	serum insulin	Compound	GCK	mRNA	0	1	15123649	Insulin selectively increased SREBP-1c and LGK expression in primary hepatocytes. Adenoviral expression of SREBP-1c stimulated LGK expression
59698	10723	 6309	serum insulin	Compound	GPBP1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
59751	10723	13414	serum insulin	Compound	SERPINE1	mRNA	0	1	14515181	insulin, as we have previously shown, directly stimulates PAI-1 production
59981	10723	17787	serum insulin	Compound	AMY2A	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
60316	10723	 7889	serum insulin	Compound	LNPEP	mRNA	0	1	14749039	insulin induces P-LAP expression in trophoblasts
61416	10723	17154	serum insulin	Compound	HMGB2	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
61757	10723	 7962	serum insulin	Compound	RRAD	mRNA	0	1	10194465	Some individuals with type 2 diabetes have been identified with a high expression level of Rad. In cultured myotubes and adipocytes, overexpression of Rad decreases insulin-dependent glucose uptake (101). Rad is also an insulin-regulated gene (102).
61889	10723	 1431	serum insulin	Compound	B3GNT2	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
62025	10723	20054	serum insulin	Compound	MATR3	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
62033	10723	10340	serum insulin	Compound	YIPF5	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
62096	10723	 9318	serum insulin	Compound	SLC7A2	mRNA	0	1	15064952	Insulin induces vasodilatation in human subjects and increases L-arginine transport and NO synthesis in human umbilical vein endothelial cells (HUVEC). Insulin increased L-arginine transport and the mRNA levels for hCAT-1 and hCAT-2B and eNOS expression and activity.
 6218	10723	 5480	serum insulin	Compound	DEK	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
63145	10723	 6968	serum insulin	Compound	PPRC1	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
  634	10723	  156	serum insulin	Compound	SCFD1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
63778	10723	12113	serum insulin	Compound	CCRN4L	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
63886	10723	12543	serum insulin	Compound	IGFBP1	mRNA	-1	-1	15769984	Insulin decreased IGF binding protein-1
63972	10723	 5950	serum insulin	Compound	CCL7	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
64311	10723	 4072	serum insulin	Compound	SNTB2	mRNA	0	1	14530283	TABLE IV Genes that are up-regulated by insulin and demonstrate a blunted response to insulin in IR adipocytes
64380	10723	10877	serum insulin	Compound	PTGES	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
65437	10723	19519	serum insulin	Compound	CPT1A	mRNA	-1	-1	11356173	Both glucagon and 3,3p,5-tri-iodothyronine (T(3)) enhanced the transcription of the gene encoding L-CPT I, whereas insulin had the opposite effect.
65628	10723	 6557	serum insulin	Compound	ALAS1	mRNA	0	-1	11716532	Wortmannin and LY294002, PI3-kinase inhibitors, as well as lovastatin and PD152440, Ras farnesylation inhibitors, and MEK inhibitor PD98059 abolished the insulin repression of ALAS transcription.
65717	10723	 7879	serum insulin	Compound	C12orf45	mRNA	0	1	14530283	TABLE II Genes that are up-regulated by insulin and continue to respond to insulin in IR adipocytes
 6588	10723	 1123	serum insulin	Compound	PIK3C3	mRNA	0	-1	14530283	TABLE III Genes that are down-regulated by insulin and continue to respond to insulin in IR adipocytes
65911	10723	 2631	serum insulin	Compound	PPARGC1A	mRNA	0	-1	11557984	PGC-1 reporter activity was blocked in cells treated with insulin
  670	10723	14336	serum insulin	Compound	PDK2	mRNA	0	-1	11812733	Insulin also decreased the abundance of the PDK2 message
 6806	10723	13125	serum insulin	Compound	CBX3	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
 6953	10723	10139	serum insulin	Compound	FBP2	mRNA	0	-1	11742412	Insulin can also influence glucose metabolism indirectly by changes in free fatty acids generated from visceral fat, the so called psingle gatewayp hypothesis64. Because visceral fat is less sensitive to insulin than subcutaneous fat, even after a meal there is little suppression of lipolysis by the hormone in this fat depot. The resulting direct flux of fatty acids derived from these fat cells through the portal vein to the liver can stimulate glucose production, thus providing a signal for both insulin action and insulin resistance in the liver It [insulin] inhibits the transcription of the gene encoding phosphoenolpyruvate carboxylase, the rate-limiting step in gluconeogenesis66. The hormone also decreases transcription of the genes encoding fructose-1,6-bisphosphatase and glucose-6- phosphatase, and increases transcription of glycolytic enzymes such as glucokinase and pyruvate kinase, and lipogenic enzymes such as fatty acid synthase and acetyl-CoA carboxylase.
   71	10723	 9497	serum insulin	Compound	APOA5	mRNA	0	-1	16891307	Finally, insulin treatment of human HEPG2 cell lines and HepG2 cells caused repression of PGC1alpha and a concomitant down-regulation of ApoCIII, PEPCK, AldoB, and OTC.
 7280	10723	16053	serum insulin	Compound	PKLR	mRNA	-1	1	11742412	Insulin can also influence glucose metabolism indirectly by changes in free fatty acids generated from visceral fat, the so called psingle gatewayp hypothesis64. Because visceral fat is less sensitive to insulin than subcutaneous fat, even after a meal there is little suppression of lipolysis by the hormone in this fat depot. The resulting direct flux of fatty acids derived from these fat cells through the portal vein to the liver can stimulate glucose production, thus providing a signal for both insulin action and insulin resistance in the liver It [insulin] inhibits the transcription of the gene encoding phosphoenolpyruvate carboxylase, the rate-limiting step in gluconeogenesis66. The hormone also decreases transcription of the genes encoding fructose-1,6-bisphosphatase and glucose-6- phosphatase, and increases transcription of glycolytic enzymes such as glucokinase and pyruvate kinase, and lipogenic enzymes such as fatty acid synthase and acetyl-CoA carboxylase.
 7351	10723	16458	serum insulin	Compound	UCP1	mRNA	0	1	12538620	24 h of insulin stimulation induced the expression of both uncoupling protein-1 and CCAAT/enhancer-binding protein alpha (C/EBPalpha) in wild-type brown adipocytes;
 7458	10723	11420	serum insulin	Compound	MIF	mRNA	0	1	11861802	Ariadne: Insulin has been shown to have a potential anti-inflammatory activity, since it inhibits the expression of the proinflammatory adhesion  molecule intercellular adhesion molecule-1 by endothelial cells (Aljad et al., 2000 ) and increases the expression of the mRNA for macrophage migration inhibitory factor (Sakaue et al., 1999 ).
 9048	10723	11644	serum insulin	Compound	IRS1	mRNA	0	1	12133893	Table 1.
10653	19539	 3198	Iloprost	Compound	TFRC	mRNA	-1	1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
11038	19539	 8037	Iloprost	Compound	KLF6	mRNA	1	-1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
11547	19539	 7885	Iloprost	Compound	ISG20	mRNA	1	1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
14052	19539	10458	Iloprost	Compound	MYH11	mRNA	0	1	16399867	We report that the prostacyclin analog iloprost induces differentiation of VSMC from this synthetic, proliferative phenotype to a quiescent, contractile phenotype. Iloprost induced expression of smooth muscle (SM)-specific differentiation markers, including SM-myosin heavy chain, calponin, h-caldesmon, and SM alpha-actin, as determined by Western blotting and RT-PCR analysis.
16346	19539	17741	Iloprost	Compound	RUNX1T1	mRNA	1	-1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
19116	19539	12812	Iloprost	Compound	CALD1	mRNA	0	1	16399867	We report that the prostacyclin analog iloprost induces differentiation of VSMC from this synthetic, proliferative phenotype to a quiescent, contractile phenotype. Iloprost induced expression of smooth muscle (SM)-specific differentiation markers, including SM-myosin heavy chain, calponin, h-caldesmon, and SM alpha-actin, as determined by Western blotting and RT-PCR analysis.
20767	19539	 4461	Iloprost	Compound	ACTA2	mRNA	0	1	16399867	We report that the prostacyclin analog iloprost induces differentiation of VSMC from this synthetic, proliferative phenotype to a quiescent, contractile phenotype. Iloprost induced expression of smooth muscle (SM)-specific differentiation markers, including SM-myosin heavy chain, calponin, h-caldesmon, and SM alpha-actin, as determined by Western blotting and RT-PCR analysis.
23409	19539	 9226	Iloprost	Compound	CITED2	mRNA	1	-1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
32885	19539	11449	Iloprost	Compound	CASP9	mRNA	1	1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
35304	19539	13085	Iloprost	Compound	HMGA2	mRNA	-1	-1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
39948	19539	 6114	Iloprost	Compound	NFKBIA	mRNA	1	1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
45025	19539	 1183	Iloprost	Compound	CNN1	mRNA	0	1	16399867	We report that the prostacyclin analog iloprost induces differentiation of VSMC from this synthetic, proliferative phenotype to a quiescent, contractile phenotype. Iloprost induced expression of smooth muscle (SM)-specific differentiation markers, including SM-myosin heavy chain, calponin, h-caldesmon, and SM alpha-actin, as determined by Western blotting and RT-PCR analysis.
53881	19539	  441	Iloprost	Compound	ATP1B3	mRNA	1	1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
61215	19539	 5969	Iloprost	Compound	GAS1	mRNA	-1	1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
62207	19539	 8131	Iloprost	Compound	RARA	mRNA	0	1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
62956	19539	 7195	Iloprost	Compound	GADD45A	mRNA	-1	-1	14757176	In order to identify new cellular targets of PGI2/cAMP action, we have used microarray screening to examine changes in the transcriptional profile in human vascular SMC in response to exposure to the stable PGI2 mimetic iloprost. We have identified 83 genes with significantly altered expression after iloprost (100 nM) exposure for 6 hr.
13438	12526	 6415	bexarotene	Compound	CCNB2	mRNA	0	-1	17163412	The effect of budesonide on the mRNA expression of caspase 3, cyclin B2, cyclin E1, iNOS and survivin was determined, because targretin, another effective chemopreventive agent, was reported to decrease the expression of the 5 genes in mouse lung tumors.[11]
21919	12526	 3995	bexarotene	Compound	ESR1	mRNA	-1	-1	17849452	Bexarotene decreased the mRNA expression of Caspase-3, Dnmt-3a, EP3, and survivin, as well as the expression of the Cyclin E1, estrogen receptor-alpha, and iNOS genes.
44156	12526	 6531	bexarotene	Compound	CCNE1	mRNA	0	-1	17163412	The effect of budesonide on the mRNA expression of caspase 3, cyclin B2, cyclin E1, iNOS and survivin was determined, because targretin, another effective chemopreventive agent, was reported to decrease the expression of the 5 genes in mouse lung tumors.[11]
45401	12526	 3512	bexarotene	Compound	CASP3	mRNA	0	-1	17163412	The effect of budesonide on the mRNA expression of caspase 3, cyclin B2, cyclin E1, iNOS and survivin was determined, because targretin, another effective chemopreventive agent, was reported to decrease the expression of the 5 genes in mouse lung tumors.[11]
48105	12526	13471	bexarotene	Compound	BIRC5	mRNA	0	-1	17163412	The effect of budesonide on the mRNA expression of caspase 3, cyclin B2, cyclin E1, iNOS and survivin was determined, because targretin, another effective chemopreventive agent, was reported to decrease the expression of the 5 genes in mouse lung tumors.[11]
54050	12526	 5118	bexarotene	Compound	NOS2	mRNA	0	-1	17163412	The effect of budesonide on the mRNA expression of caspase 3, cyclin B2, cyclin E1, iNOS and survivin was determined, because targretin, another effective chemopreventive agent, was reported to decrease the expression of the 5 genes in mouse lung tumors.[11]
12773	 4646	17369	cholesterol	Compound	IL6	mRNA	0	-1	11278795	Table 1 - Effect of sterol depletion on adipocyte gene expression
17232	 4646	15016	cholesterol	Compound	APP	mRNA	0	1	12206998	High cholesterol levels increase APP and apoE expression in human NT2 neuron progenitor cells.
 2219	 4646	 5419	cholesterol	Compound	TNF	mRNA	0	-1	11278795	Table 1 - Effect of sterol depletion on adipocyte gene expression
 2476	 4646	17889	cholesterol	Compound	SLC2A4	mRNA	1	1	11278795	Table 1 - Effect of sterol depletion on adipocyte gene expression
26681	 4646	18713	cholesterol	Compound	SCARB1	mRNA	0	-1	11278795	Table 1 - Effect of sterol depletion on adipocyte gene expression
27867	 4646	 1166	cholesterol	Compound	SLC2A1	mRNA	-1	-1	11278795	Table 1 - Effect of sterol depletion on adipocyte gene expression
28942	 4646	 8443	cholesterol	Compound	STARD5	mRNA	0	1	15760897	StarD5 expression increased 3-fold in free cholesterol-loaded macrophages
35176	 4646	17804	cholesterol	Compound	NOTCH1	mRNA	0	1	12923166	Expression of 38 of the genes assayed was altered by the presence of dietary cholesterol, including 25 genes that were activated and 13 repressed by cholesterol (Table II). Liver RNA from mice fed each of the five diets was hybridized to Affymetrix MU11K oligonucleotide microarrays to assess the relative expression levels of thousands of mouse genes and ESTs. \Cholesterol-activated genes\ were those having at least 2-fold higher levels on all three diets containing cholesterol (Ath, No Cholate, and No Fat diets) than on the two diets lacking cholesterol (Chow and No Cholesterol diets).
40968	 4646	 4582	cholesterol	Compound	NOS3	mRNA	1	1	10400908	These results show that cholesterol treatment increases eNOS expression, whereas ROS treatment decreases eNOS expression and the association of eNOS with caveolin in caveolae-enriched membranes.
46693	 4646	16217	cholesterol	Compound	CYP8B1	mRNA	0	-1	11741989	Cholesterol, on the other hand, down-regulates expression of the 12 alpha-hydroxylase gene
 4746	 4646	 7009	cholesterol	Compound	SREBF1	mRNA	0	1	12364560	cholesterol rich diets induce Srebf1 gene expression and maturation
49369	 4646	18288	cholesterol	Compound	UCP3	mRNA	0	1	11278795	Table 1 - Effect of sterol depletion on adipocyte gene expression
49536	 4646	14497	cholesterol	Compound	AGT	mRNA	0	-1	11278795	Table 1 - Effect of sterol depletion on adipocyte gene expression
49604	 4646	 1390	cholesterol	Compound	ABCD2	mRNA	0	-1	16249184	Cholesterol lowering activates human ABCD2 in cultured cells... a sterol regulatory element (SRE) in the murine Abcd2 promoter that is directly bound by SRE-binding proteins (SREBPs)... Abcd2 is induced by SREBP1c
51682	 4646	  219	cholesterol	Compound	FASLG	mRNA	-1	-1	11714653	In an animal model of atherosclerosis, estradiol restores FasL expression, which is suppressed by atherogenic levels of serum cholesterol.
56108	 4646	 8294	cholesterol	Compound	CAV2	mRNA	0	-1	11278795	Table 1 - Effect of sterol depletion on adipocyte gene expression
56773	 4646	18995	cholesterol	Compound	FASN	mRNA	0	-1	11278795	Table 1 - Effect of sterol depletion on adipocyte gene expression
57363	 4646	10643	cholesterol	Compound	Scd1	mRNA	0	1	12364560	the transcriptional repression by n-3 and n-6 polyunsaturated fatty acids and the induction by cholesterol of the Scd1 gene are dependent on the maturation of Srebp1c
 8135	 4646	12288	cholesterol	Compound	SREBF2	mRNA	0	-1	11278795	We also produced cholesterol depletion by mevastatin treatment, which activates SREBP-2
11070	 2390	11467	Tretinoin	Compound	TFDP1	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
11296	 2390	 4503	Tretinoin	Compound	GBX2	mRNA	0	1	15722554	Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3p member of the Hoxa cluster and a retinoic acid (RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells (named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development (e.g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain (e.g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes (e.g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers (e.g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.
11794	 2390	10947	Tretinoin	Compound	HOXC9	mRNA	0	1	15722554	Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3p member of the Hoxa cluster and a retinoic acid (RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells (named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development (e.g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain (e.g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes (e.g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers (e.g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.
11842	 2390	16365	Tretinoin	Compound	IL1A	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
12058	 2390	 3093	Tretinoin	Compound	RB1	mRNA	0	1	11832495	Genes induced by retinoic acid
12318	 2390	13913	Tretinoin	Compound	GNB1	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
14555	 2390	 1512	Tretinoin	Compound	RARB	mRNA	0	-1	12000752	We show that the mRNA levels of the differentiation-inhibiting basic helix-loop-helix transcription factors ID1, ID2, and ID3 are down-regulated during RA-induced differentiation of SH-SY5Y cells. The levels of ID proteins decreased in parallel to the observed transcriptional repression. The blot was hybridized sequentially with 32P-labeled DNA probes specific for the mRNAs for RARbeta (RARB, 3 kb), c-myc (MYC, 2.5 kb), ID3
16363	 2390	10564	Tretinoin	Compound	ADD3	mRNA	-1	1	14573779	Table 1. List of Genes Up-Regulated in NB4 Cells by ATRA
16459	 2390	 6087	Tretinoin	Compound	ZNF503	mRNA	0	1	14983057	Nolz-1 mRNA was dramatically induced on neural induction of P19 embryonal carcinoma cells by retinoic acid, suggesting that Nolz-1 activation may be involved in neural differentiation
16466	 2390	10390	Tretinoin	Compound	MYH10	mRNA	0	-1	18511453	Here, we show that treatment of VSMCs with ATRA resulted in significant inhibition of proliferation and migration of VSMCs, as well as up-regulation of KLF4 and the VSMC differentiation marker genes SM22alpha and SM alpha-actin (alpha-SMA). At the same time, the KLF4 target gene p53 was up-regulated, while the VSMC dedifferentiation marker gene nonmuscle myosin heavy chain-B (SMemb) was down-regulated.
19610	 2390	 4649	Tretinoin	Compound	MSX2	mRNA	0	-1	12175513	Semi-quantitative reverse transcriptase-polymerase chain reaction verified that the mRNA levels of mouse DN 38, COL VI 3 alpha, cul-1, alpha-tropomyosin, and PP2A-C alpha were substantially increased, whereas mouse Msh 2, Ndufa2, Ribosomal protein S19, sFRP-1, GDAP-10 and mSmcD were significantly decreased in vitamin A deficient (VAD) embryos compared to the control embryos.
19654	 2390	16486	Tretinoin	Compound	SPP1	mRNA	1	1	 1659122	Alkaline phosphatase mRNA was absent in the preosteoblast cell lines but was induced by treatment with 10(-6) M RA, which also increased the steady-state levels of mRNA for osteopontin and BMP1.
20396	 2390	 1252	Tretinoin	Compound	GPRC5B	mRNA	0	1	18000218	Three RA-inducible genes related to GPRC5A, referred to as GPRC5B (RAIG2), GPRC5C (RAIG3), and GPRC5D [in human]
20772	 2390	 4461	Tretinoin	Compound	ACTA2	mRNA	0	1	18511453	Here, we show that treatment of VSMCs with ATRA resulted in significant inhibition of proliferation and migration of VSMCs, as well as up-regulation of KLF4 and the VSMC differentiation marker genes SM22alpha and SM alpha-actin (alpha-SMA). At the same time, the KLF4 target gene p53 was up-regulated, while the VSMC dedifferentiation marker gene nonmuscle myosin heavy chain-B (SMemb) was down-regulated.
21151	 2390	 9088	Tretinoin	Compound	GNB2	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
21285	 2390	10233	Tretinoin	Compound	GSTA4	mRNA	0	1	11832495	Genes induced by retinoic acid
23307	 2390	 7455	Tretinoin	Compound	CTSB	mRNA	0	1	11832495	Genes induced by retinoic acid
24128	 2390	 1209	Tretinoin	Compound	OGN	mRNA	0	1	11832495	Genes induced by retinoic acid
24563	 2390	 2720	Tretinoin	Compound	TAGLN	mRNA	-1	1	18511453	Here, we show that treatment of VSMCs with ATRA resulted in significant inhibition of proliferation and migration of VSMCs, as well as up-regulation of KLF4 and the VSMC differentiation marker genes SM22alpha and SM alpha-actin (alpha-SMA). At the same time, the KLF4 target gene p53 was up-regulated, while the VSMC dedifferentiation marker gene nonmuscle myosin heavy chain-B (SMemb) was down-regulated.
28103	 2390	18341	Tretinoin	Compound	MUC5B	mRNA	0	1	17646388	The depletion of CREB using small interfering RNA abolished not only the RA-induced MUC5AC but also RA-induced MUC2 and MUC5B.
28213	 2390	 1220	Tretinoin	Compound	SFRP1	mRNA	0	-1	12175513	Semi-quantitative reverse transcriptase-polymerase chain reaction verified that the mRNA levels of mouse DN 38, COL VI 3 alpha, cul-1, alpha-tropomyosin, and PP2A-C alpha were substantially increased, whereas mouse Msh 2, Ndufa2, Ribosomal protein S19, sFRP-1, GDAP-10 and mSmcD were significantly decreased in vitamin A deficient (VAD) embryos compared to the control embryos.
 2852	 2390	 7254	Tretinoin	Compound	MAP3K11	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
34469	 2390	 9258	Tretinoin	Compound	CDKN2B	mRNA	0	1	12527889	Moreover, TGF-beta and retinoic acid (RA) cooperatively induce growth inhibition as well as transcription of the p15(ink4b) gene, while PLZF-RARalpha represses TGF-beta-induced expression of the p15(ink4b) gene.
35000	 2390	  463	Tretinoin	Compound	MAP3K1	mRNA	-1	-1	14573779	Table 2. List of Genes Down-Regulated in NB4 Cells by ATRA
35068	 2390	 9217	Tretinoin	Compound	NRIP1	mRNA	0	1	11832495	Genes induced by retinoic acid
36040	 2390	18535	Tretinoin	Compound	KCTD11	mRNA	0	1	12186855	We report here the identification of a novel gene, REN, upregulated by neurogenic signals (retinoic acid, EGF, and NGF) in pluripotent embryonal stem (ES) cells and neural progenitor cell lines in association with neurotypic differentiation.
  361	 2390	 4079	Tretinoin	Compound	PPP2R3A	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
36515	 2390	  950	Tretinoin	Compound	RBL1	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
39221	 2390	 7376	Tretinoin	Compound	TNFSF10	mRNA	-1	1	15241475	retinoid-induced interferon regulatory factor-1 (IRF-1), a tumor suppressor, is critically required for TRAIL induction by both RA and IFNgamma. Exposure of breast cancer cells to both antitumor agents results in enhanced TRAIL promoter occupancy by IRF-1 and coactivator recruitment, leading to strong histone acetylation and synergistic induction of TRAIL expression.
39531	 2390	13230	Tretinoin	Compound	TCF3	mRNA	0	1	15744343	In addition, a strong downregulation of E2A was observed.
39977	 2390	13740	Tretinoin	Compound	BGLAP	mRNA	0	1	10446999	To monitor the ability of ATRA and VD to activate the genetic program underlying monocytic differentiation in the M2 cellular context, we have investigated the expression of VD-responsive genes (Fig. 8) such as HMSE-1, CD14, and hOC by RT-PCR and the expression of genes controlled by a functional VDRE, such as p21waf-1 (51) , or RARE, such as E3 (52) , IRF-1 (53) and p21waf-1 (68) , by Northern blot analysis after different times of ATRA or VD treatment. Fig. 8 shows that both ATRA and VD treatment of Kasumi-1 cells causes a rapid induction of HMSE-1, CD14, and hOC expression, demonstrating VDR involvement in ATRA-dependent monocytic differentiation of M2-type blast cells.
40919	 2390	17113	Tretinoin	Compound	ADCY2	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
41505	 2390	 7075	Tretinoin	Compound	HLA-A	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
42839	 2390	 3879	Tretinoin	Compound	FAS	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
43023	 2390	16897	Tretinoin	Compound	ITGB5	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
43027	 2390	 1749	Tretinoin	Compound	SOX17	mRNA	0	1	15722554	Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3p member of the Hoxa cluster and a retinoic acid (RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells (named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development (e.g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain (e.g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes (e.g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers (e.g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.
44313	 2390	 8760	Tretinoin	Compound	GPRC5C	mRNA	0	1	18000218	Three RA-inducible genes related to GPRC5A, referred to as GPRC5B (RAIG2), GPRC5C (RAIG3), and GPRC5D [in human]
44662	 2390	18702	Tretinoin	Compound	SEPT3	mRNA	0	1	15200239	Human septin 3 was originally cloned during a screening of genes expressed in human teratocarcinoma cells induced to differentiate with retinoic acid Also from Entrez Gene summary - Expression is upregulated by retinoic acid in a human teratocarcinoma cell line
44758	 2390	 4862	Tretinoin	Compound	PDGFA	mRNA	-1	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
45348	 2390	14987	Tretinoin	Compound	BCL2	mRNA	1	-1	14573779	Table 2. List of Genes Down-Regulated in NB4 Cells by ATRA
46325	 2390	14384	Tretinoin	Compound	NR2F2	mRNA	0	1	11168401	Expression of COUP-TFII induced by either retinoic acid or dimethyl sulfoxide in differentiating P19 cells increases NHE expression. The results show that COUP-TF regulates expression of the NHE
46340	 2390	14793	Tretinoin	Compound	CLEC3B	mRNA	0	-1	11699639	We have recently reported that retinoic acid inhibits dexamethasone-induced alkaline phosphatase activity and mineralization in human osteoblastic cell line SV-HFO. In this study, we show that this inhibitory effect on alkaline phosphatase activity depends on the stage of cell differentiation; however, expression of tetranectin, which is a recently reported bone matrix protein, was completely inhibited by treatment with retinoic acid, irrespective of the stage of cell differentiation. Similarly, mineral deposit formation in SV-HFO cells was phase-independently inhibited by retinoic acid. To our knowledge, this is the first report that retinoic acid downregulates the tetranectin expression in human osteoblastic cells independent of the stage of cell differentiation, and is correlated with inhibition of mineralization.
46477	 2390	19036	Tretinoin	Compound	EPHA2	mRNA	0	1	15722554	Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3p member of the Hoxa cluster and a retinoic acid (RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells (named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development (e.g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain (e.g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes (e.g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers (e.g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.
46728	 2390	17712	Tretinoin	Compound	WNT9B	mRNA	0	1	12429992	WNT2, WNT7Band WNT14B are up-regulated
46811	 2390	 9215	Tretinoin	Compound	CMKLR1	mRNA	0	1	15792532	Real-time reverse transcriptase-PCR experiments of cmklr1b expression in all-trans retinoic acid (ATRA)- stimulated BV2 cells showed strong up-regulation of receptor transcript
47010	 2390	17438	Tretinoin	Compound	CD38	mRNA	0	1	10969805	Furthermore, expression of CD38 mRNA mediated through RAR alpha is induced synergistically by treatment with ATRA + GM-CSF.
47830	 2390	10326	Tretinoin	Compound	CCND3	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
48236	 2390	 6910	Tretinoin	Compound	PDE7A	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
49757	 2390	17602	Tretinoin	Compound	WNT3A	mRNA	0	-1	12429992	WNT3A, WNT8A, WNT8B, WNT10B andWNT11 are down-regulated in NT2 cells after ATRA treatment,
50265	 2390	19026	Tretinoin	Compound	TLE2	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
50297	 2390	19526	Tretinoin	Compound	COL4A1	mRNA	0	1	15722554	Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3p member of the Hoxa cluster and a retinoic acid (RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells (named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development (e.g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain (e.g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes (e.g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers (e.g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.
50597	 2390	 6256	Tretinoin	Compound	CLTB	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
51218	 2390	19545	Tretinoin	Compound	PRDM2	mRNA	0	1	11591891	Treatment with retinoic acid induced a selective expression of PRDM2 in HL60 cell line
 5155	 2390	18057	Tretinoin	Compound	HDAC1	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
51852	 2390	 2954	Tretinoin	Compound	GRB10	mRNA	0	1	15722554	Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3p member of the Hoxa cluster and a retinoic acid (RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells (named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development (e.g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain (e.g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes (e.g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers (e.g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.
52159	 2390	19073	Tretinoin	Compound	DAB2	mRNA	0	1	15722554	Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3p member of the Hoxa cluster and a retinoic acid (RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells (named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development (e.g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain (e.g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes (e.g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers (e.g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.
52592	 2390	11506	Tretinoin	Compound	APCDD1	mRNA	0	1	11832495	Genes induced by retinoic acid
52722	 2390	13417	Tretinoin	Compound	WNT7B	mRNA	0	1	12429992	WNT2, WNT7Band WNT14B are up-regulated
53378	 2390	 4185	Tretinoin	Compound	ZNF91	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
54809	 2390	13349	Tretinoin	Compound	MOSC2	mRNA	0	1	11832495	Genes induced by retinoic acid
54951	 2390	 9263	Tretinoin	Compound	PPP2R1A	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
56236	 2390	15199	Tretinoin	Compound	BDNF	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
61092	 2390	10237	Tretinoin	Compound	EGF	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
61212	 2390	 5969	Tretinoin	Compound	GAS1	mRNA	-1	1	15466718	Table 3. Group 2: Genes induced by RA at all times
61834	 2390	 9554	Tretinoin	Compound	PKIA	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
62208	 2390	 8131	Tretinoin	Compound	RARA	mRNA	0	1	12401878	These genes are up - regulated by RA
 6448	 2390	19359	Tretinoin	Compound	GAS6	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
 7718	 2390	13251	Tretinoin	Compound	DVL1	mRNA	0	1	17805463	RA treatment also led to a pronounced decrease of Vangl2 mRNA at 4 and 18 h and a pronounced increase at 66 h after maternal treatment, as detected by reverse transcription-polymerase chain reaction. Western blot analysis showed a marked decrease of Vangl2 protein at 18 and 42 h and a marked increase at 66 and 90 h after maternal treatment. Dishevelled1/2/3 mRNA was significantly down-regulated at 4 and 18 h and up-regulated at 42 h in the fetus after RA treatment
  785	 2390	10012	Tretinoin	Compound	CDK8	mRNA	1	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
  804	 2390	 7467	Tretinoin	Compound	SOS2	mRNA	-1	1	16249480	TABLE 2. Upregulated Gene Expression (80 Genes) in HCjE Cells Treated with RA for 24 and 48 Hours
 9695	 2390	 7296	Tretinoin	Compound	FGFR1	mRNA	0	1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
 9895	 2390	 4650	Tretinoin	Compound	PPP1R1A	mRNA	0	-1	12601020	PURPOSE: To understand the genetic regulatory pathways underlying the retinoic acid (RA) induction of cone arrestin, gene array technology and other molecular tools were used to profile global gene expression changes in human retinoblastoma cells. METHODS: Weri-Rb-1 retinoblastoma cells were cultured in the absence or presence of RA for various periods. DNA microarray analysis profiled gene expression followed by real-time PCR and Northern and immunoblot analyses to confirm the change in expression of selected retinal genes and their gene products. Additional methodology included flow cytometry analysis, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. RESULTS: DNA microarray analysis of approximately 6800 genes revealed RA-induced upregulation of cone-specific genes and downregulation of rod-specific genes in Weri-Rb-1 cells. Other significantly upregulated mRNAs included chicken ovalbumin upstream promoter-transcription factor (COUP-TF1), retinoid X receptor (RXR)-gamma, thyroid hormone receptor (TR)-beta2, and guanylyl cyclase-activating protein (GCAP)-1. Real-time PCR and/or Northern blot analysis confirmed the expression changes of a subset of genes including the upregulation of a pineal- and retina-specific transcription factor, CRX. RA treatment also led to G(0)/G(1) cell cycle arrest and increased both the intensity of human cone arrestin (hCAR)-immunoreactivity and the number of apoptotic cells. The cell-cycle-arrest stage correlated with the observed microarray results in which the RA treatment downregulated critical genes such as cyclins (cyclin E, cyclin D3) and cyclin-dependent kinases (CDK5, CDK10). CONCLUSIONS: These data suggest that RA induces a subpopulation of retinoblastoma cells to differentiate toward a cone cell lineage while selectively leading other cells into apoptosis.
 9950	 2390	11100	Tretinoin	Compound	RNASE1	mRNA	0	1	11832495	Genes induced by retinoic acid
10773	 8153	  289	gemcitabine	Compound	DHCR7	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
13062	 8153	17239	gemcitabine	Compound	PXN	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
13494	 8153	11809	gemcitabine	Compound	RPS6KB1	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
 1358	 8153	19210	gemcitabine	Compound	EBP	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
16494	 8153	18083	gemcitabine	Compound	BNIP3	mRNA	-1	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
17073	 8153	20120	gemcitabine	Compound	PCCB	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
24324	 8153	 2380	gemcitabine	Compound	BAIAP2L2	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
25148	 8153	 7753	gemcitabine	Compound	CREM	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
26709	 8153	11502	gemcitabine	Compound	LMNB1	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
28333	 8153	17166	gemcitabine	Compound	TNNI3	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
31975	 8153	14994	gemcitabine	Compound	IGFBP7	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
34039	 8153	 3482	gemcitabine	Compound	SLC25A1	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
35617	 8153	17544	gemcitabine	Compound	SGCE	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
36337	 8153	 7642	gemcitabine	Compound	CDA	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
42581	 8153	15039	gemcitabine	Compound	P2RX4	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
 4328	 8153	19709	gemcitabine	Compound	RGS2	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
45061	 8153	19944	gemcitabine	Compound	CDC42EP1	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
49027	 8153	12929	gemcitabine	Compound	HLTF	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
51491	 8153	17064	gemcitabine	Compound	TECR	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
53927	 8153	14436	gemcitabine	Compound	RBMS2	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
54244	 8153	 5674	gemcitabine	Compound	SERPINF2	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
54280	 8153	 6594	gemcitabine	Compound	TCN2	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
55257	 8153	12794	gemcitabine	Compound	PAICS	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
 6172	 8153	11473	gemcitabine	Compound	MPDZ	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
66181	 8153	11443	gemcitabine	Compound	DNM1	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
 7300	 8153	11479	gemcitabine	Compound	RDX	mRNA	-1	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
 9511	 8153	10954	gemcitabine	Compound	CHAF1B	mRNA	0	1	15837765	Table 1. Genes relatively overexpressed in gemcitabine-sensitive pancreatic cancer cell lines
13272	18654	18903	FOXD3	Protein	FOXA2	mRNA	0	1	11891324	Modified assertion
13496	18654	10470	FOXD3	Protein	NANOG	mRNA	0	1	16790525	we performed cotransfection of Nanog promoter reporter with FoxD3 expression vector in F9 EC cells. As shown in Fig. 2B , FoxD3 activated Nanog promoter in a dose-dependent fashion in F9 cells (Fig. 2B ). To further confirm this finding, we performed the same experiments in ES cells and NIH3T3 cells. As expected, FoxD3 strongly up-regulated the activity of Nanog in ES cells (Fig. 2C ), but surprisingly, had no effect on the same reporter in nonpluripotent NIH3T3 cells (Fig. 2D ). These findings suggest that FoxD3 may activate Nanog in a pluripotency-specific manner.  FoxD3 was originally identified as a transcription repressor through binding an AT rich cis-element (20) . To map the cis-elements that FoxD3 utilizes to activate Nanog, a series of deletions were made in Nanog promoter and their activities analyzed. As shown in Fig. 2E , FoxD3 strongly activated reporters bearing 554, 676, and 733 deletions but failed to activate a construct deleting sequences upstream of 269, suggesting that there is a FoxD3 binding site between 269 and 544 in Nanog promoter. Indeed, ChiP analysis confirmed the binding of FoxD3 within this region in vivo in F9 cells (Fig. 2F ). A closer examination of the sequences in the 269 and 554 region identified an AT rich element, which is highly homologous to the identified ES specific enhancer (Fig. 2G, H ). This enhancer was shown as a FoxD3 binding site in vitro (20) . To further investigate this AT element, we inserted three copies of this element upstream of a minimal TK promoter driving a luciferase reporter (Fig. 2H ). When coexpressed with FoxD3, we found that this element is indeed regulated by FoxD3, albeit negatively as reported previously (Fig. 2H ; ref 19 ). Given our finding that FoxD3 activates Nanog expression transcriptionally, we suggest that FoxD3 may assume a dual role in regulating downstream genes, either activation or repression, depending on the context of the target promoter. In the case of Nanog, we showed here that FoxD3 is an activator and, thus, may play an important role in sustaining the expression of Nanog in ES cells.
19689	18654	16486	FOXD3	Protein	SPP1	mRNA	1	1	11891324	Cotransfection of Oct-4 and FoxD3 expression vectors bound to and activated the osteopontin enhancer, which is expressed in totipotent embryonic stem cells.
24012	18654	12087	FOXD3	Protein	ZNF175	mRNA	0	-1	19034670	We have cloned the OTK18 promoter region proximal to the transcriptional start site and determined the region responsible (-884/+1) for the basal transcriptional activity in a microglia cell line. Sequential deletion mutation analyses reveal three important response elements: Yingyang-1 (YY1; -805/-777), an HIV-1 response element for promoter activation; FoxD3 (-743/-725), a negative regulatory element; and Ets response element (-725/-707), a basal transcriptional activity response element. HIV-1 infection-induced upregulation of YY1 and c-Ets-1 protein, binding to the promoter region as determined by immunoblotting and chromatin immunoprecipitation and polymerase chain reaction (PCR) assays, and induction of YY1 was also observed in virus-infected monocyte-derived macrophages. Silencing of FoxD3 and YY1 in the cell line by small interfering RNA duplexes specific to these molecules significantly up- and downregulated basal OTK18 promoter activity in FoxD3 and YY1 response element-dependent manners, respectively.
 7132	18654	14713	FOXD3	Protein	FOXA1	mRNA	0	1	11891324	Modified assertion
10588	15855	 6826	NOTCH Family	Protein	NFKB2	mRNA	0	1	14570040	the oncogenic effects of Notch include phosphatidylinositol 3-kinase (PI3K) activation and induction of ERBB2 and NF-?B2 expression. The mechanism by which PI3K is activated by NOTCH1-IC is not known, but the induction of ERBB2 and NF-?B2 - the promoters of which contain CSL-binding sites - is  almost certainly mediated  by the transactivation function of NOTCH1-IC. PI3K signalling confers resistance to anoikis 80,81 and p53-mediated apoptosis 82, whereas ERBB2 stimulates proliferation and growth of cells.
  128	15855	15643	NOTCH Family	Protein	HES7	mRNA	0	1	16023591	Jagged1 on tumor cells binds to Notch receptor(s) on endothelial cells. Upon ligand binding, the Notch intracellular domain (NICD) is released from the endothelial cell plasma membrane by the secretase-dependent proteolytic cleavages of Notch receptor. The NICD then translocates to the nucleus, where it interacts with the CSL (named for mammalian CBF1/RBP, Drosophila Su(H), and C. elegans Lag-1) transcription repressor to activate the transcription of target genes.The basic-helix-loop-helix proteins (bHLH) Hairy/Enhancer of Split (Hes1, -5, and -7) and Hes-related proteins (Hey1, -2, and -L) are the best-characterized downstream targets.
20332	15855	 2815	NOTCH Family	Protein	TP53	mRNA	0	1	14678992	transient transfection of Notch1 ICN decreased expression of cyclin A (3.5-fold), cyclin D1 (2-fold), cyclin E (4.5-fold), CDK2 (2.8-fold), and the phosphorylated form of retinoblastoma protein (3-fold). Up-regulation of p21(waf/cip1) protein expression was observed in SMMC7721-ICN cells stably expressing active Notch1 but not in SMMC7721-GFP cells, which only express GFP. Furthermore, a 12-fold increase in p53 expression and an increase (4.8-fold) in Jun-NH(2)-terminal kinase activation were induced in SMMC7721-ICN cells compared with SMMC7721-GFP cells.
27512	15855	  245	NOTCH Family	Protein	HES5	mRNA	0	1	16023591	Jagged1 on tumor cells binds to Notch receptor(s) on endothelial cells. Upon ligand binding, the Notch intracellular domain (NICD) is released from the endothelial cell plasma membrane by the secretase-dependent proteolytic cleavages of Notch receptor. The NICD then translocates to the nucleus, where it interacts with the CSL (named for mammalian CBF1/RBP, Drosophila Su(H), and C. elegans Lag-1) transcription repressor to activate the transcription of target genes.The basic-helix-loop-helix proteins (bHLH) Hairy/Enhancer of Split (Hes1, -5, and -7) and Hes-related proteins (Hey1, -2, and -L) are the best-characterized downstream targets.
28116	15855	17708	NOTCH Family	Protein	FOSL1	mRNA	0	1	14570040	activated NOTCH1 can decrease AP1 activity via repression of c-FOS expression and a concomitant increase in FRA1, resulting in inhibition of cellular proliferation
 3203	15855	16645	NOTCH Family	Protein	CCND1	mRNA	0	-1	14678992	transient transfection of Notch1 ICN decreased expression of cyclin A (3.5-fold), cyclin D1 (2-fold), cyclin E (4.5-fold), CDK2 (2.8-fold), and the phosphorylated form of retinoblastoma protein (3-fold). Up-regulation of p21(waf/cip1) protein expression was observed in SMMC7721-ICN cells stably expressing active Notch1 but not in SMMC7721-GFP cells, which only express GFP. Furthermore, a 12-fold increase in p53 expression and an increase (4.8-fold) in Jun-NH(2)-terminal kinase activation were induced in SMMC7721-ICN cells compared with SMMC7721-GFP cells.
35011	15855	 7998	NOTCH Family	Protein	ERBB2	mRNA	0	1	14570040	Figure 6  Notch function in cervical cancer. A theoretical model of how the tumour-suppressor properties of NOTCH1 can, in principle, be sidestepped in HPV-infected cervical cancer cells, allowing manifestation of growth-promoting properties of NOTCH1. Apart from HPV E6 and E7 proteins, cervical cancers frequently express increased levels of the phosphatidylinositol 3-kinase (PI3K) subunit p110? and ?Np63 as a result of amplification of the q26-29 locus of chromosome 3. Experiments show that Notch-induced PI3K confers resistance to anoikis in epithelial cells. Whether ERBB2 is induced by NOTCH in cervical cancer remains to be elucidated.
35590	15855	 1857	NOTCH Family	Protein	CCNA1	mRNA	0	-1	14678992	transient transfection of Notch1 ICN decreased expression of cyclin A (3.5-fold), cyclin D1 (2-fold), cyclin E (4.5-fold), CDK2 (2.8-fold), and the phosphorylated form of retinoblastoma protein (3-fold). Up-regulation of p21(waf/cip1) protein expression was observed in SMMC7721-ICN cells stably expressing active Notch1 but not in SMMC7721-GFP cells, which only express GFP. Furthermore, a 12-fold increase in p53 expression and an increase (4.8-fold) in Jun-NH(2)-terminal kinase activation were induced in SMMC7721-ICN cells compared with SMMC7721-GFP cells.
36266	15855	 1611	NOTCH Family	Protein	HEY1	mRNA	0	1	11486044	Indeed, a constitutively active NICD indiscriminately up-regulates expression of both HERP1 and HERP2 mRNAs.
44159	15855	 6531	NOTCH Family	Protein	CCNE1	mRNA	0	-1	14678992	transient transfection of Notch1 ICN decreased expression of cyclin A (3.5-fold), cyclin D1 (2-fold), cyclin E (4.5-fold), CDK2 (2.8-fold), and the phosphorylated form of retinoblastoma protein (3-fold). Up-regulation of p21(waf/cip1) protein expression was observed in SMMC7721-ICN cells stably expressing active Notch1 but not in SMMC7721-GFP cells, which only express GFP. Furthermore, a 12-fold increase in p53 expression and an increase (4.8-fold) in Jun-NH(2)-terminal kinase activation were induced in SMMC7721-ICN cells compared with SMMC7721-GFP cells.
48031	15855	11629	NOTCH Family	Protein	FOS	mRNA	0	-1	14570040	activated NOTCH1 can decrease AP1 activity via repression of c-FOS expression and a concomitant increase in FRA1, resulting in inhibition of cellular proliferation
48527	15855	 2627	NOTCH Family	Protein	CDK2	mRNA	0	-1	14678992	transient transfection of Notch1 ICN decreased expression of cyclin A (3.5-fold), cyclin D1 (2-fold), cyclin E (4.5-fold), CDK2 (2.8-fold), and the phosphorylated form of retinoblastoma protein (3-fold). Up-regulation of p21(waf/cip1) protein expression was observed in SMMC7721-ICN cells stably expressing active Notch1 but not in SMMC7721-GFP cells, which only express GFP. Furthermore, a 12-fold increase in p53 expression and an increase (4.8-fold) in Jun-NH(2)-terminal kinase activation were induced in SMMC7721-ICN cells compared with SMMC7721-GFP cells.
50990	15855	13884	NOTCH Family	Protein	CDKN1A	mRNA	1	1	14678992	transient transfection of Notch1 ICN decreased expression of cyclin A (3.5-fold), cyclin D1 (2-fold), cyclin E (4.5-fold), CDK2 (2.8-fold), and the phosphorylated form of retinoblastoma protein (3-fold). Up-regulation of p21(waf/cip1) protein expression was observed in SMMC7721-ICN cells stably expressing active Notch1 but not in SMMC7721-GFP cells, which only express GFP. Furthermore, a 12-fold increase in p53 expression and an increase (4.8-fold) in Jun-NH(2)-terminal kinase activation were induced in SMMC7721-ICN cells compared with SMMC7721-GFP cells.
58355	15855	 3685	NOTCH Family	Protein	HEYL	mRNA	0	1	16023591	Jagged1 on tumor cells binds to Notch receptor(s) on endothelial cells. Upon ligand binding, the Notch intracellular domain (NICD) is released from the endothelial cell plasma membrane by the secretase-dependent proteolytic cleavages of Notch receptor. The NICD then translocates to the nucleus, where it interacts with the CSL (named for mammalian CBF1/RBP, Drosophila Su(H), and C. elegans Lag-1) transcription repressor to activate the transcription of target genes.The basic-helix-loop-helix proteins (bHLH) Hairy/Enhancer of Split (Hes1, -5, and -7) and Hes-related proteins (Hey1, -2, and -L) are the best-characterized downstream targets.
10022	19910	18909	GATA6	Protein	CYB5A	mRNA	0	1	15831526	In JEG-3 cells, GATA-4 was inactive, GATA-6 augmented -327/Luc activity to 231% over the control, and steroidogenic factor 1 augmented activity to 655% over the control; these activities required the Sp and NF-1 sites.
16060	19910	 1471	GATA6	Protein	COL1A2	mRNA	-1	1	15226419	_ GeneRif: Data show that pro-collagen type I alpha 2 expression is activated through binding of Nkx2.5 and is repressed by the binding of deltaEF1/ZEB1 Furthermore, we show that the expression is activated through the binding of the homeodomain protein Nkx2.5, which is further potentiated in the presence of GATA6. In contrast, this element was repressed by the binding of the zinc-finger protein deltaEF1/ZEB1.
20498	19910	 6218	GATA6	Protein	VCAM1	mRNA	0	1	11397697	The mRNA expression of GATA-6 was increased, whereas GATA-3 mRNA was decreased by TNF-alpha stimulation. Electrophoretic mobility shift assay showed that TNF-alpha stimulation increased the DNA binding of GATA-6 but decreased that of GATA-3. Experiments using protein overexpression or antisense oligonucleotides revealed that GATA-6 potently acts as a positive regulator of VCAM-1 gene transcription.
25030	19910	11217	GATA6	Protein	NPPA	mRNA	0	1	16199874	The Hey basic helix-loop-helix transcription factors are downstream effectors of Notch signaling in the cardiovascular system. Mice lacking Hey2 develop cardiac hypertrophy, often associated with congenital heart defects, whereas combined Hey1/Hey2 deficiency leads to severe vascular defects and embryonic lethality around embryonic day E9.5. The molecular basis of these disorders is poorly understood, however, since target genes of Hey transcription factors in the affected tissues remain elusive. To identify genes regulated by Hey factors we have generated a conditional Hey1 knockout mouse. This strain was used to generate paired Hey2- and Hey1/2-deficient embryonic stem cell lines. Comparison of these cell lines by microarray analysis identified GATA4 and GATA6 as differentially expressed genes. Loss of Hey1/2 leads to elevated GATA4/6 and ANF mRNA levels in embryoid bodies, while forced expression of Hey factors strongly represses expression of the GATA4 and GATA6 promoter in various cell lines. In addition, the promoter activity of the GATA4/6 target gene ANF was inhibited by Hey1, Hey2, and HeyL. Protein interaction and mutation analyses suggest that repression is due to direct binding of Hey proteins to GATA4 and GATA6, blocking their transcriptional activity. In Hey2-deficient fetal hearts we observed elevated mRNA levels of ANF and CARP. Expression of ANF and Hey2 is normally restricted to the trabecular and compact myocardial layer, respectively. Intriguingly, loss of Hey2 leads to ectopic ANF expression in the compact layer, suggesting a direct role for Hey2 in limiting ANF expression in this cardiac compartment.
35230	19910	 5296	GATA6	Protein	PLAU	mRNA	1	-1	15231498	laminar shear stress activated transcription factor GATA6, which binds to a GATA consensus element located between -692 and -687 bp in the uPA promoter, thereby inhibiting uPA gene transcription.
37162	19910	 9198	GATA6	Protein	TFF2	mRNA	0	1	10684977	In MKN45, KATOIII and LS174T, cotransfection with TFF reporter genes and GATA-6 expression vectors revealed that GATA-6 activates TFF1 and TFF2 4-6-fold, without an effect on TFF3.
 4797	19910	19463	GATA6	Protein	ABCA3	mRNA	0	1	17890326	FOXA2, C/EBPalpha, GATA-6, TTF-1, and NFATc3 increased the activity of the Abca3 luciferase construct in a dose-dependent manner.
55161	19910	17653	GATA6	Protein	TFF1	mRNA	0	1	10684977	In MKN45, KATOIII and LS174T, cotransfection with TFF reporter genes and GATA-6 expression vectors revealed that GATA-6 activates TFF1 and TFF2 4-6-fold, without an effect on TFF3.
49698	 7663	 6430	OSR1	Protein	MDM2	mRNA	1	-1	14990790	HES1, HEY1, and TFAP4, which are members of the basic helix-loop-helix transcription family, and OSR1 were shown to activate p53 through repression of HDM2 transcription.
13583	 7687	 1438	raloxifene	Compound	VEGFA	mRNA	0	1	15084346	The maximum level of VEGF mRNA was observed at 1 h after raloxifene and 6 h after tamoxifen or ospemifene treatment. Maximum levels of the c-fos and VEGF mRNA after raloxifene treatment were higher than those seen after treatments with E2 or a corresponding dose of tamoxifen or ospemifene.
14138	 7687	 4864	raloxifene	Compound	HBP1	mRNA	-1	1	16497877	TABLE 1 Genes regulated by raloxifene
19926	 7687	17834	raloxifene	Compound	CCNG2	mRNA	-1	1	16497877	TABLE 1 Genes regulated by raloxifene
22667	 7687	 7012	raloxifene	Compound	DMBT1	mRNA	0	1	15564322	In rats, uterine DMBT1 RNA levels were dramatically up regulated by estrogen. Consistent with the transfection study, tamoxifen and raloxifene increased DMBT1 RNA levels in vivo, but ICI 182,780 inhibited an estrogen-induced increase.
23729	 7687	12255	raloxifene	Compound	SLC3A2	mRNA	0	1	16497877	TABLE 1 Genes regulated by raloxifene
34216	 7687	14474	raloxifene	Compound	ESR2	mRNA	0	1	11810032	Tamoxifen increased ER beta mRNA levels in hypothalamus, while raloxifene increased ER beta mRNA levels in amygdala.
48070	 7687	11629	raloxifene	Compound	FOS	mRNA	0	1	15084346	The maximum level of VEGF mRNA was observed at 1 h after raloxifene and 6 h after tamoxifen or ospemifene treatment. Maximum levels of the c-fos and VEGF mRNA after raloxifene treatment were higher than those seen after treatments with E2 or a corresponding dose of tamoxifen or ospemifene.
51047	 7687	13884	raloxifene	Compound	CDKN1A	mRNA	1	1	16497877	TABLE 1 Genes regulated by raloxifene
55413	 7687	16991	raloxifene	Compound	PPP1R15A	mRNA	1	1	16079270	The pharmacological preservation of bone in the ovariectomized rat by estrogen, selective estrogen receptor modulators (SERMs), and bisphosphonates has been well described. However, comprehensive molecular analysis of the effects of these pharmacologically diverse antiresorptive agents on gene expression in bone has not been performed. This study used DNA microarrays to analyze RNA from the proximal femur metaphysis of sham and ovariectomized vehicle-treated rats, and ovariectomized rats treated for 35 days with maximally efficacious doses of 17-alpha ethinyl estradiol, the benzothiophene SERM, raloxifene, the benzopyran SERM, (S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-be ... nzopyran-7-ol (EM652), and the aminobisphosphonate, alendronate. Ovariectomy resulted in 644 significant probe set changes relative to sham control rats (p 765, 652, and 737 probe sets, respectively, relative to ovariectomized control rats. An intersection of these data sets yielded 334 unique genes that were altered after ovariectomy and additionally changed by one or more antiresorptive treatment. Clustering analysis showed that the transcript profile was distinctly different for each pharmaceutical agent and that raloxifene maintained more genes at sham levels than any other treatment. In addition, E2 and alendronate suppressed a cluster of genes associated with bone formation activity below that of sham, whereas raloxifene had little effect on these genes. These data indicate stronger suppressive effects of E2 and alendronate on bone formation activity and that ovariectomy plus raloxifene resembles sham more closely than ovariectomized animals treated with E2, EM652, or alendronate.
58398	 7687	15117	raloxifene	Compound	PGR	mRNA	0	1	12779079	Modified assertion
11194	 2198	 3959	HRAS	Protein	RAB34	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
11336	 2198	12387	HRAS	Protein	MYB	mRNA	0	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
11519	 2198	 9932	HRAS	Protein	GNAZ	mRNA	-1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
13572	 2198	19840	HRAS	Protein	GNG2	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
13906	 2198	 1706	HRAS	Protein	RAB2A	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
16065	 2198	 1471	HRAS	Protein	COL1A2	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
16325	 2198	 9826	HRAS	Protein	PDCD2	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
16327	 2198	17097	HRAS	Protein	DOK2	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
16360	 2198	10564	HRAS	Protein	ADD3	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
17220	 2198	 7449	HRAS	Protein	SIPA1	mRNA	0	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
17313	 2198	11138	HRAS	Protein	RBBP7	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
17442	 2198	14361	HRAS	Protein	CXCL12	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
17604	 2198	15035	HRAS	Protein	FZD3	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
17824	 2198	18046	HRAS	Protein	RAF1	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
19313	 2198	 1981	HRAS	Protein	ST6GAL1	mRNA	1	1	15355339	Transformation by human K-Ras or H-Ras (S12 and V12 point mutations, respectively) results in a 10-fold increase in ST6Gal I mRNA, but no alteration in the expression of related sialyltransferases.
19704	 2198	16486	HRAS	Protein	SPP1	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
19893	 2198	14849	HRAS	Protein	TGFB2	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
20138	 2198	 7815	HRAS	Protein	GZMB	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
20159	 2198	   35	HRAS	Protein	DUSP9	mRNA	-1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
20605	 2198	12621	HRAS	Protein	ANXA7	mRNA	-1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
21244	 2198	15029	HRAS	Protein	MATN2	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
21365	 2198	 9730	HRAS	Protein	EID1	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
23041	 2198	 5147	HRAS	Protein	NUPR1	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
23306	 2198	 7455	HRAS	Protein	CTSB	mRNA	0	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
23322	 2198	 5854	HRAS	Protein	GIPC1	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
23394	 2198	 9226	HRAS	Protein	CITED2	mRNA	1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
23644	 2198	17594	HRAS	Protein	CCNG1	mRNA	0	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
23675	 2198	 8853	HRAS	Protein	PARD6A	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
24518	 2198	 8958	HRAS	Protein	RAB18	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
24581	 2198	 2720	HRAS	Protein	TAGLN	mRNA	-1	-1	11773051	_ Ariadne: First, we showed that the expression of transgelin is  abolished at the level of transcription by oncogenic Ras in NIH 3T3 mouse  fibroblasts, RIE-1 rat intestinal epithelial cells, and HT1080 human  fibrosarcoma cells. [Expression] _ Ariadne: We further  characterized transgelin as a gene whose expression was abolished by Ras. [Regulation]
 2538	 2198	 3128	HRAS	Protein	FZD1	mRNA	0	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
25479	 2198	14974	HRAS	Protein	GNL1	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
25960	 2198	15317	HRAS	Protein	PGK1	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
26615	 2198	 2240	HRAS	Protein	POU2F1	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
26701	 2198	19098	HRAS	Protein	RAP2B	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
26749	 2198	 5465	HRAS	Protein	CBX4	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
26820	 2198	16947	HRAS	Protein	MAPK8IP2	mRNA	-1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
26844	 2198	17395	HRAS	Protein	RAD21	mRNA	0	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
27218	 2198	  618	HRAS	Protein	WEE1	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
28243	 2198	 7832	HRAS	Protein	THBS1	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
29093	 2198	18125	HRAS	Protein	RGNEF	mRNA	0	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
 3112	 2198	 3901	HRAS	Protein	FOXD3	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
32831	 2198	12649	HRAS	Protein	ETS1	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
32873	 2198	12564	HRAS	Protein	ERF	mRNA	0	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
32884	 2198	11449	HRAS	Protein	CASP9	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
33960	 2198	14949	HRAS	Protein	ERBB3	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
34405	 2198	15589	HRAS	Protein	NFIX	mRNA	0	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
34824	 2198	 6558	HRAS	Protein	RBBP4	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
35003	 2198	  463	HRAS	Protein	MAP3K1	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
35168	 2198	17804	HRAS	Protein	NOTCH1	mRNA	0	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
35243	 2198	 5296	HRAS	Protein	PLAU	mRNA	1	1	10347197	Further, the expression of the catalytically inactive mutants of Ha-Ras, RhoA, c-Raf, and Erk2 or addition of the Mek1-specific inhibitor PD 098059 abrogated the stimulation of the urokinase promoter by HGF/SF.
35303	 2198	13085	HRAS	Protein	HMGA2	mRNA	-1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
35872	 2198	19603	HRAS	Protein	ATF2	mRNA	1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
36741	 2198	 4528	HRAS	Protein	PKM2	mRNA	0	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
37482	 2198	11531	HRAS	Protein	Msx3	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
38730	 2198	18764	HRAS	Protein	AKT1	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
38816	 2198	10290	HRAS	Protein	FOXM1	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
38824	 2198	14027	HRAS	Protein	COL5A1	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
39045	 2198	14766	HRAS	Protein	ROCK2	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
41098	 2198	11896	HRAS	Protein	MCM5	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
41380	 2198	 8370	HRAS	Protein	Nkx2-3	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
41439	 2198	12214	HRAS	Protein	RAB9A	mRNA	0	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
42108	 2198	13115	HRAS	Protein	EGR1	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
42692	 2198	10589	HRAS	Protein	HDAC2	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
42940	 2198	15885	HRAS	Protein	ACTB	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
43612	 2198	 2451	HRAS	Protein	YWHAG	mRNA	-1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
44152	 2198	 6531	HRAS	Protein	CCNE1	mRNA	0	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
44503	 2198	10804	HRAS	Protein	CYCS	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
44507	 2198	 2005	HRAS	Protein	SPTB	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
44765	 2198	 4862	HRAS	Protein	PDGFA	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
  451	 2198	14844	HRAS	Protein	ACTG1	mRNA	-1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
45361	 2198	14987	HRAS	Protein	BCL2	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
45740	 2198	19032	HRAS	Protein	ACTN4	mRNA	1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
45922	 2198	17870	HRAS	Protein	DCC	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
48872	 2198	 5601	HRAS	Protein	DUSP16	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
49171	 2198	19884	HRAS	Protein	RANBP9	mRNA	0	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
49563	 2198	15740	HRAS	Protein	CCNI	mRNA	1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
49695	 2198	 6430	HRAS	Protein	MDM2	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
50190	 2198	 8138	HRAS	Protein	NRP1	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
50425	 2198	17619	HRAS	Protein	SHARPIN	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
 5094	 2198	14376	HRAS	Protein	ERBB4	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
51028	 2198	13884	HRAS	Protein	CDKN1A	mRNA	1	1	10702805	activated V12-H-Ras can induce the p21 promoter through the same region of the p21 promoter by a p53-independent mechanism in NIH3T3 cells E2F1 is required for induction of the p21 promoter by activated Ras
51295	 2198	12868	HRAS	Protein	RAB4B	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
 5136	 2198	 4927	HRAS	Protein	RASA1	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
51426	 2198	 9638	HRAS	Protein	EPHB2	mRNA	1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
52858	 2198	12924	HRAS	Protein	HOXB3	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
 5321	 2198	 8803	HRAS	Protein	Nkx2-9	mRNA	-1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
53636	 2198	 8671	HRAS	Protein	RHOC	mRNA	-1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
53968	 2198	14880	HRAS	Protein	CUX1	mRNA	1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
53977	 2198	11581	HRAS	Protein	ITGB1	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
54275	 2198	  322	HRAS	Protein	GADD45G	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
54314	 2198	13783	HRAS	Protein	LMX1B	mRNA	0	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
54355	 2198	 1814	HRAS	Protein	POU5F1	mRNA	-1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
55245	 2198	12981	HRAS	Protein	COL3A1	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
55354	 2198	 4481	HRAS	Protein	COL5A2	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
55646	 2198	19007	HRAS	Protein	STAT5B	mRNA	0	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
55751	 2198	 4958	HRAS	Protein	ARHGDIG	mRNA	0	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
55787	 2198	 3250	HRAS	Protein	COL4A5	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
56102	 2198	  913	HRAS	Protein	RAB14	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
56155	 2198	10811	HRAS	Protein	FN1	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
58363	 2198	  209	HRAS	Protein	CEBPG	mRNA	0	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
 5904	 2198	 5636	HRAS	Protein	AURKA	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
59519	 2198	 2671	HRAS	Protein	RHOU	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
60964	 2198	 2450	HRAS	Protein	ITGA6	mRNA	-1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
61217	 2198	 5969	HRAS	Protein	GAS1	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
62314	 2198	 2016	HRAS	Protein	ARHGEF1	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
62439	 2198	 1273	HRAS	Protein	FZD9	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
63870	 2198	12543	HRAS	Protein	IGFBP1	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
64227	 2198	17883	HRAS	Protein	RANGAP1	mRNA	1	1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
64268	 2198	12085	HRAS	Protein	MSN	mRNA	0	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
 6470	 2198	12489	HRAS	Protein	ERCC5	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
 6546	 2198	 5374	HRAS	Protein	MXD4	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
66079	 2198	 8334	HRAS	Protein	SLIT2	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
 7299	 2198	11479	HRAS	Protein	RDX	mRNA	-1	-1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
  784	 2198	10012	HRAS	Protein	CDK8	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
 7972	 2198	17931	HRAS	Protein	MAPK6	mRNA	1	1	12730683	Table 2 Summary of genes regulated by H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL [activated forms]
  805	 2198	 7467	HRAS	Protein	SOS2	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
 8934	 2198	 3998	HRAS	Protein	KRAS	mRNA	1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
 9001	 2198	15003	HRAS	Protein	AATK	mRNA	-1	-1	16254190	Table 2. Alteration of Gene Expression Specially Associated with H-ras Status in Skin Tumorigenesis _[JL] constituitively active HRAS
  118	 5728	 8755	CD437	Compound	GDF15	mRNA	0	1	16582595	Several RRMs (CD437, ST1926 and MX3350-1) but not the retinoids all-trans- retinoic acid and 4HPR were able to induce GDF-15 in H460 cells.
13385	 5728	10696	CD437	Compound	JUN	mRNA	0	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
20834	 5728	12908	CD437	Compound	ENO1	mRNA	1	-1	12958071	Table 2.. Gene profiling in NB4 cells treated with ST1926 and CD437
23583	 5728	 4571	CD437	Compound	GADD45B	mRNA	0	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
32018	 5728	 4292	CD437	Compound	DDIT3	mRNA	0	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
42109	 5728	13115	CD437	Compound	EGR1	mRNA	-1	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
45701	 5728	 8412	CD437	Compound	LGALS1	mRNA	0	-1	12958071	Table 2.. Gene profiling in NB4 cells treated with ST1926 and CD437
48021	 5728	11629	CD437	Compound	FOS	mRNA	0	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
 4969	 5728	12073	CD437	Compound	IRF1	mRNA	0	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
51017	 5728	13884	CD437	Compound	CDKN1A	mRNA	1	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
51658	 5728	14103	CD437	Compound	PGAM1	mRNA	1	-1	12958071	Table 2.. Gene profiling in NB4 cells treated with ST1926 and CD437
51825	 5728	 3000	CD437	Compound	ZFP36	mRNA	0	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
51973	 5728	 1178	CD437	Compound	NR4A1	mRNA	0	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
58827	 5728	 9550	CD437	Compound	CDK4	mRNA	1	-1	12958071	Table 2.. Gene profiling in NB4 cells treated with ST1926 and CD437
61255	 5728	 1552	CD437	Compound	ODC1	mRNA	1	-1	12958071	Table 2.. Gene profiling in NB4 cells treated with ST1926 and CD437
62949	 5728	 7195	CD437	Compound	GADD45A	mRNA	-1	1	11550093	Human lung carcinoma H460 cells were treated with AHPN (2.5 muM) or vehicle. After 8 h incubation, poly(A)+ RNA was isolated and used in cDNA-array screening. Egr-1, Nur77, GADD45, MyD118, GAD153, c-jun, c-fos, interferon response factor (IRF)-1, tristetraproline (TTP), and the cdk-inhibitor p21WAF1/Cip1 where among the genes identified by cDNA array screening.
 8309	 5728	10425	CD437	Compound	PNPLA6	mRNA	-1	-1	12958071	Table 2.. Gene profiling in NB4 cells treated with ST1926 and CD437
25726	14472	15592	ETS Family	Protein	VWF	mRNA	0	1	11895773	The GATA and Ets transcription factors were shown to function as activators of transcription, whereas NF1 and Oct1 were shown to repress transcription.
33111	14472	 5703	ETS Family	Protein	ITGA2B	mRNA	0	1	15121870	GATA, Ets, and Sp1 consensus sequences within this region are each necessary and function combinatorially in ERK-activated transcription.
36235	14472	 9322	ETS Family	Protein	FGF1	mRNA	0	1	10849427	These results link signaling pathways previously shown to be associated with cell proliferation (18) and cytoskeletal organization (29, 30) to growth factor gene activation and identify a cis element in FGF1 promoter 1D that can be defined as an SRE. This SRE is comprised of Ets and CArG sites. These sites are targets of regulation by divergent signaling pathways; Ets site target of Ras, Rac1, and Cdc42 regulation; and the CArG site target of de novo protein synthesis-independent cascade.
 5900	14472	 5636	ETS Family	Protein	AURKA	mRNA	1	1	11790771	We conclude that the transcription of aurora A is positively regulated by E4TF1, a ubiquitously expressed ETS family protein, and that the CDE/CHR element was essential for the G(2)/M-specific transcription of aurora A.
14447	10357	13598	MEIS1	Protein	CD14	mRNA	0	-1	11687616	In Hoxa9HF1 cells, Meis1a prevented G-CSF-induced transcriptional up-regulation of the genes encoding gp91phox (subunit of the respiratory burst oxidase), lactoferrin, Egr-1, neutrophil gelatinase B, and the lipopolysaccharide receptor (CD14), each of which is normally activated coincident with neutrophil differentiation (Fig. 1  J)
20697	10357	 4937	MEIS1	Protein	PBX1	mRNA	0	1	10764806	Mercader et al. (1999) described the role of homeobox genes Meis1, Meis2, and Pbx1 (176310) in the development of mouse, chicken, and Drosophila limbs. Mercader et al. (1999) found that Meis1 and Meis2 expression is restricted to the proximal domain, coincident with the previously reported domain in which Pbx1 is localized to the nucleus. Meis1 regulates Pbx1 activity by promoting nuclear import of the Pbx1 protein. Mercader et al. (1999) also demonstrated that ectopic expression of Meis1 in chicken disrupts distal limb development and induces distal-to-proximal transformations. Mercader et al. (1999) concluded that the restriction of Meis1 to proximal regions of the vertebrate limb is essential to specify cell fates and differentiation patterns along the proximodistal axis of the limb.
23682	10357	 3777	MEIS1	Protein	Hbb-y	mRNA	1	1	18375036	Genes were considered to be differentially expressed if they had a difference in expression level between the two conditions that was at least twofold and the extent of difference in expression was statistically significant (p ! 0.05) in a parametric Welsh-analysis of variance t-test. Only genes that showed concordant results in all three replicates were selected for further evaluation. Genes that differed significantly between wild-type Meis1 and the nonleukemogenic Meis1DHD mutant (lacking its DNAbinding domain) were then identified. With this approach 134 genes (70 increased and 64 decreased, Table 1) could be identified as significantly differentially expressed and linked to the oncogenicity of Meis1.
24309	10357	 7440	MEIS1	Protein	PF4	mRNA	0	1	12609849	Platelet factor 4 (PF4) is expressed during megakaryocytic differentiation. We previously reported that GATA-1 and ETS-1 regulate the rat PF4 promoter and transactivate the PF4 gene. For the present study, we investigated the regulatory elements and their transcription factors responsible for the lineage-specific expression of the PF4 gene. The promoter activities of deletion constructs were evaluated, and a novel regulatory element termed TME (tandem repeat of MEIS1 binding element) (-219 to -182) was defined. Binding proteins to TME were strongly detected in HEL nuclear extracts by electrophoresis mobility shift assay (EMSA), and they were purified by DNA affinity chromatography. By performing Western blottings and supershift assays, the binding proteins were identified as homeodomain proteins, MEIS1, PBX1B, and PBX2. These factors are expressed in megakaryocytes differentiated from CD34+ cells in human cord blood. MEIS1 and PBXs bind to the TME as MEIS1/PBX complexes and activate the PF4 promoter. In nonmegakaryocytic HepG2 cells, GATA-1 and ETS-1 activate the PF4 promoter approximately 10-fold. Surprisingly, we found that additional expression of both MEIS1 and PBX2 multiplied this major activation another 2-fold. This activation was not observed when MEIS1 binding sites in the TME were disrupted. Furthermore, inhibition of the binding of endogenous MEIS1/PBX complexes to the TME decreased the promoter activity by almost one half, in megakaryocytic HEL cells. Thus, these studies demonstrate that the homeodomain proteins, MEIS1, PBX1B, and PBX2, play an important role in megakaryocytic gene expression.
 2793	10357	  908	MEIS1	Protein	MMP9	mRNA	0	-1	11687616	In Hoxa9HF1 cells, Meis1a prevented G-CSF-induced transcriptional up-regulation of the genes encoding gp91phox (subunit of the respiratory burst oxidase), lactoferrin, Egr-1, neutrophil gelatinase B, and the lipopolysaccharide receptor (CD14), each of which is normally activated coincident with neutrophil differentiation (Fig. 1  J)
28255	10357	 7832	MEIS1	Protein	THBS1	mRNA	-1	-1	18375036	Genes were considered to be differentially expressed if they had a difference in expression level between the two conditions that was at least twofold and the extent of difference in expression was statistically significant (p ! 0.05) in a parametric Welsh-analysis of variance t-test. Only genes that showed concordant results in all three replicates were selected for further evaluation. Genes that differed significantly between wild-type Meis1 and the nonleukemogenic Meis1DHD mutant (lacking its DNAbinding domain) were then identified. With this approach 134 genes (70 increased and 64 decreased, Table 1) could be identified as significantly differentially expressed and linked to the oncogenicity of Meis1.
35170	10357	17804	MEIS1	Protein	NOTCH1	mRNA	0	-1	18375036	Genes were considered to be differentially expressed if they had a difference in expression level between the two conditions that was at least twofold and the extent of difference in expression was statistically significant (p ! 0.05) in a parametric Welsh-analysis of variance t-test. Only genes that showed concordant results in all three replicates were selected for further evaluation. Genes that differed significantly between wild-type Meis1 and the nonleukemogenic Meis1DHD mutant (lacking its DNAbinding domain) were then identified. With this approach 134 genes (70 increased and 64 decreased, Table 1) could be identified as significantly differentially expressed and linked to the oncogenicity of Meis1.
40243	10357	11058	MEIS1	Protein	LTF	mRNA	0	-1	11687616	In Hoxa9HF1 cells, Meis1a prevented G-CSF-induced transcriptional up-regulation of the genes encoding gp91phox (subunit of the respiratory burst oxidase), lactoferrin, Egr-1, neutrophil gelatinase B, and the lipopolysaccharide receptor (CD14), each of which is normally activated coincident with neutrophil differentiation (Fig. 1  J)
42106	10357	13115	MEIS1	Protein	EGR1	mRNA	-1	-1	11687616	In Hoxa9HF1 cells, Meis1a prevented G-CSF-induced transcriptional up-regulation of the genes encoding gp91phox (subunit of the respiratory burst oxidase), lactoferrin, Egr-1, neutrophil gelatinase B, and the lipopolysaccharide receptor (CD14), each of which is normally activated coincident with neutrophil differentiation (Fig. 1  J)
44725	10357	11405	MEIS1	Protein	Lilrb3	mRNA	0	-1	11687616	In Hoxa9HF1 cells, Meis1a prevented G-CSF-induced transcriptional up-regulation of the genes encoding gp91phox (subunit of the respiratory burst oxidase), lactoferrin, Egr-1, neutrophil gelatinase B, and the lipopolysaccharide receptor (CD14), each of which is normally activated coincident with neutrophil differentiation (Fig. 1  J)
10682	16475	 6335	gefitinib	Compound	PPIG	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
10952	16475	20215	gefitinib	Compound	TFAMP1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
11000	16475	 6564	gefitinib	Compound	SIX6	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
11163	16475	 2754	gefitinib	Compound	TMEM9B	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
11174	16475	12500	gefitinib	Compound	FAF1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
11275	16475	16177	gefitinib	Compound	EMP1	mRNA	0	-1	19996456	Table S2: Transcriptional profiles of GTL16 and DiFi cells treated with PHA or gefitinib.Shown are the intensity values (IV) derived from Illumina microarrays (3 replicates/condition) following rank invariant normalization, fold change computations (LOG2R) and differential score (DS) analyses.
12079	16475	 8353	gefitinib	Compound	KDM4A	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
12262	16475	 8413	gefitinib	Compound	FBN1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
13101	16475	 8237	gefitinib	Compound	NGRN	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
13489	16475	 6426	gefitinib	Compound	SETD1B	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
13495	16475	11809	gefitinib	Compound	RPS6KB1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
13573	16475	 1438	gefitinib	Compound	VEGFA	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
13960	16475	 8106	gefitinib	Compound	NLRC4	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
14645	16475	 5355	gefitinib	Compound	IMP3	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
15505	16475	 2075	gefitinib	Compound	HSD11B2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
16017	16475	15914	gefitinib	Compound	TOP2A	mRNA	0	-1	17638894	The BAM1A cell line was isolated from mammary of a transgenic mouse which overexpresses an active dominant mutant ERBB2/ HER2 and overexpresses ERBB3. These genes are from supplemental table 3 which are those genes changed after Gefitinib (Iressa).
16081	16475	  103	gefitinib	Compound	ARF1	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
16184	16475	12037	gefitinib	Compound	ARL4D	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
16467	16475	 4077	gefitinib	Compound	ALS2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
17071	16475	13027	gefitinib	Compound	PCDHA10	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
17463	16475	14102	gefitinib	Compound	PI3	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
17546	16475	 4769	gefitinib	Compound	LEPROT	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
17558	16475	17756	gefitinib	Compound	RCN1	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
20020	16475	11153	gefitinib	Compound	TK1	mRNA	0	-1	19996456	Table S2: Transcriptional profiles of GTL16 and DiFi cells treated with PHA or gefitinib.Shown are the intensity values (IV) derived from Illumina microarrays (3 replicates/condition) following rank invariant normalization, fold change computations (LOG2R) and differential score (DS) analyses.
20688	16475	 2799	gefitinib	Compound	TM9SF3	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
20714	16475	 4803	gefitinib	Compound	EIF2AK2	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
20753	16475	10469	gefitinib	Compound	ATP6AP2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
20836	16475	12908	gefitinib	Compound	ENO1	mRNA	1	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
20857	16475	 6849	gefitinib	Compound	HDAC7	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
21372	16475	13892	gefitinib	Compound	CTSD	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
21658	16475	 5114	gefitinib	Compound	CRLS1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 2175	16475	 4234	gefitinib	Compound	ZFP37	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
21839	16475	 7428	gefitinib	Compound	DHFR	mRNA	0	-1	17638894	The BAM1A cell line was isolated from mammary of a transgenic mouse which overexpresses an active dominant mutant ERBB2/ HER2 and overexpresses ERBB3. These genes are from supplemental table 3 which are those genes changed after Gefitinib (Iressa).
22321	16475	14160	gefitinib	Compound	LAPTM4A	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
22847	16475	12245	gefitinib	Compound	APOC2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
22916	16475	 2892	gefitinib	Compound	C9orf16	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
23045	16475	  493	gefitinib	Compound	DNAH8	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
23516	16475	11010	gefitinib	Compound	TRPC4AP	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
23578	16475	 4571	gefitinib	Compound	GADD45B	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
23970	16475	 3958	gefitinib	Compound	MOB1B	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
  242	16475	20187	gefitinib	Compound	RPA4	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
24238	16475	 9468	gefitinib	Compound	ZAP70	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
24551	16475	 9992	gefitinib	Compound	MTTP	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
25261	16475	 4907	gefitinib	Compound	NPM1	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
25547	16475	 8993	gefitinib	Compound	EREG	mRNA	0	-1	19138957	To examine whether EREG expression was EGFR dependent, HCC827 cells were treated with gefitinib, an EGFR tyrosine kinase inhibitor. Gefitinib sharply reduced EREG mRNA levels (Fig. 2B).
 2594	16475	 4897	gefitinib	Compound	TNFAIP1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
26093	16475	 1343	gefitinib	Compound	BCL3	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
26734	16475	 2261	gefitinib	Compound	RPS20	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
26803	16475	15826	gefitinib	Compound	TUBB	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 2702	16475	12731	gefitinib	Compound	UBQLN1	mRNA	1	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
27396	16475	17529	gefitinib	Compound	XBP1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
27480	16475	 5345	gefitinib	Compound	ENG	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
28907	16475	14639	gefitinib	Compound	CAMK2D	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
29529	16475	10272	gefitinib	Compound	SLC43A1	mRNA	1	-1	19996456	Table S2: Transcriptional profiles of GTL16 and DiFi cells treated with PHA or gefitinib.Shown are the intensity values (IV) derived from Illumina microarrays (3 replicates/condition) following rank invariant normalization, fold change computations (LOG2R) and differential score (DS) analyses.
29777	16475	16604	gefitinib	Compound	TYMS	mRNA	0	-1	19529774	From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells (SNU216 gastric cancer cell line). Figure 2. Lapatinib downregulates fluoropyrimidine-target genes. The expressions of representative nucleotide synthesis-related genes [E2F-1, TS, TK1 (thymidine kinase 1), DHFR(dihydrofolate reductase), RRM2 (ribonucleotide reductase M2 polypeptide), DUT (DUTP pyrophosphatase), NME1 (nuclear diphosphate kinase 1)] were reduced as the result of gefitinib or lapatinib treatment in TKI-sensitive cells.
29825	16475	  252	gefitinib	Compound	BCL2L11	mRNA	0	1	17973573	Gefitinib caused a rapid increase in the level of the proapoptotic BH3-only protein BIM (also called BCL2-like 11) through both transcriptional and post-translational mechanisms.
30004	16475	16451	gefitinib	Compound	PDE3B	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
30056	16475	19484	gefitinib	Compound	TBCE	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
33546	16475	16948	gefitinib	Compound	CAMKK1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
34950	16475	 6261	gefitinib	Compound	IL1RN	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
35004	16475	14718	gefitinib	Compound	NKAPL	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
35256	16475	 4038	gefitinib	Compound	PAH	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
35308	16475	15605	gefitinib	Compound	E2F1	mRNA	0	-1	19529774	From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells (SNU216 gastric cancer cell line). Figure 2. Lapatinib downregulates fluoropyrimidine-target genes. The expressions of representative nucleotide synthesis-related genes [E2F-1, TS, TK1 (thymidine kinase 1), DHFR(dihydrofolate reductase), RRM2 (ribonucleotide reductase M2 polypeptide), DUT (DUTP pyrophosphatase), NME1 (nuclear diphosphate kinase 1)] were reduced as the result of gefitinib or lapatinib treatment in TKI-sensitive cells.
36607	16475	 5448	gefitinib	Compound	MED17	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
37292	16475	19646	gefitinib	Compound	ANXA8L2	mRNA	1	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
37389	16475	 9189	gefitinib	Compound	MMP2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
37983	16475	10890	gefitinib	Compound	NFE2L1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
38245	16475	15340	gefitinib	Compound	TMEM50B	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
38732	16475	18764	gefitinib	Compound	AKT1	mRNA	1	-1	17908981	Table 4.  Increases (>2.0) and decreases (<0.5) in gene expression following exposure to gefitinib (500 mg/d)
38745	16475	 8342	gefitinib	Compound	HSF2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
   39	16475	11396	gefitinib	Compound	CCNA2	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
39142	16475	12551	gefitinib	Compound	MED16	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
39218	16475	 7376	gefitinib	Compound	TNFSF10	mRNA	-1	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
39309	16475	13799	gefitinib	Compound	SMARCA5	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
39474	16475	14512	gefitinib	Compound	KRT19	mRNA	0	1	19996456	Table S2: Transcriptional profiles of GTL16 and DiFi cells treated with PHA or gefitinib.Shown are the intensity values (IV) derived from Illumina microarrays (3 replicates/condition) following rank invariant normalization, fold change computations (LOG2R) and differential score (DS) analyses.
39486	16475	15804	gefitinib	Compound	COL4A3BP	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
40064	16475	 4781	gefitinib	Compound	ARX	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
40098	16475	10705	gefitinib	Compound	MRVI1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
40304	16475	20181	gefitinib	Compound	ZNF529	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
40646	16475	11291	gefitinib	Compound	NXPH1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
41093	16475	11896	gefitinib	Compound	MCM5	mRNA	1	-1	19996456	Table S2: Transcriptional profiles of GTL16 and DiFi cells treated with PHA or gefitinib.Shown are the intensity values (IV) derived from Illumina microarrays (3 replicates/condition) following rank invariant normalization, fold change computations (LOG2R) and differential score (DS) analyses.
41264	16475	  449	gefitinib	Compound	CCS	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
42435	16475	 5089	gefitinib	Compound	C20orf4	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
42648	16475	 5382	gefitinib	Compound	OAT	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
42691	16475	10589	gefitinib	Compound	HDAC2	mRNA	-1	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
43024	16475	16897	gefitinib	Compound	ITGB5	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
43094	16475	 9701	gefitinib	Compound	CA5BP1	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
43126	16475	 7087	gefitinib	Compound	ZADH2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
43457	16475	 5666	gefitinib	Compound	PAPOLA	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
43836	16475	 7420	gefitinib	Compound	RGP1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
44025	16475	 8584	gefitinib	Compound	RGS4	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
44119	16475	 6801	gefitinib	Compound	ATG4B	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
44774	16475	 4862	gefitinib	Compound	PDGFA	mRNA	-1	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
44966	16475	17206	gefitinib	Compound	VBP1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
44992	16475	  775	gefitinib	Compound	MYO6	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
45042	16475	 7291	gefitinib	Compound	HLA-DOA	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
45076	16475	18755	gefitinib	Compound	TOP1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
45122	16475	 3424	gefitinib	Compound	PHLDA2	mRNA	0	-1	19996456	Table S2: Transcriptional profiles of GTL16 and DiFi cells treated with PHA or gefitinib.Shown are the intensity values (IV) derived from Illumina microarrays (3 replicates/condition) following rank invariant normalization, fold change computations (LOG2R) and differential score (DS) analyses.
45142	16475	 4880	gefitinib	Compound	VPS33B	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
45206	16475	18181	gefitinib	Compound	TUSC3	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
45563	16475	17588	gefitinib	Compound	PPIF	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 4622	16475	12438	gefitinib	Compound	TM2D3	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
46986	16475	 8580	gefitinib	Compound	TRAPPC8	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
47587	16475	 9766	gefitinib	Compound	MAPK8IP3	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
47617	16475	11030	gefitinib	Compound	CDK5R1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
49055	16475	20128	gefitinib	Compound	EPB41L4A	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
49057	16475	 9568	gefitinib	Compound	LARP4	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
49180	16475	13393	gefitinib	Compound	SHMT2	mRNA	0	-1	19996456	Table S2: Transcriptional profiles of GTL16 and DiFi cells treated with PHA or gefitinib.Shown are the intensity values (IV) derived from Illumina microarrays (3 replicates/condition) following rank invariant normalization, fold change computations (LOG2R) and differential score (DS) analyses.
 4940	16475	10424	gefitinib	Compound	JAG1	mRNA	0	-1	19996456	Table S2: Transcriptional profiles of GTL16 and DiFi cells treated with PHA or gefitinib.Shown are the intensity values (IV) derived from Illumina microarrays (3 replicates/condition) following rank invariant normalization, fold change computations (LOG2R) and differential score (DS) analyses.
49919	16475	10207	gefitinib	Compound	PKIB	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 5025	16475	11084	gefitinib	Compound	SCP2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
50309	16475	19526	gefitinib	Compound	COL4A1	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 5035	16475	11796	gefitinib	Compound	CPEB4	mRNA	-1	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 5043	16475	18002	gefitinib	Compound	PGM1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 5095	16475	14492	gefitinib	Compound	PCDHB5	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
51418	16475	  501	gefitinib	Compound	BCAT2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
51647	16475	  185	gefitinib	Compound	YKT6	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
51890	16475	19719	gefitinib	Compound	PBX2	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
51982	16475	 4253	gefitinib	Compound	BYSL	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
52158	16475	19073	gefitinib	Compound	DAB2	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 5250	16475	 5378	gefitinib	Compound	NME1	mRNA	0	-1	19529774	From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells (SNU216 gastric cancer cell line). Figure 2. Lapatinib downregulates fluoropyrimidine-target genes. The expressions of representative nucleotide synthesis-related genes [E2F-1, TS, TK1 (thymidine kinase 1), DHFR(dihydrofolate reductase), RRM2 (ribonucleotide reductase M2 polypeptide), DUT (DUTP pyrophosphatase), NME1 (nuclear diphosphate kinase 1)] were reduced as the result of gefitinib or lapatinib treatment in TKI-sensitive cells.
52881	16475	19485	gefitinib	Compound	CAPZA1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 5298	16475	  568	gefitinib	Compound	PSMC6	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
53567	16475	13775	gefitinib	Compound	HOXC10	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
54250	16475	 1312	gefitinib	Compound	KRT16	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
54352	16475	 1814	gefitinib	Compound	POU5F1	mRNA	-1	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
54538	16475	10710	gefitinib	Compound	MAPK9	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
54580	16475	14051	gefitinib	Compound	LTBP2	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
54641	16475	10480	gefitinib	Compound	LAMTOR1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
54895	16475	 2857	gefitinib	Compound	IKZF1	mRNA	0	-1	17638894	The BAM1A cell line was isolated from mammary of a transgenic mouse which overexpresses an active dominant mutant ERBB2/ HER2 and overexpresses ERBB3. These genes are from supplemental table 3 which are those genes changed after Gefitinib (Iressa).
55018	16475	 2179	gefitinib	Compound	AIG1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
55303	16475	10996	gefitinib	Compound	LEMD3	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
55584	16475	16323	gefitinib	Compound	BSG	mRNA	0	-1	14633669	The induction of EMMPRIN by AR was mediated by epidermal growth factor receptor (EGFR) tyrosine kinase activation and inhibited by ZD1839.
55842	16475	 3559	gefitinib	Compound	PNPLA2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
56176	16475	17528	gefitinib	Compound	HOPX	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
56349	16475	19283	gefitinib	Compound	GIMAP6	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
56601	16475	 5128	gefitinib	Compound	HOXD8	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 5704	16475	19701	gefitinib	Compound	PSMA4	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
57866	16475	 8535	gefitinib	Compound	TSSC1	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
58450	16475	 5816	gefitinib	Compound	STEAP2	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
58547	16475	 5851	gefitinib	Compound	ARF5	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
58549	16475	14765	gefitinib	Compound	C3orf39	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
58574	16475	 5626	gefitinib	Compound	CLDN1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
58604	16475	 5691	gefitinib	Compound	SNAPC5	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
58857	16475	 6524	gefitinib	Compound	EIF4A2	mRNA	0	1	17638894	The BAM1A cell line was isolated from mammary of a transgenic mouse which overexpresses an active dominant mutant ERBB2/ HER2 and overexpresses ERBB3. These genes are from supplemental table 3 which are those genes changed after Gefitinib (Iressa).
58991	16475	   37	gefitinib	Compound	HADHB	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
59295	16475	13313	gefitinib	Compound	BST2	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
59419	16475	 4082	gefitinib	Compound	PPT1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
59744	16475	13414	gefitinib	Compound	SERPINE1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
59903	16475	 8001	gefitinib	Compound	RAB10	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
60178	16475	10658	gefitinib	Compound	CCNC	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
60435	16475	 5024	gefitinib	Compound	CCL5	mRNA	0	1	16835747	normal T-cell expressed and secreted (RANTES) were elevated after gefitinib treatment.
60450	16475	15749	gefitinib	Compound	TBL2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
60565	16475	14758	gefitinib	Compound	SLC24A3	mRNA	0	1	19996456	Table S2: Transcriptional profiles of GTL16 and DiFi cells treated with PHA or gefitinib.Shown are the intensity values (IV) derived from Illumina microarrays (3 replicates/condition) following rank invariant normalization, fold change computations (LOG2R) and differential score (DS) analyses.
60966	16475	 2450	gefitinib	Compound	ITGA6	mRNA	-1	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 6113	16475	16922	gefitinib	Compound	RRM2	mRNA	0	-1	17638894	The BAM1A cell line was isolated from mammary of a transgenic mouse which overexpresses an active dominant mutant ERBB2/ HER2 and overexpresses ERBB3. These genes are from supplemental table 3 which are those genes changed after Gefitinib (Iressa).
61279	16475	17871	gefitinib	Compound	LRP6	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
62001	16475	11918	gefitinib	Compound	PSMD8	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
62028	16475	20054	gefitinib	Compound	MATR3	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
62190	16475	 3757	gefitinib	Compound	AGXT2L1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
62615	16475	 4925	gefitinib	Compound	IGFBP3	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
62656	16475	 2746	gefitinib	Compound	PRKRIR	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
63256	16475	 4411	gefitinib	Compound	VAPA	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
63620	16475	 5821	gefitinib	Compound	TP53INP2	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
63775	16475	13589	gefitinib	Compound	LRRC2	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
64263	16475	 2982	gefitinib	Compound	FUCA1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 6922	16475	 6366	gefitinib	Compound	MAP3K10	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 7048	16475	 6241	gefitinib	Compound	DCAF13	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 7091	16475	 7694	gefitinib	Compound	TEK	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 7137	16475	14713	gefitinib	Compound	FOXA1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 7182	16475	13397	gefitinib	Compound	PTPN6	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 7365	16475	13637	gefitinib	Compound	LYPLA1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 7584	16475	 3863	gefitinib	Compound	ZBED5	mRNA	0	-1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 7930	16475	 2367	gefitinib	Compound	PCDHA12	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 7953	16475	 9734	gefitinib	Compound	ID4	mRNA	0	1	17638894	The BAM1A cell line was isolated from mammary of a transgenic mouse which overexpresses an active dominant mutant ERBB2/ HER2 and overexpresses ERBB3. These genes are from supplemental table 3 which are those genes changed after Gefitinib (Iressa).
 7970	16475	15068	gefitinib	Compound	FNDC3A	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
  879	16475	 8414	gefitinib	Compound	CCAR1	mRNA	0	1	16543231	reatments of cells with ERRP or Iressa (an EGFR tyrosine kinase inhibitor) results in elevated CARP-1 levels, whereas antisense-dependent depletion of CARP-1 causes inhibition of apoptosis by ERRP.
 8844	16475	19611	gefitinib	Compound	SKI	mRNA	0	1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 9488	16475	16113	gefitinib	Compound	CHMP3	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 9560	16475	13478	gefitinib	Compound	CCNH	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
 9658	16475	17696	gefitinib	Compound	FRAS1	mRNA	0	1	12792773	To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839.
 9822	16475	13075	gefitinib	Compound	PRIM1	mRNA	0	-1	15475436	See table 6: Genes regulated by gefitinib or cetuximab in A431 cells and with fold change of at least 1.5.
13615	 6216	 1438	Sirolimus	Compound	VEGFA	mRNA	0	-1	15059936	p70S6K inhibitor rapamycin (RAPA) targets mesenchymal cells to shut down the sustained expression of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), via silencing of the PDGFRalpha-p70S6K pathway
17304	 6216	16992	Sirolimus	Compound	SCD	mRNA	0	-1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.;MCF-7 breast cancer cell line, RPS6KB1-suppressed
19911	 6216	 8943	Sirolimus	Compound	IFI44L	mRNA	0	-1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.;MCF-7 breast cancer cell line, RPS6KB1-suppressed
19916	 6216	17834	Sirolimus	Compound	CCNG2	mRNA	-1	1	19816606	Table S1 - Genes that show differential expression in response to rapamycin in WB-F344 (non-tumorigenic rat liver epithelial cell line)
  206	 6216	16874	Sirolimus	Compound	PIK3R1	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
21325	 6216	12944	Sirolimus	Compound	OASL	mRNA	0	-1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.;MCF-7 breast cancer cell line, RPS6KB1-suppressed
23915	 6216	 5783	Sirolimus	Compound	CEBPB	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
27869	 6216	 1166	Sirolimus	Compound	SLC2A1	mRNA	-1	-1	12588811	mRNA levels of GLUT4, the insulin-responsive glucose transporter, are not altered in mice devoid of 4E-BP1-deficient mice (12). rapamycin abrogates insulin-mediated increase in GLUT1 protein in 3T3-L1 adipocytes through partial inhibition of GLUT1 mRNA translation, whereas chronic insulin treatment decreases GLUT-4 protein levels because of a decrease in mRNA and decrease in protein half-life (95).
32872	 6216	12564	Sirolimus	Compound	ERF	mRNA	0	1	11943782	Rapamycin has been shown to affect translation. We have utilized two complementary approaches to identify genes that are predominantly affected by rapamycin in Jurkat T cells. One was to compare levels of polysome-bound and total RNA using oligonucleotide microarrays complementary to 6,300 human genes. Another was to determine protein synthesis levels using two-dimensional PAGE. Analysis of expression changes at the polysome-bound RNA levels showed that translation of most of the expressed genes was partially reduced following rapamycin treatment. However, translation of 136 genes (6% of the expressed genes) was totally inhibited. This group included genes encoding RNA-binding proteins and several proteasome subunit members. Translation of a set of 159 genes (7%) was largely unaffected by rapamycin treatment. These genes included transcription factors, kinases, phosphatases, and members of the RAS superfamily. Analysis of [(35)S]methionine-labeled proteins from the same cell populations using two-dimensional PAGE showed that the integrated intensity of 111 of 830 protein spots changed in rapamycin-treated cells by at least 3-fold (70 increased, 41 decreased). We identified 22 affected protein spots representing protein products of 16 genes. The combined microarray and proteomic approach has uncovered novel genes affected by rapamycin that may be involved in its immunosuppressive effect and other genes that are not affected at the level of translation in a context of general inhibition of cap-dependent translation.
34468	 6216	 9258	Sirolimus	Compound	CDKN2B	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
44264	 6216	 2405	Sirolimus	Compound	PANK1	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
48281	 6216	 7237	Sirolimus	Compound	INSR	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
51077	 6216	13884	Sirolimus	Compound	CDKN1A	mRNA	1	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
53300	 6216	12033	Sirolimus	Compound	ALDH3A2	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
 5854	 6216	 3510	Sirolimus	Compound	TRIM32	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
 5949	 6216	 1713	Sirolimus	Compound	MYOG	mRNA	0	-1	11861503	Transient reporter assays showed that both inhibitors repress muscle creatine kinase (MCK) and myogenin gene transcription.
 6011	 6216	18706	Sirolimus	Compound	TSC1	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
61547	 6216	 6777	Sirolimus	Compound	XDH	mRNA	0	1	18678646	XDH, TSC1, and INSR are three examples of a larger subset of genes whose regulation by mTOR is p73 dependent at the transcriptional level. An increase in all three genes after treatment with rapamycin in the absence of serum is abrogated by p73 knockdown,
61749	 6216	 7962	Sirolimus	Compound	RRAD	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
63917	 6216	12841	Sirolimus	Compound	CKM	mRNA	0	-1	11861503	Transient reporter assays showed that both inhibitors repress muscle creatine kinase (MCK) and myogenin gene transcription.
 7742	 6216	17459	Sirolimus	Compound	EVC	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
 8335	 6216	 6202	Sirolimus	Compound	BTG1	mRNA	-1	1	11943782	Rapamycin has been shown to affect translation. We have utilized two complementary approaches to identify genes that are predominantly affected by rapamycin in Jurkat T cells. One was to compare levels of polysome-bound and total RNA using oligonucleotide microarrays complementary to 6,300 human genes. Another was to determine protein synthesis levels using two-dimensional PAGE. Analysis of expression changes at the polysome-bound RNA levels showed that translation of most of the expressed genes was partially reduced following rapamycin treatment. However, translation of 136 genes (6% of the expressed genes) was totally inhibited. This group included genes encoding RNA-binding proteins and several proteasome subunit members. Translation of a set of 159 genes (7%) was largely unaffected by rapamycin treatment. These genes included transcription factors, kinases, phosphatases, and members of the RAS superfamily. Analysis of [(35)S]methionine-labeled proteins from the same cell populations using two-dimensional PAGE showed that the integrated intensity of 111 of 830 protein spots changed in rapamycin-treated cells by at least 3-fold (70 increased, 41 decreased). We identified 22 affected protein spots representing protein products of 16 genes. The combined microarray and proteomic approach has uncovered novel genes affected by rapamycin that may be involved in its immunosuppressive effect and other genes that are not affected at the level of translation in a context of general inhibition of cap-dependent translation.
  862	 6216	  759	Sirolimus	Compound	ST3GAL6	mRNA	-1	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
 8763	 6216	19346	Sirolimus	Compound	CREB3	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
 8859	 6216	11977	Sirolimus	Compound	HGF	mRNA	0	-1	15059936	p70S6K inhibitor rapamycin (RAPA) targets mesenchymal cells to shut down the sustained expression of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), via silencing of the PDGFRalpha-p70S6K pathway
 8978	 6216	16272	Sirolimus	Compound	NUAK2	mRNA	0	1	18678646	We found that 12 out of the 17 candidate target genes identified using our ad hoc selection method exhibited an increase in expression after treatment with rapamycin that was abrogated by depletion of p73 (Fig. 7C).
11801	  479	18802	GH1	Protein	NEUROG1	mRNA	0	-1	12368809	We also report that growth hormone inhibited Ngn1 expression and neuronal production, and this action was blocked by SOCS2 overexpression
13276	  479	18903	GH1	Protein	FOXA2	mRNA	0	1	12865419	Foxa-2 and Pref-1 expression can be enhanced in primary preadipocytes by growth hormone
13534	  479	 3789	GH1	Protein	IGF1	mRNA	0	1	15964559	Northern and Western blot analysis detected significantly higher levels of IGF-1 in cells overexpressing GH.
27881	  479	 1166	GH1	Protein	SLC2A1	mRNA	-1	-1	 2254335	3T3-F442A cells were treated with growth hormone for 24 hours substantially decreased the levels of Glut-1 mRNA.
38813	  479	10290	GH1	Protein	FOXM1	mRNA	1	1	14647066	GH treatment also was found to stimulate hepatocyte proliferation and expression of Foxm1b protein without partial hepatectomy (PHx)
39367	  479	18612	GH1	Protein	SOD2	mRNA	-1	-1	11815672	A 41% and 27% decrease in catalase activity was detected in cells treated with GH, whereas IGF-1 reduced CAT activity levels to a greater extent than GH (P < 0.0001). The activity and protein levels of GPX were also significantly depressed in cells treated with GH, whereas activity alone was decreased in cells treated with IGF-1 (P < 0.04). GH significantly suppressed MnSOD levels by 40% and 66% in 1.0 and 0.1 microg/ml concentrations, respectively. Similarly, IGF-1 decreased MnSOD protein levels
42093	  479	13115	GH1	Protein	EGR1	mRNA	-1	1	 9813041	Growth hormone promotes the expression of Egr.
45793	  479	 4835	GH1	Protein	PPARA	mRNA	0	-1	12127257	Previous in vitro studies have shown that growth hormone (GH) can inhibit PPARalpha-dependent gene expression by down-regulation of PPARalpha expression and by a novel inhibitory cross-talk involving the GH-activated transcription factor STAT5b. ...A corresponding increase in mRNA, was observed in the STAT5b-deficient mice, suggesting a transcriptional mechanism for the observed increases.
48084	  479	11629	GH1	Protein	FOS	mRNA	0	1	10531366	In 3T3-F442A fibroblasts stably expressing the c-fos promoter mutated at the C/EBP binding site upstream of luciferase, c-fos promoter activity is stimulated by GH 6-7-fold; wild type c-fos promoter shows only a 2-fold induction by GH.
51281	  479	 2430	GH1	Protein	Mup2	mRNA	0	1	14759523	The expression of MUP2 is known to be stimulated by growth hormone (GH), through the GH receptor (GHR), Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5 (STAT5) signal transduction pathway.
52734	  479	17478	GH1	Protein	ADIPOR2	mRNA	0	1	14759511	Furthermore, growth hormone (GH) induced AdipoR2, but not AdipoR1 mRNA by up to 2.4-fold in a dose- and time-dependent fashion with significant stimulation detectable at concentrations as low as 5 ng/ml GH and as early as 2 h after effector addition. The positive effect of GH on AdipoR2 expression could be reversed by withdrawal of the hormone for 24 h
53858	  479	 2903	GH1	Protein	SLC1A2	mRNA	0	1	10527818	These data indicate that an excess level of GH stimulates GLT1 (EAAT2) expression and that a normal level of IGF-II is required for typical expression of GLT1 (EAAT2), GLAST1 (EAAT1) and EAAC1 (EAAT3), but that IGF-II downregulates the expression of EAAT4 and CAT1.
60887	  479	10386	GH1	Protein	DLK1	mRNA	0	1	12865419	Foxa-2 and Pref-1 expression can be enhanced in primary preadipocytes by growth hormone
 7320	  479	16458	GH1	Protein	UCP1	mRNA	0	-1	12563029	the level of uncoupling protein-1 (UCP1) RNA was found to be higher in dwarf mice and lower in giant animals relative to controls, suggesting that GH-mediated signaling may negatively regulate UCP1 gene expression in BAT.
10101	 1483	 7502	DLX5	Protein	STAR	mRNA	0	1	18276760	We examined the effect of Dlx5 expression on the promoter activation of the steroidogenic acute regulatory protein (StAR) gene, which is essential for gonadal and adrenal steroidogenesis, in a Leydig cell line. Dlx5 efficiently activates the StAR promoter when GATA-4, another transcription factor essential for testicular steroidogenesis, was coexpressed. The transcriptional activation required the GATA-4-recognition element in the StAR promoter region and Dlx5 can physically interact with GATA-4. Furthermore, we herein show that the double inactivation of Dlx5 and Dlx6 in the mouse leads to decreased testosterone level and abnormal masculinization phenotype.
19685	 1483	16486	DLX5	Protein	SPP1	mRNA	1	1	16000302	Furthermore, ChIP assays revealed that DLX5 is selectively associated with chromatin in the vicinity of the C site only when Bsp is transcriptionally active
45035	 1483	10783	DLX5	Protein	RUNX2	mRNA	0	1	17060321	Our studies further show regulation of the Runx2 gene by several homeodomain proteins: MSX2 and CDP/cut repress whereas DLX3 and DLX5 activate endogenous Runx2 expression and promoter activity in non-osseous cells and osteoblasts.
62422	 1483	11013	DLX5	Protein	IBSP	mRNA	0	1	10788516	We further found that the Dlx5 homeoprotein, which is able to regulate the osteoblast-specific osteocalcin promoter, can bind this element and stimulate its enhancer activity when overexpressed in COS7 cells.
 6908	 1483	 2204	DLX5	Protein	COL1A1	mRNA	0	1	11471195	The 2.3 kb rat COL1A1 promoter fragment contains elements responsive to Dlx5, and the self-inactivating retroviral vector allows these elements to be used appropriately.
12795	10252	17369	histamine	Compound	IL6	mRNA	0	1	14575147	In the presence of tumor necrosis factor (TNF)-alpha histamine also increased IL-12 p40 and IL-6 production.
14561	10252	 3387	histamine	Compound	CD86	mRNA	0	1	11342615	Histamine induces CD86 expression on immature DC in a dose-dependent (significant at 10(-7) M) and transient manner (maximal after 24-h stimulation).
24517	10252	 8958	histamine	Compound	RAB18	mRNA	-1	1	10648831	The histamine-induced time-dependent increase of rab18 mRNA expression in human umbilical vein endothelial cells and peripheral blood mononuclear cells indicates for the first time a link between receptor-mediated signal transduction and the regulation of rab gene expression.
37284	10252	 8901	histamine	Compound	IL12B	mRNA	0	1	14575147	Histamine treatment of iDC significantly increased the IL-12 p40 mRNA and protein levels
38130	10252	 5870	histamine	Compound	HRH1	mRNA	0	1	14575147	Histamine treatment significantly increased the expression of H2R mRNA in iDC and H1R mRNA in LPS-activated DC
 4787	10252	12369	histamine	Compound	HRH2	mRNA	0	1	14575147	Histamine treatment significantly increased the expression of H2R mRNA in iDC and H1R mRNA in LPS-activated DC
58899	10252	10064	histamine	Compound	SELP	mRNA	-1	1	 8906207	Among mast-cell mediators, histamine was already known to induce a rapid and transient expression of P-selectin; we demonstrated that histamine also induced an IL-6 and IL-8 secretion by HUVEC, which was concentration-dependent and inhibited by H1 or H2 receptor antagonists.
 7344	10252	16458	histamine	Compound	UCP1	mRNA	0	1	12746338	Central administration of histamine into the lateral cerebroventricle decreased cumulative food intake and body weight in A(y)/a obese mice. Histamine treatment also decreased mRNA expression of ob gene in epididymal white adipose tissue and up-regulated uncoupling protein 1 mRNA expression in brown adipose tissue.
 8184	10252	16644	histamine	Compound	NR1D2	mRNA	0	1	11121585	Histamine induced a time- and concentration-dependent upregulation of HZF2 level with a 6-fold peak increase of mRNA at 30 min. HZF2 upregulation was abolished by different NOS isozyme inhibitors. Guanylate cyclase inhibition resulted in a significant decrease of HZF2 expression
13628	 7045	 1438	rosiglitazone	Compound	VEGFA	mRNA	0	1	11334422	_ Ariadne: We further demonstrated that troglitazone, as well as rosiglitazone, at the plasma concentrations observed in patients, increased VEGF mRNA levels in 3T3-L1 adipocytes. [Regulation]
19949	 7045	 5757	rosiglitazone	Compound	ADIPOQ	mRNA	0	1	16026420	ZAG has recently been shown to be directly synthesized by white (and brown) adipocytes, there being a powerful upregulation at both the gene expression and protein levels in mice bearing the MAC16 tumour (a model for cachexia) (Bing et al. 2004). ZAG mRNA was increased 10-fold in the WAT of tumourbearing mice, while the level of leptin mRNA was reduced some 30-fold (Bing et al. 2004). In studies using human SGBS (Simpson-Golabi-Behmel syndrome) adipocytes, ZAG has now been shown to be released from fat cells, indicating that it is an adipokine (Bao et al. 2005). Expression of ZAG in human adipocytes is stimulated by the PPAR-c agonist rosiglitazone and suppressed by TNF-a, and this is similar to adiponectin (Bao et al. 2005).
21332	 7045	13132	rosiglitazone	Compound	PC	mRNA	1	1	15520860	Table 1  Rosiglitazone-induced mitochondrial gene expression in ob/ob mouse adipocytes
21699	 7045	 2572	rosiglitazone	Compound	CAV1	mRNA	0	1	12813462	In contrast, in HT-29 cells [adenocarcinoma], caveolin expression was not correlated with differentiation. In HT-29 cells, induction of caveolin-1 and -2 by rosiglitazone occurred in subconfluent cells within 24 h and caveolins were maintained elevated at confluency
24497	 7045	 4562	rosiglitazone	Compound	UPK2	mRNA	0	1	15054105	Two high-affinity activators of PPARgamma, troglitazone (TZ) and rosiglitazone (RZ) induced the expression of mRNA for UPII and UPIb
 2483	 7045	17889	rosiglitazone	Compound	SLC2A4	mRNA	1	1	11474486	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.
 2963	 7045	  884	rosiglitazone	Compound	AZGP1	mRNA	0	1	16026420	ZAG has recently been shown to be directly synthesized by white (and brown) adipocytes, there being a powerful upregulation at both the gene expression and protein levels in mice bearing the MAC16 tumour (a model for cachexia) (Bing et al. 2004). ZAG mRNA was increased 10-fold in the WAT of tumourbearing mice, while the level of leptin mRNA was reduced some 30-fold (Bing et al. 2004). In studies using human SGBS (Simpson-Golabi-Behmel syndrome) adipocytes, ZAG has now been shown to be released from fat cells, indicating that it is an adipokine (Bao et al. 2005). Expression of ZAG in human adipocytes is stimulated by the PPAR-c agonist rosiglitazone and suppressed by TNF-a, and this is similar to adiponectin (Bao et al. 2005).
36662	 7045	11314	rosiglitazone	Compound	PCK2	mRNA	-1	1	11474486	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.
44487	 7045	  104	rosiglitazone	Compound	UPK1B	mRNA	0	1	15054105	Two high-affinity activators of PPARgamma, troglitazone (TZ) and rosiglitazone (RZ) induced the expression of mRNA for UPII and UPIb
44498	 7045	10804	rosiglitazone	Compound	CYCS	mRNA	-1	1	17456854	Of 248 probe sets, 241 (97%) were called ?present? in the inguinal adipose tissue, composed of BAT and white adipose tissue (WAT) (21). Figure 1 shows that the expression of the majority of the OXPHOS/TCA/FAO genes in the tissue was suppressed in db/db and HFD mice compared with those in db/ and SFD mice, respectively. In a dose-dependent manner, RSG induced the expression of most of the OXPHOS/TCA/FAO genes in both db/db and HFD mice. At 10 mg/kg, RSG increased the expression of the majority of the genes to a level equivalent to or higher than that in db/ and SFD mice.
44676	 7045	12342	rosiglitazone	Compound	PTEN	mRNA	0	1	12535639	The selective PPARgamma ligand rosiglitazone increased PTEN expression in AsPC-1 cells; concurrent treatment with GW9662, which inhibits PPARgamma activation, prevented the increase in PTEN protein levels.
48837	 7045	 9823	rosiglitazone	Compound	HSD11B1	mRNA	0	-1	11278270	rosiglitazone inhibited expression of 11beta-HSD-1 in adipose tissue
51087	 7045	13884	rosiglitazone	Compound	CDKN1A	mRNA	1	1	17122083	TABLE 1. Fold change at 72 h for Rosi-treated U-33/2 cells compared with Rosi-treated U-33/c cells in expression for proliferation and differentiation genes in the adipocyte and osteoblast pathways
51183	 7045	11839	rosiglitazone	Compound	PCK1	mRNA	0	1	11474486	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.
52977	 7045	 5718	rosiglitazone	Compound	APOC3	mRNA	0	1	11474486	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.
55397	 7045	12303	rosiglitazone	Compound	SOCS3	mRNA	0	1	12584205	15d-PGJ(2) and rosiglitazone rapidly induce the transcription of suppressor of cytokine signaling (SOCS) 1 and 3, which in turn inhibit JAK activity in activated glial cells.
55705	 7045	15411	rosiglitazone	Compound	INSIG1	mRNA	0	1	15073165	Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
 5588	 7045	 4642	rosiglitazone	Compound	HP	mRNA	0	-1	14697247	Increases in haptoglobin mRNA level were also induced by dexamethasone, noradrenaline, isoprenaline, and a beta3-adrenoceptor agonist. In contrast, haptoglobin mRNA was reduced by nicotinic acid and the PPARgamma agonist, rosiglitazone
56107	 7045	 8294	rosiglitazone	Compound	CAV2	mRNA	0	1	12813462	In contrast, in HT-29 cells [adenocarcinoma], caveolin expression was not correlated with differentiation. In HT-29 cells, induction of caveolin-1 and -2 by rosiglitazone occurred in subconfluent cells within 24 h and caveolins were maintained elevated at confluency
60133	 7045	 4430	rosiglitazone	Compound	SOCS1	mRNA	0	1	12584205	15d-PGJ(2) and rosiglitazone rapidly induce the transcription of suppressor of cytokine signaling (SOCS) 1 and 3, which in turn inhibit JAK activity in activated glial cells.
   74	 7045	 9497	rosiglitazone	Compound	APOA5	mRNA	0	1	16570166	Both rosiglitazone and the fish oil diet significantly increased Apoa5 mRNA, by about 70%, but tended to lower liver and plasma apoAV.
 8933	 7045	 3998	rosiglitazone	Compound	KRAS	mRNA	1	-1	17122083	TABLE 2. Micro-array expression changes in components of the GH/IGF-I axis in U-33/{gamma}2 cells treated with Rosi compared with nontreated cells...TABLE 3. Microarray expression changes for genes involved in the IGF-I signaling pathway in U-33/{gamma}2 cells treated with Rosi vs. nontreated cells
11253	14253	19608	KLF7	Protein	LEP	mRNA	0	-1	17164435	In search of the molecular mechanism responsible for inducible effect of (-)-catechin on adiponectin expression, we found that (-)-catechin markedly suppresses the expression of Kruppel-like factor 7 (KLF7) protein, which has recently been reported to inhibit the expression of adiponectin and other adipogenesis related genes, including leptin, PPARgamma, C/EBPalpha, and aP2 in adipocytes.
 1606	14253	 9722	KLF7	Protein	CEBPA	mRNA	0	-1	17164435	In search of the molecular mechanism responsible for inducible effect of (-)-catechin on adiponectin expression, we found that (-)-catechin markedly suppresses the expression of Kruppel-like factor 7 (KLF7) protein, which has recently been reported to inhibit the expression of adiponectin and other adipogenesis related genes, including leptin, PPARgamma, C/EBPalpha, and aP2 in adipocytes.
17021	14253	 3722	KLF7	Protein	PPARG	mRNA	0	-1	17164435	In search of the molecular mechanism responsible for inducible effect of (-)-catechin on adiponectin expression, we found that (-)-catechin markedly suppresses the expression of Kruppel-like factor 7 (KLF7) protein, which has recently been reported to inhibit the expression of adiponectin and other adipogenesis related genes, including leptin, PPARgamma, C/EBPalpha, and aP2 in adipocytes.
22924	14253	14092	KLF7	Protein	OMP	mRNA	0	1	17123745	Cell transfection experiments, on the other hand, demonstrated that the promoters of the genes encoding the OSN-specific OMP and the adhesion molecule L1 are both activated by KLF7 binding to CACCC motifs.
25232	14253	 1741	KLF7	Protein	L1CAM	mRNA	0	1	17123745	Cell transfection experiments, on the other hand, demonstrated that the promoters of the genes encoding the OSN-specific OMP and the adhesion molecule L1 are both activated by KLF7 binding to CACCC motifs.
50884	14253	16714	KLF7	Protein	FABP4	mRNA	0	-1	17164435	In search of the molecular mechanism responsible for inducible effect of (-)-catechin on adiponectin expression, we found that (-)-catechin markedly suppresses the expression of Kruppel-like factor 7 (KLF7) protein, which has recently been reported to inhibit the expression of adiponectin and other adipogenesis related genes, including leptin, PPARgamma, C/EBPalpha, and aP2 in adipocytes.
50991	14253	13884	KLF7	Protein	CDKN1A	mRNA	1	1	14729953	KLF7 stimulates p21WAF1/Cip1 transcription.Chromatin immunoprecipitation experiments demonstrated KLF7 binding to the p21(WAF1/Cip1) gene while transient transfection assays documented KLF7 stimulation of the p21(WAF1/Cip1) proximal promoter.
54329	14253	 7460	KLF7	Protein	GAP43	mRNA	0	1	17123745	Cell transfection experiments, on the other hand, demonstrated that the promoters of the genes encoding the OSN-specific OMP and the adhesion molecule L1 are both activated by KLF7 binding to CACCC motifs.
 6590	14253	 5220	KLF7	Protein	NTRK1	mRNA	0	1	11443140	Second, KLF7 may directly regulate expression of TrkA, which, as the receptor for nerve growth factor, is required for normal maturation and differentiation of sensory and sympathetic neurons ( 25 ).
13841	 8142	17250	Flavopiridol	Compound	PTGS2	mRNA	0	-1	14630924	Flavopiridol also inhibited the expression of the TNF-induced NF-kappaB-regulated gene products cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9.
25360	 8142	16061	Flavopiridol	Compound	KIT	mRNA	0	-1	16740725	We also show that flavopiridol suppresses KIT mRNA expression through positive transcriptional elongation factor inhibition and decreases KIT promoter activity. This causes a global decrease in the level of functionally mature KIT at the cell surface, resulting in a decrease in autophosphorylation at tyrosine residues 703 and 721, which characterizes activated KIT
 2795	 8142	  908	Flavopiridol	Compound	MMP9	mRNA	0	-1	14630924	Flavopiridol also inhibited the expression of the TNF-induced NF-kappaB-regulated gene products cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9.
 3177	 8142	16645	Flavopiridol	Compound	CCND1	mRNA	0	-1	14630924	Flavopiridol also inhibited the expression of the TNF-induced NF-kappaB-regulated gene products cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9.
51054	 8142	13884	Flavopiridol	Compound	CDKN1A	mRNA	1	-1	12771887	Flavopiridol completely abolished depsipeptide-mediated dose-dependent upregulation of p21/WAF1 expression.
13584	11066	 1438	lovastatin	Compound	VEGFA	mRNA	0	-1	10225445	Ras-3T3 tumor cells produced increased amounts of vascular endothelial growth factor (VEGF) and lovastatin effectively suppressed VEGF production by these cells.
28232	11066	 7832	lovastatin	Compound	THBS1	mRNA	-1	-1	10543307	In summary, lovastatin and simvastatin predominantly decrease the expression of the glycoprotein thrombospondin-1, which is functionally associated with smooth muscle cell migration and proliferation.
35319	11066	15605	lovastatin	Compound	E2F1	mRNA	0	-1	11577016	We have shown in this study that transcriptional regulation and proteasomal degradation of E2F-1 are critical regulatory events in lovastatin-induced cell death.
40955	11066	 4582	lovastatin	Compound	NOS3	mRNA	1	1	 9395516	In a concentration-dependent manner, simvastatin, and to a lesser extent, lovastatin, prevented the down-regulation of ecNOS expression by hypoxia.
45380	11066	14987	lovastatin	Compound	BCL2	mRNA	1	-1	10473109	Lovastatin treatment resulted in decreased expression of the antiapoptotic protein bcl-2 and increased the expression of the proapoptotic protein bax.
55227	11066	12981	lovastatin	Compound	COL3A1	mRNA	-1	-1	15358814	TABLE 2  Distinct alterations in gene expression induced by lovastatin, simvastatin, or pravastatin in the cerebral cortex of C57BL/6 mice
55388	11066	12303	lovastatin	Compound	SOCS3	mRNA	0	1	14644448	This effect is specific for SOCS-3 and could be blocked by mevalonate, farnesyl pyrophosphate and geranylgeranyl pyrophosphate
59515	11066	 2671	lovastatin	Compound	RHOU	mRNA	-1	1	15358814	TABLE 1  Overlap in alterations of gene expression induced by lovastatin, simvastatin, and pravastatin in the cerebral cortex of C57BL/6 mice
59696	11066	10088	lovastatin	Compound	Acta2	mRNA	0	-1	12694870	Furthermore, lovastatin inhibited induction of alpha-smooth muscle actin expression in the course of primary culture.
 6733	11066	10999	lovastatin	Compound	HSPB1	mRNA	0	1	12801507	Lovastatin, another statin, also induced the HSP27 accumulation and SB203580 suppressed the HSP27 accumulation.
11358	16477	14199	Ras Family	Protein	Olfr1508	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
12045	16477	18819	Ras Family	Protein	TSLP	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
14738	16477	 3063	Ras Family	Protein	PIP5K1A	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
14877	16477	14770	Ras Family	Protein	RHOB	mRNA	0	-1	15169915	Here we demonstrate that Ras downregulates RhoB expression by a phosphatidylinositol 3-kinase (PI3K)- and Akt- but not Mek-dependent mechanism.
17977	16477	  467	Ras Family	Protein	ALDH1A3	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
22102	16477	17945	Ras Family	Protein	LGALS7	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
23498	16477	 1867	Ras Family	Protein	SELPLG	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
29593	16477	17642	Ras Family	Protein	ADRA2C	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
34713	16477	 2278	Ras Family	Protein	NPPB	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
 3514	16477	 6139	Ras Family	Protein	STK10	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
45165	16477	11605	Ras Family	Protein	TMOD2	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
46198	16477	12676	Ras Family	Protein	COL18A1	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
48157	16477	12541	Ras Family	Protein	UPP1	mRNA	0	1	12874036	Transcriptional up-regulation of uridine phosphorylase is shown to be mediated in a DNA binding-dependent manner, and reporter gene assays demonstrated that EWS/FLI1 and RAS mediate activation through a single activator protein 1/ETS site located in the uridine phosphorylase promoter.
49211	16477	 4945	Ras Family	Protein	SOX5	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
51092	16477	13884	Ras Family	Protein	CDKN1A	mRNA	1	1	15572689	Under these circumstances activated RhoA is reported to prevent the expression of the CKI p21Cip1, a major mediator of RAS- or RAF-induced cell cycle arrest in mouse fibroblasts (43).
56505	16477	14504	Ras Family	Protein	ALKBH3	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
57777	16477	 9065	Ras Family	Protein	KLF3	mRNA	1	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
58345	16477	15922	Ras Family	Protein	CLCF1	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
58888	16477	 5635	Ras Family	Protein	SERPINB2	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
64127	16477	12215	Ras Family	Protein	RNF19B	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
  650	16477	  704	Ras Family	Protein	SH3RF1	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
65660	16477	20171	Ras Family	Protein	Oas1h	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
 6697	16477	 1185	Ras Family	Protein	CRISP3	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
 7669	16477	14163	Ras Family	Protein	CGREF1	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
 9087	16477	 8469	Ras Family	Protein	PKP1	mRNA	0	1	15492243	Extensive data indicate that oncoproteins, such as oncogenic H-Ras, initiate signal transduction cascades that ultimately lead to the activation of specific transcription factors. We and others have previously demonstrated that Ras activates the inherent transcriptional activation function of the transcription factor nuclear factor kappaB (NF-kappaB). Supportive of the importance of NF-kappaB in transformation, Ras-induced cellular transformation can be suppressed by expression of IkappaBalpha, an inhibitor of NF-kappaB, or by dominant-negative forms of the upstream activator IkappaB kinase (IKK). However, conclusive evidence for a requirement for NF-kappaB subunits in oncogenic transformation has not been reported. Furthermore, there is little understanding of the gene targets controlled by NF-kappaB that might support oncogenic conversion. The data presented here demonstrate that, although both p65 and c-Rel enhance the frequency of Ras-induced cellular transformation, these NF-kappaB subunits are not essential for Ras to transform spontaneously immortalized murine fibroblasts. Microarray analysis identified a set of genes induced by Ras that is dependent on NF-kappaB for their expression and that likely play contributory roles in promoting Ras-induced oncogenic transformation.
10155	 8519	 4403	Helicobacter pylori infection	Compound	SRGN	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
10580	 8519	16629	Helicobacter pylori infection	Compound	HSFY1	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
10677	 8519	 4044	Helicobacter pylori infection	Compound	FGF16	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
11561	 8519	 1299	Helicobacter pylori infection	Compound	CCL20	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
11720	 8519	 2959	Helicobacter pylori infection	Compound	TNFRSF10D	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
12761	 8519	13474	Helicobacter pylori infection	Compound	Ccl8	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
14454	 8519	13598	Helicobacter pylori infection	Compound	CD14	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
16404	 8519	15208	Helicobacter pylori infection	Compound	CD48	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
16883	 8519	 5075	Helicobacter pylori infection	Compound	RLIM	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
16922	 8519	 1054	Helicobacter pylori infection	Compound	KLKB1	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
17543	 8519	 5517	Helicobacter pylori infection	Compound	NCAM2	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
18092	 8519	  284	Helicobacter pylori infection	Compound	CXCL10	mRNA	0	1	16849720	GES-1 cells infected with spiral H. pylori have higher expression of cxcl10, ccl11, ccl5, groalpha, TLR5, ATF3, fos, fosl2, gadd45a and myc. The cells infected with coccoid H. pylori had higher expression of survivin.
19311	 8519	 1981	Helicobacter pylori infection	Compound	ST6GAL1	mRNA	1	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
20510	 8519	 6218	Helicobacter pylori infection	Compound	VCAM1	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
 2113	 8519	13316	Helicobacter pylori infection	Compound	TFE3	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
21984	 8519	16678	Helicobacter pylori infection	Compound	NLGN4X	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
22013	 8519	13206	Helicobacter pylori infection	Compound	CCL11	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
22367	 8519	14167	Helicobacter pylori infection	Compound	PCDH19	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
23017	 8519	  425	Helicobacter pylori infection	Compound	COL8A1	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
 2340	 8519	11437	Helicobacter pylori infection	Compound	ADRA1A	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
23490	 8519	 1867	Helicobacter pylori infection	Compound	SELPLG	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
 2421	 8519	 6662	Helicobacter pylori infection	Compound	FGFR2	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
24345	 8519	18209	Helicobacter pylori infection	Compound	MMP3	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
24474	 8519	 3534	Helicobacter pylori infection	Compound	PCDHB2	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
24699	 8519	10166	Helicobacter pylori infection	Compound	URI1	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
24833	 8519	 5863	Helicobacter pylori infection	Compound	MYC	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
24981	 8519	14056	Helicobacter pylori infection	Compound	HSFY2	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
25136	 8519	 7070	Helicobacter pylori infection	Compound	ITGAE	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
25306	 8519	13534	Helicobacter pylori infection	Compound	CCNE2	mRNA	-1	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
25398	 8519	 6683	Helicobacter pylori infection	Compound	GABRB2	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
27797	 8519	16845	Helicobacter pylori infection	Compound	CD22	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
28104	 8519	18341	Helicobacter pylori infection	Compound	MUC5B	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
28842	 8519	 4624	Helicobacter pylori infection	Compound	RAP2A	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
28934	 8519	10269	Helicobacter pylori infection	Compound	CD74	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
28967	 8519	 6303	Helicobacter pylori infection	Compound	C5	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
32500	 8519	19410	Helicobacter pylori infection	Compound	CXCL11	mRNA	0	1	16849720	GES-1 cells infected with spiral H. pylori have higher expression of cxcl10, ccl11, ccl5, groalpha, TLR5, ATF3, fos, fosl2, gadd45a and myc. The cells infected with coccoid H. pylori had higher expression of survivin.
32814	 8519	 8882	Helicobacter pylori infection	Compound	TNFSF15	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
33039	 8519	14077	Helicobacter pylori infection	Compound	HTR2B	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
34062	 8519	19970	Helicobacter pylori infection	Compound	IL17A	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
36761	 8519	 3532	Helicobacter pylori infection	Compound	NR4A2	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
37354	 8519	19457	Helicobacter pylori infection	Compound	TLR5	mRNA	0	1	16849720	GES-1 cells infected with spiral H. pylori have higher expression of cxcl10, ccl11, ccl5, groalpha, TLR5, ATF3, fos, fosl2, gadd45a and myc. The cells infected with coccoid H. pylori had higher expression of survivin.
37467	 8519	 1084	Helicobacter pylori infection	Compound	ALDOC	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
38772	 8519	12443	Helicobacter pylori infection	Compound	MMP10	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
39100	 8519	12767	Helicobacter pylori infection	Compound	STK17B	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
40230	 8519	 8971	Helicobacter pylori infection	Compound	IL26	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
41513	 8519	12381	Helicobacter pylori infection	Compound	SPI1	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
42096	 8519	13115	Helicobacter pylori infection	Compound	EGR1	mRNA	-1	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
42425	 8519	 6832	Helicobacter pylori infection	Compound	RGS6	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
42576	 8519	 5280	Helicobacter pylori infection	Compound	VGF	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
 4317	 8519	19709	Helicobacter pylori infection	Compound	RGS2	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
43822	 8519	20009	Helicobacter pylori infection	Compound	CXCR4	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
44010	 8519	 6965	Helicobacter pylori infection	Compound	TNFAIP3	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
44194	 8519	17791	Helicobacter pylori infection	Compound	SFTPD	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
44802	 8519	 9015	Helicobacter pylori infection	Compound	MGAT4A	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
44850	 8519	14630	Helicobacter pylori infection	Compound	IL18	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
45218	 8519	 4775	Helicobacter pylori infection	Compound	CCL13	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
45997	 8519	 9455	Helicobacter pylori infection	Compound	ITGA5	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
46487	 8519	19036	Helicobacter pylori infection	Compound	EPHA2	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
47204	 8519	 2052	Helicobacter pylori infection	Compound	ATF3	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
47478	 8519	 5083	Helicobacter pylori infection	Compound	EGR4	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
47644	 8519	14557	Helicobacter pylori infection	Compound	APLP1	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
47652	 8519	17551	Helicobacter pylori infection	Compound	IL2RG	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
48023	 8519	11629	Helicobacter pylori infection	Compound	FOS	mRNA	0	1	16849720	GES-1 cells infected with spiral H. pylori have higher expression of cxcl10, ccl11, ccl5, groalpha, TLR5, ATF3, fos, fosl2, gadd45a and myc. The cells infected with coccoid H. pylori had higher expression of survivin.
48117	 8519	13471	Helicobacter pylori infection	Compound	BIRC5	mRNA	0	1	16849720	GES-1 cells infected with spiral H. pylori have higher expression of cxcl10, ccl11, ccl5, groalpha, TLR5, ATF3, fos, fosl2, gadd45a and myc. The cells infected with coccoid H. pylori had higher expression of survivin.
48181	 8519	 5738	Helicobacter pylori infection	Compound	MX1	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
48237	 8519	 6910	Helicobacter pylori infection	Compound	PDE7A	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
48942	 8519	  324	Helicobacter pylori infection	Compound	NRP2	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
49509	 8519	10600	Helicobacter pylori infection	Compound	CXCL1	mRNA	0	1	16849720	GES-1 cells infected with spiral H. pylori have higher expression of cxcl10, ccl11, ccl5, groalpha, TLR5, ATF3, fos, fosl2, gadd45a and myc. The cells infected with coccoid H. pylori had higher expression of survivin.
50219	 8519	19778	Helicobacter pylori infection	Compound	DGKD	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
 5054	 8519	  341	Helicobacter pylori infection	Compound	PLCD1	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
50587	 8519	17279	Helicobacter pylori infection	Compound	IRX5	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
 5096	 8519	14492	Helicobacter pylori infection	Compound	PCDHB5	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
51643	 8519	19521	Helicobacter pylori infection	Compound	TANK	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
51763	 8519	 3665	Helicobacter pylori infection	Compound	MYBL1	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
52346	 8519	12532	Helicobacter pylori infection	Compound	TAF5	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
52380	 8519	17434	Helicobacter pylori infection	Compound	ALK	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
52394	 8519	  630	Helicobacter pylori infection	Compound	MUC4	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
52541	 8519	 9092	Helicobacter pylori infection	Compound	CXCL6	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
52569	 8519	17593	Helicobacter pylori infection	Compound	ITGA9	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
52879	 8519	  486	Helicobacter pylori infection	Compound	HOXD3	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
53602	 8519	13717	Helicobacter pylori infection	Compound	PCDHB8	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
  543	 8519	 4126	Helicobacter pylori infection	Compound	HTR2C	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
54497	 8519	 7132	Helicobacter pylori infection	Compound	FOSL2	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
55768	 8519	18155	Helicobacter pylori infection	Compound	IER3	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
58959	 8519	19663	Helicobacter pylori infection	Compound	REG1A	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
60029	 8519	12976	Helicobacter pylori infection	Compound	IL8	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
60134	 8519	 4430	Helicobacter pylori infection	Compound	SOCS1	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
60415	 8519	 5024	Helicobacter pylori infection	Compound	CCL5	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
62582	 8519	14820	Helicobacter pylori infection	Compound	HMGN5	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
62932	 8519	 7195	Helicobacter pylori infection	Compound	GADD45A	mRNA	-1	1	16849720	GES-1 cells infected with spiral H. pylori have higher expression of cxcl10, ccl11, ccl5, groalpha, TLR5, ATF3, fos, fosl2, gadd45a and myc. The cells infected with coccoid H. pylori had higher expression of survivin.
 6765	 8519	 7996	Helicobacter pylori infection	Compound	CLEC6A	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
 7737	 8519	17853	Helicobacter pylori infection	Compound	TCF15	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
 7752	 8519	16468	Helicobacter pylori infection	Compound	NFAT5	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
 8541	 8519	 1320	Helicobacter pylori infection	Compound	IL25	mRNA	0	1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
 9093	 8519	 7400	Helicobacter pylori infection	Compound	TEAD1	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
 9526	 8519	19712	Helicobacter pylori infection	Compound	CXCL13	mRNA	0	1	17101721	genes up-regulated in H. felis-infected mice...genes that increased in a time dependent profile (Table 1). _[JL] - they used H. felis - which is related to H. pylori, and we donpt have a H. felis term, so Ipm consolidating onto H. pylori, since these mice develop adenocarcinoma in response to H. felis infection
 9956	 8519	 4598	Helicobacter pylori infection	Compound	GTF2H1	mRNA	0	-1	16849720	Table 2. Differentially expressed genes in spiral and coccoid H. pylori-infected GES-1 cells
23793	 9748	 6636	POU4F1	Protein	BCL2L1	mRNA	0	1	12432261	We show that both full length Brn-3a and the isolated POU domain interact with the EWS transcription factor and its oncogenic derivative EWS-Fli1. Moreover, EWS can block Brn-3a-mediated activation of the Bcl-x promoter whereas this effect is lost in EWS-Fli1.
25363	 9748	16061	POU4F1	Protein	KIT	mRNA	0	1	15253936	Table 2. Decreased transcripts in the trigeminal ganglion of Brn3a mutant mouse embryos
28263	 9748	 7832	POU4F1	Protein	THBS1	mRNA	-1	-1	15253936	Table 1. Increased transcripts in the trigeminal ganglion of Brn3a mutant mouse embryos
45371	 9748	14987	POU4F1	Protein	BCL2	mRNA	1	1	15021903	In contrast, upregulation of Bcl-2 expression and inhibition of apoptosis by Brn-3a is antagonized more by EWS than by EWS/Fli-1.
50986	 9748	13884	POU4F1	Protein	CDKN1A	mRNA	1	1	12433990	In contrast, a minimal p21 promoter is activated by Brn-3a and such activation cannot be abolished without abolishing basal promoter activity.
 6227	 9748	10856	POU4F1	Protein	SNAP25	mRNA	0	1	15021903	Furthermore, overexpression of EWS/Fli-1 but not EWS or Fli-1 inhibits Brn-3a-associated growth arrest and neurite outgrowth in neuronal cells, and specifically inhibits Brn-3a-dependent activation of p21 and SNAP-25 transcription.
11861	 3822	16365	troglitazone	Compound	IL1A	mRNA	0	1	12080324	Moreover, troglitazone treatment increased the expression of interleukin-1 alpha, a multifunctional cytokine implicated in antitumor immunity.
13671	 3822	 1438	troglitazone	Compound	VEGFA	mRNA	0	1	11334422	_ Ariadne: We further demonstrated that troglitazone, as well as rosiglitazone, at the plasma concentrations observed in patients, increased VEGF mRNA levels in 3T3-L1 adipocytes. [Regulation]
14106	 3822	14961	troglitazone	Compound	CEBPD	mRNA	0	-1	12215492	Moreover, PPAR-gamma ligands suppressed protein expression and transcription of C/EBP-delta through dephosphorylation of signal transducer and activator of transcription 3.
17043	 3822	 3722	troglitazone	Compound	PPARG	mRNA	0	1	11172467	Troglitazone and pioglitazone, which are ligands/activators for PPARgamma, also induced PPARalpha gene and protein expression and increased CuZn-SOD gene expression and protein levels in addition to increasing PPARgamma gene and protein expression in endothelial cells.
19120	 3822	12812	troglitazone	Compound	CALD1	mRNA	0	1	15345487	TG (50 microM) induced GLUT4 and h-caldesmon expression in 24-h culture of explanted carotid arteries of DOCA salt-hypertensive rats,
19648	 3822	16486	troglitazone	Compound	SPP1	mRNA	1	-1	NA	PMA-induced OPN expression was significantly decreased by troglitazone (Tro) and other PPARgamma ligands. is translated to Inhibition of SPP1 (Homo sapiens) Gene Expression by Troglitazone
24498	 3822	 4562	troglitazone	Compound	UPK2	mRNA	0	1	15054105	Two high-affinity activators of PPARgamma, troglitazone (TZ) and rosiglitazone (RZ) induced the expression of mRNA for UPII and UPIb
24852	 3822	 5863	troglitazone	Compound	MYC	mRNA	0	1	11344222	Troglitazone significantly increased the expression of c-myc messenger RNA but had no effect on the expression of bcl-2 and bax in thyroid carcinoma cells.
 2498	 3822	17889	troglitazone	Compound	SLC2A4	mRNA	1	1	11756319	After troglitazone treatment, GLUT4 protein expression was increased twofold (202 +/- 42%, P < 0.05).
 2897	 3822	 4252	troglitazone	Compound	ABCA1	mRNA	0	-1	11909955	Troglitazone, but not other TZD compounds, inhibited Abca1 expression and cholesterol efflux in both control and Pparg-deficient macrophages.
29873	 3822	10162	troglitazone	Compound	CDKN2C	mRNA	0	1	11343236	HLF, which was deficient in the protein product of the retinoblastoma tumor-suppressor gene (pRb), responded most profoundly to troglitazone, showing an increased expression in not only p21, but also in p27 and in p18.
38304	 3822	 6799	troglitazone	Compound	SLC2A5	mRNA	0	-1	11244250	GLUT5 protein expression levels in the troglitazone-treated ZDF rats were 50% below the untreated ZDF rats.
39573	 3822	13744	troglitazone	Compound	CDKN1B	mRNA	-1	1	11343236	HLF, which was deficient in the protein product of the retinoblastoma tumor-suppressor gene (pRb), responded most profoundly to troglitazone, showing an increased expression in not only p21, but also in p27 and in p18.
40253	 3822	10582	troglitazone	Compound	TBXAS1	mRNA	0	-1	10930400	XS mRNA expression and the transcription activity of 5pFL-TXS were inhibited by PPARgamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J(2) (PGJ(2)), and the thiazolidinedione troglitazone (TRO) in a dose-dependent manner.
44490	 3822	  104	troglitazone	Compound	UPK1B	mRNA	0	1	15054105	Two high-affinity activators of PPARgamma, troglitazone (TZ) and rosiglitazone (RZ) induced the expression of mRNA for UPII and UPIb
44564	 3822	 6521	troglitazone	Compound	MMP7	mRNA	0	-1	12027200	Troglitazone strongly inhibited the production of MMP-7, an enzyme associated with invasiveness of cancer cells, by both subclones.
45789	 3822	 4835	troglitazone	Compound	PPARA	mRNA	0	1	11172467	Troglitazone and pioglitazone, which are ligands/activators for PPARgamma, also induced PPARalpha gene and protein expression and increased CuZn-SOD gene expression and protein levels in addition to increasing PPARgamma gene and protein expression in endothelial cells.
48788	 3822	 9909	troglitazone	Compound	VIL1	mRNA	0	1	10076568	Finally, troglitazone induced expression of mRNAs for villin and intestinal alkaline phosphatase, markers for enterocyte differentiation.
 4962	 3822	12073	troglitazone	Compound	IRF1	mRNA	0	1	14656743	Using Northern and Western blot analyses, we documented that PPARgamma ligands, including ciglitazone, troglitazone, and GW7845, significantly increased IRF-1 expression in VSMCs
51001	 3822	13884	troglitazone	Compound	CDKN1A	mRNA	1	1	NA	Troglitazone treatment increased expression of two cyclin-dependent kinase inhibitors, p21(WAF1/CIP1) and p16(INK4), and reduced cyclin D1 expression, consistent with G1 arrest. is translated to Activation of CDKN2A (Homo sapiens) Gene Expression by Troglitazone
53683	 3822	14116	troglitazone	Compound	PLIN2	mRNA	0	1	14671211	exposure of cultured human trophoblasts to the PPARgamma ligand troglitazone resulted in a concentration-dependent increase in adipophilin expression.
54048	 3822	 5118	troglitazone	Compound	NOS2	mRNA	0	-1	11057759	Troglitazone pre-treatment blocked the LPS-induced expression of iNOS in adipose tissue and the increase in serum nitrite concentration.
55719	 3822	17702	troglitazone	Compound	SKP2	mRNA	0	-1	12717389	In conclusion, troglitazone attenuated Skp2 expression, thereby promoting p27(Kip1) accumulation in human hepatoma cells.
59773	 3822	13414	troglitazone	Compound	SERPINE1	mRNA	0	-1	10770198	By contrast, in human aortic smooth muscle cells, 3 microg/mL troglitazone decreased basal PAI-1 expression by 23% (P = 0.037) and decreased transforming growth factor-beta-induced expression by 34% (P = 0.026).
62921	 3822	 7195	troglitazone	Compound	GADD45A	mRNA	-1	1	11068018	both the mRNA and protein expression levels of p53 and Gadd45 markedly increased in response to troglitazone.
 9248	 3822	11654	troglitazone	Compound	DRG1	mRNA	0	1	10676663	Moreover, the expression of Drg-1 is controlled by several known cell differentiation reagents, such as ligands of peroxisome proliferator-activated receptor gamma (troglitazone and BRL46593) and of retinoid X receptor (LG268), and histone deacetylase inhibitors (trichostatin A, suberoylanilide hydroxamic acid, and tributyrin).
20873	 7348	19071	BATF	Protein	IL2	mRNA	0	-1	12594265	To examine how BATF-mediated negative control of AP-1 activity influences specific transitions in thymic T cell development, the p56lck proximal promoter was used to drive expression of an HA Ag-tagged BATF protein in mice. Two founder animals positive for the transgene were bred to generate the FVB-lck line 2 and FVB-lck line 4 mice used in these studies (Fig. 1A).  To determine whether the overexpression of BATF influences cytokine gene expression, thymocytes and splenocytes from wild-type and transgenic FVB-lck line 2 littermates were stimulated in vitro with plate-bound anti-CD3{epsilon} mAb. Total RNA was isolated after 24 h, and RPA was performed. The induction of IL-2, IL-4, IL-5, IL-10, and IL-13 mRNA by transgenic thymocytes is impaired relative to that in wild-type controls, while the expression of IL-6 and IFN-{gamma} mRNA is comparable (Fig. 2A). Transgenic splenocytes showed reduced expression of IL-4 and IL-5 and enhanced expression of IL-2 (Fig. 2A). The RPA was repeated with RNA prepared from FVB-lck line 4 animals, and similar results were obtained (data not shown).
23699	 7348	 8837	BATF	Protein	IL5	mRNA	0	-1	12594265	To examine how BATF-mediated negative control of AP-1 activity influences specific transitions in thymic T cell development, the p56lck proximal promoter was used to drive expression of an HA Ag-tagged BATF protein in mice. Two founder animals positive for the transgene were bred to generate the FVB-lck line 2 and FVB-lck line 4 mice used in these studies (Fig. 1A).  To determine whether the overexpression of BATF influences cytokine gene expression, thymocytes and splenocytes from wild-type and transgenic FVB-lck line 2 littermates were stimulated in vitro with plate-bound anti-CD3{epsilon} mAb. Total RNA was isolated after 24 h, and RPA was performed. The induction of IL-2, IL-4, IL-5, IL-10, and IL-13 mRNA by transgenic thymocytes is impaired relative to that in wild-type controls, while the expression of IL-6 and IFN-{gamma} mRNA is comparable (Fig. 2A). Transgenic splenocytes showed reduced expression of IL-4 and IL-5 and enhanced expression of IL-2 (Fig. 2A). The RPA was repeated with RNA prepared from FVB-lck line 4 animals, and similar results were obtained (data not shown).
36152	 7348	17271	BATF	Protein	IL13	mRNA	0	-1	12594265	To examine how BATF-mediated negative control of AP-1 activity influences specific transitions in thymic T cell development, the p56lck proximal promoter was used to drive expression of an HA Ag-tagged BATF protein in mice. Two founder animals positive for the transgene were bred to generate the FVB-lck line 2 and FVB-lck line 4 mice used in these studies (Fig. 1A).  To determine whether the overexpression of BATF influences cytokine gene expression, thymocytes and splenocytes from wild-type and transgenic FVB-lck line 2 littermates were stimulated in vitro with plate-bound anti-CD3{epsilon} mAb. Total RNA was isolated after 24 h, and RPA was performed. The induction of IL-2, IL-4, IL-5, IL-10, and IL-13 mRNA by transgenic thymocytes is impaired relative to that in wild-type controls, while the expression of IL-6 and IFN-{gamma} mRNA is comparable (Fig. 2A). Transgenic splenocytes showed reduced expression of IL-4 and IL-5 and enhanced expression of IL-2 (Fig. 2A). The RPA was repeated with RNA prepared from FVB-lck line 4 animals, and similar results were obtained (data not shown).
36786	 7348	 8660	BATF	Protein	IL4	mRNA	0	-1	12594265	Although IL-4 mRNA was detected in wild-type splenocytes, no expression was detected in splenocytes from BATF transgenic mice (Fig. 5B). The same result was obtained for IL-13 mRNA (Fig. 5B). In contrast, the induction of IFN-{gamma} mRNA, which is not an exclusive property of NKT cells within this time-frame (24, 27), was similar in wild-type and transgenic mice (Fig. 5B). These results are consistent with the data in Fig. 5A and suggest that the overexpression of BATF negatively impacts the NKT cell compartment in these animals.
38930	 7348	  337	BATF	Protein	IL3	mRNA	1	-1	12594265	Although IL-4 mRNA was detected in wild-type splenocytes, no expression was detected in splenocytes from BATF transgenic mice (Fig. 5B). The same result was obtained for IL-13 mRNA (Fig. 5B). In contrast, the induction of IFN-{gamma} mRNA, which is not an exclusive property of NKT cells within this time-frame (24, 27), was similar in wild-type and transgenic mice (Fig. 5B). These results are consistent with the data in Fig. 5A and suggest that the overexpression of BATF negatively impacts the NKT cell compartment in these animals.
 8384	 7348	 4791	BATF	Protein	IL10	mRNA	0	-1	12594265	To examine how BATF-mediated negative control of AP-1 activity influences specific transitions in thymic T cell development, the p56lck proximal promoter was used to drive expression of an HA Ag-tagged BATF protein in mice. Two founder animals positive for the transgene were bred to generate the FVB-lck line 2 and FVB-lck line 4 mice used in these studies (Fig. 1A).  To determine whether the overexpression of BATF influences cytokine gene expression, thymocytes and splenocytes from wild-type and transgenic FVB-lck line 2 littermates were stimulated in vitro with plate-bound anti-CD3{epsilon} mAb. Total RNA was isolated after 24 h, and RPA was performed. The induction of IL-2, IL-4, IL-5, IL-10, and IL-13 mRNA by transgenic thymocytes is impaired relative to that in wild-type controls, while the expression of IL-6 and IFN-{gamma} mRNA is comparable (Fig. 2A). Transgenic splenocytes showed reduced expression of IL-4 and IL-5 and enhanced expression of IL-2 (Fig. 2A). The RPA was repeated with RNA prepared from FVB-lck line 4 animals, and similar results were obtained (data not shown).
12767	10816	17369	leukotriene B4	Compound	IL6	mRNA	0	1	18852255	In cultured monocytes, LTB4 upregulated IL-6, MCP-1, and TNF-a expression at 3 h (Real Time-PCR). U-75302, Ly-2552837, and PTX significantly diminished LTB4-mediated gene overexpression (Figure 5A).
13798	10816	18311	leukotriene B4	Compound	FDX1	mRNA	0	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
14901	10816	  282	leukotriene B4	Compound	KLRK1	mRNA	0	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
19635	10816	16486	leukotriene B4	Compound	SPP1	mRNA	1	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
 2204	10816	 5419	leukotriene B4	Compound	TNF	mRNA	0	1	18852255	In cultured monocytes, LTB4 upregulated IL-6, MCP-1, and TNF-a expression at 3 h (Real Time-PCR). U-75302, Ly-2552837, and PTX significantly diminished LTB4-mediated gene overexpression (Figure 5A).
23387	10816	 4614	leukotriene B4	Compound	CSF1	mRNA	0	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
33713	10816	 1040	leukotriene B4	Compound	CD36	mRNA	0	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
35231	10816	 5296	leukotriene B4	Compound	PLAU	mRNA	1	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
 3885	10816	 1969	leukotriene B4	Compound	SLA	mRNA	0	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
42294	10816	16433	leukotriene B4	Compound	CD44	mRNA	0	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
44435	10816	13271	leukotriene B4	Compound	CCL2	mRNA	0	1	14656734	The data (Figure 1) demonstrate that LTB4 enhanced the expression of mRNA and protein levels of CD36 (Figure 1A, 1C, and 1E) and CCL2 (Figure 1B, 1D,and 1F). ....Moreover, the expression of both mRNAs and the corresponding proteins were dependent on Gi-protein signaling, as evidenced by near-complete inhibition of induction in cells treated with pertussis toxin.
47173	10816	 7052	leukotriene B4	Compound	NR2F1	mRNA	0	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
54621	10816	11395	leukotriene B4	Compound	RASSF5	mRNA	0	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
 7180	10816	13397	leukotriene B4	Compound	PTPN6	mRNA	0	1	14656734	Table 1 - Microarray Analysis of Changes in LTB4-induced Gene Expression.
19702	12453	16486	Adenosine triphosphate	Compound	SPP1	mRNA	1	1	15557322	In the context of vascular remodeling, soluble factors, such as angiotensin II, basic fibroblast growth factor, platelet-derived growth factor, interleukin-1 (9), and the nucleotides ATP and UTP (10), all induce expression of OPN.
23468	12453	  845	Adenosine triphosphate	Compound	IDO1	mRNA	0	1	16118322	analysis of ATP-stimulated human DCs revealed inter alia a drastic up-regulation of 2 genes encoding mediators involved in immunosuppression: thrombospondin-1 (TSP-1) and indoleamine 2,3-dioxygenase (IDO)
28257	12453	 7832	Adenosine triphosphate	Compound	THBS1	mRNA	-1	1	16118322	analysis of ATP-stimulated human DCs revealed inter alia a drastic up-regulation of 2 genes encoding mediators involved in immunosuppression: thrombospondin-1 (TSP-1) and indoleamine 2,3-dioxygenase (IDO)
42149	12453	 6102	Adenosine triphosphate	Compound	C5orf62	mRNA	0	1	11288140	In addition to a robust induction by NGF and FGF, both of which cause PC12 cells to differentiate, NID67 is strongly induced by forskolin, A23187 and ATP
42898	12453	 7577	Adenosine triphosphate	Compound	HSP90AA1	mRNA	0	1	14699958	We show that both ATP and NGF upregulate the expression of the stress-induced heat shock protein HSP70 and HSP90
50988	12453	13884	Adenosine triphosphate	Compound	CDKN1A	mRNA	1	1	12135987	addition of ATP increased the expression of myogenin and p21, as judged by RT-PCR
 5943	12453	 1713	Adenosine triphosphate	Compound	MYOG	mRNA	0	1	12135987	addition of ATP increased the expression of myogenin and p21, as judged by RT-PCR
  111	19928	 8755	cisplatin	Compound	GDF15	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
11645	19928	16413	cisplatin	Compound	HMGCS1	mRNA	0	-1	17616683	Microarray analysis of the transcriptome of H1975 cells treated with BMS-690514 or CDDP. H1975 cells were treated with either 5 mol/L (1 mol/L) BMS-690514 and 50 mol/L (25 mol/L) CDDP for 24 h (48 h) and subjected to RNA isolation. Total RNA was then retrotranscribed into double-stranded cDNA followed by T7 RNA polymerase?mediated linear amplification, labeling, and hybridization to a human whole genome 44k oligonucleotide array. Samples from treated cultures were compared with cRNAs obtained through the same procedure from untreated cells.  From Supplementary Table S1, which contains a complete list of genes that are transcriptionally modulated by BMS-690514 by a factor higher than 2. n.s., nonstatistically significant P value (>10?5). H1975 cells have a secondary somatic EGFR mutation T790M which confers resistance to erlotinib. BMS-690514, a novel panHER/VEGFR inhibitor described here, exerted antiproliferative and pro-apoptotic effects on NSCLC cell lines, with prominent efficacy on H1975 cells expressing the T790M mutation.(I included only 24h time points-JSP)
16913	19928	 3686	cisplatin	Compound	TRIM22	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
17974	19928	  467	cisplatin	Compound	ALDH1A3	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
20766	19928	 4461	cisplatin	Compound	ACTA2	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
21157	19928	 3164	cisplatin	Compound	FADS3	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
21686	19928	 2572	cisplatin	Compound	CAV1	mRNA	0	1	15546613	In order to determine the functional targets of ATF2 and c-Jun, we analyzed the agreement of the ATF2/c-Jun promoter binding profile with gene expression using Affymetrix GeneChips. Total RNA of BT474 cells prepared 3 hr following treatment with cisplatin was analyzed. Of 9177 unique genes represented on the Affymetrix U95Av2 oligonucleotide array, 352 genes show significant change by the double criteria that fold change >|2| and p < 0.05. Of these, 143 genes are present on our promoter array (Figure 6).
22921	19928	 6989	cisplatin	Compound	CXCL14	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
23005	19928	 3398	cisplatin	Compound	GPR87	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
24160	19928	 9854	cisplatin	Compound	PLAT	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
24386	19928	 8168	cisplatin	Compound	PHLDA3	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
24817	19928	 5863	cisplatin	Compound	MYC	mRNA	0	-1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
25142	19928	 3978	cisplatin	Compound	HESX1	mRNA	0	-1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
28125	19928	17708	cisplatin	Compound	FOSL1	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
30042	19928	 5696	cisplatin	Compound	NEFL	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
30234	19928	 3975	cisplatin	Compound	ANXA4	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
34797	19928	18651	cisplatin	Compound	INPP5D	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
38351	19928	 1872	cisplatin	Compound	BTG2	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
39410	19928	 5243	cisplatin	Compound	SESN1	mRNA	-1	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
39923	19928	 5010	cisplatin	Compound	ZMAT3	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
42816	19928	 3879	cisplatin	Compound	FAS	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
42973	19928	 6385	cisplatin	Compound	EPS8L2	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
44663	19928	11229	cisplatin	Compound	TNFRSF10C	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
45452	19928	 3166	cisplatin	Compound	BBS9	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
 4560	19928	14819	cisplatin	Compound	LMNA	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
46280	19928	10963	cisplatin	Compound	ANXA1	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
47503	19928	12618	cisplatin	Compound	C12orf5	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
48545	19928	19123	cisplatin	Compound	DDB2	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
48584	19928	19774	cisplatin	Compound	ENDOG	mRNA	0	1	15280156	At day 4 after cisplatin injection mRNA, protein levels and enzyme activity of proapoptotic renal endonuclease G (Endo G) were increased compared with saline-treated mice. % In situ hybridization and immunohistochemical studies localized the increased expression of Endo G mRNA to the cytosolic compartment and Endo G protein to the nuclear compartment of proximal tubules in cisplatin-treated mice
51095	19928	13884	cisplatin	Compound	CDKN1A	mRNA	1	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
51246	19928	15531	cisplatin	Compound	HSD17B3	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
52656	19928	  695	cisplatin	Compound	FDXR	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
52676	19928	10310	cisplatin	Compound	GLS2	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
53316	19928	 9562	cisplatin	Compound	PLK2	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
55084	19928	 4733	cisplatin	Compound	PPM1D	mRNA	-1	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
55157	19928	 6563	cisplatin	Compound	RPS27L	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
55777	19928	18155	cisplatin	Compound	IER3	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
57502	19928	 5731	cisplatin	Compound	ACOX1	mRNA	0	-1	12234291	Cisplatin decreased mRNA levels of peroxisomal acyl-CoA enzyme in mouse kidney and also reduced the mRNA levels and enzyme activities of acyl-CoA and mitochondrial CPT-1 in LLCPK1 cells.
59737	19928	 5494	cisplatin	Compound	LPIN1	mRNA	0	-1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
59760	19928	13414	cisplatin	Compound	SERPINE1	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
60154	19928	 2356	cisplatin	Compound	STK17A	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
60303	19928	16684	cisplatin	Compound	CYP26A1	mRNA	0	-1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
60364	19928	 9157	cisplatin	Compound	PLK3	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
60618	19928	20152	cisplatin	Compound	PDE4A	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
61571	19928	 2095	cisplatin	Compound	DDIT4	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
62307	19928	11938	cisplatin	Compound	DGKA	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
62950	19928	 7195	cisplatin	Compound	GADD45A	mRNA	-1	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
 6429	19928	16586	cisplatin	Compound	CPT2	mRNA	0	-1	12234291	Cisplatin decreased mRNA levels of peroxisomal acyl-CoA enzyme in mouse kidney and also reduced the mRNA levels and enzyme activities of acyl-CoA and mitochondrial CPT-1 in LLCPK1 cells.
65482	19928	16219	cisplatin	Compound	PROCR	mRNA	0	1	17616683	Microarray analysis of the transcriptome of H1975 cells treated with BMS-690514 or CDDP. H1975 cells were treated with either 5 mol/L (1 mol/L) BMS-690514 and 50 mol/L (25 mol/L) CDDP for 24 h (48 h) and subjected to RNA isolation. Total RNA was then retrotranscribed into double-stranded cDNA followed by T7 RNA polymerase?mediated linear amplification, labeling, and hybridization to a human whole genome 44k oligonucleotide array. Samples from treated cultures were compared with cRNAs obtained through the same procedure from untreated cells.  From Supplementary Table S1, which contains a complete list of genes that are transcriptionally modulated by BMS-690514 by a factor higher than 2. n.s., nonstatistically significant P value (>10?5). H1975 cells have a secondary somatic EGFR mutation T790M which confers resistance to erlotinib. BMS-690514, a novel panHER/VEGFR inhibitor described here, exerted antiproliferative and pro-apoptotic effects on NSCLC cell lines, with prominent efficacy on H1975 cells expressing the T790M mutation.(I included only 24h time points-JSP)
65916	19928	 2631	cisplatin	Compound	PPARGC1A	mRNA	0	-1	12234291	Cisplatin diminished the expression of PGC-1 mRNA levels in mouse kidney
  698	19928	 8903	cisplatin	Compound	PIDD	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
 7196	19928	13296	cisplatin	Compound	ANK1	mRNA	0	1	15940259	Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation.
 9195	19928	 8408	cisplatin	Compound	PPARGC1B	mRNA	0	-1	12234291	Cisplatin diminished the expression of PGC-1 mRNA levels in mouse kidney and also in LLCPK1 cells. Transient expression of PGC-1 shows the nuclear localization of PGC-1 protein and increased PPARalpha transcriptional activity in LLCPK1 cells.
12722	18115	13434	Akt Family	Protein	HIF1A	mRNA	0	1	14982927	FSH-stimulated HIF-1 activity is inhibited by the PI 3-kinase inhibitor LY294002, the Rheb inhibitor FTI-277 (farnesyltransferase inhibitor-277), and the mTOR inhibitor rapamycin. These results show that FSH enhances HIF-1 activity downstream of the PI 3-kinase/AKT/Rheb/mTOR pathway in GCs and that HIF-1 activity is necessary for FSH to induce multiple follicular differentiation markers.
13884	18115	17250	Akt Family	Protein	PTGS2	mRNA	0	1	11289146	Thus, Akt/PKB activity is involved in K-Ras-induced expression of COX-2 and stabilization of COX-2 mRNA largely depends on the activation of Akt/PKB.
24572	18115	 2720	Akt Family	Protein	TAGLN	mRNA	-1	-1	12882977	Consistent with the results obtained with transient co-transfections with myr-Akt, the AVP-mediated increase in SM-{alpha}-actin and SM22{alpha} promoter activity was also blocked in cells stably expressing myr-Akt (Fig. 6).
29091	18115	15583	Akt Family	Protein	IKBKB	mRNA	0	1	12566451	It was found that the inhibition of Akt, mediated by K10 expression, leads to impaired NF-kappa B activity. This appears to occur through the decreased expression of IKK beta and IKK gamma. Remarkably, increased production of tumor necrosis factor alpha and concomitant JNK activation was observed in the epidermis of these transgenic mice.
29821	18115	  252	Akt Family	Protein	BCL2L11	mRNA	0	-1	19088189	On Myr-Akt expression (constitutively activated Akt), we have noticed a significant reduction in Bim expression (Fig. S5), and induction of FoxO3a phosphorylation and nuclear exclusion (Fig. 3D).
 3190	18115	16645	Akt Family	Protein	CCND1	mRNA	0	1	15572689	To dissect the biochemical mechanism(s) underlying the ability of these protein kinases to promote the cell division cycle, we used Western blotting to assess the effects of RAF and AKT on the expression of a number of proteins known to be targets of RAF or AKT signaling. Of the various immediate- early targets of RAF signaling that we analyzed (e.g., Fos, Jun, c-Myc, and HB-EGF), none showed evidence of cooperative regulation in response to coactivation of AKT and RAF (data not shown) (11, 33, 34). However, we observed cooperative effects of RAF and AKT on the expression of two key cell cycle regulators, cyclin D1 and p27Kip1. Activation of AKT or RAF alone led to a two- or threefold induction of cyclin D1 expression, respectively (Fig. 2A).
34661	18115	 2414	Akt Family	Protein	IKBKG	mRNA	0	1	12566451	It was found that the inhibition of Akt, mediated by K10 expression, leads to impaired NF-kappa B activity. This appears to occur through the decreased expression of IKK beta and IKK gamma. Remarkably, increased production of tumor necrosis factor alpha and concomitant JNK activation was observed in the epidermis of these transgenic mice.
39562	18115	13744	Akt Family	Protein	CDKN1B	mRNA	-1	-1	15572689	However, coactivation of both signaling pathways led to a sixfold induction of cyclin D1. These observations are consistent with previous reports of cooperative regulation of cyclin D1 by RAS effector pathways and with the reported effects of the ERK mitogen-activated protein kinase pathway on cyclin D1 gene transcription and of AKT on cyclin D1 protein stabilization (1, 2, 13, 19). Activation of AKT alone had only a modest effect on p27Kip1 expression, consistent with previous observations that suggest that AKT activation reduces p27Kip1 expression by 50% (38). By contrast, activation of RAF alone led to significant repression of p27Kip1 expression, but this was not clearly manifest until 12 to 24 h after RAF activation. Strikingly, coactivation of RAF and AKT led to a rapid and profound repression of p27Kip1 expression that was clearly evident at 6 h and continued up to 24 h (Fig. 2A). It is noteworthy that the effects of RAF activation alone on cyclin D1 and p27Kip1 expression, especially at later time points, are likely enhanced due to activation of PI3p-kinase signaling through the release of autocrine growth factors such as HB-EGF (34, 58). The expression of p27Kip1 is reported to be under both transcriptional and posttranscriptional control (31, 38, 42, 54, 61). To investigate the mechanism(s) underlying the regulated expression of p27Kip1 by RAF and AKT, we assessed the effects of these protein kinases on KIP1 mRNA expression in 3T3-RA cells (Fig. 2B and C). Consistent with previous observations, activation of AKT alone led to a 50% reduction of KIP1 mRNA that was evident after 24 h (38).
 4729	18115	 7009	Akt Family	Protein	SREBF1	mRNA	0	1	14505487	Variant PKBCaaX has constitutive PKB activity and induces GCK and SREBP1 mRNAs
51228	18115	 6941	Akt Family	Protein	TFAM	mRNA	0	1	16230352	The oxidant response was also abrogated by specific inhibition of Akt/protein kinase B.
51493	18115	15841	Akt Family	Protein	FBXO32	mRNA	-1	-1	15781459	In cardiac myocyte cultures, transduction with constitutively active Akt or treatment with IGF suppressed atrogin-1 mRNA expression, whereas transduction with FOXO3a stimulated its expression.
57249	18115	 3616	Akt Family	Protein	CD40	mRNA	0	1	17660512	Coimmunoprecipitation analysis revealed that leptin promoted immune complex formation between Akt and the IkappaB kinase subunits as well as STAT-1alpha. Blocking the activity of Akt demonstrated a crucial role for Akt in translocation of STAT-1alpha and NF-kappaB to the nucleus and activation of the CD40 promoter. [CD40 mRNA and protein]
59665	18115	 7590	Akt Family	Protein	GCK	mRNA	0	1	14505487	Variant PKBCaaX has constitutive PKB activity and induces GCK and SREBP1 mRNAs
59691	18115	10088	Akt Family	Protein	Acta2	mRNA	0	-1	12882977	PDGF decreased expression of SM alpha-actin. PI3K inhibitor almost completely reversed this inhibition. Expression of activated form of Akt also suppressed SM alpha-actin promoter activity.
14480	 5271	18103	FOXF2	Protein	LPL	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
15491	 5271	18775	FOXF2	Protein	PFKFB3	mRNA	0	-1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
17015	 5271	 3722	FOXF2	Protein	PPARG	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
 2470	 5271	17889	FOXF2	Protein	SLC2A4	mRNA	1	-1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
36743	 5271	 4528	FOXF2	Protein	PKM2	mRNA	0	-1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
44220	 5271	17671	FOXF2	Protein	KCNJ11	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
45795	 5271	 4835	FOXF2	Protein	PPARA	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
 4727	 5271	 7009	FOXF2	Protein	SREBF1	mRNA	0	-1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
56869	 5271	 2025	FOXF2	Protein	KCNJ8	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
 6553	 5271	 5466	FOXF2	Protein	ACACB	mRNA	0	-1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
 8362	 5271	13252	FOXF2	Protein	ABCC9	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
25846	11577	19027	BACH1	Protein	HMOX1	mRNA	0	-1	20083128	As shown in Fig. 4F, without addition of arsenite, Bach1or Bach1 mutants suppressed HO-1 reporter activity. When arsenite was added, Bach1-mediated repression of reporter activity was reactivated, while it was attenuated in cells transfected with Bach1 C557S or C574S mutant compared to the wild type.
28898	11577	 8621	BACH1	Protein	NQO1	mRNA	0	-1	15734732	Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants
36839	11577	 7294	BACH1	Protein	TXNRD1	mRNA	0	-1	17901053	Bach1 Repression of Ferritin and Thioredoxin Reductase1
39155	11577	10733	BACH1	Protein	FTL	mRNA	0	-1	17901053	Bach1 Repression of Ferritin and Thioredoxin Reductase1
40256	11577	10582	BACH1	Protein	TBXAS1	mRNA	0	-1	15613547	A ChIP assay with UT-7/TPO cells demonstrated that BACH1 bound to the promoter and enhancer regions in vivo. ....As expected, cotransfection with BACH1 or B1K expression plasmids repressed the reporter gene activity driven by the TXAS promoter in a dose-dependent manner (Figure 9)
61148	11577	 7669	BACH1	Protein	FTH1	mRNA	0	-1	17901053	Bach1 Repression of Ferritin and Thioredoxin Reductase1
62005	11577	 2608	BACH1	Protein	HBB	mRNA	1	-1	15175654	Bach1 is a transcriptional repressor of heme oxygenase-1 and beta-globin genes, both of which are known to be transcriptionally induced by heme.
19577	18852	 3106	Mapk Erk Family	Protein	ADCYAP1R1	mRNA	0	1	12358767	The mitogen-activated protein kinase (MAPK) kinase inhibitor, PD98059, prevented the transcriptional effects both in PC12 and cerebellar granule cells
19644	18852	16486	Mapk Erk Family	Protein	SPP1	mRNA	1	1	15557322	USF proteins are regulated by the extracellular signal-regulated kinase (ERK)1/2 pathway, just as the earlier discovered AP-1 complex, whereas NFkappaB is up-regulated through PKCdelta signals.
19757	18852	 8410	Mapk Erk Family	Protein	GJB1	mRNA	0	-1	15350541	The downregulated connexin32 expression was inhibited by treatment with a MAP-kinase inhibitor (PD98059), whereas the upregulated claudin-2 expression was blocked by p38 MAP and PI3-kinase inhibitors (SB203580 and LY294002)
28238	18852	 7832	Mapk Erk Family	Protein	THBS1	mRNA	-1	1	16019429	We show that PDGF-BB induces TSP-1 and TGF-beta1 via the src kinase pathway whereas TNF-a utilizes the MAPK/Erk pathway
43525	18852	10899	Mapk Erk Family	Protein	TGFB1	mRNA	0	1	16019429	We show that PDGF-BB induces TSP-1 and TGF-beta1 via the src kinase pathway whereas TNF-a utilizes the MAPK/Erk pathway
23780	16322	 6636	Stat5 Family	Protein	BCL2L1	mRNA	0	1	10469654	The mutant STAT5 possessed constitutive tyrosine phosphorylation and DNA binding activity, induced expression of bcl-xL and pim-1 in the absence of IL-3 in Ba/F3 cells,
24826	16322	 5863	Stat5 Family	Protein	MYC	mRNA	0	1	10679091	STAT molecules conventionally require both a conserved tyrosine phosphorylation site and a C-terminal TAD to mediate transcription. c-myc is induced in an immediate-early fashion, suggesting that Stat5 may interact directly with promoter of this gene rather than via an intermediary transcription factor.
43132	16322	16764	Stat5 Family	Protein	PIM1	mRNA	0	1	10469654	The mutant STAT5 possessed constitutive tyrosine phosphorylation and DNA binding activity, induced expression of bcl-xL and pim-1 in the absence of IL-3 in Ba/F3 cells,
43667	16322	 6939	Stat5 Family	Protein	NSUN5	mRNA	0	1	16641140	We demonstrate the importance of STAT3 and STAT5 in mediating the G-CSF response with respect to p120 expression by transient transfection analysis, oligonucleotide pull-down assays, and the loss of p120 expression in the bone marrow of mice lacking normal STAT3 signaling.
45362	16322	14987	Stat5 Family	Protein	BCL2	mRNA	1	1	10679091	Stat5 mediates c-myc, bcl-2, and bcl-x mRNA induction through its TAD.
57392	16322	 3336	Stat5 Family	Protein	CCND2	mRNA	0	1	11160217	Modified assertion
32441	 9777	20190	NFYB	Protein	ABCB1	mRNA	0	1	10644769	This  mutant NF-YA, which sequesters NF-YB and NF-YC into a functionally inactive  heterotrimer ( 32 ), significantly reduced activation of the MDR1 promoter by  UV irradiation (Fig. 3 A ), indicating a role for NF-Y in the UV response......We have previously shown that the CCAAT box-binding protein, NF-Y, mediates MDR1 activation by the histone deacetylase inhibitors, trichostatin A and sodium butyrate, through the recruitment of the co-activator, P/CAF. (9632821)--[shows direct NF-Y subunit binding --DD]
38823	 9777	14027	NFYB	Protein	COL5A1	mRNA	-1	1	12805369	However, our recent study indicated that CBF/NF-Y is also responsible for the basal promoter activity of the alpha1(V) collagen gene. 2 These observations suggest that CBF/NF-Y plays an important role in the basal transcriptional regulation of some fibrillar collagens (alpha1(XI) and alpha1(V) in addition to alpha1(I) and alpha2(I), as described previously) that are expressed in non-cartilaginous tissues.......As shown in Fig. 4C, the DNA-protein complex was only supershifted by anti-CBF antibodies, namely anti-CBF-A/NF-YB (Fig. 4C, lane 3), CBF-B/NF-YA (Fig. 4C, lane 4), and CBF-C/NF-YC (Fig. 4C, lane 5).
46149	 9777	 4406	NFYB	Protein	CD34	mRNA	0	1	10572091	Figure 5B shows that addition of either of the two anti-NFYA antibodies to the binding reactions supershifted a prominent complex (lanes 3 and 4) and the anti-NFYB antibody diminished binding significantly (lane 5).   To test the functional effect of NFY binding to the +60/+64 region, we introduced point mutations abolishing the binding of NFY to its site (see Fig 5A and Fig 5B; lane 14) and incorporated them into a luciferase plasmid containing base pairs -391/+175 from the human CD34 promoter (constructs diagramed in Fig 5C). As shown in Fig 5D, mutating the NFY site (Y-M+ construct) resulted in a 5-fold decrease in luciferase activity in transiently transfected KG1a cells and a 4-fold decrease in RPMI-8402 cells, as compared with the wild-type construct (Y+M+ construct).
14532	12703	 8287	Pravastatin	Compound	ATP7A	mRNA	-1	1	16678288	BACKGROUND: Beyond lipid lowering, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) has been found to have anti-inflammatory and anti-thrombotic effects. However, the genetic expression pattern changes in atherosclerotic lesions produced by statin are rarely studied. METHODS: Cholesterol-fed apolipoprotein (Apo) E-deficient mice were examined for the treatment effect of statin on aortic gene expression. ApoE-deficient mice were fed with a hypercholesterolemic diet started at 8 weeks of age for a total of 22 weeks. In the statin treatment group (n=25), the ApoE-deficient mice were treated with pravastatin (80 mg/kg/day) dissolved in water by daily oral inoculation from 25 to 30 weeks of age. For the control group (n=25), the ApoE-deficient mice were orally inoculated with water only for the same period of time. The aortic gene expression affected by pravastatin was identified using oligonucleotide microarray technology with Agilent gene chips. RESULTS: The total cholesterol and atherosclerotic lesion/total aortic area were significantly lower in the pravastatin treatment group. Microarray analysis of the expression of 20,281 murine genes in the aortas between the two groups indicated that 94 genes were significantly regulated. Thirty genes were up-regulated and 64 genes were down-regulated. The most up-regulated genes were troponin T3, actin alpha(1), tubulin alpha(1), regulator of G-protein signaling 5 (Rgs5), stathmin-like 2 and myosin light chain kinase. Most of them are related with cytoskeleton organization, while Rgs5 is a G-protein signal transduction molecule. The most down-regulated genes were adenosine deaminase, atrial natriuretic peptide, troponin T(2), FXYD domain-containing ion transport regulator 3, and glutathione S-transferase alpha(4). CONCLUSIONS: The beneficial effect of the 6-week statin treatment in ApoE-deficient mice is largely dependent on its influence on the cytoskeleton organization. Our study results might provide insight into the clinical benefits of chronic statin treatment.
23044	12703	 5147	Pravastatin	Compound	NUPR1	mRNA	1	1	16678288	BACKGROUND: Beyond lipid lowering, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) has been found to have anti-inflammatory and anti-thrombotic effects. However, the genetic expression pattern changes in atherosclerotic lesions produced by statin are rarely studied. METHODS: Cholesterol-fed apolipoprotein (Apo) E-deficient mice were examined for the treatment effect of statin on aortic gene expression. ApoE-deficient mice were fed with a hypercholesterolemic diet started at 8 weeks of age for a total of 22 weeks. In the statin treatment group (n=25), the ApoE-deficient mice were treated with pravastatin (80 mg/kg/day) dissolved in water by daily oral inoculation from 25 to 30 weeks of age. For the control group (n=25), the ApoE-deficient mice were orally inoculated with water only for the same period of time. The aortic gene expression affected by pravastatin was identified using oligonucleotide microarray technology with Agilent gene chips. RESULTS: The total cholesterol and atherosclerotic lesion/total aortic area were significantly lower in the pravastatin treatment group. Microarray analysis of the expression of 20,281 murine genes in the aortas between the two groups indicated that 94 genes were significantly regulated. Thirty genes were up-regulated and 64 genes were down-regulated. The most up-regulated genes were troponin T3, actin alpha(1), tubulin alpha(1), regulator of G-protein signaling 5 (Rgs5), stathmin-like 2 and myosin light chain kinase. Most of them are related with cytoskeleton organization, while Rgs5 is a G-protein signal transduction molecule. The most down-regulated genes were adenosine deaminase, atrial natriuretic peptide, troponin T(2), FXYD domain-containing ion transport regulator 3, and glutathione S-transferase alpha(4). CONCLUSIONS: The beneficial effect of the 6-week statin treatment in ApoE-deficient mice is largely dependent on its influence on the cytoskeleton organization. Our study results might provide insight into the clinical benefits of chronic statin treatment.
27861	12703	 1166	Pravastatin	Compound	SLC2A1	mRNA	-1	-1	16678288	BACKGROUND: Beyond lipid lowering, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) has been found to have anti-inflammatory and anti-thrombotic effects. However, the genetic expression pattern changes in atherosclerotic lesions produced by statin are rarely studied. METHODS: Cholesterol-fed apolipoprotein (Apo) E-deficient mice were examined for the treatment effect of statin on aortic gene expression. ApoE-deficient mice were fed with a hypercholesterolemic diet started at 8 weeks of age for a total of 22 weeks. In the statin treatment group (n=25), the ApoE-deficient mice were treated with pravastatin (80 mg/kg/day) dissolved in water by daily oral inoculation from 25 to 30 weeks of age. For the control group (n=25), the ApoE-deficient mice were orally inoculated with water only for the same period of time. The aortic gene expression affected by pravastatin was identified using oligonucleotide microarray technology with Agilent gene chips. RESULTS: The total cholesterol and atherosclerotic lesion/total aortic area were significantly lower in the pravastatin treatment group. Microarray analysis of the expression of 20,281 murine genes in the aortas between the two groups indicated that 94 genes were significantly regulated. Thirty genes were up-regulated and 64 genes were down-regulated. The most up-regulated genes were troponin T3, actin alpha(1), tubulin alpha(1), regulator of G-protein signaling 5 (Rgs5), stathmin-like 2 and myosin light chain kinase. Most of them are related with cytoskeleton organization, while Rgs5 is a G-protein signal transduction molecule. The most down-regulated genes were adenosine deaminase, atrial natriuretic peptide, troponin T(2), FXYD domain-containing ion transport regulator 3, and glutathione S-transferase alpha(4). CONCLUSIONS: The beneficial effect of the 6-week statin treatment in ApoE-deficient mice is largely dependent on its influence on the cytoskeleton organization. Our study results might provide insight into the clinical benefits of chronic statin treatment.
 2814	12703	 7073	Pravastatin	Compound	FXYD3	mRNA	-1	-1	16678288	BACKGROUND: Beyond lipid lowering, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) has been found to have anti-inflammatory and anti-thrombotic effects. However, the genetic expression pattern changes in atherosclerotic lesions produced by statin are rarely studied. METHODS: Cholesterol-fed apolipoprotein (Apo) E-deficient mice were examined for the treatment effect of statin on aortic gene expression. ApoE-deficient mice were fed with a hypercholesterolemic diet started at 8 weeks of age for a total of 22 weeks. In the statin treatment group (n=25), the ApoE-deficient mice were treated with pravastatin (80 mg/kg/day) dissolved in water by daily oral inoculation from 25 to 30 weeks of age. For the control group (n=25), the ApoE-deficient mice were orally inoculated with water only for the same period of time. The aortic gene expression affected by pravastatin was identified using oligonucleotide microarray technology with Agilent gene chips. RESULTS: The total cholesterol and atherosclerotic lesion/total aortic area were significantly lower in the pravastatin treatment group. Microarray analysis of the expression of 20,281 murine genes in the aortas between the two groups indicated that 94 genes were significantly regulated. Thirty genes were up-regulated and 64 genes were down-regulated. The most up-regulated genes were troponin T3, actin alpha(1), tubulin alpha(1), regulator of G-protein signaling 5 (Rgs5), stathmin-like 2 and myosin light chain kinase. Most of them are related with cytoskeleton organization, while Rgs5 is a G-protein signal transduction molecule. The most down-regulated genes were adenosine deaminase, atrial natriuretic peptide, troponin T(2), FXYD domain-containing ion transport regulator 3, and glutathione S-transferase alpha(4). CONCLUSIONS: The beneficial effect of the 6-week statin treatment in ApoE-deficient mice is largely dependent on its influence on the cytoskeleton organization. Our study results might provide insight into the clinical benefits of chronic statin treatment.
38733	12703	18764	Pravastatin	Compound	AKT1	mRNA	1	1	16891763	Pravastatin significantly increased the number of EPC and decreased the number of SMPC. mRNA expression of VEGF, endothelial nitric oxide synthase, VEGF receptor-2 (KDR), and Akt were up-regulated, and VEGF secretion was increased by pravastatin.
40959	12703	 4582	Pravastatin	Compound	NOS3	mRNA	1	1	16891763	Pravastatin significantly increased the number of EPC and decreased the number of SMPC. mRNA expression of VEGF, endothelial nitric oxide synthase, VEGF receptor-2 (KDR), and Akt were up-regulated, and VEGF secretion was increased by pravastatin.
59516	12703	 2671	Pravastatin	Compound	RHOU	mRNA	-1	1	15358814	TABLE 1  Overlap in alterations of gene expression induced by lovastatin, simvastatin, and pravastatin in the cerebral cortex of C57BL/6 mice
66085	12703	16821	Pravastatin	Compound	DST	mRNA	1	-1	16678288	BACKGROUND: Beyond lipid lowering, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) has been found to have anti-inflammatory and anti-thrombotic effects. However, the genetic expression pattern changes in atherosclerotic lesions produced by statin are rarely studied. METHODS: Cholesterol-fed apolipoprotein (Apo) E-deficient mice were examined for the treatment effect of statin on aortic gene expression. ApoE-deficient mice were fed with a hypercholesterolemic diet started at 8 weeks of age for a total of 22 weeks. In the statin treatment group (n=25), the ApoE-deficient mice were treated with pravastatin (80 mg/kg/day) dissolved in water by daily oral inoculation from 25 to 30 weeks of age. For the control group (n=25), the ApoE-deficient mice were orally inoculated with water only for the same period of time. The aortic gene expression affected by pravastatin was identified using oligonucleotide microarray technology with Agilent gene chips. RESULTS: The total cholesterol and atherosclerotic lesion/total aortic area were significantly lower in the pravastatin treatment group. Microarray analysis of the expression of 20,281 murine genes in the aortas between the two groups indicated that 94 genes were significantly regulated. Thirty genes were up-regulated and 64 genes were down-regulated. The most up-regulated genes were troponin T3, actin alpha(1), tubulin alpha(1), regulator of G-protein signaling 5 (Rgs5), stathmin-like 2 and myosin light chain kinase. Most of them are related with cytoskeleton organization, while Rgs5 is a G-protein signal transduction molecule. The most down-regulated genes were adenosine deaminase, atrial natriuretic peptide, troponin T(2), FXYD domain-containing ion transport regulator 3, and glutathione S-transferase alpha(4). CONCLUSIONS: The beneficial effect of the 6-week statin treatment in ApoE-deficient mice is largely dependent on its influence on the cytoskeleton organization. Our study results might provide insight into the clinical benefits of chronic statin treatment.
43613	19725	 2451	cytokine	Compound	YWHAG	mRNA	-1	1	15010287	This study indicates that 14-3-3gamma expression is induced in arterial trauma by cytokines
60970	19725	 2450	cytokine	Compound	ITGA6	mRNA	-1	-1	 8999943	Moreover, cytokine treatment resulted in down-modulated expression of the alpha6 integrin subunit and the 67LR.
32360	10428	 3118	MLXIPL	Protein	ACACA	mRNA	0	1	14985368	Decreased ChREBP gene expression, achieved using small interfering RNA, results in a loss of glucose effect on endogenous glycolytic (l-PK) and lipogenic (FAS, ACC) gene expression,
56733	10428	18995	MLXIPL	Protein	FASN	mRNA	0	1	15496471	ACC, FAS, and LPK mRNA levels were higher in WT hepatocytes cultured with high (25 mM) rather than low (5.5 mM) glucose medium, but there was no effect of glucose concentration on these mRNA levels in ChREBP(-/-) hepatocytes. Similarly, reporter constructs containing ACC, FAS, or LPK gene ChREs were responsive to glucose when transfected into WT but not ChREBP(-/-) hepatocytes, and glucose transactivation of the constructs in ChREBP(-/-) hepatocytes was restored by cotransfection with a ChREBP expression plasmid. ChREBP binding to ACC, FAS, and LPK ChRE sequences in vitro was demonstrated by electrophoretic mobility super shift assays.
 7275	10428	16053	MLXIPL	Protein	PKLR	mRNA	-1	1	15496471	ACC, FAS, and LPK mRNA levels were higher in WT hepatocytes cultured with high (25 mM) rather than low (5.5 mM) glucose medium, but there was no effect of glucose concentration on these mRNA levels in ChREBP(-/-) hepatocytes. Similarly, reporter constructs containing ACC, FAS, or LPK gene ChREs were responsive to glucose when transfected into WT but not ChREBP(-/-) hepatocytes, and glucose transactivation of the constructs in ChREBP(-/-) hepatocytes was restored by cotransfection with a ChREBP expression plasmid. ChREBP binding to ACC, FAS, and LPK ChRE sequences in vitro was demonstrated by electrophoretic mobility super shift assays.
13658	18932	 1438	Prka Family	Protein	VEGFA	mRNA	0	1	17464208	These results indicate that PKA phosphorylates CREB and so induces VEGF gene expression.
16257	18932	15838	Prka Family	Protein	PER1	mRNA	0	1	11876785	inhibitors of protein kinase A and phospholipase C mediated signalling. Our results demonstrate that both pathways are involved in VIP induced per gene expression
23901	18932	 5783	Prka Family	Protein	CEBPB	mRNA	0	1	15299028	PGE2-dependent activation of C/EBPbeta was blocked by expression of a mutated regulatory subunit of protein kinase A or by mutation of two previously identified cAMP-sensitive cis-acting regulatory elements within the promoter between bp -111 and -61. Nuclear protein binding to these elements was induced by PGE2, required new protein synthesis, and was sensitive to antibody to the transcription factor termed Fos-related antigen 2 (Fra-2).
25146	18932	 7753	Prka Family	Protein	CREM	mRNA	0	1	12753864	PTH(1-34), forskolin (FSK), and 8-bromo-cAMP (8Br-cAMP) induced ICER expression, while phorbol myristate acetate (PMA), ionomycin, and PTH(3-34) did not.
35085	18932	14468	Prka Family	Protein	CARTPT	mRNA	0	1	15207912	Changes in Cocaine- and Amphetamine-Regulated Transcript (CART) mRNA levels have been observed in brain as a result of various physiologic stimuli including feeding, drugs of abuse, stress and glucocorticoids, and activators of the cyclic AMP (cAMP) and protein kinase A (PKA) pathway.
39953	18932	 6114	Prka Family	Protein	NFKBIA	mRNA	1	1	12050158	NE activated a 1.3-kilobase I kappa B alpha promoter transfected into astrocytes or C6 glioma cells, and this activation was prevented by a beta-antagonist and by protein kinase A inhibitors but not by an NF kappa B inhibitor.
40848	18932	11880	Prka Family	Protein	AGXT	mRNA	0	1	12169688	Transcription of mitochondrial serine:pyruvate aminotransferase (SPT) mRNA (SPTm-mRNA) in rat liver is unique in that it occurs from the upstream site of the two transcription start sites within the first exon of the SPT gene and is selectively enhanced by cAMP via the protein kinase A (PKA) signaling pathway.
43545	18932	17125	Prka Family	Protein	PER2	mRNA	0	1	11876785	inhibitors of protein kinase A and phospholipase C mediated signalling. Our results demonstrate that both pathways are involved in VIP induced per gene expression
57399	18932	 3336	Prka Family	Protein	CCND2	mRNA	0	1	16625003	promoter activity of cyclin D2 was shown to be induced by FSH and the catalytic alpha subunit of PKA (PRKACA)
59564	18932	12930	Prka Family	Protein	OXTR	mRNA	0	1	11264328	Ariadne: In vitro , OTR  expression is increased by activation of protein kinase A (PKA) or protein kinase C (PKC) (Bale and Dorsa, 1998 ).
 6109	18932	16922	Prka Family	Protein	RRM2	mRNA	0	-1	11900481	The NE stimulation of R2 expression in preadipocytes was mimicked by forskolin and abolished by H89, demonstrating mediation via cAMP and protein kinase A (PKA). Also, inhibitors of Src and of Erk1/2 kinases markedly reduced NE-stimulated R2 expression.
13814	 6626	17250	KAT5	Protein	PTGS2	mRNA	0	1	12963740	There is an initial activation of cPLA2 that induces  expression of Group V PLA2, which in turn induces both the expression of COX-2  and most of the arachidonic acid substrate for COX-2-dependent prostaglandin E2  generation.
24874	 6626	 5863	KAT5	Protein	MYC	mRNA	0	-1	12551922	Furthermore, interleukin-9-induced c-myc expression, which depends on STAT3 activity, is abrogated by exogenous expression of Tip60.
 3430	 6626	10915	KAT5	Protein	BAX	mRNA	0	-1	18499675	TIP60 also negatively regulated the expression of p73beta downstream target genes such as p21 and Bax.
34437	 6626	13145	KAT5	Protein	APBA1	mRNA	0	-1	15331662	Binding of AICD to X11alpha was associated with decreased nuclear levels of AICD. (E) Co-expression of Tip60 had no effect on the extranuclear localization of either X11alpha or AICD.
51079	 6626	13884	KAT5	Protein	CDKN1A	mRNA	1	-1	18499675	TIP60 also negatively regulated the expression of p73beta downstream target genes such as p21 and Bax.
  220	13314	16238	histone deacetylase inhibitor	Compound	PSAP	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
26426	13314	 3644	histone deacetylase inhibitor	Compound	RPN2	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
41523	13314	16466	histone deacetylase inhibitor	Compound	MT-ND4L	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
42478	13314	16141	histone deacetylase inhibitor	Compound	EPB41	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
 4815	13314	 4107	histone deacetylase inhibitor	Compound	FLRT3	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
50983	13314	13884	histone deacetylase inhibitor	Compound	CDKN1A	mRNA	1	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
56200	13314	  101	histone deacetylase inhibitor	Compound	MT-ATP8	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
61082	13314	17053	histone deacetylase inhibitor	Compound	HSPA1A	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
65496	13314	20004	histone deacetylase inhibitor	Compound	PTRF	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
 8574	13314	19313	histone deacetylase inhibitor	Compound	GRN	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
 8810	13314	 1900	histone deacetylase inhibitor	Compound	PRDX1	mRNA	0	1	16278420	The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Table 2. List of11genes up-regulated (>2-fold changes at least at one time point) in both T.Tn and TE2 cells
54351	18063	 1814	SALL4	Protein	POU5F1	mRNA	-1	1	16980957	Sall4 regulates transcription of Pou5f1 which encodes Oct4. Sall4 binds to the highly conserved regulatory region of the Pou5f1 distal enhancer and activates Pou5f1 expression in vivo and in vitro.
 8022	18063	17704	SALL4	Protein	BMI1	mRNA	0	1	17557835	Here, we demonstrate that transcription from the Bmi-1 promoter is strikingly activated by SALL4 in a dose-dependent manner by using a luciferase reporter gene assay. Both promoter deletion construct studies and ChIP from a myeloid stem cell line, 32D, demonstrate that SALL4 binds to a specific region of the Bmi-1 promoter. Deletion of one copy of Sall4 by gene targeting in mouse bone marrow significantly reduced Bmi-1 expression. Reducing SALL4 expression by siRNA in the HL-60 leukemia cell line also results in significant down-regulation of Bmi-1. Furthermore, Bmi-1 expression is up-regulated in transgenic mice that constitutively overexpress human SALL4, and the levels of Bmi-1
16472	 1655	18083	PLAGL2	Protein	BNIP3	mRNA	-1	1	11832486	The expression of PLAGL2 in Balb/c3T3 cells led to the mRNA expression of a proapoptotic factor, Nip3, which can dimerize with Bcl-2
32423	 1655	 9825	PLAGL2	Protein	LDHA	mRNA	0	1	11832486	Furthermore, mouse PLAGL2 and Zac1 can activate the transcription of the  LDHA promoter, which contains HRE ( 17 ).
52171	 1655	 8500	PLAGL2	Protein	EPO	mRNA	0	1	11832486	Furthermore, the transient  expression of PLAGL2 led to the stimulation of luciferase reporter activities  of the LDHA and erythropoietin promoters that carry HRE ( 17 ).
65568	 1655	14743	PLAGL2	Protein	IGF2	mRNA	0	1	11888928	the PLAG1- and PLAGL2-induced transformation is accompanied by a drastic up-regulation of insulin-like growth factor-II, which we prove is a target of PLAG1 and PLAGL2
11201	16154	 3894	Wnt Family	Protein	CLK2	mRNA	0	1	14707084	The up-regulated genes included proliferation-inducing transcription factors such as c-fos, fosB, and other nuclear proteins (AHNAK, glucocorticoid-induced lymphoid Zinc finger (GILZ), and cysteine- rich protein (CRP)1 and CRP2), cell cycle regulators (checkpoint suppressor 1, cyclin-dependent kinase 15 kinase, cdc-like kinase 2, and end-binding protein 3, which binds mitotic spindles), and signaling molecules such as the CL100 dual-specificity phosphatase.
13898	16154	17250	Wnt Family	Protein	PTGS2	mRNA	0	1	15225871	Cyclin D1 and MYC are examples of direct Wnt target genes in proliferation and whose activation requires the LEF/TCF sites in the respective promoters (He et al., 1998 and Tetsu and McCormick, 1999). Cyclin D1 and MYC have critical roles in G1 progression, but Cyclin D1 expression best correlates with breast proliferation.
20173	16154	14301	Wnt Family	Protein	FOXN3	mRNA	0	1	14707084	The up-regulated genes included proliferation-inducing transcription factors such as c-fos, fosB, and other nuclear proteins (AHNAK, glucocorticoid-induced lymphoid Zinc finger (GILZ), and cysteine- rich protein (CRP)1 and CRP2), cell cycle regulators (checkpoint suppressor 1, cyclin-dependent kinase 15 kinase, cdc-like kinase 2, and end-binding protein 3, which binds mitotic spindles), and signaling molecules such as the CL100 dual-specificity phosphatase.
21514	16154	 5054	Wnt Family	Protein	CSRP1	mRNA	0	1	14707084	The up-regulated genes included proliferation-inducing transcription factors such as c-fos, fosB, and other nuclear proteins (AHNAK, glucocorticoid-induced lymphoid Zinc finger (GILZ), and cysteine- rich protein (CRP)1 and CRP2), cell cycle regulators (checkpoint suppressor 1, cyclin-dependent kinase 15 kinase, cdc-like kinase 2, and end-binding protein 3, which binds mitotic spindles), and signaling molecules such as the CL100 dual-specificity phosphatase.
24861	16154	 5863	Wnt Family	Protein	MYC	mRNA	0	1	15225871	Cyclin D1 and MYC are examples of direct Wnt target genes in proliferation and whose activation requires the LEF/TCF sites in the respective promoters (He et al., 1998 and Tetsu and McCormick, 1999). Cyclin D1 and MYC have critical roles in G1 progression, but Cyclin D1 expression best correlates with breast proliferation.
 3123	16154	16645	Wnt Family	Protein	CCND1	mRNA	0	1	15225871	Cyclin D1 and MYC are examples of direct Wnt target genes in proliferation and whose activation requires the LEF/TCF sites in the respective promoters (He et al., 1998 and Tetsu and McCormick, 1999). Cyclin D1 and MYC have critical roles in G1 progression, but Cyclin D1 expression best correlates with breast proliferation.
34183	16154	 3650	Wnt Family	Protein	CSRP2	mRNA	0	1	14707084	The up-regulated genes included proliferation-inducing transcription factors such as c-fos, fosB, and other nuclear proteins (AHNAK, glucocorticoid-induced lymphoid Zinc finger (GILZ), and cysteine- rich protein (CRP)1 and CRP2), cell cycle regulators (checkpoint suppressor 1, cyclin-dependent kinase 15 kinase, cdc-like kinase 2, and end-binding protein 3, which binds mitotic spindles), and signaling molecules such as the CL100 dual-specificity phosphatase.
46467	16154	 3085	Wnt Family	Protein	FOSB	mRNA	0	1	14707084	The up-regulated genes included proliferation-inducing transcription factors such as c-fos, fosB, and other nuclear proteins (AHNAK, glucocorticoid-induced lymphoid Zinc finger (GILZ), and cysteine- rich protein (CRP)1 and CRP2), cell cycle regulators (checkpoint suppressor 1, cyclin-dependent kinase 15 kinase, cdc-like kinase 2, and end-binding protein 3, which binds mitotic spindles), and signaling molecules such as the CL100 dual-specificity phosphatase.
48078	16154	11629	Wnt Family	Protein	FOS	mRNA	0	1	14707084	The up-regulated genes included proliferation-inducing transcription factors such as c-fos, fosB, and other nuclear proteins (AHNAK, glucocorticoid-induced lymphoid Zinc finger (GILZ), and cysteine- rich protein (CRP)1 and CRP2), cell cycle regulators (checkpoint suppressor 1, cyclin-dependent kinase 15 kinase, cdc-like kinase 2, and end-binding protein 3, which binds mitotic spindles), and signaling molecules such as the CL100 dual-specificity phosphatase.
53004	16154	19009	Wnt Family	Protein	TSC22D3	mRNA	1	1	14707084	The up-regulated genes included proliferation-inducing transcription factors such as c-fos, fosB, and other nuclear proteins (AHNAK, glucocorticoid-induced lymphoid Zinc finger (GILZ), and cysteine- rich protein (CRP)1 and CRP2), cell cycle regulators (checkpoint suppressor 1, cyclin-dependent kinase 15 kinase, cdc-like kinase 2, and end-binding protein 3, which binds mitotic spindles), and signaling molecules such as the CL100 dual-specificity phosphatase.
56185	16154	18720	Wnt Family	Protein	AHNAK	mRNA	0	1	14707084	The up-regulated genes included proliferation-inducing transcription factors such as c-fos, fosB, and other nuclear proteins (AHNAK, glucocorticoid-induced lymphoid Zinc finger (GILZ), and cysteine- rich protein (CRP)1 and CRP2), cell cycle regulators (checkpoint suppressor 1, cyclin-dependent kinase 15 kinase, cdc-like kinase 2, and end-binding protein 3, which binds mitotic spindles), and signaling molecules such as the CL100 dual-specificity phosphatase.
 5635	16154	18424	Wnt Family	Protein	DUSP1	mRNA	0	1	14707084	The up-regulated genes included proliferation-inducing transcription factors such as c-fos, fosB, and other nuclear proteins (AHNAK, glucocorticoid-induced lymphoid Zinc finger (GILZ), and cysteine- rich protein (CRP)1 and CRP2), cell cycle regulators (checkpoint suppressor 1, cyclin-dependent kinase 15 kinase, cdc-like kinase 2, and end-binding protein 3, which binds mitotic spindles), and signaling molecules such as the CL100 dual-specificity phosphatase.
 7281	 8570	16053	THRSP	Protein	PKLR	mRNA	-1	1	 8999918	We recently showed that S14 acts at the transcriptional level in the transduction of signals for increased expression of genes encoding lipogenic enzymes Spot 14 protein acts in the induction of mRNAs coding for key lipogenic (malic enzyme, ATP citrate-lyase, fatty acid synthase), glycolytic (pyruvate kinase), and gluconeogenic enzymes (phosphoenolpyruvate carboxykinase), as well as the diet-responsive type I deiodinase,
17437	 2207	14361	omeprazole	Compound	CXCL12	mRNA	-1	-1	15827235	Potent acid inhibition with proton pump inhibitors (PPIs) is widely used in clinical medicine, especially for gastroesophageal reflux disease. PPIs cause profound changes in the intragastric environment with near-neutral pH and increase serum concentration of the gastric secretagogue hormone gastrin. Long-term hypergastrinemia increases mucosal thickness and enterochromaffin-like cell density in gastric corpus mucosa and results in development of gastric carcinoids in experimental animals. Our aim was to study responses to potent acid inhibition by characterizing genome-wide gene expression changes in gastric corpus mucosa in rats dosed with the PPI omeprazole. Nine rats received 400 micromol/kg omeprazole daily for 10 wk. Seven rats received vehicle only. Analysis of gastric corpus with microarrays representing 11,848 genes identified 134 genes with changed gene expression levels in omeprazole-dosed rats. Several of the identified genes were previously known to be affected by potent acid inhibition. Of the 62 genes with known functions that changed gene expression levels after PPI dosing, 27 are known to be involved in proliferation and apoptosis and immune, inflammatory, and stress responses. Our study indicates that microarray analysis can detect relevant gene expression changes in the complex gastric tissue, and that cellular processes involved in cell growth and defense responses are strongly affected by PPI dosing. Many genes are identified that were not previously known to be affected by inhibition of gastric acid secretion or that have unknown biological functions. Characterization of the roles of these genes may give new insight into molecular responses to treatment with PPIs.
42079	 2207	13115	omeprazole	Compound	EGR1	mRNA	-1	-1	15827235	Potent acid inhibition with proton pump inhibitors (PPIs) is widely used in clinical medicine, especially for gastroesophageal reflux disease. PPIs cause profound changes in the intragastric environment with near-neutral pH and increase serum concentration of the gastric secretagogue hormone gastrin. Long-term hypergastrinemia increases mucosal thickness and enterochromaffin-like cell density in gastric corpus mucosa and results in development of gastric carcinoids in experimental animals. Our aim was to study responses to potent acid inhibition by characterizing genome-wide gene expression changes in gastric corpus mucosa in rats dosed with the PPI omeprazole. Nine rats received 400 micromol/kg omeprazole daily for 10 wk. Seven rats received vehicle only. Analysis of gastric corpus with microarrays representing 11,848 genes identified 134 genes with changed gene expression levels in omeprazole-dosed rats. Several of the identified genes were previously known to be affected by potent acid inhibition. Of the 62 genes with known functions that changed gene expression levels after PPI dosing, 27 are known to be involved in proliferation and apoptosis and immune, inflammatory, and stress responses. Our study indicates that microarray analysis can detect relevant gene expression changes in the complex gastric tissue, and that cellular processes involved in cell growth and defense responses are strongly affected by PPI dosing. Many genes are identified that were not previously known to be affected by inhibition of gastric acid secretion or that have unknown biological functions. Characterization of the roles of these genes may give new insight into molecular responses to treatment with PPIs.
48785	 2207	17731	omeprazole	Compound	DCN	mRNA	-1	1	15827235	Potent acid inhibition with proton pump inhibitors (PPIs) is widely used in clinical medicine, especially for gastroesophageal reflux disease. PPIs cause profound changes in the intragastric environment with near-neutral pH and increase serum concentration of the gastric secretagogue hormone gastrin. Long-term hypergastrinemia increases mucosal thickness and enterochromaffin-like cell density in gastric corpus mucosa and results in development of gastric carcinoids in experimental animals. Our aim was to study responses to potent acid inhibition by characterizing genome-wide gene expression changes in gastric corpus mucosa in rats dosed with the PPI omeprazole. Nine rats received 400 micromol/kg omeprazole daily for 10 wk. Seven rats received vehicle only. Analysis of gastric corpus with microarrays representing 11,848 genes identified 134 genes with changed gene expression levels in omeprazole-dosed rats. Several of the identified genes were previously known to be affected by potent acid inhibition. Of the 62 genes with known functions that changed gene expression levels after PPI dosing, 27 are known to be involved in proliferation and apoptosis and immune, inflammatory, and stress responses. Our study indicates that microarray analysis can detect relevant gene expression changes in the complex gastric tissue, and that cellular processes involved in cell growth and defense responses are strongly affected by PPI dosing. Many genes are identified that were not previously known to be affected by inhibition of gastric acid secretion or that have unknown biological functions. Characterization of the roles of these genes may give new insight into molecular responses to treatment with PPIs.
60965	 2207	 2450	omeprazole	Compound	ITGA6	mRNA	-1	-1	15827235	Potent acid inhibition with proton pump inhibitors (PPIs) is widely used in clinical medicine, especially for gastroesophageal reflux disease. PPIs cause profound changes in the intragastric environment with near-neutral pH and increase serum concentration of the gastric secretagogue hormone gastrin. Long-term hypergastrinemia increases mucosal thickness and enterochromaffin-like cell density in gastric corpus mucosa and results in development of gastric carcinoids in experimental animals. Our aim was to study responses to potent acid inhibition by characterizing genome-wide gene expression changes in gastric corpus mucosa in rats dosed with the PPI omeprazole. Nine rats received 400 micromol/kg omeprazole daily for 10 wk. Seven rats received vehicle only. Analysis of gastric corpus with microarrays representing 11,848 genes identified 134 genes with changed gene expression levels in omeprazole-dosed rats. Several of the identified genes were previously known to be affected by potent acid inhibition. Of the 62 genes with known functions that changed gene expression levels after PPI dosing, 27 are known to be involved in proliferation and apoptosis and immune, inflammatory, and stress responses. Our study indicates that microarray analysis can detect relevant gene expression changes in the complex gastric tissue, and that cellular processes involved in cell growth and defense responses are strongly affected by PPI dosing. Many genes are identified that were not previously known to be affected by inhibition of gastric acid secretion or that have unknown biological functions. Characterization of the roles of these genes may give new insight into molecular responses to treatment with PPIs.
22093	 3552	 3952	NFIX	Protein	Nkx2-1	mRNA	0	1	11046146	We conclude that NFI binding to two NFI elements, at bp -264 to -153, positively regulates TTF-1 expression and controls constitutive TTF-1 levels.
43477	 3552	18799	NFIX	Protein	SLC25A5	mRNA	0	-1	12777383	Furthermore, overexpression of NF1-A, -C, and -X in NIH3T3 cells repressed expression of an ANT2-driven reporter gene construct
44759	 3552	 4862	NFIX	Protein	PDGFA	mRNA	-1	-1	11823426	NF1/X repressed PDGF-A promoter-dependent transcription and endogenous mRNA expression,
51056	 3552	13884	NFIX	Protein	CDKN1A	mRNA	1	-1	17130157	Transfection of recombinant constructs bearing mutations in the p21 NFI site demonstrated that NFI acts as a repressor of p21 gene expression in various types of cultured cells. Inhibition of NFI in human skin fibroblasts through RNAi considerably increased p21 promoter activity suggesting that NFI is a key repressor of p21 transcription. Over-expression of each of the four NFI isoforms in HCT116 cells established that each of them contribute to various extend to the repression of the p21 gene.
 8864	 3552	11977	NFIX	Protein	HGF	mRNA	0	-1	10851080	We found that the NF1/X and NF1/Red1 isoforms strongly suppressed HGF promoter activity
11338	 7336	12387	Nkx2-1	Protein	MYB	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
12836	 7336	17369	Nkx2-1	Protein	IL6	mRNA	0	1	11820807	In mice with the highest transgene expression, TTF-1 caused severe inflammation, pulmonary fibrosis, respiratory failure, and death, associated with eosinophil infiltration and increased expression of eotaxin and IL-6.
13127	 7336	 8824	Nkx2-1	Protein	LRG1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
13645	 7336	 1438	Nkx2-1	Protein	VEGFA	mRNA	0	1	12829717	Genes Modulating Lung Vasculogenesis? Regional decreases in vascularity of the abnormal peripheral lung tubules, as detected by PECAM staining, were associated with decreased VEGF-A mRNA, indicating that TTF-1 phosphorylation is required for normal levels of expression of VEGF in the developing respiratory epithelium.
14018	 7336	 8544	Nkx2-1	Protein	RNASE4	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
14049	 7336	10458	Nkx2-1	Protein	MYH11	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
14450	 7336	13598	Nkx2-1	Protein	CD14	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
16141	 7336	18748	Nkx2-1	Protein	CASD1	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
16223	 7336	  670	Nkx2-1	Protein	TFF3	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
 1634	 7336	12060	Nkx2-1	Protein	S100G	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
16751	 7336	13930	Nkx2-1	Protein	Reg3g	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
17688	 7336	11325	Nkx2-1	Protein	CHAD	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
  187	 7336	18408	Nkx2-1	Protein	H2-T3	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
19272	 7336	 7760	Nkx2-1	Protein	RAG1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
19317	 7336	 9493	Nkx2-1	Protein	Pscr2	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
19350	 7336	13042	Nkx2-1	Protein	PFN2	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
19814	 7336	 5798	Nkx2-1	Protein	TSHB	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
20659	 7336	 5708	Nkx2-1	Protein	KITLG	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
20948	 7336	 5943	Nkx2-1	Protein	SERPINB9	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
21073	 7336	17907	Nkx2-1	Protein	NOP56	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
21076	 7336	16861	Nkx2-1	Protein	HHEX	mRNA	0	1	12655000	TTF-1 produced 3-4-fold increases in the Hex promoter activity.
21287	 7336	10233	Nkx2-1	Protein	GSTA4	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
21336	 7336	13132	Nkx2-1	Protein	PC	mRNA	1	1	12829717	table III - genes downregulated in TTF-1 mutant mice
21354	 7336	10792	Nkx2-1	Protein	PON1	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
22103	 7336	17643	Nkx2-1	Protein	MATN4	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
23269	 7336	 6097	Nkx2-1	Protein	HCK	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
23445	 7336	 7422	Nkx2-1	Protein	ENPP2	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
23656	 7336	13425	Nkx2-1	Protein	PGLYRP1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
24133	 7336	 9515	Nkx2-1	Protein	ENC1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
25162	 7336	12524	Nkx2-1	Protein	HS2ST1	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
26623	 7336	12376	Nkx2-1	Protein	POLG	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
27438	 7336	16610	Nkx2-1	Protein	Lyz2	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
27789	 7336	 9332	Nkx2-1	Protein	TG	mRNA	0	1	12907760	These results show that Ttf1 haploinsufficiency causes a reduction in the expression of TSHr and thyroglobulin, genes with TTF1 binding sites in their promoter regions.
   28	 7336	 3258	Nkx2-1	Protein	FGFR4	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
28038	 7336	12723	Nkx2-1	Protein	FAM3D	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
 2818	 7336	 7073	Nkx2-1	Protein	FXYD3	mRNA	-1	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
28242	 7336	 7832	Nkx2-1	Protein	THBS1	mRNA	-1	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
28838	 7336	13509	Nkx2-1	Protein	RAC2	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
28933	 7336	10269	Nkx2-1	Protein	CD74	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
28969	 7336	 6303	Nkx2-1	Protein	C5	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
29226	 7336	15188	Nkx2-1	Protein	LEF1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
32766	 7336	 5733	Nkx2-1	Protein	SPRR2A	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
33377	 7336	16075	Nkx2-1	Protein	LRP2	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
34019	 7336	15766	Nkx2-1	Protein	TCF7	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
34474	 7336	 9258	Nkx2-1	Protein	CDKN2B	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
35532	 7336	 3097	Nkx2-1	Protein	Ear1	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
 3563	 7336	11752	Nkx2-1	Protein	WNT4	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
36675	 7336	 2305	Nkx2-1	Protein	LCK	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
36899	 7336	13831	Nkx2-1	Protein	CKS1B	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
37159	 7336	 9198	Nkx2-1	Protein	TFF2	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
39437	 7336	 3880	Nkx2-1	Protein	INMT	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
40628	 7336	 3694	Nkx2-1	Protein	FOXF2	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
40844	 7336	12023	Nkx2-1	Protein	SLC34A2	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
43026	 7336	 1749	Nkx2-1	Protein	SOX17	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
43792	 7336	  555	Nkx2-1	Protein	PDPN	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
44150	 7336	 8923	Nkx2-1	Protein	PNLIPRP1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
44196	 7336	17791	Nkx2-1	Protein	SFTPD	mRNA	0	1	15173172	NFATc3 and TTF-1 activated the Sftpd promoter, synergized transcription, co-immunoprecipitated from mouse lung epithelial cells, and physically interacted in vitro.
44518	 7336	13400	Nkx2-1	Protein	TMEM37	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
45772	 7336	10377	Nkx2-1	Protein	FAM60A	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
47241	 7336	 9824	Nkx2-1	Protein	AGER	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
47812	 7336	19866	Nkx2-1	Protein	EMP2	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
 4798	 7336	19463	Nkx2-1	Protein	ABCA3	mRNA	0	1	17890326	FOXA2, C/EBPalpha, GATA-6, TTF-1, and NFATc3 increased the activity of the Abca3 luciferase construct in a dose-dependent manner.
49234	 7336	 3798	Nkx2-1	Protein	CA4	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
49658	 7336	 1632	Nkx2-1	Protein	SFTPC	mRNA	0	1	18239190	Foxp2 dose-dependently inhibited Nkx2.1-mediated activation of SP-C in MLE-15 cells. While electrophoretic mobility shift assays and chromatin immunoprecipitations revealed an interaction between Foxp2 and the conserved consensus motif in the SP-C promoter, Nkx2.1-mediated activation of the 318-bp proximal SP-C promoter (which lacks a Foxp2 consensus) was attenuated by increasing amounts of Foxp2.
49867	 7336	14534	Nkx2-1	Protein	Saa3	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
50227	 7336	13634	Nkx2-1	Protein	QKI	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
50938	 7336	 6827	Nkx2-1	Protein	AREG	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
51324	 7336	 4950	Nkx2-1	Protein	AGTR2	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
51690	 7336	10165	Nkx2-1	Protein	PCDHA4	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
51722	 7336	14080	Nkx2-1	Protein	SCN7A	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
 5265	 7336	10813	Nkx2-1	Protein	GJB3	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
52749	 7336	 3898	Nkx2-1	Protein	Ear2	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
53365	 7336	17021	Nkx2-1	Protein	WNT11	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
54349	 7336	 6200	Nkx2-1	Protein	LCN2	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
54597	 7336	 8683	Nkx2-1	Protein	LSP1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
54606	 7336	13928	Nkx2-1	Protein	PDGFRA	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
55774	 7336	18155	Nkx2-1	Protein	IER3	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
56061	 7336	19588	Nkx2-1	Protein	HELLS	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
56286	 7336	16157	Nkx2-1	Protein	NES	mRNA	0	1	11584016	In addition, we showed that overexpressing TTF-1 activates the endogenous rat nestin gene transcription.
56554	 7336	 6928	Nkx2-1	Protein	MAPT	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
56571	 7336	 5131	Nkx2-1	Protein	CLU	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
57354	 7336	10643	Nkx2-1	Protein	Scd1	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
57896	 7336	14044	Nkx2-1	Protein	TSHR	mRNA	0	1	12907760	These results show that Ttf1 haploinsufficiency causes a reduction in the expression of TSHr and thyroglobulin, genes with TTF1 binding sites in their promoter regions.
58037	 7336	 2400	Nkx2-1	Protein	Bcl2a1d	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
59330	 7336	 1297	Nkx2-1	Protein	DCK	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
61328	 7336	19226	Nkx2-1	Protein	AGR2	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
61419	 7336	17154	Nkx2-1	Protein	HMGB2	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
61605	 7336	  662	Nkx2-1	Protein	IGFBP6	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
62170	 7336	 4718	Nkx2-1	Protein	QSOX1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
62748	 7336	11027	Nkx2-1	Protein	H2-Q1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
62885	 7336	17086	Nkx2-1	Protein	AKTIP	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
63520	 7336	 2719	Nkx2-1	Protein	CCKAR	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
64404	 7336	14151	Nkx2-1	Protein	BTG3	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
66238	 7336	 7404	Nkx2-1	Protein	MIA	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
 6691	 7336	 2228	Nkx2-1	Protein	Tcrb-J	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
 7082	 7336	10452	Nkx2-1	Protein	ROS1	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
 7815	 7336	 6013	Nkx2-1	Protein	BEX1	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
 8145	 7336	 7803	Nkx2-1	Protein	THY1	mRNA	0	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
 9537	 7336	20162	Nkx2-1	Protein	SATB1	mRNA	-1	-1	12829717	table II - genes upregulated in TTF-1 mutant mice
 9568	 7336	 3342	Nkx2-1	Protein	AQP1	mRNA	0	1	12829717	table III - genes downregulated in TTF-1 mutant mice
13679	11360	 1438	CSDA	Protein	VEGFA	mRNA	0	-1	12433987	We find that single strand DNA-specific cold shock domain (CSD or Y-box) proteins repress the HR region via a binding site downstream of the HIF-1 site
17699	11360	 3766	CSDA	Protein	CDK5	mRNA	0	-1	10100871	We have determined that a C-terminal 172 amino acid domain of the DNA binding protein, dbpA, binds to Cdk5. Biochemical analyses reveal that this fragment (dbpA(Cdelta)) strongly inhibits p35-activated Cdk5 kinase
42708	11360	10154	CSDA	Protein	PRM1	mRNA	0	-1	12117816	Translational repression of protamine 1 (Prm1) mRNA requires sequences present in its 3p untranslated region (UTR) and substantial evidence suggests a role for the murine Y-box protein MSY4 in this process
45157	11360	19062	CSDA	Protein	PRM2	mRNA	0	-1	12117816	Altered translational activation resulted in defective processing of protamine 2 and severe defects in sperm morphogenesis
58822	11360	 9550	CSDA	Protein	CDK4	mRNA	1	-1	10100871	The protein also interacts with Cdk4 and inhibits the Cdk4/cyclin D1 enzyme
12056	16630	 3093	FLI1	Protein	RB1	mRNA	0	-1	10330185	Modified assertion
16071	16630	 1471	FLI1	Protein	COL1A2	mRNA	-1	-1	11278621	We demonstrate that the expression of collagenous proteins and collagen alpha2(I) (COL1A2) mRNA was inhibited following stable transfection of Fli-1 in dermal fibroblasts. We propose that Fli-1 inhibits COL1A2 promoter activity by competition with Ets-1.
17459	16630	 6253	FLI1	Protein	GP9	mRNA	0	1	12556498	Reciprocally, we also show that EKLF itself represses the FLI-1-dependent megakaryocytic GPIX gene promoter, thus further suggesting that functional cross-antagonism between FLI-1 and EKLF might be involved in the control of the erythrocytic versus megakaryocytic differentiation of bipotential progenitors.
27992	16630	14558	FLI1	Protein	FLI1	mRNA	0	1	11991951	Furthermore, endogenous Fli-1 was found to be bound to its own gene promoter and to be able to promote the transactivation of its gene.
32000	16630	 4292	FLI1	Protein	DDIT3	mRNA	0	1	10510472	Modified assertion
62012	16630	 2608	FLI1	Protein	HBB	mRNA	1	-1	12556498	We show here that FLI-1 represses the transcriptional activity of the beta-globin gene promoter in MEL cells and interacts with two of its critical transactivators, GATA-1 and EKLF.
11333	17161	12387	HBP1	Protein	MYB	mRNA	0	-1	16179914	Overexpression of HBP1 modulated mRNA levels for myeloid-specific transcription factors C/EBPalpha, c-Myb, c-Myc, and JunB, as well as lineage-specific transcription factors PU.1, GATA-1, and RUNX1.
12254	17161	 3207	HBP1	Protein	MPO	mRNA	0	1	11368363	human myeloperoxidase (MPO) promoter we, for the first time, identified and cloned the cDNA and genomic DNA for human HBP1 (HMG-Box containing protein 1),
24814	17161	 5863	HBP1	Protein	MYC	mRNA	0	-1	15024088	HBP1 represses growth regulatory genes (e.g., N-Myc, c-Myc, and cyclin D1) and is an inhibitor of G(1) progression.
28589	17161	 7738	HBP1	Protein	NCF1	mRNA	0	-1	15024088	Furthermore, HBP1 repressed the expression of the endogenous p47phox gene through sequence-specific binding.
 3153	17161	16645	HBP1	Protein	CCND1	mRNA	0	-1	15225871	Our detailed investigation showed that both Cyclin D1 and c-MYC expression was extinguished upon HBP1 expression.
32641	17161	 2963	HBP1	Protein	GATA1	mRNA	0	-1	16179914	Overexpression of HBP1 modulated mRNA levels for myeloid-specific transcription factors C/EBPalpha, c-Myb, c-Myc, and JunB, as well as lineage-specific transcription factors PU.1, GATA-1, and RUNX1.
41514	17161	12381	HBP1	Protein	SPI1	mRNA	0	-1	16179914	Overexpression of HBP1 modulated mRNA levels for myeloid-specific transcription factors C/EBPalpha, c-Myb, c-Myc, and JunB, as well as lineage-specific transcription factors PU.1, GATA-1, and RUNX1.
42322	17161	16570	HBP1	Protein	RUNX1	mRNA	0	-1	16179914	Overexpression of HBP1 modulated mRNA levels for myeloid-specific transcription factors C/EBPalpha, c-Myb, c-Myc, and JunB, as well as lineage-specific transcription factors PU.1, GATA-1, and RUNX1.
44958	17161	 7342	HBP1	Protein	NCF1C	mRNA	0	-1	15225871	In addition, Bar-Sagi and colleagues have shown that superoxide production is necessary for Rac-dependent G1 progression and cellular shape changes (Joneson and Bar-Sagi, 1998). Together, these and other observations highlight a role for ROS in growth factor signaling and mitogenesis.  2.3.2.2. HBP1 and the p47 phox gene As depicted in Fig. 5, we demonstrate that the transcriptional repressor HBP1 regulates the gene for the p47phox regulatory subunit of the NADPH oxidase. The promoter of the p47phox gene contains six tandem high-affinity HBP1 DNA binding elements at ?1243 to ?1318 bp from the transcriptional start site and which were required for repression. Furthermore, HBP1 repressed the expression of the endogenous p47phox gene through sequence-specific binding.
47824	17161	10326	HBP1	Protein	CCND3	mRNA	0	-1	16179914	We prepared transient and stable transfectants of the myeloblast cell line K562, which overexpress HBP1 mRNA and protein. HBP1 transfectants displayed slower growth in cell culture and reduced colony formation in soft agar, retardation of S-phase progression, reduced expression of cyclin D1 and D3 mRNAs and increased expression of p21 mRNA.
50998	17161	13884	HBP1	Protein	CDKN1A	mRNA	1	1	16179914	We prepared transient and stable transfectants of the myeloblast cell line K562, which overexpress HBP1 mRNA and protein. HBP1 transfectants displayed slower growth in cell culture and reduced colony formation in soft agar, retardation of S-phase progression, reduced expression of cyclin D1 and D3 mRNAs and increased expression of p21 mRNA.
51677	17161	  219	HBP1	Protein	FASLG	mRNA	-1	1	16179914	Fas ligand mRNA levels were increased in HBP1 transfectants, suggesting involvement of the Fas/Fas ligand pathway.
57317	17161	 4298	HBP1	Protein	JUNB	mRNA	0	-1	16179914	Overexpression of HBP1 modulated mRNA levels for myeloid-specific transcription factors C/EBPalpha, c-Myb, c-Myc, and JunB, as well as lineage-specific transcription factors PU.1, GATA-1, and RUNX1.
 6368	17161	10638	HBP1	Protein	H1F0	mRNA	0	1	10958660	we demonstrated that both HBP1 and RB were involved in the activation of H1(0) gene expression.
66290	17161	15406	HBP1	Protein	CD2	mRNA	0	1	10562551	Here, we identified the HMG box containing protein-1 (HBP1) as a factor binding to HSS3 of the hCD2 LCR
10655	 1384	 3198	SP5	Protein	TFRC	mRNA	-1	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
11374	 1384	19987	SP5	Protein	CTCF	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
11790	 1384	19405	SP5	Protein	TBL1XR1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
12301	 1384	  881	SP5	Protein	KCNIP3	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
13302	 1384	15707	SP5	Protein	CAPRIN1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
16188	 1384	10134	SP5	Protein	TUBGCP4	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
16835	 1384	18481	SP5	Protein	CORO1C	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
17922	 1384	  661	SP5	Protein	UGCG	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
19576	 1384	 3106	SP5	Protein	ADCYAP1R1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
20211	 1384	  335	SP5	Protein	MSMO1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
20386	 1384	12125	SP5	Protein	PAFAH1B2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
  204	 1384	16874	SP5	Protein	PIK3R1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
20755	 1384	19482	SP5	Protein	CBX5	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
20810	 1384	 6454	SP5	Protein	MTX1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
20899	 1384	15122	SP5	Protein	DUS3L	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
  211	 1384	11596	SP5	Protein	NAA15	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
23011	 1384	20080	SP5	Protein	BRD3	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
23530	 1384	  434	SP5	Protein	MTHFD2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
24407	 1384	 9819	SP5	Protein	SORT1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
25067	 1384	 6923	SP5	Protein	RAB8A	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
25300	 1384	12845	SP5	Protein	PDLIM5	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
25670	 1384	13082	SP5	Protein	NDN	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 2832	 1384	  931	SP5	Protein	TP53INP1	mRNA	-1	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
29791	 1384	12747	SP5	Protein	MAP2K4	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
30413	 1384	19533	SP5	Protein	RAB3B	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 3131	 1384	16645	SP5	Protein	CCND1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
32320	 1384	 3016	SP5	Protein	FMR1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
32451	 1384	  685	SP5	Protein	C9orf40	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
32453	 1384	 9106	SP5	Protein	HIP1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
33001	 1384	 3936	SP5	Protein	SMAD5	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
33250	 1384	17680	SP5	Protein	ATP1B2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
33926	 1384	12760	SP5	Protein	SLC12A2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
35087	 1384	17258	SP5	Protein	C1GALT1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 3598	 1384	11498	SP5	Protein	FZD2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
36850	 1384	16300	SP5	Protein	TRIP4	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
39304	 1384	18587	SP5	Protein	VPS35	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
39846	 1384	 5209	SP5	Protein	CTDSP2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 3985	 1384	13045	SP5	Protein	MAP2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
40014	 1384	  173	SP5	Protein	KIF1B	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
43108	 1384	  301	SP5	Protein	KIF11	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
44857	 1384	15528	SP5	Protein	SPRY4	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
46226	 1384	18896	SP5	Protein	SERINC3	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
46943	 1384	  594	SP5	Protein	STARD4	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
48465	 1384	 9763	SP5	Protein	SMC1A	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
48554	 1384	10738	SP5	Protein	POLDIP3	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
48666	 1384	 7095	SP5	Protein	SYNCRIP	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
49089	 1384	 8341	SP5	Protein	LMAN1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
49172	 1384	19884	SP5	Protein	RANBP9	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
49669	 1384	20176	SP5	Protein	BAZ1B	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
49696	 1384	 6430	SP5	Protein	MDM2	mRNA	1	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
50899	 1384	11675	SP5	Protein	MBTPS1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
51894	 1384	10193	SP5	Protein	Epb4.1l4a	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
52103	 1384	18897	SP5	Protein	TAGLN2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
52445	 1384	10297	SP5	Protein	KIF1A	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
52720	 1384	13417	SP5	Protein	WNT7B	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
52771	 1384	10375	SP5	Protein	CD24	mRNA	1	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
53381	 1384	 7161	SP5	Protein	PTPRS	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
54905	 1384	17175	SP5	Protein	KIF2A	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
55517	 1384	 3623	SP5	Protein	REV3L	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
55661	 1384	16667	SP5	Protein	EIF2S3	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
55716	 1384	17702	SP5	Protein	SKP2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
56288	 1384	16157	SP5	Protein	NES	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
57274	 1384	  374	SP5	Protein	GIT2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
57350	 1384	10643	SP5	Protein	Scd1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
57393	 1384	 3336	SP5	Protein	CCND2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
57704	 1384	 4223	SP5	Protein	DDX6	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
57778	 1384	 9065	SP5	Protein	KLF3	mRNA	1	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 5861	 1384	18756	SP5	Protein	FAM120A	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
58815	 1384	15254	SP5	Protein	SHOC2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
60102	 1384	10371	SP5	Protein	Rpl14	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
60127	 1384	 7960	SP5	Protein	RRBP1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
60200	 1384	 7582	SP5	Protein	SNRNP27	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 6032	 1384	11115	SP5	Protein	6820431F20Rik	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
60877	 1384	 8641	SP5	Protein	HNRNPAB	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 6161	 1384	 7249	SP5	Protein	FSCN1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
62316	 1384	 2016	SP5	Protein	ARHGEF1	mRNA	1	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
62442	 1384	 1056	SP5	Protein	KIAA0100	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
63089	 1384	 3527	SP5	Protein	EIF4G1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
64266	 1384	12085	SP5	Protein	MSN	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
65803	 1384	13859	SP5	Protein	USP1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 7203	 1384	17237	SP5	Protein	CLCN6	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 7412	 1384	 6570	SP5	Protein	SKA2	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 7779	 1384	 4439	SP5	Protein	TRIM27	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 8917	 1384	17379	SP5	Protein	CYB5R3	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 9532	 1384	18566	SP5	Protein	SMARCC1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 9677	 1384	18215	SP5	Protein	XPR1	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
 9935	 1384	12991	SP5	Protein	MYO10	mRNA	0	-1	17090534	TABLE 1. List of genes downregulated in Sp5-overexpressing primary neurospheres. From a total of 107 genes downregulated >2-fold, only those containing Sp1 binding sites in their regulatory regions (-500/+1 and 5 UTR) are shown. References indicate previous studies of the genes with respect to Sp1 regulation
14029	17857	 7407	IFN1@	Protein	PSME2	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
16800	17857	19679	IFN1@	Protein	STAT1	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
17486	17857	 4203	IFN1@	Protein	H2-T23	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
18083	17857	  284	IFN1@	Protein	CXCL10	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
20598	17857	17514	IFN1@	Protein	IFI35	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
20718	17857	 4803	IFN1@	Protein	EIF2AK2	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
22767	17857	 9362	IFN1@	Protein	TAP2	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
23603	17857	  514	IFN1@	Protein	PSMB8	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
23962	17857	17118	IFN1@	Protein	NAMPT	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
24139	17857	10439	IFN1@	Protein	Iigp1	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
25975	17857	12140	IFN1@	Protein	PML	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
28019	17857	12208	IFN1@	Protein	Ifi202b	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
29275	17857	 4095	IFN1@	Protein	GBP4	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
30051	17857	13864	IFN1@	Protein	PNPT1	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
31910	17857	 7289	IFN1@	Protein	MX2	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
32056	17857	18014	IFN1@	Protein	H2-Q2	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
32428	17857	12761	IFN1@	Protein	Igtp	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
36126	17857	 3649	IFN1@	Protein	TBRG1	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
 3683	17857	17650	IFN1@	Protein	IFIT2	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
37319	17857	  404	IFN1@	Protein	Tgtp1	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
40743	17857	 2915	IFN1@	Protein	ISG15	mRNA	-1	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
44103	17857	14347	IFN1@	Protein	USP18	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
44932	17857	 8466	IFN1@	Protein	Ifi47	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
45408	17857	 6411	IFN1@	Protein	APOBEC1	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
45470	17857	 1805	IFN1@	Protein	IRF9	mRNA	0	1	15644321	IFN-dependent induction of two genes known to be of importance in the generation of IFN responses, Isg15 and Irf-9, was diminished in the absence of Mkk3 and Mkk6.
 4548	17857	15684	IFN1@	Protein	LGALS3BP	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
45716	17857	 1590	IFN1@	Protein	RSAD2	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
45768	17857	19191	IFN1@	Protein	CMPK2	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
46632	17857	 9425	IFN1@	Protein	MPEG1	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
47369	17857	  777	IFN1@	Protein	H2-T10	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
47979	17857	 4684	IFN1@	Protein	IFIT1	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
48173	17857	 5738	IFN1@	Protein	MX1	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
48962	17857	 7117	IFN1@	Protein	IRF7	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
49385	17857	13109	IFN1@	Protein	AW112010	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
52415	17857	18433	IFN1@	Protein	ZNFX1	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
52535	17857	 7961	IFN1@	Protein	ZBP1	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
52780	17857	 6836	IFN1@	Protein	ADAR	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
52825	17857	  556	IFN1@	Protein	IFI16	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
53036	17857	19668	IFN1@	Protein	Trim30a	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
53407	17857	14985	IFN1@	Protein	Irgm2	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
57710	17857	11275	IFN1@	Protein	IFIH1	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
58039	17857	 6190	IFN1@	Protein	TRIM25	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
59299	17857	 9075	IFN1@	Protein	IRGM	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
59617	17857	17598	IFN1@	Protein	TAP1	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
61543	17857	 6777	IFN1@	Protein	XDH	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
61608	17857	 3875	IFN1@	Protein	SLC29A3	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
63041	17857	 6905	IFN1@	Protein	Ly6c1	mRNA	0	1	11559440	In vitro experiments tested the effects of cytokines on Ly-6C expression and confirmed interferon-alpha (IFN-alpha) as a primary cytokine that induces Ly-6C expression on CD4+ and CD8+ T cells.
64423	17857	 2077	IFN1@	Protein	GBP1	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
66280	17857	 7166	IFN1@	Protein	H2-T22	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
66342	17857	12673	IFN1@	Protein	IFITM3	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
66369	17857	15809	IFN1@	Protein	GBP2	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
 6986	17857	 5325	IFN1@	Protein	Gbp6	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
 7379	17857	  349	IFN1@	Protein	LGALS8	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
 7648	17857	 7875	IFN1@	Protein	IFIT3	mRNA	1	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
 7726	17857	15873	IFN1@	Protein	PSMB9	mRNA	0	1	12502840	TABLE 2. IFN-g- and IFN-a/b-regulated hepatocellular genes tightly associated with inhibition of HBV replication
 8534	17857	13312	IFN1@	Protein	TOR3A	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
 9309	17857	15334	IFN1@	Protein	PSMB10	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
 9618	17857	17078	IFN1@	Protein	B2M	mRNA	0	1	15956575	Alpha/beta interferons (IFNs-alpha/beta) are cytokines that play an essential role in the host defense against viral infection. Our previous studies have shown that the key IFN signaling molecule STAT1 is highly elevated and activated in central nervous system neurons during viral infection and in transgenic mice with astrocyte production of IFN-alpha (glial fibrillary acidic protein [GFAP]-IFN-alpha), suggesting that neurons are a very responsive target cell population for IFNs. To elucidate the genomic response of neurons to IFN-alpha, we undertook studies both in vitro and in vivo. Gene chip analysis was applied to RNA from IFN-alpha-treated or untreated primary cortical neuronal cultures derived from embryonic day 15 fetal wild-type or STAT1 knockout (KO) mice. The expression of 51 known and 5 unknown genes was increased significantly by more than twofold after exposure of wild-type but not STAT1 KO neurons to IFN-alpha. Some more highly expressed genes included IFN-induced 15-kDa protein, ubiquitin-specific protease 18, glucocorticoid attenuated response genes, IFN-induced GTPases, and the chemokine CXCL10. For several of these genes, the gene chip findings were confirmed by RNase protection assays. In addition, examination of the expression of some of these selected genes revealed that they were increased in neurons in the brain of either GFAP-IFN-alpha mice or mice infected with lymphocytic choriomeningitis virus. In conclusion, our study revealed a robust STAT1-dependent genomic response of neurons to IFN-alpha, highlighting an innate potential of these cells to defend against viral infection in the brain.
28237	 2155	 7832	paricalcitol	Compound	THBS1	mRNA	-1	-1	16095599	Fig. 3 shows that paricalcitol downregulated the expression of BNP and THBS1 mRNA in a dose-dependent manner with EC50 value at 3.2 and 39 nM, respectively.
14830	 5945	10938	Norepinephrine	Compound	H2AFY	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
16260	 5945	15838	Norepinephrine	Compound	PER1	mRNA	0	1	12729908	noradrenaline transiently induced the expression of mPer1, mPer2, and mE4bp4 1-2 h after alpha(1)-receptor activation
19452	 5945	 6094	Norepinephrine	Compound	RAD9A	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
25274	 5945	13876	Norepinephrine	Compound	IKBKAP	mRNA	0	1	12050158	NE dose-dependently increased the expression of inhibitory I kappa B alpha protein accompanied by an increase in steady state levels of I kappa B alpha mRNA
26405	 5945	 2576	Norepinephrine	Compound	USP33	mRNA	0	1	12865408	VDU1, but not VDU2, is markedly increased in brown adipocytes by norepinephrine or cold exposure, further amplifying the increase in D2 activity that results from catecholamine-stimulated de novo synthesis.
41370	 5945	15861	Norepinephrine	Compound	RPRM	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
42296	 5945	 9608	Norepinephrine	Compound	DDB1	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
42628	 5945	 6875	Norepinephrine	Compound	CHEK1	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
43539	 5945	17125	Norepinephrine	Compound	PER2	mRNA	0	1	12729908	noradrenaline transiently induced the expression of mPer1, mPer2, and mE4bp4 1-2 h after alpha(1)-receptor activation
44017	 5945	16725	Norepinephrine	Compound	ERCC6	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
44098	 5945	17959	Norepinephrine	Compound	RAD52	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
44182	 5945	10908	Norepinephrine	Compound	NFIL3	mRNA	0	1	12729908	noradrenaline transiently induced the expression of mPer1, mPer2, and mE4bp4 1-2 h after alpha(1)-receptor activation
48161	 5945	 3148	Norepinephrine	Compound	ERCC8	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
48190	 5945	 6706	Norepinephrine	Compound	EXT1	mRNA	-1	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 4837	 5945	 4355	Norepinephrine	Compound	BBC3	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
51641	 5945	18678	Norepinephrine	Compound	MYH7	mRNA	0	-1	11055982	T3 and NE also increased alpha-myosin heavy chain (MyHC) mRNA and reduced beta-MyHC.
51891	 5945	18265	Norepinephrine	Compound	ERCC3	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
53528	 5945	15594	Norepinephrine	Compound	CDC25C	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 5594	 5945	 4642	Norepinephrine	Compound	HP	mRNA	0	1	14697247	Increases in haptoglobin mRNA level were also induced by dexamethasone, noradrenaline, isoprenaline, and a beta3-adrenoceptor agonist. In contrast, haptoglobin mRNA was reduced by nicotinic acid and the PPARgamma agonist, rosiglitazone
 6107	 5945	16922	Norepinephrine	Compound	RRM2	mRNA	0	1	11900481	NE stimulation, which promotes DNA synthesis and proliferation of brown preadipocytes, resulted in an increased expression of the R2 gene in proliferating cells (1.6-fold),
61180	 5945	  457	Norepinephrine	Compound	MYH6	mRNA	0	1	11055982	T3 and NE also increased alpha-myosin heavy chain (MyHC) mRNA and reduced beta-MyHC.
 6393	 5945	17846	Norepinephrine	Compound	CDC25B	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 8925	 5945	15240	Norepinephrine	Compound	PTPRCAP	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
20517	10382	 6218	FOXL1	Protein	VCAM1	mRNA	0	1	12648490	This alteration is shown to be due to the delayed formation of Peyerps patches organizing centers as revealed by the expressions of VCAM1 and IL-7 receptor alpha-chain at 17.5 days postcoitus.
20648	10382	18274	FOXL1	Protein	IL7R	mRNA	0	1	12648490	This alteration is shown to be due to the delayed formation of Peyerps patches organizing centers as revealed by the expressions of VCAM1 and IL-7 receptor alpha-chain at 17.5 days postcoitus.
 3559	10382	11752	FOXL1	Protein	WNT4	mRNA	0	-1	16469829	Furthermore, real-time quantitative PCR indicated that a subset of Wnt family genes was highly expressed in the gut mesenchyme of Foxl1-deficient mice compared with that of wild-type mice. A previous study has demonstrated that Foxl1 is involved in the regulation of the beta-catenin signaling pathway (26). We also confirmed that the nuclear beta-catenin translocation was enhanced in the small intestinal epithelium of Foxl1/ mice by Western blot analysis (Fig. 5).
39273	10382	10998	FOXL1	Protein	GPC3	mRNA	0	-1	16469829	Furthermore, real-time quantitative PCR indicated that a subset of Wnt family genes was highly expressed in the gut mesenchyme of Foxl1-deficient mice compared with that of wild-type mice. A previous study has demonstrated that Foxl1 is involved in the regulation of the beta-catenin signaling pathway (26). We also confirmed that the nuclear beta-catenin translocation was enhanced in the small intestinal epithelium of Foxl1/ mice by Western blot analysis (Fig. 5).
51425	10382	 9638	FOXL1	Protein	EPHB2	mRNA	1	-1	16469829	The small intestine of Foxl1-deficient mice manifested aberrant crypt structure, including widely distributed Paneth cells, which coincided with the ectopic and increased expression of EphB2 and EphB3, which are key regulators of epithelial cell positioning.
53366	10382	17021	FOXL1	Protein	WNT11	mRNA	0	-1	16469829	Furthermore, real-time quantitative PCR indicated that a subset of Wnt family genes was highly expressed in the gut mesenchyme of Foxl1-deficient mice compared with that of wild-type mice. A previous study has demonstrated that Foxl1 is involved in the regulation of the beta-catenin signaling pathway (26). We also confirmed that the nuclear beta-catenin translocation was enhanced in the small intestinal epithelium of Foxl1/ mice by Western blot analysis (Fig. 5).
59822	10382	 3795	FOXL1	Protein	SDC2	mRNA	0	-1	16469829	Furthermore, real-time quantitative PCR indicated that a subset of Wnt family genes was highly expressed in the gut mesenchyme of Foxl1-deficient mice compared with that of wild-type mice. A previous study has demonstrated that Foxl1 is involved in the regulation of the beta-catenin signaling pathway (26). We also confirmed that the nuclear beta-catenin translocation was enhanced in the small intestinal epithelium of Foxl1/ mice by Western blot analysis (Fig. 5).
 6232	10382	10856	FOXL1	Protein	SNAP25	mRNA	0	1	15240114	Among the molecules involved in the membrane fusion event, only SNAP25 showed a significant decrease in mRNA expression, which likely caused the impairment in acid secretion from parietal cells in Foxl1-deficient mice, with the reduction in H+,K(+)-ATPase expression contributing to additional effect.
 6813	10382	 7782	FOXL1	Protein	EPHB3	mRNA	0	-1	16469829	The small intestine of Foxl1-deficient mice manifested aberrant crypt structure, including widely distributed Paneth cells, which coincided with the ectopic and increased expression of EphB2 and EphB3, which are key regulators of epithelial cell positioning.
10650	 8809	 3198	nitric oxide	Compound	TFRC	mRNA	-1	1	 7742556	In this study, exogenous NO produced by adding the NO-generator S-nitroso-N-acetyl penicillamine gave a dose-dependent upregulation of transferrin receptor expression by K562 erythroleukemia cells and increased levels of transferrin receptor mRNA.
10764	 8809	 5030	nitric oxide	Compound	TLN1	mRNA	1	1	10551887	Our findings show that mechanical stimulation of muscle cells in vivo and in vitro causes an increase in the expression of vinculin and talin that is mediated by nitric oxide.
11161	 8809	 9789	nitric oxide	Compound	HSPE1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
11302	 8809	11173	nitric oxide	Compound	ARG1	mRNA	-1	-1	15242832	The present study tested the hypothesis that acute increases in nitric oxide (NO) exert substantial influences on gene transcription in endothelial cells (ECs) via guanylyl cyclase (GC). Human umbilical veins ECs (HUVECs) were exposed to 0.1, 1, and 10 mM of sodium nitroprusside (SNP) for 4 h and to 1 mM SNP or 250 microM of (Z)-1[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate) for 2, 4, 8, and 24 h. Also, cells were exposed to DETA-NONOate in the presence and absence of the GC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ; 10 microM) for 4 h. RNA was isolated, reverse transcribed, Cy3 and Cy5 labeled, and analyzed using cDNA microarrays. Increasing doses of SNP predominantly depressed gene expression in HUVECs. Gene function was related to growth, adhesion, and cell structure. DETA-NONOate evoked a wave of expression changes (maximum at 4 h), with a remarkable downregulation of the transcription factors MSX1, RELB, and Egr-1. Both SNP- and DETA-NONOate-induced gene expression had faded after 24 h, despite continued elevation of cGMP in the medium. Coadministration of ODQ decreased many, but not all, of the transcriptional responses to DETA-NONOate. NO pronouncedly depressed EC gene expression, in particular of transcription factors. The observation that many, but not all, transcriptional changes induced by NO could be inhibited by inhibition of GC indicates the presence of GC-independent NO actions on gene expression. Thus EC gene expression responds to NO; however, the transcriptional response fades during prolonged exposure. This could allow the EC to respond to increased shear, without vigorous changes in gene expression.
16476	 8809	18083	nitric oxide	Compound	BNIP3	mRNA	-1	1	15855057	long-term ()NO treatment influenced transcription rates of a rather limited set of genes, including CIDE-B, BNIP3, p21/Cip1, molybdopterin synthase, and TRAF4 -associated factor 1.
16593	 8809	10839	nitric oxide	Compound	SLC6A6	mRNA	0	1	11698241	RT-PCR analysis and nuclear run-on assays provided evidence for upregulation of the transporter gene. This study provides the first evidence of an increase in taurine transporter gene expression in human RPE cells cultured under conditions of elevated levels of NO
16867	 8809	18255	nitric oxide	Compound	VCL	mRNA	-1	1	10551887	Our findings show that mechanical stimulation of muscle cells in vivo and in vitro causes an increase in the expression of vinculin and talin that is mediated by nitric oxide.
16945	 8809	19193	nitric oxide	Compound	MT2A	mRNA	0	1	14617770	In addition, we found that, endogenously via iNOS, synthesized NO increases the constitutive mRNA expression of both MT-1 and MT-2 genes and that nitrosative stress exogenously applied via an NO donor increases constitutive MT mRNA expression via intracellular Zn2+ release.
19637	 8809	16486	nitric oxide	Compound	SPP1	mRNA	1	1	14722087	OPN transcription and promoter activity are significantly up-regulated in response to NO
19840	 8809	13642	nitric oxide	Compound	DNAJB9	mRNA	0	1	14516790	Mdg1/ERdj4 mRNA is induced by activated macrophages, by nitric oxide (NO) and heat shock, and during terminal cell differentiation, whereas shear stress does not affect Mdg1/ERdj4 expression levels.
20337	 8809	 2815	nitric oxide	Compound	TP53	mRNA	0	1	10845916	Modified assertion
20435	 8809	 3025	nitric oxide	Compound	GUCY1A3	mRNA	0	-1	15312990	NO has been described to inhibit sGC expression and sGC activity in a cGMP-dependent manner (Filippov et al., 1997).
23649	 8809	17594	nitric oxide	Compound	CCNG1	mRNA	0	-1	15242832	The present study tested the hypothesis that acute increases in nitric oxide (NO) exert substantial influences on gene transcription in endothelial cells (ECs) via guanylyl cyclase (GC). Human umbilical veins ECs (HUVECs) were exposed to 0.1, 1, and 10 mM of sodium nitroprusside (SNP) for 4 h and to 1 mM SNP or 250 microM of (Z)-1[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate) for 2, 4, 8, and 24 h. Also, cells were exposed to DETA-NONOate in the presence and absence of the GC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ; 10 microM) for 4 h. RNA was isolated, reverse transcribed, Cy3 and Cy5 labeled, and analyzed using cDNA microarrays. Increasing doses of SNP predominantly depressed gene expression in HUVECs. Gene function was related to growth, adhesion, and cell structure. DETA-NONOate evoked a wave of expression changes (maximum at 4 h), with a remarkable downregulation of the transcription factors MSX1, RELB, and Egr-1. Both SNP- and DETA-NONOate-induced gene expression had faded after 24 h, despite continued elevation of cGMP in the medium. Coadministration of ODQ decreased many, but not all, of the transcriptional responses to DETA-NONOate. NO pronouncedly depressed EC gene expression, in particular of transcription factors. The observation that many, but not all, transcriptional changes induced by NO could be inhibited by inhibition of GC indicates the presence of GC-independent NO actions on gene expression. Thus EC gene expression responds to NO; however, the transcriptional response fades during prolonged exposure. This could allow the EC to respond to increased shear, without vigorous changes in gene expression.
23842	 8809	 3648	nitric oxide	Compound	P4HA1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
25801	 8809	19027	nitric oxide	Compound	HMOX1	mRNA	0	1	12788480	Thus, NO upregulates TIEG1 mRNA by stabilization independently of TGF-beta. The TIEG1 mRNA now joins heme oxygenase-1 mRNA in displaying regulation by NO-mediated stabilization
26477	 8809	 7394	nitric oxide	Compound	BAG3	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
28258	 8809	 7832	nitric oxide	Compound	THBS1	mRNA	-1	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
28971	 8809	16957	nitric oxide	Compound	ASAH1	mRNA	-1	-1	15679111	Accordingly, the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP, 0.2 mM)... The inhibitor of the NO synthase, N(G)-nitro-L-arginine-methyl ester (L-NAME, 10... Both, SNAP and L-NAME, decreased the mRNA levels of all proteins involved in ceramide metabolism.
29080	 8809	  620	nitric oxide	Compound	PHLDA1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
35469	 8809	18531	nitric oxide	Compound	ICAM1	mRNA	0	-1	12869663	, whereas Rucker et al. (2001) observed in vivo decreased ICAM-1 expression in a model of arterial injury when HO-1 was up-regulated prior to injury. This model may thus provide a plausible molecular basis for the previously reported anti-inflammatory properties of HO-1.  The HO-2 and HO-3 isoforms probably function normally as first defense against oxidative/inflammatory insults, whereas upon stress HO-1 is swiftly up-regulated and strongly protects against further injurious signals. HO-2, which is highly expressed in brains and testis, protects, e.g., neurons against oxidative stress. HO-2 may function as a physiologic regulator of cellular function, whereas HO-1 plays a role in modulating tissue responses to injury in pathophysiologic states (Wagener et al., 1999).  Adhesion molecule expression can be down-regulated by anti-oxidants and the gaseous mediator NO (De Caterina et al., 1995; Berendji-Grun et al., 2001).
35796	 8809	 9011	nitric oxide	Compound	HSPH1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
38397	 8809	11805	nitric oxide	Compound	CSRP3	mRNA	0	-1	12642365	SNAP negatively controls MLP mRNA (-49%, P<0.01) and protein
39384	 8809	18612	nitric oxide	Compound	SOD2	mRNA	-1	1	15993853	stress. We present evidence that the sequential induction of HO-1 and MnSOD protects astrocytes from NO toxicity: (1) both HO-1 and MnSOD expression were induced by NO;
39963	 8809	 6114	nitric oxide	Compound	NFKBIA	mRNA	1	1	 9620666	However, NO, but not antioxidants, induced IkappaB-alpha promoter activity.
42103	 8809	13115	nitric oxide	Compound	EGR1	mRNA	-1	-1	10436166	Treatment of ECs with an NO donor, S-nitroso-N-acetylpenicillamine (SNAP) or 3-morpholinosydnonimine (SIN-1), inhibited this shear stress-induced Egr-1 expression.
42903	 8809	 7577	nitric oxide	Compound	HSP90AA1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
44408	 8809	13271	nitric oxide	Compound	CCL2	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
46277	 8809	15281	nitric oxide	Compound	CTH	mRNA	0	-1	16491094	Nitroflurbiprofen (3-30 mg kg(-1), i.p.) administration resulted in a dose-dependent inhibition of the LPS-mediated increase in plasma TNF-alpha, IL-1beta and NO(x) concentration, liver H2S synthesis (55.00+/-0.95 nmole mg protein(-1), c.f. 62.38+/-0.47 nmole mg protein(-1), n = 5, P<0.05), CSE mRNA, iNOS, MPO activity and NF-kappaB activation. Flurbiprofen (21 mg kg(-1), i.p.) was without effect.
47198	 8809	 2052	nitric oxide	Compound	ATF3	mRNA	0	1	19892011	Figure 1 - Comparison of mRNA levels of genes sensitive to various NO fluxes. U937 cells were exposed to (A) 500 ?M DPTA-NO for 3 h or (B) 200 uM DETA-NO for 17 h. mRNA levels were measured by TaqMan low-density array analysis.
51014	 8809	13884	nitric oxide	Compound	CDKN1A	mRNA	1	1	15855057	long-term ()NO treatment influenced transcription rates of a rather limited set of genes, including CIDE-B, BNIP3, p21/Cip1, molybdopterin synthase, and TRAF4 -associated factor 1.
 5113	 8809	 2649	nitric oxide	Compound	DNAJB1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
51413	 8809	11635	nitric oxide	Compound	DHCR24	mRNA	1	1	15242832	The present study tested the hypothesis that acute increases in nitric oxide (NO) exert substantial influences on gene transcription in endothelial cells (ECs) via guanylyl cyclase (GC). Human umbilical veins ECs (HUVECs) were exposed to 0.1, 1, and 10 mM of sodium nitroprusside (SNP) for 4 h and to 1 mM SNP or 250 microM of (Z)-1[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate) for 2, 4, 8, and 24 h. Also, cells were exposed to DETA-NONOate in the presence and absence of the GC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ; 10 microM) for 4 h. RNA was isolated, reverse transcribed, Cy3 and Cy5 labeled, and analyzed using cDNA microarrays. Increasing doses of SNP predominantly depressed gene expression in HUVECs. Gene function was related to growth, adhesion, and cell structure. DETA-NONOate evoked a wave of expression changes (maximum at 4 h), with a remarkable downregulation of the transcription factors MSX1, RELB, and Egr-1. Both SNP- and DETA-NONOate-induced gene expression had faded after 24 h, despite continued elevation of cGMP in the medium. Coadministration of ODQ decreased many, but not all, of the transcriptional responses to DETA-NONOate. NO pronouncedly depressed EC gene expression, in particular of transcription factors. The observation that many, but not all, transcriptional changes induced by NO could be inhibited by inhibition of GC indicates the presence of GC-independent NO actions on gene expression. Thus EC gene expression responds to NO; however, the transcriptional response fades during prolonged exposure. This could allow the EC to respond to increased shear, without vigorous changes in gene expression.
53103	 8809	13624	nitric oxide	Compound	CNGA2	mRNA	0	1	12225972	Our results demonstrate that exogenous NO upregulates CNGA2 expression
 5322	 8809	13578	nitric oxide	Compound	GUCY1B3	mRNA	0	-1	15312990	NO has been described to inhibit sGC expression and sGC activity in a cGMP-dependent manner (Filippov et al., 1997).
57261	 8809	 5741	nitric oxide	Compound	RDBP	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
58334	 8809	 8795	nitric oxide	Compound	MORF4L2	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
59018	 8809	 4174	nitric oxide	Compound	STBD1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
 5902	 8809	 5636	nitric oxide	Compound	AURKA	mRNA	1	1	15855057	Among the selected genes, 11 (ATF-4, c-maf, SGK-1, PBEF, ATPase 8, NADH dehydrogenase 4, STK6, TRAF4-associated factor 1, molybdopterin synthase, CKS1, and CIDE-B) have not been previously reported to be sensitive to ()NO.
59759	 8809	13414	nitric oxide	Compound	SERPINE1	mRNA	0	-1	11502712	long-term NOS inhibition induces expression of plasminogen activator inhibitor-1 (PAI-1) in vascular tissues
60014	 8809	12976	nitric oxide	Compound	IL8	mRNA	0	1	19892011	Figure 1 - Comparison of mRNA levels of genes sensitive to various NO fluxes. U937 cells were exposed to (A) 500 ?M DPTA-NO for 3 h or (B) 200 uM DETA-NO for 17 h. mRNA levels were measured by TaqMan low-density array analysis.
60117	 8809	15187	nitric oxide	Compound	DDX3Y	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
61741	 8809	14946	nitric oxide	Compound	ACO2	mRNA	0	1	15287097	RESULTS: SNP upregulated mACON enzymatic activity and gene expression in PC-3 cells.
61783	 8809	 1730	nitric oxide	Compound	KLF10	mRNA	1	1	12788480	Thus, NO upregulates TIEG1 mRNA by stabilization independently of TGF-beta. The TIEG1 mRNA now joins heme oxygenase-1 mRNA in displaying regulation by NO-mediated stabilization
62310	 8809	11938	nitric oxide	Compound	DGKA	mRNA	0	1	17197391	NO*-mediated PPARgamma binding and NO* induction of cyclooxygenase-2 (COX-2), diacylglycerol (DAG) kinase alpha (DGKalpha), and heme oxygenase-1 (HO-1), genes with well-characterized PPRE motifs, were cGMP independent.
63639	 8809	 2408	nitric oxide	Compound	ALB	mRNA	0	1	11726507	Treatment of TNF-alpha mice with antioxidants or NOS inhibitors prevented phosphorylation of C/EBPbeta on Ser239
66054	 8809	 5646	nitric oxide	Compound	MT1A	mRNA	0	1	14617770	In addition, we found that, endogenously via iNOS, synthesized NO increases the constitutive mRNA expression of both MT-1 and MT-2 genes and that nitrosative stress exogenously applied via an NO donor increases constitutive MT mRNA expression via intracellular Zn2+ release.
 6899	 8809	 2204	nitric oxide	Compound	COL1A1	mRNA	0	-1	11502712	% Cardiac type I collagen mRNA expression was greater in control (P<0.01) and L-NAME-treated PAI-1(-/-) (P<0.05) groups than in control WT mice, indicating that PAI-1 deficiency prevents the increase of collagen deposition
11725	 6342	 2388	HOXC6	Protein	CHRNA2	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
20522	 6342	 6218	HOXC6	Protein	VCAM1	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
21358	 6342	16395	HOXC6	Protein	BMP7	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
22653	 6342	 2621	HOXC6	Protein	SH3D19	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
22975	 6342	 4678	HOXC6	Protein	ERRFI1	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
 2418	 6342	 6662	HOXC6	Protein	FGFR2	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
24186	 6342	10932	HOXC6	Protein	FAM49A	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
25171	 6342	 9553	HOXC6	Protein	C14orf37	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
29427	 6342	 5144	HOXC6	Protein	PLXDC1	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
29797	 6342	13663	HOXC6	Protein	SIPA1L1	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
29804	 6342	16533	HOXC6	Protein	PDE4DIP	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
30290	 6342	 7653	HOXC6	Protein	SENP8	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
33736	 6342	12102	HOXC6	Protein	COL23A1	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
34789	 6342	10164	HOXC6	Protein	MEGF10	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
35788	 6342	16445	HOXC6	Protein	IRAK4	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
37203	 6342	14425	HOXC6	Protein	CNTN1	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
38724	 6342	 9624	HOXC6	Protein	ZNF536	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
39929	 6342	16367	HOXC6	Protein	SLC44A1	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
48782	 6342	17731	HOXC6	Protein	DCN	mRNA	-1	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
49273	 6342	 4689	HOXC6	Protein	SEPT7	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
51404	 6342	 5563	HOXC6	Protein	SLC1A3	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
52374	 6342	19923	HOXC6	Protein	RFX7	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
54608	 6342	13928	HOXC6	Protein	PDGFRA	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
55805	 6342	10718	HOXC6	Protein	TNFAIP8	mRNA	-1	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
56669	 6342	18918	HOXC6	Protein	AMELY	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
57724	 6342	 7159	HOXC6	Protein	GAS2L3	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
60953	 6342	19999	HOXC6	Protein	NCAM1	mRNA	0	1	10356360	We now show that in osteoblast-like cells, rhBMP-2 inhibits NCAM expression, while HOXC6 increases its expression, both acting via the same region of the promoter.
61894	 6342	14900	HOXC6	Protein	BCO2	mRNA	0	-1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
62127	 6342	17405	HOXC6	Protein	PAK1	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
64462	 6342	 5068	HOXC6	Protein	ZBTB7C	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
 9107	 6342	 6686	HOXC6	Protein	APBB1	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
 9940	 6342	 2310	HOXC6	Protein	FAM101A	mRNA	0	1	18339881	See Table 2. HOXC6 direct targets affected by loss of HOXC6 expression in normal mouse prostates. All fold changes are greater than or equal to 1.5
11045	 3130	 8037	NANOG	Protein	KLF6	mRNA	1	-1	16518401	Depletion of Nanog induced Nrp2 and Klf6 expression.
21663	 3130	 4615	NANOG	Protein	NR0B1	mRNA	1	1	16518401	Changes in gene expression after Nanog overexpression including Esrrb, Foxd3, Tcfcp2l1, Nr0b1 and Bmp4.
 3113	 3130	 3901	NANOG	Protein	FOXD3	mRNA	1	1	16518401	Changes in gene expression after Nanog overexpression including Esrrb, Foxd3, Tcfcp2l1, Nr0b1 and Bmp4.
45698	 3130	 8412	NANOG	Protein	LGALS1	mRNA	0	-1	16501172	FROM TEXT and Figure 6: Hybridization to the U133A DNA microarray,Genes downregulated in NANOG overexpressing cells and 2- day-old EBs compared with wild-type ES cells (Fig. 6D). These may be ICM (and therefore ES cell) markers that are downregulated upon the transition to primitive ectoderm. Among these genes are LECTIN (LGALS1), a known marker of HESCs (Dvash et al., 2004) that is absent from all samples but ES cells, and HOXA1 (homeo box A1), a transcription factor involved in development. Among the genes downregulated in NANOG overexpressing cells but to a smaller extent are genes suggested to be downstream targets of HOXA1 (Shen et al., 2000), such as GBX2 and BMP2.
55233	 3130	12981	NANOG	Protein	COL3A1	mRNA	-1	-1	16501172	FROM TEXT and Figure 6: Hybridization to the U133A DNA microarray,Genes downregulated in NANOG overexpressing cells and 2- day-old EBs compared with wild-type ES cells (Fig. 6D). These may be ICM (and therefore ES cell) markers that are downregulated upon the transition to primitive ectoderm. Among these genes are LECTIN (LGALS1), a known marker of HESCs (Dvash et al., 2004) that is absent from all samples but ES cells, and HOXA1 (homeo box A1), a transcription factor involved in development. Among the genes downregulated in NANOG overexpressing cells but to a smaller extent are genes suggested to be downstream targets of HOXA1 (Shen et al., 2000), such as GBX2 and BMP2.
16720	11936	19507	NRF1	Protein	EIF2S2	mRNA	0	1	10634932	The mechanism for the increased protein synthesis and growth appeared to be a transcriptional upregulation of the eIF-2alpha and eIF-2beta genes.
 2484	11936	17889	NRF1	Protein	SLC2A4	mRNA	1	1	12958173	expression of MEF2A and GLUT4 was increased in NRF-1 transgenic muscle.
33114	11936	 4034	NRF1	Protein	E2F6	mRNA	0	1	15257658	To understand how cells control E2F6 expression, we analysed the activity of the previously cloned promoter region of the human E2F6 gene. DNase I footprinting, gel electrophoreticmobility shift, transient transfection and site-directed mutagenesis experiments allowed the identification of two functional NRF-1/alpha-PAL (nuclear respiratory factor-1/alpha-palindrome-binding protein)-binding sites within the human E2F6 core promoter region, which are conserved in the mouse and rat E2F6 promoter region. Moreover, ChIP (chromatin immunoprecipitation) analysis demonstrated that overexpressed NRF-1/alpha-PAL is associated in vivo with the E2F6 promoter. Furthermore, overexpression of full-length NRF-1/alpha-PAL enhanced E2F6 promoter activity, whereas expression of its dominant-negative form reduced the promoter activity. Our results indicate that NRF-1/alpha-PAL is implicated in the regulation of basal E2F6 gene expression.
33482	11936	 6302	NRF1	Protein	NDUFA8	mRNA	0	1	12031478	These genes come from a Table 1. I have taken only the human genes; there is additional animal data. Omitted from this list are human facts in the table that we already have.
34397	11936	 5456	NRF1	Protein	TFB1M	mRNA	0	1	12031478	These genes come from a Table 1. I have taken only the human genes; there is additional animal data. Omitted from this list are human facts in the table that we already have.
35310	11936	15605	NRF1	Protein	E2F1	mRNA	0	-1	10634932	The mechanism for the cell cycle downregulation appeared to be a transcriptional downregulation of E2F-1, a transcription factor that regulates genes required for cell cycle progression beyond the G1/S interphase.
35816	11936	12034	NRF1	Protein	UROS	mRNA	1	1	12832613	These are additional genes from Figure 1B.
41021	11936	 1427	NRF1	Protein	SDHD	mRNA	0	1	12031478	These genes come from a Table 1. I have taken only the human genes; there is additional animal data. Omitted from this list are human facts in the table that we already have.
44494	11936	10804	NRF1	Protein	CYCS	mRNA	-1	1	12832613	This is the starred list from Figure 1A.
50258	11936	16618	NRF1	Protein	VDAC3	mRNA	0	1	12031478	These genes come from a Table 1. I have taken only the human genes; there is additional animal data. Omitted from this list are human facts in the table that we already have.
51227	11936	 6941	NRF1	Protein	TFAM	mRNA	0	1	12031478	These genes come from a Table 1. I have taken only the human genes; there is additional animal data. Omitted from this list are human facts in the table that we already have.
53443	11936	 6316	NRF1	Protein	MEF2A	mRNA	0	1	12958173	expression of MEF2A and GLUT4 was increased in NRF-1 transgenic muscle.
65440	11936	19519	NRF1	Protein	CPT1A	mRNA	-1	1	12149506	HIF-1alpha-regulated genes (aldolase A, alpha- and beta-enolase, lactate dehydrogenase A, liver and muscle phosphofructokinase) and NRF-1-regulated genes (cytochrome c, Va subunit of cytochrome oxidase, and carnitine palmitoyltransferase I )
65639	11936	 6557	NRF1	Protein	ALAS1	mRNA	0	1	12832613	These are additional genes from Figure 1B.
 7240	11936	16823	NRF1	Protein	ALAS2	mRNA	1	1	12205177	increase in AMPK activity during contraction increases NRF-1 (Bergeron et al. 2001; Murakami et al. 1998; Xia et al. 1997), a transcription factor, which, in turn, binds to the ALA synthase and mTFA gene promoters, resulting in increases in these proteins (Gordon et al. 2001) and consequently increases cytochrome c protein concentration and mitochondrial density (Hood, 2001).
  886	11936	19574	NRF1	Protein	MRPS12	mRNA	0	1	12031478	These genes come from a Table 1. I have taken only the human genes; there is additional animal data. Omitted from this list are human facts in the table that we already have.
13487	18927	 4693	NKX2-5	Protein	SLC8A1	mRNA	0	1	10212268	Modified assertion
16053	18927	 1471	NKX2-5	Protein	COL1A2	mRNA	-1	1	15226419	_ GeneRif: Data show that pro-collagen type I alpha 2 expression is activated through binding of Nkx2.5 and is repressed by the binding of deltaEF1/ZEB1 Furthermore, we show that the expression is activated through the binding of the homeodomain protein Nkx2.5, which is further potentiated in the presence of GATA6. In contrast, this element was repressed by the binding of the zinc-finger protein deltaEF1/ZEB1.
25027	18927	11217	NKX2-5	Protein	NPPA	mRNA	0	1	12692125	the procollagen lysyl hydroxylase (PLOD1) promoter is regulated by Nkx2.5. Mechanistically, PITX2C and Nkx2.5 synergistically regulate ANF and PLOD1 expression through binding to their respective DNA elements. Surprisingly, PITX2A activation of the ANF and PLOD1 promoters is repressed by co-transfection of Nkx2.5 in the C3H10T1/2 embryonic fibroblast cell line
 2694	18927	 4168	NKX2-5	Protein	TBX5	mRNA	0	1	15653675	Modified assertion
30291	18927	13398	NKX2-5	Protein	PLOD1	mRNA	0	1	12692125	the procollagen lysyl hydroxylase (PLOD1) promoter is regulated by Nkx2.5. Mechanistically, PITX2C and Nkx2.5 synergistically regulate ANF and PLOD1 expression through binding to their respective DNA elements. Surprisingly, PITX2A activation of the ANF and PLOD1 promoters is repressed by co-transfection of Nkx2.5 in the C3H10T1/2 embryonic fibroblast cell line
38260	18927	15460	NKX2-5	Protein	IRX4	mRNA	0	1	10625552	Modified assertion
46061	18927	15021	NKX2-5	Protein	CALR	mRNA	0	1	11106640	Modified assertion
54335	18927	 4922	NKX2-5	Protein	NAB2	mRNA	0	1	10710348	Modified assertion
58681	18927	18695	NKX2-5	Protein	MYOCD	mRNA	0	1	14645532	Modified assertion
12153	16760	  877	testosterone	Compound	VCAN	mRNA	0	1	12586779	In cultured granulosa cells, forskolin and phorbol 12 myristate 13-acetate or FSH + testosterone increased expression of versican.
12292	16760	11308	testosterone	Compound	Sep15	mRNA	0	1	12446617	Figure 2. Real-time quantitative RT-PCR measurement of thioredoxin (TRX), peroxiredoxin 5 (PRX5), superoxide dismutase 2 (SOD2), selenoprotein 15 kDa (SL), VDUP 1, and ezrin gene expression in normal (N), 1- and 4-d castrated (C1 and C4), and 4-d testosterone replacement (T4) rat ventral prostate. The RNA pools used for microarray experiments were used as starting material for the analysis. Each column represents the average of four measurements, and error bars represent SD. Values for normal animals were set to 100%. Statistical analysis of the data was performed by unpaired, two-tailed t test. *, P < 0.05 compared with normal animals; _, P < 0.05 compared with 4-d castrated animals.
13716	16760	 1438	testosterone	Compound	VEGFA	mRNA	0	1	10375015	Similarly, testosterone upregulated the expression of VEGF mRNA in the S115 cells.
19646	16760	16486	testosterone	Compound	SPP1	mRNA	1	1	11780360	The results showed that vitamin K, testosterone and estradiol up-regulated the expression of OPN mRNA and its protein
20444	16760	11234	testosterone	Compound	TUBB4B	mRNA	0	1	11520906	Treatment of proliferating SH-SY5Y cells with testosterone resulted in an up-regulation of alpha- and beta-tubulin We also show that an up-regulation of the ubiquitous beta(II)-tubulin and of the neurone-specific beta(III)-tubulin isoforms contributes to the overall increase in tubulin in response to androgen treatment
27646	16760	12781	testosterone	Compound	AR	mRNA	1	1	12960001	Androgen receptor mRNA and protein levels were low at baseline but increased after testosterone or DHT treatment.
39377	16760	18612	testosterone	Compound	SOD2	mRNA	-1	1	14633623	Testosterone replacement in castrated rats partially reduced expression of Noxs but restored expression of superoxide dismutase 2, glutathione peroxidase 1, thioredoxin, and peroxiredoxin 5 to complete normalcy and induced a compensatory increase in expression of catalase, glutathione reductase, gamma-glutamyl transpeptidase, and glutathione synthetase
56573	16760	 5131	testosterone	Compound	CLU	mRNA	0	1	17325745	we demonstrated that testosterone increased basal reactive oxygen species (bROS) levels, resulting in dose-dependent activation of phospho-p38 and pAKT, and increased expression of clusterin, catalase, and manganese superoxide dismutase.
58371	16760	 6053	testosterone	Compound	CAT	mRNA	-1	1	17325745	we demonstrated that testosterone increased basal reactive oxygen species (bROS) levels, resulting in dose-dependent activation of phospho-p38 and pAKT, and increased expression of clusterin, catalase, and manganese superoxide dismutase.
61251	16760	 1552	testosterone	Compound	ODC1	mRNA	1	1	15539552	pharmacological doses of testosterone simultaneously down-regulated the level of OAT protein and up-regulated the expression of arginase II and ODC genes
66241	16760	16419	testosterone	Compound	TUBB3	mRNA	0	1	11520906	Treatment of proliferating SH-SY5Y cells with testosterone resulted in an up-regulation of alpha- and beta-tubulin We also show that an up-regulation of the ubiquitous beta(II)-tubulin and of the neurone-specific beta(III)-tubulin isoforms contributes to the overall increase in tubulin in response to androgen treatment
10675	 7706	17927	ZBTB17	Protein	CKAP4	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
20900	 7706	19478	ZBTB17	Protein	SRPK1	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
21758	 7706	 5096	ZBTB17	Protein	INHBE	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
29688	 7706	 9741	ZBTB17	Protein	TUBA1A	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
41948	 7706	 8833	ZBTB17	Protein	ANAPC5	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
46705	 7706	  502	ZBTB17	Protein	TTK	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
48110	 7706	13471	ZBTB17	Protein	BIRC5	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
53895	 7706	 5099	ZBTB17	Protein	KATNB1	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
55834	 7706	10719	ZBTB17	Protein	DENR	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
 5896	 7706	 5636	ZBTB17	Protein	AURKA	mRNA	1	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
62369	 7706	15481	ZBTB17	Protein	FGF3	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
 6414	 7706	 5554	ZBTB17	Protein	MST1	mRNA	0	1	14704274	Analysis of Genes Down-Regulated by Depletion of MIZ-1. Within this list of down-regulated genes are several that have been implicated in cytoskeletal structure and growth regulation, including anaphase promoting complex subunit 5, splicing factor arginine/serine-rich (SFRS) protein kinase 1, cytoskeleton-associated protein 4 (p63, a p53 homolog), katanin p80, tubulin ( complex associated protein 3), testis thymus kinase (TTK) protein kinase, serine/threonine kinase 6, survivin, fibroblast growth factor receptor 3, macrophage stimulating 1 (hepatocyte growth factor-like), activin  E, density-regulated protein, and BCL2.
59514	12051	 2671	HES7	Protein	RHOU	mRNA	-1	-1	17681139	Here, we show that Hes7 also regulates cyclic expression of the Fgf signaling inhibitor Dusp4 and links Notch and Fgf oscillations in phase. Supplemental TAble 1.
16046	 7391	 1471	RFX5	Protein	COL1A2	mRNA	-1	-1	12968017	All three RFX5 proteins significantly down- regulated COL1A2 promoter activity (***, p < 0.001) as compared with the empty  vector control group.
 6878	 7391	 2204	RFX5	Protein	COL1A1	mRNA	0	-1	15788405	On the other hand, RFX5 interacts with both collagen type I genes with a similar binding affinity and represses both promoters equally in transient transfections. Two dominant negative forms of RFX5 activate both collagen genes coordinately.
 7756	 7391	 5263	RFX5	Protein	HLA-DRB3	mRNA	0	1	17279624	The RFX complex is comprised of three proteins, RFXB, RFXAP, and RFX5, all of which are required for DNA binding and activation of MHCII gene expression.
13406	15316	10696	MEF2 Family	Protein	JUN	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
14133	15316	 9961	MEF2 Family	Protein	AMPD3	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
 1593	15316	19629	MEF2 Family	Protein	MYL6	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
  245	15316	 4377	MEF2 Family	Protein	MSTN	mRNA	0	1	12242277	(ResnetDB) Myf5, MyoD, and MEF2 transactivate the myostatin promoter.
 2471	15316	17889	MEF2 Family	Protein	SLC2A4	mRNA	1	1	12802337	MEF2A isoform is required for striated muscle- specific expression of the insulin-responsive GLUT4 glucose transporter
26664	15316	10152	MEF2 Family	Protein	MYL3	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
29586	15316	 8656	MEF2 Family	Protein	COX7A1	mRNA	0	1	11997101	To establish the identity of binding factors, supershift assays were performed using polyclonal antibodies. The MEF2 ( Fig. 6A, lane 7), MyoD, E47 (Fig. 7, lane 5-7) and Sp1 ( Fig. 6B, lane 6) antibodies cause a supershift of the major shifted band.
30107	15316	20193	MEF2 Family	Protein	MYOD1	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
41065	15316	10934	MEF2 Family	Protein	MYH8	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
46972	15316	 8072	MEF2 Family	Protein	MYH9	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
51757	15316	 9969	MEF2 Family	Protein	MYL9	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
 5946	15316	 1713	MEF2 Family	Protein	MYOG	mRNA	0	1	10896679	Previous studies indicated that transcription of myogenin was dependent on MyoD and MEF2 proteins. We find that expression of a dominant negative form of PI3-K or growth in the presence of LY294002 inhibits cellular activity of MEF2 but not of MyoD. Evidence reveals that whereas MEF2 transcriptional activity is inhibited, its DNA binding activity remains unaffected.
60568	15316	11388	MEF2 Family	Protein	MYH14	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
  883	15316	11483	MEF2 Family	Protein	MYL5	mRNA	0	1	15294035	Examples of genes having MEF2-binding sites include GLUT4, creatine kinase, AMP deaminase, myoglobin, myosin (heavy light chains), dystrophin, MyoD and cJun (Black  Olson, 1998).
 2293	 7282	 5419	NFAT Family	Protein	TNF	mRNA	0	1	12719569	NF-AT activation by vGPCR depended upon signaling through the phosphatidylinositol 3-kinase-Akt-glycogen synthetase kinase 3 (PI3-K/Akt/GSK-3) pathway and resulted in increased expression of NF-AT-dependent cell surface molecules (CD25, CD29, Fas ligand), proinflammatory cytokines (interleukin-2 [IL-2], IL-4), and proangiogenic factors (granulocyte-macrophage colony-stimulating factor GMCSF and TNF alpha)
 2411	 7282	 2512	NFAT Family	Protein	IL2RA	mRNA	0	1	12719569	NF-AT activation by vGPCR depended upon signaling through the phosphatidylinositol 3-kinase-Akt-glycogen synthetase kinase 3 (PI3-K/Akt/GSK-3) pathway and resulted in increased expression of NF-AT-dependent cell surface molecules (CD25, CD29, Fas ligand), proinflammatory cytokines (interleukin-2 [IL-2], IL-4), and proangiogenic factors (granulocyte-macrophage colony-stimulating factor GMCSF and TNF alpha)
33245	 7282	 8352	NFAT Family	Protein	CD40LG	mRNA	0	1	18180380	we performed promoter analysis of the CD154 gene and found that NFAT, a calcium-dependent transcriptional regulator associated with activated T cells, mediated both differentiation-dependent and inducible megakaryocyte-specific CD154 expression.
34481	 7282	 3920	NFAT Family	Protein	DHX32	mRNA	0	1	16414036	These results suggest that the DHX32 expression is modulated in Jurkat T cells via a pathway that involves NF-AT.
  359	 7282	 8338	NFAT Family	Protein	C2orf28	mRNA	0	1	17387583	Furthermore, exogenous expression of a constitutively active mutant of transcription factor NFAT was able to enhance both the promoter activities of APR3.
36787	 7282	 8660	NFAT Family	Protein	IL4	mRNA	0	1	12719569	NF-AT activation by vGPCR depended upon signaling through the phosphatidylinositol 3-kinase-Akt-glycogen synthetase kinase 3 (PI3-K/Akt/GSK-3) pathway and resulted in increased expression of NF-AT-dependent cell surface molecules (CD25, CD29, Fas ligand), proinflammatory cytokines (interleukin-2 [IL-2], IL-4), and proangiogenic factors (granulocyte-macrophage colony-stimulating factor GMCSF and TNF alpha)
  484	 7282	11404	NFAT Family	Protein	CSF2	mRNA	0	1	12719569	NF-AT activation by vGPCR depended upon signaling through the phosphatidylinositol 3-kinase-Akt-glycogen synthetase kinase 3 (PI3-K/Akt/GSK-3) pathway and resulted in increased expression of NF-AT-dependent cell surface molecules (CD25, CD29, Fas ligand), proinflammatory cytokines (interleukin-2 [IL-2], IL-4), and proangiogenic factors (granulocyte-macrophage colony-stimulating factor GMCSF and TNF alpha)
51686	 7282	  219	NFAT Family	Protein	FASLG	mRNA	-1	1	12719569	NF-AT activation by vGPCR depended upon signaling through the phosphatidylinositol 3-kinase-Akt-glycogen synthetase kinase 3 (PI3-K/Akt/GSK-3) pathway and resulted in increased expression of NF-AT-dependent cell surface molecules (CD25, CD29, Fas ligand), proinflammatory cytokines (interleukin-2 [IL-2], IL-4), and proangiogenic factors (granulocyte-macrophage colony-stimulating factor GMCSF and TNF alpha)
53972	 7282	11581	NFAT Family	Protein	ITGB1	mRNA	1	1	12719569	NF-AT activation by vGPCR depended upon signaling through the phosphatidylinositol 3-kinase-Akt-glycogen synthetase kinase 3 (PI3-K/Akt/GSK-3) pathway and resulted in increased expression of NF-AT-dependent cell surface molecules (CD25, CD29, Fas ligand), proinflammatory cytokines (interleukin-2 [IL-2], IL-4), and proangiogenic factors (granulocyte-macrophage colony-stimulating factor GMCSF and TNF alpha)
52776	17971	10375	BRD2	Protein	CD24	mRNA	1	-1	15067357	In contrast, increase in tumor rejection antigen (gp96) 1 and decrease in connective tissue growth factor (CTGF), transforming growth factor-beta 1 induced transcript 1 (TGFB1Il), pim-1 oncogene (PIM1), v-maf musculoaponeurotic fibrosarcoma oncogene homologue (MAF) and CD24 antigen
11237	 1770	19608	ADRB Family	Protein	LEP	mRNA	0	-1	12020765	Leptin expression can be induced by obesity, insulin, TNF-a and glucocorticoids and is negatively regulated by fasting, b-adrenergic agonists and thiazolidinediones
19694	 1770	16486	ADRB Family	Protein	SPP1	mRNA	1	1	16371745	Messenger RNA expression for monoamine oxidase A was increased, while the expression of osteopontin decreased with propranolol treament
  499	 1770	16088	ADRB Family	Protein	GPX4	mRNA	1	1	16371745	Table 2  Gene Changes Related to Lipid Metabolism
21337	15244	13132	biotin	Compound	PC	mRNA	1	1	15623830	RT-PCR at d 0 and 28. At d 28, SLC19A3 expression had decreased to 33% of d 0 (P < 0.02 by two-tailed, paired t test). Expression of MCCA, PCCA, PC, ACCA, ACCB, HCS, biotinidase, and SMVT decreased to approximately 80% of d 0 (P < 0.05).
 1307	 5925	 7836	simvastatin	Compound	CD55	mRNA	-1	1	NA	Background Complement-mediated vascular injury is important in the pathophysiology of atherosclerosis and myocardial infarction. As recent evidence shows that the statins, HMGCoA reductase inhibitors, have beneficial effects on endothelial cell (EC) function independent of lipid-lowering, we explored the hypothesis that statins modulate vascular EC resistance to complement through upregulation of complement-inhibitory proteins. Methods/Results Human umbilical vein EC (HUVEC) were treated with atorvastatin or simvastatin and expression of decay-accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 was measured by flow-cytometry. A dose-dependent increase in DAF expression of upto 4 fold was seen 24-48h post-treatment. CD59 expression was increased by 50% whilst MCP was unchanged. Similar results were obtained with human aortic EC. Statin-induced upregulation of DAF required increased steady-state mRNA and de novo protein synthesis. Inclusion of L-mevalonate, or geranylgeranyl pyrophosphate, reversed the effect on DAF expression, confirming the role of HMGCoA reductase inhibition and suggesting that DAF expression is negatively regulated by geranylgeranylation. Neither farnesyl pyrophosphate nor squalene inhibited statin-induced DAF expression suggesting the effect is independent of cholesterol lowering. We found that statin-induced DAF expression is mediated by activation of PKC? and inhibition of RhoA and is independent of PI-3K and nitric oxide activity. The increase of DAF following statin treatment is functionally relevant, resulting in marked reduction in C3 deposition and complement-mediated EC lysis inhibitable by anti-DAF mAb 1H4 (p < 0.05). Conclusions These observations provide evidence for a novel cytoprotective action of the statins on vascular endothelium, independent of the effect on lipids, and resulting in enhanced protection against complement-mediated injury. Modulation of complement regulatory protein expression by statins may contribute to the early beneficial effects of statins in reducing morbidity and mortality associated with atherosclerosis.
21964	 5925	15307	simvastatin	Compound	Hbb-b1	mRNA	1	1	15358814	TABLE 2  Distinct alterations in gene expression induced by lovastatin, simvastatin, or pravastatin in the cerebral cortex of C57BL/6 mice
26684	 5925	18713	simvastatin	Compound	SCARB1	mRNA	0	1	18981156	(Figure legend) FIGURE 5. Simvastatin positively regulates expression of SR-BI and eNOS, but negatively regulates expression of S1P3 receptors without change in S1P1 receptor expression.
28250	 5925	 7832	simvastatin	Compound	THBS1	mRNA	-1	-1	10543307	In summary, lovastatin and simvastatin predominantly decrease the expression of the glycoprotein thrombospondin-1, which is functionally associated with smooth muscle cell migration and proliferation.
 2919	 5925	 4252	simvastatin	Compound	ABCA1	mRNA	0	-1	17466310	We determined the lowest effective concentrations for three commonly prescribed statins (atorvastatin, simvastatin, rosuvastatin) and a newly-available statin (pitavastatin) (Fig. 5AD). All four statins produced a clear reduction in ABCA1 and ABCG1 mRNA expression in THP-1 macrophages at concentrations of 50?100 nM. These effects were also seen in HMDMs at 100nM and higher (Fig. 5E),
34404	 5925	15589	simvastatin	Compound	NFIX	mRNA	0	-1	15358814	TABLE 2  Distinct alterations in gene expression induced by lovastatin, simvastatin, or pravastatin in the cerebral cortex of C57BL/6 mice
40956	 5925	 4582	simvastatin	Compound	NOS3	mRNA	1	1	11592937	Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, increases eNOS expression in the endothelium.
45358	 5925	14987	simvastatin	Compound	BCL2	mRNA	1	1	15358814	TABLE 2  Distinct alterations in gene expression induced by lovastatin, simvastatin, or pravastatin in the cerebral cortex of C57BL/6 mice
58895	 5925	10064	simvastatin	Compound	SELP	mRNA	-1	-1	12130721	Pretreatment of HCAECs with simvastatin or atorvastatin (1 and 10 microM) reduced ox-LDL-induced expression of LOX-1 as well as adhesion molecules
59318	 5925	 3216	simvastatin	Compound	ABCG1	mRNA	0	-1	17466310	We determined the lowest effective concentrations for three commonly prescribed statins (atorvastatin, simvastatin, rosuvastatin) and a newly-available statin (pitavastatin) (Fig. 5AD). All four statins produced a clear reduction in ABCA1 and ABCG1 mRNA expression in THP-1 macrophages at concentrations of 50?100 nM. These effects were also seen in HMDMs at 100nM and higher (Fig. 5E),
59517	 5925	 2671	simvastatin	Compound	RHOU	mRNA	-1	1	15358814	TABLE 1  Overlap in alterations of gene expression induced by lovastatin, simvastatin, and pravastatin in the cerebral cortex of C57BL/6 mice
62013	 5925	 2608	simvastatin	Compound	HBB	mRNA	1	1	15358814	TABLE 2 Distinct alterations in gene expression induced by lovastatin, simvastatin, or pravastatin in the cerebral cortex of C57BL/6 mice
 6835	 5925	 4435	simvastatin	Compound	S1PR3	mRNA	0	-1	18981156	(Figure legend) FIGURE 5. Simvastatin positively regulates expression of SR-BI and eNOS, but negatively regulates expression of S1P3 receptors without change in S1P1 receptor expression.
11334	 1156	12387	GCM1	Protein	MYB	mRNA	0	-1	18167345	Supplementary table 2. Genes induced in the placenta of Gcm1 knockout mice
47249	 1156	17970	GCM1	Protein	EFNA2	mRNA	1	-1	18167345	Supplementary table 2. Genes induced in the placenta of Gcm1 knockout mice
48779	 1156	17731	GCM1	Protein	DCN	mRNA	-1	-1	18167345	Supplementary table 2. Genes induced in the placenta of Gcm1 knockout mice
17185	12529	 4664	SPI1	Protein	AIF1	mRNA	0	1	11861656	Cooperation between Pu.1 and proteins binding to the interferon regulatory factor element appears to be necessary for both macrophage-specific and interferon gamma-inducible expression of the aif-1 gene.
19857	12529	10504	SPI1	Protein	OSCAR	mRNA	0	1	12695521	_ GeneRif: PU.1 and MITF transcription factors synergistically activate OSCAR gene expression, which is further enhanced by the TRANCE-induced MKK6/p38 signaling cascade.
22912	12529	17263	SPI1	Protein	CD68	mRNA	0	1	12676954	expression of CD68 in myeloid cells requires the Ets transcription factors Elf-1 and PU.1 and CD68 expression is down-regulated in lymphoid cells by combinatorial interactions between PU.1 and IRF-4.
27993	12529	14558	SPI1	Protein	FLI1	mRNA	0	1	11991951	The -270/-41 fragment contains two known Spi-1-responding Ets binding sites (EBS), which are also necessary for the activation by Ets-1.
35573	12529	 3783	SPI1	Protein	MCM3AP	mRNA	0	1	15034025	Lyn controls the formation and proliferation of germinal centers via GANP. GANP promoter activity was higher in wild-type vs Lyn-deficient cells. Mutation of the PU.1 binding site reduced activity in wild-type cells and had no effect in Lyn-deficient cells. The presence of Lyn enhanced PU.1 expression in a Northern blot. Thus, the following new signaling pathway has been described: Lyn-->PU.1-->GANP.
42949	12529	 8368	SPI1	Protein	CXCL9	mRNA	0	1	15959530	MUM1 activated the MIG promoter in cooperation with PU.1,
43098	12529	  980	SPI1	Protein	PTPRC	mRNA	0	1	11114304	Although CD45 is normally expressed in all leukocyte lineages, it is critically regulated by PU.1 only in myeloid cells. Whereas myeloid cells from PU.1 null mice failed to express CD45, lymphoid cells were CD45(+) by flow cytometry. Additionally, mRNA for CD45 was absent from PU.1-deficient myeloid cells.
44843	12529	14630	SPI1	Protein	IL18	mRNA	0	1	12429737	Ariadne: ICSBP and  PU.1 may also have a role in enhancing expression of the toll-like receptor 4  and IL-18 through a similar element ( 47 , 48 ). [Expression]
45249	12529	 6072	SPI1	Protein	REL	mRNA	0	1	11672537	c-rel Appears to Be a Direct Target Gene of Both PU.1 and Spi-B
47793	12529	 6938	SPI1	Protein	CTSE	mRNA	-1	1	 9611252	PU.1 and C/EBPalpha are transcription factors essential for normal myeloid development. Loss-of-function mutation of PU.1 leads to an absolute block in monocyte/macrophage development and abnormal granulocytic development while that of C/EBPalpha causes a selective block in neutrophilic differentiation. In order to understand these phenotypes, we studied the role of PU.1 and C/EBPalpha in the regulation of myeloid target genes in vivo . Northern blot analysis revealed that mRNAs encoding receptors for M-CSF, G-CSF and GM-CSF, were expressed at low levels in PU.1(-/-) fetal liver compared with wild type. To identify additional myeloid genes regulated by PU.1 and C/EBPalpha, we performed representational difference analysis (RDA), a PCR-based subtractive hybridization using fetal livers from wild type and PU.1 or C/EBPalpha knockout mice. By introducing a new modification of RDA, that of tissue-specific gene suppression, we could selectively identify a set of differentially expressed genes specific to myeloid cells. Differentially expressed genes included both primary and secondary granule protein genes. In addition, eight novel genes were identified that were upregulated in expression during myeloid differentiation. These methods provide a general strategy for elucidating the genes affected in murine knockout models.
52161	12529	19073	SPI1	Protein	DAB2	mRNA	0	1	11823414	Both ICSBP and the Ets-transcription factor PU.1 bind to the Dab2 promoter, whereby ICSBP represses PU.1-induced Dab2 promoter transactivation in vitro.
 5237	12529	18461	SPI1	Protein	EPX	mRNA	0	1	12515729	MBP and EPX mRNAs were absent in a PU.1-null myeloid cell line established from the embryonic liver of PU.1(-/-) mice. Restitution of PU.1 protein expression restored MBP and EPX protein expression.
54120	12529	  822	SPI1	Protein	PIK3CD	mRNA	0	1	12444140	Interestingly, the PI3K kinase subunit p110{gamma} and its related adaptor subunit p101 were present in MH-S cells, absent in mAMGFP+ and restored by PU.1 expression in mAMPU.1+ cells. The PI3I kinase subunit p110{delta} exhibited a similar pattern of expression to the p110{gamma} subunit.
55755	12529	 8256	SPI1	Protein	PIK3R5	mRNA	0	1	12444140	Interestingly, the PI3K kinase subunit p110{gamma} and its related adaptor subunit p101 were present in MH-S cells, absent in mAMGFP+ and restored by PU.1 expression in mAMPU.1+ cells. The PI3I kinase subunit p110{delta} exhibited a similar pattern of expression to the p110{gamma} subunit.
55914	12529	 6160	SPI1	Protein	PIK3CG	mRNA	0	1	12444140	Interestingly, the PI3K kinase subunit p110{gamma} and its related adaptor subunit p101 were present in MH-S cells, absent in mAMGFP+ and restored by PU.1 expression in mAMPU.1+ cells. The PI3I kinase subunit p110{delta} exhibited a similar pattern of expression to the p110{gamma} subunit.
63153	12529	15160	SPI1	Protein	CTSK	mRNA	0	1	15304486	5p-deletion constructs of the cathepsin K gene promoter indicates that limited sets of the transcription factors such as NFATc1, PU.1, and microphthalmia transcription factor indeed enhance synergistically the gene expression when overexpressed in RAW264 cells.
64028	12529	15079	SPI1	Protein	OPRM1	mRNA	0	-1	14998994	In co-transfection studies PU.1 represses MOR promoter reporter constructs through its PU.1 binding site. When the PU.1 gene is disrupted as in PU.1 knock-out mice and using small interfering RNA-based strategy in RAW264.7 cells, the transcription of the endogenous target MOR gene is increased significantly.
 6781	12529	 2988	SPI1	Protein	TLR4	mRNA	0	1	16093364	Endotoxemia in animals caused the similar inducible interaction between PU.1 and IRF4 and the TLR4 promoter in lung tissue of mice that was treated with a single intraperitoneal injection of endotoxin.
 9861	12529	 4164	SPI1	Protein	P2RY10	mRNA	0	1	10567398	The Ets Factors PU.1 and Spi-B Regulate the Transcription in Vivo of P2Y10
16512	 4160	 9971	ZHX2	Protein	NPHS1	mRNA	0	1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
 1734	 4160	 4872	ZHX2	Protein	NID1	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
22047	 4160	16639	ZHX2	Protein	ANGPT2	mRNA	0	1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
33930	 4160	 9325	ZHX2	Protein	COL4A4	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
35537	 4160	 9783	ZHX2	Protein	Enpep	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
46577	 4160	12000	ZHX2	Protein	CD2AP	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
47806	 4160	16870	ZHX2	Protein	PODXL	mRNA	0	-1	17056598	Downregulation of COL4A3, COL4A4, angiopoietin 2 and vascular endothelial growth factor (VEGF) during the recovery phase is explained by nuclear entry of newly synthesized ZHX3 protein, whereas podocalyxin and ?1 integrin downregulation are likely related to nuclear entry of small amounts of free ZHX2 during the mild ZHX3 knockdown.
53982	 4160	11581	ZHX2	Protein	ITGB1	mRNA	1	-1	17056598	Downregulation of COL4A3, COL4A4, angiopoietin 2 and vascular endothelial growth factor (VEGF) during the recovery phase is explained by nuclear entry of newly synthesized ZHX3 protein, whereas podocalyxin and ?1 integrin downregulation are likely related to nuclear entry of small amounts of free ZHX2 during the mild ZHX3 knockdown.
54315	 4160	13783	ZHX2	Protein	LMX1B	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
61274	 4160	 1331	ZHX2	Protein	WT1	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
 6601	 4160	10646	ZHX2	Protein	KIRREL	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
11305	13186	11173	Cyclic GMP	Compound	ARG1	mRNA	-1	-1	15242832	The present study tested the hypothesis that acute increases in nitric oxide (NO) exert substantial influences on gene transcription in endothelial cells (ECs) via guanylyl cyclase (GC). Human umbilical veins ECs (HUVECs) were exposed to 0.1, 1, and 10 mM of sodium nitroprusside (SNP) for 4 h and to 1 mM SNP or 250 microM of (Z)-1[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate) for 2, 4, 8, and 24 h. Also, cells were exposed to DETA-NONOate in the presence and absence of the GC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ; 10 microM) for 4 h. RNA was isolated, reverse transcribed, Cy3 and Cy5 labeled, and analyzed using cDNA microarrays. Increasing doses of SNP predominantly depressed gene expression in HUVECs. Gene function was related to growth, adhesion, and cell structure. DETA-NONOate evoked a wave of expression changes (maximum at 4 h), with a remarkable downregulation of the transcription factors MSX1, RELB, and Egr-1. Both SNP- and DETA-NONOate-induced gene expression had faded after 24 h, despite continued elevation of cGMP in the medium. Coadministration of ODQ decreased many, but not all, of the transcriptional responses to DETA-NONOate. NO pronouncedly depressed EC gene expression, in particular of transcription factors. The observation that many, but not all, transcriptional changes induced by NO could be inhibited by inhibition of GC indicates the presence of GC-independent NO actions on gene expression. Thus EC gene expression responds to NO; however, the transcriptional response fades during prolonged exposure. This could allow the EC to respond to increased shear, without vigorous changes in gene expression.
23646	13186	17594	Cyclic GMP	Compound	CCNG1	mRNA	0	-1	15242832	The present study tested the hypothesis that acute increases in nitric oxide (NO) exert substantial influences on gene transcription in endothelial cells (ECs) via guanylyl cyclase (GC). Human umbilical veins ECs (HUVECs) were exposed to 0.1, 1, and 10 mM of sodium nitroprusside (SNP) for 4 h and to 1 mM SNP or 250 microM of (Z)-1[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate) for 2, 4, 8, and 24 h. Also, cells were exposed to DETA-NONOate in the presence and absence of the GC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ; 10 microM) for 4 h. RNA was isolated, reverse transcribed, Cy3 and Cy5 labeled, and analyzed using cDNA microarrays. Increasing doses of SNP predominantly depressed gene expression in HUVECs. Gene function was related to growth, adhesion, and cell structure. DETA-NONOate evoked a wave of expression changes (maximum at 4 h), with a remarkable downregulation of the transcription factors MSX1, RELB, and Egr-1. Both SNP- and DETA-NONOate-induced gene expression had faded after 24 h, despite continued elevation of cGMP in the medium. Coadministration of ODQ decreased many, but not all, of the transcriptional responses to DETA-NONOate. NO pronouncedly depressed EC gene expression, in particular of transcription factors. The observation that many, but not all, transcriptional changes induced by NO could be inhibited by inhibition of GC indicates the presence of GC-independent NO actions on gene expression. Thus EC gene expression responds to NO; however, the transcriptional response fades during prolonged exposure. This could allow the EC to respond to increased shear, without vigorous changes in gene expression.
25864	13186	19027	Cyclic GMP	Compound	HMOX1	mRNA	0	1	12869663	View this table: [in this window] [in a new window] TABLE 1 Summary of the various functions of HO isoforms, their tissue distribution, and gene regulation      Maines et al. (1986) were the first to report the identification of a second form of HO from rat liver microsomes, designated HO-2. Only recently, a third isoform, HO-3, was discovered (McCoubrey et al., 1997). HO-1 and HO-2 share little similarity in amino acid sequence (40%), whereas the HO-2 and HO-3 isoform are far more homologous (90%). All HO isoforms are highly conserved among species in evolution. HO is expressed in virtually all life forms; in prokaryotic bacteria as well as in fungi, plants, and humans, regulating a wide spectrum of cellular processes (Terry et al., 2002). The homology between rat, mouse, and human is for HO-1 and HO-2 proteins higher than 80% and 90%, respectively.  Under normal physiological conditions, most cells express low or undetectable levels of HO-1 protein, whereas HO-2 proteins are constitutively expressed. HO-3 protein expression awaits further characterization. HO-2 transcription is only up-regulated by few agents, such as opiates and adrenal glucocorticoids (Li and David Clark, 2000; Liu et al., 2000).  HO-1 gene expression is highly inducible by more diverse stimuli than any other enzyme described to date (Maines, 1997) and involves a multitude of signaling pathways (Table 2) (Immenschuh and Ramadori, 2000). HO-1 expression is mainly regulated at the transcriptional level.     View this table: [in this window] [in a new window] TABLE 2 Selection of different inducers of HO-1 gene expression
28259	13186	 7832	Cyclic GMP	Compound	THBS1	mRNA	-1	-1	12882934	Expression of the catalytic domain prevented high glucose-mediated increases in transcription of the TSP1 gene with no alteration in TSP1 mRNA stability.
28970	13186	16957	Cyclic GMP	Compound	ASAH1	mRNA	-1	-1	15242832	The present study tested the hypothesis that acute increases in nitric oxide (NO) exert substantial influences on gene transcription in endothelial cells (ECs) via guanylyl cyclase (GC). Human umbilical veins ECs (HUVECs) were exposed to 0.1, 1, and 10 mM of sodium nitroprusside (SNP) for 4 h and to 1 mM SNP or 250 microM of (Z)-1[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate) for 2, 4, 8, and 24 h. Also, cells were exposed to DETA-NONOate in the presence and absence of the GC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ; 10 microM) for 4 h. RNA was isolated, reverse transcribed, Cy3 and Cy5 labeled, and analyzed using cDNA microarrays. Increasing doses of SNP predominantly depressed gene expression in HUVECs. Gene function was related to growth, adhesion, and cell structure. DETA-NONOate evoked a wave of expression changes (maximum at 4 h), with a remarkable downregulation of the transcription factors MSX1, RELB, and Egr-1. Both SNP- and DETA-NONOate-induced gene expression had faded after 24 h, despite continued elevation of cGMP in the medium. Coadministration of ODQ decreased many, but not all, of the transcriptional responses to DETA-NONOate. NO pronouncedly depressed EC gene expression, in particular of transcription factors. The observation that many, but not all, transcriptional changes induced by NO could be inhibited by inhibition of GC indicates the presence of GC-independent NO actions on gene expression. Thus EC gene expression responds to NO; however, the transcriptional response fades during prolonged exposure. This could allow the EC to respond to increased shear, without vigorous changes in gene expression.
51414	13186	11635	Cyclic GMP	Compound	DHCR24	mRNA	1	1	15242832	The present study tested the hypothesis that acute increases in nitric oxide (NO) exert substantial influences on gene transcription in endothelial cells (ECs) via guanylyl cyclase (GC). Human umbilical veins ECs (HUVECs) were exposed to 0.1, 1, and 10 mM of sodium nitroprusside (SNP) for 4 h and to 1 mM SNP or 250 microM of (Z)-1[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate) for 2, 4, 8, and 24 h. Also, cells were exposed to DETA-NONOate in the presence and absence of the GC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ; 10 microM) for 4 h. RNA was isolated, reverse transcribed, Cy3 and Cy5 labeled, and analyzed using cDNA microarrays. Increasing doses of SNP predominantly depressed gene expression in HUVECs. Gene function was related to growth, adhesion, and cell structure. DETA-NONOate evoked a wave of expression changes (maximum at 4 h), with a remarkable downregulation of the transcription factors MSX1, RELB, and Egr-1. Both SNP- and DETA-NONOate-induced gene expression had faded after 24 h, despite continued elevation of cGMP in the medium. Coadministration of ODQ decreased many, but not all, of the transcriptional responses to DETA-NONOate. NO pronouncedly depressed EC gene expression, in particular of transcription factors. The observation that many, but not all, transcriptional changes induced by NO could be inhibited by inhibition of GC indicates the presence of GC-independent NO actions on gene expression. Thus EC gene expression responds to NO; however, the transcriptional response fades during prolonged exposure. This could allow the EC to respond to increased shear, without vigorous changes in gene expression.
28861	12462	17518	Oxidized High Density LipoProtein	Compound	ANXA6	mRNA	-1	-1	17000557	Macrophages obtained from healthy blood donors were treated with native and oxidized HDL for 1 day and altered gene expression was detected using the cDNA microarray method. The genes that showed at least a 2-fold up- or down-regulation according to the ratio of time-matched oxidized lipoprotein to native lipoprotein-treated cells (e.g. ratio of oxidized to native LDL or HDL for 1 or alternatively for 3 days) were selected for statistical analysis.
39371	12462	18612	Oxidized High Density LipoProtein	Compound	SOD2	mRNA	-1	-1	17000557	Macrophages obtained from healthy blood donors were treated with native and oxidized HDL for 1 day and altered gene expression was detected using the cDNA microarray method. The genes that showed at least a 2-fold up- or down-regulation according to the ratio of time-matched oxidized lipoprotein to native lipoprotein-treated cells (e.g. ratio of oxidized to native LDL or HDL for 1 or alternatively for 3 days) were selected for statistical analysis.
42938	12462	15885	Oxidized High Density LipoProtein	Compound	ACTB	mRNA	1	-1	17000557	Macrophages obtained from healthy blood donors were treated with native and oxidized HDL for 1 day and altered gene expression was detected using the cDNA microarray method. The genes that showed at least a 2-fold up- or down-regulation according to the ratio of time-matched oxidized lipoprotein to native lipoprotein-treated cells (e.g. ratio of oxidized to native LDL or HDL for 1 or alternatively for 3 days) were selected for statistical analysis.
44757	12462	 4862	Oxidized High Density LipoProtein	Compound	PDGFA	mRNA	-1	-1	17000557	Macrophages obtained from healthy blood donors were treated with native and oxidized HDL for 1 day and altered gene expression was detected using the cDNA microarray method. The genes that showed at least a 2-fold up- or down-regulation according to the ratio of time-matched oxidized lipoprotein to native lipoprotein-treated cells (e.g. ratio of oxidized to native LDL or HDL for 1 or alternatively for 3 days) were selected for statistical analysis.
45697	12462	 8412	Oxidized High Density LipoProtein	Compound	LGALS1	mRNA	0	1	17000557	Macrophages obtained from healthy blood donors were treated with native and oxidized HDL 3 days and altered gene expression was detected using the cDNA microarray method. The genes that showed at least a 2-fold up- or down-regulation according to the ratio of time-matched oxidized lipoprotein to native lipoprotein-treated cells (e.g. ratio of oxidized to native LDL or HDL for 1 or alternatively for 3 days) were selected for statistical analysis.
62218	12462	 8131	Oxidized High Density LipoProtein	Compound	RARA	mRNA	0	-1	17000557	Macrophages obtained from healthy blood donors were treated with native and oxidized HDL for 1 day and altered gene expression was detected using the cDNA microarray method. The genes that showed at least a 2-fold up- or down-regulation according to the ratio of time-matched oxidized lipoprotein to native lipoprotein-treated cells (e.g. ratio of oxidized to native LDL or HDL for 1 or alternatively for 3 days) were selected for statistical analysis.
66366	12462	 7914	Oxidized High Density LipoProtein	Compound	ANXA5	mRNA	0	-1	17000557	Macrophages obtained from healthy blood donors were treated with native and oxidized HDL for 1 day and altered gene expression was detected using the cDNA microarray method. The genes that showed at least a 2-fold up- or down-regulation according to the ratio of time-matched oxidized lipoprotein to native lipoprotein-treated cells (e.g. ratio of oxidized to native LDL or HDL for 1 or alternatively for 3 days) were selected for statistical analysis.
14827	12200	10938	Epinephrine	Compound	H2AFY	mRNA	0	-1	15126512	The impact on metabolism was illustrated by coordinated regulations of genes involved in carbohydrate and protein metabolisms.
19451	12200	 6094	Epinephrine	Compound	RAD9A	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
31994	12200	 4292	Epinephrine	Compound	DDIT3	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
39413	12200	 5243	Epinephrine	Compound	SESN1	mRNA	-1	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
39774	12200	 2306	Epinephrine	Compound	ERCC1	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
41369	12200	15861	Epinephrine	Compound	RPRM	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
42298	12200	 9608	Epinephrine	Compound	DDB1	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
42626	12200	 6875	Epinephrine	Compound	CHEK1	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
44277	12200	13802	Epinephrine	Compound	CDC25A	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
45600	12200	 4559	Epinephrine	Compound	CDC20	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
48162	12200	 3148	Epinephrine	Compound	ERCC8	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 4841	12200	 4355	Epinephrine	Compound	BBC3	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
48544	12200	19123	Epinephrine	Compound	DDB2	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
51892	12200	18265	Epinephrine	Compound	ERCC3	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
53525	12200	15594	Epinephrine	Compound	CDC25C	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
58896	12200	10064	Epinephrine	Compound	SELP	mRNA	-1	1	 9588422	In vitro we found a synergistic increase in epinephrine-induced CD62 expression in the presence of dobutamine.
 6396	12200	17846	Epinephrine	Compound	CDC25B	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 8927	12200	15240	Epinephrine	Compound	PTPRCAP	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 9930	12200	17940	Epinephrine	Compound	RAD50	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
48012	 7120	11629	NTF4	Protein	FOS	mRNA	0	1	10501184	In cultures  of cerebellar granule cells, BDNF, NT-3, and NT-4/5 triggered the  phosphorylation of Shc, PI 3-K, and ERK/MAPKs, and the expression of c-fos,  whereas only BDNF and NT-4/5 seemed to activate PLCgamma (Lindholm et al., 1993  ; Zirrgiebel et al., 1995 ; Nonomura et al., 1996 ; Zirrgiebel and Lindholm,  1996 ).
50192	 7120	 8138	NTF4	Protein	NRP1	mRNA	-1	1	 9712655	Neutralizing anti-neuropilin-1 blocked the repellant influence of E12 arch Ib in the presence of NT-4/5 (Fig. 3 F ) or in its absence (Fig. 3 G ).
39233	19298	 7376	IKBK/CHUK Family	Protein	TNFSF10	mRNA	-1	1	11553609	Tax stimulated TRAIL mRNA expression was almost completely blocked in the IKK-gamma deficient cells. This functional defect was largely rescued when the mutant cells were reconstituted with IKK-gamma.
12252	 4500	14603	HOXA13	Protein	LYVE1	mRNA	0	-1	18483557	TABLE 2. Loss of HOXA13 function causes increased sinusoidal and lymphatic endothelial gene expression.
12267	 4500	 8413	HOXA13	Protein	FBN1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
13083	 4500	13086	HOXA13	Protein	TRO	mRNA	0	1	18483557	Table 1. Microarray and qRT-PCR analysis of gene transcription comparing mutant and wild-type tissue. Twelve microarray hybridizations (6 mutant; 6 wild type) were performed using independent isolates of placental labyrinth total RNA. Statistical analysis of the gene expression signals detected by the microarray probe sets identified significant reductions in pro-vascular gene expression (FDR?0.05)
 1339	 4500	13998	HOXA13	Protein	PTGIS	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
16625	 4500	 7054	HOXA13	Protein	GSTT1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
17598	 4500	 1323	HOXA13	Protein	CELF4	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
18171	 4500	17761	HOXA13	Protein	MYO7A	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
19249	 4500	17149	HOXA13	Protein	NGEF	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
19273	 4500	 7760	HOXA13	Protein	RAG1	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
19759	 4500	  437	HOXA13	Protein	AIM1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
20153	 4500	 9913	HOXA13	Protein	HOXA13	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
21252	 4500	15637	HOXA13	Protein	LIPA	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
21682	 4500	 2572	HOXA13	Protein	CAV1	mRNA	0	1	18483557	Table 1. Microarray and qRT-PCR analysis of gene transcription comparing mutant and wild-type tissue. Twelve microarray hybridizations (6 mutant; 6 wild type) were performed using independent isolates of placental labyrinth total RNA. Statistical analysis of the gene expression signals detected by the microarray probe sets identified significant reductions in pro-vascular gene expression (FDR?0.05)
23446	 4500	 7422	HOXA13	Protein	ENPP2	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
23650	 4500	19796	HOXA13	Protein	ST5	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
24156	 4500	10682	HOXA13	Protein	R3HCC1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
25569	 4500	17586	HOXA13	Protein	ITPR2	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
25668	 4500	13082	HOXA13	Protein	NDN	mRNA	0	1	18483557	Table 1. Microarray and qRT-PCR analysis of gene transcription comparing mutant and wild-type tissue. Twelve microarray hybridizations (6 mutant; 6 wild type) were performed using independent isolates of placental labyrinth total RNA. Statistical analysis of the gene expression signals detected by the microarray probe sets identified significant reductions in pro-vascular gene expression (FDR?0.05)
26857	 4500	12195	HOXA13	Protein	MFAP5	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
27275	 4500	 5826	HOXA13	Protein	SRRM1	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
27979	 4500	15591	HOXA13	Protein	FGF8	mRNA	0	1	12783783	we show that Hoxa13 is essential for normal expression of Fgf8 and Bmp7 in the urethral plate epithelium.
28802	 4500	 3307	HOXA13	Protein	RAMP3	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
28833	 4500	 1043	HOXA13	Protein	EBF3	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
29808	 4500	 1484	HOXA13	Protein	EXTL3	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
32099	 4500	 8057	HOXA13	Protein	Ly6a	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
33721	 4500	 1040	HOXA13	Protein	CD36	mRNA	0	1	18483557	Table 1. Microarray and qRT-PCR analysis of gene transcription comparing mutant and wild-type tissue. Twelve microarray hybridizations (6 mutant; 6 wild type) were performed using independent isolates of placental labyrinth total RNA. Statistical analysis of the gene expression signals detected by the microarray probe sets identified significant reductions in pro-vascular gene expression (FDR?0.05)
34085	 4500	  439	HOXA13	Protein	IGFBP4	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
34482	 4500	 9183	HOXA13	Protein	SELENBP1	mRNA	0	-1	18483557	TABLE 2. Loss of HOXA13 function causes increased sinusoidal and lymphatic endothelial gene expression.
35859	 4500	18179	HOXA13	Protein	LEPREL4	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
36637	 4500	18136	HOXA13	Protein	FSTL1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
36708	 4500	15198	HOXA13	Protein	MAGEL2	mRNA	0	1	18483557	Table 1. Microarray and qRT-PCR analysis of gene transcription comparing mutant and wild-type tissue. Twelve microarray hybridizations (6 mutant; 6 wild type) were performed using independent isolates of placental labyrinth total RNA. Statistical analysis of the gene expression signals detected by the microarray probe sets identified significant reductions in pro-vascular gene expression (FDR?0.05)
37295	 4500	19646	HOXA13	Protein	ANXA8L2	mRNA	1	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
37316	 4500	  404	HOXA13	Protein	Tgtp1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
38721	 4500	14697	HOXA13	Protein	ADCY7	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
38967	 4500	 1158	HOXA13	Protein	ALDH2	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
38988	 4500	14353	HOXA13	Protein	ADM	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
39211	 4500	 3311	HOXA13	Protein	NGF	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
39528	 4500	13230	HOXA13	Protein	TCF3	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
 4117	 4500	 7628	HOXA13	Protein	P4HA2	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
41297	 4500	 1008	HOXA13	Protein	CASP8AP2	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
 4145	 4500	 3058	HOXA13	Protein	SHROOM3	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
 4181	 4500	15414	HOXA13	Protein	ANK3	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
42441	 4500	17458	HOXA13	Protein	BLNK	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
42600	 4500	 9136	HOXA13	Protein	TAF1D	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
42690	 4500	17469	HOXA13	Protein	CD200	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
42801	 4500	 7824	HOXA13	Protein	SYT8	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
42967	 4500	 7163	HOXA13	Protein	COPZ2	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
 4313	 4500	19709	HOXA13	Protein	RGS2	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
44805	 4500	 9117	HOXA13	Protein	DDA1	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
45673	 4500	11191	HOXA13	Protein	Gm3716	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
47751	 4500	15578	HOXA13	Protein	Tpbpb	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
47988	 4500	 4684	HOXA13	Protein	IFIT1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
50193	 4500	 8138	HOXA13	Protein	NRP1	mRNA	-1	1	18483557	Table 1. Microarray and qRT-PCR analysis of gene transcription comparing mutant and wild-type tissue. Twelve microarray hybridizations (6 mutant; 6 wild type) were performed using independent isolates of placental labyrinth total RNA. Statistical analysis of the gene expression signals detected by the microarray probe sets identified significant reductions in pro-vascular gene expression (FDR?0.05)
50879	 4500	16714	HOXA13	Protein	FABP4	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
51604	 4500	 5673	HOXA13	Protein	ID1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
 5266	 4500	10813	HOXA13	Protein	GJB3	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
52900	 4500	16792	HOXA13	Protein	COL4A2	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
53088	 4500	10202	HOXA13	Protein	GHR	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
53380	 4500	 7538	HOXA13	Protein	GCOM1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
53715	 4500	14860	HOXA13	Protein	FHL1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
55252	 4500	12981	HOXA13	Protein	COL3A1	mRNA	-1	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
55363	 4500	 4481	HOXA13	Protein	COL5A2	mRNA	1	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
56415	 4500	14358	HOXA13	Protein	SYNPO	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
60443	 4500	18346	HOXA13	Protein	Klra4	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
62039	 4500	10091	HOXA13	Protein	INTS9	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
62602	 4500	 4925	HOXA13	Protein	IGFBP3	mRNA	0	-1	18483557	TABLE 2. Loss of HOXA13 function causes increased sinusoidal and lymphatic endothelial gene expression.
63045	 4500	 6905	HOXA13	Protein	Ly6c1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
63429	 4500	 2980	HOXA13	Protein	GAS2	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
63962	 4500	 9990	HOXA13	Protein	LAMB3	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
65908	 4500	  681	HOXA13	Protein	COX20	mRNA	0	-1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
 6801	 4500	14177	HOXA13	Protein	S100A13	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
 6814	 4500	 7782	HOXA13	Protein	EPHB3	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
 7098	 4500	16438	HOXA13	Protein	ADRB1	mRNA	0	1	18483557	Table 1. Microarray and qRT-PCR analysis of gene transcription comparing mutant and wild-type tissue. Twelve microarray hybridizations (6 mutant; 6 wild type) were performed using independent isolates of placental labyrinth total RNA. Statistical analysis of the gene expression signals detected by the microarray probe sets identified significant reductions in pro-vascular gene expression (FDR?0.05)
 8030	 4500	   64	HOXA13	Protein	TMEM45A	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
  806	 4500	 2054	HOXA13	Protein	ALDH3A1	mRNA	0	1	15733672	Hox genes encode transcription factors that regulate the morphogenesis of developing embryos. In mammals, knowledge of the genetic pathways, including the possible direct or indirect targets, regulated by HOX proteins is extremely limited. To identify the downstream genes regulated by posterior HOX proteins, we expressed HOXA13 in mouse embryonic fibroblasts lacking paralog group 13 expression using a bicistronic HOXA13/EGFP retroviral vector. Microarray analysis identified 68 genes with significant, reproducible RNA expression changes (50 activated; 18 repressed) in stable HOXA13-expressing cells. Genes with the GO annotation terms \extracellular matrix\ and \basement membran\ were greatly overrepresented, and several were shown to be regulated by HOX proteins in other studies. Among the genes strongly activated by HOXA13 were Enpp2, a bifunctional enzyme known to modulate tumor and normal cell motility and which is expressed in precartilaginous condensations; Fhl1, a transcription factor implicated in muscle cell differentiation and development; and M32486, a putative integral membrane molecule expressed in the female reproductive tract. Expression differences in the HOXA13-expressing cells were confirmed for selected downstream genes using semi-quantitative RT-PCR, and in vivo coexpression with Hoxa13 in the limb interdigital mesenchyme was demonstrated for many. For two candidates, Igfbp4 and Fstl, interdigital limb bud expression was reduced in Hoxa13 mutants. To explore whether paralogous and nonparalogous HOX proteins could regulate the same genes, we created new HOX cell lines and examined the expression of selected genes identified by the HOXA13 screen. HOXD13 similarly activatedrepressed 6 tested candidates, demonstrating that multiple downstream genetic pathways may be regulated by paralog HOX proteins. In contrast, HOXA9 was only able to repress expression of some gene targets. A HOXD13 mutant, HOXD13(IQN >)(AAA), incapable of monomeric DNA-binding, activated the expression of 5 HOXA13-upregulated genes; but was incapable of repressing the expression of Ngef and Casp8ap2. Our results suggest that HOX protein-protein interactions without direct HOX DNA-binding may play a larger role in HOX transcriptional regulation than generally assumed, and DNA-binding appears critical for repression.
16049	 9865	 1471	erlotinib	Compound	COL1A2	mRNA	-1	1	16144925	Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment.   To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxonps signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis).
25307	 9865	13534	erlotinib	Compound	CCNE2	mRNA	-1	-1	17909047	About 35 mRNAs were dysregulated in the erlotinib-treated group, whereas no significant change in the mRNAs from the celecoxib alone?treated group was found. Analysis of these results revealed that a large subset of genes involved in cell cycle progression or cellular proliferation was differentially regulated. The effect of celecoxib and erlotinib on mRNA levels of these genes are summarized in Table 1 . (HCA-7 cells, a human colorectal cancer cell line, were injected s.c. into the flank region of athymic nu/nu mice.)
29006	 9865	11331	erlotinib	Compound	RAD51	mRNA	0	-1	19671683	Erlotinib decreased cellular levels of phosphorylated ERK1/2, phosphorylated AKT, Rad51 protein, and mRNA in erlotinib-sensitive H1650, A549, and H1869 cells, leading to cell death via apoptosis     (also Erlotinib decreased Rad51 protein levels by enhancing Rad51 mRNA and protein instability, so will add protein as well as exp)
46041	 9865	12530	erlotinib	Compound	HPGD	mRNA	-1	1	17909047	About 35 mRNAs were dysregulated in the erlotinib-treated group, whereas no significant change in the mRNAs from the celecoxib alone?treated group was found. Analysis of these results revealed that a large subset of genes involved in cell cycle progression or cellular proliferation was differentially regulated. The effect of celecoxib and erlotinib on mRNA levels of these genes are summarized in Table 1 . (HCA-7 cells, a human colorectal cancer cell line, were injected s.c. into the flank region of athymic nu/nu mice.)
55231	 9865	12981	erlotinib	Compound	COL3A1	mRNA	-1	1	16144925	Supplemental table: Genes changed in one EGFR+ tumor with erlotinib treatment.   To identify significantly changed genes in one pair of EGFR-positive tumors, each probe set on post-therapy array (11 probes per probe set) was compared with the corresponding one of pre-therapy array using Wilcoxonps signed rank test. It was considered to be statistically significant if P < 0.003 for increase or P > 0.997 for decrease (Affymetrix Microarray Suite 5.0 Comparison Analysis).
56162	 9865	10811	erlotinib	Compound	FN1	mRNA	-1	-1	16144925	Table 1. Top 33 genes associated with erlotinib treatment in EGFR-negative tumors.  The following is from Materials and Methods:
13216	19148	16200	MAP2K Family	Protein	PPP1R14B	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
14751	19148	16094	MAP2K Family	Protein	CLDN2	mRNA	0	1	10833473	Inhibition of MEK reduced the activated and basal expression of claudin-2 messenger RNA and protein expression
17294	19148	14807	MAP2K Family	Protein	CANX	mRNA	0	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
19664	19148	16486	MAP2K Family	Protein	SPP1	mRNA	1	1	15857938	high levels of Bcr-Abl activate a signaling cascade involving the sequential activation of Ras, phosphatidylinositol-3 kinase, atypical protein kinase C, Raf-1, and mitogen-activated protein kinase kinase, leading to the ultimate expression of OPN.
20910	19148	14760	MAP2K Family	Protein	PALLD	mRNA	0	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
22269	19148	19636	MAP2K Family	Protein	OPTN	mRNA	0	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
28235	19148	 7832	MAP2K Family	Protein	THBS1	mRNA	-1	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
 3185	19148	16645	MAP2K Family	Protein	CCND1	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
39230	19148	 7376	MAP2K Family	Protein	TNFSF10	mRNA	-1	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
39512	19148	 5625	MAP2K Family	Protein	NFKBIE	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
44982	19148	13553	MAP2K Family	Protein	NUCB1	mRNA	0	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
51768	19148	 3656	MAP2K Family	Protein	PANX1	mRNA	0	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
59778	19148	13414	MAP2K Family	Protein	SERPINE1	mRNA	0	1	14515181	the MEK (ERK kinase) inhibitors, PD98059 and UO126, completely prevented PAI-1 induction by Wy-14,643
62226	19148	 9862	MAP2K Family	Protein	PPP2R5D	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
62970	19148	12293	MAP2K Family	Protein	COBRA1	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
 6434	19148	19584	MAP2K Family	Protein	TGM2	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
19871	 1255	19589	FSH	Compound	LOX	mRNA	0	-1	11181522	Two of these clones detected transcripts that were strongly down-regulated by FSH. One corresponded to connective tissue growth factor (CTGF), a cysteine-rich secreted protein related to platelet-derived growth factor that is implicated in mitogenesis and angiogenesis, and a second was identical to lysyl oxidase (LO), a key participant in extracellular matrix deposition.
40814	 1255	13739	FSH	Compound	CTGF	mRNA	0	-1	11181522	Two of these clones detected transcripts that were strongly down-regulated by FSH. One corresponded to connective tissue growth factor (CTGF), a cysteine-rich secreted protein related to platelet-derived growth factor that is implicated in mitogenesis and angiogenesis, and a second was identical to lysyl oxidase (LO), a key participant in extracellular matrix deposition.
43806	 1255	11318	FSH	Compound	MAP2K5	mRNA	1	1	17053000	Urinary gonadotrophins differentially up-regulated the expression of 30 genes
66225	 1255	 6460	FSH	Compound	FAM198B	mRNA	-1	1	17053000	Urinary gonadotrophins differentially up-regulated the expression of 30 genes
 7656	 1255	 7875	FSH	Compound	IFIT3	mRNA	1	1	17053000	Urinary gonadotrophins differentially up-regulated the expression of 30 genes
 1309	10722	 7836	Metribolone	Compound	CD55	mRNA	-1	-1	16195407	To meet this objective, the current study was designed to identify immediate-early genes expressed in response to the synthetic androgen R1881 in cultured rat ventral prostate epithelial cells. Rat ventral prostate epithelial cells, purified from 20-d-old rats, were cultured, and the presence of AR and the response to androgen were established. The cells were then treated with R1881 for 2 and 12 h to capture immediate-early genes in an Affymetrix-based gene chip platform. A total of 66 nonredundant genes were identified that were responsive to R1881. Table II: Top list of R1881 regulated genes in the rat ventral prostate epithelial cells and their classification based on the biological process influenced minimum +/- 30% FC from 0-2 hr timepoint
39382	10722	18612	Metribolone	Compound	SOD2	mRNA	-1	-1	16195407	To meet this objective, the current study was designed to identify immediate-early genes expressed in response to the synthetic androgen R1881 in cultured rat ventral prostate epithelial cells. Rat ventral prostate epithelial cells, purified from 20-d-old rats, were cultured, and the presence of AR and the response to androgen were established. The cells were then treated with R1881 for 2 and 12 h to capture immediate-early genes in an Affymetrix-based gene chip platform. A total of 66 nonredundant genes were identified that were responsive to R1881. Table II: Top list of R1881 regulated genes in the rat ventral prostate epithelial cells and their classification based on the biological process influenced minimum +/- 30% FC from 0-2 hr timepoint
65644	10722	 6557	Metribolone	Compound	ALAS1	mRNA	0	-1	16195407	To meet this objective, the current study was designed to identify immediate-early genes expressed in response to the synthetic androgen R1881 in cultured rat ventral prostate epithelial cells. Rat ventral prostate epithelial cells, purified from 20-d-old rats, were cultured, and the presence of AR and the response to androgen were established. The cells were then treated with R1881 for 2 and 12 h to capture immediate-early genes in an Affymetrix-based gene chip platform. A total of 66 nonredundant genes were identified that were responsive to R1881. Table II: Top list of R1881 regulated genes in the rat ventral prostate epithelial cells and their classification based on the biological process influenced minimum +/- 30% FC from 0-2 hr timepoint
21794	 9229	17937	FOXD3	Protein	SOX10	mRNA	0	1	18367558	Examining expression of Sox10, a marker of early NC, revealed reduced expression in the developing trigeminal, facial and vestibulocochlear ganglia and no expression in the glossopharyngeal and vagus ganglia. Sox10 expression was also reduced along the trunk of the embryo (Fig. 3D). Expression of other NC-specific genes {Msx1, Dlx5, Crabp) in the PAs uniformly showed reduced expression in PAs 1 and 2 (see Fig. S1 in the supplementary material). Together, these data suggest that the initial specification of NC occurs in Foxd3 mutants, but there is an overall failure to maintain NC progenitors as demonstrated by a loss of PA-derived structures and a concomitant decrease in expression of NC-specific genes.
33254	 9229	19738	FOXD3	Protein	MSX1	mRNA	0	1	18367558	Examining expression of Sox10, a marker of early NC, revealed reduced expression in the developing trigeminal, facial and vestibulocochlear ganglia and no expression in the glossopharyngeal and vagus ganglia. Sox10 expression was also reduced along the trunk of the embryo (Fig. 3D). Expression of other NC-specific genes {Msx1, Dlx5, Crabp) in the PAs uniformly showed reduced expression in PAs 1 and 2 (see Fig. S1 in the supplementary material). Together, these data suggest that the initial specification of NC occurs in Foxd3 mutants, but there is an overall failure to maintain NC progenitors as demonstrated by a loss of PA-derived structures and a concomitant decrease in expression of NC-specific genes.
44747	 9229	14152	FOXD3	Protein	DLX5	mRNA	0	1	18367558	Examining expression of Sox10, a marker of early NC, revealed reduced expression in the developing trigeminal, facial and vestibulocochlear ganglia and no expression in the glossopharyngeal and vagus ganglia. Sox10 expression was also reduced along the trunk of the embryo (Fig. 3D). Expression of other NC-specific genes {Msx1, Dlx5, Crabp) in the PAs uniformly showed reduced expression in PAs 1 and 2 (see Fig. S1 in the supplementary material). Together, these data suggest that the initial specification of NC occurs in Foxd3 mutants, but there is an overall failure to maintain NC progenitors as demonstrated by a loss of PA-derived structures and a concomitant decrease in expression of NC-specific genes.
54353	 9229	 1814	FOXD3	Protein	POU5F1	mRNA	-1	1	16790525	we cloned the promoter region of Oct4 and analyzed its expression in the context of Nanog, FoxD3, and Oct4 itself. When analyzed with Nanog and FoxD3, the Oct4 promoter was activated strongly by both factors in a dose-dependent fashion (Fig. 3B and C ). Interestingly, when cotransfected with Oct4, we found that Oct4 protein appeared to be a repressor of its own promoter (Fig. 3D ).
59335	 9229	12659	FOXD3	Protein	CRABP1	mRNA	0	1	18367558	Examining expression of Sox10, a marker of early NC, revealed reduced expression in the developing trigeminal, facial and vestibulocochlear ganglia and no expression in the glossopharyngeal and vagus ganglia. Sox10 expression was also reduced along the trunk of the embryo (Fig. 3D). Expression of other NC-specific genes {Msx1, Dlx5, Crabp) in the PAs uniformly showed reduced expression in PAs 1 and 2 (see Fig. S1 in the supplementary material). Together, these data suggest that the initial specification of NC occurs in Foxd3 mutants, but there is an overall failure to maintain NC progenitors as demonstrated by a loss of PA-derived structures and a concomitant decrease in expression of NC-specific genes.
11158	15498	 9789	NOS1	Protein	HSPE1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
23841	15498	 3648	NOS1	Protein	P4HA1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
26479	15498	 7394	NOS1	Protein	BAG3	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
28219	15498	 7832	NOS1	Protein	THBS1	mRNA	-1	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
29085	15498	  620	NOS1	Protein	PHLDA1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
35797	15498	 9011	NOS1	Protein	HSPH1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
42894	15498	 7577	NOS1	Protein	HSP90AA1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
44427	15498	13271	NOS1	Protein	CCL2	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
 5105	15498	 2649	NOS1	Protein	DNAJB1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
57260	15498	 5741	NOS1	Protein	RDBP	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
58336	15498	 8795	NOS1	Protein	MORF4L2	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
59013	15498	 4174	NOS1	Protein	STBD1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
60118	15498	15187	NOS1	Protein	DDX3Y	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
24310	12478	 7440	PKNOX1	Protein	PF4	mRNA	0	1	12732210	This study focuses on Pbx regulating protein 1 (PREP1), a MEIS1 homolog protein, for its transcriptional activity in the PF4 promoter. PREP1 binds to the TME in HEL cells.
34372	12478	19822	PKNOX1	Protein	FABP7	mRNA	0	1	12771203	in vitro specific binding of PKNOX1 to the Pbx/POU site of the FABP7 promoter; (iii) in vivo FABP7 promoter trans-activation in cultured neuroblastoma cells caused by PKNOX1 overexpression.
54911	12478	19961	PKNOX1	Protein	GNRH1	mRNA	0	1	15138251	We show that heterodimers containing Pbx/Prep1 or Pbx/Meis1 TALE homeodomain proteins bind to four functional elements within the GnRH regulatory region, each in close proximity to an Oct-1-binding site. Cotransfection experiments indicate that TALE proteins are essential for GnRH promoter activity in the GT1-7 cells. Moreover, Pbx1 and Oct-1, as well as Prep1 and Oct-1, form functional complexes that enhance GnRH gene expression. Moreover, Pbx1 and Oct-1, as well as Prep1 and Oct-1, form functional complexes that enhance GnRH gene expression.
55351	12478	 4481	PKNOX1	Protein	COL5A2	mRNA	1	1	10748126	DNA binding assays and cell transfection experiments revealed that the bipartite core sequence of FPB (5p-ATCAATCA-3p) binds the PBX1/2, PREP1, and HOXB1 proteins, and this in turn leads to promoter transactivation.
45370	14440	14987	CDX1	Protein	BCL2	mRNA	1	1	11431360	Our studies have identified  two positive regulatory transcription factors, CREB and a Cdx/A-Myb complex,  that activate the bcl -2 promoter in B cells (11 , 12) .
18072	13668	 8835	NEUROG3	Protein	Nkx2-2	mRNA	0	1	14576336	Neurogenin3 bound to and effectively activated transcription through the nkx2.2 and PAX4 E boxes. In contrast, Neurogenin3 strongly repressed the NEUROG3 promoter, although a proximal E box was required for activity in the absence of Neurogenin3, suggesting that a ubiquitous transcriptional activator may bind to this site, and that Neurogenin3 could act as a competitive inhibitor of this activator.
21231	13668	15906	NEUROG3	Protein	PAX4	mRNA	0	1	14576336	Neurogenin3 bound to and effectively activated transcription through the nkx2.2 and PAX4 E boxes. In contrast, Neurogenin3 strongly repressed the NEUROG3 promoter, although a proximal E box was required for activity in the absence of Neurogenin3, suggesting that a ubiquitous transcriptional activator may bind to this site, and that Neurogenin3 could act as a competitive inhibitor of this activator.
48940	13668	15296	NEUROG3	Protein	NEUROG3	mRNA	0	-1	14576336	Neurogenin3 bound to and effectively activated transcription through the nkx2.2 and PAX4 E boxes. In contrast, Neurogenin3 strongly repressed the NEUROG3 promoter, although a proximal E box was required for activity in the absence of Neurogenin3, suggesting that a ubiquitous transcriptional activator may bind to this site, and that Neurogenin3 could act as a competitive inhibitor of this activator.
51067	13668	13884	NEUROG3	Protein	CDKN1A	mRNA	1	1	17032746	To understand the molecular mechanisms regulating pancreatic endocrine development and function, pancreatic gene expression was compared between Ngn3-deficient mice and littermate controls on embryonic days 13 and 15. Microarray analysis identified 504 genes with significant differences in expression. Fifty-two of these showed at least twofold reduction in Ngn3 knockouts compared to controls. Many of them were previously described to be involved in endocrine development and function. Among the genes not previously characterized were Rhomboid veinlet-like 4, genes involved in tetrahydrobiopterin biosynthesis and the Iroquois-type homeobox gene Irx1, the latter was selected for further investigation. In situ hybridisation demonstrated that two Iroquois genes, Irx1 and Irx2, were expressed in pancreatic endoderm of wild-type, but not Ngn3 mutant embryos. Furthermore, ectopic Ngn3 induced prominent Irx2 expression in chicken endoderm. Co-labelling established that Irx1 and Irx2 mRNA is located to glucagon-, but not insulin- or somatostatin-producing cells in mice and chicken. These data suggest that Irx1 and Irx2 serve an evolutionary conserved role in the regulation of alpha-cell-specific gene expression.
63236	13668	16398	NEUROG3	Protein	NKX2-2	mRNA	0	1	12604598	HNF3eta and neurogenin-3 cooperatively activate the nkx2.2 1a  promoter.
10042	 2058	 7928	IRF5	Protein	TGFBR2	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
10574	 2058	 3275	IRF5	Protein	BTF3	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
11346	 2058	14652	IRF5	Protein	ZNF217	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 1224	 2058	13189	IRF5	Protein	GCH1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
12320	 2058	13913	IRF5	Protein	GNB1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
12478	 2058	   93	IRF5	Protein	BTF3P13	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
12842	 2058	17369	IRF5	Protein	IL6	mRNA	0	1	15665823	Here, we demonstrate that the transcription factor IRF-5 is generally involved downstream of the TLR-MyD88 signalling pathway for gene induction of proinflammatory cytokines, such as interleukin-6 (IL-6), IL-12 and tumour-necrosis factor-alpha. In haematopoietic cells from mice deficient in the Irf5 gene (Irf5-/- mice), the induction of these cytokines by various TLR ligands is severely impaired
13981	 2058	 9482	IRF5	Protein	TMPO	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 1433	 2058	11536	IRF5	Protein	PCBP1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
16324	 2058	 9826	IRF5	Protein	PDCD2	mRNA	-1	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 1675	 2058	17075	IRF5	Protein	MAT2A	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
16804	 2058	19679	IRF5	Protein	STAT1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
16915	 2058	 3686	IRF5	Protein	TRIM22	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
17436	 2058	14361	IRF5	Protein	CXCL12	mRNA	-1	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
20558	 2058	 7796	IRF5	Protein	UBE2D2	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
20716	 2058	 4803	IRF5	Protein	EIF2AK2	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
21250	 2058	15637	IRF5	Protein	LIPA	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
22006	 2058	 2856	IRF5	Protein	CTNNA1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
22595	 2058	15547	IRF5	Protein	GLUL	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 2266	 2058	 5419	IRF5	Protein	TNF	mRNA	0	1	15665823	Here, we demonstrate that the transcription factor IRF-5 is generally involved downstream of the TLR-MyD88 signalling pathway for gene induction of proinflammatory cytokines, such as interleukin-6 (IL-6), IL-12 and tumour-necrosis factor-alpha. In haematopoietic cells from mice deficient in the Irf5 gene (Irf5-/- mice), the induction of these cytokines by various TLR ligands is severely impaired
23415	 2058	 4465	IRF5	Protein	RP2	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
23607	 2058	  514	IRF5	Protein	PSMB8	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
23614	 2058	 3643	IRF5	Protein	MAFF	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
23648	 2058	17594	IRF5	Protein	CCNG1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
23965	 2058	17118	IRF5	Protein	NAMPT	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
24107	 2058	 1944	IRF5	Protein	TERF1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
25784	 2058	12968	IRF5	Protein	CEACAM1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
27421	 2058	17966	IRF5	Protein	MXI1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 2878	 2058	12537	IRF5	Protein	CCL4	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
   29	 2058	 3258	IRF5	Protein	FGFR4	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
29225	 2058	15188	IRF5	Protein	LEF1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
29411	 2058	13946	IRF5	Protein	IL12A	mRNA	0	1	15665823	Here, we demonstrate that the transcription factor IRF-5 is generally involved downstream of the TLR-MyD88 signalling pathway for gene induction of proinflammatory cytokines, such as interleukin-6 (IL-6), IL-12 and tumour-necrosis factor-alpha. In haematopoietic cells from mice deficient in the Irf5 gene (Irf5-/- mice), the induction of these cytokines by various TLR ligands is severely impaired
 3074	 2058	17401	IRF5	Protein	HMGCR	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
31892	 2058	 4125	IRF5	Protein	DDX18	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
32319	 2058	 3016	IRF5	Protein	FMR1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
32481	 2058	19569	IRF5	Protein	C1orf38	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
32499	 2058	19410	IRF5	Protein	CXCL11	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
32732	 2058	 3909	IRF5	Protein	NFE2L2	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
34822	 2058	 6558	IRF5	Protein	RBBP4	mRNA	-1	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
36311	 2058	 2716	IRF5	Protein	HOXC4	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
36944	 2058	19798	IRF5	Protein	OAS1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
37276	 2058	 8901	IRF5	Protein	IL12B	mRNA	0	1	15665823	Here, we demonstrate that the transcription factor IRF-5 is generally involved downstream of the TLR-MyD88 signalling pathway for gene induction of proinflammatory cytokines, such as interleukin-6 (IL-6), IL-12 and tumour-necrosis factor-alpha. In haematopoietic cells from mice deficient in the Irf5 gene (Irf5-/- mice), the induction of these cytokines by various TLR ligands is severely impaired
37564	 2058	 6614	IRF5	Protein	HSPA1B	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
37928	 2058	 1985	IRF5	Protein	DENND4A	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
39227	 2058	 7376	IRF5	Protein	TNFSF10	mRNA	-1	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
40074	 2058	17902	IRF5	Protein	RAN	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
40922	 2058	13617	IRF5	Protein	SMAD4	mRNA	-1	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
41288	 2058	 6882	IRF5	Protein	PMAIP1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
41945	 2058	12326	IRF5	Protein	SP110	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
42824	 2058	 3879	IRF5	Protein	FAS	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
43458	 2058	 5666	IRF5	Protein	PAPOLA	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
45402	 2058	 3512	IRF5	Protein	CASP3	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
45713	 2058	 1590	IRF5	Protein	RSAD2	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
47982	 2058	 4684	IRF5	Protein	IFIT1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
   48	 2058	11396	IRF5	Protein	CCNA2	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
49070	 2058	14748	IRF5	Protein	CCL3	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
50226	 2058	13634	IRF5	Protein	QKI	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
51013	 2058	13884	IRF5	Protein	CDKN1A	mRNA	1	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
51828	 2058	 3000	IRF5	Protein	ZFP36	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
53286	 2058	 4829	IRF5	Protein	IFNB1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
53364	 2058	10278	IRF5	Protein	VAMP1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
53587	 2058	15179	IRF5	Protein	TAF2	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
54285	 2058	  255	IRF5	Protein	UBE2I	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
54529	 2058	 5177	IRF5	Protein	IFI44	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
54535	 2058	10710	IRF5	Protein	MAPK9	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
55708	 2058	15411	IRF5	Protein	INSIG1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
56362	 2058	 4754	IRF5	Protein	PLSCR1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
57328	 2058	 4298	IRF5	Protein	JUNB	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
58255	 2058	 5983	IRF5	Protein	CD164	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
58598	 2058	10493	IRF5	Protein	PSMA3	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
59052	 2058	19175	IRF5	Protein	ZNF148	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
59326	 2058	 5363	IRF5	Protein	ZNF443	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
59767	 2058	13414	IRF5	Protein	SERPINE1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
60950	 2058	19999	IRF5	Protein	NCAM1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
60975	 2058	18050	IRF5	Protein	NAP1L1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
61065	 2058	17053	IRF5	Protein	HSPA1A	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
61925	 2058	 7040	IRF5	Protein	SC5DL	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
62129	 2058	17405	IRF5	Protein	PAK1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 6258	 2058	12740	IRF5	Protein	ZNF267	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
63230	 2058	 9458	IRF5	Protein	BACH1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
64469	 2058	15063	IRF5	Protein	ASS1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
65666	 2058	 3488	IRF5	Protein	MAX	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
  709	 2058	12268	IRF5	Protein	P4HB	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 8037	 2058	19377	IRF5	Protein	MYD88	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 9015	 2058	14391	IRF5	Protein	RIPK1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 9045	 2058	11644	IRF5	Protein	IRS1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
 9322	 2058	 8814	IRF5	Protein	CDK1	mRNA	0	1	15308637	TABLE V   Selected genes up-regulated by IRF-5
11138	 8451	11640	PLAG1	Protein	TRAF1	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
 1327	 8451	14584	PLAG1	Protein	MAPK11	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
13641	 8451	 1438	PLAG1	Protein	VEGFA	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
14549	 8451	13318	PLAG1	Protein	ACVR2B	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
19755	 8451	 8410	PLAG1	Protein	GJB1	mRNA	0	-1	14712223	Table 3. Identification of genes consistently and significantly repressed by PLAG1
19968	 8451	17377	PLAG1	Protein	PTP4A2	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
20786	 8451	13855	PLAG1	Protein	CGB	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
23026	 8451	 6929	PLAG1	Protein	NFATC1	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
29846	 8451	18163	PLAG1	Protein	CDKN1C	mRNA	0	1	14712223	Confirmation of up-regulated Plag1 targets by Northern blot analysis.
38422	 8451	16191	PLAG1	Protein	EFNB1	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
38851	 8451	16079	PLAG1	Protein	CD300C	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
39278	 8451	 5989	PLAG1	Protein	PPIC	mRNA	0	-1	14712223	Table 3. Identification of genes consistently and significantly repressed by PLAG1
40867	 8451	 9368	PLAG1	Protein	CNKSR1	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
44260	 8451	20106	PLAG1	Protein	NPTXR	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
45377	 8451	14987	PLAG1	Protein	BCL2	mRNA	1	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
45932	 8451	11879	PLAG1	Protein	CRABP2	mRNA	0	1	14712223	Confirmation of up-regulated Plag1 targets by Northern blot analysis.
45950	 8451	17831	PLAG1	Protein	ATF5	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
47858	 8451	12105	PLAG1	Protein	MLXIP	mRNA	0	-1	14712223	Table 3. Identification of genes consistently and significantly repressed by PLAG1
51254	 8451	 1971	PLAG1	Protein	SRPK3	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
54593	 8451	 8683	PLAG1	Protein	LSP1	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
55342	 8451	13713	PLAG1	Protein	CDC42EP4	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
56639	 8451	14686	PLAG1	Protein	TPSAB1	mRNA	0	-1	14712223	Table 3. Identification of genes consistently and significantly repressed by PLAG1
57259	 8451	19850	PLAG1	Protein	SMARCD1	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
59493	 8451	12301	PLAG1	Protein	LILRB3	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
62573	 8451	 9454	PLAG1	Protein	AKAP8L	mRNA	0	-1	14712223	Table 3. Identification of genes consistently and significantly repressed by PLAG1
63358	 8451	11721	PLAG1	Protein	PGF	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
63632	 8451	 1923	PLAG1	Protein	RNASEH1	mRNA	0	-1	14712223	Table 3. Identification of genes consistently and significantly repressed by PLAG1
65552	 8451	14743	PLAG1	Protein	IGF2	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
65699	 8451	10219	PLAG1	Protein	CREB3L1	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
 7398	 8451	19160	PLAG1	Protein	CYTL1	mRNA	0	1	14712223	Table 2. Identification of genes consistently and significantly induced by PLAG1. Genes induced by at least 2.5-fold in each of 2 sets of Plag1 overexpressing clones compared to 2 sets of control cells.
 9518	 8451	14710	PLAG1	Protein	PIR	mRNA	0	-1	14712223	Table 3. Identification of genes consistently and significantly repressed by PLAG1
33928	11519	12760	SIX1	Protein	SLC12A2	mRNA	0	1	15955062	(A) Trans-activation of Gas1 promoter by Six1 and Six4. (B) Regulation of Clcn5 promoter by Six1 and Six4. (C) Trans-activation of Slc12a2 promoter by Six1 and Six4. (D) Trans-activation of myogenin promoter by Six1 and Six4. Clcn5 promoter showed a moderate repression by Six1 and a strong repression by Six4 in a dose-dependent manner
 5714	11519	 4445	SIX1	Protein	SALL1	mRNA	0	1	16670092	Transcriptional activation of the SALL1 by the human SIX1 homeodomain during kidney development
 5944	11519	 1713	SIX1	Protein	MYOG	mRNA	0	1	15955062	(A) Trans-activation of Gas1 promoter by Six1 and Six4. (B) Regulation of Clcn5 promoter by Six1 and Six4. (C) Trans-activation of Slc12a2 promoter by Six1 and Six4. (D) Trans-activation of myogenin promoter by Six1 and Six4. Clcn5 promoter showed a moderate repression by Six1 and a strong repression by Six4 in a dose-dependent manner
61213	11519	 5969	SIX1	Protein	GAS1	mRNA	-1	1	15955062	(A) Trans-activation of Gas1 promoter by Six1 and Six4. (B) Regulation of Clcn5 promoter by Six1 and Six4. (C) Trans-activation of Slc12a2 promoter by Six1 and Six4. (D) Trans-activation of myogenin promoter by Six1 and Six4. Clcn5 promoter showed a moderate repression by Six1 and a strong repression by Six4 in a dose-dependent manner
 8192	11519	13909	SIX1	Protein	CLCN5	mRNA	0	-1	15955062	(A) Trans-activation of Gas1 promoter by Six1 and Six4. (B) Regulation of Clcn5 promoter by Six1 and Six4. (C) Trans-activation of Slc12a2 promoter by Six1 and Six4. (D) Trans-activation of myogenin promoter by Six1 and Six4. Clcn5 promoter showed a moderate repression by Six1 and a strong repression by Six4 in a dose-dependent manner
11029	15543	 8037	Prkc Family	Protein	KLF6	mRNA	1	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
13859	15543	17250	Prkc Family	Protein	PTGS2	mRNA	0	1	12201673	TPA-induced expression of cyclooxygenase-2
14909	15543	14108	Prkc Family	Protein	EDNRB	mRNA	0	1	12750545	CONCLUSIONS: The results suggest that, in fresh MCA, the ETA receptor is the most prominent subtype, while after organ culture ETB receptors also contribute to the contraction. This upregulation is due to de novo transcription of receptors. Protein kinase C is involved in the upregulation as Ro-31-8220 attenuates the contraction and the mRNA increase.
16589	15543	10839	Prkc Family	Protein	SLC6A6	mRNA	0	-1	12870156	These results demonstrate that high glucose considerably and specifically decreases intracellular taurine content, taurine transport activity, and TAUT mRNA, possibly through PKC-mediated transcriptional and posttranslational pathways
18030	15543	12757	Prkc Family	Protein	THRB	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
19698	15543	16486	Prkc Family	Protein	SPP1	mRNA	1	1	16528250	High glucose, angiotensin II, phorbol 12-myristate 13-acetate and transforming growth factor-beta 1 (TGF-beta1) stimulated OPN mRNA expression in IRPTCs
23318	15543	 7455	Prkc Family	Protein	CTSB	mRNA	0	-1	 2751829	The TSH-induced increase in cathepsin B mRNA concentrations (approximately fivefold over that in untreated cells) was partially mimicked by forskolin (approximately threefold) and ionomycin, while phorbol ester decreased cathepsin B mRNA concentrations. Similar changes were observed for thyroglobulin and actin mRNA concentrations.... These results demonstrate (1) that cathepsin B expression in the thyroid is regulated in parallel with that of thyroglobulin and actin, and (2) that cyclic AMP- and Ca2+-dependent processes stimulate gene expression, while phorbol ester treatment inhibits gene expression in FRTL5 cells.
 2676	15543	 8126	Prkc Family	Protein	S100B	mRNA	0	1	12388300	The activation of the S100B promoter was mediated through the PKC signaling pathway.
28261	15543	 7832	Prkc Family	Protein	THBS1	mRNA	-1	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
28348	15543	14168	Prkc Family	Protein	ANKH	mRNA	0	1	11746513	Ank gene expression is also upregulated after treating quiescent fibroblasts with several other mitogenic agents (e.g., calf serum or platelet-derived growth factor-BB) or the tumor promoter phorbol 12-myristate 13-acetate.
 3176	15543	16645	Prkc Family	Protein	CCND1	mRNA	0	1	12397090	Modified assertion
31896	15543	11633	Prkc Family	Protein	THRA	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
36186	15543	  340	Prkc Family	Protein	SDC1	mRNA	0	1	12453641	Glypican-1 and syndecan-1 mRNA expression was up-regulated under PKC activation
38349	15543	 1872	Prkc Family	Protein	BTG2	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
 3893	15543	18007	Prkc Family	Protein	IFRD1	mRNA	0	1	16204248	% 12-O-Tetradecanoylphorbol-13-acetate-induced sequence 7 (TIS7) acts as a transcriptional co-repressor
42117	15543	13115	Prkc Family	Protein	EGR1	mRNA	-1	1	 2677677	When GM-CSF-deprived 32D clone 3 cells were exposed to GM-CSF or to TPA, four TIS mRNAs (TIS7, TIS8, TIS10, and TIS11) were rapidly and transiently induced.
42178	15543	14895	Prkc Family	Protein	S100A8	mRNA	0	1	12082614	We show that expression is coordinately induced by the phorbol ester TPA in epithelial cells as well as infiltrating leukocytes.
42931	15543	15885	Prkc Family	Protein	ACTB	mRNA	1	1	 1572414	Pretreatment of cells with phorbol ester for 24 h, reducing functional protein kinase C activity, abolished the ability of phorbol esters to increase beta-actin transcription.
43795	15543	  555	Prkc Family	Protein	PDPN	mRNA	0	1	12640676	TPA-induced genes, such as Sprr1A, Saa3, JunB, Il4ralpha, Gp38, RalGDS and Slpi
44066	15543	15206	Prkc Family	Protein	ATP2A2	mRNA	0	-1	12606313	SERCA2 downregulation can be simulated in cultured neonatal rat ventricular myocytes (NRVM) by treatment with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA)
48565	15543	18949	Prkc Family	Protein	IL4R	mRNA	0	1	12640676	TPA-induced genes, such as Sprr1A, Saa3, JunB, Il4ralpha, Gp38, RalGDS and Slpi
49161	15543	 7729	Prkc Family	Protein	SLPI	mRNA	0	1	12640676	TPA-induced genes, such as Sprr1A, Saa3, JunB, Il4ralpha, Gp38, RalGDS and Slpi
56549	15543	12647	Prkc Family	Protein	S100A9	mRNA	0	1	12082614	We show that expression is coordinately induced by the phorbol ester TPA in epithelial cells as well as infiltrating leukocytes.
56843	15543	20050	Prkc Family	Protein	PDIA3	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
57312	15543	 4298	Prkc Family	Protein	JUNB	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
58311	15543	 5913	Prkc Family	Protein	CYR61	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
59563	15543	12930	Prkc Family	Protein	OXTR	mRNA	0	1	11264328	Ariadne: In vitro , OTR  expression is increased by activation of protein kinase A (PKA) or protein kinase C (PKC) (Bale and Dorsa, 1998 ).
61250	15543	 1552	Prkc Family	Protein	ODC1	mRNA	1	1	12201673	TPA-induced epidermal ODC activity and ODC mRNA expression.
65596	15543	 7139	Prkc Family	Protein	RALGDS	mRNA	0	1	12640676	TPA-induced genes, such as Sprr1A, Saa3, JunB, Il4ralpha, Gp38, RalGDS and Slpi
65637	15543	 6557	Prkc Family	Protein	ALAS1	mRNA	0	-1	 9169013	protein kinase C (PKC) activation negatively influences ALA-S mRNA levels
66061	15543	 5646	Prkc Family	Protein	MT1A	mRNA	0	1	14576086	Experiments using signal transduction inhibitors and a metal transcription factor (MTF)-1 null cell line demonstrate that copper-inducible MT-I transcription is regulated by protein kinase C and mitogen-activated protein kinase signaling pathways and requires MTF-1.
66197	15543	16011	Prkc Family	Protein	GPC1	mRNA	0	1	12453641	Glypican-1 and syndecan-1 mRNA expression was up-regulated under PKC activation
66301	15543	13248	Prkc Family	Protein	TSC22D1	mRNA	0	1	15881652	tsc-22 mRNA is expressed in almost all organs of mice and humans and its expression is induced in a variety of cell lines by many different factors including TGF-beta, phorbol ester, serum, and progestin
 6909	15543	 2204	Prkc Family	Protein	COL1A1	mRNA	0	1	10493907	In addition, TGFbeta(1)- and BMP-2-induced increases in alpha1(I) collagen mRNA levels were both dependent on protein kinase C and protein tyrosine kinase activities.
 7903	15543	19902	Prkc Family	Protein	ACHE	mRNA	0	1	12805285	_ Ariadne: In confirmation of the linkage of P2Y1 receptor activation in the muscle cells to PKC ( Fig. 1 A ), the application of PKC inhibitors staurosporine (Sp) and chelerythrine chloride (ChCl) significantly reduced the P2Y1 receptor-mediated AChE gene activation. [Regulation] The pathway to activation of the AChE gene was shown to involve protein kinase C and intracellular Ca 2+ release.
26821	15056	16947	GK	Protein	MAPK8IP2	mRNA	-1	-1	16368706	Glycerol kinase deficiency (GKD) is an X-linked inborn error of metabolism with metabolic and neurological crises. Liver shows the highest level of glycerol kinase (GK) activity in humans and mice. Absence of genotype-phenotype correlations in patients with GKD indicates the involvement of modifier genes, including other network partners. To understand the molecular pathogenesis of GKD, we performed microarray analysis on liver mRNA from neonatal glycerol kinase (Gyk) knockout (KO) and wild-type (WT) mice. Unsupervised learning revealed that the overall gene expression profile of the KO mice was different from that of WT. Real-time PCR confirmed the differences for selected genes. Functional gene enrichment analysis was used to find 56 increased and 37 decreased gene functional categories. PathwayAssist analysis identified changes in gene expression levels of genes involved in organic acid metabolism indicating that GK was part of the same metabolic network which correlates well with the patients with GKD having metabolic acidemia during their episodic crises. Network component analysis (NCA) showed that transcription factors sterol regulatory element-binding protein (SREBP)-1c, carbohydrate response element-binding protein (ChREBP), hepatocyte nuclear factor-4 alpha (HNF-4alpha) and peroxisome proliferative-activated receptor-alpha (PPARalpha) had increased activity in the Gyk KO mice compared with WT mice, whereas SREBP-2 was less active in the Gyk KO mice. These studies show that Gyk deletion causes alterations in expression of genes in several regulatory networks and is the first time NCA has been used to expand on microarray data from a mouse KO model of a human disease.
51653	15056	14103	GK	Protein	PGAM1	mRNA	1	-1	16368706	Glycerol kinase deficiency (GKD) is an X-linked inborn error of metabolism with metabolic and neurological crises. Liver shows the highest level of glycerol kinase (GK) activity in humans and mice. Absence of genotype-phenotype correlations in patients with GKD indicates the involvement of modifier genes, including other network partners. To understand the molecular pathogenesis of GKD, we performed microarray analysis on liver mRNA from neonatal glycerol kinase (Gyk) knockout (KO) and wild-type (WT) mice. Unsupervised learning revealed that the overall gene expression profile of the KO mice was different from that of WT. Real-time PCR confirmed the differences for selected genes. Functional gene enrichment analysis was used to find 56 increased and 37 decreased gene functional categories. PathwayAssist analysis identified changes in gene expression levels of genes involved in organic acid metabolism indicating that GK was part of the same metabolic network which correlates well with the patients with GKD having metabolic acidemia during their episodic crises. Network component analysis (NCA) showed that transcription factors sterol regulatory element-binding protein (SREBP)-1c, carbohydrate response element-binding protein (ChREBP), hepatocyte nuclear factor-4 alpha (HNF-4alpha) and peroxisome proliferative-activated receptor-alpha (PPARalpha) had increased activity in the Gyk KO mice compared with WT mice, whereas SREBP-2 was less active in the Gyk KO mice. These studies show that Gyk deletion causes alterations in expression of genes in several regulatory networks and is the first time NCA has been used to expand on microarray data from a mouse KO model of a human disease.
62920	15056	 7195	GK	Protein	GADD45A	mRNA	-1	1	16368706	Glycerol kinase deficiency (GKD) is an X-linked inborn error of metabolism with metabolic and neurological crises. Liver shows the highest level of glycerol kinase (GK) activity in humans and mice. Absence of genotype-phenotype correlations in patients with GKD indicates the involvement of modifier genes, including other network partners. To understand the molecular pathogenesis of GKD, we performed microarray analysis on liver mRNA from neonatal glycerol kinase (Gyk) knockout (KO) and wild-type (WT) mice. Unsupervised learning revealed that the overall gene expression profile of the KO mice was different from that of WT. Real-time PCR confirmed the differences for selected genes. Functional gene enrichment analysis was used to find 56 increased and 37 decreased gene functional categories. PathwayAssist analysis identified changes in gene expression levels of genes involved in organic acid metabolism indicating that GK was part of the same metabolic network which correlates well with the patients with GKD having metabolic acidemia during their episodic crises. Network component analysis (NCA) showed that transcription factors sterol regulatory element-binding protein (SREBP)-1c, carbohydrate response element-binding protein (ChREBP), hepatocyte nuclear factor-4 alpha (HNF-4alpha) and peroxisome proliferative-activated receptor-alpha (PPARalpha) had increased activity in the Gyk KO mice compared with WT mice, whereas SREBP-2 was less active in the Gyk KO mice. These studies show that Gyk deletion causes alterations in expression of genes in several regulatory networks and is the first time NCA has been used to expand on microarray data from a mouse KO model of a human disease.
11343	 9887	14652	estradiol	Compound	ZNF217	mRNA	0	-1	15072547	Figure 2 Gene expression variations measured by cDNA arrays in independent E2 (E2), OH-Tam, ICI 182,780 (ICI) and E2+OH-Tam experiments.
11992	 9887	 6285	estradiol	Compound	SPTAN1	mRNA	0	1	12801995	The present study confirms previous findings and identifies several genes with expressions not previously known to be influenced by estrogen. These genes include follistatin-related protein, Thy-1 glycoprotein, alpha-fodrin, CD24, immediate early response 5, insulin-like growth factor-binding protein 2, growth response protein CL-6 (INSIG-1), ladinin1, class I major histocompatibility complex heavy chain, lactadherin, ezrin, and Fas-activated serine/threonine kinase
13242	 9887	13513	estradiol	Compound	AKR1C1	mRNA	0	-1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
14003	 9887	  411	estradiol	Compound	PLAG1	mRNA	0	1	15579445	Estrogen has been postulated to be involved in inhibition of vascular smooth muscle cell (VSMC) proliferation mainly via estrogen receptor (ER), but the detailed mechanism has remained primarily unknown. Therefore, in this study, microarray analysis was used in two types of cultured human VSMCs: one positive for ER alpha, and the other for ER beta, which were treated by estrogens to detect the estrogen-responsive genes. We also used quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to evaluate mRNA levels of selective target gene (TG) in these cells. We further studied whether the TG product was involved in inhibition of proliferation using small interfering RNA (siRNA) of the TG transfection. We subsequently used quantitative RT-PCR and in situ hybridization analysis to evaluate the expression of these gene products in human aorta. E4F1, a possible inducer of cell growth arrest, was markedly increased only in ER alpha-positive VSMCs by estrogens in both microarray and RT-PCR analyses. Blocking of E4F1 using siRNA suppressed estrogenic inhibition of ER alpha-positive VSMC proliferation. E4F1 mRNA was abundant in premenopausal female aorta with mild atherosclerotic changes. E4F1 is therefore considered one of the estrogen-responsive genes involving ER alpha-mediated inhibition of VSMC proliferation and may play an important role in estrogen-related atheroprotection of human aorta.
16917	 9887	 8002	estradiol	Compound	PTGDS	mRNA	0	1	12072388	17alpha-Ethinyl estradiol (EE) pretreatment reduced the IL-1beta induction of approximately one third of these genes. Estrogen receptor alpha (ERalpha) was required for this inhibitory activity, because EE inhibition of IL-1beta-stimulated gene expression occurred in ERbeta knockout mice, but not in ERalpha knockout mice. Table 2. EE induction of gene expression in the mouse liver
17115	 9887	 9869	estradiol	Compound	HSPA4	mRNA	0	1	16239301	In breast cancers, estrogen receptor (ER) levels are highly correlated with response to endocrine therapies. We sought to define mechanisms of estrogen (E) signaling in a solid breast tumor model using gene expression profiling. ER(+) T47D-Y human breast cancer cells were grown as xenografts in ovariectomized nude mice under four conditions: 1) 17beta-estradiol for 8 wk (E); 2) without E for 8 wk (control); 3) E for 7 wk followed by 1 wk of E withdrawal (Ewd); or 4) E for 8 wk plus tamoxifen for the last week. E-regulated genes were defined as those that differed significantly between control and E and/or between E and Ewd or control and Ewd. These protocols generated 188 in vivo E-regulated genes that showed two major patterns of regulation. Approximately 46% returned to basal states after Ewd (class I genes); 53% did not (class II genes). In addition, more than 70% of class II-regulated genes also failed to reverse in response to tamoxifen. These genes may be interesting for the study of hormone-resistance issues. A subset of in vivo E-regulated genes appears on lists of clinical ER discriminator genes. These may be useful therapeutic targets or markers of E activity. Comparison of in vivo E-regulated genes with those regulated in identical cells in vitro after 6 and 24 h of E treatment demonstrate only 11% overlap. This indicates the extent to which gene expression profiles are uniquely dependent on hormone-treatment times and the cellular microenvironment.
17206	 9887	 6527	estradiol	Compound	SOX3	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
17216	 9887	16024	estradiol	Compound	CD5L	mRNA	0	1	12072388	17alpha-Ethinyl estradiol (EE) pretreatment reduced the IL-1beta induction of approximately one third of these genes. Estrogen receptor alpha (ERalpha) was required for this inhibitory activity, because EE inhibition of IL-1beta-stimulated gene expression occurred in ERbeta knockout mice, but not in ERalpha knockout mice. Table 2. EE induction of gene expression in the mouse liver
19305	 9887	 5967	estradiol	Compound	CIRBP	mRNA	0	-1	17673513	Table 1 Downregulated genes in WT testis exposed to E2 (> 2fold change)
19473	 9887	14571	estradiol	Compound	RBM15	mRNA	0	1	16636675	BARX2 and E2 independently increased the expression of the RBM15 and dynein light chain (DNLC1) genes
19521	 9887	17317	estradiol	Compound	FAM91A1	mRNA	0	-1	17673513	Table 1 Downregulated genes in WT testis exposed to E2 (> 2fold change)
19915	 9887	17834	estradiol	Compound	CCNG2	mRNA	-1	-1	16608856	estradiol represses expression of the cyclin G2 gene, which encodes a negative regulator of the cell cycle, our aim was to understand the mechanism by which cyclin G2 is repressed by estrogen.
20102	 9887	17814	estradiol	Compound	PIK3IP1	mRNA	0	-1	17351261	See Table 2: Representative Gene Expression Changes after 2h of EE (17 alpha-ethinyl estradiol) Exposure. All changes are greater than or equal to 1.5
20239	 9887	11948	estradiol	Compound	KRT4	mRNA	0	1	12072388	17alpha-Ethinyl estradiol (EE) pretreatment reduced the IL-1beta induction of approximately one third of these genes. Estrogen receptor alpha (ERalpha) was required for this inhibitory activity, because EE inhibition of IL-1beta-stimulated gene expression occurred in ERbeta knockout mice, but not in ERalpha knockout mice. Table 2. EE induction of gene expression in the mouse liver
20384	 9887	 2274	estradiol	Compound	RAB11A	mRNA	0	1	10379897	In transient transfection experiments, we observed that overexpression of estrogen receptor (ER) alpha or beta induced endogenous rab11 mRNA in a hormone-dependent manner. ER bound to an antagonist, ICI 182,780, failed to activate this gene expression.
 2108	 9887	18630	estradiol	Compound	ITGB3	mRNA	0	-1	14603529	Modified assertion
21556	 9887	 9145	estradiol	Compound	MARVELD2	mRNA	0	-1	17673513	Table 1 Downregulated genes in WT testis exposed to E2 (> 2fold change)
21676	 9887	 2572	estradiol	Compound	CAV1	mRNA	0	1	15514030	Table 1. Estrogen-Induced/AP-1-Independent Genes
23339	 9887	 4117	estradiol	Compound	SLC22A5	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
23407	 9887	 9226	estradiol	Compound	CITED2	mRNA	1	-1	16239301	In breast cancers, estrogen receptor (ER) levels are highly correlated with response to endocrine therapies. We sought to define mechanisms of estrogen (E) signaling in a solid breast tumor model using gene expression profiling. ER(+) T47D-Y human breast cancer cells were grown as xenografts in ovariectomized nude mice under four conditions: 1) 17beta-estradiol for 8 wk (E); 2) without E for 8 wk (control); 3) E for 7 wk followed by 1 wk of E withdrawal (Ewd); or 4) E for 8 wk plus tamoxifen for the last week. E-regulated genes were defined as those that differed significantly between control and E and/or between E and Ewd or control and Ewd. These protocols generated 188 in vivo E-regulated genes that showed two major patterns of regulation. Approximately 46% returned to basal states after Ewd (class I genes); 53% did not (class II genes). In addition, more than 70% of class II-regulated genes also failed to reverse in response to tamoxifen. These genes may be interesting for the study of hormone-resistance issues. A subset of in vivo E-regulated genes appears on lists of clinical ER discriminator genes. These may be useful therapeutic targets or markers of E activity. Comparison of in vivo E-regulated genes with those regulated in identical cells in vitro after 6 and 24 h of E treatment demonstrate only 11% overlap. This indicates the extent to which gene expression profiles are uniquely dependent on hormone-treatment times and the cellular microenvironment.
24144	 9887	 8611	estradiol	Compound	DTWD1	mRNA	0	-1	17351261	See Table 2: Representative Gene Expression Changes after 2h of EE (17 alpha-ethinyl estradiol) Exposure. All changes are greater than or equal to 1.5
25059	 9887	 2351	estradiol	Compound	DYNLL1	mRNA	0	1	16636675	BARX2 and E2 independently increased the expression of the RBM15 and dynein light chain (DNLC1) genes
27866	 9887	 1166	estradiol	Compound	SLC2A1	mRNA	-1	1	10433217	E2-stimulated changes in the steady state levels of messenger RNA (mRNA) and protein were measured for Glut1 and Glut4 by quantitative competitive RT-PCR and Western blots. Both Glut1 mRNA and protein increased approximately 3- to 4-fold within 4-8 h.
28973	 9887	16957	estradiol	Compound	ASAH1	mRNA	-1	-1	16239301	Table 1. Class I E-regulated genes in tumors.
29291	 9887	  111	estradiol	Compound	TFAP2C	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
29519	 9887	18773	estradiol	Compound	GRB14	mRNA	1	-1	12655037	The profound effects of 17beta-estradiol on cell growth, differentiation, and general homeostasis of the reproductive and other systems, are mediated mostly by regulation of temporal and cell type-specific expression of different genes. In order to understand better the molecular events associated with the activation of the estrogen receptor (ER), we have used microarray technology to determine the transcriptional program and dose-response characteristics of exposure to a potent synthetic estrogen, 17 alpha-ethynyl estradiol (EE), during prepubertal development. Changes in patterns of gene expression were determined in the immature uterus and ovaries of Sprague-Dawley rats on postnatal day (PND) 24, 24 h after exposure to EE, at 0.001, 0.01, 0.1, 1 and 10 micro g EE/kg/day (sc), for four days (dosing from PND 20 to 23). The transcript profiles were compared between treatment groups and controls using oligonucleotide arrays to determine the expression level of approximately 7000 annotated rat genes and over 1740 expressed sequence tags (ESTs). Quantification of the number of genes whose expression was modified by the treatment, for each of the various doses of EE tested, showed clear evidence of a dose-dependent treatment effect that follows a monotonic response, concordant with the dose-response pattern of uterine wet-weight gain and luminal epithelial cell height. The number of genes whose expression is affected by EE exposure increases according to dose. At the highest dose tested of EE, we determined that the expression level of over 300 genes was modified significantly (p dose-dependent analysis of the transcript profile revealed a set of 88 genes whose expression is significantly and reproducibly modified (increased or decreased) by EE exposure (p demonstrate that, exposure to a potent estrogenic chemical during prepubertal maturation changes the gene expression profile of estrogen-sensitive tissues. Furthermore, the products of the EE-regulated genes identified in these tissues have a physiological role in different intracellular pathways, information that will be valuable to determine the mechanism of action of estrogens. Moreover, those genes could be used as biomarkers to identify chemicals with estrogenic activity.
32783	 9887	 3630	estradiol	Compound	PA2G4	mRNA	0	1	11085516	table 1 - genes induced by E2 in breast cancer cells
33162	 9887	 1167	estradiol	Compound	LAD1	mRNA	0	1	12801995	The present study confirms previous findings and identifies several genes with expressions not previously known to be influenced by estrogen. These genes include follistatin-related protein, Thy-1 glycoprotein, alpha-fodrin, CD24, immediate early response 5, insulin-like growth factor-binding protein 2, growth response protein CL-6 (INSIG-1), ladinin1, class I major histocompatibility complex heavy chain, lactadherin, ezrin, and Fas-activated serine/threonine kinase
33680	 9887	12902	estradiol	Compound	SEC16B	mRNA	0	1	12244571	Moreover, the RGPR-p117 mRNA expression in H4-II-E cells was stimulated in the presence of dibutyryl cAMP, PMA, insulin, 17beta-estradiol, or serum in culture medium
34334	 9887	18170	estradiol	Compound	ISYNA1	mRNA	0	1	17351261	See Table 2: Representative Gene Expression Changes after 2h of EE (17 alpha-ethinyl estradiol) Exposure. All changes are greater than or equal to 1.5
35182	 9887	18109	estradiol	Compound	NAT2	mRNA	0	-1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
36293	 9887	 8679	estradiol	Compound	MET	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
36710	 9887	 2758	estradiol	Compound	SHANK2	mRNA	0	-1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
36802	 9887	12885	estradiol	Compound	EGR3	mRNA	0	1	15579445	Estrogen has been postulated to be involved in inhibition of vascular smooth muscle cell (VSMC) proliferation mainly via estrogen receptor (ER), but the detailed mechanism has remained primarily unknown. Therefore, in this study, microarray analysis was used in two types of cultured human VSMCs: one positive for ER alpha, and the other for ER beta, which were treated by estrogens to detect the estrogen-responsive genes. We also used quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to evaluate mRNA levels of selective target gene (TG) in these cells. We further studied whether the TG product was involved in inhibition of proliferation using small interfering RNA (siRNA) of the TG transfection. We subsequently used quantitative RT-PCR and in situ hybridization analysis to evaluate the expression of these gene products in human aorta. E4F1, a possible inducer of cell growth arrest, was markedly increased only in ER alpha-positive VSMCs by estrogens in both microarray and RT-PCR analyses. Blocking of E4F1 using siRNA suppressed estrogenic inhibition of ER alpha-positive VSMC proliferation. E4F1 mRNA was abundant in premenopausal female aorta with mild atherosclerotic changes. E4F1 is therefore considered one of the estrogen-responsive genes involving ER alpha-mediated inhibition of VSMC proliferation and may play an important role in estrogen-related atheroprotection of human aorta.
37488	 9887	13065	estradiol	Compound	RASD1	mRNA	0	1	17351261	See Table 2: Representative Gene Expression Changes after 2h of EE (17 alpha-ethinyl estradiol) Exposure. All changes are greater than or equal to 1.5
37596	 9887	16953	estradiol	Compound	SHMT1	mRNA	0	-1	17673513	Table 1 Downregulated genes in WT testis exposed to E2 (> 2fold change)
38008	 9887	 9005	estradiol	Compound	SUSD3	mRNA	0	-1	17673513	Table 1 Downregulated genes in WT testis exposed to E2 (> 2fold change)
38168	 9887	16815	estradiol	Compound	CKLF	mRNA	0	1	15579445	Estrogen has been postulated to be involved in inhibition of vascular smooth muscle cell (VSMC) proliferation mainly via estrogen receptor (ER), but the detailed mechanism has remained primarily unknown. Therefore, in this study, microarray analysis was used in two types of cultured human VSMCs: one positive for ER alpha, and the other for ER beta, which were treated by estrogens to detect the estrogen-responsive genes. We also used quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to evaluate mRNA levels of selective target gene (TG) in these cells. We further studied whether the TG product was involved in inhibition of proliferation using small interfering RNA (siRNA) of the TG transfection. We subsequently used quantitative RT-PCR and in situ hybridization analysis to evaluate the expression of these gene products in human aorta. E4F1, a possible inducer of cell growth arrest, was markedly increased only in ER alpha-positive VSMCs by estrogens in both microarray and RT-PCR analyses. Blocking of E4F1 using siRNA suppressed estrogenic inhibition of ER alpha-positive VSMC proliferation. E4F1 mRNA was abundant in premenopausal female aorta with mild atherosclerotic changes. E4F1 is therefore considered one of the estrogen-responsive genes involving ER alpha-mediated inhibition of VSMC proliferation and may play an important role in estrogen-related atheroprotection of human aorta.
38819	 9887	14027	estradiol	Compound	COL5A1	mRNA	-1	1	12655037	The profound effects of 17beta-estradiol on cell growth, differentiation, and general homeostasis of the reproductive and other systems, are mediated mostly by regulation of temporal and cell type-specific expression of different genes. In order to understand better the molecular events associated with the activation of the estrogen receptor (ER), we have used microarray technology to determine the transcriptional program and dose-response characteristics of exposure to a potent synthetic estrogen, 17 alpha-ethynyl estradiol (EE), during prepubertal development. Changes in patterns of gene expression were determined in the immature uterus and ovaries of Sprague-Dawley rats on postnatal day (PND) 24, 24 h after exposure to EE, at 0.001, 0.01, 0.1, 1 and 10 micro g EE/kg/day (sc), for four days (dosing from PND 20 to 23). The transcript profiles were compared between treatment groups and controls using oligonucleotide arrays to determine the expression level of approximately 7000 annotated rat genes and over 1740 expressed sequence tags (ESTs). Quantification of the number of genes whose expression was modified by the treatment, for each of the various doses of EE tested, showed clear evidence of a dose-dependent treatment effect that follows a monotonic response, concordant with the dose-response pattern of uterine wet-weight gain and luminal epithelial cell height. The number of genes whose expression is affected by EE exposure increases according to dose. At the highest dose tested of EE, we determined that the expression level of over 300 genes was modified significantly (p dose-dependent analysis of the transcript profile revealed a set of 88 genes whose expression is significantly and reproducibly modified (increased or decreased) by EE exposure (p demonstrate that, exposure to a potent estrogenic chemical during prepubertal maturation changes the gene expression profile of estrogen-sensitive tissues. Furthermore, the products of the EE-regulated genes identified in these tissues have a physiological role in different intracellular pathways, information that will be valuable to determine the mechanism of action of estrogens. Moreover, those genes could be used as biomarkers to identify chemicals with estrogenic activity.
39572	 9887	13744	estradiol	Compound	CDKN1B	mRNA	-1	1	 9048598	Furthermore, expression of the cdk inhibitor p27Kip1, a key regulator of uterine functions, is induced by E2 in this organ.
39968	 9887	 6114	estradiol	Compound	NFKBIA	mRNA	1	-1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
40021	 9887	16637	estradiol	Compound	ZFP36L1	mRNA	0	1	16239301	In breast cancers, estrogen receptor (ER) levels are highly correlated with response to endocrine therapies. We sought to define mechanisms of estradiol (E) signaling in a solid breast tumor model using gene expression profiling. ER+ T47D-Y human breast cancer cells were grown as xenografts in ovariectomized nude mice under four conditions: i. E for 8 weeks (E); ii. without E for 8 weeks (controls, C); iii. E for 7 weeks followed by 1 week of E withdrawal (Ewd), or iv. E for 8 weeks with Tamoxifen for the last week (E+Tam). E-regulated genes were defined as those that differed significantly between C and E, and/or between E and Ewd. These protocols generated 188 in vivo E-regulated genes that showed two major patterns of regulation. Approximately 46% returned to basal states after Ewd (Class I genes); 53% did not (Class II genes). In addition, more than 70% of Class II regulated genes also failed to reverse in response to Tamoxifen. These genes may be interesting to study hormone resistance issues. A subset of in vivo E-regulated genes appears on lists of clinical  \ER discriminator \ genes. These may be useful therapeutic targets or markers of E activity. Comparison of in vivo E-regulated genes to those regulated in identical cells in vitro after 6 and 24 h of E treatment demonstrate only 11% overlap. This indicates the extent to which gene expression profiles are uniquely dependent on hormone treatment times and the cellular microenvironment.
40758	 9887	13236	estradiol	Compound	Cyp2d9	mRNA	0	1	12072388	17alpha-Ethinyl estradiol (EE) pretreatment reduced the IL-1beta induction of approximately one third of these genes. Estrogen receptor alpha (ERalpha) was required for this inhibitory activity, because EE inhibition of IL-1beta-stimulated gene expression occurred in ERbeta knockout mice, but not in ERalpha knockout mice. Table 2. EE induction of gene expression in the mouse liver
41009	 9887	 3809	estradiol	Compound	HSPA8	mRNA	0	1	11085516	table 1 - genes induced by E2 in breast cancer cells
42462	 9887	13544	estradiol	Compound	AGTR1	mRNA	0	-1	16675453	For example, Ang II (8), cAMP stimulating agents (9), and estrogens (10, 11) decrease rat AT1AR expression by stimulating rat AT1AR mRNA decay. In contrast, insulin (12), low density lipoprotein (13), and progesterone (11) up-regulate receptor expression by decreasing AT1AR mRNA decay rates. Additionally, rat AT1AR expression is regulated by translational mechanisms via cytosolic proteins that interact with the 5p-UTR of the receptor mRNA (10, 1418).
43803	 9887	11318	estradiol	Compound	MAP2K5	mRNA	1	-1	12047351	Table 2 List of oestrogen-repressed genes.
44424	 9887	13271	estradiol	Compound	CCL2	mRNA	0	-1	11872210	Modified assertion
44808	 9887	 7438	estradiol	Compound	ZEB1	mRNA	0	1	14965470	estrogen induces the expression of the gene encoding delta EF1
45671	 9887	18679	estradiol	Compound	H2AFZ	mRNA	0	1	11085516	table 1 - genes induced by E2 in breast cancer cells
45691	 9887	 8412	estradiol	Compound	LGALS1	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
45949	 9887	17831	estradiol	Compound	ATF5	mRNA	0	1	16239301	In breast cancers, estrogen receptor (ER) levels are highly correlated with response to endocrine therapies. We sought to define mechanisms of estrogen (E) signaling in a solid breast tumor model using gene expression profiling. ER(+) T47D-Y human breast cancer cells were grown as xenografts in ovariectomized nude mice under four conditions: 1) 17beta-estradiol for 8 wk (E); 2) without E for 8 wk (control); 3) E for 7 wk followed by 1 wk of E withdrawal (Ewd); or 4) E for 8 wk plus tamoxifen for the last week. E-regulated genes were defined as those that differed significantly between control and E and/or between E and Ewd or control and Ewd. These protocols generated 188 in vivo E-regulated genes that showed two major patterns of regulation. Approximately 46% returned to basal states after Ewd (class I genes); 53% did not (class II genes). In addition, more than 70% of class II-regulated genes also failed to reverse in response to tamoxifen. These genes may be interesting for the study of hormone-resistance issues. A subset of in vivo E-regulated genes appears on lists of clinical ER discriminator genes. These may be useful therapeutic targets or markers of E activity. Comparison of in vivo E-regulated genes with those regulated in identical cells in vitro after 6 and 24 h of E treatment demonstrate only 11% overlap. This indicates the extent to which gene expression profiles are uniquely dependent on hormone-treatment times and the cellular microenvironment.
46308	 9887	  546	estradiol	Compound	LEFTY2	mRNA	0	-1	17673513	Table 1 Downregulated genes in WT testis exposed to E2 (> 2fold change)
46334	 9887	15575	estradiol	Compound	SLC35F2	mRNA	0	-1	17673513	Table 1 Downregulated genes in WT testis exposed to E2 (> 2fold change)
47017	 9887	17438	estradiol	Compound	CD38	mRNA	0	1	11870063	A cell surface glycoprotein, CD38, catalyzes the synthesis and breakdown of cADPR and thus possesses bifunctional enzymatic activity. The results demonstrate that cyclase and hydrolase activities are associated with a single protein fraction, similar to CD38 in uteri from both ovariectomized and estradiol-treated rats, and estradiol-17 beta causes 1) increased CD38 mRNA and protein expression and 2) significantly enhanced cyclase but not hydrolase activity.
47154	 9887	 5176	estradiol	Compound	COQ10B	mRNA	0	1	17351261	See Table 2: Representative Gene Expression Changes after 2h of EE (17 alpha-ethinyl estradiol) Exposure. All changes are greater than or equal to 1.5
47194	 9887	 9874	estradiol	Compound	KRT86	mRNA	0	-1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
48477	 9887	12961	estradiol	Compound	CCT2	mRNA	0	1	11085516	table 1 - genes induced by E2 in breast cancer cells
49825	 9887	16514	estradiol	Compound	EIF3B	mRNA	0	1	16239301	In breast cancers, estrogen receptor (ER) levels are highly correlated with response to endocrine therapies. We sought to define mechanisms of estrogen (E) signaling in a solid breast tumor model using gene expression profiling. ER(+) T47D-Y human breast cancer cells were grown as xenografts in ovariectomized nude mice under four conditions: 1) 17beta-estradiol for 8 wk (E); 2) without E for 8 wk (control); 3) E for 7 wk followed by 1 wk of E withdrawal (Ewd); or 4) E for 8 wk plus tamoxifen for the last week. E-regulated genes were defined as those that differed significantly between control and E and/or between E and Ewd or control and Ewd. These protocols generated 188 in vivo E-regulated genes that showed two major patterns of regulation. Approximately 46% returned to basal states after Ewd (class I genes); 53% did not (class II genes). In addition, more than 70% of class II-regulated genes also failed to reverse in response to tamoxifen. These genes may be interesting for the study of hormone-resistance issues. A subset of in vivo E-regulated genes appears on lists of clinical ER discriminator genes. These may be useful therapeutic targets or markers of E activity. Comparison of in vivo E-regulated genes with those regulated in identical cells in vitro after 6 and 24 h of E treatment demonstrate only 11% overlap. This indicates the extent to which gene expression profiles are uniquely dependent on hormone-treatment times and the cellular microenvironment.
49884	 9887	15228	estradiol	Compound	TIMP3	mRNA	0	-1	14568914	Estradiol induced a significant reduction in uterine TIMP-3 expression in wild-type mice
50256	 9887	16618	estradiol	Compound	VDAC3	mRNA	0	-1	12606449	Estradiol-17beta pellets were implanted into ovariectomized mice and removed 4 days later (Day 0). The apoptotic index (percentage of apoptotic cells) of the luminal epithelium increased markedly, peaking on Day 2, whereas that of the glandular epithelium increased much less. Expression of VDAC1, 2, and 3 mRNAs increased in the luminal epithelium in correlation with the apoptotic index of the luminal epithelium.
51453	 9887	 7564	estradiol	Compound	WNT5A	mRNA	0	1	15358837	We show here that estrogen in an ER-independent manner rapidly up-regulates the expression of Wnt4 and Wnt5a of the Wnt family and frizzled-2 of the Wnt receptor family in the mouse uterus.
 5163	 9887	 4295	estradiol	Compound	CD53	mRNA	0	1	12072388	17alpha-Ethinyl estradiol (EE) pretreatment reduced the IL-1beta induction of approximately one third of these genes. Estrogen receptor alpha (ERalpha) was required for this inhibitory activity, because EE inhibition of IL-1beta-stimulated gene expression occurred in ERbeta knockout mice, but not in ERalpha knockout mice. Table 2. EE induction of gene expression in the mouse liver
51762	 9887	 3665	estradiol	Compound	MYBL1	mRNA	0	1	16239301	In breast cancers, estrogen receptor (ER) levels are highly correlated with response to endocrine therapies. We sought to define mechanisms of estrogen (E) signaling in a solid breast tumor model using gene expression profiling. ER(+) T47D-Y human breast cancer cells were grown as xenografts in ovariectomized nude mice under four conditions: 1) 17beta-estradiol for 8 wk (E); 2) without E for 8 wk (control); 3) E for 7 wk followed by 1 wk of E withdrawal (Ewd); or 4) E for 8 wk plus tamoxifen for the last week. E-regulated genes were defined as those that differed significantly between control and E and/or between E and Ewd or control and Ewd. These protocols generated 188 in vivo E-regulated genes that showed two major patterns of regulation. Approximately 46% returned to basal states after Ewd (class I genes); 53% did not (class II genes). In addition, more than 70% of class II-regulated genes also failed to reverse in response to tamoxifen. These genes may be interesting for the study of hormone-resistance issues. A subset of in vivo E-regulated genes appears on lists of clinical ER discriminator genes. These may be useful therapeutic targets or markers of E activity. Comparison of in vivo E-regulated genes with those regulated in identical cells in vitro after 6 and 24 h of E treatment demonstrate only 11% overlap. This indicates the extent to which gene expression profiles are uniquely dependent on hormone-treatment times and the cellular microenvironment.
53043	 9887	 3486	estradiol	Compound	CFP	mRNA	0	1	12072388	17alpha-Ethinyl estradiol (EE) pretreatment reduced the IL-1beta induction of approximately one third of these genes. Estrogen receptor alpha (ERalpha) was required for this inhibitory activity, because EE inhibition of IL-1beta-stimulated gene expression occurred in ERbeta knockout mice, but not in ERalpha knockout mice. Table 2. EE induction of gene expression in the mouse liver
53121	 9887	16414	estradiol	Compound	Ccl6	mRNA	0	-1	15294957	As compared with noninflamed tissue, these chemokine mRNA l evels were strongly up-regulated in the spinal cord of placebo-treated WT mice, but remained at basal level in E2-treated WT animals (Fig. 2D).
53495	 9887	18036	estradiol	Compound	WISP2	mRNA	0	1	12659671	WISP-2 is an estrogen-induced early response gene in MCF-7 cells and the expression was continuously increased to reach a maximum level at 24 h.
 5366	 9887	 6171	estradiol	Compound	CECR6	mRNA	0	1	17962382	Figure 2 - fold difference after E2 binding vs. control
53714	 9887	14860	estradiol	Compound	FHL1	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
53879	 9887	  441	estradiol	Compound	ATP1B3	mRNA	1	1	15901920	upregulated by Estradiol
54337	 9887	 4922	estradiol	Compound	NAB2	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
54392	 9887	18907	estradiol	Compound	RAP1A	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
54950	 9887	10940	estradiol	Compound	HAP1	mRNA	0	1	15579445	Estrogen has been postulated to be involved in inhibition of vascular smooth muscle cell (VSMC) proliferation mainly via estrogen receptor (ER), but the detailed mechanism has remained primarily unknown. Therefore, in this study, microarray analysis was used in two types of cultured human VSMCs: one positive for ER alpha, and the other for ER beta, which were treated by estrogens to detect the estrogen-responsive genes. We also used quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to evaluate mRNA levels of selective target gene (TG) in these cells. We further studied whether the TG product was involved in inhibition of proliferation using small interfering RNA (siRNA) of the TG transfection. We subsequently used quantitative RT-PCR and in situ hybridization analysis to evaluate the expression of these gene products in human aorta. E4F1, a possible inducer of cell growth arrest, was markedly increased only in ER alpha-positive VSMCs by estrogens in both microarray and RT-PCR analyses. Blocking of E4F1 using siRNA suppressed estrogenic inhibition of ER alpha-positive VSMC proliferation. E4F1 mRNA was abundant in premenopausal female aorta with mild atherosclerotic changes. E4F1 is therefore considered one of the estrogen-responsive genes involving ER alpha-mediated inhibition of VSMC proliferation and may play an important role in estrogen-related atheroprotection of human aorta.
55358	 9887	 4481	estradiol	Compound	COL5A2	mRNA	1	1	12655037	The profound effects of 17beta-estradiol on cell growth, differentiation, and general homeostasis of the reproductive and other systems, are mediated mostly by regulation of temporal and cell type-specific expression of different genes. In order to understand better the molecular events associated with the activation of the estrogen receptor (ER), we have used microarray technology to determine the transcriptional program and dose-response characteristics of exposure to a potent synthetic estrogen, 17 alpha-ethynyl estradiol (EE), during prepubertal development. Changes in patterns of gene expression were determined in the immature uterus and ovaries of Sprague-Dawley rats on postnatal day (PND) 24, 24 h after exposure to EE, at 0.001, 0.01, 0.1, 1 and 10 micro g EE/kg/day (sc), for four days (dosing from PND 20 to 23). The transcript profiles were compared between treatment groups and controls using oligonucleotide arrays to determine the expression level of approximately 7000 annotated rat genes and over 1740 expressed sequence tags (ESTs). Quantification of the number of genes whose expression was modified by the treatment, for each of the various doses of EE tested, showed clear evidence of a dose-dependent treatment effect that follows a monotonic response, concordant with the dose-response pattern of uterine wet-weight gain and luminal epithelial cell height. The number of genes whose expression is affected by EE exposure increases according to dose. At the highest dose tested of EE, we determined that the expression level of over 300 genes was modified significantly (p dose-dependent analysis of the transcript profile revealed a set of 88 genes whose expression is significantly and reproducibly modified (increased or decreased) by EE exposure (p demonstrate that, exposure to a potent estrogenic chemical during prepubertal maturation changes the gene expression profile of estrogen-sensitive tissues. Furthermore, the products of the EE-regulated genes identified in these tissues have a physiological role in different intracellular pathways, information that will be valuable to determine the mechanism of action of estrogens. Moreover, those genes could be used as biomarkers to identify chemicals with estrogenic activity.
  565	 9887	 1295	estradiol	Compound	CLSTN2	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
56642	 9887	16427	estradiol	Compound	EFNA1	mRNA	0	-1	15072547	Figure 2 Gene expression variations measured by cDNA arrays in independent E2 (E2), OH-Tam, ICI 182,780 (ICI) and E2+OH-Tam experiments.
56720	 9887	 3492	estradiol	Compound	EEF2K	mRNA	0	-1	17351261	See Table 2: Representative Gene Expression Changes after 2h of EE (17 alpha-ethinyl estradiol) Exposure. All changes are greater than or equal to 1.5
56852	 9887	10747	estradiol	Compound	YBX2	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
57722	 9887	 1608	estradiol	Compound	C1QC	mRNA	0	1	12072388	17alpha-Ethinyl estradiol (EE) pretreatment reduced the IL-1beta induction of approximately one third of these genes. Estrogen receptor alpha (ERalpha) was required for this inhibitory activity, because EE inhibition of IL-1beta-stimulated gene expression occurred in ERbeta knockout mice, but not in ERalpha knockout mice. Table 2. EE induction of gene expression in the mouse liver
59740	 9887	 5494	estradiol	Compound	LPIN1	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
60319	 9887	18948	estradiol	Compound	ANGPTL7	mRNA	0	-1	17673513	Table 1 Downregulated genes in WT testis exposed to E2 (> 2fold change)
60501	 9887	19830	estradiol	Compound	APOD	mRNA	0	-1	16239301	Table 1. Class I E-regulated genes in tumors.
61792	 9887	 1730	estradiol	Compound	KLF10	mRNA	1	1	 9492071	rapid, but transient, induction of TIEG steady-state messenger RNA (mRNA) levels by 17beta-estradiol (E2) in estrogen receptor (ER)-positive, human fetal osteoblastic (hFOB/ER) cells.
61969	 9887	15013	estradiol	Compound	IRF6	mRNA	0	-1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
62931	 9887	 7195	estradiol	Compound	GADD45A	mRNA	-1	1	12047351	Table 1 List of oestrogen-activated genes.
63158	 9887	 9286	estradiol	Compound	PLEC	mRNA	0	1	16239301	Table 1. Class I E-regulated genes in tumors.
63914	 9887	14839	estradiol	Compound	CDV3	mRNA	0	1	15831674	Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.
65485	 9887	 7048	estradiol	Compound	HERC2	mRNA	1	1	15637295	Examples of genes whose expression was increased or decreased by E2 are provided in Tables 3 and 4, respectively. TABLE 3. Examples of genes up-regulated by E2
65621	 9887	 6557	estradiol	Compound	ALAS1	mRNA	0	-1	15901920	TABLE 5 Gene Expression Changes Induced by Transplacental Exposure to EE, Ges, or BPA in the Fetal Testis/Epididymis downregulated by Estradiol
 6914	 9887	 8725	estradiol	Compound	NCOA1	mRNA	0	-1	14680484	For example, thyroid hormone upregulates NCoA-1 mRNA levels in the anterior pituitary, whereas E2 downregulates its expression [33]. Both the mRNA and protein levels of NCoA-3 can be suppressed by E2, and this repression is reversed by antiestrogens or all-trans retinoic acid [35].
 8848	 9887	12565	estradiol	Compound	FAM102A	mRNA	0	1	14605097	EEIG1 was clearly induced by 17 beta-estradiol
 9561	 9887	 7602	estradiol	Compound	CAP2	mRNA	0	1	16239301	In breast cancers, estrogen receptor (ER) levels are highly correlated with response to endocrine therapies. We sought to define mechanisms of estrogen (E) signaling in a solid breast tumor model using gene expression profiling. ER(+) T47D-Y human breast cancer cells were grown as xenografts in ovariectomized nude mice under four conditions: 1) 17beta-estradiol for 8 wk (E); 2) without E for 8 wk (control); 3) E for 7 wk followed by 1 wk of E withdrawal (Ewd); or 4) E for 8 wk plus tamoxifen for the last week. E-regulated genes were defined as those that differed significantly between control and E and/or between E and Ewd or control and Ewd. These protocols generated 188 in vivo E-regulated genes that showed two major patterns of regulation. Approximately 46% returned to basal states after Ewd (class I genes); 53% did not (class II genes). In addition, more than 70% of class II-regulated genes also failed to reverse in response to tamoxifen. These genes may be interesting for the study of hormone-resistance issues. A subset of in vivo E-regulated genes appears on lists of clinical ER discriminator genes. These may be useful therapeutic targets or markers of E activity. Comparison of in vivo E-regulated genes with those regulated in identical cells in vitro after 6 and 24 h of E treatment demonstrate only 11% overlap. This indicates the extent to which gene expression profiles are uniquely dependent on hormone-treatment times and the cellular microenvironment.
10009	 8538	 4597	Nutlin 3	Compound	UBE2C	mRNA	1	-1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
 1135	 8538	15597	Nutlin 3	Compound	DLGAP5	mRNA	0	-1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
17425	 8538	18131	Nutlin 3	Compound	NOXA1	mRNA	0	1	17700533	Dissociation of p73 and HDM2 leads to increased p73 transcriptional activity with upregulation of p73 target genes noxa, puma and p21 (RT-PCR and Western Blot)  Noxa, puma and p21waf1/cip1 mRNA levels increased by 2.5-, 2.3- and 3.2- fold, respectively, following Nutlin-3 treatment (Figures 3a and b and Supplementary Figure S1
17772	 8538	16517	Nutlin 3	Compound	KRT15	mRNA	1	1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
25305	 8538	13534	Nutlin 3	Compound	CCNE2	mRNA	-1	-1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
26412	 8538	 6397	Nutlin 3	Compound	CEP55	mRNA	1	-1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
38808	 8538	10290	Nutlin 3	Compound	FOXM1	mRNA	1	-1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
39414	 8538	 5243	Nutlin 3	Compound	SESN1	mRNA	-1	1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
41096	 8538	11896	Nutlin 3	Compound	MCM5	mRNA	1	-1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
42621	 8538	19799	Nutlin 3	Compound	SMC2	mRNA	1	-1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
43778	 8538	16606	Nutlin 3	Compound	SAP30	mRNA	0	-1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
 4840	 8538	 4355	Nutlin 3	Compound	BBC3	mRNA	0	1	17700533	Dissociation of p73 and HDM2 leads to increased p73 transcriptional activity with upregulation of p73 target genes noxa, puma and p21 (RT-PCR and Western Blot)  Noxa, puma and p21waf1/cip1 mRNA levels increased by 2.5-, 2.3- and 3.2- fold, respectively, following Nutlin-3 treatment (Figures 3a and b and Supplementary Figure S1
49676	 8538	 6430	Nutlin 3	Compound	MDM2	mRNA	1	1	17671205	from full text - The activation of p53 by nutlin-3a was confirmed by immunoblot analysis that showed stabilization of p53, increased p53 phosphorylation at Ser18, and increased levels of the p53 downstream targets MDM2 and p21 ( Fig. 1D).
50982	 8538	13884	Nutlin 3	Compound	CDKN1A	mRNA	1	1	17700533	Dissociation of p73 and HDM2 leads to increased p73 transcriptional activity with upregulation of p73 target genes noxa, puma and p21 (RT-PCR and Western Blot)  Noxa, puma and p21waf1/cip1 mRNA levels increased by 2.5-, 2.3- and 3.2- fold, respectively, following Nutlin-3 treatment (Figures 3a and b and Supplementary Figure S1
 5897	 8538	 5636	Nutlin 3	Compound	AURKA	mRNA	1	-1	16443686	Supplemental Table I.  Probe sets altered by nutlin-3a treatment.  From results: Of ?40,000 human transcripts represented on the chip, 143 genes (166 probe sets) were found differentially expressed in HCT116 cells treated with nutlin-3a (Fig. 1D and Table 1, which is published as supporting information on the PNAS web site). The list included multiple genes previously shown to be affected by p53 activation (19?21), including 32 transcripts reported as directly regulated by p53. Changes in the expression of many genes may reflect the altered cell-cycle distribution in cells that arrest predominantly in G1 and G2 phases as a result of p53 activation (12). With the exception of a few genes that were marginally down-regulated in HCT116 cells, the inactive enantiomer did not significantly change the gene expression profile of both cell lines. Taken together, the data in Fig. 1 indicate that nutlin-3a is a highly selective MDM2 antagonist and p53 inducer. *Differential expression was determined as 3-fold altered in HCT116 treated with nutlin-3a vs. vehicle and P < 0.05, and no change (<1.5-fold change) in the H1299 cells or HCT116 treated with nutlin-3b. **Expression vaules are the average of three replicates of Affymetrix MAS5 signal intensities scaled to the median of the experiment.  P value calculations are a simple t test P value of the null hypothesis of no difference between nutlin-3a treated samples vs. DMSO-treated samples.
16250	11346	15838	DBP	Protein	PER1	mRNA	0	1	10848603	The mPer1 promoter is cooperatively activated by DBP and CLOCK-BMAL1.
19312	11346	 1981	DBP	Protein	ST6GAL1	mRNA	1	1	 1737800	\Regulated expression of alpha 2,6-sialyltransferase by the liver-enriched transcription factors HNF-1, DBP, and LAP.\ Expression vectors containing cDNAs of these factors are capable of trans-activating transcription of the alpha 2,6ST promoter, demonstrating their ability to regulate transcription of this promoter.
36669	11346	11314	DBP	Protein	PCK2	mRNA	-1	1	 1328227	We now show that the albumin promoter D-site-binding protein (DBP), a transcription factor whose expression is limited to the liver, is also able to trans-activate the PEPCK promoter through sequence-specific binding.
12339	 3273	15924	KAT5	Protein	HDC	mRNA	0	-1	17827213	Consistently, knock down of Tip60 or HDAC7 gene expression by specific shRNA increased endogenous HDC mRNA level. Co-immunoprecipitation assays showed that HDAC7 was pulled down by KLF4 and Tip60, suggesting that these three proteins form a repressive complex. Further chromatin immuno-precipitation indicated that all three proteins associated with HDC promoter.
27644	 3273	12781	KAT5	Protein	AR	mRNA	1	1	11994312	Together, these findings implicate Tip60-mediated AR acetylation as an important step in up-regulating AR activity. . ....Fig. 8.   HDAC1 and Tip60 associate with AR on the PSA gene promoter under different hormone-induced states.
33187	 3273	15981	KAT5	Protein	HIST2H4A	mRNA	0	1	17967892	The results shown in Fig. 4 indicate that, similar to TRRAP, Tip60 associates with histone promoters in an NPAT-dependent fashion.......As shown in Fig. 7B and C, the suppression of Tip60 expression inhibits both the H2B and the H4 promoter activities, suggesting that Tip60 is also required for histone gene transcriptional activation.
65674	 3273	13587	KAT5	Protein	HIST2H2BE	mRNA	0	1	17967892	The results shown in Fig. 4 indicate that, similar to TRRAP, Tip60 associates with histone promoters in an NPAT-dependent fashion.......As shown in Fig. 7B and C, the suppression of Tip60 expression inhibits both the H2B and the H4 promoter activities, suggesting that Tip60 is also required for histone gene transcriptional activation.
16038	  131	19146	Lithium	Compound	IMPA1	mRNA	0	1	12479670	It has also been reported previously that both lithium and inositol mildly up-regulate IMPA1 (encoding mammalian inositol monophosphatase) expression in human cells
42374	  131	 3180	Lithium	Compound	IMPA2	mRNA	0	-1	15504365	IMPA2 promoter activity in both cell lines is downregulated, in a dose-dependent manner, by lithium
51037	  131	13884	Lithium	Compound	CDKN1A	mRNA	1	1	11337498	Lithium also increased the expression of p21(Cip), a cyclin-dependent kinase inhibitor, both at the protein and RNA levels.
57268	  131	 8148	Lithium	Compound	GCG	mRNA	0	1	12421827	We show here that lithium, an inhibitor of GSK-3beta, activates proglucagon gene transcription and stimulates GLP-1 synthesis in an intestinal endocrine L cell line, GLUTag.
29875	11327	10162	MLL	Protein	CDKN2C	mRNA	0	1	15640349	Menin activates transcription by means of a mechanism involving recruitment of MLL to the p27Kip1 and p18Ink4c promoters and coding regions. Loss of function of either MLL or menin results in down-regulation of p27Kip1 and p18Ink4c expression and deregulated cell growth.
39564	11327	13744	MLL	Protein	CDKN1B	mRNA	-1	1	15640349	Menin activates transcription by means of a mechanism involving recruitment of MLL to the p27Kip1 and p18Ink4c promoters and coding regions. Loss of function of either MLL or menin results in down-regulation of p27Kip1 and p18Ink4c expression and deregulated cell growth.
51501	 7039	15841	oxandrolone	Compound	FBXO32	mRNA	-1	-1	16263771	Table 3. Genes downregulated twofold or more in DMD muscle in response to oxandrolone
60903	 7039	15700	oxandrolone	Compound	PRDX2	mRNA	1	-1	16263771	Table 3. Genes downregulated twofold or more in DMD muscle in response to oxandrolone
13289	   57	 2780	HOXA9	Protein	MTUS1	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
17802	   57	 5117	HOXA9	Protein	SAT1	mRNA	1	-1	15849172	downregulated
19675	   57	16486	HOXA9	Protein	SPP1	mRNA	1	-1	11042172	Modified assertion
20244	   57	 6485	HOXA9	Protein	Slfn4	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
22844	   57	18024	HOXA9	Protein	IGSF6	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
24405	   57	 9819	HOXA9	Protein	SORT1	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
 2537	   57	 3128	HOXA9	Protein	FZD1	mRNA	0	1	15849172	Table 1. Genes modified by HOXA9 overexpression in human CD34+ cord blood cells upregulated
27299	   57	14658	HOXA9	Protein	RHOJ	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
28224	   57	 7832	HOXA9	Protein	THBS1	mRNA	-1	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
31903	   57	16136	HOXA9	Protein	Akr1c13	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
35192	   57	12421	HOXA9	Protein	CSF2RA	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
38166	   57	 1765	HOXA9	Protein	CELA2A	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
42447	   57	  635	HOXA9	Protein	PDE2A	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
43610	   57	 2451	HOXA9	Protein	YWHAG	mRNA	-1	-1	14604967	Figure 2 - Gene expression changes due to overexpression of HOXA9 in human hematopoietic cell lines __BW__
47590	   57	19487	HOXA9	Protein	CTNND1	mRNA	1	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
48843	   57	 9823	HOXA9	Protein	HSD11B1	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
52991	   57	19009	HOXA9	Protein	TSC22D3	mRNA	1	-1	14604967	Figure 2 - Gene expression changes due to overexpression of HOXA9 in human hematopoietic cell lines __BW__
53935	   57	18911	HOXA9	Protein	RNF128	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
54921	   57	12609	HOXA9	Protein	HMBS	mRNA	1	-1	15849172	downregulated
56098	   57	 8304	HOXA9	Protein	OSBPL9	mRNA	1	1	14604967	Figure 6. HOXA9 target genes that are expressed in CD34+ stem cells
62283	   57	16368	HOXA9	Protein	EPHB4	mRNA	0	1	14764452	Modified assertion
62313	   57	17657	HOXA9	Protein	ABCA13	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
63115	   57	  729	HOXA9	Protein	TNFSF13	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
64228	   57	 1532	HOXA9	Protein	TFEC	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
64267	   57	12085	HOXA9	Protein	MSN	mRNA	0	1	15849172	Table 2. HOXA10-modulated genes in human CD34+ cord blood cells upregulated
64418	   57	 8027	HOXA9	Protein	GDA	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
65619	   57	 6557	HOXA9	Protein	ALAS1	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
 6783	   57	 2988	HOXA9	Protein	TLR4	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
 7486	   57	 3897	HOXA9	Protein	BSCL2	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
 9988	   57	 8916	HOXA9	Protein	CLEC7A	mRNA	0	1	15755900	Table 2. Genomic signature of progenitors immortalized by Hoxa9 versus Hoxa9 plus Meis1 Increased expression in Hoxa9-immortalized progenitors
53000	 2138	19009	Telomestatin	Compound	TSC22D3	mRNA	1	1	14760100	from full text - Table 1 Gene expression profiles of MMIS myeloma cells after 1 and 7 days of telomestatin treatment (day 7 results)
22094	11236	 3952	NFIA	Protein	Nkx2-1	mRNA	0	1	11046146	We conclude that NFI binding to two NFI elements, at bp -264 to -153, positively regulates TTF-1 expression and controls constitutive TTF-1 levels.
34370	11236	19822	NFIA	Protein	FABP7	mRNA	0	1	10896661	the most proximal NFI site is essential for B-FABP promoter activity in transiently transfected malignant glioma cells.
43473	11236	18799	NFIA	Protein	SLC25A5	mRNA	0	-1	12777383	Furthermore, overexpression of NF1-A, -C, and -X in NIH3T3 cells repressed expression of an ANT2-driven reporter gene construct
48225	11236	14986	NFIA	Protein	RGN	mRNA	0	1	11835404	Modified assertion
49657	11236	 1632	NFIA	Protein	SFTPC	mRNA	0	1	14645514	NFI family members differentially activate the SP-C promoter.
51053	11236	13884	NFIA	Protein	CDKN1A	mRNA	1	-1	17130157	Transfection of recombinant constructs bearing mutations in the p21 NFI site demonstrated that NFI acts as a repressor of p21 gene expression in various types of cultured cells. Inhibition of NFI in human skin fibroblasts through RNAi considerably increased p21 promoter activity suggesting that NFI is a key repressor of p21 transcription. Over-expression of each of the four NFI isoforms in HCT116 cells established that each of them contribute to various extend to the repression of the p21 gene.
60369	11236	19732	NFIA	Protein	IGFBP5	mRNA	0	-1	18809517	All four NFI genes were expressed in human osteoblast cultures and osteosarcoma cell lines. Co-transfection with human IGFBP5 promoter luciferase reporter and murine Nfi expression vectors showed that Nfib was the most active in stimulating transcription. Nfix was less active and Nfia and Nfic were inhibitory. ......All four NFI proteins bound the NFI site in electrophoretic mobility shift experiments and NFIB bound in chromatin immunoprecipitation assays.
14560	  823	 3387	Tgfbr Family	Protein	CD86	mRNA	0	-1	11601034	Moreover, TGF-beta 1 markedly suppressed the expression of antigen peresenting molecule Ia and co-stimulatory molecule CD86 on the surface of cultured Lin- c-kit+ HPCs. Examination of RT-PCR showed that TGF-beta 1 could also inhibit the expression of MHC class II trans-activator (CTIIA) mRNA
16043	  823	 1471	Tgfbr Family	Protein	COL1A2	mRNA	-1	1	11007770	TGFbeta stimulates the gene coding for human alpha2(I)-collagen (COL1A2) by inducing binding of an Sp1-containing complex to an upstream promoter element (TGFbeta responsive element or TbRE) that contains a CAGA box. Here we report that the CAGA box of the TbRE is the binding site of the Smad3/Smad4 complex, and that the binding of the complex is required for TGFbeta-induced COL1A2 up-regulation. Recombinant Smad3 and Smad4 bind in vitro to the CAGA box of COL1A2; TGFbeta treatment of cultured fibroblasts induces Smad3/Smad4 binding to the TbRE; transient overexpression of Smad3 and Smad4 in fibroblasts transactivates TbRE-driven transcription;
17861	  823	18271	Tgfbr Family	Protein	ACTA1	mRNA	0	1	12702545	Transforming growth factor-beta (TGF-beta)-induced alpha-smooth muscle actin (ASMA) expression
21500	  823	 7854	Tgfbr Family	Protein	SLC25A4	mRNA	0	1	14720305	We recently showed that rodent Ant1 is upregulated by transforming growth factor-beta (TGF-beta) in reactive astrocytes
28248	  823	 7832	Tgfbr Family	Protein	THBS1	mRNA	-1	1	15927970	TSP-1 mRNA, which was markedly induced by TGF-beta, and basic fibroblast growth factor
30165	  823	14890	Tgfbr Family	Protein	Gm10499	mRNA	0	-1	11601034	Moreover, TGF-beta 1 markedly suppressed the expression of antigen peresenting molecule Ia and co-stimulatory molecule CD86 on the surface of cultured Lin- c-kit+ HPCs. Examination of RT-PCR showed that TGF-beta 1 could also inhibit the expression of MHC class II trans-activator (CTIIA) mRNA
56151	  823	10811	Tgfbr Family	Protein	FN1	mRNA	-1	1	11934704	CTGF antisense ODN transfected into cultured renal fibroblasts significantly attenuated TGF-beta-stimulated upregulation of fibronectin mRNA and protein compared with control ODN transfection, together with inhibited synthesis of type I collagen.
57415	  823	 3336	Tgfbr Family	Protein	CCND2	mRNA	0	1	15192076	Smad3 is an important mediator of the TGF beta signaling pathway Smad3-/- follicles have impaired growth, increased atresia, and altered differentiation in the presence of high FSH levels, normal expression of FSHR, and lower expression of cyclin D2
 5985	  823	14470	Tgfbr Family	Protein	CIITA	mRNA	0	-1	11601034	Moreover, TGF-beta 1 markedly suppressed the expression of antigen peresenting molecule Ia and co-stimulatory molecule CD86 on the surface of cultured Lin- c-kit+ HPCs. Examination of RT-PCR showed that TGF-beta 1 could also inhibit the expression of MHC class II trans-activator (CTIIA) mRNA
63100	  823	11460	Tgfbr Family	Protein	PLA2G2A	mRNA	0	-1	15878884	Conversely, the receptors for transforming growth factor-beta and platelet-derived growth factor, which contributed to down-regulation of sPLA2-IIA expression, were decreased following 12/15-LOX overexpression
64016	  823	 9412	Tgfbr Family	Protein	MMP11	mRNA	0	1	15272933	MMP-11 expression was stimulated to a level greater than 100%, by 48 hour treatments of IL-1beta, IL-2, TGF-beta, fibronectin and collagen V
66299	  823	13248	Tgfbr Family	Protein	TSC22D1	mRNA	0	1	15881652	tsc-22 mRNA is expressed in almost all organs of mice and humans and its expression is induced in a variety of cell lines by many different factors including TGF-beta, phorbol ester, serum, and progestin
 7259	  823	15475	Tgfbr Family	Protein	FGFBP1	mRNA	0	-1	16690027	We demonstrate here that TGF-beta signaling significantly represses FGF-BP1 expression in mesenchymal and neural crest cells undergoing in vitro smooth muscle differentiation.
21911	17068	 3995	CTCFL	Protein	ESR1	mRNA	-1	1	18195709	The link between BORIS and PR/ER was further confirmed by the ability of BORIS to activate the promoters of the PR and ER genes in the reporter assays.
24854	17068	 5863	CTCFL	Protein	MYC	mRNA	0	1	18765639	This work identifies SET1A, an H3K4 methyltransferase, and BAT3, a cochaperone recruiter, as binding partners for BORIS, and these proteins bind to the upstream promoter regions of two well-characterized procarcinogenic genes, Myc and BRCA1. RNA interference (RNAi) knockdown of BAT3, as well as SET1A, decreased Myc and BRCA1 gene expression but did not affect the binding properties of BORIS, but RNAi knockdown of BORIS prevented the assembly of BAT3 and SET1A at the Myc and BRCA1 promoters. Finally, chromatin analysis suggested that BORIS and BAT3 exert their effects on gene expression by recruiting proteins such as SET1A that are linked to changes in H3K4 dimethylation.
33686	17068	 8874	CTCFL	Protein	BAG1	mRNA	0	1	18413740	BORIS short hairpin RNA knockdown decreased both promoter DNA-binding, as well as BAG-1 expression, and changed the dimethyl-H3-K4/dimethyl-H3-K9 ratio to that characteristic of a nonpermissive chromatin state. These results suggest that DNMT1 and DNMT3B regulate BAG-1 expression via insulator protein DNA-binding and chromatin dynamics by regulating histone dimethylation.
36033	17068	 7956	CTCFL	Protein	BRCA1	mRNA	0	1	18765639	This work identifies SET1A, an H3K4 methyltransferase, and BAT3, a cochaperone recruiter, as binding partners for BORIS, and these proteins bind to the upstream promoter regions of two well-characterized procarcinogenic genes, Myc and BRCA1. RNA interference (RNAi) knockdown of BAT3, as well as SET1A, decreased Myc and BRCA1 gene expression but did not affect the binding properties of BORIS, but RNAi knockdown of BORIS prevented the assembly of BAT3 and SET1A at the Myc and BRCA1 promoters. Finally, chromatin analysis suggested that BORIS and BAT3 exert their effects on gene expression by recruiting proteins such as SET1A that are linked to changes in H3K4 dimethylation.
11042	 2633	 8037	Map2k Family	Protein	KLF6	mRNA	1	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
18032	 2633	12757	Map2k Family	Protein	THRB	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
28241	 2633	 7832	Map2k Family	Protein	THBS1	mRNA	-1	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
30283	 2633	 6115	Map2k Family	Protein	ADRBK1	mRNA	0	-1	12592402	Fig. 6 Model of TLR4 and chemokine receptor crosstalk. MIP-2 binding to CXCR2 induces PMN migration, as well as GRK2 and GRK5 expression, through PI3K-? signaling. Increased GRK2 and GRK5 expression results in chemokine receptor internalization and desensitization, thereby negatively regulating PMN migration. Thus, PI3K-?-activated signaling is postulated to be a feedback mechanism regulating PMN migration. Because persistent infection requires continued PMN infiltration, LPS acting through the TLR4 signaling pathway transcriptionally downregulates expression of GRK2 and GRK5 in response to MIP-2. This decreases chemokine receptor desensitization by preventing CXCR2 internalization and thus augments PMN migration. MEK kinase is involved in mediating the crosstalk between TLR4 and chemokine receptors. Dashed lines indicate inhibitory signals.
31893	 2633	11633	Map2k Family	Protein	THRA	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
38352	 2633	 1872	Map2k Family	Protein	BTG2	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
42080	 2633	13115	Map2k Family	Protein	EGR1	mRNA	-1	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
 4345	 2633	10234	Map2k Family	Protein	GRK5	mRNA	0	-1	12592402	Fig. 6 Model of TLR4 and chemokine receptor crosstalk. MIP-2 binding to CXCR2 induces PMN migration, as well as GRK2 and GRK5 expression, through PI3K-? signaling. Increased GRK2 and GRK5 expression results in chemokine receptor internalization and desensitization, thereby negatively regulating PMN migration. Thus, PI3K-?-activated signaling is postulated to be a feedback mechanism regulating PMN migration. Because persistent infection requires continued PMN infiltration, LPS acting through the TLR4 signaling pathway transcriptionally downregulates expression of GRK2 and GRK5 in response to MIP-2. This decreases chemokine receptor desensitization by preventing CXCR2 internalization and thus augments PMN migration. MEK kinase is involved in mediating the crosstalk between TLR4 and chemokine receptors. Dashed lines indicate inhibitory signals.
48075	 2633	11629	Map2k Family	Protein	FOS	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
51832	 2633	 3000	Map2k Family	Protein	ZFP36	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
56838	 2633	20050	Map2k Family	Protein	PDIA3	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
57342	 2633	 4298	Map2k Family	Protein	JUNB	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
58321	 2633	 5913	Map2k Family	Protein	CYR61	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
13268	 6409	 1829	ELF1	Protein	CD3D	mRNA	0	1	12324448	Modified assertion
22907	 6409	17263	ELF1	Protein	CD68	mRNA	0	1	12676954	expression of CD68 in myeloid cells requires the Ets transcription factors Elf-1 and PU.1 and CD68 expression is down-regulated in lymphoid cells by combinatorial interactions between PU.1 and IRF-4.
40973	 6409	 4582	ELF1	Protein	NOS3	mRNA	1	-1	 9915847	Modified assertion
17017	10183	 3722	PLAGL1	Protein	PPARG	mRNA	0	1	17178896	we identify peroxisome proliferator-activated receptor gamma (PPARgamma) as a new bona fide Zac target gene, which is induced by direct Zac binding to the proximal PPARgamma1 promoter.
43013	10183	17766	PLAGL1	Protein	APAF1	mRNA	0	1	11896574	We also show that the p53 activation of the Apaf-1 luciferase construct can be enhanced by the putative tumor suppressor gene product, Zac-1, a transcription factor that has previously been shown to inhibit cell proliferation. Furthermore, we demonstrate that Zac-1 is a possible direct target of p53 since the sequence upstream to the first coding exon of Zac-1 contains a p53 recognition site and the luciferase construct containing this region is activated by p53
51093	10183	13884	PLAGL1	Protein	CDKN1A	mRNA	1	1	17109628	We have shown previously that Zac1 induces p21WAF1/CIP1 (p21) promoter activity and protein expression through a p53-dependent pathway in HeLa cells [23]. .....Importantly, our ChIP analysis revealed that the working complex on the Sp1-responsive elements of the p21 promoter in HeLa cells contained Sp1, Zac1 and importin a1, but not p53 (Figure 6c).
65555	10183	14743	PLAGL1	Protein	IGF2	mRNA	0	1	11888928	the PLAG1- and PLAGL2-induced transformation is accompanied by a drastic up-regulation of insulin-like growth factor-II, which we prove is a target of PLAG1 and PLAGL2
65603	10183	16485	PLAGL1	Protein	ABCC6	mRNA	0	1	18850323	we identified ABCC6 as a target gene for transcriptional induction by PLAG1 and PLAGL1, transcription factors from the PLAG family of cell cycle progression-related DNA-binding proteins. Both these factors are shown to bind to the same single consensus-binding element in the ABCC6 proximal promoter in cell lines of hepatic and renal origin by reporter gene assay, electrophoretic mobility shift assay and chromatin immunoprecipitation.
23418	 3479	19221	CBFA2T3	Protein	GFI1B	mRNA	0	-1	16407974	we identify the ETO2 repressor as a novel component recruited to TAL-1 complexes through interaction with E2A/HEB. Ectopic expression and siRNA knockdown experiments in hematopoietic progenitor cells show that ETO2 actively represses erythroid TAL-1 target genes and governs the expansion of erythroid progenitors. At the onset of erythroid differentiation, a change in the stoichiometry of ETO2 within the TAL-1 complex activates the expression of known erythroid-specific TAL-1 target genes and of Gfi-1b and p21(Cip), encoding two essential regulators of erythroid cell proliferation.
24312	 3479	 7440	CBFA2T3	Protein	PF4	mRNA	0	-1	18625887	Knockdown of ETO2 expression promotes megakaryocyte differentiation and enhances expression of select genes expressed in terminal megakaryocyte maturation, eg, platelet factor 4 (Pf4). ETO2-dependent direct repression of the Pf4 proximal promoter is mediated by GATA-binding sites and an E-Box motif.
25017	 3479	 8758	CBFA2T3	Protein	EPB42	mRNA	0	-1	16407974	we identify the ETO2 repressor as a novel component recruited to TAL-1 complexes through interaction with E2A/HEB. Ectopic expression and siRNA knockdown experiments in hematopoietic progenitor cells show that ETO2 actively represses erythroid TAL-1 target genes and governs the expansion of erythroid progenitors. At the onset of erythroid differentiation, a change in the stoichiometry of ETO2 within the TAL-1 complex activates the expression of known erythroid-specific TAL-1 target genes and of Gfi-1b and p21(Cip), encoding two essential regulators of erythroid cell proliferation.
30171	 3479	 2666	CBFA2T3	Protein	TCF12	mRNA	-1	-1	18456661	Our results show that the E-box gene HEB is a direct target of CBFA2T3-ZNF652-mediated transcriptional repression. The CBFA2T3-ZNF652 complex regulates HEB expression by binding to a single ZNF652 response element located within the promoter sequence of HEB. This study also shows that the NHR3 and NHR4 domains of CBFA2T3 interact with a conserved proline-rich region located within the C terminus of ZNF652.
51073	 3479	13884	CBFA2T3	Protein	CDKN1A	mRNA	1	-1	16407974	we identify the ETO2 repressor as a novel component recruited to TAL-1 complexes through interaction with E2A/HEB. Ectopic expression and siRNA knockdown experiments in hematopoietic progenitor cells show that ETO2 actively represses erythroid TAL-1 target genes and governs the expansion of erythroid progenitors. At the onset of erythroid differentiation, a change in the stoichiometry of ETO2 within the TAL-1 complex activates the expression of known erythroid-specific TAL-1 target genes and of Gfi-1b and p21(Cip), encoding two essential regulators of erythroid cell proliferation.
 5148	 3479	12350	CBFA2T3	Protein	GYPA	mRNA	0	-1	16407974	we identify the ETO2 repressor as a novel component recruited to TAL-1 complexes through interaction with E2A/HEB. Ectopic expression and siRNA knockdown experiments in hematopoietic progenitor cells show that ETO2 actively represses erythroid TAL-1 target genes and governs the expansion of erythroid progenitors. At the onset of erythroid differentiation, a change in the stoichiometry of ETO2 within the TAL-1 complex activates the expression of known erythroid-specific TAL-1 target genes and of Gfi-1b and p21(Cip), encoding two essential regulators of erythroid cell proliferation.
10048	15648	 7928	ONECUT1	Protein	TGFBR2	mRNA	0	-1	15562441	we demonstrated that TGF-beta signaling was increased in the absence of HNF-6, and that this resulted from upregulation of TGF-beta receptor II expression.
20818	15648	 7064	ONECUT1	Protein	Cyp2a2	mRNA	0	-1	15539409	CYP2A2 promoter activity was inhibited approximately 85% by transfection of HNF3beta or HNF6, both of which are more highly expressed in female than male liver and can strongly trans-activate the female-specific CYP2C12 promoter.
26740	15648	  293	ONECUT1	Protein	HNF1B	mRNA	0	1	11934848	HNF6 can stimulate the Hnf1beta promoter.
38812	15648	10290	ONECUT1	Protein	FOXM1	mRNA	1	1	 9593691	Modified assertion
 7129	15648	14713	ONECUT1	Protein	FOXA1	mRNA	0	-1	15562441	Modified assertion
 8149	15648	17697	ONECUT1	Protein	SLC2A2	mRNA	0	1	15304484	acetylation of the HNF6 protein by CBP increased both HNF6 protein stability and its ability to stimulate transcription of the glucose transporter 2 promoter.
10017	 5652	19515	Low Density LipoProtein	Compound	UBAC1	mRNA	1	1	16466844	Table 4 Relative expression (RE) of 29 selected cellular genes in four study models by real-time RT-PCR - see comparisons below:  Model 2 (M2) values were normalized against the untreated control macrophages of model 1 (M1) at 24 h. Model 3 (M3) values were normalized against M1 at 72 h. Models 4 and 5 (M4 and M5) were normalized against M1 at 96 h.  M1@24, M1@72 and M1@96 denote control untreated macrophages whose RNAs were harvested and analyzed at 24, 72 and 96 h, respectively. M2@24 denotes LDL-treated macrophages with RNA analyzed at 24 h. M3@72 denotes macrophages infected with C. pneumoniae and RNA analyzed at 72 h. M4@96 denotes macrophages treated with LDL for 24 h, followed by C. pneumoniae infection for another 72 h before analyzing RNA at 96 h. M5@96 denotes macrophages infected with C. pneumoniae first for 72 h, followed by LDL treatment for another 24 h before analyzing RNA at 96 h. {for M4 and M5, results were combined and only the overlapping gene changes were modeled}  (from methods) The two-tailed t-test was then conducted to ascertain the statistical significance of the differences between the normalized relative expression values for each gene under the conditions stipulated for study models 2, 3, 4 and 5
25490	 5652	11591	Low Density LipoProtein	Compound	NR4A3	mRNA	0	1	14962944	LDL induced NOR-1 expression in a time- and dose-dependent manner.
 3442	 5652	10915	Low Density LipoProtein	Compound	BAX	mRNA	0	1	12482829	Western blots showed that SMCs did not express DAP kinase protein when cultured in the absence of agLDL. In contrast, strong upregulation of DAP kinase protein could be detected after 2 days of agLDL treatment (Figure 3A). DAP kinase expression was associated with enhanced levels of the tumor suppressor protein p53. We also observed a progressive increase in Bax and TNF receptor 2 expression during foam cell formation. Furthermore, it was demonstrated that agLDL could significantly induce (3-fold) both DAP kinase and Bax gene transcription (Figure 3B).
42074	 5652	13115	Low Density LipoProtein	Compound	EGR1	mRNA	-1	1	 8484785	LDL induces a dose-dependent expression of the Egr-1 mRNA
42464	 5652	13544	Low Density LipoProtein	Compound	AGTR1	mRNA	0	1	16675453	For example, Ang II (8), cAMP stimulating agents (9), and estrogens (10, 11) decrease rat AT1AR expression by stimulating rat AT1AR mRNA decay. In contrast, insulin (12), low density lipoprotein (13), and progesterone (11) up-regulate receptor expression by decreasing AT1AR mRNA decay rates. Additionally, rat AT1AR expression is regulated by translational mechanisms via cytosolic proteins that interact with the 5p-UTR of the receptor mRNA (10, 1418).
43722	 5652	 8405	Low Density LipoProtein	Compound	OSBPL1A	mRNA	0	1	10588946	Culturing the cells in lipoprotein-deficient serum for 2 days decreased their total cholesterol concentration by 25% (from 68 to 51ug cholesterol/mg protein) but did not significantly alter the ORP-1 mRNA levels. However, when the partially delipidated cells were loaded with LDL for 24 h, the ORP-1 transcript was up-regulated by 2-fold (Fig. 5). Simultaneously, the cellular cholesterol level returned back to normal (not shown). Short-term treatment of the sterol-depleted cells with 25-hydroxycholesterol (5 ug/ml of 25-hydroxycholesterol for 4 h), a condition known to stimulate the translocation of OSBP to the Golgi apparatus (10, 13), had a minor (1.5-fold) stimulatory effect on the expression of the ORP-1 mRNA (Fig. 5).
44417	 5652	13271	Low Density LipoProtein	Compound	CCL2	mRNA	0	1	12626661	Monocyte chemoattractant protein-1 (MCP-1) is a potent chemotactic agent for monocytes and other cells and is thought to be involved in atherosclerosis, recruiting monocytes to the subendothelial space or to the site of inflammation. Angiotensin II has been demonstrated, at least in animal models, to stimulate MCP-1 expression. We investigated the effect of the angiotensin II type 1 (AT1) receptor antagonists irbesartan and losartan on MCP-1 production by freshly isolated human monocytes. Irbesartan and losartan inhibited basal MCP-1 production in a dose-dependent manner. Low-density lipoprotein (LDL) stimulated MCP-1 in a concentration-dependent manner, with 200 microg/ml LDL protein giving a 2-fold increase in MCP-1. Irbesartan and losartan dose dependently blocked LDL-stimulated MCP-1. An angiotensin II type 2 receptor antagonist, S-(+)-1-([4-(dimethylamino)-3-methylphenyl]methyl)-5-(diphenylacetyl)-4,5,6,7- ... tetrahydro-1H-imidazo(4,5-c)pyridine-6-carboxylic acid (PD123319), had no significant effect on basal MCP-1 levels or LDL-stimulated MCP-1. After noting homology between the AT1 receptor and the platelet-activating factor (PAF) receptor, we showed that irbesartan inhibited both [3H]PAF binding to human monocytes and carbamyl-PAF stimulation of MCP-1. However, irbesartan affinity for the PAF receptor was 700 times less than PAF, suggesting that there may be another mechanism for irbesartan inhibition of PAF-stimulated MCP-1. This is the first report showing that AT1 receptor antagonists inhibit basal as well as LDL- and PAF-stimulated MCP-1 production in freshly isolated human monocytes.
  448	 5652	14844	Low Density LipoProtein	Compound	ACTG1	mRNA	-1	1	16466844	Many studies on atherosclerosis have indicated an association with Chlamydophila pneumoniae, a respiratory intracellular pathogen that can infect bronchoalveolar macrophages, and be transported to sites of vascular injury. Furthermore, the connection between low density lipoprotein (LDL), macrophages, foam cell formation, and atherosclerosis is well established. Five study models were designed to mimic the early events in plaque formation, i.e. untreated U937 human macrophages as control; macrophages treated with LDL only; macrophages infected with the AR-39 strain of C. pneumoniae only; and the last two models in which macrophages were exposed to both C. pneumoniae and LDL but in different order. Differential display RT-PCR was employed to analyze mRNAs from the five models to elucidate the transcriptional responses arising from macrophage interactions with C. pneumoniae and/or LDL. Out of 235 expressed sequence tags, the altered expression patterns of 29 selected genes at various time-points were authenticated by semi-quantitative and real-time RT-PCR. In relation to atherosclerosis, some interesting modified transcripts are involved in cell proliferation (CDC2, CDC27, CDC42EP3, GBDR1, GPR6, RPL27A, Similar to COX2), apoptosis (BCL2A1), ubiquitination (CTSH, HSPC150, NUC2), and structural integrity (ACTG1, FLOT1). Other genes exhibiting altered expression include those that modulate inflammatory and immune responses or signal transduction linking infection to host immunity (ARPP-19, BLAME, HCA58, IK cytokine, IRS2, STAT1P1). The transcriptional alterations of critical human genes in response to C. pneumoniae infection and foam cell development provide insights into certain key molecular pathophysiological mechanisms of atherosclerosis.
 5429	 5652	10230	Low Density LipoProtein	Compound	F3	mRNA	0	1	17141748	Simvastatin reduced TF mRNA expression (more than 50%) in control, nLDL or agLDL-exposed VSMC (data not shown).
61882	 5652	 9387	Low Density LipoProtein	Compound	DAPK1	mRNA	0	1	12482829	Western blots showed that SMCs did not express DAP kinase protein when cultured in the absence of agLDL. In contrast, strong upregulation of DAP kinase protein could be detected after 2 days of agLDL treatment (Figure 3A). DAP kinase expression was associated with enhanced levels of the tumor suppressor protein p53. We also observed a progressive increase in Bax and TNF receptor 2 expression during foam cell formation. Furthermore, it was demonstrated that agLDL could significantly induce (3-fold) both DAP kinase and Bax gene transcription (Figure 3B).
65889	 5652	13225	Low Density LipoProtein	Compound	COL6A1	mRNA	0	1	14697233	Furthermore, our data unveil a previously unexpected link between extracellular matrix production and LDL signaling.
10766	18805	 5905	serum glucose	Compound	PSMB7	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
10775	18805	  289	serum glucose	Compound	DHCR7	mRNA	0	1	16885160	The expression of 283 genes was significantly changed at a threshold of 1.8-fold by switching from low glucose to high glucose conditions (Supplemental Table 1). Of these, 224 genes were induced in high glucose conditions, whereas 59 were repressed (Fig. 1). Differentially expressed genes were selected at a threshold of 1.8-fold difference between groups with a significance level of p  0.01.
11106	18805	11925	serum glucose	Compound	PRR14	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
11693	18805	11709	serum glucose	Compound	UCP2	mRNA	0	1	12196468	In islets exposed to high glucose or FFA, glucose-stimulated PDH activity was impaired and UCP-2 was overexpressed.
12141	18805	 6967	serum glucose	Compound	ECH1	mRNA	0	1	14762175	Table 9. DNA repair and apoptosis genes
12374	18805	 6089	serum glucose	Compound	GCGR	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
  126	18805	 8684	serum glucose	Compound	DPF2	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
13422	18805	 6451	serum glucose	Compound	LEPR	mRNA	0	1	16885160	The expression of 283 genes was significantly changed at a threshold of 1.8-fold by switching from low glucose to high glucose conditions (Supplemental Table 1). Of these, 224 genes were induced in high glucose conditions, whereas 59 were repressed (Fig. 1). Differentially expressed genes were selected at a threshold of 1.8-fold difference between groups with a significance level of p  0.01.
13666	18805	 1438	serum glucose	Compound	VEGFA	mRNA	0	1	11901189	Insulin-induced VEGF expression requires p38 MAPK and PI 3-kinase, whereas hyperglycemia-induced VEGF expression is HIF-1alpha-independent and requires PKC and p42/p44 MAPK.
16592	18805	10839	serum glucose	Compound	SLC6A6	mRNA	0	-1	12870156	These results demonstrate that high glucose considerably and specifically decreases intracellular taurine content, taurine transport activity, and TAUT mRNA, possibly through PKC-mediated transcriptional and posttranslational pathways
16869	18805	18255	serum glucose	Compound	VCL	mRNA	-1	1	15039483	from full text - Table 2. Large functional clusters of genes that exhibited differential expression in rat mesangial cells in response to high glucose: Cell cycle and proliferation and Cytoskeleton
 1689	18805	  114	serum glucose	Compound	CAPN6	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
17684	18805	19562	serum glucose	Compound	ACTR1A	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
17759	18805	10190	serum glucose	Compound	SEPT4	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
19641	18805	16486	serum glucose	Compound	SPP1	mRNA	1	1	14670931	Rho/Rho kinase pathway functions downstream of protein kinase C and the hexosamine pathways and upstream of ERK in mediating high-glucose-induced upregulation of osteopontin expression. Pitavastatin, an HMG-CoA reductase inhibitor, effectively suppressed abnormally upregulated expression of OPN mRNA
20428	18805	 6937	serum glucose	Compound	POLR1C	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
20664	18805	 9140	serum glucose	Compound	TGFBR1	mRNA	0	1	12939231	High glucose (20 mmol/L) increased VSMC TGF-beta1 and TGF-beta-R1 expression
20828	18805	12908	serum glucose	Compound	ENO1	mRNA	1	1	10811900	Table 1.   Transcripts differentially regulated in high vs. low glucose
21678	18805	 2572	serum glucose	Compound	CAV1	mRNA	0	-1	12679365	Caveolin-1 (Cav-1) is highly expressed in adult SCs, and changes in its expression can regulate signaling through Erb B2, a co-receptor that mediates the effects of neuregulins in promoting SC growth and differentiation. nerve growth factor antagonized the enhanced mitogenic response of SCs to neuregulin1-beta1 and inhibited the glucose-induced down-regulation of Cav-1 transcription, mRNA, and protein expression through p75NTR-dependent activation of JNK.
 2211	18805	 5419	serum glucose	Compound	TNF	mRNA	0	1	16728431	Exposure of bone marrow precursor cells from NOD mice to a hyperglycemic environment during differentiation into macrophages resulted in elevated levels of TLR2 and TLR4 and the cytokine TNFalpha.
23309	18805	 7455	serum glucose	Compound	CTSB	mRNA	0	1	 7621999	Exposure of cells to high glucose media resulted in significant reductions in collagenase and cathepsin B activities as well as impairment in gelatin-degrading activity. Collagenase IV and cathepsin B and D mRNA levels were also decreased by glucose loading.
23888	18805	 5783	serum glucose	Compound	CEBPB	mRNA	0	-1	15102854	transcription from the human C/EBPbeta gene is induced in response to endoplasmic reticulum stress, such as glucose deprivation, or treatment of cells with tunicamycin or thapsigargin.
24516	18805	 8958	serum glucose	Compound	RAB18	mRNA	-1	1	15039483	from full text - Table 4. Large functional clusters of genes that exhibited differential expression in rat mesangial cells in response to high glucose: Protein synthesis, sorting, and degradation
 2479	18805	17889	serum glucose	Compound	SLC2A4	mRNA	1	1	16885160	The expression of 283 genes was significantly changed at a threshold of 1.8-fold by switching from low glucose to high glucose conditions (Supplemental Table 1). Of these, 224 genes were induced in high glucose conditions, whereas 59 were repressed (Fig. 1). Differentially expressed genes were selected at a threshold of 1.8-fold difference between groups with a significance level of p  0.01.
24868	18805	 5863	serum glucose	Compound	MYC	mRNA	0	1	11848444	Results show that acute hyperglycaemia induces an up-regulation of seven major genes, four of which were not previously reported in the literature. Northern blot analyses, performed on these 4 genes, confirm macroarrays results for alphav, beta4, c-myc, and MUC18. Moreover, time course analysis (0, 2, 4, 8, 2, 16, 24 h) of alphav, beta4 c-myc, and MUC18 mRNA expression, observed by northern blot assays, showed a peak at time points situated between 2 to 8 h. The 3 other genes (ICAM-1, beta1, and IL-8), were shown by others to be significantly upregulated after glucose stimulation.
24935	18805	19864	serum glucose	Compound	FADS1	mRNA	0	1	11792729	after refeeding, there was a considerable reduction in the expression of both desaturases in SRebp1 null mice, showing a much lower level than in the re-fed wild-type mice
25276	18805	 5272	serum glucose	Compound	GCC2	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
 2553	18805	  326	serum glucose	Compound	TXNIP	mRNA	0	1	16885160	The expression of 283 genes was significantly changed at a threshold of 1.8-fold by switching from low glucose to high glucose conditions (Supplemental Table 1). Of these, 224 genes were induced in high glucose conditions, whereas 59 were repressed (Fig. 1). Differentially expressed genes were selected at a threshold of 1.8-fold difference between groups with a significance level of p  0.01.
25697	18805	  801	serum glucose	Compound	PNPLA3	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
25708	18805	 9645	serum glucose	Compound	6720489N17Rik	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
25752	18805	19166	serum glucose	Compound	TAGLN3	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
26491	18805	11970	serum glucose	Compound	C1orf85	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
27804	18805	 7688	serum glucose	Compound	RAB7L1	mRNA	0	1	14720509	The lysosomal genes neuraminidase, CLN3, and CLCN5 and the small GTP-binding proteins Rab7L1 and Arl7 were also increased. A Rab7L1-GFP fusion protein was overexpressed in human fibroblasts and was demonstrated to localize primarily to the Golgi apparatus, and in some cells to the membranes bounding vesicles in the perinuclear region.
27862	18805	 1166	serum glucose	Compound	SLC2A1	mRNA	-1	1	 8141777	Glucose deprivation generally resulted in a discrete decrease in the levels of all transporter mRNAs in all clones, one exception being GLUT2 GLUT4 was undetectable in all the clones.
29645	18805	13006	serum glucose	Compound	HMGCS2	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
 3058	18805	18599	serum glucose	Compound	GYS2	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
32353	18805	 3118	serum glucose	Compound	ACACA	mRNA	0	1	16885160	The expression of 283 genes was significantly changed at a threshold of 1.8-fold by switching from low glucose to high glucose conditions (Supplemental Table 1). Of these, 224 genes were induced in high glucose conditions, whereas 59 were repressed (Fig. 1). Differentially expressed genes were selected at a threshold of 1.8-fold difference between groups with a significance level of p  0.01.
34209	18805	13000	serum glucose	Compound	EEF2	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
35443	18805	18531	serum glucose	Compound	ICAM1	mRNA	0	1	11848444	Results show that acute hyperglycaemia induces an up-regulation of seven major genes, four of which were not previously reported in the literature. Northern blot analyses, performed on these 4 genes, confirm macroarrays results for alphav, beta4, c-myc, and MUC18. Moreover, time course analysis (0, 2, 4, 8, 2, 16, 24 h) of alphav, beta4 c-myc, and MUC18 mRNA expression, observed by northern blot assays, showed a peak at time points situated between 2 to 8 h. The 3 other genes (ICAM-1, beta1, and IL-8), were shown by others to be significantly upregulated after glucose stimulation.
36101	18805	12491	serum glucose	Compound	MCAM	mRNA	0	1	11848444	Results show that acute hyperglycaemia induces an up-regulation of seven major genes, four of which were not previously reported in the literature. Northern blot analyses, performed on these 4 genes, confirm macroarrays results for alphav, beta4, c-myc, and MUC18. Moreover, time course analysis (0, 2, 4, 8, 2, 16, 24 h) of alphav, beta4 c-myc, and MUC18 mRNA expression, observed by northern blot assays, showed a peak at time points situated between 2 to 8 h. The 3 other genes (ICAM-1, beta1, and IL-8), were shown by others to be significantly upregulated after glucose stimulation.
36314	18805	 3205	serum glucose	Compound	SKP1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
36330	18805	 9519	serum glucose	Compound	Acnat2	mRNA	0	1	14762175	Table 9. DNA repair and apoptosis genes
38299	18805	 6799	serum glucose	Compound	SLC2A5	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
39343	18805	 7862	serum glucose	Compound	CYBA	mRNA	0	1	12679469	The p22(phox) and HO-1 gene expressions were also determined during (plasma glucose 363 +/- 40 mg/dl) and after (125 +/- 11 mg/dl) metabolic decompensation in 10 type 2 diabetic patients. The correction of the metabolic milieu was associated with a 19% +/- 3% (P < 0.01) and 30% +/- 3% (P < 0.01) decrease in the p22(phox) and HO-1 gene expressions, respectively.
39944	18805	 6114	serum glucose	Compound	NFKBIA	mRNA	1	-1	17303805	We found that doubling fasting blood glucose values while maintaining plasma insulin in the fasting range modifies the expression of 316 genes in skeletal muscle and 336 genes in adipose tissue. More than 80% of them were downregulated during the clamp, indicating a drastic effect of acute high glucose, in the absence of insulin, on mRNA levels in human fat and muscle tissues.
40072	18805	13822	serum glucose	Compound	TSPAN5	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
40291	18805	 2153	serum glucose	Compound	EFHA1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
41273	18805	  313	serum glucose	Compound	COX7B	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
42777	18805	  763	serum glucose	Compound	Ces3a	mRNA	0	-1	14762175	Table 9. DNA repair and apoptosis genes
43544	18805	17125	serum glucose	Compound	PER2	mRNA	0	-1	12213820	We found among others immediately up-regulated genes encoding transcriptional regulators TIEG1, VDUP1, and HES1, in addition to cooperatively regulated genes that are associated with cholesterol biosynthesis and cell cycle. The immediate up-regulation of Tieg1 and Vdup1 expression was dependent on glucose metabolism but not on protein synthesis, suggesting that the transcriptional regulators mediate the glucose-induced down-regulation of Per1 and Per2 expression
45690	18805	 8412	serum glucose	Compound	LGALS1	mRNA	0	-1	11784718	Summary of cDNAs identified by SSH as being down-regulated in mesangial cells cultured in high glucose
45788	18805	 4835	serum glucose	Compound	PPARA	mRNA	0	-1	11792729	expression of Ppara was induced by the fasting and suppressed by refeeding, whereas the Srebf1c mRNA level showed the opposite response
46815	18805	 6850	serum glucose	Compound	Ces1e	mRNA	0	-1	14762175	Table 9. DNA repair and apoptosis genes
48513	18805	15438	serum glucose	Compound	TMEM27	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
48620	18805	19172	serum glucose	Compound	ACLY	mRNA	0	1	16885160	The expression of 283 genes was significantly changed at a threshold of 1.8-fold by switching from low glucose to high glucose conditions (Supplemental Table 1). Of these, 224 genes were induced in high glucose conditions, whereas 59 were repressed (Fig. 1). Differentially expressed genes were selected at a threshold of 1.8-fold difference between groups with a significance level of p  0.01.
49112	18805	 2802	serum glucose	Compound	BRD2	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
 4970	18805	12073	serum glucose	Compound	IRF1	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
49812	18805	 4701	serum glucose	Compound	FBP1	mRNA	0	1	16885160	The expression of 283 genes was significantly changed at a threshold of 1.8-fold by switching from low glucose to high glucose conditions (Supplemental Table 1). Of these, 224 genes were induced in high glucose conditions, whereas 59 were repressed (Fig. 1). Differentially expressed genes were selected at a threshold of 1.8-fold difference between groups with a significance level of p  0.01.
50292	18805	19526	serum glucose	Compound	COL4A1	mRNA	0	1	12882934	Glucose stimulation of TSP1 protein expression and TGF-beta bioactivity were also downregulated. TGF-beta-dependent fibronectin and type IV collagen expression under high glucose conditions were significantly reduced upon catalytic domain expression in transfected RMCs.
51597	18805	 5673	serum glucose	Compound	ID1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
52016	18805	18084	serum glucose	Compound	SARS	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
52732	18805	17478	serum glucose	Compound	ADIPOR2	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
53055	18805	16278	serum glucose	Compound	ID2	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
53243	18805	13017	serum glucose	Compound	MAFA	mRNA	0	-1	16154098	hyperglycemia suppresses MafA expression in vivo and that MafA inhibition can be prevented by transgenic expression of constitutively nuclear FoxO1 in beta cells.
53594	18805	 4691	serum glucose	Compound	FDPS	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
53694	18805	14116	serum glucose	Compound	PLIN2	mRNA	0	1	14762175	Table 9. DNA repair and apoptosis genes
53980	18805	11581	serum glucose	Compound	ITGB1	mRNA	1	1	11848444	Results show that acute hyperglycaemia induces an up-regulation of seven major genes, four of which were not previously reported in the literature. Northern blot analyses, performed on these 4 genes, confirm macroarrays results for alphav, beta4, c-myc, and MUC18. Moreover, time course analysis (0, 2, 4, 8, 2, 16, 24 h) of alphav, beta4 c-myc, and MUC18 mRNA expression, observed by northern blot assays, showed a peak at time points situated between 2 to 8 h. The 3 other genes (ICAM-1, beta1, and IL-8), were shown by others to be significantly upregulated after glucose stimulation.
54366	18805	12644	serum glucose	Compound	TOB1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
54372	18805	  991	serum glucose	Compound	INS	mRNA	0	1	12771145	Palmitate Decreases Glucose-stimulated Rat Insulin Promoter  Activity
55061	18805	 7690	serum glucose	Compound	ITGAV	mRNA	0	1	11848444	Results show that acute hyperglycaemia induces an up-regulation of seven major genes, four of which were not previously reported in the literature. Northern blot analyses, performed on these 4 genes, confirm macroarrays results for alphav, beta4, c-myc, and MUC18. Moreover, time course analysis (0, 2, 4, 8, 2, 16, 24 h) of alphav, beta4 c-myc, and MUC18 mRNA expression, observed by northern blot assays, showed a peak at time points situated between 2 to 8 h. The 3 other genes (ICAM-1, beta1, and IL-8), were shown by others to be significantly upregulated after glucose stimulation.
55191	18805	 9791	serum glucose	Compound	SLIRP	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
55380	18805	 8000	serum glucose	Compound	ACSS2	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
55738	18805	 2223	serum glucose	Compound	HES1	mRNA	0	1	12213820	We found among others immediately up-regulated genes encoding transcriptional regulators TIEG1, VDUP1, and HES1, in addition to cooperatively regulated genes that are associated with cholesterol biosynthesis and cell cycle. The immediate up-regulation of Tieg1 and Vdup1 expression was dependent on glucose metabolism but not on protein synthesis, suggesting that the transcriptional regulators mediate the glucose-induced down-regulation of Per1 and Per2 expression
55776	18805	18155	serum glucose	Compound	IER3	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
55985	18805	16973	serum glucose	Compound	Mlxipl	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
56129	18805	10811	serum glucose	Compound	FN1	mRNA	-1	1	10026205	Here, suppression subtractive hybridization identified 15 genes differentially induced when primary human mesangial cells are exposed to high glucose (30 mM versus 5 mM) in vitro. These genes included (a) known regulators of mesangial cell activation in diabetic nephropathy (fibronectin, caldesmon, thrombospondin, and plasminogen activator inhibitor-1), (b) novel genes, and (c) known genes whose induction by high glucose has not been reported. Prominent among the latter were genes encoding cytoskeleton-associated proteins and connective tissue growth factor (CTGF), a modulator of fibroblast matrix production.
56475	18805	 2554	serum glucose	Compound	NUDT7	mRNA	0	-1	14762175	Table 9. DNA repair and apoptosis genes
56781	18805	18995	serum glucose	Compound	FASN	mRNA	0	-1	14762175	Table 9. DNA repair and apoptosis genes
56839	18805	20050	serum glucose	Compound	PDIA3	mRNA	0	-1	10464281	is induced by glucose deprivation
57759	18805	 8036	serum glucose	Compound	CRAT	mRNA	0	1	14762175	Table 9. DNA repair and apoptosis genes
57970	18805	12957	serum glucose	Compound	BMS1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
59006	18805	18757	serum glucose	Compound	YARS	mRNA	0	-1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
59249	18805	 8309	serum glucose	Compound	KRIT1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
59697	18805	 6309	serum glucose	Compound	GPBP1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
60024	18805	12976	serum glucose	Compound	IL8	mRNA	0	1	11848444	Results show that acute hyperglycaemia induces an up-regulation of seven major genes, four of which were not previously reported in the literature. Northern blot analyses, performed on these 4 genes, confirm macroarrays results for alphav, beta4, c-myc, and MUC18. Moreover, time course analysis (0, 2, 4, 8, 2, 16, 24 h) of alphav, beta4 c-myc, and MUC18 mRNA expression, observed by northern blot assays, showed a peak at time points situated between 2 to 8 h. The 3 other genes (ICAM-1, beta1, and IL-8), were shown by others to be significantly upregulated after glucose stimulation.
60466	18805	 8312	serum glucose	Compound	PPP1R3B	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
61254	18805	 1552	serum glucose	Compound	ODC1	mRNA	1	1	10811900	Table 1.   Transcripts differentially regulated in high vs. low glucose
61359	18805	  140	serum glucose	Compound	SLC25A10	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
61780	18805	 1730	serum glucose	Compound	KLF10	mRNA	1	1	12213820	An analysis with high density oligonucleotide microarrays identified >100 glucose-regulated genes. We found among others immediately up-regulated genes encoding transcriptional regulators TIEG1, VDUP1, and HES1
 6245	18805	12449	serum glucose	Compound	TLR2	mRNA	0	1	16728431	Exposure of bone marrow precursor cells from NOD mice to a hyperglycemic environment during differentiation into macrophages resulted in elevated levels of TLR2 and TLR4 and the cytokine TNFalpha.
  633	18805	  156	serum glucose	Compound	SCFD1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
63996	18805	 3679	serum glucose	Compound	GPD1	mRNA	0	1	16885160	The expression of 283 genes was significantly changed at a threshold of 1.8-fold by switching from low glucose to high glucose conditions (Supplemental Table 1). Of these, 224 genes were induced in high glucose conditions, whereas 59 were repressed (Fig. 1). Differentially expressed genes were selected at a threshold of 1.8-fold difference between groups with a significance level of p  0.01.
65650	18805	  707	serum glucose	Compound	GPI	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
65767	18805	11283	serum glucose	Compound	ME1	mRNA	0	1	16885160	Table 1: genes induced by both glucose and inhibited by dominant negative Mlx (dn-MLX blocks DNA binding of the glucose-induced MLX:MLXIPL transcription factor complex)
  672	18805	14336	serum glucose	Compound	PDK2	mRNA	0	1	16885160	The expression of 283 genes was significantly changed at a threshold of 1.8-fold by switching from low glucose to high glucose conditions (Supplemental Table 1). Of these, 224 genes were induced in high glucose conditions, whereas 59 were repressed (Fig. 1). Differentially expressed genes were selected at a threshold of 1.8-fold difference between groups with a significance level of p  0.01.
 6805	18805	13125	serum glucose	Compound	CBX3	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
 7582	18805	15080	serum glucose	Compound	SPTY2D1	mRNA	0	1	15161754	table 1 - Gene regulation by glucose, ranked according to fold change, is compared with that by KCl-induced depolarization and with insulin treatment
10006	10111	 4597	fulvestrant	Compound	UBE2C	mRNA	1	-1	14973112	Table 6 Genes up-regulated or down-regulated by one or more of the compounds [ICI, Ral or trans-hydroxytamoxifen (TOT)-1 M] but not by E2 (10 nM)
11335	10111	12387	fulvestrant	Compound	MYB	mRNA	0	-1	14973112	Table 6 Genes up-regulated or down-regulated by one or more of the compounds [ICI, Ral or trans-hydroxytamoxifen (TOT)-1 M] but not by E2 (10 nM)
 1248	10111	18332	fulvestrant	Compound	NDRG1	mRNA	0	1	10395947	It was increased in mammary carcinoma MCF-7 cells treated by retinoids and by the anti-estrogen ICI 182,780 but not by 4-hydroxytamoxifen.
27216	10111	  618	fulvestrant	Compound	WEE1	mRNA	-1	-1	14973112	Table 6 Genes up-regulated or down-regulated by one or more of the compounds [ICI, Ral or trans-hydroxytamoxifen (TOT)-1 M] but not by E2 (10 nM)
38806	10111	10290	fulvestrant	Compound	FOXM1	mRNA	1	-1	14973112	Table 6 Genes up-regulated or down-regulated by one or more of the compounds [ICI, Ral or trans-hydroxytamoxifen (TOT)-1 M] but not by E2 (10 nM)
41097	10111	11896	fulvestrant	Compound	MCM5	mRNA	1	-1	14973112	Table 6 Genes up-regulated or down-regulated by one or more of the compounds [ICI, Ral or trans-hydroxytamoxifen (TOT)-1 M] but not by E2 (10 nM)
45063	10111	  564	fulvestrant	Compound	WFDC1	mRNA	0	1	15677758	antiestrogen treatment led to up-regulation of ps20.
47757	10111	13695	fulvestrant	Compound	CUZD1	mRNA	0	-1	11416020	_ Ariadne: UO-44 gene expression in the uterus is strictly regulated  by estrogens, tamoxifen, and GH, whereas the pure antiestrogen ICI 182780 is inhibitory. [Expression]
55383	10111	12303	fulvestrant	Compound	SOCS3	mRNA	0	-1	16055089	The suppressor of cytokine signalling (SOCS) protein family negatively regulates cytokine action. In this study, we investigated the effects of estrogen (E2) on SOCS-3 expression in T47D and MCF-7 human breast cancer cells. Real-time PCR analysis of E2-treated T47D cells revealed a ligand and time-dependent increase in of SOCS-3 mRNA levels. Cloning of a 1.7 kb fragment of the human SOCS-3 5p flanking sequence, and subsequent analysis of potential transcription factor-binding sites identified an incomplete ERE motif located -1493 to -1489 upstream of the start site. Transient transfection of the cloned fragment in MCF-7 cells showed that both E2 and genistein treatment caused an increase in reporter gene activity, which was inhibited by co-treatment with ICI 182,780. Chromatin immunoprecipitation analysis revealed an E2 and time-dependent recruitment of ERalpha to the E2 responsive region of the human SOCS-3 promoter. In summary, this study shows that ERalpha directly regulates human SOCS-3 promoter activity in human breast cancer cells, thus modulating cytokine activity.
58406	10111	15117	fulvestrant	Compound	PGR	mRNA	0	-1	12779079	Modified assertion
 5898	10111	 5636	fulvestrant	Compound	AURKA	mRNA	1	-1	14973112	Table 6 Genes up-regulated or down-regulated by one or more of the compounds [ICI, Ral or trans-hydroxytamoxifen (TOT)-1 M] but not by E2 (10 nM)
  783	10111	10012	fulvestrant	Compound	CDK8	mRNA	1	-1	14973112	Table 6 Genes up-regulated or down-regulated by one or more of the compounds [ICI, Ral or trans-hydroxytamoxifen (TOT)-1 M] but not by E2 (10 nM)
 8849	10111	12565	fulvestrant	Compound	FAM102A	mRNA	0	-1	14605097	EEIG1 was expressed in ER-positive but not in ER-negative breast cancer cell lines.  EEIG1 expression was repressed by antiestrogens 4-OH-tamoxifen and ICI 182,780
54356	 6935	 1814	NANOG	Protein	POU5F1	mRNA	-1	1	16518401	Among the Nanog-bound genes, notable ones are Pou5f1, Sox2, Rif1 and REST. Depletion of Nanog resulted in downregulation of their expression (Fig. 6f),
11231	16585	13301	Testosterone propionate	Compound	CCNB1	mRNA	0	1	11451350	CDK1 and CDK2, and cyclin A and cyclin B1 messenger RNAs were decreased 6 days after castration, increased 6-12 hours after TP treatment, and were expressed at high levels in recurrent CWR22 tumor
35589	16585	 1857	Testosterone propionate	Compound	CCNA1	mRNA	0	1	11451350	CDK1 and CDK2, and cyclin A and cyclin B1 messenger RNAs were decreased 6 days after castration, increased 6-12 hours after TP treatment, and were expressed at high levels in recurrent CWR22 tumor
35603	16585	 1571	Testosterone propionate	Compound	RBL2	mRNA	-1	1	12435483	Subcutaneous injection of 5alpha-dihydrotestosterone as well as testosterone propionate to PN2 neonatal rats significantly increased p130 gene expression at PN3, whereas estradiol benzoate did not have a significant effect. These results suggest that expression of the p130 gene in the neonatal rat hypothalamus is responsive to androgens and may be involved in sexual differentiation of the brain.
48529	16585	 2627	Testosterone propionate	Compound	CDK2	mRNA	0	1	11451350	CDK1 and CDK2, and cyclin A and cyclin B1 messenger RNAs were decreased 6 days after castration, increased 6-12 hours after TP treatment, and were expressed at high levels in recurrent CWR22 tumor
 9327	16585	 8814	Testosterone propionate	Compound	CDK1	mRNA	0	1	11451350	CDK1 and CDK2, and cyclin A and cyclin B1 messenger RNAs were decreased 6 days after castration, increased 6-12 hours after TP treatment, and were expressed at high levels in recurrent CWR22 tumor
10970	15948	15395	E2F Family	Protein	ORC1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
11072	15948	11467	E2F Family	Protein	TFDP1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
17752	15948	20005	E2F Family	Protein	FBXO5	mRNA	0	1	11988738	Emi1 promotes mitotic entry in Xenopus laevis embryos by inhibiting the APC(Cdc20) ubiquitination complex to allow accumulation of cyclin B. We show here that human Emi1 (hEmi1) functions to promote cyclin A accumulation and S phase entry in somatic cells by inhibiting the APC(Cdh1) complex. At the G1-S transition, hEmi1 is transcriptionally induced by the E2F transcription factor, much like cyclin A. hEmi1 overexpression accelerates S phase entry and can override a G1 block caused by overexpression of Cdh1 or the E2F-inhibitor p105 retinoblastoma protein (pRb). Depleting cells of hEmi1 through RNA interference prevents accumulation of cyclin A and inhibits S phase entry. These data suggest that E2F can activate both transcription of cyclin A and the hEmi1-dependent stabilization of APC(Cdh1) targets, such as cyclin A, to promote S phase entry.
 1800	15948	 2383	E2F Family	Protein	EZH1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
23025	15948	 6929	E2F Family	Protein	NFATC1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
24847	15948	 5863	E2F Family	Protein	MYC	mRNA	0	1	12757710	We identified an age-specific C/EBPalpha-Rb-E2F4 complex that binds to E2F-dependent promoters and represses these genes. The C/EBPalpha-Rb-E2F4 complex occupies the c-myc promoter and blocks induction of c-myc in livers of old animals
29440	15948	18942	E2F Family	Protein	CDKN2D	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
29731	15948	 2566	E2F Family	Protein	CASP7	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
29872	15948	10162	E2F Family	Protein	CDKN2C	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
  299	15948	 6461	E2F Family	Protein	POLA1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
32182	15948	 3228	E2F Family	Protein	MCM6	mRNA	0	1	10327050	Our results demonstrated that the growth-regulated expression of mammalian MCM5 and MCM6 genes, and presumably other MCM members, is primarily regulated by E2F through binding to multiple E2F sites in the promoters.
33459	15948	12280	E2F Family	Protein	KPNA2	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
36036	15948	 7956	E2F Family	Protein	BRCA1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
37181	15948	11378	E2F Family	Protein	TMEM126B	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
37291	15948	19646	E2F Family	Protein	ANXA8L2	mRNA	1	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
39568	15948	13744	E2F Family	Protein	CDKN1B	mRNA	-1	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
40355	15948	 6997	E2F Family	Protein	NFATC3	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
41088	15948	11896	E2F Family	Protein	MCM5	mRNA	1	1	10327050	Our results demonstrated that the growth-regulated expression of mammalian MCM5 and MCM6 genes, and presumably other MCM members, is primarily regulated by E2F through binding to multiple E2F sites in the promoters.
44155	15948	 6531	E2F Family	Protein	CCNE1	mRNA	0	1	11867723	Table 1.  E2f responsive genes upregulated 4-fold or higher by the IE86 protein (cytomegalovirus).  FROM FULL TEXT: An increase in the level of steady-state RNA from E2F-responsive genes was detected by Northern blot analysis in Ad-IE86 transduced cells but not in Ad-GFP transduced cells (Fig. 4). E2F-responsive genes such as A-myb, cdk-2, RR2, MCM4, and Cdc7 were not included in Table 1 because these genes were up-regulated 4-fold or higher in one microarray but not in both microarrays (data not shown).  JParker, 05282008
45395	15948	 3512	E2F Family	Protein	CASP3	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
45684	15948	10242	E2F Family	Protein	NUSAP1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
48684	15948	14467	E2F Family	Protein	HMGB3	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
48919	15948	15613	E2F Family	Protein	HOXA7	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
 5058	15948	12413	E2F Family	Protein	HOXA9	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
51538	15948	 5120	E2F Family	Protein	MCM4	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
51853	15948	18025	E2F Family	Protein	WDR76	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
52759	15948	20220	E2F Family	Protein	BUB1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
  536	15948	14107	E2F Family	Protein	AURKB	mRNA	0	-1	12446714	E2F mediates sustained G2 arrest and down-regulation of Stathmin and AIM-1 expression in response to genotoxic stress.
53930	15948	14105	E2F Family	Protein	YY1	mRNA	0	-1	16918502	The repressive effects of prohibitin on the YY1 promoter were mediated through E2F binding sites, as seen by mutational analysis and chromatin immunoprecipitation assays. Further, depletion of E2F1 prevented prohibitin from repressing the YY1 promoter.
54386	15948	 5827	E2F Family	Protein	CDK7	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
59065	15948	 3851	E2F Family	Protein	MCM2	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
59331	15948	 1297	E2F Family	Protein	DCK	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
59588	15948	18432	E2F Family	Protein	RANBP1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
 6029	15948	10651	E2F Family	Protein	RTCD1	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
 6720	15948	 5011	E2F Family	Protein	HOXA10	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
 7951	15948	 9734	E2F Family	Protein	ID4	mRNA	0	1	12020800	E2F1,2,3 indicated in Rb-independent repression of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1)
  901	15948	18314	E2F Family	Protein	STMN1	mRNA	0	-1	12446714	E2F mediates sustained G2 arrest and down-regulation of Stathmin and AIM-1 expression in response to genotoxic stress.
11209	 2191	13301	HDAC Family	Protein	CCNB1	mRNA	0	-1	12054478	We conclude that histone deacetylation contributes to the repression of cyclin B1 expression in G(0) and G(1), and that this mechanism requires, in part, the E-box.
23760	 2191	 6636	HDAC Family	Protein	BCL2L1	mRNA	0	1	15123634	inhibitors of deacetylase activity sensitized colon cancer cells to IFNgamma-induced apoptosis through cooperative negative regulation of Bcl-x expression
36794	 2191	 8660	HDAC Family	Protein	IL4	mRNA	0	-1	12097386	Ariadne: Thus, Bcl6 binds to the IL-4 silencer region in Th1  cells and may deacetylate histones of the chromosomal region to repress  expression of those cytokine genes by recruiting the SMRT and histone  deacetylase complex.
42198	 2191	 2152	HDAC Family	Protein	HLA-DRA	mRNA	0	-1	11533238	treatment of these Rb-defective tumor cell lines with histone deacetylase, HDAC, inhibitors rescued IFN-gamma-inducible HLA-DRA and -DRB mRNA and cell surface protein expression, demonstrating repression of these genes by endogenous cellular HDAC activity
45703	 2191	 8412	HDAC Family	Protein	LGALS1	mRNA	0	-1	 9917496	We studied the roles of butyrate and galectin-1 in the induction of differentiation and apoptosis in the prostate cancer cell line LNCaP. Treatment of LNCaP cells with butyrate resulted in induction of galectin-1 expression in a time- and dose-dependent manner.
53115	 2191	 1187	HDAC Family	Protein	PTPLAD1	mRNA	0	-1	16516406	Histone deacetylase inhibitors (HDIs) induced expression of the B-ind1 protein that is a component of Rac-1-signaling pathways leading to the modulation of gene expression.
55525	 2191	17318	HDAC Family	Protein	KRT23	mRNA	0	-1	11135429	K23 mRNA was highly induced by NaBu in different pancreatic cancer cells. Trichostatin A (TSA), a potent and specific inhibitor of histone deacetylase, similarly induced K23 mRNA expression.
58553	 2191	  497	HDAC Family	Protein	SIRT1	mRNA	-1	1	14523559	Chemically different types of HDAC inhibitors, such as TSA, apicidin, SAHA, M344 and n-butyrate induced remarkably similar responses in SIRT1-7 mRNA expression patterns
 7463	 2191	19396	HDAC Family	Protein	C3	mRNA	0	1	10851266	Like sodium butyrate, trichostatin A enhanced TNF-alpha-induced C3 secretion, but suppressed TNF-alpha-induced factor B secretion. These effects were also observed at the level of mRNA. Trichostatin A modulated TNF-alpha-induced C3 and factor B secretion in a manner similar to that induced by sodium butyrate, suggesting that both sodium butyrate and trichostatin A exert certain counter-regulatory effects associated with histone hyperacetylation
17025	 3014	 3722	gamma-tocopherol	Compound	PPARG	mRNA	0	1	19838939	Our previous studies in the colon have demonstrated that gamma-tocopherol treatment could upregulate the expression of peroxisome proliferator-activated preceptors (PPAR) gamma
19932	 3014	 5757	gamma-tocopherol	Compound	ADIPOQ	mRNA	0	1	19833717	Adiponectin mRNA and protein secretion were also increased by vitamin E (alpha- and gamma-tocopherol) in 3T3-L1 cells
28314	 3014	10956	gamma-tocopherol	Compound	TNFRSF10B	mRNA	0	1	18022315	gammaT was shown to induce cancer cells but not normal cells to undergo apoptosis, sensitize cancer cells to Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL)-induced apoptosis, and increase death receptor 5 (DR5) mRNA, protein and cell surface expression. Knockdown of DR5 attenuated gammaT-induced apoptosis. Investigations of post-receptor signaling showed: caspase-8, Bid and Bax activation, increases in mitochondria permeability, cytochrome c release and caspase-9 activation
 3147	 3014	16645	gamma-tocopherol	Compound	CCND1	mRNA	0	-1	19838939	Expression of proteins downstream of the PPAR gamma pathway were examined. Cyclin D1, cyclin D3, bcl-2, and NFkappa B proteins were found to be downregulated following gamma-tocopherol treatment
40978	 3014	 4582	gamma-tocopherol	Compound	NOS3	mRNA	1	1	17825498	In rodents, gamma-tocopherol is reported to increase arterial expression of eNOS while up-regulating an activating phosphorylation of this enzyme.
45347	 3014	14987	gamma-tocopherol	Compound	BCL2	mRNA	1	-1	19838939	Expression of proteins downstream of the PPAR gamma pathway were examined. Cyclin D1, cyclin D3, bcl-2, and NFkappa B proteins were found to be downregulated following gamma-tocopherol treatment
47833	 3014	10326	gamma-tocopherol	Compound	CCND3	mRNA	0	-1	19838939	Expression of proteins downstream of the PPAR gamma pathway were examined. Cyclin D1, cyclin D3, bcl-2, and NFkappa B proteins were found to be downregulated following gamma-tocopherol treatment
48672	 3014	19384	gamma-tocopherol	Compound	ALOX15B	mRNA	0	1	19838939	Growth arrest (40%) and PPAR gamma mRNA and protein upregulation was achieved with gamma-tocopherol within 6 h. gamma-Tocopherol-mediated growth arrest was demonstrated to be PPAR gamma dependent using the agonist GW9662 and a PPAR gamma dominant negative vector. gamma-tocopherol was shown not to be a direct PPAR gamma ligand, but rather 15-S-HETE (an endogenous PPAR gamma ligand) was upregulated by gamma-tocopherol treatment. 15-Lipoxygenase-2, a tumor suppressor and the enzyme that converts arachidonic acid to 15-S-HETE, was upregulated at 3 h following gamma-tocopherol treatment.
66337	 3014	18006	gamma-tocopherol	Compound	NFKB1	mRNA	0	-1	19838939	Expression of proteins downstream of the PPAR gamma pathway were examined. Cyclin D1, cyclin D3, bcl-2, and NFkappa B proteins were found to be downregulated following gamma-tocopherol treatment
12733	17303	13434	MTF1	Protein	HIF1A	mRNA	0	1	16216223	Loss of MTF-1 in transformed Mtf1 null mouse embryonic fibroblasts (MEFs) results in an attenuation of nuclear HIF-1alpha protein accumulation, HIF-1 transcriptional activity, and expression of an established HIF-1 target gene, glucose transporter-1 (Glut1)
14546	17303	13318	MTF1	Protein	ACVR2B	mRNA	0	-1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
20606	17303	19120	MTF1	Protein	HSPA5	mRNA	0	1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
27831	17303	12681	MTF1	Protein	AFP	mRNA	0	1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
27871	17303	 1166	MTF1	Protein	SLC2A1	mRNA	-1	1	16216223	Loss of MTF-1 in transformed Mtf1 null mouse embryonic fibroblasts (MEFs) results in an attenuation of nuclear HIF-1alpha protein accumulation, HIF-1 transcriptional activity, and expression of an established HIF-1 target gene, glucose transporter-1 (Glut1)
33626	17303	 6887	MTF1	Protein	RBP4	mRNA	0	1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
45657	17303	 6491	MTF1	Protein	NFYB	mRNA	0	-1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
46565	17303	19536	MTF1	Protein	ARHGAP1	mRNA	0	1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
49274	17303	 4689	MTF1	Protein	SEPT7	mRNA	0	-1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
50185	17303	10283	MTF1	Protein	BMPR1B	mRNA	0	1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
 6027	17303	12258	MTF1	Protein	PMP22	mRNA	0	1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
61111	17303	15274	MTF1	Protein	LCN1	mRNA	0	1	11266553	We have analyzed the binding properties of these MREs in EMSAs and found them to bind to MTF-1 (Fig. 2). Furthermore, we tested fusion constructs in which the human tear lipocalin upstream region was fused to the OVEC reporter gene. In cell transfection experiments the tear lipocalin promoter could indeed confer zinc/MTF-1-responsive expression on the reporter gene
  842	17303	 1146	MTF1	Protein	GCLC	mRNA	0	1	11266553	Previously we found by northern blot analysis that gamma-GCShc mRNA is down- regulated in E13.5 MTF-1 knockout embryos
 9697	17303	 7296	MTF1	Protein	FGFR1	mRNA	0	1	11266553	Here we report on a multi-pronged search for potential target genes of MTF-1, including microarray screening, SABRE selective amplification, a computer search for MREs (DNA-binding sites of MTF-1) and transfection of reporter genes driven by candidate gene promoters.
11712	10489	11709	NOS2	Protein	UCP2	mRNA	0	-1	11003590	Modified assertion
14964	10489	 3861	NOS2	Protein	TIMP2	mRNA	0	-1	18796497	Here, we had also found that the pretreatment of L-NAME to A549 cells diminished the gNOregulated protein and mRNA levels of MMP-2 and TIMP-2 (Figs. 4B-E).
16479	10489	18083	NOS2	Protein	BNIP3	mRNA	-1	-1	11592958	Modified assertion
37367	10489	 9189	NOS2	Protein	MMP2	mRNA	0	1	18796497	Here, we had also found that the pretreatment of L-NAME to A549 cells diminished the gNOregulated protein and mRNA levels of MMP-2 and TIMP-2 (Figs. 4B-E).
45873	10489	 9262	NOS2	Protein	CYP1A1	mRNA	0	1	17588258	Both TNF-alpha and LPS repressed the beta-naphthoflavone (betaNF)-mediated induction of Cyp1a1 and Nqo1 at mRNA and activity levels. The downregulation of Cyp1a1, but not Nqo1, was significantly prevented by L-NIL, a Nos2 inhibitor.
60431	10489	 5024	NOS2	Protein	CCL5	mRNA	0	-1	10727427	Modified assertion
21537	13337	17505	Isoproterenol	Compound	LGALS12	mRNA	0	-1	12370119	treatment of 3T3-L1 cells for 16 h with 10 micromol/l isoproterenol, 100 nmol/l insulin, 0.6 nmol/l tumor necrosis factor alpha (TNFalpha), and 100 nmol/l dexamethasone reduced galectin-12 gene expression between 47% and 85%.
25455	13337	 5701	Isoproterenol	Compound	ID3	mRNA	0	1	10585876	We here demonstrated that there was a dramatic rise of Id2 and Id3 mRNA levels when 3T3-L1 adipocytes or isolated rat fat cells were exposed to lipolytic and anti-lipogenic agents, forskolin and isoproterenol.
38736	13337	18764	Isoproterenol	Compound	AKT1	mRNA	1	1	18086945	Table 1. Downregulation of Growth Signaling Pathways in Isoproterenol-Stimulated Versus MG132-Cotreated Cardiomocytes (>2 fold reduction in gene expression in MG132-cotreated cells)
 4097	13337	 9978	Isoproterenol	Compound	GNAI2	mRNA	1	1	18086945	Table 1. Downregulation of Growth Signaling Pathways in Isoproterenol-Stimulated Versus MG132-Cotreated Cardiomocytes (>2 fold reduction in gene expression in MG132-cotreated cells)
53049	13337	16278	Isoproterenol	Compound	ID2	mRNA	0	1	10585876	We here demonstrated that there was a dramatic rise of Id2 and Id3 mRNA levels when 3T3-L1 adipocytes or isolated rat fat cells were exposed to lipolytic and anti-lipogenic agents, forskolin and isoproterenol.
23702	  445	 8837	POU2F2	Protein	IL5	mRNA	0	1	10491186	As shown in Fig. 5B , IL-5 promoter activity could be induced significantly in the presence of Oct-2 in either unstimulated or PMA/A23187-stimulated Jurkat cells in comparison to cotransfection with the pCG control.....However, the ability of both octamer factors to activate the IL-5 reporter gene was reduced significantly when the octamer binding site in CLE0 was destroyed confirming the importance of CLE0 in the transcriptional activation by Oct proteins.
28732	  445	 3434	POU2F2	Protein	IVL	mRNA	0	1	15120610	Octamer-binding sites were noticed in this fragment and the specific binding of Oct-2 transcription factor was detected. Oct-2 appears to be implicated in an epithelial-specific repression activity recorded only in keratinocytes and C33-A cell line. Overexpression of Oct-2 repressed the involucrin promoter activity in epithelial cells and in the presence of the silencer element.
33450	  445	 6984	POU2F2	Protein	RETN	mRNA	0	1	17107342	These results show that Oct-2 exists in RAW264.7 macrophages and binds to the Octamer element of the resistin promoter.....Figure 3 Oct-2 transactivates the resistin promoter
36780	  445	 8660	POU2F2	Protein	IL4	mRNA	0	-1	11781715	In addition, over-expression of either Oct-1 or Oct-2 decreased wild-type IL-4 promoter activity, while increasing IL-2 promoter activity.....Thus, the transcription factors, Oct-1 and Oct-2, appear to decrease IL-4 transcription, via interaction with the proximal octamer site located between the IL-4 promoter proximal NFAT binding sites, P0 and P1, while enhancing IL-2 gene transcription.
45356	  445	14987	POU2F2	Protein	BCL2	mRNA	1	1	16186795	Furthermore, Oct-2 induced bcl-2 promoter activity and mediated this effect through three regions in the bcl-2 P2 promoter. Although these regions did not contain canonical octamer motifs, we observed the direct interaction of Oct-2 with all three sites both in vitro by EMSA and in vivo by chromatin immunoprecipitation assay.
48600	  445	 6071	POU2F2	Protein	CD79B	mRNA	0	1	10679093	This  octamer motif is a major determinant of B29 promoter activity in that mutations  that eliminated Oct-1 and Oct-2 binding also abolished B29 promoter function (  5 ).
58157	  445	18845	POU2F2	Protein	MUCL1	mRNA	0	1	16720387	Site-directed mutagenesis of a putative octamer-binding transcription factor binding site located within this latter region led to a strong decrease of the transcriptional activity of the SBEM promoter. Furthermore, transient over-expression of Oct1 and Oct2 not only increased SBEM promoter reporter activity, but also enhanced endogenous SBEM mRNA level.
23590	19445	 4571	Acetaminophen	Compound	GADD45B	mRNA	0	1	15618236	Table II. Changes in expression in liver determined by QRT-PCR after treatment for 2 weeks with different known carcinogens and non-carcinogens
 2774	19445	  908	Acetaminophen	Compound	MMP9	mRNA	0	1	14550746	Acetaminophen-induced expression of MCP-1, IL-1beta, CTGF, and MMP-9 mRNA was also delayed or reduced in TNFR1(-/-) mice relative to wild-type mice.
40802	19445	13739	Acetaminophen	Compound	CTGF	mRNA	0	1	14550746	Acetaminophen-induced expression of MCP-1, IL-1beta, CTGF, and MMP-9 mRNA was also delayed or reduced in TNFR1(-/-) mice relative to wild-type mice.
44465	19445	13271	Acetaminophen	Compound	CCL2	mRNA	0	1	14550746	Acetaminophen-induced expression of MCP-1, IL-1beta, CTGF, and MMP-9 mRNA was also delayed or reduced in TNFR1(-/-) mice relative to wild-type mice.
46674	19445	 3471	Acetaminophen	Compound	IL1B	mRNA	0	1	14550746	Acetaminophen-induced expression of MCP-1, IL-1beta, CTGF, and MMP-9 mRNA was also delayed or reduced in TNFR1(-/-) mice relative to wild-type mice.
63866	19445	12543	Acetaminophen	Compound	IGFBP1	mRNA	-1	1	15618236	Table II. Changes in expression in liver determined by QRT-PCR after treatment for 2 weeks with different known carcinogens and non-carcinogens
19716	17323	16486	lipid	Compound	SPP1	mRNA	1	1	15885730	AS rats experienced extensive fat accumulation and minimal liver injury. Moderate induction in OPN was observed in AS group.
 4740	17323	 7009	lipid	Compound	SREBF1	mRNA	0	1	15680331	We show here that high-fat feeding, which induces hyperlipidemia and atherogenesis, stimulates the expression of both PGC-1beta and SREBP1c and 1a in liver.
 9193	17323	 8408	lipid	Compound	PPARGC1B	mRNA	0	1	15680331	We show here that high-fat feeding, which induces hyperlipidemia and atherogenesis, stimulates the expression of both PGC-1beta and SREBP1c and 1a in liver.
11156	  518	 9789	NOS3	Protein	HSPE1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
13880	  518	17250	NOS3	Protein	PTGS2	mRNA	0	1	12881220	Modified assertion
 2281	  518	 5419	NOS3	Protein	TNF	mRNA	0	1	12506117	Modified assertion
23845	  518	 3648	NOS3	Protein	P4HA1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
26481	  518	 7394	NOS3	Protein	BAG3	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
28228	  518	 7832	NOS3	Protein	THBS1	mRNA	-1	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
29072	  518	  620	NOS3	Protein	PHLDA1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
35795	  518	 9011	NOS3	Protein	HSPH1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
37131	  518	12112	NOS3	Protein	TH	mRNA	0	1	12181441	Modified assertion
42058	  518	13115	NOS3	Protein	EGR1	mRNA	-1	-1	10436166	Treatment of ECs with an NO donor, S-nitroso-N-acetylpenicillamine (SNAP) or 3-morpholinosydnonimine (SIN-1), inhibited this shear stress-induced Egr-1 expression.
42906	  518	 7577	NOS3	Protein	HSP90AA1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
44227	  518	 9200	NOS3	Protein	PCNA	mRNA	0	-1	10330227	Modified assertion
44413	  518	13271	NOS3	Protein	CCL2	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
 5116	  518	 2649	NOS3	Protein	DNAJB1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
57262	  518	 5741	NOS3	Protein	RDBP	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
58335	  518	 8795	NOS3	Protein	MORF4L2	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
59011	  518	 4174	NOS3	Protein	STBD1	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
60115	  518	15187	NOS3	Protein	DDX3Y	mRNA	0	1	12709511	Table 2. Genes with similar changes in expression in NOS3-/- and NOS1-/- relative to WT
11763	 6117	 9867	fenofibrate	Compound	MAPK1	mRNA	0	-1	11474486	We identified a novel target in liver, mitogen-activated phosphokinase phosphatase 1, whose down-regulation by PPAR-alpha agonists may improve insulin sensitivity in that tissue by prolonging insulin responses.
16768	 6117	13585	fenofibrate	Compound	FADS2	mRNA	0	1	11792729	administration of fibrate, a pharmacological ligand for Ppar alpha, caused a significant increase in expression of both desaturases
24930	 6117	19864	fenofibrate	Compound	FADS1	mRNA	0	1	11792729	administration of fibrate, a pharmacological ligand for Ppar alpha, caused a significant increase in expression of both desaturases
33390	 6117	11976	fenofibrate	Compound	PDK4	mRNA	0	1	19395589	Additionally, expression of PDK4, CPT1-M {Official Gene Symbol: CPT1B}, CPT2, and FACO {Official Gene Symbol: ACOX1} mRNAs was increased.
36664	 6117	11314	fenofibrate	Compound	PCK2	mRNA	-1	-1	11474486	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.
45317	 6117	17025	fenofibrate	Compound	APOA1	mRNA	0	1	12882972	Staels et. al reports that treatment with a Ppara agonist, fenofibrate, markedly reduced heaptic apoA1 mRNA. In contrast, Vu-Dac et. al, reported that fibrates increase human apoA1 production due to stimulation of apoAI gene expression in liver.
45702	 6117	 8412	fenofibrate	Compound	LGALS1	mRNA	0	1	11798191	From chart, results for a greater than 2 fold change
51160	 6117	11839	fenofibrate	Compound	PCK1	mRNA	0	-1	11474486	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.
52620	 6117	  183	fenofibrate	Compound	MGST3	mRNA	0	1	11798191	From chart, results for a greater than 2 fold change
52985	 6117	 5718	fenofibrate	Compound	APOC3	mRNA	0	-1	11474486	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.
  859	 6117	  759	fenofibrate	Compound	ST3GAL6	mRNA	-1	-1	11798191	From chart, results for a greater than 2 fold change
 1411	18355	20060	RAR Family	Protein	BCL2A1	mRNA	0	1	11201846	Am80-induced expression of bfl-1 and suppression of bcl-2
39527	18355	13230	RAR Family	Protein	TCF3	mRNA	0	1	15744343	In addition, a strong downregulation of E2A was observed.
45379	18355	14987	RAR Family	Protein	BCL2	mRNA	1	-1	11201846	Am80-induced expression of bfl-1 and suppression of bcl-2
51175	18355	11839	RAR Family	Protein	PCK1	mRNA	0	1	11399762	In contrast, RAR/RAR, RAR/thyroid receptor, RAR/RXR, COUP-TF, and HNF-4  activate expression of the PEPCK gene via gAF1/PCK1 in hepatocytes ( 39 , 40 ,  59 , 60 ).
51619	18355	 5673	RAR Family	Protein	ID1	mRNA	0	1	15744343	ATRA induced a rapid increase in ID1 and ID2, both in the APL cell line NB4 as well as in primary patient cells
53080	18355	16278	RAR Family	Protein	ID2	mRNA	0	1	15744343	ATRA induced a rapid increase in ID1 and ID2, both in the APL cell line NB4 as well as in primary patient cells
58642	18355	15470	RAR Family	Protein	RARRES2	mRNA	0	1	14675762	homology to neuropeptide and chemoattractant receptors. Tazarotene, a synthetic retinoid activating retinoic acid receptor (RAR), up-regulates tazarotene-induced gene-2 (TIG2).
59577	18355	  831	RAR Family	Protein	DMD	mRNA	0	1	11731283	We followed by competitive PCR the expression of DAP complex components during retinoic acid (RA)-induced neuronal differentiation of P19 cells. Transcripts for the full-length dystrophin, Dp427, and the short isoform, Dp71, as well as for alpha-dystrobrevin 2 increased in parallel with days in culture after RA stimulation,
28316	10156	10956	camptothecin	Compound	TNFRSF10B	mRNA	0	1	14500373	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.
43804	10156	11318	camptothecin	Compound	MAP2K5	mRNA	1	-1	15026349	Table 1 Differentially expressed genes following camptothecin treatment of HeLa cells: B. Largest fold decreases
46620	10156	 4208	camptothecin	Compound	TNFRSF10A	mRNA	0	1	14500373	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.
50191	10156	 8138	camptothecin	Compound	NRP1	mRNA	-1	-1	15026349	Table 1 Differentially expressed genes following camptothecin treatment of HeLa cells: B. Largest fold decreases
55148	10156	 8359	camptothecin	Compound	ATP6V0C	mRNA	0	1	12133827	We have confirmed that both camptothecin and etoposide induce ATP6L promoter activity (data not shown).
62964	10156	 7195	camptothecin	Compound	GADD45A	mRNA	-1	1	15026349	Table 1 Differentially expressed genes following camptothecin treatment of HeLa cells:C. Most significant changes
19930	20165	17834	HTT	Protein	CCNG2	mRNA	-1	1	17189290	(from text) We confirmed this essential role for huntingtin on our arrays, detecting the general down-regulation of genes involved in growth, proliferation and cellular differentiation (Fig. 6). A subset of these transcripts appear to function specifically within the brain: Serpinf1, Emp3, Tcfap2c, Dlx3 and Elavl4. Many general growth-related or mitogenic mRNAs (Ghrh, Scgb3a1, Cdkn1c, Sp6, Gkn1, Igf2) also exhibited reduced expression. Conversely, Hdh null neurons consistently overexpressed Ccng2, a negative regulator of cell proliferation and cell cycle progression.
 5118	20165	 2649	HTT	Protein	DNAJB1	mRNA	0	-1	11606565	Co-transfection of HSP 40 with 120Q dramatically inhibited the formation of huntingtin aggregates (Fig. 2 A ).
54376	20165	  991	HTT	Protein	INS	mRNA	0	-1	12586550	Disrupted expression of a subset of transcription factors in pancreatic beta cells by a polyglutamine expansion tract in the huntingtin protein selectively impairs insulin gene expression to result in insulin deficiency and diabetes.
56230	20165	15199	HTT	Protein	BDNF	mRNA	0	1	11408619	Here we demonstrate that wild-type huntingtin up-regulates transcription of brain-derived neurotrophic factor (BDNF), a pro-survival factor produced by cortical neurons that is necessary for survival of striatal neurons in the brain.
 4101	13616	13994	GABPB1	Protein	NDST2	mRNA	0	1	11342428	GA binding protein (GABP) bound the GGAA motif and increased the amount of NDST-2 transcript.
42852	13616	 3879	GABPB1	Protein	FAS	mRNA	0	1	10575005	Fas (CD95 or APO-1), a transmembrane cell surface receptor of the tumor necrosis factor receptor family, is up-regulated in activated T lymphocytes. Our present study identified an upstream enhancer element (between nucleotide positions -862 and -682) containing a GA-binding protein (GABP) site and a low affinity activating protein-1 (AP-1)-binding site. T cell activation increased the DNA binding of GABP and AP-1 to this enhancer site.
55715	13616	17702	GABPB1	Protein	SKP2	mRNA	0	1	12907639	\Supershift\ analysis indicated that the protein-probe complexes detected by electrophoretic mobility shift assays contain GABP. Endogenous GABP bound to Skp2 promoter element in a cell cycle-dependent manner. Furthermore, overexpression of GABPbeta increased Skp2 promoter activity, and suppression of GABPalpha or GABPbeta by a small interfering RNA resulted in the reduction of Skp2 promoter activity.
 5899	13616	 5636	GABPB1	Protein	AURKA	mRNA	1	1	11790771	coexpression of E4TF1-60 and E4TF1-53 (GABPB2) markedly increased aurora A promoter activity.
10012	15426	 4597	hydrogen peroxide	Compound	UBE2C	mRNA	1	-1	12414654	Table 3 Gene expression for HP-, MEN-, TBH-treated cells according to functional categories
11030	15426	 8037	hydrogen peroxide	Compound	KLF6	mRNA	1	1	17148688	On-line supplement: Tables 1 - 13. Genes with altered expression in cardiac myocytes exposed to 0.2 mM H2O2. Results are mean expression relative to controls (n=3). Changes >1.75-fold are indicated in bold type Table 1 Genes associated with transcriptional regulation.
12781	15426	17369	hydrogen peroxide	Compound	IL6	mRNA	0	1	10925306	The PD98059 treatment significantly reduced the TGF-b1-induced IL-6 gene expression as well as H2O2- and ionomycin-induced IL-6 gene expression (Fig. 7A).
 1319	15426	19951	hydrogen peroxide	Compound	HAMP	mRNA	0	-1	17349976	ROS levels were significantly elevated in hypoxic HepG2 cells, and anti-oxidants prevented the hypoxic down-regulation of hepcidin. Conversely, a prooxidant, H(2)O(2), suppressed hepcidin expression in these cells even in normoxia.
16495	15426	18083	hydrogen peroxide	Compound	BNIP3	mRNA	-1	-1	17397968	cDNA microarrays were employed to profile the gene expression changes in N27 cells exposed to 100 ?M H2O2 for 4 hrs. Gene expression was significantly altered by H2O2-treatment, with increases in sixty-five and decreases in forty-five candidate genes, respectively.  (Table 2)
17010	15426	 3722	hydrogen peroxide	Compound	PPARG	mRNA	0	-1	10382590	In addition, hydrogen peroxide, lysophosphatidylcholine or phorbol 12-myristate 13-acetate also decreased the expression of PPARgamma.
18046	15426	 6856	hydrogen peroxide	Compound	ADAM9	mRNA	0	1	17018608	We found that ADAM9 mRNA and protein expressions were elevated on exposure of human prostate cancer cells to stress conditions such as cell crowding, hypoxia, and hydrogen peroxide.
19297	15426	 5967	hydrogen peroxide	Compound	CIRBP	mRNA	0	-1	10641716	The presence of H2O2 in the culture media inhibited dose dependently this induction as well as constitutive expression, suggesting that the effect of brain ischemia on CIRP expression is related to generation of reactive oxygen species.
21179	15426	 9710	hydrogen peroxide	Compound	GSS	mRNA	0	1	19646463	Enhanced mRNA expression and enzyme activity of NQO1 and gamma glutamyl cysteine ligase (GCL) were elicited by oxidant exposure (e.g., hyperoxia, hydrogen peroxide) in pulmonary tissues or cells (Whitney and Frank, 1993; Rahman et al., 1996).
22643	15426	18267	hydrogen peroxide	Compound	KLF2	mRNA	0	1	18406357	H2O2 increased expression of Klf2, Klf4 and Klf6, but interleukin-1beta or tumor necrosis factor alpha downregulated Klf2 expression with no effect on Klf4 or Klf6.
22840	15426	16335	hydrogen peroxide	Compound	PGGT1B	mRNA	0	1	12414654	Table 3 Gene expression for HP-, MEN-, TBH-treated cells according to functional categories
 2569	15426	  326	hydrogen peroxide	Compound	TXNIP	mRNA	0	-1	12386145	PDGF and H2O2 time-dependently suppressed VDUP-1 expression (13-fold and 30-fold reduction after 1 hour, respectively; P<0.001), and this was inhibited by the cell-permeable antioxidants N-acetylcysteine and 4,5-dihydroxy-1,3-benzene-disulfonic acid (Tiron).
28883	15426	 8621	hydrogen peroxide	Compound	NQO1	mRNA	0	1	19646463	Enhanced mRNA expression and enzyme activity of NQO1 and gamma glutamyl cysteine ligase (GCL) were elicited by oxidant exposure (e.g., hyperoxia, hydrogen peroxide) in pulmonary tissues or cells (Whitney and Frank, 1993; Rahman et al., 1996).
32833	15426	12649	hydrogen peroxide	Compound	ETS1	mRNA	1	1	17148688	On-line supplement: Tables 1 - 13. Genes with altered expression in cardiac myocytes exposed to 0.2 mM H2O2. Results are mean expression relative to controls (n=3). Changes >1.75-fold are indicated in bold type Table 1 Genes associated with transcriptional regulation.
32895	15426	14012	hydrogen peroxide	Compound	SRXN1	mRNA	0	1	17148688	On-line supplement: Tables 1 - 13. Genes with altered expression in cardiac myocytes exposed to 0.2 mM H2O2. Table 3 Genes associated with metabolism and redox.
37240	15426	 9096	hydrogen peroxide	Compound	TGFB1I1	mRNA	0	1	10092676	The Hic-5 protein is encoded by a transforming growth factor-beta1- and hydrogen peroxide-inducible gene, hic-5, and has striking similarity to paxillin, especially in their C-terminal LIM domains.
38731	15426	18764	hydrogen peroxide	Compound	AKT1	mRNA	1	-1	17397968	cDNA microarrays were employed to profile the gene expression changes in N27 cells exposed to 100 ?M H2O2 for 4 hrs. Gene expression was significantly altered by H2O2-treatment, with increases in sixty-five and decreases in forty-five candidate genes, respectively.  (Table 2)
38815	15426	10290	hydrogen peroxide	Compound	FOXM1	mRNA	1	-1	12414654	Table 3 Gene expression for HP-, MEN-, TBH-treated cells according to functional categories
39383	15426	18612	hydrogen peroxide	Compound	SOD2	mRNA	-1	1	 9535218	We found that MnSOD protein expression and mRNA production were markedly enhanced after 4 h exposure to oxLDL, C2-ceramide, H2O2, or TNF-a (Fig. 1A, B). Similar results were obtained when p53 protein and mRNA levels of stimulated cells were analyzed (Fig. 2A, B)
40949	15426	 4582	hydrogen peroxide	Compound	NOS3	mRNA	1	1	14656742	hydrogen peroxide also activates eNOS transcription via a pathway dependent on Jak2, CaM kinase II, and Sp1.43,44
42063	15426	13115	hydrogen peroxide	Compound	EGR1	mRNA	-1	1	17148688	On-line supplement: Tables 1 - 13. Genes with altered expression in cardiac myocytes exposed to 0.2 mM H2O2. Results are mean expression relative to controls (n=3). Changes >1.75-fold are indicated in bold type Table 1 Genes associated with transcriptional regulation.
42886	15426	 7577	hydrogen peroxide	Compound	HSP90AA1	mRNA	0	1	11231909	H 2 O 2 stimulated  expression of both HSP70 (Figure 5 ) and HSP90 (data not shown)
45369	15426	14987	hydrogen peroxide	Compound	BCL2	mRNA	1	-1	12721309	Bcl-2, Bax, and Bad were all down-regulated in myocytes exposed to 0.2 mm H2O2, a concentration that induces apoptosis
49677	15426	 6430	hydrogen peroxide	Compound	MDM2	mRNA	1	1	15155764	Table II. The MCF-7a genomic response to H2O2 at 5 hours. Genes with a significant change in gene expression between treated and untreated samples in 2 independent experiments are listed.
51008	15426	13884	hydrogen peroxide	Compound	CDKN1A	mRNA	1	1	12414654	Table 3 Gene expression for HP-, MEN-, TBH-treated cells according to functional categories
51504	15426	15841	hydrogen peroxide	Compound	FBXO32	mRNA	-1	1	12773310	H2O2 upregulates expression of specific E3 and E2 proteins that are thought to regulate muscle catabolism, including atrogin1/MAFbx, MuRF1, and E214k.
51667	15426	  219	hydrogen peroxide	Compound	FASLG	mRNA	-1	1	10699758	Simultaneous overexpression of selenophosphate synthetase and phospholipid-hydroperoxide GSH peroxidase (PHGPx) [250] blocks activation of NF-kB by IL-1. Overexpression of SOD [84] or GSH peroxidase [81, 211] abolished NF-kB activation by preventing degradation of IkB after stimulation with TNF-a. The precise mechanism(s) through which oxidants and reductants influence activation of NF-kB is presently unknown; however, there is evidence that antioxidant enzyme (AOE372), a redox-sensitive thioredoxin peroxidase, regulates IkB phosphorylation [246]. Phosphatases The phosphatases are an important component of most signal transduction pathways, because failure to reverse kinase actions can disrupt normal cellular functions. For example, transfection of human fibroblasts with constitutively active ras (hRasV12) inhibits cell growth and ultimately results in a senescentlike phenotype [441]. Similarly, constitutive ERK activation has an inhibitory effect on cell cycle progression [442,443]. Both the serine/threonine phosphatases and the PTPs are known to be redox-sensitive [82,144,153,156,271,281, 444-449]. The mechanism of redox effects on activity is probably best understood for the PTPs. Without exception, the PTPs contain a highly conserved region of 11 amino acid residues in their catalytic domain; specifi- cally, (Ile/Val)-His-Cys-X-Ala-Gly-X-X-Arg-(Ser/Thr)- Gly, where X is a nonconserved amino acid [17]. Either oxidation or mutation of the cysteine renders these molecules inactive [17,281]. H2O2 is a potent inhibitor of PTPs. As in the case of other oxidants, H2O2 probably oxidizes the thiolate anion at the catalytic site [280]. Because formation of a phosphorylcysteine intermediate seems to be critical to PTP activity [450-452], blocking it through oxidation of the cysteine inactivates the molecules. In many cases, treatment of cells with H2O2 stimulates increases in protein phosphorylation by inhibiting phosphatase-catalyzed removal of phosphate groups. Furthermore, mitogens that increase cellular ox- idant production may stimulate phosphorylation indirectly by decreasing phosphatase activity. Additional mechanisms are involved in stimulation of pathways activated by growth factors that increase oxidant production, however, because there are known instances in which the oxidants they produce have no effect on protein phosphorylation. For example, TGF-b1 stimulates phosphorylation of numerous proteins and has been shown to cause a large increase in H2O2 production; however, its effects on protein phosphorylation are not blocked by catalase [453]. Furthermore, H2O2 is effective in promoting phosphorylation of phospholipase D, the PDGF receptor, and PKC-a even after pretreatment of Swiss 3T3 fibroblasts with orthovanadate to inhibit phosphatases [454]. Thus, although diminished phosphatase activity may partially account for increased phosphorylation in some cases, it cannot totally account for oxidation effects on phosphorylation in every case. SPECIFICITY In general, there is good agreement between studies on redox effects on any given gene; albeit, not all oxidizing or reducing treatments exert equivalent effects. This is clearly demonstrated in studies of pag , which encodes a protein associated with cellular proliferation. Pag protein inhibits the tyrosine kinase activity of the Abelson (abl ) protein by binding to its SH3-binding domain [455]. BSO, menadione, sodium arsenate, and diethyl maleate all stimulate pag expression, but H2O2 does not [269]. Conversely, H2O2 stimulates c-fos expression (Table 1), although 4-hydroynonenal (a product of v-6-polyunsaturated fatty acid peroxidation) not only fails to induce c-fos expression but is actually inhibitory to c-fos induction by EGF and PDGF [185]. Similarly, some oxidants such as diamide decrease hypoxia-induced signals [201], although others such as H2O2 increase them [124]. As might be expected, the effects of any stimu...
54168	15426	  722	hydrogen peroxide	Compound	MSRA	mRNA	0	1	16514415	To further assess the functional relevance of the enzyme, its expression in response to UVB, UVA, and H(2)O(2) was investigated in HaCaT cells. While UVB lowered protein expression of MSRA, an upregulation was observed in response to low doses of UVA and H(2)O(2).
54602	15426	13928	hydrogen peroxide	Compound	PDGFRA	mRNA	0	1	16192649	Hydrogen peroxide (H2O2) at nanomolar concentrations stimulated levels of Ets-1 and increased PDGF-Ralpha transcription and mRNA expression without affecting Sp1 expression.
55085	15426	 4733	hydrogen peroxide	Compound	PPM1D	mRNA	-1	1	15155764	Table IV. The MRC-9 genomic response to H2O2 at 5 hours. Genes with a significant change in gene expression between treated and untreated samples in 2 independent experiments are listed.
55645	15426	19007	hydrogen peroxide	Compound	STAT5B	mRNA	0	1	17397968	cDNA microarrays were employed to profile the gene expression changes in N27 cells exposed to 100 ?M H2O2 for 4 hrs. Gene expression was significantly altered by H2O2-treatment, with increases in sixty-five and decreases in forty-five candidate genes, respectively.  (Table 2)
56126	15426	10811	hydrogen peroxide	Compound	FN1	mRNA	-1	1	12874439	antioxidants effectively inhibit high glucose- and H2O2-induced TGF-b1 and fibronectin upregulation
58370	15426	 6053	hydrogen peroxide	Compound	CAT	mRNA	-1	1	 8762051	Because H2O2 is considered to play a major role in reperfusion injury to the heart, this study was undertaken to examine if H2O2 alters the expression of these enzymes in the rat neonatal myocytes. The results suggest that H2O2-induced expression of catalase was in part due to transcriptional activation.
58554	15426	  497	hydrogen peroxide	Compound	SIRT1	mRNA	-1	-1	17317627	Exposure of HDFs to hydrogen peroxide (H2O2) caused a significant, dose-dependent reduction in SIRT1 mRNA and protein levels
58901	15426	10064	hydrogen peroxide	Compound	SELP	mRNA	-1	1	11457873	In cultured endothelial cells, activation of GC-A augmented H2O2-induced P-selectin expression.
 5901	15426	 5636	hydrogen peroxide	Compound	AURKA	mRNA	1	-1	17397968	cDNA microarrays were employed to profile the gene expression changes in N27 cells exposed to 100 ?M H2O2 for 4 hrs. Gene expression was significantly altered by H2O2-treatment, with increases in sixty-five and decreases in forty-five candidate genes, respectively.  (Table 2)
59928	15426	13264	hydrogen peroxide	Compound	TRIM63	mRNA	-1	1	12773310	H2O2 upregulates expression of specific E3 and E2 proteins that are thought to regulate muscle catabolism, including atrogin1/MAFbx, MuRF1, and E214k.
60038	15426	12976	hydrogen peroxide	Compound	IL8	mRNA	0	1	15456740	We show that concomitant exposure of cells to CSC along with TNF-? treatment significantly decreased the IL-8 expression compared with TNF-? or H2O2 alone (Fig. 8). Interestingly, co-incubation of TNF-? with CSC or H2O2 inhibited IL-8 release in a dosedependant manner (Figs. 9 and 12).
62922	15426	 7195	hydrogen peroxide	Compound	GADD45A	mRNA	-1	1	15155764	Table III. The MCF-7b genomic response to H2O2 at 5 hours. Genes with a significant change in gene expression between treated and untreated samples in 2 independent experiments are listed.
 6471	15426	12489	hydrogen peroxide	Compound	ERCC5	mRNA	-1	1	17207589	Exposure of human pulmonary epithelial cells (A549) to non-toxic doses of 100muM H(2)O(2) indeed showed a 2 to 4.5-fold increase in expression of XPA, XPC, ERCC4, and ERCC5, whereas the expression of ERCC1 was 5-fold decreased.
 7902	15426	19902	hydrogen peroxide	Compound	ACHE	mRNA	0	1	18385943	We show that H(2)O(2) increases acetylcholinesterase (AChE) expression via transcriptional activation through c-Jun N-terminal kinase (JNK)
 8799	15426	 1900	hydrogen peroxide	Compound	PRDX1	mRNA	0	1	11295360	Microsequencing analysis revealed that these HPRPs corresponded to at least six pairs of proteins. Of these, four pairs of HPRPs were thioredoxin peroxidase I (TPx I), TPx II, TPx III, and the product of human ORF06, all of which belong to the peroxiredoxin (Prx) family and all of which are involved in the elimination of hydroperoxides. The other two pairs corresponded to heat shock protein 27 (HSP27) and glyceraldehyde-3-phosphate dehydrogenase (G3PDH), respectively.
42930	  163	15885	ZFP161	Protein	ACTB	mRNA	1	-1	 9092617	Using transient cotransfection assays, ZF5 was shown to activate the HIV-1 LTR and repress the beta-actin promoter.
11222	 7401	13301	androgen	Compound	CCNB1	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
 1127	 7401	10867	androgen	Compound	SLC45A3	mRNA	0	1	11245466	Prostein expression is androgen responsive because treatment of LNCaP cells with androgen up-regulates prostein message and protein expression levels.
11543	 7401	 7885	androgen	Compound	ISG20	mRNA	1	1	15115731	FIG. 1. Genes upregulated by androgen throughout the entire epididymis
11651	 7401	16413	androgen	Compound	HMGCS1	mRNA	0	1	11579213	androgens stimulate the expression of fatty acid synthase and hydroxymethylglutaryl-coenzyme A synthase
12014	 7401	13964	androgen	Compound	PLTP	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
12331	 7401	 9601	androgen	Compound	SPTSSB	mRNA	0	1	15777716	While ADMP expression is androgen independent in the hpg prostate, it appears to be androgen-dependent in the kidney and brain of normal intact mouse suggesting tissue specific regulation of ADMP by androgens.
12891	 7401	 5762	androgen	Compound	DHRS3	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
13908	 7401	 1706	androgen	Compound	RAB2A	mRNA	-1	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
13999	 7401	10628	androgen	Compound	SLC37A2	mRNA	0	-1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
14508	 7401	18103	androgen	Compound	LPL	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
14756	 7401	 5124	androgen	Compound	PTPN18	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
  166	 7401	13982	androgen	Compound	AES	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
16841	 7401	 5958	androgen	Compound	POSTN	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
17197	 7401	11456	androgen	Compound	TF	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
 1722	 7401	16730	androgen	Compound	MAN2A1	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
17237	 7401	15016	androgen	Compound	APP	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
17510	 7401	   42	androgen	Compound	GSN	mRNA	0	-1	12941811	expressionof GSN is enhanced in LNCaP cells, LNCaP xenografts, and human prostate tumorsafter androgen depletion.
17519	 7401	11513	androgen	Compound	MESP2	mRNA	0	1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
 1753	 7401	  785	androgen	Compound	PDIA4	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
17621	 7401	19456	androgen	Compound	LPAR3	mRNA	0	1	12185249	The human prostate gland is an important target organ of androgenic hormones. Testosterone and dihydrotestosterone interact with the androgen receptor to regulate vital aspects of prostate growth and function including cellular proliferation, differentiation, apoptosis, metabolism, and secretory activity. Our objective in this study was to characterize the temporal program of transcription that reflects the cellular response to androgens and to identify specific androgen-regulated genes (ARGs) or gene networks that participate in these responses. We used cDNA microarrays representing about 20,000 distinct human genes to profile androgen-responsive transcripts in the LNCaP adenocarcinoma cell line and identified 146 genes with transcript alterations more than 3-fold. Of these, 103 encode proteins with described functional roles, and 43 represent transcripts that have yet to be characterized. Temporal gene expression profiles grouped the ARGs into four distinct cohorts. Five uncharacterized ARGs demonstrated exclusive or high expression levels in the prostate relative to other tissues studied. A search of available DNA sequence upstream of 28 ARGs identified 25 with homology to the androgen response-element consensus-binding motif. These results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens; further, they provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
18045	 7401	 6856	androgen	Compound	ADAM9	mRNA	0	1	19005493	ADAM9 and ADAM10 mRnA levels increase in prostate cancer cell lines in response to androgens and other growth factors22.
19489	 7401	16140	androgen	Compound	ELF5	mRNA	0	-1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
20442	 7401	11234	androgen	Compound	TUBB4B	mRNA	0	1	11520906	Treatment of proliferating SH-SY5Y cells with testosterone resulted in an up-regulation of alpha- and beta-tubulin We also show that an up-regulation of the ubiquitous beta(II)-tubulin and of the neurone-specific beta(III)-tubulin isoforms contributes to the overall increase in tubulin in response to androgen treatment
21352	 7401	10792	androgen	Compound	PON1	mRNA	0	-1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
21775	 7401	 3728	androgen	Compound	HSD17B11	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
22009	 7401	 2856	androgen	Compound	CTNNA1	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
22341	 7401	 7058	androgen	Compound	ALYREF	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
22972	 7401	 3600	androgen	Compound	PPFIA2	mRNA	0	-1	12119554	The downregulation of Liprin-alpha2 mRNA expression in LNCaP cells was observed after treatment with DHT for 8 and 24 hour.
23338	 7401	 4117	androgen	Compound	SLC22A5	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
23361	 7401	17849	androgen	Compound	SNAI1	mRNA	0	1	16541421	\Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG.\ DHT marginally upregulated mRNA expression of SREBP-1c, SREBP-2, and SNAIL, but not SREBP-1a, while dramatically increased SLUG mRNA expression, in a dose-dependent manner.
23557	 7401	10973	androgen	Compound	PRKCH	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
23761	 7401	 6636	androgen	Compound	BCL2L1	mRNA	0	1	18196538	androgen treatment significantly increased Bcl-xL expression at mRNA and protein levels via an AR-dependent mechanism.
24426	 7401	 1861	androgen	Compound	STK39	mRNA	0	1	11514053	We report here that SPAK, a recently identified STE20/SPS1-related kinase that modulates p38 MAP kinase activity, exhibited increased expression in androgen-treated LNCaP cells. Androgen regulation of SPAK was both dose- and time-dependent. R1881-induced SPAK expression was completely abrogated by the antiandrogen casodex and by actinomycin D indicating that androgen induction of SPAK requires the androgen receptor and transcription
25235	 7401	20010	androgen	Compound	ALCAM	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
25783	 7401	12968	androgen	Compound	CEACAM1	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
25908	 7401	17410	androgen	Compound	HERPUD1	mRNA	0	1	12483528	This study focuses on our new observations of the coordinated androgen induction of genes (NDRG1, PDIR, HERPUD1, ORP150) involved in the endoplasmic reticulum (ER) stress response pathway.
26616	 7401	 2240	androgen	Compound	POU2F1	mRNA	-1	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
26845	 7401	17395	androgen	Compound	RAD21	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
27223	 7401	 1840	androgen	Compound	AKR7A2	mRNA	0	1	10965890	The AIAR messenger RNA (mRNA) content of the ventral prostate was low in normal and castrated rats, transiently increased after androgen administration to castrated rats, attaining a peak 12-24 h after the treatment
27647	 7401	12781	androgen	Compound	AR	mRNA	1	1	15472231	Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment
28231	 7401	 7832	androgen	Compound	THBS1	mRNA	-1	-1	15665307	Androgen repression of TSP1 production occurred at the transcriptional level
28746	 7401	 3588	androgen	Compound	ZFHX3	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
28929	 7401	10269	androgen	Compound	CD74	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
29076	 7401	  620	androgen	Compound	PHLDA1	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
29612	 7401	 2068	androgen	Compound	TMPRSS2	mRNA	0	1	12185249	The human prostate gland is an important target organ of androgenic hormones. Testosterone and dihydrotestosterone interact with the androgen receptor to regulate vital aspects of prostate growth and function including cellular proliferation, differentiation, apoptosis, metabolism, and secretory activity. Our objective in this study was to characterize the temporal program of transcription that reflects the cellular response to androgens and to identify specific androgen-regulated genes (ARGs) or gene networks that participate in these responses. We used cDNA microarrays representing about 20,000 distinct human genes to profile androgen-responsive transcripts in the LNCaP adenocarcinoma cell line and identified 146 genes with transcript alterations more than 3-fold. Of these, 103 encode proteins with described functional roles, and 43 represent transcripts that have yet to be characterized. Temporal gene expression profiles grouped the ARGs into four distinct cohorts. Five uncharacterized ARGs demonstrated exclusive or high expression levels in the prostate relative to other tissues studied. A search of available DNA sequence upstream of 28 ARGs identified 25 with homology to the androgen response-element consensus-binding motif. These results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens; further, they provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
29770	 7401	14559	androgen	Compound	RDH11	mRNA	0	1	12185249	The human prostate gland is an important target organ of androgenic hormones. Testosterone and dihydrotestosterone interact with the androgen receptor to regulate vital aspects of prostate growth and function including cellular proliferation, differentiation, apoptosis, metabolism, and secretory activity. Our objective in this study was to characterize the temporal program of transcription that reflects the cellular response to androgens and to identify specific androgen-regulated genes (ARGs) or gene networks that participate in these responses. We used cDNA microarrays representing about 20,000 distinct human genes to profile androgen-responsive transcripts in the LNCaP adenocarcinoma cell line and identified 146 genes with transcript alterations more than 3-fold. Of these, 103 encode proteins with described functional roles, and 43 represent transcripts that have yet to be characterized. Temporal gene expression profiles grouped the ARGs into four distinct cohorts. Five uncharacterized ARGs demonstrated exclusive or high expression levels in the prostate relative to other tissues studied. A search of available DNA sequence upstream of 28 ARGs identified 25 with homology to the androgen response-element consensus-binding motif. These results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens; further, they provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
30207	 7401	 1262	androgen	Compound	CREB3L4	mRNA	0	1	11830526	Comparison of the mRNA expression profiles of control and R1881-treated cultures of LNCaP human prostate cancer cells using cDNA subtraction led to the identification of a novel transcription factor that we named Androgen-Induced bZIP (AIbZIP) protein. Androgens up-regulate AIbZIP mRNA and protein levels in a dose-dependent manner.
30313	 7401	13721	androgen	Compound	SP100	mRNA	0	-1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
 3184	 7401	16645	androgen	Compound	CCND1	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
32781	 7401	 3630	androgen	Compound	PA2G4	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
33121	 7401	12179	androgen	Compound	FST	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
33134	 7401	 7360	androgen	Compound	RARG	mRNA	1	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
33657	 7401	13246	androgen	Compound	CENPN	mRNA	0	1	12185249	The human prostate gland is an important target organ of androgenic hormones. Testosterone and dihydrotestosterone interact with the androgen receptor to regulate vital aspects of prostate growth and function including cellular proliferation, differentiation, apoptosis, metabolism, and secretory activity. Our objective in this study was to characterize the temporal program of transcription that reflects the cellular response to androgens and to identify specific androgen-regulated genes (ARGs) or gene networks that participate in these responses. We used cDNA microarrays representing about 20,000 distinct human genes to profile androgen-responsive transcripts in the LNCaP adenocarcinoma cell line and identified 146 genes with transcript alterations more than 3-fold. Of these, 103 encode proteins with described functional roles, and 43 represent transcripts that have yet to be characterized. Temporal gene expression profiles grouped the ARGs into four distinct cohorts. Five uncharacterized ARGs demonstrated exclusive or high expression levels in the prostate relative to other tissues studied. A search of available DNA sequence upstream of 28 ARGs identified 25 with homology to the androgen response-element consensus-binding motif. These results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens; further, they provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
 3446	 7401	10915	androgen	Compound	BAX	mRNA	0	-1	11454715	Androgen attenuated BAX expression
35072	 7401	 9217	androgen	Compound	NRIP1	mRNA	0	1	16527872	Finally, we provided evidence for a stimulation of RIP140 mRNA expression in LNCaP cells under androgen treatment
 3534	 7401	 4200	androgen	Compound	CCDC97	mRNA	0	1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
35604	 7401	 1571	androgen	Compound	RBL2	mRNA	-1	1	12435483	Subcutaneous injection of 5alpha-dihydrotestosterone as well as testosterone propionate to PN2 neonatal rats significantly increased p130 gene expression at PN3, whereas estradiol benzoate did not have a significant effect. These results suggest that expression of the p130 gene in the neonatal rat hypothalamus is responsive to androgens and may be involved in sexual differentiation of the brain.
36162	 7401	11189	androgen	Compound	Lcn5	mRNA	-1	1	15115731	FIG. 1. Genes upregulated by androgen throughout the entire epididymis
36344	 7401	19718	androgen	Compound	SHANK1	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
36924	 7401	 8765	androgen	Compound		mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
37175	 7401	17999	androgen	Compound	BRP44	mRNA	0	1	12185249	The human prostate gland is an important target organ of androgenic hormones. Testosterone and dihydrotestosterone interact with the androgen receptor to regulate vital aspects of prostate growth and function including cellular proliferation, differentiation, apoptosis, metabolism, and secretory activity. Our objective in this study was to characterize the temporal program of transcription that reflects the cellular response to androgens and to identify specific androgen-regulated genes (ARGs) or gene networks that participate in these responses. We used cDNA microarrays representing about 20,000 distinct human genes to profile androgen-responsive transcripts in the LNCaP adenocarcinoma cell line and identified 146 genes with transcript alterations more than 3-fold. Of these, 103 encode proteins with described functional roles, and 43 represent transcripts that have yet to be characterized. Temporal gene expression profiles grouped the ARGs into four distinct cohorts. Five uncharacterized ARGs demonstrated exclusive or high expression levels in the prostate relative to other tissues studied. A search of available DNA sequence upstream of 28 ARGs identified 25 with homology to the androgen response-element consensus-binding motif. These results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens; further, they provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
37256	 7401	11791	androgen	Compound	RGMA	mRNA	0	1	12185249	The human prostate gland is an important target organ of androgenic hormones. Testosterone and dihydrotestosterone interact with the androgen receptor to regulate vital aspects of prostate growth and function including cellular proliferation, differentiation, apoptosis, metabolism, and secretory activity. Our objective in this study was to characterize the temporal program of transcription that reflects the cellular response to androgens and to identify specific androgen-regulated genes (ARGs) or gene networks that participate in these responses. We used cDNA microarrays representing about 20,000 distinct human genes to profile androgen-responsive transcripts in the LNCaP adenocarcinoma cell line and identified 146 genes with transcript alterations more than 3-fold. Of these, 103 encode proteins with described functional roles, and 43 represent transcripts that have yet to be characterized. Temporal gene expression profiles grouped the ARGs into four distinct cohorts. Five uncharacterized ARGs demonstrated exclusive or high expression levels in the prostate relative to other tissues studied. A search of available DNA sequence upstream of 28 ARGs identified 25 with homology to the androgen response-element consensus-binding motif. These results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens; further, they provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
 3761	 7401	13283	androgen	Compound	HEXB	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
39274	 7401	10998	androgen	Compound	GPC3	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
39356	 7401	 7613	androgen	Compound	PURA	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
39475	 7401	14512	androgen	Compound	KRT19	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
39567	 7401	13744	androgen	Compound	CDKN1B	mRNA	-1	-1	10547394	Mid-to-late events included progressive and sustained increases in p27 and p16 protein expression, a decrease in retinoblastoma protein expression, and an increase in the transcription factor E2F1
39870	 7401	17098	androgen	Compound	TSG101	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
39940	 7401	 6114	androgen	Compound	NFKBIA	mRNA	1	1	 9865729	The level of IkappaB-alpha (NFKBIA) mRNA was decreased after castration of mice bearing CWR22 tumors. Treatment of castrated mice with TP (Testosterone pellets) restored expression of mRNA to levels seen in the intact CWR22. Further in the recurrent tumors, the levels of NFKBIA mRNA were higher than in CWR22 tumors after castration and similar to levels in androgen-stimulated tumors from intact mice.
40605	 7401	15960	androgen	Compound	STX2	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
41092	 7401	11896	androgen	Compound	MCM5	mRNA	1	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
41282	 7401	  256	androgen	Compound	BCAR1	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
41347	 7401	 4976	androgen	Compound	ANXA2	mRNA	0	1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
 4195	 7401	 4280	androgen	Compound	PHGDH	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
42070	 7401	13115	androgen	Compound	EGR1	mRNA	-1	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
42248	 7401	 5633	androgen	Compound	AMD1	mRNA	0	1	12483528	On treatment of LNCaP cells with R1881 (synthetic androgen), it was observed that the expression levels of adenosylmethionine decarboxylase 1 (AMD1) was high when compared with untreated cells. Androgen up-regulates AMD1, indicating that AMD1 is an androgen-regulated gene (ARG) in polyamine biosynthesis pathway.
42670	 7401	16734	androgen	Compound	DNAJA4	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
43134	 7401	16764	androgen	Compound	PIM1	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
43230	 7401	14283	androgen	Compound	MAPK14	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
43256	 7401	12473	androgen	Compound	PIK3AP1	mRNA	0	1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
43690	 7401	10653	androgen	Compound	RT1-EC2	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
44153	 7401	 6531	androgen	Compound	CCNE1	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
44574	 7401	 7848	androgen	Compound	HYOU1	mRNA	0	1	12483528	This study focuses on our new observations of the coordinated androgen induction of genes (NDRG1, PDIR, HERPUD1, ORP150) involved in the endoplasmic reticulum (ER) stress response pathway.
44983	 7401	13553	androgen	Compound	NUCB1	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
44987	 7401	20180	androgen	Compound	C4B	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
45354	 7401	14987	androgen	Compound	BCL2	mRNA	1	-1	14676836	The oncogene Bcl-2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl-2 overexpression may contribute to the androgen-refractory relapse of the disease.
45450	 7401	14921	androgen	Compound	FZD6	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
45592	 7401	 4559	androgen	Compound	CDC20	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
45675	 7401	16976	androgen	Compound	SPPL3	mRNA	0	-1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
46058	 7401	15021	androgen	Compound	CALR	mRNA	0	1	10213498	Androgen treatment upregulates the calreticulin expression in LNCaP cells. Androgen treatment time for inducing calreticulin mRNA in LNCaP cells was 36 hour in the presence of CHX and anisomycin. Similar to mRNA protein levels of calreticulin was also regulated by androgen.
47489	 7401	 1303	androgen	Compound	TAX1BP1	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
 4754	 7401	 7009	androgen	Compound	SREBF1	mRNA	0	1	11579213	androgens results in increased nuclear levels of active SREBP
47561	 7401	 6526	androgen	Compound	HMGN1	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
 4784	 7401	 7224	androgen	Compound	TUBB4A	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
47930	 7401	 7929	androgen	Compound	SCAP	mRNA	0	1	11579213	androgens induce a major increase in the expression of sterol regulatory element-binding protein cleavage-activating protein (SCAP)
48539	 7401	13031	androgen	Compound	Slpi	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
48914	 7401	 7863	androgen	Compound	PDIA5	mRNA	0	1	12483528	This study focuses on our new observations of the coordinated androgen induction of genes (NDRG1, PDIR, HERPUD1, ORP150) involved in the endoplasmic reticulum (ER) stress response pathway.
48960	 7401	 7117	androgen	Compound	IRF7	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
49683	 7401	 6430	androgen	Compound	MDM2	mRNA	1	-1	10547394	Androgen-independent sublines emerged 80-400 days after androgen withdrawal, and these sublines had variable growth phenotypes but were associated with mdm2 protein overexpression and increased expression of cyclin D1.
49765	 7401	15260	androgen	Compound	MARCH7	mRNA	0	1	12185249	The human prostate gland is an important target organ of androgenic hormones. Testosterone and dihydrotestosterone interact with the androgen receptor to regulate vital aspects of prostate growth and function including cellular proliferation, differentiation, apoptosis, metabolism, and secretory activity. Our objective in this study was to characterize the temporal program of transcription that reflects the cellular response to androgens and to identify specific androgen-regulated genes (ARGs) or gene networks that participate in these responses. We used cDNA microarrays representing about 20,000 distinct human genes to profile androgen-responsive transcripts in the LNCaP adenocarcinoma cell line and identified 146 genes with transcript alterations more than 3-fold. Of these, 103 encode proteins with described functional roles, and 43 represent transcripts that have yet to be characterized. Temporal gene expression profiles grouped the ARGs into four distinct cohorts. Five uncharacterized ARGs demonstrated exclusive or high expression levels in the prostate relative to other tissues studied. A search of available DNA sequence upstream of 28 ARGs identified 25 with homology to the androgen response-element consensus-binding motif. These results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens; further, they provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
49905	 7401	15228	androgen	Compound	TIMP3	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
50926	 7401	 6827	androgen	Compound	AREG	mRNA	0	-1	15651060	A fraction of growth factors showed a steady increase in the mRNA expression reaching between fourfold and eightfold 30 days after castration, including amphiregulin (P < 0.005) and epiregulin (P < 0.001).
   51	 7401	11396	androgen	Compound	CCNA2	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
 5107	 7401	 2649	androgen	Compound	DNAJB1	mRNA	0	1	15767336	Finally, resveratrol did not oppose all transcriptional changes induced by androgen. A subset of 153 genes was up-regulated by both resveratrol and androgen. However, many of these genes, such as JUNB, HSP40, SERP1, and STCH seem to reflect cellular stress.
51510	 7401	 6739	androgen	Compound	PMEPA1	mRNA	0	1	12907594	PMEPA1 was originally identified as a highly androgen-induced gene
51767	 7401	 9101	androgen	Compound	DPM3	mRNA	0	1	11420690	The gene whose expression correlated most strongly with lack of invasion was identified as a potential invasion suppressor and called prostin-1. Pharmacological inhibition of PLC gamma (U73122) confirmed that PLC gamma signaling suppressed prostin-1 in that U73122 treatment caused induction of prostin-1 in PLC gamma competent cells. The prostin-1 gene, conserved through phylogeny, is induced by androgen in LNCaP cells and encodes a 92 amino acid protein. The protein shares no extensive homologies with other known genes, yet was recently identified as a small stabilizer subunit of the dolichol-phosphate-mannose (DPM) synthase complex.   ***Did not curate*** line below because COS cells are monkey That DPM3/prostin-1 might suppress tumor progression was supported by the finding that exogenous expression in COS cells leads to apoptosis. These findings support the use of model cell lines to identify putative tumor suppressors and promoters.
52031	 7401	 3467	androgen	Compound	HSP90AB1	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
52293	 7401	17148	androgen	Compound	SPARCL1	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
52337	 7401	 2491	androgen	Compound	JTB	mRNA	0	1	10762645	. The expression of this gene was down regulated by androgens in androgen sensitive prostate cells, but not in the hormone resistant cell lines.
52585	 7401	12415	androgen	Compound	CYP4V2	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
 5267	 7401	10813	androgen	Compound	GJB3	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
53541	 7401	 8374	androgen	Compound	SNCA	mRNA	-1	-1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
53863	 7401	18211	androgen	Compound	NCAPD3	mRNA	0	1	12185249	The human prostate gland is an important target organ of androgenic hormones. Testosterone and dihydrotestosterone interact with the androgen receptor to regulate vital aspects of prostate growth and function including cellular proliferation, differentiation, apoptosis, metabolism, and secretory activity. Our objective in this study was to characterize the temporal program of transcription that reflects the cellular response to androgens and to identify specific androgen-regulated genes (ARGs) or gene networks that participate in these responses. We used cDNA microarrays representing about 20,000 distinct human genes to profile androgen-responsive transcripts in the LNCaP adenocarcinoma cell line and identified 146 genes with transcript alterations more than 3-fold. Of these, 103 encode proteins with described functional roles, and 43 represent transcripts that have yet to be characterized. Temporal gene expression profiles grouped the ARGs into four distinct cohorts. Five uncharacterized ARGs demonstrated exclusive or high expression levels in the prostate relative to other tissues studied. A search of available DNA sequence upstream of 28 ARGs identified 25 with homology to the androgen response-element consensus-binding motif. These results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens; further, they provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
53981	 7401	11581	androgen	Compound	ITGB1	mRNA	1	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
 5401	 7401	15330	androgen	Compound	LAMA5	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
54119	 7401	 6512	androgen	Compound	C1orf116	mRNA	0	1	15525603	SARG mRNA expression can be up-regulated by androgens, but not by glucocorticoids. SARG mRNA expression is high in prostate tissue.
54268	 7401	  322	androgen	Compound	GADD45G	mRNA	1	1	12639908	On treatment of LNCaP cells with Mibolerone (a synthetic androgen analog) with various concentrations, it was observed that growth arrest and DNA-damage-inducible, gamma (GADD45G) gene was up-regulated by 1nM Mibolerone or higher concentrations.
 5427	 7401	10230	androgen	Compound	F3	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
54283	 7401	17096	androgen	Compound	XPOT	mRNA	0	-1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
54293	 7401	 4554	androgen	Compound	BUB1B	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
54363	 7401	12644	androgen	Compound	TOB1	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
55022	 7401	 2565	androgen	Compound	SDC3	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
55163	 7401	17653	androgen	Compound	TFF1	mRNA	0	-1	12089361	_ sentences for pubmedID=12089361: _ Ariadne: In ZR-75-1 cells, androgens inhibit estrogen-induced cathepsin D and pS2 expression levels and regulate the secretion of apolipoprotein D and PIP/ GCDFP-15 proteins ( 44 , 89 ). [Regulation]
55602	 7401	10366	androgen	Compound	ACSL3	mRNA	0	1	15178414	Androgen withdrawal (DCC-serum), in the presence of antiandrogen Casodex or in AR-negative prostate cancer cells (PC3 and DU145), vitamin D(3) failed to regulate FACL3/ACS3 expression. The upregulation of FACL3/ACS3 expression by vitamin D(3) was recovered by the addition of DHT in DCC-serum medium. Western blot analysis showed that the expression of androgen receptor (AR) protein was consistent with vitamin D(3) regulation of FACL3/ACS3 expression
56186	 7401	18720	androgen	Compound	AHNAK	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
56577	 7401	 5131	androgen	Compound	CLU	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
56686	 7401	 8640	androgen	Compound	TMEFF2	mRNA	0	1	12101412	dihydrotestosterone markedly increasing TMEFF2 expression in LNCaP cells
57345	 7401	 4298	androgen	Compound	JUNB	mRNA	0	1	15767336	Finally, resveratrol did not oppose all transcriptional changes induced by androgen. A subset of 153 genes was up-regulated by both resveratrol and androgen. However, many of these genes, such as JUNB, HSP40, SERP1, and STCH seem to reflect cellular stress.
58451	 7401	 5816	androgen	Compound	STEAP2	mRNA	0	1	15897894	STAMP2 expression is exquisitely androgen regulated in the androgen-sensitive, androgen receptor-positive prostate cancer cell line LNCaP, but not in androgen receptor-negative prostate cancer cell lines PC-3 and DU145.
58825	 7401	 9550	androgen	Compound	CDK4	mRNA	1	1	 9377562	We found that expression of CDK2 and CDK4 genes were up-regulated within hours of androgen treatment as detected in Northern and Western blot analyses. Kinase assay also confirmed that there was increased CDK2 kinase activity upon androgen stimulation.
59456	 7401	10148	androgen	Compound	IFNGR1	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
59713	 7401	18763	androgen	Compound	CLDN7	mRNA	0	1	14502431	These two forms of CLDN-7 are able to regulate the expression of a tissue-specific protein, the prostate-specific antigen (PSA), in the LNCaP prostate cancer cell line. We also found that the expression of CLDN-7 is responsive to androgen stimulation in the LNCaP cell line, suggesting that this protein is involved in the regulatory mechanism of androgen.
60698	 7401	10690	androgen	Compound	PEG3	mRNA	0	-1	10580840	Treatment with Synthetic Androgen (R1881) resulted in a consistent downregulation of mRNA expression of Peg3 mRNA in LNCaP cells. Combined addition of androgen and actinomycin D revealed no change in the stability of Peg3 mRNA suggesting that androgens decrease Peg3 expression by inhibiting the rate of transcription
61091	 7401	10237	androgen	Compound	EGF	mRNA	0	1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
61263	 7401	 1552	androgen	Compound	ODC1	mRNA	1	1	12483528	On treatment of LNCaP cells with R1881 (synthetic androgen), it was observed that the expression levels of ornithine decarboxylase 1 (ODC1) was high when compared with untreated cells. Androgen up-regulates ODC1, indicating that ODC1 is an androgen-regulated gene (ARG) in polyamine biosynthesis pathway.
61448	 7401	11512	androgen	Compound	PRNP	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
61672	 7401	 7558	androgen	Compound	CTSL1	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
61782	 7401	 1730	androgen	Compound	KLF10	mRNA	1	-1	 8584037	Androgens were observed to induce a down-regulation of EGR alpha mRNA expression (70% in 72 h), while epidermal growth factor induced a rapid transient up-regulation (6-fold in 100 min)
61982	 7401	 7235	androgen	Compound	HSPA13	mRNA	0	1	15767336	Finally, resveratrol did not oppose all transcriptional changes induced by androgen. A subset of 153 genes was up-regulated by both resveratrol and androgen. However, many of these genes, such as JUNB, HSP40, SERP1, and STCH seem to reflect cellular stress.
62163	 7401	  900	androgen	Compound	RT1-Bb	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
62899	 7401	 4641	androgen	Compound	GPNMB	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
 6320	 7401	15220	androgen	Compound	Mkrn1	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
64161	 7401	19660	androgen	Compound	SEC23B	mRNA	0	1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
65652	 7401	  707	androgen	Compound	GPI	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
65900	 7401	 7341	androgen	Compound	SMPDL3A	mRNA	0	-1	12639908	TABLE 3. Genes down-regulated by androgens 2.3-fold or more in the microarray study
66166	 7401	18323	androgen	Compound	YWHAH	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
66242	 7401	16419	androgen	Compound	TUBB3	mRNA	0	1	11520906	Treatment of proliferating SH-SY5Y cells with testosterone resulted in an up-regulation of alpha- and beta-tubulin We also show that an up-regulation of the ubiquitous beta(II)-tubulin and of the neurone-specific beta(III)-tubulin isoforms contributes to the overall increase in tubulin in response to androgen treatment
 6743	 7401	10999	androgen	Compound	HSPB1	mRNA	0	-1	16322258	Using a tissue microarray of 232 specimens of hormone-naive and post-hormone ablation-treated prostate cancer, we found that Hsp27 levels increase after androgen ablation to become highly expressed (4-fold,
 7491	 7401	15006	androgen	Compound	MAP7D1	mRNA	0	1	12185249	The human prostate gland is an important target organ of androgenic hormones. Testosterone and dihydrotestosterone interact with the androgen receptor to regulate vital aspects of prostate growth and function including cellular proliferation, differentiation, apoptosis, metabolism, and secretory activity. Our objective in this study was to characterize the temporal program of transcription that reflects the cellular response to androgens and to identify specific androgen-regulated genes (ARGs) or gene networks that participate in these responses. We used cDNA microarrays representing about 20,000 distinct human genes to profile androgen-responsive transcripts in the LNCaP adenocarcinoma cell line and identified 146 genes with transcript alterations more than 3-fold. Of these, 103 encode proteins with described functional roles, and 43 represent transcripts that have yet to be characterized. Temporal gene expression profiles grouped the ARGs into four distinct cohorts. Five uncharacterized ARGs demonstrated exclusive or high expression levels in the prostate relative to other tissues studied. A search of available DNA sequence upstream of 28 ARGs identified 25 with homology to the androgen response-element consensus-binding motif. These results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens; further, they provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
 7982	 7401	13689	androgen	Compound	DGCR6	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
 8035	 7401	 8150	androgen	Compound	Klk1b4	mRNA	0	1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
 8136	 7401	12288	androgen	Compound	SREBF2	mRNA	0	1	16541421	\Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG.\ DHT marginally upregulated mRNA expression of SREBP-1c, SREBP-2, and SNAIL, but not SREBP-1a, while dramatically increased SLUG mRNA expression, in a dose-dependent manner.
 8873	 7401	12306	androgen	Compound	PPAP2A	mRNA	0	1	16304452	Table 2. The Most Highly Significant Genes Ordered by Expression Ratio - \Up\ signifies up-regulation, and \Down\ signifies down-regulation in testosterone-treated males.
 9249	 7401	11654	androgen	Compound	DRG1	mRNA	0	1	10428464	Androgen induces Drg1 mRNA expression by 14 fold in LNCaP cells. Induction became evident after 8-16 hour of treatment and culminated after 24 hour. Further experiments suggested that Androgen induction of Drg1 does not depend on the synthesis of intermediary proteins.
 9389	 7401	17289	androgen	Compound	SERP1	mRNA	0	1	15767336	Finally, resveratrol did not oppose all transcriptional changes induced by androgen. A subset of 153 genes was up-regulated by both resveratrol and androgen. However, many of these genes, such as JUNB, HSP40, SERP1, and STCH seem to reflect cellular stress.
 9577	 7401	19700	androgen	Compound	SSRP1	mRNA	0	1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
 9691	 7401	 7296	androgen	Compound	FGFR1	mRNA	0	-1	17023530	Androgens are the primary regulators of epididymal structure and functions. Principal cells are the major cell type of the tissue and are particularly sensitive to androgen removal. To distinguish the direct effects of androgens on this cell type, DNA microarrays were used to identify androgen-regulated genes in the mouse proximal caput epididymidis (PC-1) cell line. PC-1 cells display tissue- and caput-specific gene expression. We examined changes in gene expression occurring 2, 4, and 6 d after androgen deprivation and 2 d after androgen supplementation after being deprived of androgen for 2 or 4 d. Changes in transcript levels were investigated for mediators of androgen action; selected genes were analyzed by real-time RT-PCR, and changes at the protein levels were examined. Four distinct patterns of gene expression were activated after androgen withdrawal; the vast majority of genes displayed an early or late transient increase in expression levels. A differential ability of rescue was seen among androgen-regulated genes, depending on time of androgen supplementation. Many of the genes that were rescued at 4 d were functionally linked by direct interactions and converged on IGF-I. The ability for rescue after 4 d of androgen deprivation was severely compromised in many genes belonging to specific functional gene families (cell adhesion, cell growth, apoptosis, and cell cycle) and may be mediated in part by changes in androgen receptor coregulator expression. These results provide novel insights into the mechanisms of androgen regulation in epididymal principal cells.
 9735	 7401	  339	androgen	Compound	SNAI2	mRNA	0	1	16541421	\Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG.\ DHT marginally upregulated mRNA expression of SREBP-1c, SREBP-2, and SNAIL, but not SREBP-1a, while dramatically increased SLUG mRNA expression, in a dose-dependent manner.
51045	11660	13884	prostaglandin A2	Compound	CDKN1A	mRNA	1	1	 9048599	In addition to specifically regulating the expression of the IGF-I gene, PGA2 also decreases the abundance of cyclin D1 mRNA and increases the abundance of Waf1 mRNA.
12144	 1621	 6967	BHLHE40	Protein	ECH1	mRNA	0	-1	14581485	we performed microarray analyses of differential gene expression in the liver between wild type and Stra13-/- mice and identified 42 target genes including a subset of 20 previously known as clock-controlled genes metabolism genes
 1367	 1621	19956	BHLHE40	Protein	UBE2E1	mRNA	1	-1	14581485	proteolysis
15062	 1621	11367	BHLHE40	Protein	BHLHE41	mRNA	0	-1	16462771	In reporter assays, DEC1 transactivated the survivin promoter but repressed the DEC2 promoter. In contrast to the repression, the activation was delayed and varied depending on serum concentrations and cycle blockers. Studies with reporter mutants located, in the survivin promoter, two Sp1 sites that supported DEC1 transactivation
16217	 1621	 2205	BHLHE40	Protein	DBP	mRNA	0	-1	14672706	Forced expression of Clock/Bmal increased endogenous Dec1 mRNA level, and overexpression of Dec1 resulted in suppression of Dec2, Per2, and Dbp expression
16252	 1621	15838	BHLHE40	Protein	PER1	mRNA	0	-1	12397359	The proteins Clock and Bmal1 form a heterodimer which activates the transcription of the Per gene from the E-box elements in its promoter region. Protein products of Per act together with Cry proteins to inhibit Per transcription, thus closing the autoregulatory feedback loop. We found that Dec1 and Dec2, basic helix-loop-helix transcription factors, repressed Clock/Bmal1-induced transactivation of the mouse Per1 promoter through direct protein-protein interactions with Bmal1 and/or competition for E-box elements.
17038	 1621	 3722	BHLHE40	Protein	PPARG	mRNA	0	-1	15970569	From full text of Table 1 and following up on references in table 1: A list of potential BHLHB2- and BHLHB3-target genes
24879	 1621	 5863	BHLHE40	Protein	MYC	mRNA	0	-1	15970569	From full text of Table 1 and following up on references in table 1: A list of potential BHLHB2- and BHLHB3-target genes
25867	 1621	19027	BHLHE40	Protein	HMOX1	mRNA	0	1	15970569	From full text of Table 1 and following up on references in table 1: A list of potential BHLHB2- and BHLHB3-target genes
26613	 1621	10457	BHLHE40	Protein	TAT	mRNA	0	-1	14581485	we performed microarray analyses of differential gene expression in the liver between wild type and Stra13-/- mice and identified 42 target genes including a subset of 20 previously known as clock-controlled genes metabolism genes
27685	 1621	10905	BHLHE40	Protein	Keg1	mRNA	0	-1	14581485	miscellaneous
27785	 1621	16474	BHLHE40	Protein	F12	mRNA	0	-1	14581485	serum proteins
28343	 1621	 6934	BHLHE40	Protein	GSTT2	mRNA	0	-1	14581485	detoxification genes
 3071	 1621	17401	BHLHE40	Protein	HMGCR	mRNA	0	-1	14581485	we performed microarray analyses of differential gene expression in the liver between wild type and Stra13-/- mice and identified 42 target genes including a subset of 20 previously known as clock-controlled genes metabolism genes
32973	 1621	 3116	BHLHE40	Protein	AQP4	mRNA	0	-1	14581485	miscellaneous
33938	 1621	17033	BHLHE40	Protein	Cd59a	mRNA	0	-1	14581485	immunity
33959	 1621	14949	BHLHE40	Protein	ERBB3	mRNA	-1	-1	14581485	cell growth
34593	 1621	 5982	BHLHE40	Protein	RBM3	mRNA	0	-1	14581485	miscellaneous
35248	 1621	15587	BHLHE40	Protein	Hamp2	mRNA	0	-1	14581485	miscellaneous
 3554	 1621	 9847	BHLHE40	Protein	REN	mRNA	0	-1	14581485	proteolysis
36157	 1621	 5614	BHLHE40	Protein	Cyp2c70	mRNA	0	-1	14581485	detoxification genes
36670	 1621	11314	BHLHE40	Protein	PCK2	mRNA	-1	-1	15970569	From full text of Table 1 and following up on references in table 1: A list of potential BHLHB2- and BHLHB3-target genes
 3752	 1621	15363	BHLHE40	Protein	CYP2A6	mRNA	0	-1	14581485	detoxification genes
38738	 1621	 2994	BHLHE40	Protein	YTHDF2	mRNA	0	-1	14581485	miscellaneous
41793	 1621	  621	BHLHE40	Protein	MLH1	mRNA	0	-1	18345027	In this study, we focused on the downregulation of a key MMR gene, MLH1, and demonstrated that hypoxia-inducible transcription repressors, differentiated embryo chondrocytes (DEC1 and 2), participated in its transcriptional regulation via their bindings to E-box-like motif(s) in MLH1 promoter region. Co-transfection reporter assay revealed that DEC1 and, to greater extent, DEC2 as well as hypoxia-repressed MLH1 promoter activity. We further found that the action was remarkably inhibited by trichostatin A, and identified a possible DEC-response element in the MLH1 promoter. In vitro electrophoretic gel mobility shift and chromatin immunoprecipitation assays demonstrated that DEC1 or 2 directly bounds to the suggested element, and transient transfection assay revealed that overexpression of DEC2 repressed endogenous MLH1 expression in the cells.
42647	 1621	 5382	BHLHE40	Protein	OAT	mRNA	0	-1	14581485	we performed microarray analyses of differential gene expression in the liver between wild type and Stra13-/- mice and identified 42 target genes including a subset of 20 previously known as clock-controlled genes metabolism genes
42837	 1621	 3879	BHLHE40	Protein	FAS	mRNA	0	1	15970569	From full text of Table 1 and following up on references in table 1: A list of potential BHLHB2- and BHLHB3-target genes
43538	 1621	17125	BHLHE40	Protein	PER2	mRNA	0	-1	14672706	Modified assertion
43672	 1621	 3457	BHLHE40	Protein	NR1D1	mRNA	0	-1	18342625	Consistently, cotransfection assays demonstrate that STRA13 and DEC2 both antagonize CLOCK:BMAL1 dependent transactivation of the Rev-erbalpha {NR1D1} and Dbp promoters.
45212	 1621	16310	BHLHE40	Protein	AHCY	mRNA	0	-1	14581485	miscellaneous
47336	 1621	 7783	BHLHE40	Protein	Erh	mRNA	0	-1	14581485	cell growth
47754	 1621	 7100	BHLHE40	Protein	AADAC	mRNA	0	-1	14581485	we performed microarray analyses of differential gene expression in the liver between wild type and Stra13-/- mice and identified 42 target genes including a subset of 20 previously known as clock-controlled genes metabolism genes
47796	 1621	 6938	BHLHE40	Protein	CTSE	mRNA	-1	-1	14581485	proteolysis
48113	 1621	13471	BHLHE40	Protein	BIRC5	mRNA	0	1	16462771	DEC1 is abundantly expressed in tumors and protects against apoptosis induced by serum starvation. In this study, we report that DEC1 antiapoptosis is achieved by inducing survivin, an antiapoptotic protein. In paired tumor-normal tissues, survivin and DEC1 exhibited a paralleled expression pattern. Tetracycline-induced expression of DEC1 in stable lines proportionally increased the expression of survivin.
 5038	 1621	  825	BHLHE40	Protein	Raet1c	mRNA	0	-1	14581485	immunity
51163	 1621	11839	BHLHE40	Protein	PCK1	mRNA	0	-1	15733865	when a SHARP-2 expression plasmid was transiently transfected with various reporter plasmids into MH1C1 cells, the promoter activity of a PEPCK reporter plasmid was specifically decreased
52443	 1621	 3824	BHLHE40	Protein	CTSS	mRNA	0	-1	14581485	proteolysis
53700	 1621	  414	BHLHE40	Protein	MID1IP1	mRNA	0	-1	14581485	miscellaneous
55273	 1621	17640	BHLHE40	Protein	HSD3B1	mRNA	0	-1	14581485	we performed microarray analyses of differential gene expression in the liver between wild type and Stra13-/- mice and identified 42 target genes including a subset of 20 previously known as clock-controlled genes metabolism genes
55859	 1621	 5857	BHLHE40	Protein	BHLHE40	mRNA	0	-1	19221497	from full text - Table 1
 5709	 1621	 2942	BHLHE40	Protein	EPB41L4A-AS1	mRNA	0	-1	14581485	miscellaneous
58024	 1621	 6971	BHLHE40	Protein	0610005C13Rik	mRNA	0	-1	14581485	miscellaneous
58760	 1621	12886	BHLHE40	Protein	Erdr1	mRNA	0	-1	14581485	miscellaneous
59418	 1621	 6304	BHLHE40	Protein	SPG21	mRNA	0	-1	14581485	miscellaneous
61339	 1621	12385	BHLHE40	Protein	BCKDHB	mRNA	0	-1	14581485	we performed microarray analyses of differential gene expression in the liver between wild type and Stra13-/- mice and identified 42 target genes including a subset of 20 previously known as clock-controlled genes metabolism genes
63868	 1621	12543	BHLHE40	Protein	IGFBP1	mRNA	-1	-1	14581485	serum proteins
64396	 1621	14151	BHLHE40	Protein	BTG3	mRNA	0	-1	14581485	cell growth
65623	 1621	 6557	BHLHE40	Protein	ALAS1	mRNA	0	-1	14581485	detoxification genes
 6964	 1621	 9586	BHLHE40	Protein	Saa2	mRNA	0	-1	14581485	serum proteins
11294	15309	 4503	ARX	Protein	GBX2	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
12068	15309	12785	ARX	Protein	SOX8	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
13067	15309	 6659	ARX	Protein	KHDRBS2	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
14797	15309	 2028	ARX	Protein	LGI1	mRNA	0	-1	18799476	he microarray data set was validated by performing quantitative polymerase chain reaction (qPCR) on three independent pairs of subpallia from E14.5 mutant (Arx?/Y; Pou3f4-Cre+) and control (Arx+/Y; Pou3f4Cre+) embryos. A subset of 10 genes identified as differentially expressed, along with three genes that did not change significantly, were selected for testing. All 10 genes designated as differentially expressed by microarray analysis changed at least 2-fold by qPCR, whereas the three control genes that failed to change on the microarray also showed no difference in expression by qPCR (Fig. 2D). Log2 expression observed by microarray analysis was found to positively and significantly correlate to the log2 expression observed by qPCR (Pearson r2 = 0.7031, P < 0.001) (Fig. 2E).
16523	15309	 8321	ARX	Protein	EBF1	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
20657	15309	 5708	ARX	Protein	KITLG	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
 2181	15309	 4631	ARX	Protein	CALB1	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
22365	15309	 7917	ARX	Protein	ZNF644	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
24061	15309	15279	ARX	Protein	ETV1	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
25669	15309	13082	ARX	Protein	NDN	mRNA	0	-1	18799476	he microarray data set was validated by performing quantitative polymerase chain reaction (qPCR) on three independent pairs of subpallia from E14.5 mutant (Arx?/Y; Pou3f4-Cre+) and control (Arx+/Y; Pou3f4Cre+) embryos. A subset of 10 genes identified as differentially expressed, along with three genes that did not change significantly, were selected for testing. All 10 genes designated as differentially expressed by microarray analysis changed at least 2-fold by qPCR, whereas the three control genes that failed to change on the microarray also showed no difference in expression by qPCR (Fig. 2D). Log2 expression observed by microarray analysis was found to positively and significantly correlate to the log2 expression observed by qPCR (Pearson r2 = 0.7031, P < 0.001) (Fig. 2E).
29242	15309	12103	ARX	Protein	STK33	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
29290	15309	 8055	ARX	Protein	SKOR1	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
29803	15309	16533	ARX	Protein	PDE4DIP	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
32836	15309	12649	ARX	Protein	ETS1	mRNA	1	-1	18799476	he microarray data set was validated by performing quantitative polymerase chain reaction (qPCR) on three independent pairs of subpallia from E14.5 mutant (Arx?/Y; Pou3f4-Cre+) and control (Arx+/Y; Pou3f4Cre+) embryos. A subset of 10 genes identified as differentially expressed, along with three genes that did not change significantly, were selected for testing. All 10 genes designated as differentially expressed by microarray analysis changed at least 2-fold by qPCR, whereas the three control genes that failed to change on the microarray also showed no difference in expression by qPCR (Fig. 2D). Log2 expression observed by microarray analysis was found to positively and significantly correlate to the log2 expression observed by qPCR (Pearson r2 = 0.7031, P < 0.001) (Fig. 2E).
 3406	15309	16149	ARX	Protein	CADPS2	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
34787	15309	 4089	ARX	Protein	APLP2	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
36372	15309	 1806	ARX	Protein	PDE1C	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
36706	15309	15198	ARX	Protein	MAGEL2	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
37580	15309	  677	ARX	Protein	MEF2C	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
39125	15309	17159	ARX	Protein	CDH8	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
40068	15309	 4781	ARX	Protein	ARX	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
43815	15309	20009	ARX	Protein	CXCR4	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
45650	15309	  603	ARX	Protein	CELF2	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
45665	15309	 9037	ARX	Protein	MYL1	mRNA	0	1	17932502	The apparent increase in the differentiation of the cells overexpressing hARX was accompanied by increased levels of MLC1/3F and Myogenin, as determined by PCR and western blot (Figure 4l and m)
47523	15309	13427	ARX	Protein	PLCXD3	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
47681	15309	14846	ARX	Protein	RASGEF1B	mRNA	0	-1	18799476	he microarray data set was validated by performing quantitative polymerase chain reaction (qPCR) on three independent pairs of subpallia from E14.5 mutant (Arx?/Y; Pou3f4-Cre+) and control (Arx+/Y; Pou3f4Cre+) embryos. A subset of 10 genes identified as differentially expressed, along with three genes that did not change significantly, were selected for testing. All 10 genes designated as differentially expressed by microarray analysis changed at least 2-fold by qPCR, whereas the three control genes that failed to change on the microarray also showed no difference in expression by qPCR (Fig. 2D). Log2 expression observed by microarray analysis was found to positively and significantly correlate to the log2 expression observed by qPCR (Pearson r2 = 0.7031, P < 0.001) (Fig. 2E).
49037	15309	 8804	ARX	Protein	NTS	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
49920	15309	 2583	ARX	Protein	FAM196A	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
51317	15309	 4607	ARX	Protein	MAF	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
53274	15309	 5876	ARX	Protein	FOXP1	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
53886	15309	 6691	ARX	Protein	UNCX	mRNA	-1	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
54793	15309	 4666	ARX	Protein	MARCH1	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
54795	15309	19635	ARX	Protein	EIF2S1	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
54949	15309	10940	ARX	Protein	HAP1	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
55670	15309	19080	ARX	Protein	CNTN2	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
58354	15309	 7365	ARX	Protein	SORCS3	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
 5860	15309	 7280	ARX	Protein	PCYT1B	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
 5951	15309	 1713	ARX	Protein	MYOG	mRNA	0	1	17932502	The apparent increase in the differentiation of the cells overexpressing hARX was accompanied by increased levels of MLC1/3F and Myogenin, as determined by PCR and western blot (Figure 4l and m)
63310	15309	 1416	ARX	Protein	SHROOM2	mRNA	0	-1	18799476	he microarray data set was validated by performing quantitative polymerase chain reaction (qPCR) on three independent pairs of subpallia from E14.5 mutant (Arx?/Y; Pou3f4-Cre+) and control (Arx+/Y; Pou3f4Cre+) embryos. A subset of 10 genes identified as differentially expressed, along with three genes that did not change significantly, were selected for testing. All 10 genes designated as differentially expressed by microarray analysis changed at least 2-fold by qPCR, whereas the three control genes that failed to change on the microarray also showed no difference in expression by qPCR (Fig. 2D). Log2 expression observed by microarray analysis was found to positively and significantly correlate to the log2 expression observed by qPCR (Pearson r2 = 0.7031, P < 0.001) (Fig. 2E).
63398	15309	 5472	ARX	Protein	LMO4	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
64030	15309	15079	ARX	Protein	OPRM1	mRNA	0	1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
65758	15309	 7991	ARX	Protein	LMO3	mRNA	0	-1	18799476	Supplementary Table 1. Genes with altered expression, as defined by FDR-adjusted p < 0.05 and >=1/5 or <=-1 log2-fold change, in subpallium from Arx-/Y; Pou3f4-Cre+ mice when compared to genes expressed in the subpallium of Arxwt/Y; Pou3f4-Cre+ mice. {4 WT and 4 KO mice used in analysis}
  758	15309	18794	ARX	Protein	SST	mRNA	0	-1	18799476	he microarray data set was validated by performing quantitative polymerase chain reaction (qPCR) on three independent pairs of subpallia from E14.5 mutant (Arx?/Y; Pou3f4-Cre+) and control (Arx+/Y; Pou3f4Cre+) embryos. A subset of 10 genes identified as differentially expressed, along with three genes that did not change significantly, were selected for testing. All 10 genes designated as differentially expressed by microarray analysis changed at least 2-fold by qPCR, whereas the three control genes that failed to change on the microarray also showed no difference in expression by qPCR (Fig. 2D). Log2 expression observed by microarray analysis was found to positively and significantly correlate to the log2 expression observed by qPCR (Pearson r2 = 0.7031, P < 0.001) (Fig. 2E).
20319	 6933	 2815	POU4F1	Protein	TP53	mRNA	0	1	12431761	Here we demonstrate that Brn-3a is able to stimulate p53 expression.
42104	 6933	13115	POU4F1	Protein	EGR1	mRNA	-1	1	10640682	In this work, we describe the evidence for a functional interaction between Brn-3a and Rin and demonstrate the role of Rin in modulating the activation of the Brn-3a regulated egr-1 promoter by the N-terminal domain of Brn-3a.
10092	12656	 7502	PRKA Family	Protein	STAR	mRNA	0	1	12933667	PGE(2) caused a rapid increase in StAR expression that involves activation of the EP2 receptor-coupled protein kinase A pathway.
10656	12656	 3198	PRKA Family	Protein	TFRC	mRNA	-1	-1	 7781766	Treatment of HL-60 cells with phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, or dibutyryl-cyclic AMP (dbcAMP), a protein kinase A (PKA) activator, resulted in a 90% decrease in the level of TfR mRNA
11782	12656	 2258	PRKA Family	Protein	PLIN3	mRNA	0	1	12631276	PP17b synthesis in HeLa cells, which was significantly inhibited by protein kinase C (PKC) inhibitor This data shows that PP17b is a neutral lipid droplet-associated protein, and its expression is regulated by PKC- and PKA-dependent pathways.
17329	12656	 9108	PRKA Family	Protein	CYP1B1	mRNA	0	1	16567417	PKA signaling pathway is involved in the xenobiotic responsive element (XRE)-mediated transactivation of the human CYP1B1 gene
20765	12656	 4461	PRKA Family	Protein	ACTA2	mRNA	0	-1	15238360	SM-alpha-actin and SM22, are extremely sensitive to regulation by PKA, and even transient PKA activation by ATP is sufficient for their downregulation
21921	12656	 3995	PRKA Family	Protein	ESR1	mRNA	-1	1	15033909	stimulation of ERalpha transcription by the PKA-dependent pathway
24121	12656	 1238	PRKA Family	Protein	CYP51A1	mRNA	0	1	12145339	Activation is abolished when either CRE or SRE are removed/mutated. Furthermore, mutation of CRE abolishes SREBP-dependent activation after overexpression of SREBP-1a and CRE binding protein (CREB). This shows that CRE is essential, and that under ex vivo conditions CREB and SREBP cooperate in transactivating CYP51. Interestingly, protein kinase A shows a marked stimulation of the CYP51 promoter activity when overexpressed together with SREBP-1a but not when overexpressed with CREB, suggesting phosphorylation of SREBP-1a. Using a DNA probe containing all three regulatory elements, it is found that SREBP-1a, a CREB-like factor, and specificity protein (Sp1) all probably bind the CYP51 promoter. While SREBP-1a and the CRE-bound proteins are essential for the SREBP-dependent response, Sp1 apparently functions only to maximize sterol regulation of CYP51.
24571	12656	 2720	PRKA Family	Protein	TAGLN	mRNA	-1	-1	15238360	SM-alpha-actin and SM22, are extremely sensitive to regulation by PKA, and even transient PKA activation by ATP is sufficient for their downregulation
25485	12656	11591	PRKA Family	Protein	NR4A3	mRNA	0	1	15910753	PTH induces NR4A members through the cAMP-protein kinase A (PKA) pathway in vitro
25860	12656	19027	PRKA Family	Protein	HMOX1	mRNA	0	1	14523007	Fig. 2. Induction of HO-1 expression by OxPAPC involves PKA, PKC, p38MAPK, and ERK.
 3410	12656	18701	PRKA Family	Protein	POU2AF1	mRNA	0	1	15024018	Beta2-adrenergic receptor stimulation increased CREB phosphorylation, OCA-B expression, and OCA-B binding to the 3p-IgH enhancer in a protein kinase A-dependent manner
36760	12656	 3532	PRKA Family	Protein	NR4A2	mRNA	0	1	15910753	PTH induces NR4A members through the cAMP-protein kinase A (PKA) pathway in vitro
51401	12656	 5563	PRKA Family	Protein	SLC1A3	mRNA	0	1	10804201	PACAP induced expression of GLAST  via activation of PKA-dependent signaling pathways only, but it affected the  expression of GLT-1 via both PKA and PKC-dependent signaling pathways.
51554	12656	17867	PRKA Family	Protein	ADSSL1	mRNA	0	1	12522136	The induction was mediated through the protein kinase A and mammalian target of rapamycin signaling pathways and required a cyclic AMP response element associated with the promoter region of the Adss1 gene.
51596	12656	 5673	PRKA Family	Protein	ID1	mRNA	0	1	12947323	In the TPC-1 cell line, stimulation by TSH and serum up-regulated Id-1 mRNA expression 1.5- and 4.0-fold, respectively. Activation of the mitogen intracellular protein kinase A and protein kinase C signaling pathways also up-regulated Id-1 mRNA expression
51951	12656	 1178	PRKA Family	Protein	NR4A1	mRNA	0	1	15910753	PTH induces NR4A members through the cAMP-protein kinase A (PKA) pathway in vitro
53861	12656	 2903	PRKA Family	Protein	SLC1A2	mRNA	0	1	10804201	PACAP induced expression of GLAST  via activation of PKA-dependent signaling pathways only, but it affected the  expression of GLT-1 via both PKA and PKC-dependent signaling pathways.
61262	12656	 1552	PRKA Family	Protein	ODC1	mRNA	1	1	 1356108	Transcription of the ornithine decarboxylase (ODC) gene is rapidly elevated by activation of protein kinase A (PKA). The additive influence of three cis-acting elements is responsible for this regulation in an adrenal carcinoma cell line. Two sites, CRE2 at -48 base pairs (bp) relative to the start of transcription and CRE3 at +95 bp, are identical to the core motif of the cAMP-responsive element (CRE) of the somatostatin gene and are conserved in the mouse, rat, and human ODC genes. Mutation of CRE2 resulted in a substantial decrease in basal promoter activity, as well as a 5-fold decrease in inducibility of the ODC promoter by PKA. CRE3 did not contribute to the basal activity of the ODC promoter, but mutation of this site resulted in a 2-fold decrease in inducibility by PKA. Deletion of a 45-bp sequence (GC-box) located 5p of CRE2, also resulted in a 2-fold decrease in inducibility of the ODC promoter. DNase I protection revealed the presence of protein binding at CRE2, the TATA box, and the GC-box of the ODC promoter. Mutation of CRE2 resulted in loss of protection of this sequence, as well as the 3p extension of the footprint over the TATA box, without affecting interactions at the GC box. Antibodies to the well characterized CRE-binding protein CREB recognized proteins binding to CRE2, suggesting that binding of CREB, or an antigenically related protein, is important for the activity of CRE2. Additionally, recombinant CREB bound to a DNA probe containing the CRE2 sequence.
 6128	12656	 9018	PRKA Family	Protein	IAPP	mRNA	0	1	14615061	These results indicate that amylin is positively regulated by cAMP and PKA through the transcription factors HNF-1 and NFY.
62419	12656	11013	PRKA Family	Protein	IBSP	mRNA	0	-1	11108282	_ Ariadne: The activators of the PKA pathway,  IBMX (10 m M ), Sp-cAMPss (10 .. M ) and forskolin (10 .. M ) significantly  decreased BSP mRNA expression. [Expression]
 7909	12656	19902	PRKA Family	Protein	ACHE	mRNA	0	-1	12140295	The increase of AChE expression was reciprocally regulated by a cAMP-dependent signaling pathway. The level of intracellular cAMP, the activity of cAMP-dependent protein kinase, the phosphorylation of cAMP-responsive element binding protein and the activity of cAMP- responsive element (CRE) were down-regulated during the myotube formation.
21133	10928	12447	FOXD1	Protein	ZIC2	mRNA	0	1	15509772	In the Foxd1 deficient retina, proteins designating the ipsilateral projection, such as Zic2 and EphB1, are missing
23638	10928	14416	FOXD1	Protein	EPHB1	mRNA	0	1	15509772	In the Foxd1 deficient retina, proteins designating the ipsilateral projection, such as Zic2 and EphB1, are missing
24993	10928	 4764	FOXD1	Protein	ISL1	mRNA	0	1	15509772	In addition, in the Foxd1 deficient ventral diencephalon, Foxg1 invades the Foxd1 domain, Zic2 and Islet1 expression are minimized, and Slit2 prematurely expands
26769	10928	 4058	FOXD1	Protein	PRKAR1A	mRNA	0	1	11943768	Modified assertion
66082	10928	 8334	FOXD1	Protein	SLIT2	mRNA	-1	-1	15509772	In addition, in the Foxd1 deficient ventral diencephalon, Foxg1 invades the Foxd1 domain, Zic2 and Islet1 expression are minimized, and Slit2 prematurely expands
16957	15702	19193	Cebp Family	Protein	MT2A	mRNA	0	1	12016146	Multiple transcription factors including AP-1 and C/EBP are also implicated in the fine-tuned up regulation of other oxidative stress-related target genes which become significantly expressed in CS-treated cells, i.e. mt1/2 (35), hsp105 and hsp90
 2499	15702	17889	Cebp Family	Protein	SLC2A4	mRNA	1	1	NA	page 266 Binding sites for the C/EBP proteins reside within the promoters of the aP2, stearoyl-CoA desaturase and insulin stimulatable glucose transporter genes
25832	15702	19027	Cebp Family	Protein	HMOX1	mRNA	0	1	12016146	he CS-dependent induction of ho-1 may be achieved potentially, at least in part, via activation of transcription factors binding to AP-1 and C/EBP recognition elements, which are both integral parts of the murine ho-1 promoter
35792	15702	 9011	Cebp Family	Protein	HSPH1	mRNA	0	1	12016146	Multiple transcription factors including AP-1 and C/EBP are also implicated in the fine-tuned up regulation of other oxidative stress-related target genes which become significantly expressed in CS-treated cells, i.e. mt1/2 (35), hsp105 and hsp90
42909	15702	 7577	Cebp Family	Protein	HSP90AA1	mRNA	0	1	12016146	Multiple transcription factors including AP-1 and C/EBP are also implicated in the fine-tuned up regulation of other oxidative stress-related target genes which become significantly expressed in CS-treated cells, i.e. mt1/2 (35), hsp105 and hsp90
49107	15702	13844	Cebp Family	Protein	HSP90B1	mRNA	0	1	12016146	Multiple transcription factors including AP-1 and C/EBP are also implicated in the fine-tuned up regulation of other oxidative stress-related target genes which become significantly expressed in CS-treated cells, i.e. mt1/2 (35), hsp105 and hsp90
52028	15702	 3467	Cebp Family	Protein	HSP90AB1	mRNA	0	1	12016146	Multiple transcription factors including AP-1 and C/EBP are also implicated in the fine-tuned up regulation of other oxidative stress-related target genes which become significantly expressed in CS-treated cells, i.e. mt1/2 (35), hsp105 and hsp90
66066	15702	 5646	Cebp Family	Protein	MT1A	mRNA	0	1	12016146	Multiple transcription factors including AP-1 and C/EBP are also implicated in the fine-tuned up regulation of other oxidative stress-related target genes which become significantly expressed in CS-treated cells, i.e. mt1/2 (35), hsp105 and hsp90
10172	11004	10387	TGFBR Family	Protein	COL12A1	mRNA	0	1	12009330	Addition of TGF-beta resulted in an increase in the amount of alpha1(XII) present and a decrease of alpha1(XIV) mRNA in a dose-dependent manner.
12266	11004	 8413	TGFBR Family	Protein	FBN1	mRNA	0	1	11012893	mRNA expression of fibrillin-1, emilin, and elastin was strong in quiescent mesangial cells; their gene expression was further up-regulated by transforming growth factor-beta1, while it was transiently reduced when cells were exposed to mitogenic 10% fetal calf serum and platelet-derived growth factor
12522	11004	 3012	TGFBR Family	Protein	CPOX	mRNA	1	1	11248690	Increases in cellular heme concomitant with a marked induction of the expression of heme-biosynthetic enzymes, including CPOX, ferrochelatase and erythroid-specific delta-aminolevulinic acid synthase, as well as of alpha-globin synthesis, were observed when cells were treated with transforming growth factor (TGF)beta 1
12834	11004	17369	TGFBR Family	Protein	IL6	mRNA	0	-1	14754879	Adenoviral overexpression of Smad3 potently repressed inducible expression of endogenous iNOS and IL-6. Conversely, TGF-beta1 inhibition of cytokine-mediated induction of iNOS and IL-6 expression was completely blocked in Smad3-deficient VSMCs
13189	11004	10423	TGFBR Family	Protein	H3F3B	mRNA	0	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
13471	11004	16612	TGFBR Family	Protein	MMP13	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
13885	11004	17250	TGFBR Family	Protein	PTGS2	mRNA	0	1	16135802	TGF-beta-induced cell cycle arrest and migration, but not epithelial-mesenchymal transition, are abolished after silencing of Smad4. Altogether our results suggest that loss of Smad4 might promote TGF-beta-mediated tumorigenesis by abolishing tumor-suppressive functions of TGF-beta while maintaining some tumor-promoting TGF-beta responses.
14916	11004	14108	TGFBR Family	Protein	EDNRB	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
16209	11004	 2348	TGFBR Family	Protein	THBS2	mRNA	0	1	15347840	After 96 h of treatment, TSP-1 and TSP-2 mRNA levels were significantly increased (p < 0.05), which also inhibited HP75 cell growth.
  168	11004	13982	TGFBR Family	Protein	AES	mRNA	0	1	12488458	Therefore, in this study, we used in-house microarrays (approximately 5500 genes) to identify pathway-specific gene clustering in TGF-beta(1)-treated cells. In addition to the seven labeled genes, this cluster contains TARBP1, TSC22, CGR19, CSNK1G2, BRF1, DCTN4, COL14A1, TWEAK, SAT, IGFBP5, AES, NR5A2, CAMP, ID3, APPBP1, SFRS8, DDIT3/GADD153, and CASP8AP2/FLASH.
17793	11004	 5117	TGFBR Family	Protein	SAT1	mRNA	1	1	12488458	Therefore, in this study, we used in-house microarrays (approximately 5500 genes) to identify pathway-specific gene clustering in TGF-beta(1)-treated cells. In addition to the seven labeled genes, this cluster contains TARBP1, TSC22, CGR19, CSNK1G2, BRF1, DCTN4, COL14A1, TWEAK, SAT, IGFBP5, AES, NR5A2, CAMP, ID3, APPBP1, SFRS8, DDIT3/GADD153, and CASP8AP2/FLASH.
20291	11004	19571	TGFBR Family	Protein	CXCL2	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
20342	11004	 2815	TGFBR Family	Protein	TP53	mRNA	0	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
21087	11004	 6179	TGFBR Family	Protein	TLR6	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
21386	11004	 1369	TGFBR Family	Protein	KRT8	mRNA	0	-1	11358848	B, effect of the selective MEK1 inhibitor PD 98059 on the mRNA expression of differentiation markers in the cell line PANC-1 after 48 h. TGF-beta1-induced down-regulation of cytokeratins 8 and 19 in PANC-1 was attenuated or blocked by pretreatment with PD 98059. In a similar manner, PD 98059 reduced the up-regulation of vimentin by TGF-beta1, even 48 h after the application of TGF-beta1 and the MEK1 inhibitor.
23584	11004	 4571	TGFBR Family	Protein	GADD45B	mRNA	0	1	14630914	Second, silencing of SMAD protein levels using short interfering RNAs revealed that TGFbeta-induced activation of the endogenous gadd45beta gene required SMAD3 and SMAD4 but not SMAD2
24560	11004	 2720	TGFBR Family	Protein	TAGLN	mRNA	-1	1	12547711	Transforming growth factor-beta1 (TGF-beta1) plays a central role in promoting extracellular matrix protein deposition by promoting the transformation of fibroblasts to myofibroblasts. To gain new insights into the transcriptional programs involved, we profiled human fetal lung fibroblast global gene expression in response to TGF-beta1 up to 24 hours using oligonucleotide microarrays. In this report, we present data for 146 genes that were up-regulated at least twofold at two time points. These genes group into several major functional categories, including genes involved in cytoskeletal reorganization (n = 30), matrix formation (n = 25), metabolism and protein biosynthesis (n = 27), cell signaling (n = 21), proliferation and survival (n = 13), gene transcription (n = 9), and of uncertain function (n = 21). For 80 of these genes, this is the first report that they are TGF-beta1-responsive. The early induction of two members of the inhibitor of differentiation (ID) family of transcriptional regulators, ID1 and ID3, was followed by the up-regulation of a number of genes that are usually expressed by highly differentiated smooth muscle cells, including smooth muscle myosin heavy chain, basic calponin, and smoothelin. These findings were confirmed at the protein level for primary adult lung fibroblasts. ID1 further behaved like a typical immediate-early gene and, unlike ID3, was expressed and induced at the protein level. Immunohistochemical analysis showed that ID1 was highly expressed by (myo)fibroblasts within fibrotic foci in experimentally induced pulmonary fibrosis. ID1 acts as a dominant-negative antagonist of basic helix-loop-helix transcription factors that drive cell lineage commitment and differentiation. These findings have important implications for our understanding of fibroblast transcriptional programming in response to TGF-beta1 during development, oncogenesis, tissue repair, and fibrosis.
27217	11004	  618	TGFBR Family	Protein	WEE1	mRNA	-1	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
27612	11004	  325	TGFBR Family	Protein	ARL4A	mRNA	0	1	15505052	Proteomic analysis indicated that there was increased proteolysis of vimentin with both treatments. Tropomyosin 1alpha was increased in both gene and protein expression, suggesting alterations of the cytoskeleton by the disease.
 2771	11004	  908	TGFBR Family	Protein	MMP9	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
27984	11004	 4245	TGFBR Family	Protein	COL16A1	mRNA	0	1	10429949	In both cell types, TGF-beta2 treatment results in an up-regulation of the collagen XVI-mRNA by approximately 50%.
 2810	11004	15988	TGFBR Family	Protein	CASP1	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
28218	11004	 7832	TGFBR Family	Protein	THBS1	mRNA	-1	1	11390996	down
28624	11004	 3297	TGFBR Family	Protein	TIMP1	mRNA	0	1	11279127	Using this stringent approach, we have identified COL1A2, COL3A1, COL6A1, COL6A3, and tissue inhibitor of metalloproteases-1 as definite TGF-beta/Smad3 targets.
 2874	11004	12537	TGFBR Family	Protein	CCL4	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
29565	11004	13348	TGFBR Family	Protein	VIM	mRNA	0	1	11358848	B, effect of the selective MEK1 inhibitor PD 98059 on the mRNA expression of differentiation markers in the cell line PANC-1 after 48 h. TGF-beta1-induced down-regulation of cytokeratins 8 and 19 in PANC-1 was attenuated or blocked by pretreatment with PD 98059. In a similar manner, PD 98059 reduced the up-regulation of vimentin by TGF-beta1, even 48 h after the application of TGF-beta1 and the MEK1 inhibitor.
 3098	11004	13945	TGFBR Family	Protein	CDC27	mRNA	0	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
33987	11004	14547	TGFBR Family	Protein	KRT18	mRNA	0	1	12547711	Transforming growth factor-beta1 (TGF-beta1) plays a central role in promoting extracellular matrix protein deposition by promoting the transformation of fibroblasts to myofibroblasts. To gain new insights into the transcriptional programs involved, we profiled human fetal lung fibroblast global gene expression in response to TGF-beta1 up to 24 hours using oligonucleotide microarrays. In this report, we present data for 146 genes that were up-regulated at least twofold at two time points. These genes group into several major functional categories, including genes involved in cytoskeletal reorganization (n = 30), matrix formation (n = 25), metabolism and protein biosynthesis (n = 27), cell signaling (n = 21), proliferation and survival (n = 13), gene transcription (n = 9), and of uncertain function (n = 21). For 80 of these genes, this is the first report that they are TGF-beta1-responsive. The early induction of two members of the inhibitor of differentiation (ID) family of transcriptional regulators, ID1 and ID3, was followed by the up-regulation of a number of genes that are usually expressed by highly differentiated smooth muscle cells, including smooth muscle myosin heavy chain, basic calponin, and smoothelin. These findings were confirmed at the protein level for primary adult lung fibroblasts. ID1 further behaved like a typical immediate-early gene and, unlike ID3, was expressed and induced at the protein level. Immunohistochemical analysis showed that ID1 was highly expressed by (myo)fibroblasts within fibrotic foci in experimentally induced pulmonary fibrosis. ID1 acts as a dominant-negative antagonist of basic helix-loop-helix transcription factors that drive cell lineage commitment and differentiation. These findings have important implications for our understanding of fibroblast transcriptional programming in response to TGF-beta1 during development, oncogenesis, tissue repair, and fibrosis.
35237	11004	 5296	TGFBR Family	Protein	PLAU	mRNA	1	1	15372629	Nontoxic concentrations of TGF beta1 upregulate uPA expression in HRA and SKOV-3 human ovariabn cancer cells
35541	11004	10510	TGFBR Family	Protein	CCR5	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
 3577	11004	 6334	TGFBR Family	Protein	MARCKSL1	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
38942	11004	12898	TGFBR Family	Protein	UGDH	mRNA	0	1	12682078	The expression of UGDH was up- and down-regulated by transforming growth factor (TGF)-beta and hypoxia, respectively.
38954	11004	 7262	TGFBR Family	Protein	ALAD	mRNA	0	1	11248690	Increases in cellular heme concomitant with a marked induction of the expression of heme-biosynthetic enzymes, including CPOX, ferrochelatase and erythroid-specific delta-aminolevulinic acid synthase, as well as of alpha-globin synthesis, were observed when cells were treated with transforming growth factor (TGF)beta 1
39470	11004	14512	TGFBR Family	Protein	KRT19	mRNA	0	-1	11358848	B, effect of the selective MEK1 inhibitor PD 98059 on the mRNA expression of differentiation markers in the cell line PANC-1 after 48 h. TGF-beta1-induced down-regulation of cytokeratins 8 and 19 in PANC-1 was attenuated or blocked by pretreatment with PD 98059. In a similar manner, PD 98059 reduced the up-regulation of vimentin by TGF-beta1, even 48 h after the application of TGF-beta1 and the MEK1 inhibitor.
39695	11004	 8195	TGFBR Family	Protein	TNFSF12	mRNA	0	1	12488458	Therefore, in this study, we used in-house microarrays (approximately 5500 genes) to identify pathway-specific gene clustering in TGF-beta(1)-treated cells. In addition to the seven labeled genes, this cluster contains TARBP1, TSC22, CGR19, CSNK1G2, BRF1, DCTN4, COL14A1, TWEAK, SAT, IGFBP5, AES, NR5A2, CAMP, ID3, APPBP1, SFRS8, DDIT3/GADD153, and CASP8AP2/FLASH.
40100	11004	 1245	TGFBR Family	Protein	SLC12A4	mRNA	0	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
40245	11004	11058	TGFBR Family	Protein	LTF	mRNA	0	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
42395	11004	 9509	TGFBR Family	Protein	AATF	mRNA	0	-1	11027528	three-dimensional collagen gel. In search of TGF-beta regulated genes involved in this differentiation process, we isolated a TGF-beta downregulated cDNA, human homologue of rat apoptosis antagonising
42813	11004	 3879	TGFBR Family	Protein	FAS	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
42865	11004	11585	TGFBR Family	Protein	ELN	mRNA	0	1	11012893	mRNA expression of fibrillin-1, emilin, and elastin was strong in quiescent mesangial cells; their gene expression was further up-regulated by transforming growth factor-beta1, while it was transiently reduced when cells were exposed to mitogenic 10% fetal calf serum and platelet-derived growth factor
46235	11004	 9584	TGFBR Family	Protein	EMILIN1	mRNA	0	1	11012893	mRNA expression of fibrillin-1, emilin, and elastin was strong in quiescent mesangial cells; their gene expression was further up-regulated by transforming growth factor-beta1, while it was transiently reduced when cells were exposed to mitogenic 10% fetal calf serum and platelet-derived growth factor
48172	11004	 5738	TGFBR Family	Protein	MX1	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
49074	11004	14748	TGFBR Family	Protein	CCL3	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
49494	11004	10600	TGFBR Family	Protein	CXCL1	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
51516	11004	 6739	TGFBR Family	Protein	PMEPA1	mRNA	0	1	12670906	PMEPA1 was identified as a gene highly up-regulated by TGF-beta treatment PMEPA1 is a direct target of TGF-beta signaling
52988	11004	 5718	TGFBR Family	Protein	APOC3	mRNA	0	1	12631740	We have shown previously that the transforming growth factor-beta (TGFbeta)-regulated Sma-Mad (Smad) protein 3 and Smad4 proteins transactivate the apolipoprotein C-III promoter in hepatic cells
53512	11004	 2322	TGFBR Family	Protein	MARCO	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
54044	11004	 5118	TGFBR Family	Protein	NOS2	mRNA	0	-1	14754879	Adenoviral overexpression of Smad3 potently repressed inducible expression of endogenous iNOS and IL-6. Conversely, TGF-beta1 inhibition of cytokine-mediated induction of iNOS and IL-6 expression was completely blocked in Smad3-deficient VSMCs
55239	11004	12981	TGFBR Family	Protein	COL3A1	mRNA	-1	1	 9729521	TGF-beta1 induced increased alpha1(I), alpha1(III), and alpha1(IV) collagen mRNA expression
56588	11004	20113	TGFBR Family	Protein	CP	mRNA	0	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
56834	11004	10206	TGFBR Family	Protein	PTHLH	mRNA	0	1	11590145	TGF beta activates PTHrP expression by specifically up-regulating transcription from the PTHrP P3 promoter
57378	11004	17981	TGFBR Family	Protein	FECH	mRNA	1	1	11248690	Increases in cellular heme concomitant with a marked induction of the expression of heme-biosynthetic enzymes, including CPOX, ferrochelatase and erythroid-specific delta-aminolevulinic acid synthase, as well as of alpha-globin synthesis, were observed when cells were treated with transforming growth factor (TGF)beta 1
57948	11004	 1612	TGFBR Family	Protein	COL14A1	mRNA	0	1	12488458	Therefore, in this study, we used in-house microarrays (approximately 5500 genes) to identify pathway-specific gene clustering in TGF-beta(1)-treated cells. In addition to the seven labeled genes, this cluster contains TARBP1, TSC22, CGR19, CSNK1G2, BRF1, DCTN4, COL14A1, TWEAK, SAT, IGFBP5, AES, NR5A2, CAMP, ID3, APPBP1, SFRS8, DDIT3/GADD153, and CASP8AP2/FLASH.
58346	11004	15724	TGFBR Family	Protein	ST8SIA5	mRNA	0	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
58427	11004	17331	TGFBR Family	Protein	SLC5A5	mRNA	0	-1	14623893	The results suggest that, through activation of Smad3, TGF-beta decreases Pax8 DNA binding activity as well as Pax8 mRNA and protein levels, which are at least partially involved in TGF-beta-induced down-regulation of NIS gene expression in thyroid follicular cells
58999	11004	 8399	TGFBR Family	Protein	COL6A3	mRNA	0	1	11279127	Using this stringent approach, we have identified COL1A2, COL3A1, COL6A1, COL6A3, and tissue inhibitor of metalloproteases-1 as definite TGF-beta/Smad3 targets.
60385	11004	19732	TGFBR Family	Protein	IGFBP5	mRNA	0	1	12488458	Therefore, in this study, we used in-house microarrays (approximately 5500 genes) to identify pathway-specific gene clustering in TGF-beta(1)-treated cells. In addition to the seven labeled genes, this cluster contains TARBP1, TSC22, CGR19, CSNK1G2, BRF1, DCTN4, COL14A1, TWEAK, SAT, IGFBP5, AES, NR5A2, CAMP, ID3, APPBP1, SFRS8, DDIT3/GADD153, and CASP8AP2/FLASH.
60906	11004	15700	TGFBR Family	Protein	PRDX2	mRNA	1	-1	15864612	When NHEK cells were treated with INF-gamma and TGF-beta1, Prx I/II were up-regulated by INF-gamma, but Prx I/II were down-regulated by TGF-beta1.
60958	11004	 2450	TGFBR Family	Protein	ITGA6	mRNA	-1	-1	11374867	We found that the expression of integrin alpha6 is downregulated by TGF-beta(1),
61261	11004	 1552	TGFBR Family	Protein	ODC1	mRNA	1	1	11180396	cell lines of varying degrees of malignant potential were examined for possible TGF-beta(1)-mediated alterations in ODC expression. Selective induction of ODC gene expression occurred.
61788	11004	 1730	TGFBR Family	Protein	KLF10	mRNA	1	1	10861837	However, TGF-beta remained the most potent of these cytokines, inducing TIEG mRNA steady-state levels at 0.1 ng/ml, with a maximum induction of 24-fold at 2.0 ng/ml. The BMP-2 (16-fold), BMP-4 (4-fold), and activin (1-3-fold) also induced TIEG mRNA levels
62681	11004	 3633	TGFBR Family	Protein	HIST1H2BC	mRNA	0	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
63404	11004	18982	TGFBR Family	Protein	CCR9	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
65885	11004	13225	TGFBR Family	Protein	COL6A1	mRNA	0	1	11279127	Using this stringent approach, we have identified COL1A2, COL3A1, COL6A1, COL6A3, and tissue inhibitor of metalloproteases-1 as definite TGF-beta/Smad3 targets.
66373	11004	19909	TGFBR Family	Protein	HBA1	mRNA	0	1	11248690	Increases in cellular heme concomitant with a marked induction of the expression of heme-biosynthetic enzymes, including CPOX, ferrochelatase and erythroid-specific delta-aminolevulinic acid synthase, as well as of alpha-globin synthesis, were observed when cells were treated with transforming growth factor (TGF)beta 1
 7253	11004	 3388	TGFBR Family	Protein	IL15	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
 8324	11004	 6202	TGFBR Family	Protein	BTG1	mRNA	-1	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
  838	11004	 1146	TGFBR Family	Protein	GCLC	mRNA	0	-1	15629866	TGF-beta downregulated expression of endogenous GCLC mRNA and GCLC protein
 8561	11004	 4840	TGFBR Family	Protein	GAS7	mRNA	0	-1	14603463	The focus of TGFbeta inhibition is observed to be directed in genes involved in chemotaxis (IL-15, CXCL1, CXCL2, CCL3, CCL4, CCL5, CCL9), chemokine receptors (CCR5, CCR9), LIF receptor, and FPR2, and on genes mediating cell migration (MMP9, MMP13, MacMARCKS, endothelin receptor B, Ena/VASP, Gas7), apoptosis (FAS, TNF, TNF receptor, caspase-1 and -11), and host response to infection (toll-like receptor 6, Mx1, and MARCO).
  890	11004	18314	TGFBR Family	Protein	STMN1	mRNA	0	1	12488458	supplemental table: apoptosis related genes upregulated in responst to TGF-beta
 9053	11004	12003	TGFBR Family	Protein	PAX8	mRNA	0	-1	14623893	The results suggest that, through activation of Smad3, TGF-beta decreases Pax8 DNA binding activity as well as Pax8 mRNA and protein levels, which are at least partially involved in TGF-beta-induced down-regulation of NIS gene expression in thyroid follicular cells
33693	18289	 1040	RUNX3	Protein	CD36	mRNA	0	-1	16887969	We present evidence that CD36 expression is negatively regulated by the RUNX3 transcription factor during myeloid cell differentiation and activation.
51038	18289	13884	RUNX3	Protein	CDKN1A	mRNA	1	1	16135801	RUNX3 binds to and activates the p21 promoter.
52056	18289	14424	RUNX3	Protein	ITGAL	mRNA	0	1	12855590	RUNX3/AML-2 binding to the CD11a promoter correlates with increased RUNX3/AML-2 protein levels and enhanced CD11a/CD18 cell surface expression.
52162	18289	11381	RUNX3	Protein	CD79A	mRNA	0	1	10748032	It has recently been shown that AML1, AML2, or both bind to their proposed binding sites in the Tbeta RE and form a complex with Smad3 to stimulate transcription from the GL Ig alpha  promoter in a cooperative manner (13, 14).
 9836	18289	 5730	RUNX3	Protein	SP7	mRNA	0	-1	17352693	These results demonstrate the transcriptional regulation of Osterix expression by Runx3
17009	 6740	 3722	TYMP	Protein	PPARG	mRNA	0	1	11888683	This significant association was observed also when PPAR gamma was expressed in the presence of PDECGF, which resulted, when considered alone, to an angiogenic factor typical of solid cancers and appeared related to poor prognosis.
35005	 6740	 7998	TYMP	Protein	ERBB2	mRNA	0	1	10845553	However, TP expression was related to high angiogenesis only in cases with absence of c-erB-2 expression (P < 0.0001). c-erbB-2 expression in poorly vascularised tumours was linked with poor outcome (P = 0.03).
51670	 6740	  219	TYMP	Protein	FASLG	mRNA	-1	1	12481413	Both Fas and FasL mRNA expression were triggered after exposing TP+ cells to the drug.
 7593	 6740	  394	TYMP	Protein	TNFRSF1A	mRNA	0	1	14573775	A role for TNF-R1 cannot be completely ruled out based on this experiment, however, because the TNF-R1 antibody alone caused a modest increase in TP expression (lane 3), and a modest attenuation of the TNFalpha-induced increase in TP mRNA (lane 4).
17433	19787	14361	quinolinic acid	Compound	CXCL12	mRNA	-1	1	15206714	QUIN induces astrocytes to produce large quantities of MCP-1 (CCL2), and lesser amounts of RANTES (CCL5), IL-8 (CXCL8). QUIN also increases SDF-1alpha (CXCL12), HuMIG (CXCL9) and fractalkine (CX3CL1) mRNA expression. Moreover, QUIN leads to up-regulation of the chemokine receptor expression of CXCR4, CCR5, and CCR3
25810	  571	19027	BLVRA	Protein	HMOX1	mRNA	0	1	16287987	GATA1 is a key factor in lineage-specific development of stem cells and may be indicative of a function for BVR in the establishment of gene-expression profiles in developing stem cells. GATA2, a marker of skeletal muscle hypertrophy (44), does not affect BVR transcription. Biliverdin Reductase: An Intracellular Transporter? There is the likelihood that in higher forms of life the conserved COOH-terminal-domain cysteines within the HCX10CC/H motif and the extensive beta- sheet in this domain are involved in interactions with other proteins, sulfhydryl reagents, in Zn/metal binding, and in dimerization; native hBVR is a Zn metalloprotein (27, 36). Functions that are assigned to this cysteine-rich domain include: 1) being the interaction site for het- erodimerization with kinases/signaling molecules and homodimerization (1); 2) its function as a \molecular switch\ in cell signaling through to -SS- interconversion; and, 3) being the site of interaction with substrate/cofactor and heme (40). The involvement of BVR in intracellular trafficking of signaling factors is consistent with the observation that BVR interacts with the insulin receptor kinase (IRK) domain (29) and localizes into the nucleus upon activation by cGMP (33). The proposed function of BVR in protein:protein interaction and intracellular transport of signaling factors is based on its kinase activity, its primary structural features, and the secondary structure of the COOH-terminal domain as a large beta-sheet made of six strands; such a structure characterizes a monomer-monomer interface site, similar to those found in intracellular-trafficking \scaffold\ proteins. Notably, two copies of the CX10C motif are present in the C1 domain of PKCs (42, 46). Oxidation of cysteine residues to the disulfide form (or covalently bonding with -SH-reactive compounds) prevents BVR dimerization and reductase activity (27). Homodimeric BVR is incapable of docking with other proteins, and this could arise from exposure to factors that affect the oxidation state of the cell and/or have affinity for sulfhydryls. Protein sulfhydryls are a target for the NO- radical (4), for example. Over two decades ago, when little was known about the primary and secondary structure of BVR, observations were made that were unexplainable at the time but when revisited in light of the current information offer support for the function of cysteine residues in BVR protein:protein interactions. In one study rat BVR was characterized as \extremely sensitive\ to -SH-reactive reagents, although biliverdin was found to fully protect the enzyme (27). Another observation (16) was the \interconversion\ of two molecular forms of rat liver BVR; a ~34-kDa form was converted to a larger molecular form (~68 kDa) when rats were treated with -SH-reactive agents. Reduced thioredoxin, an agent that can reduce disulfide bonds to sulfhydryl groups, could reverse the conversion. The larger form was found to lack sensitivity to sulfhydryl reagents. These observations would suggest occurrence of dynamic interchange between mono- and dimeric forms of BVR as the consequence of sulfhydryl disulfide interconversion in vivo. Regulation of Oxidative Response and HO-1 Expression Regulation of HO-1 by means of reductase and transcriptional activities may serve as a paradigm for gene regulation of oxidative-response gene expression by BVR. The first direct link between BVR and HO-1 response was provided by a study that demonstrated nuclear localization of BVR in rat kidneys in response to inducers of HO-1, such as bromobenzene and bacterial LPS (33). BVR nuclear localization is an active process and requires an intact nuclear localization signal (FIGURE 1) (33). Gene-array analysis suggests that BVR activates a large number of genes in cell-signaling pathways, immune, and stress-response, and further analysis showed that, indeed, ho-1 and activating transcription factor (ATF-2)/cAMP re...
35874	  571	19603	BLVRA	Protein	ATF2	mRNA	1	1	16287987	GATA1 is a key factor in lineage-specific development of stem cells and may be indicative of a function for BVR in the establishment of gene-expression profiles in developing stem cells. GATA2, a marker of skeletal muscle hypertrophy (44), does not affect BVR transcription. Biliverdin Reductase: An Intracellular Transporter? There is the likelihood that in higher forms of life the conserved COOH-terminal-domain cysteines within the HCX10CC/H motif and the extensive beta- sheet in this domain are involved in interactions with other proteins, sulfhydryl reagents, in Zn/metal binding, and in dimerization; native hBVR is a Zn metalloprotein (27, 36). Functions that are assigned to this cysteine-rich domain include: 1) being the interaction site for het- erodimerization with kinases/signaling molecules and homodimerization (1); 2) its function as a \molecular switch\ in cell signaling through to -SS- interconversion; and, 3) being the site of interaction with substrate/cofactor and heme (40). The involvement of BVR in intracellular trafficking of signaling factors is consistent with the observation that BVR interacts with the insulin receptor kinase (IRK) domain (29) and localizes into the nucleus upon activation by cGMP (33). The proposed function of BVR in protein:protein interaction and intracellular transport of signaling factors is based on its kinase activity, its primary structural features, and the secondary structure of the COOH-terminal domain as a large beta-sheet made of six strands; such a structure characterizes a monomer-monomer interface site, similar to those found in intracellular-trafficking \scaffold\ proteins. Notably, two copies of the CX10C motif are present in the C1 domain of PKCs (42, 46). Oxidation of cysteine residues to the disulfide form (or covalently bonding with -SH-reactive compounds) prevents BVR dimerization and reductase activity (27). Homodimeric BVR is incapable of docking with other proteins, and this could arise from exposure to factors that affect the oxidation state of the cell and/or have affinity for sulfhydryls. Protein sulfhydryls are a target for the NO- radical (4), for example. Over two decades ago, when little was known about the primary and secondary structure of BVR, observations were made that were unexplainable at the time but when revisited in light of the current information offer support for the function of cysteine residues in BVR protein:protein interactions. In one study rat BVR was characterized as \extremely sensitive\ to -SH-reactive reagents, although biliverdin was found to fully protect the enzyme (27). Another observation (16) was the \interconversion\ of two molecular forms of rat liver BVR; a ~34-kDa form was converted to a larger molecular form (~68 kDa) when rats were treated with -SH-reactive agents. Reduced thioredoxin, an agent that can reduce disulfide bonds to sulfhydryl groups, could reverse the conversion. The larger form was found to lack sensitivity to sulfhydryl reagents. These observations would suggest occurrence of dynamic interchange between mono- and dimeric forms of BVR as the consequence of sulfhydryl disulfide interconversion in vivo. Regulation of Oxidative Response and HO-1 Expression Regulation of HO-1 by means of reductase and transcriptional activities may serve as a paradigm for gene regulation of oxidative-response gene expression by BVR. The first direct link between BVR and HO-1 response was provided by a study that demonstrated nuclear localization of BVR in rat kidneys in response to inducers of HO-1, such as bromobenzene and bacterial LPS (33). BVR nuclear localization is an active process and requires an intact nuclear localization signal (FIGURE 1) (33). Gene-array analysis suggests that BVR activates a large number of genes in cell-signaling pathways, immune, and stress-response, and further analysis showed that, indeed, ho-1 and activating transcription factor (ATF-2)/cAMP re...
21912	 1388	 3995	STAT5 Family	Protein	ESR1	mRNA	-1	1	12670737	Transcription of the genes encoding both ERalpha (Esr1) and ERbeta (Esr2) is stimulated by PRL through the Jak2-Stat5 pathway and Stat5-response elements that are located in each of the Esr promoters.
22960	 1388	 1915	STAT5 Family	Protein	ONECUT1	mRNA	0	1	11870262	_ Ariadne: Together, these data demonstrate  that GH stimulates transcription of the hnf-6 gene by a mechanism involving  STAT5 and HNF-4. [Expression] _ Ariadne: HNF-6 expression can be  regulated and modulated by growth hormone (GH) (Lahuna et al., 1997 , 2000 ). [Expression]
23763	 1388	 6636	STAT5 Family	Protein	BCL2L1	mRNA	0	1	12091337	Finally, we demonstrated that the STAT5 target genes Bcl-X, SOCS2, and SOCS3 were up-regulated by costimulation with PGE2
34214	 1388	14474	STAT5 Family	Protein	ESR2	mRNA	0	1	12670737	Transcription of the genes encoding both ERalpha (Esr1) and ERbeta (Esr2) is stimulated by PRL through the Jak2-Stat5 pathway and Stat5-response elements that are located in each of the Esr promoters.
43135	 1388	16764	STAT5 Family	Protein	PIM1	mRNA	0	1	11867689	GM-CSF signals through JAK2 and STAT5 and stimulates the expression of STAT5 target genes, such as pim-1 and CIS.
43735	 1388	 7426	STAT5 Family	Protein	SOCS2	mRNA	0	1	12396724	we demonstrate that induction of SOCS1, SOCS2, SOCS3, and cytokine-inducible SH2-containing protein (CIS) in response to EPO stimulation appears to depend on Stat5
44855	 1388	14630	STAT5 Family	Protein	IL18	mRNA	0	1	11119255	Cotransfection of STAT5 resulted in increased induction of the IL-18 promoter in the U937 and THP-1 cells.
53288	 1388	 6651	STAT5 Family	Protein	CISH	mRNA	0	1	11115404	CIS and SOCS-2 expression was induced either via STAT1 and/or STAT3 or via STAT5 but only STAT1 and/or STAT3 were involved in SOCS-3 expression
55398	 1388	12303	STAT5 Family	Protein	SOCS3	mRNA	0	1	12396724	we demonstrate that induction of SOCS1, SOCS2, SOCS3, and cytokine-inducible SH2-containing protein (CIS) in response to EPO stimulation appears to depend on Stat5
57414	 1388	 3336	STAT5 Family	Protein	CCND2	mRNA	0	1	11779872	Modified assertion
60135	 1388	 4430	STAT5 Family	Protein	SOCS1	mRNA	0	1	12396724	we demonstrate that induction of SOCS1, SOCS2, SOCS3, and cytokine-inducible SH2-containing protein (CIS) in response to EPO stimulation appears to depend on Stat5
12746	16336	13434	Stanolone	Compound	HIF1A	mRNA	0	1	12855613	Dihydrotestosterone (DHT) activates HIF-1alpha nuclear protein expression in LNCaP cells but not in androgen receptor-negative PC-3 cells.
13582	16336	 1438	Stanolone	Compound	VEGFA	mRNA	0	1	12855613	PURPOSE: Androgen deprivation is implicated in reducing neoangiogenesis in prostate cancer (PCA). Androgens regulate the expression of the vascular endothelial growth factor (VEGF)
13918	16336	12480	Stanolone	Compound	SCGB2A1	mRNA	0	1	16020486	SCGB 2A1 is under androgen control in the androgen-responsive prostatic cell line LNCaP and can be induced more than 20-fold by dihydrotestosterone.AR is functionally required for the hormone response because induction can be inhibited with the nonsteroidal antagonist bicalutamide. Chromatin immunoprecipitation experiments demonstrated that AR is recruited to the proximal promoter 10 min after androgen treatment. Therefore we propose that SCGB 2A1 represents a new class of androgen target genes that are purely under indirect AR control mediated by DNA-bound Sp factors.
16070	16336	 1471	Stanolone	Compound	COL1A2	mRNA	-1	1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
18112	16336	17519	Stanolone	Compound	FGF2	mRNA	0	1	12390831	dihydrotestosterone (DHT)and estradiol (E2) DHT significantly upregulated bFGF expression, and E2 enhanced TGFbeta2 and smoothelin expressions.
19879	16336	19589	Stanolone	Compound	LOX	mRNA	0	1	11181522	DHT alone did not affect CTGF mRNA, but strongly enhanced LO mRNA relative to the control value.
20829	16336	12908	Stanolone	Compound	ENO1	mRNA	1	1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
21343	16336	13132	Stanolone	Compound	PC	mRNA	1	1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
22973	16336	 3600	Stanolone	Compound	PPFIA2	mRNA	0	-1	12119554	liprin-alpha2 was downregulated by dihydrotestosterone (DHT) in LNCaP cells in a time- and androgen concentration-dependent manner.
23357	16336	17849	Stanolone	Compound	SNAI1	mRNA	0	1	16541421	\Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG.\ DHT marginally upregulated mRNA expression of SREBP-1c, SREBP-2, and SNAIL, but not SREBP-1a, while dramatically increased SLUG mRNA expression, in a dose-dependent manner.
27642	16336	12781	Stanolone	Compound	AR	mRNA	1	1	12960001	Androgen receptor mRNA and protein levels were low at baseline but increased after testosterone or DHT treatment.
28353	16336	18287	Stanolone	Compound	ABCC3	mRNA	0	-1	16529719	DHT markedly repressed Mrp3 from GNX+placebo levels, however, this was not observed in the HPX model.
30112	16336	20193	Stanolone	Compound	MYOD1	mRNA	0	1	15684350	Among the genes that are modulated by both DHT and THG in the three tissues studied, it is worth noting the presence of Fos, a gene involved in multiple signaling pathways, dual specific phosphatase 1 (DUSP1), and pyruvate dehydrogenase kinase 4 (PDK4), a gene involved in glucose metabolism. MyoD, a marker of muscle differentiation, is also stimulated in the levator ani by both THG and DHT. Among the genes/transcripts found to be modulated by both DHT and THG in the prostate, it is of interest to mention that 69 of these have already been shown to be modulated by DHT in this tissue following quantitative real-time PCR measurement (Q_RTPCR).
33049	16336	 2943	Stanolone	Compound	SPDEF	mRNA	0	1	15124082	Silibinin down-regulated PSA mRNA expression and PSA secretion in conditioned medium under basal and DHT (10(-8)M) stimulated conditions, which was paralleled by PDEF down-regulation.
37997	16336	  871	Stanolone	Compound	ADAM17	mRNA	0	-1	11000516	In contrast, ADAM-17 mRNA, was significantly inhibited at 0.1 and 1.0 nM (1.7-fold decrease).
38820	16336	14027	Stanolone	Compound	COL5A1	mRNA	-1	1	15525599	transcripts involved in adipogenesis, and cell cycle and cell shape organization, such as DDX5, C/EBPalpha, cyclin I, procollagen types I, III, IV, V and VI, SPARC and matrix metalloproteinase 2, were upregulated by DHT.
42924	16336	15885	Stanolone	Compound	ACTB	mRNA	1	1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
45693	16336	 8412	Stanolone	Compound	LGALS1	mRNA	0	1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
48013	16336	11629	Stanolone	Compound	FOS	mRNA	0	1	15684350	Among the genes that are modulated by both DHT and THG in the three tissues studied, it is worth noting the presence of Fos, a gene involved in multiple signaling pathways, dual specific phosphatase 1 (DUSP1), and pyruvate dehydrogenase kinase 4 (PDK4), a gene involved in glucose metabolism. MyoD, a marker of muscle differentiation, is also stimulated in the levator ani by both THG and DHT. Among the genes/transcripts found to be modulated by both DHT and THG in the prostate, it is of interest to mention that 69 of these have already been shown to be modulated by DHT in this tissue following quantitative real-time PCR measurement (Q_RTPCR).
49564	16336	15740	Stanolone	Compound	CCNI	mRNA	1	1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
51657	16336	14103	Stanolone	Compound	PGAM1	mRNA	1	-1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
 5373	16336	18278	Stanolone	Compound	PIAS3	mRNA	0	1	11071847	Here we demonstrate that PIAS3 is expressed in prostate cancer cells and its expression is induced in response to dihydrotestosterone (DHT) treatment. Ectopic overexpression of PIAS3 suppressed AR-mediated gene activation induced by DHT-stimulation in LNCaP cells.
53984	16336	11581	Stanolone	Compound	ITGB1	mRNA	1	-1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
55226	16336	12981	Stanolone	Compound	COL3A1	mRNA	-1	1	15525599	transcripts involved in adipogenesis, and cell cycle and cell shape organization, such as DDX5, C/EBPalpha, cyclin I, procollagen types I, III, IV, V and VI, SPARC and matrix metalloproteinase 2, were upregulated by DHT.
55603	16336	10366	Stanolone	Compound	ACSL3	mRNA	0	1	15178414	the upregulation of FACL3/ACS3 expression by vitamin D(3) is through an androgen/AR-mediated pathway
56683	16336	 8640	Stanolone	Compound	TMEFF2	mRNA	0	1	12101412	dihydrotestosterone markedly increasing TMEFF2 expression in LNCaP cells
 5687	16336	18424	Stanolone	Compound	DUSP1	mRNA	0	1	15684350	Among the genes that are modulated by both DHT and THG in the three tissues studied, it is worth noting the presence of Fos, a gene involved in multiple signaling pathways, dual specific phosphatase 1 (DUSP1), and pyruvate dehydrogenase kinase 4 (PDK4), a gene involved in glucose metabolism. MyoD, a marker of muscle differentiation, is also stimulated in the levator ani by both THG and DHT. Among the genes/transcripts found to be modulated by both DHT and THG in the prostate, it is of interest to mention that 69 of these have already been shown to be modulated by DHT in this tissue following quantitative real-time PCR measurement (Q_RTPCR).
63227	16336	  460	Stanolone	Compound	SEPP1	mRNA	1	-1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
65632	16336	 6557	Stanolone	Compound	ALAS1	mRNA	0	-1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
66235	16336	 3458	Stanolone	Compound	ADAM10	mRNA	0	1	11000516	It was shown by quantitative RT-PCR using continuous fluorescence monitoring that ADAM-10 mRNA expression was regulated in a bell shaped, dose-dependent manner by DHT.
 6775	16336	 8280	Stanolone	Compound	DGAT1	mRNA	1	1	15525599	Tables 2-8 - effects of dihydrotestosterone on gene expression in adipose tissue
 8132	16336	12288	Stanolone	Compound	SREBF2	mRNA	0	1	16541421	\Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG.\ DHT marginally upregulated mRNA expression of SREBP-1c, SREBP-2, and SNAIL, but not SREBP-1a, while dramatically increased SLUG mRNA expression, in a dose-dependent manner.
 8768	16336	  406	Stanolone	Compound	ABCC4	mRNA	0	-1	16529719	In both models DHT markedly repressed Mrp4.
 9741	16336	  339	Stanolone	Compound	SNAI2	mRNA	0	1	16541421	\Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG.\ DHT marginally upregulated mRNA expression of SREBP-1c, SREBP-2, and SNAIL, but not SREBP-1a, while dramatically increased SLUG mRNA expression, in a dose-dependent manner.
20628	 6909	 2132	staurosporine	Compound	XIAP	mRNA	0	-1	12883037	The MEK-specific inhibitor U0126 or PKC inhibitor staurosporine (STP) also down-regulated XIAP expression and induced apoptosis.
40985	 6909	 4582	staurosporine	Compound	NOS3	mRNA	1	1	 7533140	The PKC inhibitor staurosporine (10 to 100 nmol/L) increased the expression of ecNOS mRNA, assessed by Northern analysis, in a dose-dependent manner.
54047	 6909	 5118	staurosporine	Compound	NOS2	mRNA	0	1	11448162	In such cells the PKC inhibitors 1-(5-isoquinolinesulphonyl)-2,5-dimethylpiperazine (H7) and staurosporine inhibited TPA-induced expression of BZLF1 and BRLF1 and reversed TPA-mediated inhibition of iNOS gene expression.
13411	 5707	10696	NFE2L1	Protein	JUN	mRNA	0	1	15988009	The basal protein and mRNA levels and nuclear binding activities of c-Jun, c-Fos, p50, and p65 were lower in F1 (Nrf1/Nfe2l1 null) and F2 (Nrf2/Nfe2l2 null) cells and exhibited a blunted response to TBH.
16946	 5707	19193	NFE2L1	Protein	MT2A	mRNA	0	-1	15738389	GSTA1 and metallothionein-1 and -2 were elevated in Nrf1LKO livers.
17671	 5707	 2409	NFE2L1	Protein	Gsta1	mRNA	0	-1	15738389	GSTA1 and metallothionein-1 and -2 were elevated in Nrf1LKO livers.
21132	 5707	 1962	NFE2L1	Protein	Gstp2	mRNA	0	1	15738389	Transcripts for GSTM3, GSTM6, and GSTP2 were clearly reduced in Nrf1LKO samples.
25885	 5707	19027	NFE2L1	Protein	HMOX1	mRNA	0	1	12968018	Nrf1 and Nrf2 Regulate a Similar Subset of Antioxidant Genes: Expression of Gclm was reduced to the same extent in both Nrf1 and Nrf2 mutant cells. NQO1 was down-regulated to a similar extent in both single mutant cells, whereas mRNA levels of heme-oxygenase-1 (HO-1), ferritin-H (FtH), and metallothionein-1 (MT-1) was lower in nrf2/ cells compared with nrf1/ cells (Fig. 6a). In all cases, however, expression in double knockout cells was abolished compared with single knockout cells, indicating a dependence on both Nrf1 and Nrf2
27282	 5707	 5221	NFE2L1	Protein	COX5B	mRNA	0	1	12533512	Down-regulation of NRF-1 target gene transcription on expression of DNRF-1 (dominant negative)
28129	 5707	17708	NFE2L1	Protein	FOSL1	mRNA	0	-1	15988009	Fra-1 and JAB1 (COPS5) levels are markedly increased in Nrf1 and Nrf2 null cells.
28896	 5707	 8621	NFE2L1	Protein	NQO1	mRNA	0	1	11013233	The various AREs bind to a complex of nuclear proteins from cells of different origins (15-23, 25). Analysis of ARE-nuclear protein complexes have identified several nuclear transcription factors including c-Jun, Jun-B, Jun-D, c-Fos, Fra1, Nrf1, Nrf2, YABP, ARE-BP1, MafK, Ah (aromatic hydrocarbon) receptor, and the estrogen receptor (15-32). Among these transcription factors, Nrf1 and Nrf2 have been shown to heterodimerize with c-Jun and up-regulate the ARE-mediated expression and induction of NQO1 in response to antioxidants and xenobiotics (26, 31).
30035	 5707	15110	NFE2L1	Protein	COX6A1	mRNA	0	1	12533512	Down-regulation of NRF-1 target gene transcription on expression of DNRF-1 (dominant negative)
36699	 5707	16564	NFE2L1	Protein	COPS5	mRNA	0	-1	15988009	Fra-1 and JAB1 (COPS5) levels are markedly increased in Nrf1 and Nrf2 null cells.
38836	 5707	 2762	NFE2L1	Protein	CYP4A11	mRNA	0	-1	15738389	RT-PCR showed a significant induction of cytochrome P450 4a10 and 4a14 (CYP4a10 and CYP4a14) in Nrf1LKO livers.
44497	 5707	10804	NFE2L1	Protein	CYCS	mRNA	-1	1	12533512	Down-regulation of NRF-1 target gene transcription on expression of DNRF-1 (dominant negative)
46453	 5707	13874	NFE2L1	Protein	GPX1	mRNA	0	1	12808106	TABLE 1. Changes in gene expression identified by quantitative RT-PCR in nrf1-/- fetal livers and erythroid progenitorsa
48087	 5707	11629	NFE2L1	Protein	FOS	mRNA	0	1	15988009	The basal protein and mRNA levels and nuclear binding activities of c-Jun, c-Fos, p50, and p65 were lower in F1 (Nrf1/Nfe2l1 null) and F2 (Nrf2/Nfe2l2 null) cells and exhibited a blunted response to TBH.
 5083	 5707	 1445	NFE2L1	Protein	RELA	mRNA	0	1	15988009	The basal protein and mRNA levels and nuclear binding activities of c-Jun, c-Fos, p50, and p65 were lower in F1 (Nrf1/Nfe2l1 null) and F2 (Nrf2/Nfe2l2 null) cells and exhibited a blunted response to TBH.
53847	 5707	  143	NFE2L1	Protein	GCLM	mRNA	0	1	12968018	Nrf1 and Nrf2 Regulate a Similar Subset of Antioxidant Genes: Expression of Gclm was reduced to the same extent in both Nrf1 and Nrf2 mutant cells. NQO1 was down-regulated to a similar extent in both single mutant cells, whereas mRNA levels of heme-oxygenase-1 (HO-1), ferritin-H (FtH), and metallothionein-1 (MT-1) was lower in nrf2/ cells compared with nrf1/ cells (Fig. 6a). In all cases, however, expression in double knockout cells was abolished compared with single knockout cells, indicating a dependence on both Nrf1 and Nrf2
54038	 5707	 5118	NFE2L1	Protein	NOS2	mRNA	0	-1	17928287	We have identified a binding site in the iNOS promoter that interacts with the nuclear heterodimer TCF11/MafG using chromatin immunoprecipitation and mutation analyses. We demonstrate that binding at this site acts to repress the induction of iNOS gene expression by cytokines.
54922	 5707	12609	NFE2L1	Protein	HMBS	mRNA	1	1	 9421508	Figure 2. TCF11 transactivates expression through the PBGD erythroid-specific promoter in a variety of cell lines as indicated
60612	 5707	11917	NFE2L1	Protein	Cyp4a14	mRNA	0	-1	15738389	RT-PCR showed a significant induction of cytochrome P450 4a10 and 4a14 (CYP4a10 and CYP4a14) in Nrf1LKO livers.
61119	 5707	 8424	NFE2L1	Protein	GSTM3	mRNA	0	1	15738389	Transcripts for GSTM3, GSTM6, and GSTP2 were clearly reduced in Nrf1LKO samples.
61158	 5707	 7669	NFE2L1	Protein	FTH1	mRNA	0	1	12968018	Nrf1 and Nrf2 Regulate a Similar Subset of Antioxidant Genes: Expression of Gclm was reduced to the same extent in both Nrf1 and Nrf2 mutant cells. NQO1 was down-regulated to a similar extent in both single mutant cells, whereas mRNA levels of heme-oxygenase-1 (HO-1), ferritin-H (FtH), and metallothionein-1 (MT-1) was lower in nrf2/ cells compared with nrf1/ cells (Fig. 6a). In all cases, however, expression in double knockout cells was abolished compared with single knockout cells, indicating a dependence on both Nrf1 and Nrf2
65641	 5707	 6557	NFE2L1	Protein	ALAS1	mRNA	0	1	15123725	hepatic nuclear factor 3 (HNF3) and nuclear factor 1 (NF1) are necessary for an appropriate expression of the ALAS gene. Insulin overrides the HNF3beta or HNF3beta plus NF1-mediated stimulation of ALAS transcriptional activity. Electrophoretic mobility shift assay and Southwestern blotting indicate that HNF3 binds to the ALAS promoter We propose a model in which insulin exerts its negative effect through the disturbance of HNF3beta binding or transactivation potential
66045	 5707	 5646	NFE2L1	Protein	MT1A	mRNA	0	1	12968018	Nrf1 and Nrf2 Regulate a Similar Subset of Antioxidant Genes: Expression of Gclm was reduced to the same extent in both Nrf1 and Nrf2 mutant cells. NQO1 was down-regulated to a similar extent in both single mutant cells, whereas mRNA levels of heme-oxygenase-1 (HO-1), ferritin-H (FtH), and metallothionein-1 (MT-1) was lower in nrf2/ cells compared with nrf1/ cells (Fig. 6a). In all cases, however, expression in double knockout cells was abolished compared with single knockout cells, indicating a dependence on both Nrf1 and Nrf2
66334	 5707	18006	NFE2L1	Protein	NFKB1	mRNA	0	1	15988009	The basal protein and mRNA levels and nuclear binding activities of c-Jun, c-Fos, p50, and p65 were lower in F1 (Nrf1/Nfe2l1 null) and F2 (Nrf2/Nfe2l2 null) cells and exhibited a blunted response to TBH.
 8143	 5707	11934	NFE2L1	Protein	Gstm6	mRNA	0	1	15738389	Transcripts for GSTM3, GSTM6, and GSTP2 were clearly reduced in Nrf1LKO samples.
  835	 5707	 1146	NFE2L1	Protein	GCLC	mRNA	0	1	12600891	Supershift analyses revealed that oxLDL stimulates binding of the transcription factors Nrf1, Nrf2, and c-jun to the AREs
 8797	 5707	 1900	NFE2L1	Protein	PRDX1	mRNA	0	1	10821856	Using peritoneal macrophages from Nrf2-deficient mice, we show here that Nrf2 also controls the expression of a group of electrophile- and oxidative stress-inducible proteins and activities, which includes heme oxygenase-1, A170, peroxiredoxin MSP23, and cystine membrane transport (system x(c)(-)) activity.
 9833	 5707	 5730	NFE2L1	Protein	SP7	mRNA	0	1	17510056	A chromatin immunoprecipitation assay with Nrf1 antibody confirmed the interaction of Nrf1 with the mouse osterix promoter. A reporter assay demonstrated that the promoter activity of mouse osterix containing an ARE was stimulated 4-fold by a 48-h treatment with AA in spontaneous fracture BMS cells. Treatment of mutant BMS cells with AA resulted in a 3.9-fold increase in the nuclear accumulation of Nrf1. Transfection of mutant BMS cells with Nrf1 small interfering RNA decreased Nrf1 protein by 4.5-fold, blocked AA induction of osterix expression, and impaired BMS cell differentiation.
13922	15135	 6858	Pdgf Family	Protein	PPARD	mRNA	0	1	11809753	we demonstrated that PPARdelta was increased by 3-4-fold in VSMC treated with platelet-derived growth factor (PDGF) (20 ng/ml).
24835	15135	 5863	Pdgf Family	Protein	MYC	mRNA	0	1	16537894	Dok-1-interacting proteins, we show that Dok-1 interferes with PDGF-stimulated c-myc induction and Ras/mitogen-activated protein kinase (MAPK) activation by tethering different signaling components to the cell membrane.
40786	15135	 7849	Pdgf Family	Protein	KLF9	mRNA	1	1	14981515	Table 1 PDGF transcriptional target genes in MEFs identified in gene-trap array screens  Gene Symbol GenBank Repressed/Induced  Arid4b NM_194262 Rep Arid5b NM_023598 Ind Axud1  NM_153287 Ind Bteb1  NM_010638 Ind Cdh11  NM_009866 Rep Epha2  NM_010139 Ind AA407809 NM_030724 Ind AA960558 NM_133942 Ind Got1  NM_010324 Ind Gpd2  NM_010274 Ind Jade1  NM_172303 Ind Mzf6d  AY149175 Rep Klf2  NM_008452 Ind Lmna  NM_019390 Ind Mcl1  NM_008562 Ind Mll5  BC036286 Repc Myo1e  NM_181072 Ind 2300006M17Rik XM_127388 Ind Schip1 NM_013928 Ind Slc2a2 NM_031197 Ind Sgpl1  NM_009163 Ind Tiparp NM_178892 Ind Txnip  NM_023719 Rep Zfp216 NM_009551 Ind
48777	15135	17731	Pdgf Family	Protein	DCN	mRNA	-1	1	 8940199	Site-directed mutagenesis experiments demonstrate that a consensus cyclic AMP response element (CRE) in the murine PGS2 promoter is essential for optimal PGS2 gene expression in response to PDGF or to serum.
42094	  619	13115	Prostratin	Compound	EGR1	mRNA	-1	1	17014716	Microarray analyses were performed and several genes related to HIV biology, including APOBEC3B, DEFA1, and S100 calcium-binding protein genes, were found to be regulated by prostratin.....Table 1  Genes relevant to HIV or T cell biology: Genes with a ? 5-fold change by prostratin were identified, and those with relevance to T cell or HIV biology are listed in Table ?Table1. .
12524	14043	 3012	HIST1H1T	Protein	CPOX	mRNA	1	1	15039436	downregulated
14123	14043	18264	HIST1H1T	Protein	OGT	mRNA	-1	1	15039436	downregulated
48873	14043	 5601	HIST1H1T	Protein	DUSP16	mRNA	-1	1	15039436	downregulated
10096	17705	 7502	arachidonic acid	Compound	STAR	mRNA	0	1	12943700	AA enhanced specific binding of the nuclear extract to a 30bp (-67/-96) sequence of the StAR promoter
10598	17705	 6826	arachidonic acid	Compound	NFKB2	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
11043	17705	 8037	arachidonic acid	Compound	KLF6	mRNA	1	1	16704987	Table I. Genes upregulated >2-fold by both triacsin C and AA at both 6 and 12 h
11716	17705	11709	arachidonic acid	Compound	UCP2	mRNA	0	1	11278377	omega-6 fatty acids and arachidonic acid induced a 3-fold rise in UCP-2 mRNA levels possibly through transcriptional activation.
12841	17705	17369	arachidonic acid	Compound	IL6	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
 1335	17705	13998	arachidonic acid	Compound	PTGIS	mRNA	0	1	12925037	Arachidonic acid induced PGI2 synthesis and Cox-2 expression through similar mechanisms to those activated by HDL [pertussis toxin-sensitive G proteins, p42/44 mitogen-activated protein kinase (MAPK), p38MAPK, and c-Jun N-terminal kinase-1 (JNK-1) pathways].
13831	17705	17250	arachidonic acid	Compound	PTGS2	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
13927	17705	 6858	arachidonic acid	Compound	PPARD	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
16062	17705	 1471	arachidonic acid	Compound	COL1A2	mRNA	-1	1	10770928	The ability of ethanol and arachidonic acid (AA), as inducers of oxidative stress and key factors in alcoholic liver disease, to up-regulate alpha 2 collagen type I (COL1A2) gene expression was studied in a hepatic stellate cell line overexpressing the ethanol-inducible cytochrome P450 2E1 (CYP2E1) (E5 cells). A time- and dose-dependent induction in COL1A2 mRNA by ethanol or AA was observed that was prevented by diallylsulfide, a CYP2E1 inhibitor.
26097	17705	 1343	arachidonic acid	Compound	BCL3	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
35478	17705	18531	arachidonic acid	Compound	ICAM1	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
42055	17705	13115	arachidonic acid	Compound	EGR1	mRNA	-1	1	16704987	Table I. Genes upregulated >2-fold by both triacsin C and AA at both 6 and 12 h
46689	17705	 3471	arachidonic acid	Compound	IL1B	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
  467	17705	11404	arachidonic acid	Compound	CSF2	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
49298	17705	 2099	arachidonic acid	Compound	CD69	mRNA	0	1	11200053	Moreover, PAF alone induced CD69 only weakly on normal eosinophils, but exogenous arachidonic acid remarkably enhanced PAF-induced CD69 expression on them.
49523	17705	10600	arachidonic acid	Compound	CXCL1	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
57332	17705	 4298	arachidonic acid	Compound	JUNB	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
60074	17705	12976	arachidonic acid	Compound	IL8	mRNA	0	1	16452198	Figure 3 B is a Table of genes induced by Arachidonate treatment. Including only those wioth a 2-fold or greater change (increase)
60961	17705	 2450	arachidonic acid	Compound	ITGA6	mRNA	-1	1	16704987	Table I. Genes upregulated >2-fold by both triacsin C and AA at both 6 and 12 h
26687	18362	18713	High Density LipoProtein	Compound	SCARB1	mRNA	0	1	16537455	In the WT recipient, plaques become rapidly exposed to a plasma environment containing a relative increase in HDL and decrease in non-HDL cholesterol, changes which are expected to promote cholesterol efflux from foam cells and thereby reverse inflammatory changes associated with the lipid loading of macrophages (e.g., refs. 1820)....the expression of LXR, ABCA1, or SR-BI was increased in cells from the plaques placed in the WT recipient. In these same cells, there was decreased expression of the NF-B-target inflammatory genes MCP-1 and VCAM-1 (Fig. 4B).
 2902	18362	 4252	High Density LipoProtein	Compound	ABCA1	mRNA	0	1	16537455	In the WT recipient, plaques become rapidly exposed to a plasma environment containing a relative increase in HDL and decrease in non-HDL cholesterol, changes which are expected to promote cholesterol efflux from foam cells and thereby reverse inflammatory changes associated with the lipid loading of macrophages (e.g., refs. 1820)....the expression of LXR, ABCA1, or SR-BI was increased in cells from the plaques placed in the WT recipient. In these same cells, there was decreased expression of the NF-B-target inflammatory genes MCP-1 and VCAM-1 (Fig. 4B).
42095	18362	13115	High Density LipoProtein	Compound	EGR1	mRNA	-1	1	 8484785	To demonstrate whether these intracellular responses are only specific to LDL we examined the effects of high- and very low density lipoprotein (HDL and VLDL) on [Ca2+]i and expression of Egr-1 mRNA. The present results show that all lipoproteins induce expression of Egr-1 mRNA and elevation in [Ca2+]i in VSMCs.
44430	18362	13271	High Density LipoProtein	Compound	CCL2	mRNA	0	-1	16537455	In the WT recipient, plaques become rapidly exposed to a plasma environment containing a relative increase in HDL and decrease in non-HDL cholesterol, changes which are expected to promote cholesterol efflux from foam cells and thereby reverse inflammatory changes associated with the lipid loading of macrophages (e.g., refs. 1820)....the expression of LXR, ABCA1, or SR-BI was increased in cells from the plaques placed in the WT recipient. In these same cells, there was decreased expression of the NF-B-target inflammatory genes MCP-1 and VCAM-1 (Fig. 4B).
  553	18362	10000	High Density LipoProtein	Compound	NR1H3	mRNA	0	1	16537455	In the WT recipient, plaques become rapidly exposed to a plasma environment containing a relative increase in HDL and decrease in non-HDL cholesterol, changes which are expected to promote cholesterol efflux from foam cells and thereby reverse inflammatory changes associated with the lipid loading of macrophages (e.g., refs. 1820)....the expression of LXR, ABCA1, or SR-BI was increased in cells from the plaques placed in the WT recipient. In these same cells, there was decreased expression of the NF-B-target inflammatory genes MCP-1 and VCAM-1 (Fig. 4B).
10618	 3062	13157	clofibrate	Compound	HADHA	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
11563	 3062	 2476	clofibrate	Compound	AHSG	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
11625	 3062	14159	clofibrate	Compound	Ugt1a7c	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
 1177	 3062	18589	clofibrate	Compound	FABP3	mRNA	0	-1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
11981	 3062	16380	clofibrate	Compound	APCS	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
12126	 3062	19506	clofibrate	Compound	ACADM	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
12146	 3062	 6967	clofibrate	Compound	ECH1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
  132	 3062	19130	clofibrate	Compound	ABAT	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
13523	 3062	 3789	clofibrate	Compound	IGF1	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
14298	 3062	16808	clofibrate	Compound	ACSL1	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
14372	 3062	11198	clofibrate	Compound	HIBCH	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
14509	 3062	18103	clofibrate	Compound	LPL	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
16770	 3062	13585	clofibrate	Compound	FADS2	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
16792	 3062	20109	clofibrate	Compound	ABCD3	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
17113	 3062	16160	clofibrate	Compound	CYP4A22	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
17195	 3062	11456	clofibrate	Compound	TF	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
17610	 3062	 8314	clofibrate	Compound	Cyp2b1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
19265	 3062	10787	clofibrate	Compound	SULT2A1	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
20465	 3062	10306	clofibrate	Compound	ANGPTL4	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
21290	 3062	15351	clofibrate	Compound	CHKB	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
23042	 3062	 5147	clofibrate	Compound	NUPR1	mRNA	1	1	12851107	400, 800 mg/kg/day treatment gene changes
24094	 3062	 8747	clofibrate	Compound	ACSM2A	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
24929	 3062	19864	clofibrate	Compound	FADS1	mRNA	0	-1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
25330	 3062	 1448	clofibrate	Compound	UGT1A5	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
 2566	 3062	  326	clofibrate	Compound	TXNIP	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
25762	 3062	12452	clofibrate	Compound	PON3	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
25916	 3062	17410	clofibrate	Compound	HERPUD1	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
26732	 3062	11941	clofibrate	Compound	BHMT	mRNA	0	-1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
27954	 3062	  700	clofibrate	Compound	ACADL	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
28743	 3062	  330	clofibrate	Compound	ACOT2	mRNA	0	1	10567408	Three highly homologous acyl-CoA thioesterase genes, Cte1, Mte1, and Pte1, are located within a narrow cluster on chromosone 12. All four thioesterases are differentially expressed in tissues examined, but all are inducible at mRNA level by treatment with the peroxisome proliferator clofibrate, or during the physiological condition of fasting, both conditions causing a perturbation in overall lipid homeostasis.
29650	 3062	13006	clofibrate	Compound	HMGCS2	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
29998	 3062	  345	clofibrate	Compound	APBA3	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
32024	 3062	13849	clofibrate	Compound	HACL1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
33396	 3062	11976	clofibrate	Compound	PDK4	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
33515	 3062	 3749	clofibrate	Compound	LOC100365112	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
 3547	 3062	 3306	clofibrate	Compound	TOMM20	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
37201	 3062	 2144	clofibrate	Compound	CPT1B	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
39790	 3062	 3499	clofibrate	Compound	GULOP	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
40845	 3062	12023	clofibrate	Compound	SLC34A2	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
41773	 3062	13215	clofibrate	Compound	LPCAT3	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
41820	 3062	 3984	clofibrate	Compound	DBI	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
42591	 3062	17361	clofibrate	Compound	GDE1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
43039	 3062	 8889	clofibrate	Compound	Sult2al1	mRNA	0	1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
43394	 3062	14524	clofibrate	Compound	RGD1565355	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
43572	 3062	  504	clofibrate	Compound	COX8A	mRNA	0	1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
43618	 3062	 3234	clofibrate	Compound	PRODH	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
43677	 3062	19111	clofibrate	Compound	Kap	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
44320	 3062	15920	clofibrate	Compound	UBD	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
44833	 3062	19354	clofibrate	Compound	ECI1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
 4526	 3062	 6120	clofibrate	Compound	POR	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
46298	 3062	 4508	clofibrate	Compound	UBE2O	mRNA	0	-1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
46772	 3062	 7004	clofibrate	Compound	CROT	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
47163	 3062	11213	clofibrate	Compound	GC	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
47826	 3062	10326	clofibrate	Compound	CCND3	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
48253	 3062	20148	clofibrate	Compound	SLC25A20	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
 4826	 3062	 1246	clofibrate	Compound	C1R	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
48746	 3062	 6352	clofibrate	Compound	Cyp3a23/3a1	mRNA	0	1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
49278	 3062	 6861	clofibrate	Compound	PLG	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
49378	 3062	16863	clofibrate	Compound	Cyp2c22	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
51444	 3062	 7697	clofibrate	Compound	DECR1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
51473	 3062	 7810	clofibrate	Compound	ALDH1A1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
51613	 3062	 5673	clofibrate	Compound	ID1	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
51783	 3062	 5265	clofibrate	Compound	VTN	mRNA	0	-1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
52302	 3062	13636	clofibrate	Compound	SLC4A2	mRNA	0	1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
52680	 3062	14273	clofibrate	Compound	ACAA1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
53681	 3062	14116	clofibrate	Compound	PLIN2	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
55323	 3062	 1914	clofibrate	Compound	SLC25A14	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
55704	 3062	15411	clofibrate	Compound	INSIG1	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
 5599	 3062	 4642	clofibrate	Compound	HP	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
56128	 3062	10811	clofibrate	Compound	FN1	mRNA	-1	-1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
56886	 3062	11653	clofibrate	Compound	FABP2	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
57366	 3062	10643	clofibrate	Compound	Scd1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
57500	 3062	 5731	clofibrate	Compound	ACOX1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
57756	 3062	 8036	clofibrate	Compound	CRAT	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
 5884	 3062	14250	clofibrate	Compound	MGLL	mRNA	0	1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
58989	 3062	   37	clofibrate	Compound	HADHB	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
60121	 3062	18114	clofibrate	Compound	NR1I2	mRNA	0	1	16243957	Transcriptional activators of PXR, such as clofibrate, do not seem to be PXR ligands or substrates for its target genes.
61321	 3062	19582	clofibrate	Compound	CPB2	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
 6156	 3062	17577	clofibrate	Compound	Hba2	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
 6174	 3062	18985	clofibrate	Compound	TMEM14C	mRNA	0	1	12851107	400, 800 mg/kg/day treatment gene changes
62015	 3062	 2608	clofibrate	Compound	HBB	mRNA	1	1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
63246	 3062	  895	clofibrate	Compound	ADH1C	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
63441	 3062	 7303	clofibrate	Compound	UGT1A1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
63651	 3062	 9623	clofibrate	Compound	Ces1c	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
64003	 3062	 3679	clofibrate	Compound	GPD1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
64476	 3062	15063	clofibrate	Compound	ASS1	mRNA	0	-1	12851107	400, 800 mg/kg/day treatment gene changes
65434	 3062	19519	clofibrate	Compound	CPT1A	mRNA	-1	1	11171094	Pubmed:gene: Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisome-proliferator-activated receptor alpha (PPARalpha)-independent pathway. Expression of the L-CPT I gene is induced by LCFAs as well as by lipid-lowering compounds such as clofibrate.
65584	 3062	10830	clofibrate	Compound	Cyp4a3	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
65631	 3062	 6557	clofibrate	Compound	ALAS1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
65787	 3062	11283	clofibrate	Compound	ME1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
66044	 3062	 5646	clofibrate	Compound	MT1A	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
  666	 3062	17651	clofibrate	Compound	CYP2B6	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
 6729	 3062	10999	clofibrate	Compound	HSPB1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
 7735	 3062	 7470	clofibrate	Compound	ALDH1L1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
 7874	 3062	12835	clofibrate	Compound	SUCLG1	mRNA	0	1	12851107	We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity.
 9019	 3062	  164	clofibrate	Compound	HES6	mRNA	0	-1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
 9413	 3062	11119	clofibrate	Compound	LOC24906	mRNA	0	1	12851107	List of genes changed upon Clofibrate  (800mg/kg/day) treatment.
10044	19551	 7928	CUX1	Protein	TGFBR2	mRNA	0	-1	10545217	We also demonstrate that the A --> G mutation increases CDP/Cut binding affinity, and that overexpression of CDP/Cut reduces transcription from TbetaR-II promoter reporter constructs.
26099	19551	10236	CUX1	Protein	SI	mRNA	0	1	12101240	Cux/CDP homozygous mutant mice displayed increased expression of SI mRNA during early postnatal development.
39579	19551	13744	CUX1	Protein	CDKN1B	mRNA	-1	-1	12438259	Deregulated expression of  the homeobox gene Cux-1 in transgenic mice results in down-regulation of p27( kip1) expression during nephrogenesis, glomerular abnormalities, and multiorgan  hyperplasia.
39974	19551	13740	CUX1	Protein	BGLAP	mRNA	0	-1	12438259	The  CCAAT displacement protein/cut homeodomain protein represses osteocalcin gene  transcription and forms complexes with the retinoblastoma protein-related  protein p107 and cyclin A.
51080	19551	13884	CUX1	Protein	CDKN1A	mRNA	1	-1	11509674	Moreover, p21 expression was  repressed equally well by either Cdc25A or CDP/Cut.
51457	19551	 7564	CUX1	Protein	WNT5A	mRNA	0	1	17227781	We found that CUTL1 transcriptionally up-regulated WNT5A on RNA, protein and promoter level.
61680	19551	 7558	CUX1	Protein	CTSL1	mRNA	0	1	15099520	We show here that cathepsin L functions in the regulation of cell cycle progression through proteolytic processing of the CDP/Cux transcription factor.
 9515	19551	 1314	CUX1	Protein	PSMD9	mRNA	0	-1	11969263	Transient transfection experiments revealed that Cux-1 is an inhibitor of p27 promoter activity.
39581	10648	13744	FOXA1	Protein	CDKN1B	mRNA	-1	1	16331276	In summary, we identified a FOXA1 binding site within the BRCA1-responsive element of the p27(Kip1) promoter and showed that FOXA1 activated the promoter alone and in conjunction with BRCA1. Furthermore, we identified high expression of FOXA1 in breast cancer cell lines and tissues, discovered a role for BRCA1 in the regulation of p27(Kip1) transcription and a possible interaction with BRCA1.
40952	18313	 4582	GATA Family	Protein	NOS3	mRNA	1	1	14656742	Early work ascribed functional importance to Sp1 and GATA proximal promoter cis-DNA elements and protein factors in the basal transcription of the TATA-less eNOS promoter.17,18
10011	14931	 4597	PIK3 Family	Protein	UBE2C	mRNA	1	1	15504738	As shown in Fig. 6A, inhibition of PI3K with LY294002 suppressed expression of six cell cycle-related genes (CKS2, HEC, MAD3L, STK15, UBE2C, and ZWINT) in a concentration-dependent manner as
11646	14931	16413	PIK3 Family	Protein	HMGCS1	mRNA	0	1	15213220	PDGF increased the amount of mature SREBP-1 and regulated the promoters of SCD and HMGCS in an SREBP-dependent manner. In line with these results, blocking SREBP processing by addition of 25-hydroxycholesterol blunted the effects of PDGF on lipogenic enzymes. SREBP activation was dependent on the phosphatidylinositol 3-kinase (PI3K) pathway, as judged from the effects of the inhibitor LY294002 and mutation of the PDGFbeta receptor tyrosines that bind the PI3K adaptor subunit p85.
12151	14931	  877	PIK3 Family	Protein	VCAN	mRNA	0	1	15668231	Phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, significantly decreased versican-Luciferase (versican-Luc) promoter activity and endogenous mRNA levels.
12724	14931	13434	PIK3 Family	Protein	HIF1A	mRNA	0	1	14982927	FSH-stimulated HIF-1 activity is inhibited by the PI 3-kinase inhibitor LY294002, the Rheb inhibitor FTI-277 (farnesyltransferase inhibitor-277), and the mTOR inhibitor rapamycin. These results show that FSH enhances HIF-1 activity downstream of the PI 3-kinase/AKT/Rheb/mTOR pathway in GCs and that HIF-1 activity is necessary for FSH to induce multiple follicular differentiation markers.
13412	14931	10696	PIK3 Family	Protein	JUN	mRNA	0	-1	16172382	We demonstrate that shear-induced cyclooxygenase (COX)-2 suppresses phosphatidylinositol 3-kinase (PI3-K) activity, which represses antioxidant response element (ARE)/NF-E2 related factor 2 (Nrf2)-mediated transcriptional response in human chondrocytes.
13525	14931	 3789	PIK3 Family	Protein	IGF1	mRNA	0	1	15809062	PTEN overexpression resulted in a significant decrease in the expression of IGF-I, -II, and IGF-IR. PTEN regulates IGFBP-3 at the transcriptional level PI3 kinase inhibitor, LY294002, upregulates IGFBP-3 expression but downregulates IGF-I and IGF-II, indicating that PTEN controls IGFBP-3 and IGFs by an Akt-dependent pathway.
13682	14931	 1438	PIK3 Family	Protein	VEGFA	mRNA	0	1	16258729	the ability of alpha 6beta 4 to stimulate the PI3-K-dependent translation of VEGF
13871	14931	17250	PIK3 Family	Protein	PTGS2	mRNA	0	1	15067356	Inhibition of PI 3-K with Wortmannin and LY294002 blocked Akt phosphorylation and inhibited expression of COX-2 in mutated-PTEN cells. Inhibition of Akt phosphorylation with specific PI 3-K inhibitors and down-regulation of COX-2 increased apoptosis in human endometrial cancer cells.
14111	14931	14961	PIK3 Family	Protein	CEBPD	mRNA	0	1	15901830	Moreover, the phosphatidylinositol 3 (PI3)-kinase inhibitor (wortmannin) and p38(MAPK) inhibitor (SB203580) inhibited the EGF-induced CREB phosphorylation and the expression of NF-IL6beta gene in cells.
14463	14931	13598	PIK3 Family	Protein	CD14	mRNA	0	1	10587349	Furthermore, induction of CD14 expression in response to D(3) was abrogated by (a) the PI 3-kinase inhibitors LY294002 and wortmannin; (b) antisense oligonucleotides to mRNA for the p110 catalytic subunit of PI 3-kinase; and (c) a dominant negative mutant of PI 3-kinase.
14749	14931	16094	PIK3 Family	Protein	CLDN2	mRNA	0	1	15350541	The downregulated connexin32 expression was inhibited by treatment with a MAP-kinase inhibitor (PD98059), whereas the upregulated claudin-2 expression was blocked by p38 MAP and PI3-kinase inhibitors (SB203580 and LY294002)
14875	14931	14770	PIK3 Family	Protein	RHOB	mRNA	0	-1	15169915	Here we demonstrate that Ras downregulates RhoB expression by a phosphatidylinositol 3-kinase (PI3K)- and Akt- but not Mek-dependent mechanism. Furthermore, genetic and pharmacological blockade of PI3K/Akt results in upregulation of RhoB expression. Oncogenic PI3K/Akt, but not Mek1/2 mediates Ras suppression of RhoB promoter transcriptional activity in NIH 3T3 cells
16020	14931	15914	PIK3 Family	Protein	TOP2A	mRNA	0	1	15504738	Five DNA replication and repair-related genes (FEN1, PCNA, RFC4, TOP2A, and TYMS) were suppressed by LY294002 treatment as detected by real time PCR (Fig. 6C).
16843	14931	 5958	PIK3 Family	Protein	POSTN	mRNA	0	1	15121739	FGF-1-induced PN expression was blocked by the FGF-1 receptor antagonist PD-166866 and by inhibitors of phosphatidylinositol 3-kinase (PI3K) (LY-294002, wortmannin), p70S6K (rapamycin), MEK1/2 (U-0126, PD-98059), and p38MAPK (SB-203580) but not of JNK (SP-600125)
19657	14931	16486	PIK3 Family	Protein	SPP1	mRNA	1	1	14703434	EGF increased the expression of OPN mRNA and protein in a dose- and time-dependent manners. Pretreatment of Wortmannin significantly reduced the EGF-induced OPN expression
20470	14931	10306	PIK3 Family	Protein	ANGPTL4	mRNA	0	-1	16870142	Insulin suppressed angptl4 mRNA expression in time- and dose-dependent manners, and the inhibitory effect was attenuated by a RNA synthesis inhibitor actinomycin D and a phosphoinositide 3-kinase (PI3K) inhibitor LY294002.
  205	14931	16874	PIK3 Family	Protein	PIK3R1	mRNA	0	1	10567366	In addition, overexpression of a constitutively active protein kinase B increased p85alphaPI 3-K mRNA levels. These results indicate that the phosphatidylinositol 3-kinase/PKB/p70S6 kinase pathway is required for the stimulation by insulin of p85alphaPI 3-K gene expression in human muscle cells.
20631	14931	 2132	PIK3 Family	Protein	XIAP	mRNA	0	1	12393602	Corresponding to enhanced apoptosis, LY294002 down-regulated expression of the antiapoptotic proteins X-linked inhibitor of apoptosis protein (XIAP)
21841	14931	 7428	PIK3 Family	Protein	DHFR	mRNA	0	-1	15782128	However, direct inhibition of PI-3 Kinase could mimic PTEN in modulating expression of DHFR, G3BP, Rap1 and RCC1, but not AKAP121.
21923	14931	 3995	PIK3 Family	Protein	ESR1	mRNA	-1	-1	10653980	Protein kinase A and phosphatidylinositol 3-kinase inhibitors blocked the IGF-I effects on ER-alpha expression and activity, suggesting that these kinases may be involved in the cross-talk between the IGF-I and ER-alpha pathways.
22650	14931	18267	PIK3 Family	Protein	KLF2	mRNA	0	1	15834135	We have also characterized a PI3K-dependent/Akt-independent pathway responsible for shear stress-induced KLF2 nuclear binding, promoter activation, and mRNA expression.
22981	14931	 4678	PIK3 Family	Protein	ERRFI1	mRNA	0	1	10600478	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed. The IEGs were classified into three categories according to their susceptibility to the inhibitors. Expression of the first group (c-fos, jun-B, egr-1, tis11, tis21, thrombospondin-1, erp, thyroid hormone receptor [N-10], cyr61, and zf9) was mainly dependent on PKC and MEK pathways, while that of the second class (gene33 and tis10) exhibited an additional dependence on PI3 kinase pathways.
25623	14931	14852	PIK3 Family	Protein	HIST1H4C	mRNA	0	1	15504738	LY294002 treatment also significantly reduced the expression of two chromatin structure-related genes HMGB2 and HIST1H4C  as demonstrated by real time PCR (Fig. 6D) and duplex PCR (Fig. 6E), respectively.
25880	14931	19027	PIK3 Family	Protein	HMOX1	mRNA	0	1	16172382	Table 3. Effects of PI3-K activity on shear-induced phase 2 gene suppression and COX-2 gene induction in chondrocytes
26013	14931	 2210	PIK3 Family	Protein	RCC1	mRNA	0	-1	15782128	However, direct inhibition of PI-3 Kinase could mimic PTEN in modulating expression of DHFR, G3BP, Rap1 and RCC1, but not AKAP121.
 2765	14931	  908	PIK3 Family	Protein	MMP9	mRNA	0	1	11280738	Modified assertion
27650	14931	12781	PIK3 Family	Protein	AR	mRNA	1	-1	16472761	Moreover, LY294002, but not PD98059, inhibited the PSA and AR suppression effect by EGF in concurrence with the suppression of phosphorylation levels of Akt.
27854	14931	 1166	PIK3 Family	Protein	SLC2A1	mRNA	-1	1	10777488	The expression of GLUT1 mRNA increased after 4 h of stimulation with IGF-I and decreased after 24 h. Blocking PI3K activity by inhibitor wortmannin abolished the effect of IGF-I on Glut1 mRNA expression in NIH-IGFR cells suggesting the involvement PI3K.
28715	14931	 4097	PIK3 Family	Protein	ZWINT	mRNA	0	1	15504738	As shown in Fig. 6A, inhibition of PI3K with LY294002 suppressed expression of six cell cycle-related genes (CKS2, HEC, MAD3L, STK15, UBE2C, and ZWINT) in a concentration-dependent manner as
28886	14931	 8621	PIK3 Family	Protein	NQO1	mRNA	0	1	16172382	Table 3. Effects of PI3-K activity on shear-induced phase 2 gene suppression and COX-2 gene induction in chondrocytes
29778	14931	16604	PIK3 Family	Protein	TYMS	mRNA	0	1	15504738	Five DNA replication and repair-related genes (FEN1, PCNA, RFC4, TOP2A, and TYMS) were suppressed by LY294002 treatment as detected by real time PCR (Fig. 6C).
 3122	14931	16645	PIK3 Family	Protein	CCND1	mRNA	0	1	10714766	Modified assertion
32436	14931	20190	PIK3 Family	Protein	ABCB1	mRNA	0	1	11960367	Transient transfection assays demonstrated that constitutively activated PI3K and Rac1 enhanced the activation of the MDR1 promoter by 2-AAF.
32890	14931	11449	PIK3 Family	Protein	CASP9	mRNA	1	-1	16172382	We demonstrate that shear-induced cyclooxygenase (COX)-2 suppresses phosphatidylinositol 3-kinase (PI3-K) activity, which represses antioxidant response element (ARE)/NF-E2 related factor 2 (Nrf2)-mediated transcriptional response in human chondrocytes.
34027	14931	14883	PIK3 Family	Protein	IL1R1	mRNA	0	1	15030977	The IL-1R1 induction was found to be PI3K/Akt-dependent but NF-kappaB-independent.
34705	14931	16881	PIK3 Family	Protein	G3BP1	mRNA	0	1	15782128	However, direct inhibition of PI-3 Kinase could mimic PTEN in modulating expression of DHFR, G3BP, Rap1 and RCC1, but not AKAP121.
35129	14931	 4060	PIK3 Family	Protein	KLF15	mRNA	0	-1	15649433	Expression of the KLF15 gene in mouse liver was also down-regulated by a euglycemic-hyperinsulinemic clamp and was increased by inhibition of phosphatidylinositol 3-kinase.
 3536	14931	 3594	PIK3 Family	Protein	CKS2	mRNA	0	1	15504738	As shown in Fig. 6A, inhibition of PI3K with LY294002 suppressed expression of six cell cycle-related genes (CKS2, HEC, MAD3L, STK15, UBE2C, and ZWINT) in a concentration-dependent manner as
36098	14931	12491	PIK3 Family	Protein	MCAM	mRNA	0	1	14534536	In this study, we show that there is a reciprocal regulation loop between AKT and MelCAM. Pharmacological inhibition of AKT in human melanoma cell lines substantially reduced the expression of MelCAM. Overexpression of constitutively active AKT upregulated the levels of MelCAM in melanoma cell lines, whereas expression of a dominant-negative PI-3 kinase downregulated MelCAM.
36400	14931	 4537	PIK3 Family	Protein	MSR1	mRNA	0	1	11597931	we show that the Gas6-induced expression of SRA was mediated by the phosphatidylinositol 3-OH kinase (PI3-kinase)-serine/threonine kinase (Akt/protein kinase B [PKB]) pathway involving Akt phosphorylation.
36680	14931	19540	PIK3 Family	Protein	RFC4	mRNA	0	1	15504738	Five DNA replication and repair-related genes (FEN1, PCNA, RFC4, TOP2A, and TYMS) were suppressed by LY294002 treatment as detected by real time PCR (Fig. 6C).
37386	14931	 9189	PIK3 Family	Protein	MMP2	mRNA	0	-1	10515879	Modified assertion
38761	14931	12605	PIK3 Family	Protein	GSTM1	mRNA	0	1	16172382	Table 3. Effects of PI3-K activity on shear-induced phase 2 gene suppression and COX-2 gene induction in chondrocytes
39547	14931	15221	PIK3 Family	Protein	EN1	mRNA	0	1	15504738	Five DNA replication and repair-related genes (FEN1, PCNA, RFC4, TOP2A, and TYMS) were suppressed by LY294002 treatment as detected by real time PCR (Fig. 6C).
39566	14931	13744	PIK3 Family	Protein	CDKN1B	mRNA	-1	-1	19648963	from full text Results - Treatment of the mouse lung tumor cell line SP10 with LY294002 led to a reduction of phospho-Akt, a reduction in phospho- FOXO, and an increase in both p27 transcript and protein levels - LY294002 not in system
 4088	14931	 4130	PIK3 Family	Protein	SH2B3	mRNA	0	1	17007883	These results suggest that TNF-alpha induces Lnk expression through PI3K-dependent signaling pathway in HUVEC. This may indicate a role for this new adaptor protein in the regulation of TNF-alpha-induced ECs activation.
41352	14931	 4976	PIK3 Family	Protein	ANXA2	mRNA	0	1	15070701	we found that annexin II expression was regulated by IL-3 mainly by Ras pathways, including Ras/phosphatidylinositol 3-kinase pathways.
 4155	14931	 9655	PIK3 Family	Protein	NDC80	mRNA	0	1	15504738	As shown in Fig. 6A, inhibition of PI3K with LY294002 suppressed expression of six cell cycle-related genes (CKS2, HEC, MAD3L, STK15, UBE2C, and ZWINT) in a concentration-dependent manner as
43047	14931	20205	PIK3 Family	Protein	RAP1GAP	mRNA	0	-1	15782128	However, direct inhibition of PI-3 Kinase could mimic PTEN in modulating expression of DHFR, G3BP, Rap1 and RCC1, but not AKAP121.
43953	14931	 4591	PIK3 Family	Protein	S100A4	mRNA	0	1	12517790	S100A4 is a direct target of ERBB2 signaling in medulloblastoma cells via a pathway involving phosphatidylinositol 3-kinase, AKT1, and extracellular signal-regulated kinase 1/2
44008	14931	 6965	PIK3 Family	Protein	TNFAIP3	mRNA	0	1	12138201	Adhesion of HUVECs to fibronectin for 4 hours resulted in the upregulation of TNFAIP3 (A20) mRNA. Upregulation of TNFAIP3 by fibronectin was found to be inhibited by the PI3K-inihibitor LY294002.
44179	14931	10908	PIK3 Family	Protein	NFIL3	mRNA	0	1	10082541	The NFIL3 (E4BP4) transcription factor, Bcl-xL, and constitutively active mutants of components in Ras signal transduction pathways have been identified as key regulation proteins affecting murine interleukin-3 (IL-3)-dependent cell survival. expression of Nfil3 is regulated by oncogenic Ras mutants through both the Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways
44225	14931	 9200	PIK3 Family	Protein	PCNA	mRNA	0	1	15504738	Five DNA replication and repair-related genes (FEN1, PCNA, RFC4, TOP2A, and TYMS) were suppressed by LY294002 treatment as detected by real time PCR (Fig. 6C).
45265	14931	 8651	PIK3 Family	Protein	IGFBP2	mRNA	0	1	17372210	To further investigate this link, we determined that IGFBP-2 expression is negatively regulated by PTEN and positively regulated by phosphatidylinositol 3-kinase (PI3K) and Akt activation.
47015	14931	17438	PIK3 Family	Protein	CD38	mRNA	0	1	12139742	Interestingly, PI3-K activity was also necessary for CD38 expression on normal marrow CD34+ cells and for the ATRA-induced upregulation of CD157, a CD38-related antigen.
47189	14931	 8579	PIK3 Family	Protein	AKT2	mRNA	0	1	15082758	Subsequent Akt activation by S473 phosphorylation was PI 3-kinase dependent and specific for Akt2 rather than Akt1
47814	14931	10326	PIK3 Family	Protein	CCND3	mRNA	0	1	11779872	Dominant negative PI-3K-pOPRSVI construct transfected K562 cells were cultured with IPTG, the inducible expression of DN-PI-3K by IPTG was involved in downregulation of CyclinD3, suggesting that PI-3K induces the upregulation of CyclinD3.
49215	14931	10305	PIK3 Family	Protein	LASP1	mRNA	0	1	15940254	Lasp-1 expression required activity of the PI3-kinase signalling pathway.
52023	14931	 8177	PIK3 Family	Protein	TYRP1	mRNA	0	-1	14632202	In this study, we show that LY294002 up-regulates the expression of the melanogenic enzymes, tyrosinase and Tyrp1, through a transcriptional mechanism that involves microphthalmia associated transcription factor
54292	14931	 4554	PIK3 Family	Protein	BUB1B	mRNA	0	1	15504738	As shown in Fig. 6A, inhibition of PI3K with LY294002 suppressed expression of six cell cycle-related genes (CKS2, HEC, MAD3L, STK15, UBE2C, and ZWINT) in a concentration-dependent manner as
54536	14931	10710	PIK3 Family	Protein	MAPK9	mRNA	0	-1	16172382	We demonstrate that shear-induced cyclooxygenase (COX)-2 suppresses phosphatidylinositol 3-kinase (PI3-K) activity, which represses antioxidant response element (ARE)/NF-E2 related factor 2 (Nrf2)-mediated transcriptional response in human chondrocytes.
56144	14931	10811	PIK3 Family	Protein	FN1	mRNA	-1	1	12218048	The inhibition of CTGF-induced p42/44 MAPK or phosphatidylinositol 3-kinase (PI3K)/protein kinase B pathway activities abrogated the induction of fibronectin expression.
57380	14931	 3336	PIK3 Family	Protein	CCND2	mRNA	0	1	11691826	Modified assertion
58008	14931	 1000	PIK3 Family	Protein	ST8SIA3	mRNA	0	1	16643848	Furthermore, as evidenced by Western blot analysis and RT-PCR, KCl-induced expression of hST8Sia III gene was dependent on the PI-3K signal transduction pathway during the neuronal differentiation of U-87 cells, as an increase in beta-tubulin III known as a neuronal differentiation marker was observed.
58823	14931	 9550	PIK3 Family	Protein	CDK4	mRNA	1	1	12657588	These data indicate that PI 3-kinase ultimately leads to activation of the cell cycle machinery in response to FGF-2. It does so by upregulating expression of Cdk4, facilitating the nuclear import of Cdk4, and sequestering Cdk4 in the nuclei as it simultaneously downregulates expression of p27 and facilitates the proteolysis of the molecule by phosphorylation.
 5945	14931	 1713	PIK3 Family	Protein	MYOG	mRNA	0	1	11861503	Transient reporter assays showed that both inhibitors repress muscle creatine kinase (MCK) and myogenin gene transcription.
59763	14931	13414	PIK3 Family	Protein	SERPINE1	mRNA	0	1	12745435	Hence, we conclude that the induction of PAI-1 gene expression is cell adhesion dependent and is through PI-3 kinase and Akt activation.
61412	14931	17154	PIK3 Family	Protein	HMGB2	mRNA	0	1	15504738	LY294002 treatment also significantly reduced the expression of two chromatin structure-related genes HMGB2 and HIST1H4C  as demonstrated by real time PCR (Fig. 6D) and duplex PCR (Fig. 6E), respectively.
61558	14931	 2095	PIK3 Family	Protein	DDIT4	mRNA	0	1	15592522	REDD1 expression is markedly reduced in PC-3 cells treated with LY294002 (LY) or Rapamycin and strongly induced under hypoxic conditions in a hypoxia-inducible factor-1 (HIF-1)-dependent manner.
62624	14931	 4925	PIK3 Family	Protein	IGFBP3	mRNA	0	-1	15809062	PTEN overexpression resulted in a significant decrease in the expression of IGF-I, -II, and IGF-IR. PTEN regulates IGFBP-3 at the transcriptional level PI3 kinase inhibitor, LY294002, upregulates IGFBP-3 expression but downregulates IGF-I and IGF-II, indicating that PTEN controls IGFBP-3 and IGFs by an Akt-dependent pathway.
63046	14931	 2839	PIK3 Family	Protein	SFN	mRNA	0	1	15187095	Preincubation with the phosphoinositide 3p-kinase inhibitor LY294002 significantly reduced the effects of IGF-I on 14-3-3sigma gene expression in these cells, suggesting that this effect of IGF-I occurs via the phosphoinositide 3p-kinase pathway.
63925	14931	12841	PIK3 Family	Protein	CKM	mRNA	0	1	11861503	Transient reporter assays showed that both inhibitors repress muscle creatine kinase (MCK) and myogenin gene transcription.
64372	14931	 6353	PIK3 Family	Protein	IRS2	mRNA	0	-1	11359902	A PI3K-specific inhibitor, LY294002, also upregulated IRS-2,
 6439	14931	19584	PIK3 Family	Protein	TGM2	mRNA	0	-1	12832399	Analysis of Ras/Raf downstream signaling with specific pharmacological inhibitors reveals that the decrease in tTG expression is mediated by the p38 MAPK, c-Jun NH2-terminal kinase, and phosphatidylinositol 3-kinase pathways.
65869	14931	11694	PIK3 Family	Protein	NEDD4	mRNA	0	1	18794886	NEDD4-1 transcription is positively regulated by PI3K pathway (Ahn et al., 2008), therefore representing a positive feedback for PTEN degradation and PI3K activation.
 8182	14931	16644	PIK3 Family	Protein	NR1D2	mRNA	0	1	12372818	the HZF2 transcription factor is induced by E2 in PI3K-dependent fashion
  832	14931	 1146	PIK3 Family	Protein	GCLC	mRNA	0	1	16172382	Table 3. Effects of PI3-K activity on shear-induced phase 2 gene suppression and COX-2 gene induction in chondrocytes
10105	16672	 7502	MAPK Erk Family	Protein	STAR	mRNA	0	-1	12727988	activation of the MAPK cascade by gonadotropins may serve as a novel mechanism to down-regulate steroidogenesis via attenuation of StAR expression
13219	16672	16200	MAPK Erk Family	Protein	PPP1R14B	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
13701	16672	 1438	MAPK Erk Family	Protein	VEGFA	mRNA	0	1	14555767	Interestingly, although VEGF-induced expression is sensitive to inhibitors of several pathways, including mitogen-activated protein kinase, phosphoinositide 3-kinase, and signal transducer and activator of transcription 3
17291	16672	14807	MAPK Erk Family	Protein	CANX	mRNA	0	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
19650	16672	16486	MAPK Erk Family	Protein	SPP1	mRNA	1	1	19798549	Further, ERK inhibitor inhibited significantly OPN expression, Elk1 phosphorylation, and activator protein-1 (AP-1)-DNA binding activation
20905	16672	14760	MAPK Erk Family	Protein	PALLD	mRNA	0	1	16794588	% Expression of the 4Ig isoform is strongly induced in fibroblast stress fibers upon TGF-beta1 treatment preceding alpha-SMA upregulation. TGF-beta1 induced upregulation of palladin is mediated both by Smad and mitogen-activated protein kinase pathways.
22270	16672	19636	MAPK Erk Family	Protein	OPTN	mRNA	0	-1	15753399	To investigate the roles of MAPK activation in tumors harboring KRAS or BRAF mutations, we inactivated MAPK in ovarian tumor cells using CI-1040, a compound that selectively inhibits MAPK kinase, an upstream regulator of MAPK and thus prevents MAPK activation. The most striking changes were down-regulation of cyclin D1, COBRA1, and transglutaminase-2 and up-regulation of tumor necrosis factor-related apoptosis-induced ligand, thrombospondin-1, optineurin, and palladin.
23902	16672	 5783	MAPK Erk Family	Protein	CEBPB	mRNA	0	1	12832471	In contrast, C/EBPbeta concentrations greatly increased following stimulation via MAP kinase-dependent induction of C/EBPbeta gene transcription.
27959	16672	19309	MAPK Erk Family	Protein	PLAUR	mRNA	0	1	15180498	The upregulation of MAPK activity was detected in breast cancers [77], and ERK1/2, JNK and p38 were identified in the stimulation of uPA and uPAR expression [78, 79]. Furthermore, inhibition of ERK1/2 and p38 down-regulated the expression of uPA/uPAR, which resulted in the inhibition of migration and decreased cell proliferation of the highly invasive breast cancer cells MDA-MB-231 [
28236	16672	 7832	MAPK Erk Family	Protein	THBS1	mRNA	-1	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
 3125	16672	16645	MAPK Erk Family	Protein	CCND1	mRNA	0	1	15753399	To investigate the roles of MAPK activation in tumors harboring KRAS or BRAF mutations, we inactivated MAPK in ovarian tumor cells using CI-1040, a compound that selectively inhibits MAPK kinase, an upstream regulator of MAPK and thus prevents MAPK activation. The most striking changes were down-regulation of cyclin D1, COBRA1, and transglutaminase-2 and up-regulation of tumor necrosis factor-related apoptosis-induced ligand, thrombospondin-1, optineurin, and palladin.
35222	16672	 5296	MAPK Erk Family	Protein	PLAU	mRNA	1	1	19768635	from full text Results - Plumbagin inhibited TPA-induced MMP-2 and u-PA expressions through suppressing phosphorylation of ERK in A549 cells     (treating TPA as background, ERK phosphorylation increases activity)
36218	16672	16306	MAPK Erk Family	Protein	CCT8	mRNA	0	1	12788937	PD98059, an inhibitor of MAPK, significantly repressed the CQE1-dependent transcription
37369	16672	 9189	MAPK Erk Family	Protein	MMP2	mRNA	0	1	19768635	from full text Results - Plumbagin inhibited TPA-induced MMP-2 and u-PA expressions through suppressing phosphorylation of ERK in A549 cells     (treating TPA as background, ERK phosphorylation increases activity)
39220	16672	 7376	MAPK Erk Family	Protein	TNFSF10	mRNA	-1	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
39513	16672	 5625	MAPK Erk Family	Protein	NFKBIE	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
44981	16672	13553	MAPK Erk Family	Protein	NUCB1	mRNA	0	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
 4943	16672	10424	MAPK Erk Family	Protein	JAG1	mRNA	0	1	16023591	The tumor associated growth factors HGF, EGF, and TGFA, produced by tumor cells and or stromal cells, induce Jagged1 expression in tumor cells probably in endothelial cells as well through MAPK pathway.
49898	16672	15228	MAPK Erk Family	Protein	TIMP3	mRNA	0	1	15468069	activation of ERK-MAPK pathway and Sp1 transcription factor play a pivotal role in the induction of TIMP-3 by TGF-beta in chondrocytes
51769	16672	 3656	MAPK Erk Family	Protein	PANX1	mRNA	0	-1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
53791	16672	16877	MAPK Erk Family	Protein	SIRPA	mRNA	-1	1	15374953	Interestingly, pharmacological inhibition of the kinase activities of EGFR, erbB2, and src and activation of mitogen-activated protein kinase, but not phosphatidylinositol 3p-kinase, significantly up-regulated SIRPalpha1 promoter activity.
56137	16672	10811	MAPK Erk Family	Protein	FN1	mRNA	-1	1	12218048	The inhibition of CTGF-induced p42/44 MAPK or phosphatidylinositol 3-kinase (PI3K)/protein kinase B pathway activities abrogated the induction of fibronectin expression.
56729	16672	18887	MAPK Erk Family	Protein	THSD1	mRNA	0	-1	15753399	To investigate the roles of MAPK activation in tumors harboring KRAS or BRAF mutations, we inactivated MAPK in ovarian tumor cells using CI-1040, a compound that selectively inhibits MAPK kinase, an upstream regulator of MAPK and thus prevents MAPK activation. The most striking changes were down-regulation of cyclin D1, COBRA1, and transglutaminase-2 and up-regulation of tumor necrosis factor-related apoptosis-induced ligand, thrombospondin-1, optineurin, and palladin.
62225	16672	 9862	MAPK Erk Family	Protein	PPP2R5D	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
62971	16672	12293	MAPK Erk Family	Protein	COBRA1	mRNA	0	1	15753399	Table 1. Differentially expressed genes after inactivation of MAPK in MPSC1 cells...CI-1040 which inhibits MEK and thus prevents activation of its downstream target, MAPK (ERK). Western blot analysis showed a dose-dependent effect on the expression of active MAPK in MPSC1 cells and active MAPK was not detectable 6 hours after treating the cells with CI-1040 at 5 mol/L, which was the concentration used in this study.
63875	16672	12543	MAPK Erk Family	Protein	IGFBP1	mRNA	-1	1	16236254	We found that overexpression of SirT1 is accompanied by enhanced mitogen-activated protein kinase (MAPK) activation...Treatment of SirT1-cotransfected cells with PD98059, which inhibits MAPK activation, decreased IGFBP-1 promoter activity
 6436	16672	19584	MAPK Erk Family	Protein	TGM2	mRNA	0	1	15753399	To investigate the roles of MAPK activation in tumors harboring KRAS or BRAF mutations, we inactivated MAPK in ovarian tumor cells using CI-1040, a compound that selectively inhibits MAPK kinase, an upstream regulator of MAPK and thus prevents MAPK activation. The most striking changes were down-regulation of cyclin D1, COBRA1, and transglutaminase-2 and up-regulation of tumor necrosis factor-related apoptosis-induced ligand, thrombospondin-1, optineurin, and palladin.
21910	15907	 3995	melatonin	Compound	ESR1	mRNA	-1	-1	12088876	Finally, Northern blot analysis demonstrated an enhanced inhibition of ERalpha mRNA expression and an enhanced induction of pancreatic spasmolytic polypeptide (pS2) by melatonin in MT(1)-transfected MCF-7 cells relative to vector-transfected MCF-7 cells.
23728	15907	12255	melatonin	Compound	SLC3A2	mRNA	0	1	16635017	Table 2. Genes showing melatonin-induced upregulation in peripheral blood mononuclear cell
39813	15907	 7769	melatonin	Compound	FOXO1	mRNA	-1	1	16635017	Table 2. Genes showing melatonin-induced upregulation in peripheral blood mononuclear cell
40977	15907	 4582	melatonin	Compound	NOS3	mRNA	1	1	16635017	Table 2. Genes showing melatonin-induced upregulation in peripheral blood mononuclear cell
54064	15907	 5118	melatonin	Compound	NOS2	mRNA	0	-1	12722978	DA-induced neuronal death, glial activation, and iNOS protein expression were attenuated significantly by melatonin treatment and were comparable to the control groups.
55167	15907	17653	melatonin	Compound	TFF1	mRNA	0	1	12088876	Northern blot analysis demonstrated an enhanced inhibition of ERalpha mRNA expression and an enhanced induction of pancreatic spasmolytic polypeptide (pS2) by melatonin in MT(1)-transfected MCF-7 cells relative to vector-transfected MCF-7 cells
55786	15907	 3250	melatonin	Compound	COL4A5	mRNA	-1	1	16635017	Table 2. Genes showing melatonin-induced upregulation in peripheral blood mononuclear cell
65575	15907	10022	melatonin	Compound	LIMK2	mRNA	-1	1	16635017	Table 2. Genes showing melatonin-induced upregulation in peripheral blood mononuclear cell
12807	17546	17369	Estrogens	Compound	IL6	mRNA	0	-1	11113455	Previous studies demonstrated that estrogens suppress IL-6-induced osteoporosis and the growth of multiple myeloma cells by repressing IL-6 and IL-6 receptor gene expression.
14665	17546	  567	Estrogens	Compound	PAX2	mRNA	0	1	16355216	Our experiments show that PAX2 is activated by oestrogen and tamoxifen in endometrial carcinomas but not in normal endometrium, and that this activation is associated with cancer-linked hypomethylation of the PAX2 promoter.
16907	17546	 2914	Estrogens	Compound	ARHGDIB	mRNA	0	1	12163132	data indicate that the transcript levels of interleukin 1 receptor antagonist (IL-1ra), beta 2-microglobulin, annexin XI and the LXR(alpha) receptor significantly increased and that Ly-GDI transcript levels significantly decreased after estrogen withdrawal;
19705	17546	16486	Estrogens	Compound	SPP1	mRNA	1	-1	10415730	In contrast, estrogen treatment decreased the expression of interleukin-6 (IL-6) (39%), carbonic anhydrase II (CA II) (36%), and osteopontin (OP) (37%)
20479	17546	 3055	Estrogens	Compound	PRLR	mRNA	0	1	12586844	PRLR expression is stimulated by GH, PRL, and  estrogens whereas GHR expression is stimulated by glucocorticoids ( 7 ).
21922	17546	 3995	Estrogens	Compound	ESR1	mRNA	-1	1	12200234	Modified assertion
24872	17546	 5863	Estrogens	Compound	MYC	mRNA	0	1	16107734	While E2 stimulated a short-term transient increase in Myc expression, E2 stimulated a sustained increase in Myc expression that was detectable at 48 h and pronounced at 5 days, the point where increased proliferation of MCF-7 cells in the absence of serum could be detected.
 3788	17546	16600	Estrogens	Compound	GJA1	mRNA	0	1	12810571	In addition, transient transfection experiments performed with estrogen receptor alpha (ERalpha) cDNA show that overexpression of Ini enhances, in a dose-dependent fashion, the up-regulation of the cx43 gene by estrogen
39138	17546	 6223	Estrogens	Compound	EGLN1	mRNA	0	1	15247232	Thus in different cell types, isoform-specific patterns of PHD induction by hypoxia and estrogen alter both the relative abundance of the PHDs and their relative contribution to the regulation of HIF.
39174	17546	 3997	Estrogens	Compound	PHF5A	mRNA	0	1	12810571	This article describes the structural and functional characterization of Ini (AF495522), a novel highly conserved zinc-finger protein that had been identified by screening an estrogen-induced rat myometrial expression library.
39392	17546	 6477	Estrogens	Compound	MTA3	mRNA	0	-1	19116762	Another member of this family, MTA3, is induced by estrogen and represses the expression of the transcriptional repressor Snail, a master regulator of \\epithelial to mesenchymal transitions\\, resulting in the expression of the cell adhesion molecule E-cadherin and maintenance of a differentiated, normal epithelial phenotype in breast cells.
40965	17546	 4582	Estrogens	Compound	NOS3	mRNA	1	1	11074525	Estrogens have been shown to upregulate ecNOS expression in different human cell culture systems.
44820	17546	13785	Estrogens	Compound	Bcl2a1b	mRNA	0	1	14702112	estrogen reduced tissue injury and enhanced antiapoptotic gene expression (bcl-2 and bfl-1)
45345	17546	14987	Estrogens	Compound	BCL2	mRNA	1	1	14702112	estrogen reduced tissue injury and enhanced antiapoptotic gene expression (bcl-2 and bfl-1)
46602	17546	11865	Estrogens	Compound	CA2	mRNA	0	-1	10415730	In contrast, estrogen treatment decreased the expression of interleukin-6 (IL-6) (39%), carbonic anhydrase II (CA II) (36%), and osteopontin (OP) (37%)
47758	17546	13695	Estrogens	Compound	CUZD1	mRNA	0	1	11416020	_  Ariadne: Because Hypox and Hypox-GH-replaced animals are rendered estrogen- deficient by pituitary ablation ( 37 ) and UO-44 expression is estrogen- dependent, estrogen deficiency may down-regulate UO-44 expression in the uterus of Hypox rats. [Expression]
55159	17546	17653	Estrogens	Compound	TFF1	mRNA	0	1	15282304	In the presence of estrogen, RIZ1 binding to estrogen target genes became less direct and followed the binding of ER to DNA and RIZ1 methyltransferase activity on H3-Lys 9 was inhibited, indicating derepression may play a role in estrogen induction of gene transcription. Reducing RIZ1 level correlated with decreased induction of pS2 gene by estrogen in MCF7 cells.
55582	17546	16323	Estrogens	Compound	BSG	mRNA	0	1	12211060	Basigin, a transmembrane glycoprotein belonging to the immunoglobulin superfamily, has been shown to be essential for fertilization and implantation. The aim of this study was to determine the expression and hormonal regulation of basigin gene in mouse uterus during the peri-implantation period. Basigin immunostaining and mRNA were strongly localized in luminal and glandular epithelium on day 1 of pregnancy and gradually decreased to a basal level from day 2-4 of pregnancy. Basigin mRNA expression in the sub-luminal stroma was first detected on day 3 of pregnancy and increased on day 4 of pregnancy. On day 5 of pregnancy, the expression of basigin protein and mRNA was only detected in the implanting embryos, and the luminal epithelium and sub-luminal stroma surrounding the embryos. A similar expression pattern of basigin was also induced in the delayed-implantation uterus which was activated by estrogen injection. On day 6-8 of pregnancy, although a basal level of basigin protein was detected in the secondary decidual zone, basigin mRNA expression was strongly seen in this location. Basigin mRNA was also highly expressed in the decidualized cells under artificial decidualization. Estrogen significantly stimulated basigin expression in the ovariectomized mouse uterus. A high level of basigin immunostaining and mRNA was also seen in proestrus and estrus uteri. These results suggest that basigin expression is closely related to mouse implantation and up-regulated by estrogen.
56123	17546	13961	Estrogens	Compound	EGLN2	mRNA	0	1	15247232	Thus in different cell types, isoform-specific patterns of PHD induction by hypoxia and estrogen alter both the relative abundance of the PHDs and their relative contribution to the regulation of HIF.
58585	17546	18077	Estrogens	Compound	EGLN3	mRNA	0	1	15247232	Thus in different cell types, isoform-specific patterns of PHD induction by hypoxia and estrogen alter both the relative abundance of the PHDs and their relative contribution to the regulation of HIF.
61041	17546	13929	Estrogens	Compound	IL6R	mRNA	0	-1	11113455	Previous studies demonstrated that estrogens suppress IL-6-induced osteoporosis and the growth of multiple myeloma cells by repressing IL-6 and IL-6 receptor gene expression.
11799	11101	18802	SOX1	Protein	NEUROG1	mRNA	0	1	15110721	Sox1 activates transcription of the proneural gene neurogenin1. Expression of Sox1 up-regulated ngn1 promoter activity in a dose-dependent manner. Overexpression of Sox1-IRES-GFP increased levels of ngn1 mRNA about 16-fold and more than doubled levels of ngn1 protein.
18379	11101	14294	SOX1	Protein	CRYAB	mRNA	0	1	15113840	Gel shift assays showed that the Sox1 and Sox2 proteins preferentially bound to E2 and E4. Moreover, disruption of E2 and E4 abolished the reporter gene expression in the lens. These results indicate that the newly identified enhancer with Sox elements activates the alphaB-crystallin promoter in the lens,
27870	11101	 1166	SOX1	Protein	SLC2A1	mRNA	-1	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
28835	11101	 4033	SOX1	Protein	LRRN1	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
28848	11101	 9036	SOX1	Protein	SOX4	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
29549	11101	13348	SOX1	Protein	VIM	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
29690	11101	 9741	SOX1	Protein	TUBA1A	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
36166	11101	 1324	SOX1	Protein	ZIC1	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
  435	11101	12318	SOX1	Protein	SOX11	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
44965	11101	 1854	SOX1	Protein	RTN1	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
48216	11101	13080	SOX1	Protein	PRMT3	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
50233	11101	13634	SOX1	Protein	QKI	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
52789	11101	15150	SOX1	Protein	KHDRBS3	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
54369	11101	 8574	SOX1	Protein	SFRP2	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
55489	11101	 9154	SOX1	Protein	MSI2	mRNA	-1	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
55746	11101	 2223	SOX1	Protein	HES1	mRNA	0	-1	15110721	Sox1 binds directly to the Hes1 promoter and suppresses Hes1 transcription, thus attenuating Notch signaling.
58514	11101	10235	SOX1	Protein	NHLH2	mRNA	0	1	12923295	See Table 1. Genes identified by microarray analysis. All changes were greater than or equal to 1.5.
28312	 7491	10956	etoposide	Compound	TNFRSF10B	mRNA	0	1	14500373	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.
46621	 7491	 4208	etoposide	Compound	TNFRSF10A	mRNA	0	1	14500373	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.
49686	 7491	 6430	etoposide	Compound	MDM2	mRNA	1	-1	10023685	We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis.
50784	 7491	12393	etoposide	Compound	GPX3	mRNA	0	1	10207030	GPX is induced by etoposide, a topoisomerase II inhibitor and a p53 activator
55152	 7491	 8359	etoposide	Compound	ATP6V0C	mRNA	0	1	12133827	We have confirmed that both camptothecin and etoposide induce ATP6L promoter activity (data not shown).
51666	 1278	  219	glutathione	Compound	FASLG	mRNA	-1	-1	10711676	tBH treatment of hRPE cells resulted in increased expression of FasL and Fas. Glutathione and NAC completely abrogated tBH-induced increase in FasL and Fas expression
10601	16473	 6270	ENO1	Protein	BRCA2	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
11227	16473	13301	ENO1	Protein	CCNB1	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
13443	16473	 6415	ENO1	Protein	CCNB2	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
19447	16473	 6094	ENO1	Protein	RAD9A	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
 3150	16473	16645	ENO1	Protein	CCND1	mRNA	0	-1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
36512	16473	  950	ENO1	Protein	RBL1	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
39561	16473	13744	ENO1	Protein	CDKN1B	mRNA	-1	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
41095	16473	11896	ENO1	Protein	MCM5	mRNA	1	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
45602	16473	 4559	ENO1	Protein	CDC20	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
49344	16473	13282	ENO1	Protein	CDK6	mRNA	0	-1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
51035	16473	13884	ENO1	Protein	CDKN1A	mRNA	1	-1	18852884	Senescent fibroblasts exhibited enhanced expression of phosphorylated and acetylated p53, and cyclin-dependent kinase inhibitor, p21. Together, these results demonstrated that knockdown of endogenous MBP-1 is involved in cellular senescence of HFF through p53-p21 pathway.
51545	16473	 5120	ENO1	Protein	MCM4	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
61846	16473	 3158	ENO1	Protein	CDKN3	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
62936	16473	 7195	ENO1	Protein	GADD45A	mRNA	-1	-1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
  763	16473	18034	ENO1	Protein	MKI67	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
 9338	16473	 8814	ENO1	Protein	CDK1	mRNA	0	1	18852884	Table 1.  Genes differentially expressed in MBP-1 depleted HFF.
10023	 4497	18909	Tetradecanoylphorbol acetate	Compound	CYB5A	mRNA	0	-1	15831526	We found b5 expression in all cell lines tested, including human adrenal NCI-H295A cells, where its mRNA is reduced by cAMP and phorbol ester.
10660	 4497	 3198	Tetradecanoylphorbol acetate	Compound	TFRC	mRNA	-1	-1	 7781766	Treatment of HL-60 cells with phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, or dibutyryl-cyclic AMP (dbcAMP), a protein kinase A (PKA) activator, resulted in a 90% decrease in the level of TfR mRNA
 1152	 4497	10092	Tetradecanoylphorbol acetate	Compound	SDHA	mRNA	0	-1	12430000	We identified four genes expressed differentially after TPA treatment. Levels of expression of two genes, human flavoprotein subunit of complex II and JKTBP, were downregulated by TPA,
11758	 4497	11155	Tetradecanoylphorbol acetate	Compound	HEMGN	mRNA	-1	-1	18599389	n this study, a dose-dependent inhibition of EDAG expression by PMA was observed in K562 cells.
11879	 4497	15372	Tetradecanoylphorbol acetate	Compound	TGM1	mRNA	0	1	11435435	HOXA7 overexpressed in normal keratinocytes attenuated the TPA-induced expression of TGM1.
 1259	 4497	18332	Tetradecanoylphorbol acetate	Compound	NDRG1	mRNA	0	1	10395947	These antibodies revealed a protein with the expected 43 kDa molecular mass, up-regulated by phorbol ester, retinoids and 1,25-(OH)2 vitamin D3 in U937 cells.
12726	 4497	13434	Tetradecanoylphorbol acetate	Compound	HIF1A	mRNA	0	1	12379645	We show that, in contrast to hypoxia, the induction of HIF-1alpha by Ang II in VSMC is dependent on active transcription and ongoing translation. We demonstrate that stimulation of VSMC by Ang II strongly increases HIF-1alpha gene expression. The activation of diacylglycerol-sensitive protein kinase C (PKC) plays a major role in the increase of HIF-1alpha gene transcription.
13078	 4497	 8308	Tetradecanoylphorbol acetate	Compound	PTPRO	mRNA	0	1	10397721	PTP-RO mRNA and protein expression are upregulated upon phorbol 12-myristate 13-acetate (PMA) treatment of the megakaryocytic cell lines CMS, CMK, and Dami.
13817	 4497	17250	Tetradecanoylphorbol acetate	Compound	PTGS2	mRNA	0	1	12201673	TPA-induced expression of cyclooxygenase-2
15480	 4497	18775	Tetradecanoylphorbol acetate	Compound	PFKFB3	mRNA	0	1	11245987	Transient expression assays of truncated promoter-reporter constructs in HeLa cells showed that this gene is induced by phorbol esters (PDB) and cyclic-AMP-dependent protein kinase signal activation
16507	 4497	13088	Tetradecanoylphorbol acetate	Compound	CLEC2D	mRNA	0	1	11455585	In this study the expression of C-type lectins during the early activation of PMA-stimulated peripheral blood lymphocytes was examined. To investigate the influence of de novo protein synthesis on activation-dependent expression of C-type lectins, cells were cultured in presence of cycloheximide (CHX) and mRNA levels were analyzed by semi-quantitative reverse transcription-polymerase chain reaction. Upregulated levels of CD69, AICL, and LLT1, but less pronounced changes of CD161/NKR-P1A and CD94 mRNA were found at early time points of cellular activation.
19710	 4497	16486	Tetradecanoylphorbol acetate	Compound	SPP1	mRNA	1	1	14670086	Both of these gene targets showed an up-regulation in message in response to PMA, and this effect was still present in the cells treated with the compound F.
22071	 4497	10299	Tetradecanoylphorbol acetate	Compound	CLEC2B	mRNA	0	1	11455585	In this study the expression of C-type lectins during the early activation of PMA-stimulated peripheral blood lymphocytes was examined. To investigate the influence of de novo protein synthesis on activation-dependent expression of C-type lectins, cells were cultured in presence of cycloheximide (CHX) and mRNA levels were analyzed by semi-quantitative reverse transcription-polymerase chain reaction. Upregulated levels of CD69, AICL, and LLT1, but less pronounced changes of CD161/NKR-P1A and CD94 mRNA were found at early time points of cellular activation.
23275	 4497	 1089	Tetradecanoylphorbol acetate	Compound	TSFM	mRNA	0	-1	12952954	We initially analyzed mRNA levels of several mt translation factors by Northern hybridization. This revealed that differentiation of HL-60RG cells by TPA promotes coordinate reduction of the mRNA level for all mt translation factors investigated (Fig. 1A). Nuclear-coded genes, i.e. initiation factor 2 (IF-2mt), elongation factor Tu (EF-Tumt), elongation factor Ts (EFTsmt), methionyl-tRNA transformylase (MTFmt), methionyltRNA synthetase (MetRSmt), and ribosomal proteins S12mt and L7_L12mt were reduced by 10_20_fold, whereas mtDNAcoded 16 S rRNA was down-regulated to a lesser extent (5- fold) (Fig. 1A, 16 S rRNA). Similar results were confirmed with the HL-60 cell line (data not shown).
23315	 4497	 7455	Tetradecanoylphorbol acetate	Compound	CTSB	mRNA	0	-1	 2751829	The TSH-induced increase in cathepsin B mRNA concentrations (approximately fivefold over that in untreated cells) was partially mimicked by forskolin (approximately threefold) and ionomycin, while phorbol ester decreased cathepsin B mRNA concentrations. Similar changes were observed for thyroglobulin and actin mRNA concentrations.... These results demonstrate (1) that cathepsin B expression in the thyroid is regulated in parallel with that of thyroglobulin and actin, and (2) that cyclic AMP- and Ca2+-dependent processes stimulate gene expression, while phorbol ester treatment inhibits gene expression in FRTL5 cells.
23768	 4497	 6636	Tetradecanoylphorbol acetate	Compound	BCL2L1	mRNA	0	1	12430000	We identified four genes expressed differentially after TPA treatment. Levels of expression of two genes, human flavoprotein subunit of complex II and JKTBP, were downregulated by TPA,
24927	 4497	17915	Tetradecanoylphorbol acetate	Compound	CCL15	mRNA	0	1	15179048	PMA-induction of Lkn-1/CCL15 in transiently transfected U937 cells was blocked by proteasome inhibitor 1. These observations demonstrate that the two NF-kappaB binding sites are essential for PMA-induced Lkn-1/CCL15 expression in human monocytes.
25469	 4497	 5701	Tetradecanoylphorbol acetate	Compound	ID3	mRNA	0	-1	12000752	Treatments with 12-O-tetradecanoylphorbol-13-acetate, another inducer of neuroblastoma cell differentiation, also resulted in coordinated down-regulation of ID gene expression, underscoring the role of ID genes in differentiation.
25500	 4497	11591	Tetradecanoylphorbol acetate	Compound	NR4A3	mRNA	0	1	12564761	The levels of Nurr1, NGFI-B and NOR-1 mRNA were elevated markedly in NTera2 teratocarcinoma-derived neurons (NTera2-N), a model of differentiated human neurons, following a 1.5 or 3 h-exposure to 1 mM dibutyryl cyclic AMP or 100 nm phorbol 12-myristate 13-acetate
25903	 4497	19027	Tetradecanoylphorbol acetate	Compound	HMOX1	mRNA	0	1	12869663	View this table: [in this window] [in a new window] TABLE 1 Summary of the various functions of HO isoforms, their tissue distribution, and gene regulation      Maines et al. (1986) were the first to report the identification of a second form of HO from rat liver microsomes, designated HO-2. Only recently, a third isoform, HO-3, was discovered (McCoubrey et al., 1997). HO-1 and HO-2 share little similarity in amino acid sequence (40%), whereas the HO-2 and HO-3 isoform are far more homologous (90%). All HO isoforms are highly conserved among species in evolution. HO is expressed in virtually all life forms; in prokaryotic bacteria as well as in fungi, plants, and humans, regulating a wide spectrum of cellular processes (Terry et al., 2002). The homology between rat, mouse, and human is for HO-1 and HO-2 proteins higher than 80% and 90%, respectively.  Under normal physiological conditions, most cells express low or undetectable levels of HO-1 protein, whereas HO-2 proteins are constitutively expressed. HO-3 protein expression awaits further characterization. HO-2 transcription is only up-regulated by few agents, such as opiates and adrenal glucocorticoids (Li and David Clark, 2000; Liu et al., 2000).  HO-1 gene expression is highly inducible by more diverse stimuli than any other enzyme described to date (Maines, 1997) and involves a multitude of signaling pathways (Table 2) (Immenschuh and Ramadori, 2000). HO-1 expression is mainly regulated at the transcriptional level.     View this table: [in this window] [in a new window] TABLE 2 Selection of different inducers of HO-1 gene expression
28115	 4497	17708	Tetradecanoylphorbol acetate	Compound	FOSL1	mRNA	0	1	13679379	In contrast to a transient induction by H2O2, TPA persistently activated fra-1 transcription, principally at the transcriptional level.
28220	 4497	 7832	Tetradecanoylphorbol acetate	Compound	THBS1	mRNA	-1	1	10067831	TSH promoted follicle formation and inhibited TSP1 production.
28345	 4497	14168	Tetradecanoylphorbol acetate	Compound	ANKH	mRNA	0	1	11746513	Ank gene expression is also upregulated after treating quiescent fibroblasts with several other mitogenic agents (e.g., calf serum or platelet-derived growth factor-BB) or the tumor promoter phorbol 12-myristate 13-acetate.
 2880	 4497	12537	Tetradecanoylphorbol acetate	Compound	CCL4	mRNA	0	1	18192506	Using primary NK cells from Bcl10(-/-), Malt1(-/-), Carma1(-/-), and Card9(-/-) mice we demonstrate a key role for Bcl10 signalosomes in the activation of canonical NF-kappaB signaling as well as JNK and p38 MAPK upon NK cell triggering. Bcl10 directly cooperates with Malt1 and depends on Carma1 (Card11) but not on Card9 for NK cell activation.
29867	 4497	10162	Tetradecanoylphorbol acetate	Compound	CDKN2C	mRNA	0	-1	15107819	12-O-tetradecanoylphorbol-13-acetate (TPA), widely used as a protein kinase C (PKC) activator, suppresses the expression of p18(INK4c) through its promoter, accompanied by the induction of human cancer cell growth.
30328	 4497	13698	Tetradecanoylphorbol acetate	Compound	IFNG	mRNA	0	1	18192506	Using primary NK cells from Bcl10(-/-), Malt1(-/-), Carma1(-/-), and Card9(-/-) mice we demonstrate a key role for Bcl10 signalosomes in the activation of canonical NF-kappaB signaling as well as JNK and p38 MAPK upon NK cell triggering. Bcl10 directly cooperates with Malt1 and depends on Carma1 (Card11) but not on Card9 for NK cell activation.
32011	 4497	 4292	Tetradecanoylphorbol acetate	Compound	DDIT3	mRNA	0	1	16301669	This was confirmed by MAPK reporter gene experiments using the pFR luciferase reporter gene and a CHOP expression plasmid (p38 MAPK dependent), which demonstrated that CHOP expression was increased upon stimulation with IL-1 and NE (Fig. 2D).
33682	 4497	12902	Tetradecanoylphorbol acetate	Compound	SEC16B	mRNA	0	1	12244571	Moreover, the RGPR-p117 mRNA expression in H4-II-E cells was stimulated in the presence of dibutyryl cAMP, PMA, insulin, 17beta-estradiol, or serum in culture medium
34445	 4497	18827	Tetradecanoylphorbol acetate	Compound	TUFM	mRNA	0	-1	12952954	We initially analyzed mRNA levels of several mt translation factors by Northern hybridization. This revealed that differentiation of HL-60RG cells by TPA promotes coordinate reduction of the mRNA level for all mt translation factors investigated (Fig. 1A). Nuclear-coded genes, i.e. initiation factor 2 (IF-2mt), elongation factor Tu (EF-Tumt), elongation factor Ts (EFTsmt), methionyl-tRNA transformylase (MTFmt), methionyltRNA synthetase (MetRSmt), and ribosomal proteins S12mt and L7_L12mt were reduced by 10_20_fold, whereas mtDNAcoded 16 S rRNA was down-regulated to a lesser extent (5- fold) (Fig. 1A, 16 S rRNA). Similar results were confirmed with the HL-60 cell line (data not shown).
36755	 4497	 3532	Tetradecanoylphorbol acetate	Compound	NR4A2	mRNA	0	1	12564761	The levels of Nurr1, NGFI-B and NOR-1 mRNA were elevated markedly in NTera2 teratocarcinoma-derived neurons (NTera2-N), a model of differentiated human neurons, following a 1.5 or 3 h-exposure to 1 mM dibutyryl cyclic AMP or 100 nm phorbol 12-myristate 13-acetate
37132	 4497	12112	Tetradecanoylphorbol acetate	Compound	TH	mRNA	0	1	11238722	Tyrosine hydroxylase (TH) gene promoter activity is increased in PC12 cells that are treated with the phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA
 3891	 4497	18007	Tetradecanoylphorbol acetate	Compound	IFRD1	mRNA	0	1	16204248	% 12-O-Tetradecanoylphorbol-13-acetate-induced sequence 7 (TIS7) acts as a transcriptional co-repressor
39794	 4497	19472	Tetradecanoylphorbol acetate	Compound	SDHB	mRNA	0	-1	12430000	We identified four genes expressed differentially after TPA treatment. Levels of expression of two genes, human flavoprotein subunit of complex II and JKTBP, were downregulated by TPA,
41017	 4497	 1427	Tetradecanoylphorbol acetate	Compound	SDHD	mRNA	0	-1	12430000	We identified four genes expressed differentially after TPA treatment. Levels of expression of two genes, human flavoprotein subunit of complex II and JKTBP, were downregulated by TPA,
 4131	 4497	 9008	Tetradecanoylphorbol acetate	Compound	SDHC	mRNA	0	-1	12430000	We identified four genes expressed differentially after TPA treatment. Levels of expression of two genes, human flavoprotein subunit of complex II and JKTBP, were downregulated by TPA,
 4191	 4497	 4280	Tetradecanoylphorbol acetate	Compound	PHGDH	mRNA	0	-1	10713460	The TPA-induced monocytic differentiation of U937, which also resulted in growth arrest, abruptly downregulated the expression of 3-PGDH. Removal of TPA restored cell growth through the retrodifferentiation process and subsequent expression of 3-PGDH
42065	 4497	13115	Tetradecanoylphorbol acetate	Compound	EGR1	mRNA	-1	1	12618431	PMA and granulocyte/macrophage colony-stimulating factor induce Egr-1 expression through ERK and p38 activation, respectively.
42682	 4497	18771	Tetradecanoylphorbol acetate	Compound	KLRD1	mRNA	0	1	11455585	Conversely, CHX blocked CD94 mRNA expression in PMA-stimulated cells, demonstrating that this process is dependent on new protein synthesis.
42827	 4497	 3879	Tetradecanoylphorbol acetate	Compound	FAS	mRNA	0	1	10575005	We further show that anti-CD3 mAb, phorbol 12-myristate 13-acetate, and phorbol 12-myristate 13-acetate/ionomycin strongly activated promoters carrying multiple copies of the Fas enhancer, and mutation of either the GABP or AP-1 binding site severely reduced transcriptional activity.
42934	 4497	15885	Tetradecanoylphorbol acetate	Compound	ACTB	mRNA	1	1	 8183567	Transcription of the cytoskeletal beta-actin gene is rapidly induced by phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore, A23187, in cultured H4IIE hepatoma (H4) cells.
43379	 4497	18968	Tetradecanoylphorbol acetate	Compound	MTIF2	mRNA	0	-1	12952954	We initially analyzed mRNA levels of several mt translation factors by Northern hybridization. This revealed that differentiation of HL-60RG cells by TPA promotes coordinate reduction of the mRNA level for all mt translation factors investigated (Fig. 1A). Nuclear-coded genes, i.e. initiation factor 2 (IF-2mt), elongation factor Tu (EF-Tumt), elongation factor Ts (EFTsmt), methionyl-tRNA transformylase (MTFmt), methionyltRNA synthetase (MetRSmt), and ribosomal proteins S12mt and L7_L12mt were reduced by 10_20_fold, whereas mtDNAcoded 16 S rRNA was down-regulated to a lesser extent (5- fold) (Fig. 1A, 16 S rRNA). Similar results were confirmed with the HL-60 cell line (data not shown).
43794	 4497	  555	Tetradecanoylphorbol acetate	Compound	PDPN	mRNA	0	1	12640676	TPA-induced genes, such as Sprr1A, Saa3, JunB, Il4ralpha, Gp38, RalGDS and Slpi
44065	 4497	15206	Tetradecanoylphorbol acetate	Compound	ATP2A2	mRNA	0	-1	12606313	SERCA2 downregulation can be simulated in cultured neonatal rat ventricular myocytes (NRVM) by treatment with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA)
44558	 4497	 6521	Tetradecanoylphorbol acetate	Compound	MMP7	mRNA	0	1	11259407	The epithelium-specific metalloprotease matrilysin (MMP-7) also contains ETS and AP-1 cis-elements in its promoter, and its expression, like that of MMP-1, is also induced by PMA, tumor necrosis factor-alpha , interleukin-1, and epidermal growth factor
44764	 4497	 4862	Tetradecanoylphorbol acetate	Compound	PDGFA	mRNA	-1	1	14573617	KLF5 mediates a novel distinct delayed persistent induction of PDGF-A chain in response to the model agonist, phorbol ester, through a cis-element previously shown to mediate phorbol ester induction on to PDGF-A chain through the early growth response factor (Egr-1)
45236	 4497	12221	Tetradecanoylphorbol acetate	Compound	MMP19	mRNA	0	1	12516088	of the 12 tested cytokines/growth factors, only TNF-alpha and PMA were able to stimulate the expression of MMP-19 mRNA in primary keratinocytes.
46037	 4497	12530	Tetradecanoylphorbol acetate	Compound	HPGD	mRNA	-1	1	10650939	PGDH promoter was strongly induced by phorbol ester
48566	 4497	18949	Tetradecanoylphorbol acetate	Compound	IL4R	mRNA	0	1	12640676	TPA-induced genes, such as Sprr1A, Saa3, JunB, Il4ralpha, Gp38, RalGDS and Slpi
48671	 4497	19384	Tetradecanoylphorbol acetate	Compound	ALOX15B	mRNA	0	1	14711820	In this study, we found TPA-induced 8S-LOX mRNA expression is a result of increased transcription in SSIN primary keratinocytes and further investigated transcriptional regulation of 8S-LOX expression by cloning its promoter.We then identified a Sp1 binding site located -77 to -68 from the ATG that is a TPA-responsive element (TRE) of the promoter and that Sp1, Sp2, and Sp3 proteins bind to the TRE.We also found that the binding of these proteins to the TRE was significantly increased by TPA treatment and inhibition of the binding by mithramycin A decreased TPA-induced promoter activity as well as 8S-LOX mRNA expression. These data suggest that increased binding of Sp1, Sp2, and Sp3 to the TRE of the 8S-LOX promoter is a mechanism by which TPA induces 8S-LOX expression in keratinocytes.induced 8S-LOX mRNA expression is a result of increased transcription in SSIN primary keratinocytes and further investigated transcriptional regulation of 8S-LOX expression by cloning its promoter.
49160	 4497	 7729	Tetradecanoylphorbol acetate	Compound	SLPI	mRNA	0	1	12640676	TPA-induced genes, such as Sprr1A, Saa3, JunB, Il4ralpha, Gp38, RalGDS and Slpi
49292	 4497	 2099	Tetradecanoylphorbol acetate	Compound	CD69	mRNA	0	1	11455585	In this study the expression of C-type lectins during the early activation of PMA-stimulated peripheral blood lymphocytes was examined. To investigate the influence of de novo protein synthesis on activation-dependent expression of C-type lectins, cells were cultured in presence of cycloheximide (CHX) and mRNA levels were analyzed by semi-quantitative reverse transcription-polymerase chain reaction. Upregulated levels of CD69, AICL, and LLT1, but less pronounced changes of CD161/NKR-P1A and CD94 mRNA were found at early time points of cellular activation.
50080	 4497	 2931	Tetradecanoylphorbol acetate	Compound	CFI	mRNA	0	1	10630630	The production of CFI by Hep G2 cells was enhanced in a dose- and time-dependent fashion by 12-O-tetradecanoyl-1,2-phorbol 13-acetate (TPA), a potent PKC activator. 4Alpha-phorbol didecanoate, an inactive phorbol ester, had no effect on CFI synthesis. The TPA-dependent increase in CFI secretion was correlated with an increase in CFI mRNA levels. These results indicate that TPA regulation of CFI gene requires PKC signalling and is mediated by via a TPA response element (TRE) in the CFI promoter region located at -136/-130
50932	 4497	 6827	Tetradecanoylphorbol acetate	Compound	AREG	mRNA	0	1	15072547	Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines
51057	 4497	13884	Tetradecanoylphorbol acetate	Compound	CDKN1A	mRNA	1	1	12917633	p21(WAF-1), which plays a central role in cell proliferation, can be activated by HTLV-I Tax protein and by TPA.
51215	 4497	19545	Tetradecanoylphorbol acetate	Compound	PRDM2	mRNA	0	1	11591891	Selective expression of PRDM2 was also induced by 12-O-tetradecanoyl-phorbol-13-acetate in the U937 and HL60 cell lines and by 1,25-dihydroxyvitamin D(3) only in HL60 cells. Tetradecanoylphorbol acetate is a synonym for 12-O-tetradecanoyl-phorbol-13-acetate Calcitriol is a synonym for 1,25-dihydroxyvitamin D(3)
51309	 4497	17260	Tetradecanoylphorbol acetate	Compound	MAOB	mRNA	0	1	11956220	In this study, we have shown that phorbol 12-myristate 13-acetate (PMA) increases human MAO B, but not MAO A, gene expression.
51627	 4497	 5673	Tetradecanoylphorbol acetate	Compound	ID1	mRNA	0	-1	12000752	Treatments with 12-O-tetradecanoylphorbol-13-acetate, another inducer of neuroblastoma cell differentiation, also resulted in coordinated down-regulation of ID gene expression, underscoring the role of ID genes in differentiation.
51924	 4497	 9802	Tetradecanoylphorbol acetate	Compound	IL6ST	mRNA	0	1	10613356	We found that the expression of gp130 was dramatically induced at both the mRNA and protein levels by the two megakaryocytic inducers sodium butyrate (NaBut) and PMA.
51939	 4497	 1178	Tetradecanoylphorbol acetate	Compound	NR4A1	mRNA	0	1	12947120	12-O-tetradecanoylphorbol-13-acetate (TPA) could induce cell apoptosis via induction of TR3 and E2F1 expression in LNCaP prostate cancer cells
53034	 4497	11588	Tetradecanoylphorbol acetate	Compound	MARS2	mRNA	0	-1	12952954	We initially analyzed mRNA levels of several mt translation factors by Northern hybridization. This revealed that differentiation of HL-60RG cells by TPA promotes coordinate reduction of the mRNA level for all mt translation factors investigated (Fig. 1A). Nuclear-coded genes, i.e. initiation factor 2 (IF-2mt), elongation factor Tu (EF-Tumt), elongation factor Ts (EFTsmt), methionyl-tRNA transformylase (MTFmt), methionyltRNA synthetase (MetRSmt), and ribosomal proteins S12mt and L7_L12mt were reduced by 10_20_fold, whereas mtDNAcoded 16 S rRNA was down-regulated to a lesser extent (5- fold) (Fig. 1A, 16 S rRNA). Similar results were confirmed with the HL-60 cell line (data not shown).
53063	 4497	16278	Tetradecanoylphorbol acetate	Compound	ID2	mRNA	0	-1	12000752	Treatments with 12-O-tetradecanoylphorbol-13-acetate, another inducer of neuroblastoma cell differentiation, also resulted in coordinated down-regulation of ID gene expression, underscoring the role of ID genes in differentiation.
54017	 4497	18156	Tetradecanoylphorbol acetate	Compound	EIF4EBP1	mRNA	0	-1	12618431	we show that the expression of 4E-BP1 protein and transcript decreases in hematopoietic cell lines cultivated in the presence of phorbol 12-myristate 13-acetate (PMA)
54531	 4497	 1256	Tetradecanoylphorbol acetate	Compound	S1PR1	mRNA	0	1	18973762	S1P1 was first cloned from endothelial cells as an immediate early transcript induced by the tumor promoter phorbol 12-myristate 13-acetate (PMA) (Hla and Maciag, 1990).
57333	 4497	 4298	Tetradecanoylphorbol acetate	Compound	JUNB	mRNA	0	1	12640676	TPA-induced genes, such as Sprr1A, Saa3, JunB, Il4ralpha, Gp38, RalGDS and Slpi
58638	 4497	 8403	Tetradecanoylphorbol acetate	Compound	RPL12	mRNA	0	-1	12952954	We initially analyzed mRNA levels of several mt translation factors by Northern hybridization. This revealed that differentiation of HL-60RG cells by TPA promotes coordinate reduction of the mRNA level for all mt translation factors investigated (Fig. 1A). Nuclear-coded genes, i.e. initiation factor 2 (IF-2mt), elongation factor Tu (EF-Tumt), elongation factor Ts (EFTsmt), methionyl-tRNA transformylase (MTFmt), methionyltRNA synthetase (MetRSmt), and ribosomal proteins S12mt and L7_L12mt were reduced by 10_20_fold, whereas mtDNAcoded 16 S rRNA was down-regulated to a lesser extent (5- fold) (Fig. 1A, 16 S rRNA). Similar results were confirmed with the HL-60 cell line (data not shown).
58854	 4497	 3120	Tetradecanoylphorbol acetate	Compound	MTFMT	mRNA	0	-1	12952954	We initially analyzed mRNA levels of several mt translation factors by Northern hybridization. This revealed that differentiation of HL-60RG cells by TPA promotes coordinate reduction of the mRNA level for all mt translation factors investigated (Fig. 1A). Nuclear-coded genes, i.e. initiation factor 2 (IF-2mt), elongation factor Tu (EF-Tumt), elongation factor Ts (EFTsmt), methionyl-tRNA transformylase (MTFmt), methionyltRNA synthetase (MetRSmt), and ribosomal proteins S12mt and L7_L12mt were reduced by 10_20_fold, whereas mtDNAcoded 16 S rRNA was down-regulated to a lesser extent (5- fold) (Fig. 1A, 16 S rRNA). Similar results were confirmed with the HL-60 cell line (data not shown).
60016	 4497	12976	Tetradecanoylphorbol acetate	Compound	IL8	mRNA	0	1	17207890	TNF-alpha stimulated expression of both chemokines, while the PKCalpha/beta activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) induced only expression of IL-8 and inhibited TNF-alpha-induced RANTES expression.
60417	 4497	 5024	Tetradecanoylphorbol acetate	Compound	CCL5	mRNA	0	-1	17207890	TNF-alpha stimulated expression of both chemokines, while the PKCalpha/beta activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) induced only expression of IL-8 and inhibited TNF-alpha-induced RANTES expression.
61257	 4497	 1552	Tetradecanoylphorbol acetate	Compound	ODC1	mRNA	1	1	12201673	TPA-induced epidermal ODC activity and ODC mRNA expression.
61355	 4497	15502	Tetradecanoylphorbol acetate	Compound	ETS2	mRNA	0	1	12646185	this activity was enhanced by protein kinase C activator, phorbol 12-myristate 13-acetate (PMA), in an ETS consensus-dependent manner, while PMA could also enhance the expression level of ETS2 Endogenous expression of GM-CSF mRNA was increased by ETS2 transfection and the increased expression was further enhanced by PMA
62830	 4497	  127	Tetradecanoylphorbol acetate	Compound	UHRF1	mRNA	0	1	12612445	Expression of the NP95 gene, which was previously found to be the gene of a murine nuclear protein associated with cell proliferation, was increased in the cultures treated by 12-O-tetradecanoylphorbol-13-acetate (TPA), okadaic acid, and orthovanadate.
65599	 4497	 7139	Tetradecanoylphorbol acetate	Compound	RALGDS	mRNA	0	1	12640676	TPA-induced genes, such as Sprr1A, Saa3, JunB, Il4ralpha, Gp38, RalGDS and Slpi
65626	 4497	 6557	Tetradecanoylphorbol acetate	Compound	ALAS1	mRNA	0	-1	12433930	We demonstrated that c-Fos, c-Jun, and JunD are involved in TPA inhibitory effect due to their ability to bind TRE-ALAS
66307	 4497	13248	Tetradecanoylphorbol acetate	Compound	TSC22D1	mRNA	0	1	15881652	tsc-22 mRNA is expressed in almost all organs of mice and humans and its expression is induced in a variety of cell lines by many different factors including TGF-beta, phorbol ester, serum, and progestin
 7357	 4497	 5400	Tetradecanoylphorbol acetate	Compound	HNRPDL	mRNA	0	-1	12430000	We identified four genes expressed differentially after TPA treatment. Levels of expression of two genes, human flavoprotein subunit of complex II and JKTBP, were downregulated by TPA,
 7955	 4497	 9734	Tetradecanoylphorbol acetate	Compound	ID4	mRNA	0	-1	12000752	Treatments with 12-O-tetradecanoylphorbol-13-acetate, another inducer of neuroblastoma cell differentiation, also resulted in coordinated down-regulation of ID gene expression, underscoring the role of ID genes in differentiation.
 8804	 4497	 1900	Tetradecanoylphorbol acetate	Compound	PRDX1	mRNA	0	1	12960165	Phorbol ester-dependent activation of peroxiredoxin I gene expression via a protein kinase C, Ras, p38 mitogen-activated protein kinase signaling pathway. The data indicate that a protein kinase C, Ras, MEKK1, p38 MAPK signaling pathway plays a major role for the transcriptional up-regulation of Prx I gene expression.
  885	 4497	19574	Tetradecanoylphorbol acetate	Compound	MRPS12	mRNA	0	-1	12952954	We initially analyzed mRNA levels of several mt translation factors by Northern hybridization. This revealed that differentiation of HL-60RG cells by TPA promotes coordinate reduction of the mRNA level for all mt translation factors investigated (Fig. 1A). Nuclear-coded genes, i.e. initiation factor 2 (IF-2mt), elongation factor Tu (EF-Tumt), elongation factor Ts (EFTsmt), methionyl-tRNA transformylase (MTFmt), methionyltRNA synthetase (MetRSmt), and ribosomal proteins S12mt and L7_L12mt were reduced by 10_20_fold, whereas mtDNAcoded 16 S rRNA was down-regulated to a lesser extent (5- fold) (Fig. 1A, 16 S rRNA). Similar results were confirmed with the HL-60 cell line (data not shown).
18087	  480	  284	TRIM28	Protein	CXCL10	mRNA	0	1	11711437	Whereas IP-10, MIP1a, MIP1b, MCP1, and IL8 mRNA levels are induced upon PMA treatment of the ?-gal antisense-ribozyme stable U937 cell line, there was a complete failure in the TIF1? antisense-ribozyme stable U937 cell lines to induce these cytokines.
 2876	  480	12537	TRIM28	Protein	CCL4	mRNA	0	1	11711437	Whereas IP-10, MIP1a, MIP1b, MCP1, and IL8 mRNA levels are induced upon PMA treatment of the ?-gal antisense-ribozyme stable U937 cell line, there was a complete failure in the TIF1? antisense-ribozyme stable U937 cell lines to induce these cytokines.
35323	  480	15605	TRIM28	Protein	E2F1	mRNA	0	-1	17704056	Ectopic expression of KAP1 represses E2F1 transcription {e2f1 target genes: Ccnd3, E2f1, p27 and Sirt1} and apoptosis functions independent of pRb.
39577	  480	13744	TRIM28	Protein	CDKN1B	mRNA	-1	-1	17704056	Ectopic expression of KAP1 represses E2F1 transcription {e2f1 target genes: Ccnd3, E2f1, p27 and Sirt1} and apoptosis functions independent of pRb.
44433	  480	13271	TRIM28	Protein	CCL2	mRNA	0	1	11711437	Whereas IP-10, MIP1a, MIP1b, MCP1, and IL8 mRNA levels are induced upon PMA treatment of the ?-gal antisense-ribozyme stable U937 cell line, there was a complete failure in the TIF1? antisense-ribozyme stable U937 cell lines to induce these cytokines.
47822	  480	10326	TRIM28	Protein	CCND3	mRNA	0	1	17704056	Ectopic expression of KAP1 represses E2F1 transcription {e2f1 target genes: Ccnd3, E2f1, p27 and Sirt1} and apoptosis functions independent of pRb.
49082	  480	14748	TRIM28	Protein	CCL3	mRNA	0	1	11711437	Whereas IP-10, MIP1a, MIP1b, MCP1, and IL8 mRNA levels are induced upon PMA treatment of the ?-gal antisense-ribozyme stable U937 cell line, there was a complete failure in the TIF1? antisense-ribozyme stable U937 cell lines to induce these cytokines.
 4966	  480	12073	TRIM28	Protein	IRF1	mRNA	0	-1	18381204	Importantly, a small-interfering RNA-mediated reduction in KAP1 expression enhanced IFN-induced STAT1-dependent IRF-1 gene expression.
50981	  480	13884	TRIM28	Protein	CDKN1A	mRNA	1	-1	17079232	Suppression of Dox-induced p21 transcription by SUMO-1-KAP1 and alleviation of transcriptional repression by KAP1(3K/R) {Trim28 mutant}.
56546	  480	12647	TRIM28	Protein	S100A9	mRNA	0	1	12167632	Moreover, DNA affinity chromatography and Western blot studies indicate that a Kruppel-related zinc finger protein and the transcriptional intermediary factor 1beta (TIF1beta) are involved in an MRE-binding complex, thereby regulating the S100A9 gene expression.
58556	  480	  497	TRIM28	Protein	SIRT1	mRNA	-1	1	17704056	Ectopic expression of KAP1 represses E2F1 transcription {e2f1 target genes: Ccnd3, E2f1, p27 and Sirt1} and apoptosis functions independent of pRb.
60034	  480	12976	TRIM28	Protein	IL8	mRNA	0	1	11711437	Whereas IP-10, MIP1a, MIP1b, MCP1, and IL8 mRNA levels are induced upon PMA treatment of the ?-gal antisense-ribozyme stable U937 cell line, there was a complete failure in the TIF1? antisense-ribozyme stable U937 cell lines to induce these cytokines.
62930	  480	 7195	TRIM28	Protein	GADD45A	mRNA	-1	-1	17942393	KAP1 complexes with ZBRK1 to repress Gadd45{alpha} transcriptional de-repression
10005	18803	 4597	ETV1	Protein	UBE2C	mRNA	1	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
10159	18803	 4403	ETV1	Protein	SRGN	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
11290	18803	17783	ETV1	Protein	DBN1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
11380	18803	 7190	ETV1	Protein	PIM3	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 1356	18803	19210	ETV1	Protein	EBP	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
14016	18803	 8544	ETV1	Protein	RNASE4	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
14706	18803	14183	ETV1	Protein	ATP1A1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
14737	18803	 3063	ETV1	Protein	PIP5K1A	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 1499	18803	 4269	ETV1	Protein	OSMR	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
16208	18803	 2348	ETV1	Protein	THBS2	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
16604	18803	 9240	ETV1	Protein	FRRS1	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 1690	18803	  114	ETV1	Protein	CAPN6	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
16924	18803	 6009	ETV1	Protein	KRT20	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
  172	18803	14641	ETV1	Protein	IVNS1ABP	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
18378	18803	14294	ETV1	Protein	CRYAB	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
19097	18803	  475	ETV1	Protein	PYCR2	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
19863	18803	19589	ETV1	Protein	LOX	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
20039	18803	10037	ETV1	Protein	PLK1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
20752	18803	10469	ETV1	Protein	ATP6AP2	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
20825	18803	16978	ETV1	Protein	MPL	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
20894	18803	19896	ETV1	Protein	LZTR1	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
21801	18803	 9116	ETV1	Protein	MYBBP1A	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
21864	18803	18158	ETV1	Protein	MCM3	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
22610	18803	15120	ETV1	Protein	SMAD7	mRNA	0	1	12947087	This activation can be mediated by the binding of the ETS transcription factor ER81 to the Smad7 promoter and involves the activation of ER81 via the Ras Raf ERK MAPK pathway (Fig. 8).
 2331	18803	13166	ETV1	Protein	LTA4H	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
23796	18803	 9647	ETV1	Protein	CDK20	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
24333	18803	18209	ETV1	Protein	MMP3	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
24549	18803	12017	ETV1	Protein	SMTN	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
25023	18803	16930	ETV1	Protein	MARK3	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
25651	18803	 4935	ETV1	Protein	CXCR7	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
26699	18803	19098	ETV1	Protein	RAP2B	mRNA	1	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
27237	18803	 4968	ETV1	Protein	DPP7	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
27318	18803	 5927	ETV1	Protein	DCLK1	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
27453	18803	 5919	ETV1	Protein	MMP1	mRNA	0	1	12917345	_ Ariadne: As  shown above (Fig. 5C ), expression of wild-type ER81 in the presence of p300 or  P/CAF resulted in significant levels of MMP-1 mRNA, detectable in our RT-PCR  analyses (Fig. 8C ). [Expression]
28944	18803	 8443	ETV1	Protein	STARD5	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
29380	18803	11262	ETV1	Protein	VPS41	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
30076	18803	18445	ETV1	Protein	PLA2G7	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
31983	18803	14994	ETV1	Protein	IGFBP7	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
32310	18803	17337	ETV1	Protein	DCTPP1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
32472	18803	13410	ETV1	Protein	FUT8	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
34446	18803	18827	ETV1	Protein	TUFM	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
35596	18803	15442	ETV1	Protein	BIRC2	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
35876	18803	 1402	ETV1	Protein	TCP11	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
36721	18803	 7233	ETV1	Protein	NOP58	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
36817	18803	  689	ETV1	Protein	LBH	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
37237	18803	20082	ETV1	Protein	XYLT2	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
38004	18803	  871	ETV1	Protein	ADAM17	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
38173	18803	 7771	ETV1	Protein	RTP4	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
38937	18803	15870	ETV1	Protein	SLC6A8	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 3901	18803	   62	ETV1	Protein	TTC3	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
39319	18803	 9758	ETV1	Protein	PSEN1	mRNA	0	1	12750007	in vitro translated ER81 indeed binds specifically to the -10 region of the PS1 promoter and that ER81 activates by two- to threefold the basal transcription of a presenilin-1 promoter-chloramphenicol acetyltransferase reporter synthetic gene
42309	18803	17408	ETV1	Protein	CETN2	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
42316	18803	15401	ETV1	Protein	POLR2A	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
42566	18803	13845	ETV1	Protein	PEA15	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
42596	18803	17626	ETV1	Protein	ATP11A	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
43760	18803	 3519	ETV1	Protein	AP3B1	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
44739	18803	 9417	ETV1	Protein	Hba-a1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
45501	18803	 3395	ETV1	Protein	AP3S1	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
45603	18803	 4559	ETV1	Protein	CDC20	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
45728	18803	  676	ETV1	Protein	Pga5	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
46324	18803	14384	ETV1	Protein	NR2F2	mRNA	0	1	15541767	the COUP-TFII promoter activity is indeed regulated by Ets-1 Ets-1 to enhance the COUP-TFII promoter activity. Furthermore, other members of the ETS family such as Ets-2 or ETV1 are also potent regulators of the COUP-TFII promoter.
47936	18803	 2629	ETV1	Protein	SEPT5	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
48150	18803	12541	ETV1	Protein	UPP1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
51509	18803	 6739	ETV1	Protein	PMEPA1	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
51600	18803	 5673	ETV1	Protein	ID1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
51655	18803	14103	ETV1	Protein	PGAM1	mRNA	1	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
52395	18803	  630	ETV1	Protein	MUC4	mRNA	0	1	12855694	Modified assertion
53529	18803	15594	ETV1	Protein	CDC25C	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
53620	18803	10993	ETV1	Protein	LAMTOR2	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
53921	18803	10601	ETV1	Protein	PPP3CA	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
53943	18803	18792	ETV1	Protein	RNF13	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
54286	18803	  255	ETV1	Protein	UBE2I	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
54364	18803	12644	ETV1	Protein	TOB1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
54405	18803	15886	ETV1	Protein	PPP2R2A	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
55224	18803	12981	ETV1	Protein	COL3A1	mRNA	-1	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
55784	18803	 3250	ETV1	Protein	COL4A5	mRNA	-1	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
56595	18803	20113	ETV1	Protein	CP	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
58866	18803	 9637	ETV1	Protein	MVD	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 6022	18803	12258	ETV1	Protein	PMP22	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
60425	18803	 5024	ETV1	Protein	CCL5	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
60960	18803	 2450	ETV1	Protein	ITGA6	mRNA	-1	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
61342	18803	15502	ETV1	Protein	ETS2	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
63042	18803	 6905	ETV1	Protein	Ly6c1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
63058	18803	10167	ETV1	Protein	DDX39A	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 6600	18803	18935	ETV1	Protein	PTPN2	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 6610	18803	  849	ETV1	Protein	GAA	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
66131	18803	19135	ETV1	Protein	EIF4B	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
  697	18803	15779	ETV1	Protein	WIZ	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 7005	18803	18295	ETV1	Protein	GYG1	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 7992	18803	  419	ETV1	Protein	TNFSF9	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 8302	18803	14204	ETV1	Protein	BICC1	mRNA	0	-1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
  888	18803	 6624	ETV1	Protein	SLC9A3R1	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
 9530	18803	19712	ETV1	Protein	CXCL13	mRNA	0	1	12748291	Tumor histologies appear to correlate with the specific DBDs rather than the particular TET component in these fusions.
10020	 7193	18909	cyclic AMP	Compound	CYB5A	mRNA	0	-1	15831526	We found b5 expression in all cell lines tested, including human adrenal NCI-H295A cells, where its mRNA is reduced by cAMP and phorbol ester.
10052	 7193	 7928	cyclic AMP	Compound	TGFBR2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
10090	 7193	 7502	cyclic AMP	Compound	STAR	mRNA	0	1	14630719	MIS also enhances the cAMP-induced expression of mRNA for steroidogenic acute regulatory protein (StAR)
10668	 7193	 3198	cyclic AMP	Compound	TFRC	mRNA	-1	-1	 7781766	Treatment of HL-60 cells with phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, or dibutyryl-cyclic AMP (dbcAMP), a protein kinase A (PKA) activator, resulted in a 90% decrease in the level of TfR mRNA
11711	 7193	11709	cyclic AMP	Compound	UCP2	mRNA	0	1	11278377	Consistent with a role of cAMP and protein kinase A, both prostaglandins induced a marked accumulation of cAMP in human myotubes, and forskolin reproduced the effect of arachidonic acid on UCP-2 mRNA expression.
12732	 7193	13434	cyclic AMP	Compound	HIF1A	mRNA	0	1	15983061	cAMP transcriptionally activates Hif1a gene in a melanocyte cell-specific manner and increases the expression of a functional hypoxia-inducible factor 1alpha (HIF1alpha) protein resulting in a stimulation of Vegf expression
13225	 7193	19706	cyclic AMP	Compound	CDC37	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
14088	 7193	14961	cyclic AMP	Compound	CEBPD	mRNA	0	1	11682632	their expression is up-regulated by the activation of leukemia inhibitory factor receptor (LIF-R) and prostacyclin receptor (IP-R) via the extracellular signal-regulated kinase (ERK) pathway and cAMP production, respectively.
14535	 7193	  850	cyclic AMP	Compound	MITF	mRNA	0	1	10898786	isolation of the Mitf promoter (Fuse et al. 1996) revealed a potential cyclic AMP response element (CRE) at position ?147 relative to the transcription startsite the increase in Mitf protein in B16 melanoma cells that results from the activation of the Mitf promoter through the CRE (Bertolotto et al. 1998a) is transient.
16093	 7193	 6100	cyclic AMP	Compound	LAMB1	mRNA	0	-1	16690806	Addition of H+dbcAMP caused an increased expression of IGFBP1, PRL, and DCN beyond that of FOXO1A alone. TIMP3 and CNR1 levels decreased even further in response to H+dbcAMP compared with FOXO1A alone. LAMB1, which was unresponsive to FOXO1A, decreased when H+dbcAMP was added
16483	 7193	18083	cyclic AMP	Compound	BNIP3	mRNA	-1	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
17199	 7193	11456	cyclic AMP	Compound	TF	mRNA	0	1	10067852	Ariadne: Schematic showing the possible mechanisms by which CREB or related cAMP-inducible proteins and bHLH proteins activate the transferrin promoter. Ariadne: The presence of a nearly conserved PRII site in the mouse transferrin promoter suggests that this PRII site is a potential candidate in regulating FSH and cAMP-induced mouse transferrin gene expression.
17978	 7193	11254	cyclic AMP	Compound	SLC31A2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
19129	 7193	 9770	cyclic AMP	Compound	CAB39	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
19669	 7193	16486	cyclic AMP	Compound	SPP1	mRNA	1	-1	10506130	_ sentences for pubmedID=10506130: _ Ariadne: Results showed that forskolin also inhibited the  expression of alkaline phosphatase, bone sialoprotein, osteopontin, and  osteocalcin genes (Fig. 2 C ). [Expression]
19966	 7193	17377	cyclic AMP	Compound	PTP4A2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
20484	 7193	 1035	cyclic AMP	Compound	AVPI1	mRNA	0	1	15140762	Ariadne: The increase in gene expression was abolished by H89 and by actinomycin D, suggesting that cAMP stimulates VIT32 mRNA expression by a PKA-mediated increase in gene transcription. [Expression] Elevation of cAMP with forskolin and IBMX increased VIT32 gene expression with a peak effect at 2 h.
20618	 7193	19120	cyclic AMP	Compound	HSPA5	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
21183	 7193	 8320	cyclic AMP	Compound	GATA6	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
21885	 7193	  174	cyclic AMP	Compound	SLC38A4	mRNA	0	-1	11566196	Treatment with forskolin increased the steady-state levels of ATA1 and ATA2 mRNAs, but decreased that of ATA3 mRNA.
22899	 7193	17923	cyclic AMP	Compound	RAB3IP	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
23889	 7193	 5783	cyclic AMP	Compound	CEBPB	mRNA	0	1	11682632	their expression is up-regulated by the activation of leukemia inhibitory factor receptor (LIF-R) and prostacyclin receptor (IP-R) via the extracellular signal-regulated kinase (ERK) pathway and cAMP production, respectively.
24892	 7193	19122	cyclic AMP	Compound	PTP4A3	mRNA	-1	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
25168	 7193	12328	cyclic AMP	Compound	SLC38A1	mRNA	0	1	11566196	Treatment with forskolin increased the steady-state levels of ATA1 and ATA2 mRNAs, but decreased that of ATA3 mRNA.
25304	 7193	13534	cyclic AMP	Compound	CCNE2	mRNA	-1	-1	14532334	Table 2. Most markedly up- and downregulated genes during the time course of decidualization in response to 8-Br-cAMP  Ontologic Category/ Gene Name  2 h  12 h  24 h  36 h  48 h A: UPREGULATED GENES Neuropeptides Preprosomatostatin    115.49  116.39  1644.4  1396.82  1324.2 L-orphan (clone 5) G-    3.62  6.56  79.77  126.18  123.26 protein coupled R Immune genes IL-11     7.1  2.62  28.3  74.9  62.98 Factor XIII precursor   NA  NA  26.98  28.78  25.815 Cell growth/ differentiation Prolactin     NA  3.88  99.45  143.41  37.135 IGFBP-1     8.38  8.375  142.52  140.54  115.78 EBAF     NA  3.48  70.49  123.86  51.37 NGFI-B/nur77 transcr. factor  106.4  NA  17.23  14.11  30.12 NOT      350.94  2.24  24.73  30.19  113.14 Extracellular matrix protease MMP-10 (stromelysin-2)   4.25  2.13  148.48  144.2  69.71 B: DOWNREGULATED GENES Cell growth IGFBP-5     NA  8.925  8.81  9.015  80.185 Enzymes L-Kynurenine hydrolase   7.61  NA  3.33  6.9  169.32 Signal transduction Activates NF-{kappa} B   7.87  17.51  2.19  4.18  369.01 Structural protein Actin, tropomyosin, calmodulin binding protein  NA  22.32  13.17  12.59  50.21 Cell cycle Cyclin B2     NA  5.69  9.07  5.17  10.2 Cyclin E2     2.12  NA  NA  NA  9.28
25468	 7193	 5701	cyclic AMP	Compound	ID3	mRNA	0	1	10585876	We here demonstrated that there was a dramatic rise of Id2 and Id3 mRNA levels when 3T3-L1 adipocytes or isolated rat fat cells were exposed to lipolytic and anti-lipogenic agents, forskolin and isoproterenol.
25493	 7193	11591	cyclic AMP	Compound	NR4A3	mRNA	0	1	15910753	PTH induces NR4A members through the cAMP-protein kinase A (PKA) pathway in vitro
26367	 7193	10421	cyclic AMP	Compound	PLD1	mRNA	0	1	10327185	The rPLD1b mRNA increased within 6 h following dbcAMP treatment and maintained a high level up to 24 h.
26676	 7193	17350	cyclic AMP	Compound	CXADR	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
26766	 7193	 4058	cyclic AMP	Compound	PRKAR1A	mRNA	0	1	12621056	FOXD2 overexpression also increased the sensitivity of the promoter to cAMP. Finally, co-expression experiments demonstrated that protein kinase Balpha/Akt1 work together with FOXD2 to induce the RIalpha1b promoter
27293	 7193	 5962	cyclic AMP	Compound	RAB3GAP2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
27638	 7193	12781	cyclic AMP	Compound	AR	mRNA	1	1	12970260	Treatment with the cAMP analog dibutyryl cAMP enhanced AR promoter activity about 4- to 6-fold in a reporter gene assay and increased AR mRNA expression in LNCaP cells
 2770	 7193	  908	cyclic AMP	Compound	MMP9	mRNA	0	1	10515879	By contrast, G-protein inhibition by pertussis toxin, or transfection with a dominant negative mutant of Ha-Ras strongly increased fibronectin-induced MMP-2 and MMP-9. Inhibition of PI3 kinase, MAPkinase (MEK1), or p38 MAPkinase by wortmannin, PD 98059, or SB 202190, respectively, strongly promoted fibronectin-induced MMP2 and MMP-9
28866	 7193	 2111	cyclic AMP	Compound	ULK1	mRNA	-1	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 2901	 7193	 4252	cyclic AMP	Compound	ABCA1	mRNA	0	1	11004510	ABC1 was upregulated in RAW cells by cAMP, concurrent with the cAMP induction of lipid efflux to apolipoprotein A1.
 3121	 7193	16645	cyclic AMP	Compound	CCND1	mRNA	0	1	10585260	Cyclin D1 and D3 mRNA levels decreased during complete differentiation induced by all-trans-retinoic acid and dibutyryl cAMP
32780	 7193	 3630	cyclic AMP	Compound	PA2G4	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
33683	 7193	12902	cyclic AMP	Compound	SEC16B	mRNA	0	1	12244571	Moreover, the RGPR-p117 mRNA expression in H4-II-E cells was stimulated in the presence of dibutyryl cAMP, PMA, insulin, 17beta-estradiol, or serum in culture medium
35330	 7193	 9354	cyclic AMP	Compound	PLAGL1	mRNA	0	1	16061485	In conclusion, our data demonstrate that, in CGC, Lot1 is under the transcriptional control of cAMP through an AP1 site regulated by the c-Fos/c-Jun heterodimer
 3561	 7193	11752	cyclic AMP	Compound	WNT4	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
36100	 7193	12491	cyclic AMP	Compound	MCAM	mRNA	0	1	12771237	cAMP, which is known to stimulate differentiation of VT, enhanced MCAM expression in JEG3 cells. Its promoting effect on MCAM expression was also observed in human chorionic villous explant cultures.
36206	 7193	16669	cyclic AMP	Compound	HSPD1	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
36913	 7193	 4187	cyclic AMP	Compound	PPP1R3C	mRNA	0	1	16627590	cAMP analogs activates the PTG promoter and significantly increases PTG levels in H4IIE
37426	 7193	15242	cyclic AMP	Compound	ATF4	mRNA	0	1	10350644	C/ATF protein levels increased after the cAMP signal stimulation
38003	 7193	  871	cyclic AMP	Compound	ADAM17	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
38729	 7193	 6609	cyclic AMP	Compound	ATP6V0E1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
39026	 7193	15612	cyclic AMP	Compound	ACSL4	mRNA	0	1	10924347	We demonstrate that ACS4 expression in steroidogenic tissues in vivo is induced by adrenocorticotropic hormone (ACTH) and suppressed by glucocorticoid. ACTH also induced ACS4 protein but not its mRNA in Y1 adrenocortical tumor cells, whereas both ACS4 mRNA and protein were increased by dibutyryl cAMP (db-cAMP) and forskolin.
40262	 7193	16388	cyclic AMP	Compound	GFAP	mRNA	0	1	16806201	Stable overexpression of GBP attenuated cAMP-induced expression of the glial fibrillary acidic protein (GFAP) gene, which was accompanied by a decrease in cAMP-induced signal transducer and activators of transcription 3 (STAT3) phosphorylation.
40849	 7193	11880	cyclic AMP	Compound	AGXT	mRNA	0	1	12169688	Transcription of mitochondrial serine:pyruvate aminotransferase (SPT) mRNA (SPTm-mRNA) in rat liver is unique in that it occurs from the upstream site of the two transcription start sites within the first exon of the SPT gene and is selectively enhanced by cAMP via the protein kinase A (PKA) signaling pathway.
42430	 7193	 4998	cyclic AMP	Compound	FPGS	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
42471	 7193	13544	cyclic AMP	Compound	AGTR1	mRNA	0	-1	16675453	For example, Ang II (8), cAMP stimulating agents (9), and estrogens (10, 11) decrease rat AT1AR expression by stimulating rat AT1AR mRNA decay. In contrast, insulin (12), low density lipoprotein (13), and progesterone (11) up-regulate receptor expression by decreasing AT1AR mRNA decay rates. Additionally, rat AT1AR expression is regulated by translational mechanisms via cytosolic proteins that interact with the 5p-UTR of the receptor mRNA (10, 1418).
 4310	 7193	19709	cyclic AMP	Compound	RGS2	mRNA	0	1	11755214	RGS2 expression was increased by activation of muscarinic receptors coupled to phosphoinositide signaling with carbachol, or by increased cyclic AMP production
44496	 7193	10804	cyclic AMP	Compound	CYCS	mRNA	-1	1	16568236	Several recognition sites are present on the promoter of the cytochrome c gene, including the cAMP response element binding-protein (CREB) and nuclear respiratory factor 1 (NRF-1). Both these transcription factors are activated by phosphorylation of serine residues (Figs. 1b, 2). In BALB/3T3 cells, cAMP leads to activation of PKA, which, in turn, activates the transcription factor CREB and up-regulates the cytochrome c gene [29].
46295	 7193	15186	cyclic AMP	Compound	SLC39A1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
47228	 7193	 2052	cyclic AMP	Compound	ATF3	mRNA	0	1	15231818	Following AC(VI) gene transfer, when cardiac myocytes were stimulated with isoproterenol or NKH477, a water-soluble forskolin analog that directly stimulates AC, expression of ATF3 protein was increased even more, which correlated with reduced expression of PLB.
 4734	 7193	 7009	cyclic AMP	Compound	SREBF1	mRNA	0	-1	11742412	Regulation of lipid synthesis and degradation As is the case with carbohydrate metabolism, insulin also promotes the synthesis of lipids, and inhibits their degradation. Recent studies suggest that many of these changes require an increase in the transcription factor steroid regulatory element-binding protein (SREBP)-1c68.
47619	 7193	 3675	cyclic AMP	Compound	GSTP1	mRNA	0	1	12210727	Western blot analysis showed a rapid, fivefold increase, in GSTP1 protein levels after treatment with 25 microM forskolin, with a peak at 2 h post-treatment. The levels of phosphorylated CRE (Ser133) binding protein-1 (CREB-1) increased rapidly, sevenfold at 30 min, and reached 10-fold at 4 h following forskolin
48279	 7193	 7237	cyclic AMP	Compound	INSR	mRNA	0	1	11112439	expression is induced through thyroid-stimulating hormone (TSHB)-mediated accumulation of cAMP
48786	 7193	17731	cyclic AMP	Compound	DCN	mRNA	-1	1	16690806	Addition of H+dbcAMP caused an increased expression of IGFBP1, PRL, and DCN beyond that of FOXO1A alone. TIMP3 and CNR1 levels decreased even further in response to H+dbcAMP compared with FOXO1A alone. LAMB1, which was unresponsive to FOXO1A, decreased when H+dbcAMP was added
49361	 7193	18288	cyclic AMP	Compound	UCP3	mRNA	0	1	15024092	catecholamine-stimulated thermogenesis in brown fat requires beta-adrenergic elevations in cyclic AMP (cAMP) to increase expression of the uncoupling protein 1 (UCP1) gene.
49897	 7193	15228	cyclic AMP	Compound	TIMP3	mRNA	0	-1	16690806	Addition of H+dbcAMP caused an increased expression of IGFBP1, PRL, and DCN beyond that of FOXO1A alone. TIMP3 and CNR1 levels decreased even further in response to H+dbcAMP compared with FOXO1A alone. LAMB1, which was unresponsive to FOXO1A, decreased when H+dbcAMP was added
50199	 7193	18110	cyclic AMP	Compound	VDAC1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
50253	 7193	16618	cyclic AMP	Compound	VDAC3	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
50918	 7193	 6827	cyclic AMP	Compound	AREG	mRNA	0	1	15284208	Furthermore, the induction of AR mRNA by cAMP was strongly suppressed by a protein kinase A type I-selective inhibitor, whereas treatment with an exchange protein directly activated by cAMP-specific agonist did not increase AR levels.
51151	 7193	 8629	cyclic AMP	Compound	SLC38A2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
51392	 7193	 9681	cyclic AMP	Compound	KCNAB3	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
51674	 7193	  219	cyclic AMP	Compound	FASLG	mRNA	-1	-1	 9188860	Forskolin not only inhibited activation-induced cell death and NF-kappa B activation, but also suppressed expression of Fas and Fas ligand (Fas-L)
 5241	 7193	 4131	cyclic AMP	Compound	NOS1	mRNA	0	1	15170357	a marked induction of nNOS mRNA, protein, and total NO production in response to dibutyryl cyclic AMP (db-cAMP)
52840	 7193	 9856	cyclic AMP	Compound	IYD	mRNA	0	1	15289438	DEHAL1 mRNA is highly expressed in the thyroid, is up-regulated by cAMP, and encodes a transmembrane protein that efficiently catalyzes the NADPH-dependent deiodination of mono (L-MIT) and diiodotyrosine (L-DIT), with greater activity vs. L-MIT.
53503	 7193	10752	cyclic AMP	Compound	VDAC2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
53708	 7193	14860	cyclic AMP	Compound	FHL1	mRNA	0	1	15170357	Three members of the recently described four-and-a-half-LIM-domain proteins (FHL1-FHL3) were found to be expressed in A673 cells; FHL-1 and FHL-3 were upregulated by cAMP
54265	 7193	  322	cyclic AMP	Compound	GADD45G	mRNA	1	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
54771	 7193	19552	cyclic AMP	Compound	IQGAP1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
55394	 7193	12303	cyclic AMP	Compound	SOCS3	mRNA	0	1	12475383	Treatment of cells with dibutyryl cAMP, a stable analogue of cAMP induced the SOCS-3 expression, indicating that stimulation of beta-adrenergic receptor by isoproterenol leads to activation of Gs-protein which inturn activates adenylyl cyclase and induces SOCS-3 expression.
55700	 7193	15411	cyclic AMP	Compound	INSIG1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
55846	 7193	 3559	cyclic AMP	Compound	PNPLA2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
55879	 7193	 5857	cyclic AMP	Compound	BHLHE40	mRNA	0	1	15970569	From full text table 4: Reagents regulating expression of the BHLHB2 and BHLHB3 genes
56455	 7193	15748	cyclic AMP	Compound	CNR1	mRNA	0	-1	16690806	Addition of H+dbcAMP caused an increased expression of IGFBP1, PRL, and DCN beyond that of FOXO1A alone. TIMP3 and CNR1 levels decreased even further in response to H+dbcAMP compared with FOXO1A alone. LAMB1, which was unresponsive to FOXO1A, decreased when H+dbcAMP was added
57873	 7193	11542	cyclic AMP	Compound	FHL3	mRNA	0	1	15170357	Three members of the recently described four-and-a-half-LIM-domain proteins (FHL1-FHL3) were found to be expressed in A673 cells; FHL-1 and FHL-3 were upregulated by cAMP
58381	 7193	11852	cyclic AMP	Compound	PLN	mRNA	0	-1	15231818	Following AC(VI) gene transfer, when cardiac myocytes were stimulated with isoproterenol or NKH477, a water-soluble forskolin analog that directly stimulates AC, expression of ATF3 protein was increased even more, which correlated with reduced expression of PLB.
58534	 7193	15461	cyclic AMP	Compound	PTPRF	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
60445	 7193	 8600	cyclic AMP	Compound	SCN2B	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 6126	 7193	 9018	cyclic AMP	Compound	IAPP	mRNA	0	1	14615061	These results indicate that amylin is positively regulated by cAMP and PKA through the transcription factors HNF-1 and NFY.
61674	 7193	 7558	cyclic AMP	Compound	CTSL1	mRNA	0	1	14563703	Mutation of the cAMP regulatory element-binding protein site in the triple Sp1 mutant construct completely blocked the inducibility of the promoter. Collectively, the data document that three Sp1/specificity protein 3 binding GC-rich regions and a functional cAMP regulatory element constitute an important transcriptional regulatory complex for expression of the cathepsin L gene in rat granulosa cells.
63097	 7193	11460	cyclic AMP	Compound	PLA2G2A	mRNA	0	1	12188923	the activation of sPLA(2) transcription by cAMP and interleukin-1beta (IL-1beta), and shown that the 500 bp region upstream of the transcription start site of the rat sPLA(2) gene is implicated in activation by synergistically acting cAMP and IL-1beta.
63118	 7193	13881	cyclic AMP	Compound	JAK1	mRNA	-1	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
63228	 7193	  460	cyclic AMP	Compound	SEPP1	mRNA	1	1	11442337	When cAMP was added to cultures at 0, 0.01, 0.1, or 1 mM, selenoprotein P mRNA expression showed dose-dependent stimulation.
63811	 7193	 5182	cyclic AMP	Compound	JAK2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
63877	 7193	12543	cyclic AMP	Compound	IGFBP1	mRNA	-1	1	16690806	Addition of H+dbcAMP caused an increased expression of IGFBP1, PRL, and DCN beyond that of FOXO1A alone. TIMP3 and CNR1 levels decreased even further in response to H+dbcAMP compared with FOXO1A alone. LAMB1, which was unresponsive to FOXO1A, decreased when H+dbcAMP was added
64348	 7193	17854	cyclic AMP	Compound	SLC15A3	mRNA	0	1	11004510	Upon Northern blot analysis, only three of these bands were confirmed as cAMP inducible mRNAs, named cI-1, cI-2, and cI-3 (for cAMP inducible genes 1-3).
64367	 7193	 6353	cyclic AMP	Compound	IRS2	mRNA	0	1	12842910	Remarkably, A-CREB severely disrupted expression of IRS2, an insulin signaling pathway component that is shown here to be a direct target for CREB action in vivo As induction of IRS2 by cAMP enhanced activation of the survival kinase Akt in response to insulin and IGF-1, our results demonstrate a novel mechanism by which opposing pathways cooperate in promoting cell survival.
65629	 7193	 6557	cyclic AMP	Compound	ALAS1	mRNA	0	1	12433930	Previous analysis of the 5p-flanking sequence of ALAS revealed the existence of two cAMP-response elements (CRE) required for basal and cAMP-stimulated expression.
65750	 7193	 3309	cyclic AMP	Compound	IGF2R	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
65912	 7193	 2631	cyclic AMP	Compound	PPARGC1A	mRNA	0	1	12107181	we show that the transcriptional induction of the PGC-1 gene by glucagon through cAMP in hepatocytes precedes that of L-CPT-1.
66196	 7193	16011	cyclic AMP	Compound	GPC1	mRNA	0	-1	12135485	FSH, through its second messengers (increase in intracellular cAMP and intracellular calcium), downregulated the glypican-1 mRNA expression in Sertoli cells from 20-day-old rats.
66285	 7193	17585	cyclic AMP	Compound	C1S	mRNA	0	1	12393260	Its mRNA expression was markedly increased during cAMP-induced glial cell differentiation.
66310	 7193	 6336	cyclic AMP	Compound	CDC42	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 6776	 7193	 8280	cyclic AMP	Compound	DGAT1	mRNA	1	1	12456799	The expression patterns of five of these genes, encoding nerve growth factor inducible gene B, PRL-1, PC3 nerve growth factor-inducible antiproliferative putative secreted protein, diacylglycerol acyltransferase, and an expressed sequence tag, in FSH- and N,Op-dibutyryl cAMP-treated rat Sertoli cells were confirmed and characterized by Northern blot analysis. Three genes that were selected for expression verification and further study with the use of Northern blots showed rapid induction at the 2-h treatment,
 6875	 7193	 2204	cyclic AMP	Compound	COL1A1	mRNA	0	-1	10679825	After 48 h of culture, parathyroid hormone, forskolin, dibutyryl cAMP, 8-bromo cAMP, and phorbol myristate acetate inhibited transgene activity, while the calcium ionophore ionomycin had no effect. These data show that the inhibitory effect of parathyroid hormone on Col1a1 expression in mouse calvariae is mediated mainly by the cAMP signaling pathway.
 7985	 7193	10330	cyclic AMP	Compound	RGS11	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 8332	 7193	 6202	cyclic AMP	Compound	BTG1	mRNA	-1	1	 9203975	this effect ws mimicked by dibutyryl cAMP which indicated the involvement of elevated cAMP in the PGE2-mediated enhancement of BTG1.
  894	 7193	18314	cyclic AMP	Compound	STMN1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 9026	 7193	10441	cyclic AMP	Compound	STAT2	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 9498	 7193	13194	cyclic AMP	Compound	CLK1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 9676	 7193	18215	cyclic AMP	Compound	XPR1	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 9885	 7193	12555	cyclic AMP	Compound	LDHB	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
14960	 4304	 3861	KLF9	Protein	TIMP2	mRNA	0	1	11476943	Compared to N and As lines, S lines also had diminished ability to grow in multi-layers and exhibited increased mRNA levels for plasminogen activator inhibitor-1 (PAI-1), secretory leukocyte protease inhibitor (SLPI), and tissue inhibitor of metalloproteinases (TIMP)-2.
21915	 4304	 3995	KLF9	Protein	ESR1	mRNA	-1	-1	15917344	In stroma (ST), the numbers of progesterone receptor (PGR) and HomeoboxA10 (HOXA10)-expressing cells were lower (3.5 and 4.5 dpc),  while those of estrogen receptor-alpha (ESR1) were higher (3.5 dpc), with Bteb1 ablation.
 3142	 4304	16645	KLF9	Protein	CCND1	mRNA	0	-1	12672823	Modified assertion
45273	 4304	 8651	KLF9	Protein	IGFBP2	mRNA	0	1	11953011	while BTEB1 and its ubiquitous family member Sp1 increased basal p21(WAF1) and IGFBP-2 transcription when added as expression constructs in the parental Hec-1-A cell line, only Sp1 activated Axl transcription, despite the presence in all three gene promoters of GC-enriched regions that presumably can bind BTEB1 and Sp1 with similar affinities.
47817	 4304	10326	KLF9	Protein	CCND3	mRNA	0	1	15117941	Modified assertion
49155	 4304	 7729	KLF9	Protein	SLPI	mRNA	0	1	11476943	Compared to N and As lines, S lines also had diminished ability to grow in multi-layers and exhibited increased mRNA levels for plasminogen activator inhibitor-1 (PAI-1), secretory leukocyte protease inhibitor (SLPI), and tissue inhibitor of metalloproteinases (TIMP)-2.
51007	 4304	13884	KLF9	Protein	CDKN1A	mRNA	1	1	11953011	while BTEB1 and its ubiquitous family member Sp1 increased basal p21(WAF1) and IGFBP-2 transcription when added as expression constructs in the parental Hec-1-A cell line, only Sp1 activated Axl transcription, despite the presence in all three gene promoters of GC-enriched regions that presumably can bind BTEB1 and Sp1 with similar affinities.
53091	 4304	10202	KLF9	Protein	GHR	mRNA	0	-1	12529387	We analyzed the promoter region of the dominant transcript (L2) of the murine GHR to determine that a cis element, L2C1, interacts with transcription factors NF-Y, BTEB1, and HMG-Y/I.  These proteins individually repress GHR expression and together form a repressosome complex in conjunction with mSin3b.
58404	 4304	15117	KLF9	Protein	PGR	mRNA	0	1	15917344	In stroma (ST), the numbers of progesterone receptor (PGR) and HomeoboxA10 (HOXA10)-expressing cells were lower (3.5 and 4.5 dpc),  while those of estrogen receptor-alpha (ESR1) were higher (3.5 dpc), with Bteb1 ablation.
59748	 4304	13414	KLF9	Protein	SERPINE1	mRNA	0	1	11476943	Compared to N and As lines, S lines also had diminished ability to grow in multi-layers and exhibited increased mRNA levels for plasminogen activator inhibitor-1 (PAI-1), secretory leukocyte protease inhibitor (SLPI), and tissue inhibitor of metalloproteinases (TIMP)-2.
 6719	 4304	 5011	KLF9	Protein	HOXA10	mRNA	0	1	15917344	In stroma (ST), the numbers of progesterone receptor (PGR) and HomeoboxA10 (HOXA10)-expressing cells were lower (3.5 and 4.5 dpc),  while those of estrogen receptor-alpha (ESR1) were higher (3.5 dpc), with Bteb1 ablation.
16452	 1121	 3007	butyric acid	Compound	HDAC4	mRNA	0	1	15234474	The expression of 10 histone deacetylases (HDAC1-10) mRNAs in mouse neuroblastoma Neuro-2a and microglia N9 cell cultures after treatment by inhibitors of HDACs, sodium butyrate and trichostatin A was studied to elucidate whether HDAC inhibitors affect the gene expression of HDACs In both Neuro-2a and N9 cells the highest increase was observed for HDAC5 and -6 mRNA, whereas, HDAC4 had a prominent increase in mRNA levels after drug treatment only in N9 microglia cell line but not in Neuro-2a.
29644	 1121	13006	butyric acid	Compound	HMGCS2	mRNA	0	1	14686922	These data suggest that the intestinal flora, through butyrate production, could control the expression of colonic mHMGCoA synthase and glutaminase.
 3139	 1121	16645	butyric acid	Compound	CCND1	mRNA	0	1	15765403	RESULTS: We show that inhibition of MCT1 expression, and hence butyrate uptake, has profound inhibitory effects on the ability of butyrate to regulate expression of key target genes: p21waf1/cip1 (p21), intestinal alkaline phosphatase (IAP), and cyclin D1, and their associated processes of proliferation and differentiation.
44326	 1121	 3261	butyric acid	Compound	ALPI	mRNA	0	1	15765403	RESULTS: We show that inhibition of MCT1 expression, and hence butyrate uptake, has profound inhibitory effects on the ability of butyrate to regulate expression of key target genes: p21waf1/cip1 (p21), intestinal alkaline phosphatase (IAP), and cyclin D1, and their associated processes of proliferation and differentiation.
 5071	 1121	 4217	butyric acid	Compound	CCR1	mRNA	0	1	10623856	_ Ariadne: These results indicated that butyric acid  and IL-5 synergistically induced the selective expression of CCR-1 and CCR-3  mRNA. [Expression]
51046	 1121	13884	butyric acid	Compound	CDKN1A	mRNA	1	1	15765403	RESULTS: We show that inhibition of MCT1 expression, and hence butyrate uptake, has profound inhibitory effects on the ability of butyrate to regulate expression of key target genes: p21waf1/cip1 (p21), intestinal alkaline phosphatase (IAP), and cyclin D1, and their associated processes of proliferation and differentiation.
59026	 1121	10099	butyric acid	Compound	CCR3	mRNA	0	1	10623856	_ Ariadne: These results indicated that butyric acid  and IL-5 synergistically induced the selective expression of CCR-1 and CCR-3  mRNA. [Expression]
11759	13325	11155	celecoxib	Compound	HEMGN	mRNA	-1	1	16835340	A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is <2-fold. Twenty-three of 25 pairs of colon biopsies taken before and after celecoxib treatment can be classified correctly by the pattern of gene expression in a leave-one-out cross-validation. Immune response, particularly T- and B-lymphocyte activation and early steps of inflammatory reaction, cell signaling and cell adhesion, response to stress, transforming growth factor-beta signaling, and regulation of apoptosis, are the main biological processes targeted by celecoxib as shown by overrepresentation analysis of the distribution of celecoxib-affected genes across Gene Ontology categories. Analysis of possible cumulative effects of celecoxib-induced changes in gene expression indicates that in healthy colon, celecoxib may suppress the immune response and early steps of inflammation, inhibit formation of focal contacts, and stimulate transforming growth factor-beta signaling.
20137	13325	 7815	celecoxib	Compound	GZMB	mRNA	1	1	16835340	A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is <2-fold. Twenty-three of 25 pairs of colon biopsies taken before and after celecoxib treatment can be classified correctly by the pattern of gene expression in a leave-one-out cross-validation. Immune response, particularly T- and B-lymphocyte activation and early steps of inflammatory reaction, cell signaling and cell adhesion, response to stress, transforming growth factor-beta signaling, and regulation of apoptosis, are the main biological processes targeted by celecoxib as shown by overrepresentation analysis of the distribution of celecoxib-affected genes across Gene Ontology categories. Analysis of possible cumulative effects of celecoxib-induced changes in gene expression indicates that in healthy colon, celecoxib may suppress the immune response and early steps of inflammation, inhibit formation of focal contacts, and stimulate transforming growth factor-beta signaling.
25049	13325	17353	celecoxib	Compound	GRIA3	mRNA	1	1	16835340	A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is <2-fold. Twenty-three of 25 pairs of colon biopsies taken before and after celecoxib treatment can be classified correctly by the pattern of gene expression in a leave-one-out cross-validation. Immune response, particularly T- and B-lymphocyte activation and early steps of inflammatory reaction, cell signaling and cell adhesion, response to stress, transforming growth factor-beta signaling, and regulation of apoptosis, are the main biological processes targeted by celecoxib as shown by overrepresentation analysis of the distribution of celecoxib-affected genes across Gene Ontology categories. Analysis of possible cumulative effects of celecoxib-induced changes in gene expression indicates that in healthy colon, celecoxib may suppress the immune response and early steps of inflammation, inhibit formation of focal contacts, and stimulate transforming growth factor-beta signaling.
28876	13325	18216	celecoxib	Compound	CA1	mRNA	-1	1	16835340	A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is <2-fold. Twenty-three of 25 pairs of colon biopsies taken before and after celecoxib treatment can be classified correctly by the pattern of gene expression in a leave-one-out cross-validation. Immune response, particularly T- and B-lymphocyte activation and early steps of inflammatory reaction, cell signaling and cell adhesion, response to stress, transforming growth factor-beta signaling, and regulation of apoptosis, are the main biological processes targeted by celecoxib as shown by overrepresentation analysis of the distribution of celecoxib-affected genes across Gene Ontology categories. Analysis of possible cumulative effects of celecoxib-induced changes in gene expression indicates that in healthy colon, celecoxib may suppress the immune response and early steps of inflammation, inhibit formation of focal contacts, and stimulate transforming growth factor-beta signaling.
46033	13325	12530	celecoxib	Compound	HPGD	mRNA	-1	1	16835340	A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is <2-fold. Twenty-three of 25 pairs of colon biopsies taken before and after celecoxib treatment can be classified correctly by the pattern of gene expression in a leave-one-out cross-validation. Immune response, particularly T- and B-lymphocyte activation and early steps of inflammatory reaction, cell signaling and cell adhesion, response to stress, transforming growth factor-beta signaling, and regulation of apoptosis, are the main biological processes targeted by celecoxib as shown by overrepresentation analysis of the distribution of celecoxib-affected genes across Gene Ontology categories. Analysis of possible cumulative effects of celecoxib-induced changes in gene expression indicates that in healthy colon, celecoxib may suppress the immune response and early steps of inflammation, inhibit formation of focal contacts, and stimulate transforming growth factor-beta signaling.
  106	14889	 8755	Aspirin	Compound	GDF15	mRNA	0	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
13350	14889	10696	Aspirin	Compound	JUN	mRNA	0	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
15034	14889	  136	Aspirin	Compound	SERPINB1	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
17714	14889	13919	Aspirin	Compound	RECK	mRNA	0	1	12447698	RT-PCR analyses showed that NS398 and aspirin up-regulated RECK mRNA level in CL-1 human lung cancer cells. Additionally, NSAIDs increased RECK protein level as detected by immunoblotting. Since RECK is a membrane-anchored glycoprotein, we also performed immunofluorescent staining to assess the expression of RECK on cell surface. Our results showed that fluorescent intensity of RECK was obviously increased after NSAID treatment.
27619	14889	18263	Aspirin	Compound	EZR	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
 3129	14889	16645	Aspirin	Compound	CCND1	mRNA	0	-1	11313997	In addition, the beta-catenin/TCF transcriptional target cyclin D1 was downregulated by both drugs.
32003	14889	 4292	Aspirin	Compound	DDIT3	mRNA	0	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
32248	14889	 2574	Aspirin	Compound	PHB	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
32446	14889	20190	Aspirin	Compound	ABCB1	mRNA	0	1	11205285	We recently found that aspirin induces the expression of P-glycoprotein (P-gp), a protein mediating drug resistance, in human prostate cancer cells.
32916	14889	17818	Aspirin	Compound	JUND	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
36900	14889	13831	Aspirin	Compound	CKS1B	mRNA	0	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
38723	14889	 8202	Aspirin	Compound	BLMH	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
43951	14889	 4591	Aspirin	Compound	S100A4	mRNA	0	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
45784	14889	 4556	Aspirin	Compound	CHMP1A	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
46121	14889	16240	Aspirin	Compound	ITGB4	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
46679	14889	 3471	Aspirin	Compound	IL1B	mRNA	0	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
47819	14889	10326	Aspirin	Compound	CCND3	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
55329	14889	14744	Aspirin	Compound	RPS16	mRNA	0	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
58902	14889	10064	Aspirin	Compound	SELP	mRNA	-1	-1	12297125	Epinephrine-stimulated P-selectin expression was inhibited by aspirin at 6 h, and after 2 and 6 h by aspirin plus cocoa.
60223	14889	13155	Aspirin	Compound	RAC1	mRNA	0	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
61264	14889	 1552	Aspirin	Compound	ODC1	mRNA	1	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
62199	14889	17946	Aspirin	Compound	MAD2L1	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
63073	14889	  863	Aspirin	Compound	EEF1A1	mRNA	0	1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
66312	14889	 6336	Aspirin	Compound	CDC42	mRNA	0	-1	14976132	Tables 1 and 2 which are the highest fold change increase and decrease, respectively, in response to 5mM aspirin
21335	 9574	13132	mifepristone	Compound	PC	mRNA	1	-1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
28260	 9574	 7832	mifepristone	Compound	THBS1	mRNA	-1	1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
29455	 9574	18475	mifepristone	Compound	TIPARP	mRNA	0	-1	19805343	Table 1. Genes affected >2-fold by dexamethasone and mifepristone whose activity is modulated by polyamide 1 and not by polyamide 2**These genes may represent glucocorticoid-responsive genes that are controlled via direct GR-binding mechanisms.
29528	 9574	10272	mifepristone	Compound	SLC43A1	mRNA	1	-1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
33139	 9574	 7360	mifepristone	Compound	RARG	mRNA	1	-1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
40788	 9574	 7849	mifepristone	Compound	KLF9	mRNA	1	-1	16384861	P induction was abolished by the PR antagonist RU486, whereas knockdown of BTEB1 with short interfering RNA reduced P-responsive BTEB1 but not SLPI expression to basal levels.
42693	 9574	10589	mifepristone	Compound	HDAC2	mRNA	-1	1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
42928	 9574	15885	mifepristone	Compound	ACTB	mRNA	1	-1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
46036	 9574	12530	mifepristone	Compound	HPGD	mRNA	-1	-1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
48780	 9574	17731	mifepristone	Compound	DCN	mRNA	-1	1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
55785	 9574	 3250	mifepristone	Compound	COL4A5	mRNA	-1	-1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
60963	 9574	 2450	mifepristone	Compound	ITGA6	mRNA	-1	1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
 7973	 9574	17931	mifepristone	Compound	MAPK6	mRNA	1	1	17584828	We used cDNA microarrays to monitor the response of the endometriuim over 24 h following administration of mifepristone in the mid-secretory phase.  Data taken from table 2.  Fold change >= or <= 2.0, P < 0.05.  181 genes
25494	20024	11591	corticotropin	Compound	NR4A3	mRNA	0	1	10875239	We demonstrate here that Nor1 is expressed in the pituitary gland and adrenal cortex, and that ACTH and angiotensin II (AngII) treatment of adrenal fasciculata cells induces Nor1 expression.
42937	20024	15885	corticotropin	Compound	ACTB	mRNA	1	1	 2169400	It was demonstrated that ACTH induces increases in mRNAs encoding c-fos and beta-actin in adrenal glands of hypophysectomized rats. These results suggest that increased expression of c-fos and beta-actin genes by ACTH may have important roles in mediating its action on adrenals.
54024	20024	11837	corticotropin	Compound	CYP11A1	mRNA	0	1	15134808	Forced expression of SIK1 inhibited the ACTH-dependent expression of CYP11A- and StAR protein-genes.
54254	20024	19529	corticotropin	Compound	SIK1	mRNA	0	1	12530631	Salt-inducible kinase (SIK), a novel serine/threonine protein kinase from adrenal glands of rats fed with a high-salt diet, is induced by ACTH in Y1 mouse adrenocortical tumor cells.
57233	20024	 2424	corticotropin	Compound	CYP17A1	mRNA	0	1	16306078	ACTH activates steroid hormone biosynthesis by acutely increasing cholesterol delivery to the mitochondrion and chronically increasing the transcription of steroidogenic genes (including CYP17) via a cAMP-dependent pathway.
10654	16696	 3198	Suberoylanilide hydroxamic acid	Compound	TFRC	mRNA	-1	-1	14695887	Ariadne: SAHA also suppresses  expression of receptors that have been shown to trigger MM cell proliferation,  survival, and/or migration, such as CD138 (syndecan-1), CD71 (transferrin  receptor), IL-21R, and CXCR-4 ( 29 ... 32 ).
39575	16696	13744	Suberoylanilide hydroxamic acid	Compound	CDKN1B	mRNA	-1	1	11126200	BACKGROUND: Suberoylanilide hydroxamic acid (SAHA) is a prototype of the newly developed, second-generation, hybrid polar compounds. It is a novel histone deacetylase inhibitor with high potency for inducing cell differentiation of cultured murine erythroleukemia cells. Studies with SAHA have primarily been performed with hematopoietic tumor cells. Here we extent these studies with SAHA to human breast cancer cell lines in an attempt to find better therapeutic agents for breast cancer treatment. MATERIALS AND METHODS: Human breast cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-435, as well as normal cells, including the normal breast epithelial cell line MCF-10A, and fibroblasts, were treated with SAHA. Cells assayed for cell survival by using trypan blue exclusion assay, colony formation assay, and cell cycle and apoptosis analysis. The effects of SAHA on cell cycle and apoptosis regulatory proteins were examined by Western blots analysis. The identification of additional target genes was carried out by differential display (DD) and reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: SAHA inhibited clonogenic growth of MCF7, MDA-MB-231, and MDA-MB-435 breast cancer cells. These cells were more sensitive to SAHA-mediated cytotoxic effects than normal breast epithelial cells and fibroblasts. The cytotoxic effects of SAHA on breast cancer cells were manifested by G1 and G2/M cell cycle arrest and eventual apoptosis. The pan-caspase inhibitor, Z-VAD.fmk, blocked SAHA-induced cell death, DNA laddering, and cleavage of poly(ADP-ribose) polymerase, indicating the involvement of caspases in SAHA-mediated apoptosis. In addition, SAHA modulated cell cycle and apoptosis regulatory proteins. For example, cyclin-dependent kinase (CDK) inhibitors p21WAF1/Cip1 and p27Kip1 were induced, and retinoblastoma protein pRb was hypophosphorylated. Moreover, SAHA induced several genes associated with differentiation and/ or growth inhibition. These genes encode gelsolin, isopentenyl-diphosphate delta isomerase (IDI1), and 1,25-dihydroxyvitamin D-3 up-regulated protein 1 (VDUP1), the last two of which were identified by DD. Induction of these genes may contribute to SAHA-mediated pro-differentiating and antiproliferative effects. CONCLUSIONS: SAHA induced growth inhibition, cell cycle arrest, and eventual apoptosis in human breast cancer cells, possibly by modulating cell cycle and apoptosis regulatory proteins, such as CDK inhibitors p21 and p27, pRb, and other differentiation and/or growth inhibition-associated genes, including gelsolin, IDI1 and VDUP1. This, together with the low toxicity in normal cells, suggests that SAHA might have therapeutic potential for the treatment of human breast cancers.
51061	16696	13884	Suberoylanilide hydroxamic acid	Compound	CDKN1A	mRNA	1	1	11126200	BACKGROUND: Suberoylanilide hydroxamic acid (SAHA) is a prototype of the newly developed, second-generation, hybrid polar compounds. It is a novel histone deacetylase inhibitor with high potency for inducing cell differentiation of cultured murine erythroleukemia cells. Studies with SAHA have primarily been performed with hematopoietic tumor cells. Here we extent these studies with SAHA to human breast cancer cell lines in an attempt to find better therapeutic agents for breast cancer treatment. MATERIALS AND METHODS: Human breast cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-435, as well as normal cells, including the normal breast epithelial cell line MCF-10A, and fibroblasts, were treated with SAHA. Cells assayed for cell survival by using trypan blue exclusion assay, colony formation assay, and cell cycle and apoptosis analysis. The effects of SAHA on cell cycle and apoptosis regulatory proteins were examined by Western blots analysis. The identification of additional target genes was carried out by differential display (DD) and reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: SAHA inhibited clonogenic growth of MCF7, MDA-MB-231, and MDA-MB-435 breast cancer cells. These cells were more sensitive to SAHA-mediated cytotoxic effects than normal breast epithelial cells and fibroblasts. The cytotoxic effects of SAHA on breast cancer cells were manifested by G1 and G2/M cell cycle arrest and eventual apoptosis. The pan-caspase inhibitor, Z-VAD.fmk, blocked SAHA-induced cell death, DNA laddering, and cleavage of poly(ADP-ribose) polymerase, indicating the involvement of caspases in SAHA-mediated apoptosis. In addition, SAHA modulated cell cycle and apoptosis regulatory proteins. For example, cyclin-dependent kinase (CDK) inhibitors p21WAF1/Cip1 and p27Kip1 were induced, and retinoblastoma protein pRb was hypophosphorylated. Moreover, SAHA induced several genes associated with differentiation and/ or growth inhibition. These genes encode gelsolin, isopentenyl-diphosphate delta isomerase (IDI1), and 1,25-dihydroxyvitamin D-3 up-regulated protein 1 (VDUP1), the last two of which were identified by DD. Induction of these genes may contribute to SAHA-mediated pro-differentiating and antiproliferative effects. CONCLUSIONS: SAHA induced growth inhibition, cell cycle arrest, and eventual apoptosis in human breast cancer cells, possibly by modulating cell cycle and apoptosis regulatory proteins, such as CDK inhibitors p21 and p27, pRb, and other differentiation and/or growth inhibition-associated genes, including gelsolin, IDI1 and VDUP1. This, together with the low toxicity in normal cells, suggests that SAHA might have therapeutic potential for the treatment of human breast cancers.
 9250	16696	11654	Suberoylanilide hydroxamic acid	Compound	DRG1	mRNA	0	1	10676663	Moreover, the expression of Drg-1 is controlled by several known cell differentiation reagents, such as ligands of peroxisome proliferator-activated receptor gamma (troglitazone and BRL46593) and of retinoid X receptor (LG268), and histone deacetylase inhibitors (trichostatin A, suberoylanilide hydroxamic acid, and tributyrin).
13867	 3834	17250	Mapk p38 Family	Protein	PTGS2	mRNA	0	1	18241616	Kumagai et al. [40] examined the relation between COX-2 mRNA stability and HNE-activated p38 MAPK pathway and found that the p38 MAPKspecific inhibitor accelerated COX-2 mRNA degradation [15,43].
14747	 3834	16094	Mapk p38 Family	Protein	CLDN2	mRNA	0	1	15350541	The downregulated connexin32 expression was inhibited by treatment with a MAP-kinase inhibitor (PD98059), whereas the upregulated claudin-2 expression was blocked by p38 MAP and PI3-kinase inhibitors (SB203580 and LY294002)
33505	 3834	14137	Mapk p38 Family	Protein	MC1R	mRNA	0	1	15358786	Here we have shown that UV-induced activation of the POMC and MC1R promoters is mediated by p38 stress-activated kinase signaling to the transcription factor, upstream stimulating factor-1 (USF-1).
40954	 3834	 4582	Mapk p38 Family	Protein	NOS3	mRNA	1	-1	12082097	The decrease in eNOS expression was signaled in large part through a p38 MAPK-dependent mechanism.
42950	 3834	 8368	Mapk p38 Family	Protein	CXCL9	mRNA	0	1	15585657	MIG induction by RANKL was also dependent on p38 mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 1 (STAT1).
55572	 3834	 9732	Mapk p38 Family	Protein	KLF5	mRNA	0	1	14711826	S1P stimulated expression of the transcription factor KLF5 in manners dependent on G(i), Ras, and ERK/p38 MAPK
59386	 3834	10348	Mapk p38 Family	Protein	POMC	mRNA	0	1	15358786	Here we have shown that UV-induced activation of the POMC and MC1R promoters is mediated by p38 stress-activated kinase signaling to the transcription factor, upstream stimulating factor-1 (USF-1).
 5950	 3834	 1713	Mapk p38 Family	Protein	MYOG	mRNA	0	1	12058061	myogenin as an important transcriptional target under the control of three intracellular signaling pathways, namely, the p38 mitogen-activated protein kinase- (MAPK), calcium-calmodulin-dependent protein kinase- (CaMK), and calcineurin-mediated pathways,... Our data support a model in which all three signaling pathways act in parallel but nonredundantly to control myogenin expression. Inhibition of any one pathway will result in abolished or reduced myogenin expression
24311	   99	 7440	PBX2	Protein	PF4	mRNA	0	1	12609849	Platelet factor 4 (PF4) is expressed during megakaryocytic differentiation. We previously reported that GATA-1 and ETS-1 regulate the rat PF4 promoter and transactivate the PF4 gene. For the present study, we investigated the regulatory elements and their transcription factors responsible for the lineage-specific expression of the PF4 gene. The promoter activities of deletion constructs were evaluated, and a novel regulatory element termed TME (tandem repeat of MEIS1 binding element) (-219 to -182) was defined. Binding proteins to TME were strongly detected in HEL nuclear extracts by electrophoresis mobility shift assay (EMSA), and they were purified by DNA affinity chromatography. By performing Western blottings and supershift assays, the binding proteins were identified as homeodomain proteins, MEIS1, PBX1B, and PBX2. These factors are expressed in megakaryocytes differentiated from CD34+ cells in human cord blood. MEIS1 and PBXs bind to the TME as MEIS1/PBX complexes and activate the PF4 promoter. In nonmegakaryocytic HepG2 cells, GATA-1 and ETS-1 activate the PF4 promoter approximately 10-fold. Surprisingly, we found that additional expression of both MEIS1 and PBX2 multiplied this major activation another 2-fold. This activation was not observed when MEIS1 binding sites in the TME were disrupted. Furthermore, inhibition of the binding of endogenous MEIS1/PBX complexes to the TME decreased the promoter activity by almost one half, in megakaryocytic HEL cells. Thus, these studies demonstrate that the homeodomain proteins, MEIS1, PBX1B, and PBX2, play an important role in megakaryocytic gene expression.
55356	   99	 4481	PBX2	Protein	COL5A2	mRNA	1	1	10748126	DNA binding assays and cell transfection experiments revealed that the bipartite core sequence of FPB (5p-ATCAATCA-3p) binds the PBX1/2, PREP1, and HOXB1 proteins, and this in turn leads to promoter transactivation.
58881	   99	18275	PBX2	Protein	EPHA8	mRNA	0	1	17178831	Meis2 and Pbx2 synergistically bind the ephA8 regulatory sequence in vitro, and this interaction is critical for the transcriptional activation of a reporter construct bearing the ephA8 regulatory region in the presence of histone deacetylase inhibitor.
60722	   99	 9087	PBX2	Protein	TLX1	mRNA	0	1	12054735	First, a PBX2 Regulatory Element PRE-1048 has been identified which contains a novel DNA-binding sequence and mediates significant activation of the HOX11 gene in K562 cells.....PBX2 binds to a distal positive element in the HOX11 promoter
12001	15072	13778	CDK2AP1	Protein	BID	mRNA	0	1	14761923	Increased DOC-1 expression in SW48(CMV-DOC-1) was associated with significantly increased expression of proapoptosis components of the caspase cascade (CASP7, CASP9) and bcl2/bax pathway (BNIP3, BNIP3L, BID)
29727	15072	 2566	CDK2AP1	Protein	CASP7	mRNA	0	1	14761923	Increased DOC-1 expression in SW48(CMV-DOC-1) was associated with significantly increased expression of proapoptosis components of the caspase cascade (CASP7, CASP9) and bcl2/bax pathway (BNIP3, BNIP3L, BID)
32880	15072	11449	CDK2AP1	Protein	CASP9	mRNA	1	1	14761923	Increased DOC-1 expression in SW48(CMV-DOC-1) was associated with significantly increased expression of proapoptosis components of the caspase cascade (CASP7, CASP9) and bcl2/bax pathway (BNIP3, BNIP3L, BID)
47897	15072	12849	CDK2AP1	Protein	BNIP3L	mRNA	-1	1	14761923	Increased DOC-1 expression in SW48(CMV-DOC-1) was associated with significantly increased expression of proapoptosis components of the caspase cascade (CASP7, CASP9) and bcl2/bax pathway (BNIP3, BNIP3L, BID).
16052	13287	 1471	cholic acid	Compound	COL1A2	mRNA	-1	1	12923166	21). Five collagen genes were activated up to 70-fold by the Ath diet: Col1a1 and Col1a2 (which encode procollagen, type I, subunits 1 and 2), Col3a1 (procollagen, type III, 1), Col4a1 (procollagen, type IV, 1), Col6a1 (procollagen, type VI, 1), and nidogen (a glycoprotein that binds type IV collagen). Omission of cholesterol from the diet had little effect on collagen gene expression, but omission of cholate prevented induction (Fig. 2c).
19666	13287	16486	cholic acid	Compound	SPP1	mRNA	1	1	12923166	Of the three Ath diet components examined here, cholate affected expression levels of the greatest number of genes, with 81 genes induced and 23 repressed by cholate (Table II; see examples in Fig. 2, c and d).
23303	13287	 7455	cholic acid	Compound	CTSB	mRNA	0	1	12923166	Of the three Ath diet components examined here, cholate affected expression levels of the greatest number of genes, with 81 genes induced and 23 repressed by cholate (Table II; see examples in Fig. 2, c and d).
23679	13287	 3777	cholic acid	Compound	Hbb-y	mRNA	1	1	12923166	Of the three Ath diet components examined here, cholate affected expression levels of the greatest number of genes, with 81 genes induced and 23 repressed by cholate (Table II; see examples in Fig. 2, c and d).
53882	13287	  441	cholic acid	Compound	ATP1B3	mRNA	1	1	12923166	Of the three Ath diet components examined here, cholate affected expression levels of the greatest number of genes, with 81 genes induced and 23 repressed by cholate (Table II; see examples in Fig. 2, c and d).
55237	13287	12981	cholic acid	Compound	COL3A1	mRNA	-1	1	12923166	21). Five collagen genes were activated up to 70-fold by the Ath diet: Col1a1 and Col1a2 (which encode procollagen, type I, subunits 1 and 2), Col3a1 (procollagen, type III, 1), Col4a1 (procollagen, type IV, 1), Col6a1 (procollagen, type VI, 1), and nidogen (a glycoprotein that binds type IV collagen). Omission of cholesterol from the diet had little effect on collagen gene expression, but omission of cholate prevented induction (Fig. 2c).
66362	13287	 7914	cholic acid	Compound	ANXA5	mRNA	0	1	12923166	Of the three Ath diet components examined here, cholate affected expression levels of the greatest number of genes, with 81 genes induced and 23 repressed by cholate (Table II; see examples in Fig. 2, c and d).
10575	 9029	16748	Allergens	Compound	MICAL2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
11069	 9029	 5022	Allergens	Compound	SERPINB4	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
11851	 9029	16365	Allergens	Compound	IL1A	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
12764	 9029	10864	Allergens	Compound	CHAC1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
12826	 9029	17369	Allergens	Compound	IL6	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
12874	 9029	 3056	Allergens	Compound	IGFL1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
14311	 9029	 1350	Allergens	Compound	NID2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
14582	 9029	 8333	Allergens	Compound	ITGB8	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
14714	 9029	 6105	Allergens	Compound	IL13RA2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
17342	 9029	15863	Allergens	Compound	LOXL2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
19822	 9029	10229	Allergens	Compound	TRBV5-4	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
20237	 9029	11948	Allergens	Compound	KRT4	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
20271	 9029	19571	Allergens	Compound	CXCL2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 2079	 9029	19174	Allergens	Compound	SCEL	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
20898	 9029	 1651	Allergens	Compound	TNIP2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
21245	 9029	15029	Allergens	Compound	MATN2	mRNA	-1	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
22519	 9029	12843	Allergens	Compound	C5orf4	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
22668	 9029	 7012	Allergens	Compound	DMBT1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
22677	 9029	 4081	Allergens	Compound	IL1RL1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
22718	 9029	17829	Allergens	Compound	VIPR1	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
23000	 9029	12084	Allergens	Compound	STC1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
23018	 9029	  425	Allergens	Compound	COL8A1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 2336	 9029	 8319	Allergens	Compound	C1orf21	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
23959	 9029	17118	Allergens	Compound	NAMPT	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
24274	 9029	17774	Allergens	Compound	SHISA2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
24383	 9029	16520	Allergens	Compound	ZNF488	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
24737	 9029	 7605	Allergens	Compound	BIRC3	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
25550	 9029	 8993	Allergens	Compound	EREG	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
27989	 9029	 4837	Allergens	Compound	SLCO4A1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
28042	 9029	 7086	Allergens	Compound	PTPRB	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
28107	 9029	18341	Allergens	Compound	MUC5B	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
28358	 9029	18287	Allergens	Compound	ABCC3	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
29433	 9029	14588	Allergens	Compound	ADAM8	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
29844	 9029	18163	Allergens	Compound	CDKN1C	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 3039	 9029	13473	Allergens	Compound	HBEGF	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
30409	 9029	19533	Allergens	Compound	RAB3B	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
33126	 9029	12179	Allergens	Compound	FST	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
34485	 9029	 9183	Allergens	Compound	SELENBP1	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
34778	 9029	 1864	Allergens	Compound	SCARA3	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
36717	 9029	15571	Allergens	Compound	CHRNB1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
36818	 9029	  689	Allergens	Compound	LBH	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
37489	 9029	13065	Allergens	Compound	RASD1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
37996	 9029	13077	Allergens	Compound	SUV420H2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
38822	 9029	14027	Allergens	Compound	COL5A1	mRNA	-1	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
42346	 9029	15033	Allergens	Compound	KRT5	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
42502	 9029	 1807	Allergens	Compound	IRAK2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
44003	 9029	 6965	Allergens	Compound	TNFAIP3	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
44858	 9029	15528	Allergens	Compound	SPRY4	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
45460	 9029	14319	Allergens	Compound	LRRC49	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
45776	 9029	15604	Allergens	Compound	SLC40A1	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
45938	 9029	11879	Allergens	Compound	CRABP2	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
46038	 9029	12530	Allergens	Compound	HPGD	mRNA	-1	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
46685	 9029	 3471	Allergens	Compound	IL1B	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
47006	 9029	16111	Allergens	Compound	DEFB1	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 4811	 9029	12864	Allergens	Compound	SYNGR3	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
49520	 9029	10600	Allergens	Compound	CXCL1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 4989	 9029	 3807	Allergens	Compound	LMCD1	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
50769	 9029	17600	Allergens	Compound	MCTP1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
50925	 9029	 6827	Allergens	Compound	AREG	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
50958	 9029	 5258	Allergens	Compound	PARK7	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 5129	 9029	20044	Allergens	Compound	SERPINE2	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
51314	 9029	 4607	Allergens	Compound	MAF	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
51759	 9029	 9969	Allergens	Compound	MYL9	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
51862	 9029	 8337	Allergens	Compound	PTX3	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
52007	 9029	15034	Allergens	Compound	CYP26B1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
52365	 9029	18844	Allergens	Compound	SERPINB8	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
52401	 9029	 2996	Allergens	Compound	DUSP6	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
52594	 9029	11506	Allergens	Compound	APCDD1	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
53543	 9029	 8374	Allergens	Compound	SNCA	mRNA	-1	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
53609	 9029	 2526	Allergens	Compound	SEMA6D	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 5430	 9029	10230	Allergens	Compound	F3	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
55276	 9029	14298	Allergens	Compound	CXCL3	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
55767	 9029	18155	Allergens	Compound	IER3	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
55802	 9029	 9187	Allergens	Compound	ALPP	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
56538	 9029	12647	Allergens	Compound	S100A9	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
56676	 9029	13453	Allergens	Compound	MUC5AC	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
59401	 9029	 6361	Allergens	Compound	EDNRA	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
59470	 9029	15083	Allergens	Compound	ETV5	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
60632	 9029	11411	Allergens	Compound	EPHA4	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
62156	 9029	  997	Allergens	Compound	PAPSS2	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
63941	 9029	16893	Allergens	Compound	SERPINF1	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
63990	 9029	15856	Allergens	Compound	RCSD1	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
64048	 9029	17132	Allergens	Compound	CAPN8	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
65764	 9029	19723	Allergens	Compound	ARRDC3	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
65788	 9029	18178	Allergens	Compound	NYNRIN	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
66024	 9029	13803	Allergens	Compound	IL11	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
66080	 9029	 8334	Allergens	Compound	SLIT2	mRNA	-1	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 7054	 9029	 8171	Allergens	Compound	LTB	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 7639	 9029	 8626	Allergens	Compound	AKR1C3	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 8077	 9029	 3667	Allergens	Compound	CACNG4	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
  881	 9029	 2165	Allergens	Compound	PPP2R2B	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 9070	 9029	 4970	Allergens	Compound	KLF4	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 9106	 9029	 6686	Allergens	Compound	APBB1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 9294	 9029	14218	Allergens	Compound	SLC7A11	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 9576	 9029	10467	Allergens	Compound	C1QTNF1	mRNA	0	1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
 9964	 9029	 7093	Allergens	Compound	ASB9	mRNA	0	-1	17919147	See table 2: Highly differentially expressed genes sorted by ontology in functional groups. All fold changes are greater than or equal to 5 p<0.01.
12734	10451	13434	HOXA5	Protein	HIF1A	mRNA	0	-1	16379594	Sustained expression of Hox A5 leads to down regulation of many pro-angiogenic genes including VEGFR2, ephrin A1, Hif1alpha and COX-2.
13870	10451	17250	HOXA5	Protein	PTGS2	mRNA	0	-1	16379594	Sustained expression of Hox A5 leads to down regulation of many pro-angiogenic genes including VEGFR2, ephrin A1, Hif1alpha and COX-2.
16199	10451	 2348	HOXA5	Protein	THBS2	mRNA	0	1	16379594	Hox A5 also upregulates expression of anti-angiogenic genes including Thrombospondin-2.
16341	10451	19219	HOXA5	Protein	IER2	mRNA	0	1	15757903	In order to decipher downstream signaling pathways of HOXA5, we utilized oligonucleotide microarray analysis to identify genes that are differentially expressed in HOXA5-induced cells compared with uninduced cells.
17803	10451	 5117	HOXA5	Protein	SAT1	mRNA	1	1	15757903	Supplementary Table 3 and 4 - Up-regulated and down-regulated genes at 9 h post induction of HOXA5 in Hs578T breast cancer cell line (GEO2241)
20330	10451	 2815	HOXA5	Protein	TP53	mRNA	0	1	10879542	Transient transfection of Hox/HOXA5 activated the p53 promoter
23585	10451	 4571	HOXA5	Protein	GADD45B	mRNA	0	1	15757903	In order to decipher downstream signaling pathways of HOXA5, we utilized oligonucleotide microarray analysis to identify genes that are differentially expressed in HOXA5-induced cells compared with uninduced cells.
39505	10451	 8303	HOXA5	Protein	PTN	mRNA	0	1	15757903	HOXA5 directly binds to HBS on PTN promoter.
42077	10451	13115	HOXA5	Protein	EGR1	mRNA	-1	1	15757903	Supplementary Table 3 and 4 - Up-regulated and down-regulated genes at 9 h post induction of HOXA5 in Hs578T breast cancer cell line (GEO2241)
56655	10451	16427	HOXA5	Protein	EFNA1	mRNA	0	-1	16379594	Sustained expression of Hox A5 leads to down regulation of many pro-angiogenic genes including VEGFR2, ephrin A1, Hif1alpha and COX-2.
58403	10451	15117	HOXA5	Protein	PGR	mRNA	0	1	10875927	Deletion and mutation analysis of the promoter identified a single HOXA5-binding site required for transactivation of the PR gene by HOXA5. HOXA5 binds directly to this site in the PR promoter.
60007	10451	12976	HOXA5	Protein	IL8	mRNA	0	1	15757903	Supplementary Table 3 and 4 - Up-regulated and down-regulated genes at 9 h post induction of HOXA5 in Hs578T breast cancer cell line (GEO2241)
61800	10451	 1730	HOXA5	Protein	KLF10	mRNA	1	1	15757903	Supplementary Table 3 and 4 - Up-regulated and down-regulated genes at 9 h post induction of HOXA5 in Hs578T breast cancer cell line (GEO2241)
66086	10451	16821	HOXA5	Protein	DST	mRNA	1	-1	10504454	Engrailed, Hoxa-5, and Hoxc-8 regulate BPAG1e promoter activity
  798	10451	13135	HOXA5	Protein	KDR	mRNA	0	-1	16379594	Sustained expression of Hox A5 leads to down regulation of many pro-angiogenic genes including VEGFR2, ephrin A1, Hif1alpha and COX-2.
11229	16853	13301	THAP1	Protein	CCNB1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 1139	16853	15597	THAP1	Protein	DLGAP5	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
11524	16853	19317	THAP1	Protein	CDCA5	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 1157	16853	16275	THAP1	Protein	PRC1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
11780	16853	16442	THAP1	Protein	TCFL5	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
11827	16853	 2718	THAP1	Protein	GJA4	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
11976	16853	 9353	THAP1	Protein	WRB	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
12029	16853	 4022	THAP1	Protein	CSE1L	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
12073	16853	11565	THAP1	Protein	DBF4	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
13444	16853	 6415	THAP1	Protein	CCNB2	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
14148	16853	 3375	THAP1	Protein	TMEM35	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
14517	16853	 9628	THAP1	Protein	GINS2	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
16219	16853	10607	THAP1	Protein	PARPBP	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
17203	16853	 5439	THAP1	Protein	LZIC	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
17754	16853	20005	THAP1	Protein	FBXO5	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
17879	16853	20216	THAP1	Protein	NUF2	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
17919	16853	 1736	THAP1	Protein	KPNB1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
20584	16853	 8300	THAP1	Protein	FAM54A	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
20644	16853	 2423	THAP1	Protein	CDCA7	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
20892	16853	13613	THAP1	Protein	DPH3	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
21535	16853	16634	THAP1	Protein	TTC32	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
22097	16853	13495	THAP1	Protein	HPDL	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
22348	16853	14180	THAP1	Protein	PBK	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
22552	16853	11978	THAP1	Protein	UCHL1	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
23287	16853	 3270	THAP1	Protein	GLTSCR2	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
23433	16853	 6300	THAP1	Protein	USP16	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
24099	16853	12973	THAP1	Protein	ANLN	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
25440	16853	 7198	THAP1	Protein	TACC3	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
25811	16853	19027	THAP1	Protein	HMOX1	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
26409	16853	 6397	THAP1	Protein	CEP55	mRNA	1	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
26704	16853	11502	THAP1	Protein	LMNB1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
26832	16853	 1533	THAP1	Protein	ITGB3BP	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 2827	16853	  931	THAP1	Protein	TP53INP1	mRNA	-1	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
28714	16853	 4097	THAP1	Protein	ZWINT	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
29402	16853	 5890	THAP1	Protein	PTTG2	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
29481	16853	 4277	THAP1	Protein	MCM7	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
30162	16853	 4549	THAP1	Protein	TIPIN	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
32924	16853	10349	THAP1	Protein	BORA	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
33658	16853	13246	THAP1	Protein	CENPN	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
34048	16853	10584	THAP1	Protein	RRS1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
35357	16853	11044	THAP1	Protein	MCM10	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
36903	16853	13831	THAP1	Protein	CKS1B	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
38807	16853	10290	THAP1	Protein	FOXM1	mRNA	1	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
39247	16853	16905	THAP1	Protein	DNMT1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 3964	16853	10885	THAP1	Protein	PCDH17	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
40278	16853	 7169	THAP1	Protein	KIF2C	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
41436	16853	14192	THAP1	Protein	SPAG5	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 4158	16853	 9655	THAP1	Protein	NDC80	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
43125	16853	 8436	THAP1	Protein	TEP1	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
45573	16853	  543	THAP1	Protein	RRM1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
45597	16853	 4559	THAP1	Protein	CDC20	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
46758	16853	 7923	THAP1	Protein	PTTG1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
48120	16853	13471	THAP1	Protein	BIRC5	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
48637	16853	 5076	THAP1	Protein	ASPM	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
49483	16853	 8723	THAP1	Protein	KIF22	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
49922	16853	17491	THAP1	Protein	RPL7L1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
50862	16853	  727	THAP1	Protein	KIF20A	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
50895	16853	16714	THAP1	Protein	FABP4	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
51260	16853	16115	THAP1	Protein	GMNN	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
51262	16853	18198	THAP1	Protein	NCAPD2	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
51907	16853	 8549	THAP1	Protein	TAF9	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
52573	16853	 6707	THAP1	Protein	HMMR	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
52708	16853	17948	THAP1	Protein	THAP1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
52760	16853	20220	THAP1	Protein	BUB1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
52842	16853	11015	THAP1	Protein	CENPM	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
53024	16853	 5763	THAP1	Protein	CENPK	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
54294	16853	 4554	THAP1	Protein	BUB1B	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
55099	16853	 9630	THAP1	Protein	ARHGAP11A	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
56225	16853	 6642	THAP1	Protein	CENPF	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
56262	16853	11760	THAP1	Protein	SECTM1	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
57898	16853	14044	THAP1	Protein	TSHR	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
59396	16853	 5320	THAP1	Protein	FAM64A	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
59839	16853	 2570	THAP1	Protein	FOXL2	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
 6114	16853	16922	THAP1	Protein	RRM2	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
61420	16853	17154	THAP1	Protein	HMGB2	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 6215	16853	 5480	THAP1	Protein	DEK	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
62197	16853	17946	THAP1	Protein	MAD2L1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
62767	16853	  772	THAP1	Protein	FEN1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
63294	16853	17193	THAP1	Protein	SPC25	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 6347	16853	 9278	THAP1	Protein	CENPE	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
63963	16853	 9990	THAP1	Protein	LAMB3	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
63974	16853	12833	THAP1	Protein	TRIP13	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
64282	16853	17081	THAP1	Protein	LGALS3	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
65445	16853	17790	THAP1	Protein	DARS2	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
65673	16853	15232	THAP1	Protein	FERMT1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
65719	16853	16941	THAP1	Protein	UBE2T	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 7744	16853	16382	THAP1	Protein	PTTG3P	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 7863	16853	10080	THAP1	Protein	DTL	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 8028	16853	   64	THAP1	Protein	TMEM45A	mRNA	0	1	17003378	Genes up-regulated after ectopic expression of THAP1 in primary EC
 8308	16853	10700	THAP1	Protein	MKKS	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 9319	16853	 8814	THAP1	Protein	CDK1	mRNA	0	-1	17003378	Table 1. Genes regulated after ectopic expression of THAP1 in endothelial cells Genes down-regulated after ectopic expression of THAP1 in primary ECs
 1241	16327	15018	Expi	Protein	CIDEA	mRNA	0	1	14720511	overexpression of the Expi gene induced expression of several genes, which included B cell activating factor (BAFF), Bax, cytochrome c, caspase-9, caspase-3, caspase-6, and CIDE-A.
21558	16327	 1294	Expi	Protein	CASP6	mRNA	0	1	14720511	overexpression of the Expi gene induced expression of several genes, which included B cell activating factor (BAFF), Bax, cytochrome c, caspase-9, caspase-3, caspase-6, and CIDE-A.
32882	16327	11449	Expi	Protein	CASP9	mRNA	1	1	14720511	overexpression of the Expi gene induced expression of several genes, which included B cell activating factor (BAFF), Bax, cytochrome c, caspase-9, caspase-3, caspase-6, and CIDE-A.
 3431	16327	10915	Expi	Protein	BAX	mRNA	0	1	14720511	overexpression of the Expi gene induced expression of several genes, which included B cell activating factor (BAFF), Bax, cytochrome c, caspase-9, caspase-3, caspase-6, and CIDE-A.
45403	16327	 3512	Expi	Protein	CASP3	mRNA	0	1	14720511	overexpression of the Expi gene induced expression of several genes, which included B cell activating factor (BAFF), Bax, cytochrome c, caspase-9, caspase-3, caspase-6, and CIDE-A.
66147	16327	 3724	Expi	Protein	TNFSF13B	mRNA	0	1	14720511	overexpression of the Expi gene induced expression of several genes, which included B cell activating factor (BAFF), Bax, cytochrome c, caspase-9, caspase-3, caspase-6, and CIDE-A.
12850	12261	17369	VEGF Family	Protein	IL6	mRNA	0	1	14991903	Furthermore, VEGF induced IL-1beta, IL-6, TNF-alpha, and nitric oxide expression to a small extent and stimulated the proliferation of immortalized chondrocytes.
14959	12261	 3861	VEGF Family	Protein	TIMP2	mRNA	0	-1	14991903	The chondrocyte cell lines C28/I2, C20/A4, and T/C28a2/a4 expressed functionally active VEGFR-2. VEGF stimulation induced receptor phosphorylation, activation of the mitogen-activated protein kinases ERK 1/2, and long-lasting activation of the transcription factor AP-1 (activator protein-1). VEGF increased secreted MMP-1, MMP-3, and especially MMP-13, which could be effectively reduced by an inhibitor of VEGFR-2 kinase activity. Interestingly, VEGF diminished the expression of TIMP-1 and especially TIMP-2.
 2231	12261	 5419	VEGF Family	Protein	TNF	mRNA	0	1	14991903	Furthermore, VEGF induced IL-1beta, IL-6, TNF-alpha, and nitric oxide expression to a small extent and stimulated the proliferation of immortalized chondrocytes.
27810	12261	 2395	VEGF Family	Protein	EP300	mRNA	0	1	11486006	Since HIF-1alpha has been also reported to associate with p300 to stimulate VEGF transcription ( 72 ), it is possible that the HIF-1/Smad association on the VEGF promoter could lead to a more efficient recruitment of p300 into the DNA-protein complex ( 1 ).
28630	12261	 3297	VEGF Family	Protein	TIMP1	mRNA	0	-1	14991903	The chondrocyte cell lines C28/I2, C20/A4, and T/C28a2/a4 expressed functionally active VEGFR-2. VEGF stimulation induced receptor phosphorylation, activation of the mitogen-activated protein kinases ERK 1/2, and long-lasting activation of the transcription factor AP-1 (activator protein-1). VEGF increased secreted MMP-1, MMP-3, and especially MMP-13, which could be effectively reduced by an inhibitor of VEGFR-2 kinase activity. Interestingly, VEGF diminished the expression of TIMP-1 and especially TIMP-2.
35245	12261	 5296	VEGF Family	Protein	PLAU	mRNA	1	1	11172729	In vitro, VEGF stimulates ECM degradation, proliferation, migration and tube formation of endothelial cells and induces in these cells the expression of uPA, PAI-1, uPAR and MMP-1 (148, 182, 183, 243). In vivo, VEGF has been shown to regulate vascular permeability, which is considered important for the initiation of angiogenesis (57).
40950	12261	 4582	VEGF Family	Protein	NOS3	mRNA	1	1	14656742	VEGF165 increased steadystate eNOS mRNA expression in HUVEC in a time- and concentration-dependent manner.8
43834	12261	20009	VEGF Family	Protein	CXCR4	mRNA	0	1	15018895	In fact, our studies indicate that VEGF/neuropilin-1 autocrine signaling promotes the migration of breast carcinoma cells by increasing the expression of the chemokine receptor CXCR4 [19]. Our finding that VEGF regulates CXCR4 expression is relevant because stromal-derived factor-1, the ligand for this receptor, is present in tumor stroma and in tissues such as lymph and lung [36], which are the primary targets of invasive breast carcinoma cells, and CXCR4 inhibitors impair metastasis.
46671	12261	 3471	VEGF Family	Protein	IL1B	mRNA	0	1	14991903	Furthermore, VEGF induced IL-1beta, IL-6, TNF-alpha, and nitric oxide expression to a small extent and stimulated the proliferation of immortalized chondrocytes.
  866	12261	12322	VEGF Family	Protein	TJP1	mRNA	0	-1	16163490	Cultured vascular endothelial cells in the presence of 5 ng/ml VEGF significantly down-regulate ZO-1alpha(+) and ZO-1alpha(-) transcripts and proteins with significant loss of their trans-epithelial resistance (TER).
11058	16603	15610	RB1	Protein	CDH6	mRNA	0	-1	11830547	Table1: Down-regulation by progesterone (fold) Gene   PRA   PRB  Fibronectin   None   2.8 Integrin a3   None   2.8 Integrin B1   None   >10 Integrin B3   8   5.6 Cadherin 6  6   8 Differences between the PR isoforms were evident: in general, PRB had a greater inhibitory effect on cellular adhesion molecule expression compared with PRA. Only PRB significantly inhibited the expression of fibronectin and the integrins 3 and B1, but both PR isoforms inhibited cadherin 6 and integrin B3.
13116	16603	 1425	RB1	Protein	ITGA3	mRNA	0	-1	11830547	Table1: Down-regulation by progesterone (fold) Gene   PRA   PRB  Fibronectin   None   2.8 Integrin a3   None   2.8 Integrin B1   None   >10 Integrin B3   8   5.6 Cadherin 6  6   8 Differences between the PR isoforms were evident: in general, PRB had a greater inhibitory effect on cellular adhesion molecule expression compared with PRA. Only PRB significantly inhibited the expression of fibronectin and the integrins 3 and B1, but both PR isoforms inhibited cadherin 6 and integrin B3.
13595	16603	 1438	RB1	Protein	VEGFA	mRNA	0	1	15026368	These results indicate that (a) PRB preferentially regulates VEGF expression in breast cancer cells
14299	16603	16808	RB1	Protein	ACSL1	mRNA	0	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
17971	16603	  467	RB1	Protein	ALDH1A3	mRNA	0	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
17979	16603	11254	RB1	Protein	SLC31A2	mRNA	0	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
 2110	16603	18630	RB1	Protein	ITGB3	mRNA	0	-1	11830547	Table1: Down-regulation by progesterone (fold) Gene   PRA   PRB  Fibronectin   None   2.8 Integrin a3   None   2.8 Integrin B1   None   >10 Integrin B3   8   5.6 Cadherin 6  6   8 Differences between the PR isoforms were evident: in general, PRB had a greater inhibitory effect on cellular adhesion molecule expression compared with PRA. Only PRB significantly inhibited the expression of fibronectin and the integrins 3 and B1, but both PR isoforms inhibited cadherin 6 and integrin B3.
34134	16603	10208	RB1	Protein	TTLL12	mRNA	0	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
40784	16603	 7849	RB1	Protein	KLF9	mRNA	1	1	11717311	Table I: Genes regulated by progesterone
46030	16603	12530	RB1	Protein	HPGD	mRNA	-1	1	10650939	In myometrial SMC, both isoforms of the progesterone receptor, PR-B and PR-A, caused a ligand-dependent activation of PGDH-2368/luc3. Transcriptional activity of PR-B was further enhanced by the addition of 8-bromo-cAMP
46257	16603	 3491	RB1	Protein	NQO2	mRNA	0	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
53979	16603	11581	RB1	Protein	ITGB1	mRNA	1	-1	11830547	Table1: Down-regulation by progesterone (fold) Gene   PRA   PRB  Fibronectin   None   2.8 Integrin a3   None   2.8 Integrin B1   None   >10 Integrin B3   8   5.6 Cadherin 6  6   8 Differences between the PR isoforms were evident: in general, PRB had a greater inhibitory effect on cellular adhesion molecule expression compared with PRA. Only PRB significantly inhibited the expression of fibronectin and the integrins 3 and B1, but both PR isoforms inhibited cadherin 6 and integrin B3.
56153	16603	10811	RB1	Protein	FN1	mRNA	-1	-1	11830547	Table1: Down-regulation by progesterone (fold) Gene   PRA   PRB  Fibronectin   None   2.8 Integrin a3   None   2.8 Integrin B1   None   >10 Integrin B3   8   5.6 Cadherin 6  6   8 Differences between the PR isoforms were evident: in general, PRB had a greater inhibitory effect on cellular adhesion molecule expression compared with PRA. Only PRB significantly inhibited the expression of fibronectin and the integrins 3 and B1, but both PR isoforms inhibited cadherin 6 and integrin B3.
57501	16603	 5731	RB1	Protein	ACOX1	mRNA	0	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
63955	16603	 7537	RB1	Protein	STAT5A	mRNA	0	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
 6449	16603	19359	RB1	Protein	GAS6	mRNA	0	1	16762974	The two, nearly identical, isoforms of human progesterone receptors (PR), PR-B and PR-A, share activation functions (AF) 1 and 2, yet they possess markedly different transcriptional profiles, with PR-B being much stronger transactivators.
 8321	16603	 6202	RB1	Protein	BTG1	mRNA	-1	1	11717311	Table I: Genes regulated by progesterone
10758	15413	 8674	HNF1A	Protein	SLC3A1	mRNA	-1	1	11679424	Mutations in hepatocyte nuclear factor 1 alpha (HNF-1A) lead to maturity-onset diabetes of the young type 3 as a result of impaired insulin secretory response in pancreatic Beta-cells. Furthermore the expression of steady-state mRNA levels of gene encoding neutral and neutral and basic amino acid transporter (Nbat) was found to be decreased in Hnf-1-/- mice. In the liver of Hnf-1-/- mice, mRNA levels of Nbat was also reduced by 2.2-fold compared with wild-type littermates, suggesting that HNF-1 alpha leads to the expression of Nbat in pancreatic islets and liver of mice.
14869	15413	15284	HNF1A	Protein	TCF4	mRNA	0	1	12750294	Synergy between tumor suppressor APC and the ?-catenin-Tcf4 target Tcf1.
  158	15413	 1554	HNF1A	Protein	PLA2G1B	mRNA	0	1	12529398	The expression levels of the gene encoding phospholipase A2 were reduced in the pancreas of HNF-1 alpha kin/kin mice (null mice), were normal in that of hepatic HNF-1 alpha revived mice.
 1595	15413	 9722	HNF1A	Protein	CEBPA	mRNA	0	1	12034748	Findings suggested that the differential role of the HNF1 sites in the different organs could be related to the abundance of C/EBP in the liver compared with the kidney.
21142	15413	18938	HNF1A	Protein	T	mRNA	0	1	11447280	Therefore, the question arose as to whether LEF-1 and TCF-1 regulate the expression of Brachyury throughout early mouse development.
26098	15413	10236	HNF1A	Protein	SI	mRNA	0	1	11395488	In transfection experiments, HNF-1 alpha activated the SI promoter via the SIF3 element, and co-expression of HNF-1 beta impaired this transcriptional activation.
28974	15413	16957	HNF1A	Protein	ASAH1	mRNA	-1	1	11279518	hepatocyte bile acid storage protein is absent from Tcf1 lacking mice
29228	15413	15188	HNF1A	Protein	LEF1	mRNA	0	1	12582159	Previously we reported that both TCF-1 and  TCF-4 were able to activate the LEF1 promoter ( 20 ).
34740	15413	 8127	HNF1A	Protein	IL1RAP	mRNA	0	1	12529398	The mRNA levels of Interleukin 1 receptor accessory protein were significantly reduced in the liver of HNF-1 alpha in HNF-1 alpha kin/kin mice, in which the expression of HNF-1 alpha was inactivated in germ line cells was indistinguishable from the HNF-1alpha null mice with regard to both the diabetes and liver phenotype. Furthermore when inactivated HNF-1 alpha gene was revived in liver by the Cre- recombinase driven by an albumin promoter, the gene mRNA level was restored to level similar to those in control mice.
39662	15413	 9974	HNF1A	Protein	DCT	mRNA	0	1	12032083	Interestingly, p45-TCF-1B, a full-length isoform of TCF-1, transactivated the DCT promoter, but no enhancing effects were observed when coexpressed with MITF-M.
41954	15413	16499	HNF1A	Protein	Reg3a	mRNA	0	-1	12529398	The expression levels of pancreatic regenerating factor, Reg IIIa were elevated in HNF-1 alpha kin/kin mice (null mice), were not present in hepatic HNF-1 alpha revived mice.
44236	15413	 9200	HNF1A	Protein	PCNA	mRNA	0	1	10574988	A Binding Site for the Transcription Factor Grainyhead/Nuclear Transcription Factor-1 Contributes to Regulation of the Drosophila Proliferating Cell Nuclear Antigen Gene Promoter * Yuko Hayashi , Masahiro Yamagishi  , Yoshio Nishimoto , Osamu Taguchi  , Akio Matsukage , and Masamitsu Yamaguchi || From the Laboratory of Cell Biology and the  Laboratory of Experimental Pathology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, 464-8681, Japan ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES
45307	15413	16190	HNF1A	Protein	C8A	mRNA	0	1	11733582	On the contrary, HNF1alpha-deficient mice failed to express this mRNA, suggesting that HNF1alpha is absolutely required for the expression of C8A.
47344	15413	16402	HNF1A	Protein	Serpina3k	mRNA	0	1	12529398	The mRNA levels of contrapsin were significantly reduced in the liver of HNF-1 alpha in HNF-1 alpha kin/kin mice, in which the expression of HNF-1 alpha was inactivated in germ line cells was indistinguishable from the HNF-1alpha null mice with regard to both the diabetes and liver phenotype. Furthermore when inactivated HNF-1 alpha gene was revived in liver by the Cre- recombinase driven by an albumin promoter, the gene mRNA level was restored to level similar to those in control mice.
 5120	15413	14475	HNF1A	Protein	Cyp2j5	mRNA	0	1	12529398	The mRNA levels of CYP2J5 was significantly reduced in the liver of HNF-1 alpha in HNF-1 alpha kin/kin mice, in which the expression of HNF-1 alpha was inactivated in germ line cells was indistinguishable from the HNF-1alpha null mice with regard to both the diabetes and liver phenotype. Furthermore when inactivated HNF-1 alpha gene was revived in liver by the Cre- recombinase driven by an albumin promoter, the gene mRNA level was restored to level similar to those in control mice.
53354	15413	  545	HNF1A	Protein	SERPINA6	mRNA	0	1	10468604	alpha1AT and CBG transcription could be rescued by transfecting the cells with expression plasmids encoding HNF-1alpha or HNF-4.
55733	15413	 2223	HNF1A	Protein	HES1	mRNA	0	1	15226394	Furthermore, HNF1alpha expression was slightly upregulated by Hes1, whereas it rather was downregulated by NICD ( Fig. 4A ).
57269	15413	 8148	HNF1A	Protein	GCG	mRNA	0	1	11679424	Mutations in hepatocyte nuclear factor 1 alpha (HNF-1A) lead to maturity-onset diabetes of the young type 3 as a result of impaired insulin secretory response in pancreatic Beta-cells. Furthermore the expression of steady-state mRNA levels of gene encoding glucagon was found to be decreased in HNF-1 -/- mice, suggesting that HNF-1 alpha leads to the expression of glucagon in pancreatic islets of mice.
59679	15413	 7590	HNF1A	Protein	GCK	mRNA	0	1	11679424	Mutations in hepatocyte nuclear factor 1 alpha (HNF-1A) lead to maturity-onset diabetes of the young type 3 as a result of impaired insulin secretory response in pancreatic Beta-cells. Furthermore the expression of steady-state mRNA levels of gene encoding gluocokinase (GCK) was found to be decreased in HNF-1 -/- mice, suggesting that HNF-1 alpha leads to the expression of GCK in pancreatic islets of mice.
59982	15413	17787	HNF1A	Protein	AMY2A	mRNA	0	1	12529398	The expression levels of the gene encoding secreted protein alpha amylase-2 were reduced in the pancreas of HNF-1 alpha kin/kin mice (null mice), were normal in that of hepatic HNF-1 alpha revived mice.
65438	15413	19519	HNF1A	Protein	CPT1A	mRNA	-1	-1	10852923	It is also unlikely that a defect in mitochondrial fatty acid import, mediated by L -CPT1, resulted in the differences between peroxisomal and mitochondrial eta-oxidation, because the expression of the gene for L -CPT1 was unaffected by HNF1alpha gene inactivation.
 7134	15413	14713	HNF1A	Protein	FOXA1	mRNA	0	1	10049364	In addition, deletion of HNF3alpha in visceral endoderm differentiated from embryoid bodies in vitro was shown to lead to an increase in the mRNA levels of HNF1alpha and HNF4alpha (Duncan et al. 1998 ).
  285	19713	  279	Dronabinol	Compound	HIPK1	mRNA	-1	1	16597638	In this study, concentrations of Delta9-THC equivalent to those found in the serum of cannabis users, i.e. approximately 20 microM, inhibited proliferation
 3469	19713	19920	Dronabinol	Compound	CDK19	mRNA	1	1	16597638	In this study, concentrations of Delta9-THC equivalent to those found in the serum of cannabis users, i.e. approximately 20 microM, inhibited proliferation
40787	19713	 7849	Dronabinol	Compound	KLF9	mRNA	1	1	16597638	In this study, concentrations of Delta9-THC equivalent to those found in the serum of cannabis users, i.e. approximately 20 microM, inhibited proliferation
11331	15447	11102	metformin	Compound	SELE	mRNA	0	-1	16636195	Furthermore, metformin attenuated the TNF-alpha-induced gene expression of various proinflammatory and cell adhesion molecules, such as vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1,
20542	15447	 6218	metformin	Compound	VCAM1	mRNA	0	-1	16636195	Furthermore, metformin attenuated the TNF-alpha-induced gene expression of various proinflammatory and cell adhesion molecules, such as vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1,
35461	15447	18531	metformin	Compound	ICAM1	mRNA	0	-1	16636195	Furthermore, metformin attenuated the TNF-alpha-induced gene expression of various proinflammatory and cell adhesion molecules, such as vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1,
39378	15447	18612	metformin	Compound	SOD2	mRNA	-1	1	16380484	Treatment with metformin and AICAR inhibited hyperglycemia-induced intracellular and mtROS production, stimulated AMP-activated protein kinase (AMPK) activity, and increased the expression of peroxisome proliferator-activated response-gamma coactivator-1alpha (PGC-1alpha) and manganese superoxide dismutase (MnSOD) mRNAs.
44415	15447	13271	metformin	Compound	CCL2	mRNA	0	-1	16636195	Furthermore, metformin attenuated the TNF-alpha-induced gene expression of various proinflammatory and cell adhesion molecules, such as vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1,
54273	15447	  322	metformin	Compound	GADD45G	mRNA	1	-1	16752183	We performed DNA microarray analysis to study global gene expression in the livers of obese diabetic db/db mice 2 h after a single administration of metformin (400 mg/kg).This analysis identified 14 genes that showed at least a 1.5-fold difference in expression following metformin treatment. Table 1 Differentially expressed genes in the liver of metformin-treated db/db mice- pooled RNA form five animals for each condition; genes with at least 1.5 fold significant difference by MAS5 and p<0.05.
57780	15447	 9065	metformin	Compound	KLF3	mRNA	1	-1	16752183	We performed DNA microarray analysis to study global gene expression in the livers of obese diabetic db/db mice 2 h after a single administration of metformin (400 mg/kg).This analysis identified 14 genes that showed at least a 1.5-fold difference in expression following metformin treatment. Table 1 Differentially expressed genes in the liver of metformin-treated db/db mice- pooled RNA form five animals for each condition; genes with at least 1.5 fold significant difference by MAS5 and p<0.05.
39949	10848	 6114	NPPA	Protein	NFKBIA	mRNA	1	1	12135603	Moreover, ANP leads to a transcriptional induction of IkappaB-alpha.
42100	10848	13115	NPPA	Protein	EGR1	mRNA	-1	-1	 8662898	To this  end, we recently found that ANP and endothelin act, respectively, as negative  or positive modulators of astrocyte proliferation ( 5 , 6 ), inhibiting or  stimulating the transcription of the immediate early gene, tis 8 , followed by  the bFGF gene and its protein product ( 3 ).
27912	 7044	18710	verapamil	Compound	GUSB	mRNA	0	-1	14618298	Treatment of HepG2 cells with verapamil revealed down-regulation of beta-gluc activity, protein, and mRNA level down to 50% of the control with EC(50) values of 25 microM. Effects were similar for both enantiomers. Moreover, it was demonstrated that reduced promoter activity contributes to the observed effects.
53969	 7044	14880	verapamil	Compound	CUX1	mRNA	1	-1	 1666033	Verapamil also decreased CDP synthesis to 49.7% at 10 microM and 32.6% at 50 microM.
10051	12713	 7928	trichostatin A	Compound	TGFBR2	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
10583	12713	 5222	trichostatin A	Compound	H2-Eb2	mRNA	0	1	11533238	the combination of TSA and Ifng treatments of cells also resulted in the rescue of Ifng-inducible H2A and H2-Eb2 mRNAs in these cells
11071	12713	11467	trichostatin A	Compound	TFDP1	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
11130	12713	19157	trichostatin A	Compound	YWHAZ	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
11217	12713	13301	trichostatin A	Compound	CCNB1	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
 1158	12713	16275	trichostatin A	Compound	PRC1	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
11781	12713	16442	trichostatin A	Compound	TCFL5	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
13124	12713	 4335	trichostatin A	Compound	ACTR2	mRNA	0	-1	12445420	TSA prevented new actin filament formation by down-regulation of two nucleating proteins, actin related protein 2 (Arp2) and Arp3, and by up-regulation of adducin like protein 70 (ADDL70) and gelsolin, two capping proteins.
 1406	12713	 8959	trichostatin A	Compound	SNRPF	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
14514	12713	 9270	trichostatin A	Compound	INHBC	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
14817	12713	 2569	trichostatin A	Compound	SIVA1	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
16041	12713	 1471	trichostatin A	Compound	COL1A2	mRNA	-1	1	15452378	The microarray analysis revealed that 8 genes including collagen type 1, alpha2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), integrin, alpha7 (ITGA7), basigin (BSG), quiescin Q6 (QSCN6), superoxide dismutase 3, extracellular (SOD3), nerve growth factor receptor (NGFR), and p53-induced protein (PIG11) exhibited substantial induction (ratio >2.0) after TSA treatment in multiple cell lines.
16122	12713	 8326	trichostatin A	Compound	CDC6	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
16200	12713	 2348	trichostatin A	Compound	THBS2	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
16451	12713	 3007	trichostatin A	Compound	HDAC4	mRNA	0	1	15234474	The expression of 10 histone deacetylases (HDAC1-10) mRNAs in mouse neuroblastoma Neuro-2a and microglia N9 cell cultures after treatment by inhibitors of HDACs, sodium butyrate and trichostatin A was studied to elucidate whether HDAC inhibitors affect the gene expression of HDACs In both Neuro-2a and N9 cells the highest increase was observed for HDAC5 and -6 mRNA, whereas, HDAC4 had a prominent increase in mRNA levels after drug treatment only in N9 microglia cell line but not in Neuro-2a.
16782	12713	13711	trichostatin A	Compound	FGF5	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
17712	12713	13919	trichostatin A	Compound	RECK	mRNA	0	1	12810630	Histone deacetylase (HDAC) inhibitors are known toexert antimetastatic and antiangiogenic activity in vitro and in vivo. RECK is a membrane-anchored glycoprotein that negatively regulates matrixmetalloproteinases (MMPs) and inhibits tumor metastasis and angiogenesis. Inthis study, we test the possibility that HDAC inhibitor may increase RECKexpression to inhibit MMP activation and cancer cell invasion. Our resultsshowed that trichostatin A (TSA) up-regulated RECK via transcriptionalactivation in CL-1 human lung cancer cells. Flow cytometric analysisdemonstrated that RECK protein on cell surface was increased after treatment ofTSA. Moreover, up-regulation of RECK expression by TSA attenuated MMP-2activity. To explore whether HDAC inhibitor-induced inhibition of MMP-2activation is indeed mediated via RECK, we used small interference RNA (siRNA)to block RECK expression and found that inhibition of RECK by siRNA abolishedthe inhibitory effect of TSA on MMP-2 activation. In addition, TSA suppressedthe invasive ability of CL-1 cells. Taken together, this study reveals a novelmechanism by which HDAC inhibitors suppress tumor invasion and provides a newstrategy for cancer therapy.
18041	12713	17139	trichostatin A	Compound	CPA3	mRNA	0	1	10383164	Trichostatin A, a potent and specific inhibitor of histone deacetylase, also induced CPA3 mRNA expression, suggesting that CPA3 gene induction is mediated by histone hyperacetylation.
19282	12713	13594	trichostatin A	Compound	HSBP1	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
19967	12713	17377	trichostatin A	Compound	PTP4A2	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
20058	12713	 2543	trichostatin A	Compound	AKR1B10	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
20471	12713	10306	trichostatin A	Compound	ANGPTL4	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
20651	12713	18274	trichostatin A	Compound	IL7R	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
21302	12713	19388	trichostatin A	Compound	DLC1	mRNA	0	1	12813468	we demonstrated that DLC-1 mRNA expression was induced, and an increase in the level of acetylated H3 and H4 was detected by the treatment with trichostatin A (TSA)
21426	12713	 9290	trichostatin A	Compound	ZNF277	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
21487	12713	 8617	trichostatin A	Compound	MAPK8	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
21837	12713	 7428	trichostatin A	Compound	DHFR	mRNA	0	1	12788094	Trichostatin A, an inhibitor of histone deacetylases, markedly stimulated dhfr promoter activity, a response that was enhanced by the deletion of an E2F element.
21950	12713	19286	trichostatin A	Compound	XRCC5	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
22987	12713	12084	trichostatin A	Compound	STC1	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
23767	12713	 6636	trichostatin A	Compound	BCL2L1	mRNA	0	-1	10746741	trichostatin A (TSA), an inhibitor of histone deacetylases Complex hybridization of cDNA arrays revealed repression of Bcl-xL, CRAB2 and TFIID/TAFII31 as well as induction of p21waf1/cip1, GATA-2, hsp86, ID1, ID2 and ID3 mRNA expression, which could be verified by Northern blotting.
25456	12713	 5701	trichostatin A	Compound	ID3	mRNA	0	1	10746741	trichostatin A (TSA), an inhibitor of histone deacetylases Complex hybridization of cDNA arrays revealed repression of Bcl-xL, CRAB2 and TFIID/TAFII31 as well as induction of p21waf1/cip1, GATA-2, hsp86, ID1, ID2 and ID3 mRNA expression, which could be verified by Northern blotting.
25652	12713	18101	trichostatin A	Compound	NCOR2	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
 2586	12713	  326	trichostatin A	Compound	TXNIP	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
26012	12713	 2210	trichostatin A	Compound	RCC1	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
26713	12713	14348	trichostatin A	Compound	NASP	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
29241	12713	18120	trichostatin A	Compound	NGFR	mRNA	0	1	15452378	The microarray analysis revealed that 8 genes including collagen type 1, alpha2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), integrin, alpha7 (ITGA7), basigin (BSG), quiescin Q6 (QSCN6), superoxide dismutase 3, extracellular (SOD3), nerve growth factor receptor (NGFR), and p53-induced protein (PIG11) exhibited substantial induction (ratio >2.0) after TSA treatment in multiple cell lines.
29280	12713	 5300	trichostatin A	Compound	IL21R	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
29782	12713	16604	trichostatin A	Compound	TYMS	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
32859	12713	19833	trichostatin A	Compound	MBD4	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
33043	12713	 6775	trichostatin A	Compound	HIST1H3H	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
33944	12713	 6727	trichostatin A	Compound	PCTP	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
34716	12713	 2278	trichostatin A	Compound	NPPB	mRNA	0	-1	19139378	Treatment with the histone deacetylase inhibitor trichostatin A resulted in decreased hBNP reporter activity. YY1 was shown to associate with histone deacetylase 2, and histone deacetylase 2 was shown to associate directly with the hBNP promoter in the intact cell.
34831	12713	 6356	trichostatin A	Compound	H2AFX	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
35017	12713	 7998	trichostatin A	Compound	ERBB2	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
35318	12713	15605	trichostatin A	Compound	E2F1	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
35591	12713	 1857	trichostatin A	Compound	CCNA1	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
35828	12713	 9034	trichostatin A	Compound	ITGA7	mRNA	0	1	15452378	The microarray analysis revealed that 8 genes including collagen type 1, alpha2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), integrin, alpha7 (ITGA7), basigin (BSG), quiescin Q6 (QSCN6), superoxide dismutase 3, extracellular (SOD3), nerve growth factor receptor (NGFR), and p53-induced protein (PIG11) exhibited substantial induction (ratio >2.0) after TSA treatment in multiple cell lines.
36224	12713	 8092	trichostatin A	Compound	ANXA3	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
36902	12713	13831	trichostatin A	Compound	CKS1B	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
38914	12713	 8088	trichostatin A	Compound	TFPI2	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
 3912	12713	 8781	trichostatin A	Compound	ANP32A	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
39863	12713	 7021	trichostatin A	Compound	TP53I11	mRNA	0	1	15452378	The microarray analysis revealed that 8 genes including collagen type 1, alpha2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), integrin, alpha7 (ITGA7), basigin (BSG), quiescin Q6 (QSCN6), superoxide dismutase 3, extracellular (SOD3), nerve growth factor receptor (NGFR), and p53-induced protein (PIG11) exhibited substantial induction (ratio >2.0) after TSA treatment in multiple cell lines.
   40	12713	11396	trichostatin A	Compound	CCNA2	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
40975	12713	 4582	trichostatin A	Compound	NOS3	mRNA	1	-1	14656742	TSA treatment of HUVEC markedly decreases steady-state levels of eNOS mRNA without affecting transcription rate as measured by nuclear runoff.100
41797	12713	 4327	trichostatin A	Compound	IL11RA	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
42200	12713	 2152	trichostatin A	Compound	HLA-DRA	mRNA	0	1	11533238	additionally, mutation of the Yy1 binding site prevented repression of the promoter by HDAC1 and partially prevented activation of the promoter by trichostatin A
42572	12713	 5280	trichostatin A	Compound	VGF	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
42766	12713	19447	trichostatin A	Compound	SOD3	mRNA	0	1	15452378	The microarray analysis revealed that 8 genes including collagen type 1, alpha2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), integrin, alpha7 (ITGA7), basigin (BSG), quiescin Q6 (QSCN6), superoxide dismutase 3, extracellular (SOD3), nerve growth factor receptor (NGFR), and p53-induced protein (PIG11) exhibited substantial induction (ratio >2.0) after TSA treatment in multiple cell lines.
42900	12713	 7577	trichostatin A	Compound	HSP90AA1	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
43491	12713	10899	trichostatin A	Compound	TGFB1	mRNA	0	1	10585285	\IGF-II enhances trichostatin A-induced TGFbeta1 and p21(Waf1,Cip1, sdi1) expression in Hep3B cells.\
43763	12713	11860	trichostatin A	Compound	G0S2	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
44161	12713	 6531	trichostatin A	Compound	CCNE1	mRNA	0	1	12414652	The cyclin E promoter was activated by p300 and the histone deacetylase inhibitor trichostatin A.
45202	12713	 6096	trichostatin A	Compound	EPHX3	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
45281	12713	 8651	trichostatin A	Compound	IGFBP2	mRNA	0	1	15452378	The microarray analysis revealed that 8 genes including collagen type 1, alpha2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), integrin, alpha7 (ITGA7), basigin (BSG), quiescin Q6 (QSCN6), superoxide dismutase 3, extracellular (SOD3), nerve growth factor receptor (NGFR), and p53-induced protein (PIG11) exhibited substantial induction (ratio >2.0) after TSA treatment in multiple cell lines.
45743	12713	19032	trichostatin A	Compound	ACTN4	mRNA	1	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
45939	12713	11879	trichostatin A	Compound	CRABP2	mRNA	0	-1	10746741	trichostatin A (TSA), an inhibitor of histone deacetylases Complex hybridization of cDNA arrays revealed repression of Bcl-xL, CRAB2 and TFIID/TAFII31 as well as induction of p21waf1/cip1, GATA-2, hsp86, ID1, ID2 and ID3 mRNA expression, which could be verified by Northern blotting.
46077	12713	20121	trichostatin A	Compound	CUL4A	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
46440	12713	10422	trichostatin A	Compound	RHOA	mRNA	0	-1	12445420	RhoA, a key mediator in the development of the actin cytoskeleton, decreased following TSA exposure.
47626	12713	15709	trichostatin A	Compound	UXT	mRNA	0	1	17761951	We found that ART-27 gene expression is repressed and its promoter is histone H3-K27 tri-methylated in human embryonic kidney cells, but not prostate cells, and the histone deacetylase inhibitor, trichostatin A, relieves this inhibition.
47738	12713	19176	trichostatin A	Compound	CRLF1	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
48530	12713	 2627	trichostatin A	Compound	CDK2	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
49092	12713	 3580	trichostatin A	Compound	KYNU	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
49331	12713	13782	trichostatin A	Compound	ACTR3	mRNA	0	-1	12445420	TSA prevented new actin filament formation by down-regulation of two nucleating proteins, actin related protein 2 (Arp2) and Arp3, and by up-regulation of adducin like protein 70 (ADDL70) and gelsolin, two capping proteins.
49820	12713	20100	trichostatin A	Compound	COL11A2	mRNA	0	1	16734381	Further experiments showed that Sp1, Sp3, CREB-binding protein (CBP), p300, and histone deacetylase (HDAC) were physically associated and HDAC inhibitors (trichostatin A or NaB) upregulated COL11A2 promoter activity and endogenous gene expression.
 4990	12713	 3807	trichostatin A	Compound	LMCD1	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
50055	12713	 6917	trichostatin A	Compound	CCK	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
50985	12713	13884	trichostatin A	Compound	CDKN1A	mRNA	1	1	10585285	\IGF-II enhances trichostatin A-induced TGFbeta1 and p21(Waf1,Cip1, sdi1) expression in Hep3B cells.\
51325	12713	13274	trichostatin A	Compound	CDC42BPB	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
51621	12713	 5673	trichostatin A	Compound	ID1	mRNA	0	1	10746741	trichostatin A (TSA), an inhibitor of histone deacetylases Complex hybridization of cDNA arrays revealed repression of Bcl-xL, CRAB2 and TFIID/TAFII31 as well as induction of p21waf1/cip1, GATA-2, hsp86, ID1, ID2 and ID3 mRNA expression, which could be verified by Northern blotting.
51848	12713	 2831	trichostatin A	Compound	BAD	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
51909	12713	 8549	trichostatin A	Compound	TAF9	mRNA	0	-1	10746741	trichostatin A (TSA), an inhibitor of histone deacetylases Complex hybridization of cDNA arrays revealed repression of Bcl-xL, CRAB2 and TFIID/TAFII31 as well as induction of p21waf1/cip1, GATA-2, hsp86, ID1, ID2 and ID3 mRNA expression, which could be verified by Northern blotting.
51976	12713	 2340	trichostatin A	Compound	DNMT3L	mRNA	0	1	15015937	Treatment of Dnmt3L non-expressive cell lines with deacetylase inhibitor trichostatin A and methyltransferase inhibitor 5-aza-2p-deoxycytidine induced the expression of Dnmt3L mRNA
52001	12713	19733	trichostatin A	Compound	HSPA2	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
52871	12713	 5973	trichostatin A	Compound	PAWR	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
53074	12713	16278	trichostatin A	Compound	ID2	mRNA	0	1	10746741	trichostatin A (TSA), an inhibitor of histone deacetylases Complex hybridization of cDNA arrays revealed repression of Bcl-xL, CRAB2 and TFIID/TAFII31 as well as induction of p21waf1/cip1, GATA-2, hsp86, ID1, ID2 and ID3 mRNA expression, which could be verified by Northern blotting.
53892	12713	14838	trichostatin A	Compound	NKIRAS2	mRNA	-1	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
55526	12713	17318	trichostatin A	Compound	KRT23	mRNA	0	1	11135429	K23 mRNA was highly induced by NaBu in different pancreatic cancer cells. Trichostatin A (TSA), a potent and specific inhibitor of histone deacetylase, similarly induced K23 mRNA expression.
55581	12713	16323	trichostatin A	Compound	BSG	mRNA	0	1	15452378	The microarray analysis revealed that 8 genes including collagen type 1, alpha2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), integrin, alpha7 (ITGA7), basigin (BSG), quiescin Q6 (QSCN6), superoxide dismutase 3, extracellular (SOD3), nerve growth factor receptor (NGFR), and p53-induced protein (PIG11) exhibited substantial induction (ratio >2.0) after TSA treatment in multiple cell lines.
55665	12713	 1243	trichostatin A	Compound	SURF1	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
55826	12713	10561	trichostatin A	Compound	TDP2	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
55872	12713	 5857	trichostatin A	Compound	BHLHE40	mRNA	0	1	15970569	From full text table 4: Reagents regulating expression of the BHLHB2 and BHLHB3 genes
55920	12713	13033	trichostatin A	Compound	MBD2	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
56221	12713	 6642	trichostatin A	Compound	CENPF	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
56539	12713	12647	trichostatin A	Compound	S100A9	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
56715	12713	 2793	trichostatin A	Compound	SBF1	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
58552	12713	  497	trichostatin A	Compound	SIRT1	mRNA	-1	-1	14523559	The Sir2 histone deacetylase gene family consists of seven mammalian sirtuins (SIRTs) which are NAD-dependent histone/protein deacetylases. Sir2 proteins regulate, for instance, genome stability by chromatin silencing in yeast. In mammals, their function is still largely unknown. Due to the NAD+ dependency, Sir2 might be the link between metabolic activity and histone/protein acetylation. Regulation of gene expression also seems to play an important role in Sir2 functions, since increasing the dosage of Sir2 genes increases genome stability in yeast and Caenorhabditis elegans. We observed that the modification of histone/protein acetylation status by several class I and II histone deacetylase (HDAC) inhibitors induces differential changes in gene expression profiles of seven SIRT mRNAs in cultured neuronal cells. SIRT2, SIRT4 and SIRT7 were upregulated, whereas SIRT1, SIRT5 and SIRT6 were downregulated by trichostatin A (TSA) and n-butyrate. The upregulation of SIRT mRNAs was inhibited by actinomycin D. Interestingly, the regulation of SIRT mRNAs was highly similar both in mouse Neuro-2a neuroblastoma cells and post-mitotic rat primary hippocampal and cerebellar granule neurons. Using a chromatin immunoprecipitation technique, we showed that the upregulation of SIRT2 expression with TSA is related to the hyperacetylation of DNA-bound histone H4 within the first 500 bp upstream of the transcription start site of the SIRT2 gene. Chemically different types of HDAC inhibitors, such as TSA, apicidin, SAHA, M344 and n-butyrate induced remarkably similar responses in SIRT1-7 mRNA expression patterns. Differential responses in SIRT mRNA expression profiles indicate that the expression of the Sir2 family of genes is selectively regulated and dependent on histone/protein acetylation status.
58831	12713	 9550	trichostatin A	Compound	CDK4	mRNA	1	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
 5903	12713	 5636	trichostatin A	Compound	AURKA	mRNA	1	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
59466	12713	16089	trichostatin A	Compound	SLC23A1	mRNA	0	1	16357148	Table 1. NHBE and A549 cells present different gene expression profiles in response to trichostatin A treatment (Table for NHBE up-regulated genes)
59509	12713	 7727	trichostatin A	Compound	DNAJC9	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
60864	12713	17451	trichostatin A	Compound	GATA2	mRNA	0	1	10746741	trichostatin A (TSA), an inhibitor of histone deacetylases Complex hybridization of cDNA arrays revealed repression of Bcl-xL, CRAB2 and TFIID/TAFII31 as well as induction of p21waf1/cip1, GATA-2, hsp86, ID1, ID2 and ID3 mRNA expression, which could be verified by Northern blotting.
62037	12713	16156	trichostatin A	Compound	PTPN12	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
62171	12713	 4718	trichostatin A	Compound	QSOX1	mRNA	0	1	15452378	The microarray analysis revealed that 8 genes including collagen type 1, alpha2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), integrin, alpha7 (ITGA7), basigin (BSG), quiescin Q6 (QSCN6), superoxide dismutase 3, extracellular (SOD3), nerve growth factor receptor (NGFR), and p53-induced protein (PIG11) exhibited substantial induction (ratio >2.0) after TSA treatment in multiple cell lines.
62761	12713	 5282	trichostatin A	Compound	PERP	mRNA	0	1	16357148	Genes up regulated in A549 in response to trichostatin A (Table 1)
63083	12713	18389	trichostatin A	Compound	SAA2	mRNA	0	1	15812237	In this study, we showed by Northern blot a synergistic induction of the acute phase protein gene SAA2 with a combination of deacetylase inhibitors (Trichostatin A or NaBu) and IL-1beta
64029	12713	15079	trichostatin A	Compound	OPRM1	mRNA	0	1	18950606	Taken together, these results suggested that TSA enhanced neuronal MOR gene expression at the transcriptional level. RT-PCR analysis further revealed that TSA also decreased the steady-state level of MOR mRNA in a time-dependent manner by enhancing its instability.
64355	12713	 6572	trichostatin A	Compound	SAP18	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
 7407	12713	 5847	trichostatin A	Compound	RAI14	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
 8582	12713	 3562	trichostatin A	Compound	TEX261	mRNA	0	-1	16357148	Genes down regulated in A549 in response to trichostatin A (Table 1
 8829	12713	 5001	trichostatin A	Compound	EPS8	mRNA	0	-1	14699156	TSA reduced the expression of Eps8 in a dose- and time-dependent manner
 8969	12713	14707	trichostatin A	Compound	TGFA	mRNA	0	-1	16357148	Genes down regulated in bronchial epithelial cells in response to trichostatin A (Table 1)
 9247	12713	11654	trichostatin A	Compound	DRG1	mRNA	0	1	10676663	Moreover, the expression of Drg-1 is controlled by several known cell differentiation reagents, such as ligands of peroxisome proliferator-activated receptor gamma (troglitazone and BRL46593) and of retinoid X receptor (LG268), and histone deacetylase inhibitors (trichostatin A, suberoylanilide hydroxamic acid, and tributyrin).
17332	 7634	 9108	flutamide	Compound	CYP1B1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
21214	 7634	  933	flutamide	Compound	GSTM4	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
21322	 7634	11773	flutamide	Compound	CHN1	mRNA	0	-1	16611858	TABLE 2 Expression data for AhR ligand-responsive genes
22782	 7634	 3531	flutamide	Compound	GSTA2	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
25763	 7634	   19	flutamide	Compound	CYP1A2	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
25855	 7634	19027	flutamide	Compound	HMOX1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
26638	 7634	 7434	flutamide	Compound	GPX2	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
27668	 7634	 7785	flutamide	Compound	SLC13A3	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
28359	 7634	18287	flutamide	Compound	ABCC3	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
28884	 7634	 8621	flutamide	Compound	NQO1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
29755	 7634	   52	flutamide	Compound	FMO1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
33277	 7634	11068	flutamide	Compound	UGT1A3	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
33600	 7634	 3700	flutamide	Compound	EPHX1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
 3496	 7634	14681	flutamide	Compound	GSR	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
 3693	 7634	  338	flutamide	Compound	Ugt2b	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
37174	 7634	 6689	flutamide	Compound	Akr7a3	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
38760	 7634	12605	flutamide	Compound	GSTM1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
40842	 7634	12023	flutamide	Compound	SLC34A2	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
43061	 7634	17347	flutamide	Compound	COMT	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
45863	 7634	 9262	flutamide	Compound	CYP1A1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
48058	 7634	11629	flutamide	Compound	FOS	mRNA	0	-1	16611858	TABLE 2 Expression data for AhR ligand-responsive genes
48745	 7634	 6352	flutamide	Compound	Cyp3a23/3a1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
51403	 7634	 5563	flutamide	Compound	SLC1A3	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
51465	 7634	 7810	flutamide	Compound	ALDH1A1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
51936	 7634	 1178	flutamide	Compound	NR4A1	mRNA	0	-1	16611858	TABLE 2 Expression data for AhR ligand-responsive genes
53860	 7634	 2903	flutamide	Compound	SLC1A2	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
56797	 7634	14674	flutamide	Compound	MGST2	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
57225	 7634	 2424	flutamide	Compound	CYP17A1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
57958	 7634	 1766	flutamide	Compound	GSTA3	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
58327	 7634	 5913	flutamide	Compound	CYR61	mRNA	0	-1	16611858	TABLE 2 Expression data for AhR ligand-responsive genes
59437	 7634	10822	flutamide	Compound	ABCG5	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
61497	 7634	11419	flutamide	Compound	CYP3A4	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
62181	 7634	 6282	flutamide	Compound	Aldh1a7	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
63440	 7634	 7303	flutamide	Compound	UGT1A1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
65657	 7634	10845	flutamide	Compound	UGT2A1	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
65786	 7634	11283	flutamide	Compound	ME1	mRNA	0	1	16611858	TABLE 2 Expression data for AhR ligand-responsive genes
 7233	 7634	16823	flutamide	Compound	ALAS2	mRNA	1	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
 8544	 7634	 6907	flutamide	Compound	GSTM2	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
 8578	 7634	16439	flutamide	Compound	UGT1A6	mRNA	0	1	16611858	TABLE 2 Expression data for AhR ligand-responsive genes
 8767	 7634	  406	flutamide	Compound	ABCC4	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
 9315	 7634	13069	flutamide	Compound	Gstt3	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
 9891	 7634	19747	flutamide	Compound	Cyp2b15	mRNA	0	-1	16611858	FIG. 7. Effect of FLU on ADME gene expression. Fifty ADME genes found in FLUps 343-gene expression profile were agglomeratively clustered using a cosine correlation against all the compound treatments, where yellow and blue represent up- and down-regulated genes, with color saturation at +3.2- and 3.2-fold, respectively. Black arrows (right) represent dose elevation from top to bottom for each compound.
17605	 7600	15035	Retinol acetate	Compound	FZD3	mRNA	-1	1	16772331	we examined gene expression changes in the developing murine limb after 3 h of culture with teratogenic concentrations of vitamin A. Embryonic day 12 CD-1 limbs were cultured in the absence or presence of vitamin A (retinol acetate) at 1.25 and 62.5muM (n = 5). TABLE 4 Genes Significantly Upregulated between 0 and 62.5M Retinol.
23313	 7600	 7455	Retinol acetate	Compound	CTSB	mRNA	0	1	16772331	we examined gene expression changes in the developing murine limb after 3 h of culture with teratogenic concentrations of vitamin A. Embryonic day 12 CD-1 limbs were cultured in the absence or presence of vitamin A (retinol acetate) at 1.25 and 62.5muM (n = 5). TABLE 3 Genes Significantly Upregulated between 0 and 6.25M Retinol.
35174	 7600	17804	Retinol acetate	Compound	NOTCH1	mRNA	0	1	16772331	we examined gene expression changes in the developing murine limb after 3 h of culture with teratogenic concentrations of vitamin A. Embryonic day 12 CD-1 limbs were cultured in the absence or presence of vitamin A (retinol acetate) at 1.25 and 62.5muM (n = 5). TABLE 3 Genes Significantly Upregulated between 0 and 6.25M Retinol.
44154	 7600	 6531	Retinol acetate	Compound	CCNE1	mRNA	0	1	16772331	we examined gene expression changes in the developing murine limb after 3 h of culture with teratogenic concentrations of vitamin A. Embryonic day 12 CD-1 limbs were cultured in the absence or presence of vitamin A (retinol acetate) at 1.25 and 62.5muM (n = 5). TABLE 4 Genes Significantly Upregulated between 0 and 62.5M Retinol.
48787	 7600	17731	Retinol acetate	Compound	DCN	mRNA	-1	1	16772331	we examined gene expression changes in the developing murine limb after 3 h of culture with teratogenic concentrations of vitamin A. Embryonic day 12 CD-1 limbs were cultured in the absence or presence of vitamin A (retinol acetate) at 1.25 and 62.5muM (n = 5). TABLE 4 Genes Significantly Upregulated between 0 and 62.5M Retinol.
62957	 7600	 7195	Retinol acetate	Compound	GADD45A	mRNA	-1	1	16772331	we examined gene expression changes in the developing murine limb after 3 h of culture with teratogenic concentrations of vitamin A. Embryonic day 12 CD-1 limbs were cultured in the absence or presence of vitamin A (retinol acetate) at 1.25 and 62.5muM (n = 5). TABLE 3 Genes Significantly Upregulated between 0 and 6.25M Retinol.
 9539	 7600	20162	Retinol acetate	Compound	SATB1	mRNA	-1	1	16772331	we examined gene expression changes in the developing murine limb after 3 h of culture with teratogenic concentrations of vitamin A. Embryonic day 12 CD-1 limbs were cultured in the absence or presence of vitamin A (retinol acetate) at 1.25 and 62.5muM (n = 5). TABLE 4 Genes Significantly Upregulated between 0 and 62.5M Retinol.
19712	 9358	16486	IFRD1	Protein	SPP1	mRNA	1	-1	16204248	Here we show that TIS7 has the capacity to inhibit OPN expression also through Lef-1, the second identified OPN regulatory element.
24878	 9358	 5863	IFRD1	Protein	MYC	mRNA	0	-1	16204248	TIS7 homologous deletion in mouse embryonic fibroblasts increased not only the TOPflash reporter gene transcriptional activity but also the expression of c-Myc and OPN
30108	 9358	20193	IFRD1	Protein	MYOD1	mRNA	0	1	15060170	Loss of TIS7 caused the down-regulation of muscle-specific genes, such as those for MyoD, myogenin, and laminin-alpha2.
55577	 9358	 2257	IFRD1	Protein	LAMA2	mRNA	0	1	15060170	Loss of TIS7 caused the down-regulation of muscle-specific genes, such as those for MyoD, myogenin, and laminin-alpha2.
 5931	 9358	 1713	IFRD1	Protein	MYOG	mRNA	0	1	15060170	Loss of TIS7 caused the down-regulation of muscle-specific genes, such as those for MyoD, myogenin, and laminin-alpha2.
14539	10032	  850	resveratrol	Compound	MITF	mRNA	0	-1	12485436	Dihydrolipoic acid, lipoic acid, and resveratrol reduced microphthalmia-associated transcription factor and tyrosinase promoter activities.
17897	10032	 2286	resveratrol	Compound	G6PC	mRNA	0	-1	16626303	resveratrol reverses insulin effects on phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, fatty acid synthase and glucokinase
19901	10032	14849	resveratrol	Compound	TGFB2	mRNA	-1	1	11813992	In addition, resveratrol significantly elevated the expression of the growth inhibitor TGF-beta2 mRNA without changes in TGF-beta1 and TGF-beta3 expression.
21369	10032	13892	resveratrol	Compound	CTSD	mRNA	0	1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
22750	10032	 4841	resveratrol	Compound	CCR6	mRNA	0	1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
23642	10032	17594	resveratrol	Compound	CCNG1	mRNA	0	1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
23752	10032	 6636	resveratrol	Compound	BCL2L1	mRNA	0	-1	19047049	Further analyses indicate that activation of SIRT1 (deacetylase) by resveratrol (a natural antioxidant) induces SIRT1-p300 association and acetyltransferase inactivation, leading to deacetylation of HA/CD44-induced beta-catenin and NFkappaB-p65, inhibition of beta-catenin-T-cell factor/lymphocyte enhancer factor and NFkappaB-specific transcriptional activation, and the impairment of MDR1 and Bcl-x(L) gene expression.
27252	10032	10644	resveratrol	Compound	ASF1B	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
27317	10032	14255	resveratrol	Compound	DNAH3	mRNA	0	1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
28288	10032	 6449	resveratrol	Compound	CFLAR	mRNA	1	1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
 3181	10032	16645	resveratrol	Compound	CCND1	mRNA	0	1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
32442	10032	20190	resveratrol	Compound	ABCB1	mRNA	0	-1	19047049	Further analyses indicate that activation of SIRT1 (deacetylase) by resveratrol (a natural antioxidant) induces SIRT1-p300 association and acetyltransferase inactivation, leading to deacetylation of HA/CD44-induced beta-catenin and NFkappaB-p65, inhibition of beta-catenin-T-cell factor/lymphocyte enhancer factor and NFkappaB-specific transcriptional activation, and the impairment of MDR1 and Bcl-x(L) gene expression.
32949	10032	11686	resveratrol	Compound	GTF2I	mRNA	-1	1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
 3532	10032	11225	resveratrol	Compound	MCL1	mRNA	0	1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
35904	10032	 2894	resveratrol	Compound	GPR133	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
36242	10032	 7572	resveratrol	Compound	KCNC4	mRNA	0	1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
38413	10032	 7762	resveratrol	Compound	FCHSD2	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
 4099	10032	12857	resveratrol	Compound	RASGRF1	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
42083	10032	13115	resveratrol	Compound	EGR1	mRNA	-1	1	12690110	resveratrol selectively up-regulates Egr1 by an Erk1/2-dependent mechanism.
44639	10032	10343	resveratrol	Compound	PRB3	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
45352	10032	14987	resveratrol	Compound	BCL2	mRNA	1	-1	12060119	In addition, Bcl-2 expression was also inhibited by resveratrol.
45737	10032	18451	resveratrol	Compound	TYR	mRNA	0	-1	12485436	Dihydrolipoic acid, lipoic acid, and resveratrol reduced microphthalmia-associated transcription factor and tyrosinase promoter activities.
45872	10032	 9262	resveratrol	Compound	CYP1A1	mRNA	0	-1	15162144	Supporting this result, resveratrol was shown to inhibit CYP1A1 and CYP1B1 gene expression, as measured by real-time reverse transcriptase-polymerase chain reaction.
46645	10032	 3471	resveratrol	Compound	IL1B	mRNA	0	-1	18424637	In coronary arteries of cigarette smoke-exposed rats, the mRNA expression of iNOS, ICAM-1, IL-6, IL-1b, and TNF-a (Fig. 6, A-E) significantly increased. The expression of these inflammatory markers was significantly attenuated by in vivo resveratrol treatment (Fig. 6, A-E). The expression of SIRT1 was significantly increased by resveratrol treatment (Fig. 6F).
48107	10032	13471	resveratrol	Compound	BIRC5	mRNA	0	1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
48860	10032	18519	resveratrol	Compound	COL2A1	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
49239	10032	19934	resveratrol	Compound	CDH23	mRNA	0	1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
49375	10032	18288	resveratrol	Compound	UCP3	mRNA	0	-1	17884810	Agents activating SIRT1, such as resveratrol, repress ucp3 gene expression.
49694	10032	 6430	resveratrol	Compound	MDM2	mRNA	1	1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
 5114	10032	 2649	resveratrol	Compound	DNAJB1	mRNA	0	1	15767336	Finally, resveratrol did not oppose all transcriptional changes induced by androgen. A subset of 153 genes was up-regulated by both resveratrol and androgen. However, many of these genes, such as JUNB, HSP40, SERP1, and STCH seem to reflect cellular stress.
51162	10032	11839	resveratrol	Compound	PCK1	mRNA	0	-1	16626303	resveratrol reverses insulin effects on phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, fatty acid synthase and glucokinase
51676	10032	  219	resveratrol	Compound	FASLG	mRNA	-1	1	 9680369	We also show that resveratrol treatment enhances CD95L expression on HL60 cells, as well as T47D breast carcinoma cells, and that resveratrol-mediated cell death is specifically CD95-signaling dependent.
51926	10032	 9802	resveratrol	Compound	IL6ST	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
54041	10032	 5118	resveratrol	Compound	NOS2	mRNA	0	-1	18424637	In coronary arteries of cigarette smoke-exposed rats, the mRNA expression of iNOS, ICAM-1, IL-6, IL-1b, and TNF-a (Fig. 6, A-E) significantly increased. The expression of these inflammatory markers was significantly attenuated by in vivo resveratrol treatment (Fig. 6, A-E). The expression of SIRT1 was significantly increased by resveratrol treatment (Fig. 6F).
54332	10032	16263	resveratrol	Compound	CD84	mRNA	0	1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
55222	10032	 4543	resveratrol	Compound	FGF23	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
56658	10032	16427	resveratrol	Compound	EFNA1	mRNA	0	1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
56780	10032	18995	resveratrol	Compound	FASN	mRNA	0	-1	16626303	resveratrol reverses insulin effects on phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, fatty acid synthase and glucokinase
57339	10032	 4298	resveratrol	Compound	JUNB	mRNA	0	1	15767336	Finally, resveratrol did not oppose all transcriptional changes induced by androgen. A subset of 153 genes was up-regulated by both resveratrol and androgen. However, many of these genes, such as JUNB, HSP40, SERP1, and STCH seem to reflect cellular stress.
59667	10032	 7590	resveratrol	Compound	GCK	mRNA	0	-1	16626303	resveratrol reverses insulin effects on phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, fatty acid synthase and glucokinase
 6033	10032	 1338	resveratrol	Compound	SEMA6A	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
60896	10032	  176	resveratrol	Compound	UBE2D3	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
61269	10032	 1552	resveratrol	Compound	ODC1	mRNA	1	1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
61979	10032	 7235	resveratrol	Compound	HSPA13	mRNA	0	1	15767336	Finally, resveratrol did not oppose all transcriptional changes induced by androgen. A subset of 153 genes was up-regulated by both resveratrol and androgen. However, many of these genes, such as JUNB, HSP40, SERP1, and STCH seem to reflect cellular stress.
62195	10032	17946	resveratrol	Compound	MAD2L1	mRNA	0	-1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
62943	10032	 7195	resveratrol	Compound	GADD45A	mRNA	-1	-1	16081268	Resveratrol increased (+) and decreased (-) gene expression associated with apoptosis (Birc5+, Cash+, Mcl-1+, Mdm2+, Rpa-like+), cellular proliferation (Ctsd+, Mdm2+, Egr1+, ODC+) and cell cycle (cyclin D+, cyclin g+, Gadd45a-, Mad2l-, Mdm2+).
63874	10032	12543	resveratrol	Compound	IGFBP1	mRNA	-1	1	16236254	This effect is mimicked by 20muM resveratrol
66168	10032	 6916	resveratrol	Compound	RAC3	mRNA	0	-1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
  722	10032	12268	resveratrol	Compound	P4HB	mRNA	0	1	17804521	Table 2: Genes changed by >2 fold in response to 1 uM resveratrol in human fibroblast cell line F0603
 7655	10032	 7875	resveratrol	Compound	IFIT3	mRNA	1	-1	17086191	Upregulation of complement, which occurs in obese and aged mice, was also observed in the HCR
 9392	10032	17289	resveratrol	Compound	SERP1	mRNA	0	1	15767336	Finally, resveratrol did not oppose all transcriptional changes induced by androgen. A subset of 153 genes was up-regulated by both resveratrol and androgen. However, many of these genes, such as JUNB, HSP40, SERP1, and STCH seem to reflect cellular stress.
20341	17811	 2815	RPS29	Protein	TP53	mRNA	0	1	12705879	downregulation of the expression of inhibitors of apoptosis proteins (IAPs) Bcl-2, Bcl-X(L), and survivin and upregulation of pro-apoptotic p53 and Bax
23784	17811	 6636	RPS29	Protein	BCL2L1	mRNA	0	-1	12705879	downregulation of the expression of inhibitors of apoptosis proteins (IAPs) Bcl-2, Bcl-X(L), and survivin and upregulation of pro-apoptotic p53 and Bax
 3426	17811	10915	RPS29	Protein	BAX	mRNA	0	1	12705879	downregulation of the expression of inhibitors of apoptosis proteins (IAPs) Bcl-2, Bcl-X(L), and survivin and upregulation of pro-apoptotic p53 and Bax
45364	17811	14987	RPS29	Protein	BCL2	mRNA	1	-1	12705879	downregulation of the expression of inhibitors of apoptosis proteins (IAPs) Bcl-2, Bcl-X(L), and survivin and upregulation of pro-apoptotic p53 and Bax
48116	17811	13471	RPS29	Protein	BIRC5	mRNA	0	-1	12705879	downregulation of the expression of inhibitors of apoptosis proteins (IAPs) Bcl-2, Bcl-X(L), and survivin and upregulation of pro-apoptotic p53 and Bax
12405	18088	 2742	ciprofibrate	Compound	APEX1	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
13089	18088	 7202	ciprofibrate	Compound	LTA	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
13373	18088	10696	ciprofibrate	Compound	JUN	mRNA	0	1	12883078	However, the increase in proliferation was greater in ciprofibrate-fed wild type mice than in ciprofibrate-fed p50 -/- mice The c-Jun and JunB mRNA levels were higher in untreated p50 -/- mice than in untreated control mice; c-Jun mRNA levels increased whereas JunB mRNA levels decreased in both groups after ciprofibrate treatment.
13545	18088	 3789	ciprofibrate	Compound	IGF1	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
13635	18088	 1438	ciprofibrate	Compound	VEGFA	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
19330	18088	16719	ciprofibrate	Compound	DNAJA1	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
19515	18088	 8018	ciprofibrate	Compound	CSNK1D	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
19599	18088	 5712	ciprofibrate	Compound	BCL6	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
21080	18088	18920	ciprofibrate	Compound	VEGFC	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
 2124	18088	 8607	ciprofibrate	Compound	MGMT	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
21948	18088	19286	ciprofibrate	Compound	XRCC5	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
23043	18088	 5147	ciprofibrate	Compound	NUPR1	mRNA	1	1	12851464	Fibrate class hypolipidemic drugs such as ciprofibrate activate the peroxisome proliferator-activated receptor-alpha (PPARalpha), which is involved in processes including lipid metabolism and hepatocyte proliferation in rodents. We examined the effects of ciprofibrate (50 mg/kg body wt per day for 60 days) on liver gene expression in rats using cDNA microarrays. The 60-day dosing period was chosen to elucidate both the metabolic and proliferative actions of this substance, while avoiding confounding effects from the hepatic carcinogenesis seen during more long-term stimulation. Ciprofibrate changed the expression of many genes including previously known PPARalpha agonist-responsive genes involved in processes such as lipid metabolism and inflammatory responses. In addition, many novel candidate genes involved in sugar metabolism, transcription, signal transduction, cell proliferation, and stress responses appeared to be differentially regulated in ciprofibrate-dosed rats. Ciprofibrate also resulted in significant increases in liver weight and hepatocyte proliferation. The cDNA microarray results were confirmed by Northern blot analysis for selected genes. This study thus identifies many genes that appear to be differentially regulated in ciprofibrate-dosed rats, and some of these are potential targets of PPARalpha. The functional diversity of these candidate genes suggests that most of them are likely to be differentially regulated as indirect consequence of the many processes affected by ciprofibrate in rodent liver. Although caution is advisable in the interpretation of genome-wide expression data, the genes identified in the present study provide candidates for further studies that may give new insight into the mechanisms of action of peroxisome proliferators.
  232	18088	15821	ciprofibrate	Compound	HSPA9	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
23950	18088	11829	ciprofibrate	Compound	CAPNS1	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
26670	18088	 8245	ciprofibrate	Compound	TIAL1	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
30118	18088	  789	ciprofibrate	Compound	SHC1	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
32318	18088	10525	ciprofibrate	Compound	RECQL4	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
32330	18088	15377	ciprofibrate	Compound	POLD1	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
32887	18088	11449	ciprofibrate	Compound	CASP9	mRNA	1	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
34093	18088	  573	ciprofibrate	Compound	CRY2	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
35607	18088	 1571	ciprofibrate	Compound	RBL2	mRNA	-1	1	12851464	Fibrate class hypolipidemic drugs such as ciprofibrate activate the peroxisome proliferator-activated receptor-alpha (PPARalpha), which is involved in processes including lipid metabolism and hepatocyte proliferation in rodents. We examined the effects of ciprofibrate (50 mg/kg body wt per day for 60 days) on liver gene expression in rats using cDNA microarrays. The 60-day dosing period was chosen to elucidate both the metabolic and proliferative actions of this substance, while avoiding confounding effects from the hepatic carcinogenesis seen during more long-term stimulation. Ciprofibrate changed the expression of many genes including previously known PPARalpha agonist-responsive genes involved in processes such as lipid metabolism and inflammatory responses. In addition, many novel candidate genes involved in sugar metabolism, transcription, signal transduction, cell proliferation, and stress responses appeared to be differentially regulated in ciprofibrate-dosed rats. Ciprofibrate also resulted in significant increases in liver weight and hepatocyte proliferation. The cDNA microarray results were confirmed by Northern blot analysis for selected genes. This study thus identifies many genes that appear to be differentially regulated in ciprofibrate-dosed rats, and some of these are potential targets of PPARalpha. The functional diversity of these candidate genes suggests that most of them are likely to be differentially regulated as indirect consequence of the many processes affected by ciprofibrate in rodent liver. Although caution is advisable in the interpretation of genome-wide expression data, the genes identified in the present study provide candidates for further studies that may give new insight into the mechanisms of action of peroxisome proliferators.
37553	18088	 6614	ciprofibrate	Compound	HSPA1B	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
38952	18088	17203	ciprofibrate	Compound	RAD51C	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
41113	18088	 3708	ciprofibrate	Compound	SUMO1	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
 4346	18088	 2607	ciprofibrate	Compound	NME3	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
45881	18088	 9262	ciprofibrate	Compound	CYP1A1	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
46452	18088	13874	ciprofibrate	Compound	GPX1	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
47904	18088	12849	ciprofibrate	Compound	BNIP3L	mRNA	-1	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
48192	18088	 8786	ciprofibrate	Compound	FGF18	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
48466	18088	 9763	ciprofibrate	Compound	SMC1A	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
48519	18088	 2627	ciprofibrate	Compound	CDK2	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
  497	18088	16088	ciprofibrate	Compound	GPX4	mRNA	1	1	12851464	Fibrate class hypolipidemic drugs such as ciprofibrate activate the peroxisome proliferator-activated receptor-alpha (PPARalpha), which is involved in processes including lipid metabolism and hepatocyte proliferation in rodents. We examined the effects of ciprofibrate (50 mg/kg body wt per day for 60 days) on liver gene expression in rats using cDNA microarrays. The 60-day dosing period was chosen to elucidate both the metabolic and proliferative actions of this substance, while avoiding confounding effects from the hepatic carcinogenesis seen during more long-term stimulation. Ciprofibrate changed the expression of many genes including previously known PPARalpha agonist-responsive genes involved in processes such as lipid metabolism and inflammatory responses. In addition, many novel candidate genes involved in sugar metabolism, transcription, signal transduction, cell proliferation, and stress responses appeared to be differentially regulated in ciprofibrate-dosed rats. Ciprofibrate also resulted in significant increases in liver weight and hepatocyte proliferation. The cDNA microarray results were confirmed by Northern blot analysis for selected genes. This study thus identifies many genes that appear to be differentially regulated in ciprofibrate-dosed rats, and some of these are potential targets of PPARalpha. The functional diversity of these candidate genes suggests that most of them are likely to be differentially regulated as indirect consequence of the many processes affected by ciprofibrate in rodent liver. Although caution is advisable in the interpretation of genome-wide expression data, the genes identified in the present study provide candidates for further studies that may give new insight into the mechanisms of action of peroxisome proliferators.
53572	18088	 8105	ciprofibrate	Compound	CDC123	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
55200	18088	 1810	ciprofibrate	Compound	MT1F	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
56310	18088	12505	ciprofibrate	Compound	CRADD	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
57314	18088	 4298	ciprofibrate	Compound	JUNB	mRNA	0	-1	12883078	However, the increase in proliferation was greater in ciprofibrate-fed wild type mice than in ciprofibrate-fed p50 -/- mice The c-Jun and JunB mRNA levels were higher in untreated p50 -/- mice than in untreated control mice; c-Jun mRNA levels increased whereas JunB mRNA levels decreased in both groups after ciprofibrate treatment.
58004	18088	10663	ciprofibrate	Compound	MATK	mRNA	0	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
58373	18088	 6053	ciprofibrate	Compound	CAT	mRNA	-1	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
60157	18088	15665	ciprofibrate	Compound	HTATIP2	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
61253	18088	 1552	ciprofibrate	Compound	ODC1	mRNA	1	1	12851464	Fibrate class hypolipidemic drugs such as ciprofibrate activate the peroxisome proliferator-activated receptor-alpha (PPARalpha), which is involved in processes including lipid metabolism and hepatocyte proliferation in rodents. We examined the effects of ciprofibrate (50 mg/kg body wt per day for 60 days) on liver gene expression in rats using cDNA microarrays. The 60-day dosing period was chosen to elucidate both the metabolic and proliferative actions of this substance, while avoiding confounding effects from the hepatic carcinogenesis seen during more long-term stimulation. Ciprofibrate changed the expression of many genes including previously known PPARalpha agonist-responsive genes involved in processes such as lipid metabolism and inflammatory responses. In addition, many novel candidate genes involved in sugar metabolism, transcription, signal transduction, cell proliferation, and stress responses appeared to be differentially regulated in ciprofibrate-dosed rats. Ciprofibrate also resulted in significant increases in liver weight and hepatocyte proliferation. The cDNA microarray results were confirmed by Northern blot analysis for selected genes. This study thus identifies many genes that appear to be differentially regulated in ciprofibrate-dosed rats, and some of these are potential targets of PPARalpha. The functional diversity of these candidate genes suggests that most of them are likely to be differentially regulated as indirect consequence of the many processes affected by ciprofibrate in rodent liver. Although caution is advisable in the interpretation of genome-wide expression data, the genes identified in the present study provide candidates for further studies that may give new insight into the mechanisms of action of peroxisome proliferators.
62947	18088	 7195	ciprofibrate	Compound	GADD45A	mRNA	-1	-1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
63402	18088	14812	ciprofibrate	Compound	ATOX1	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
 6926	18088	 6225	ciprofibrate	Compound	MNAT1	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
 8958	18088	18379	ciprofibrate	Compound	SSR1	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
 9081	18088	17800	ciprofibrate	Compound	EI24	mRNA	0	1	16081524	CYNOMOLGUS MONKEYS were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips.  Data taken from Supplementary table 4.  27 genes upregulated and 22 genes downregulated.  Probesets with p > 0.01 were selected as differentially expressed.
13630	 3091	 1438	ZHX3	Protein	VEGFA	mRNA	0	-1	17056598	Downregulation of COL4A3, COL4A4, angiopoietin 2 and vascular endothelial growth factor (VEGF) during the recovery phase is explained by nuclear entry of newly synthesized ZHX3 protein, whereas podocalyxin and ?1 integrin downregulation are likely related to nuclear entry of small amounts of free ZHX2 during the mild ZHX3 knockdown.
16511	 3091	 9971	ZHX3	Protein	NPHS1	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
19372	 3091	15659	ZHX3	Protein	CDH3	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
19888	 3091	 5366	ZHX3	Protein	CD80	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
20937	 3091	 2184	ZHX3	Protein	ZHX3	mRNA	0	-1	17056598	Both results indicate a negative feedback of ZHX3 protein on its own gene expression.
22038	 3091	16639	ZHX3	Protein	ANGPT2	mRNA	0	-1	17056598	Downregulation of COL4A3, COL4A4, angiopoietin 2 and vascular endothelial growth factor (VEGF) during the recovery phase is explained by nuclear entry of newly synthesized ZHX3 protein, whereas podocalyxin and ?1 integrin downregulation are likely related to nuclear entry of small amounts of free ZHX2 during the mild ZHX3 knockdown.
23305	 3091	 7455	ZHX3	Protein	CTSB	mRNA	0	-1	17056598	Co-transfection of Cathepsin L-A and Cathepsin B with rat ZHX3-pcDNA (Figure 6. panels A, B) caused repression of SEAP acivity with both constructs
33931	 3091	 9325	ZHX3	Protein	COL4A4	mRNA	0	-1	17056598	Downregulation of COL4A3, COL4A4, angiopoietin 2 and vascular endothelial growth factor (VEGF) during the recovery phase is explained by nuclear entry of newly synthesized ZHX3 protein, whereas podocalyxin and ?1 integrin downregulation are likely related to nuclear entry of small amounts of free ZHX2 during the mild ZHX3 knockdown.
35539	 3091	 9783	ZHX3	Protein	Enpep	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
45742	 3091	19032	ZHX3	Protein	ACTN4	mRNA	1	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
46471	 3091	15146	ZHX3	Protein	DAG1	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
46579	 3091	12000	ZHX3	Protein	CD2AP	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
61676	 3091	 7558	ZHX3	Protein	CTSL1	mRNA	0	-1	17056598	Co-transfection of Cathepsin L-A and Cathepsin B with rat ZHX3-pcDNA (Figure 6. panels A, B) caused repression of SEAP acivity with both constructs
65475	 3091	 2618	ZHX3	Protein	Col4a3	mRNA	0	-1	17056598	Downregulation of COL4A3, COL4A4, angiopoietin 2 and vascular endothelial growth factor (VEGF) during the recovery phase is explained by nuclear entry of newly synthesized ZHX3 protein, whereas podocalyxin and ?1 integrin downregulation are likely related to nuclear entry of small amounts of free ZHX2 during the mild ZHX3 knockdown.
  874	 3091	12322	ZHX3	Protein	TJP1	mRNA	0	-1	17056598	During severe knockdown, downregulation of WT1, Lmx1b and neph1 are due to larger amounts of ZHX2 migrating into the nucleus, pax2 due to ZHX1 migration
11718	18375	11709	D-Glucose, anhydrous	Compound	UCP2	mRNA	0	-1	10967113	Chronic elevated glucose reduces the expression levels of the PPAR target genes, uncoupling protein 2 and acyl-CoA oxidase
11970	18375	11518	D-Glucose, anhydrous	Compound	ACOX2	mRNA	0	-1	10967113	Chronic elevated glucose reduces the expression levels of the PPAR target genes, uncoupling protein 2 and acyl-CoA oxidase
12025	18375	15349	D-Glucose, anhydrous	Compound	ELOVL1	mRNA	0	1	12482854	Lipogenesis is hormonally regulated by insulin, and the ability of this hormone to stimulate lipogenesis is mediated by SREPBP-1c. Only the initial condensation reaction catalyzed by LCE is regulated by insulin The mRNA levels of the identified genes responsible for these reactions follow a similar pattern of regulation. The condensing enzyme, LCE, is suppressed in livers of fasted mice and increased in livers from mice that were fasted (low insulin) and refed a high carbohydrate diet(high insulin).
16258	18375	15838	D-Glucose, anhydrous	Compound	PER1	mRNA	0	-1	12213820	glucose-induced down-regulation of Per1 and Per2 expression.
21096	18375	13403	D-Glucose, anhydrous	Compound	ACOX3	mRNA	0	-1	10967113	Chronic elevated glucose reduces the expression levels of the PPAR target genes, uncoupling protein 2 and acyl-CoA oxidase
21339	18375	13132	D-Glucose, anhydrous	Compound	PC	mRNA	1	1	 9852109	Glucose increased PC transcripts from the distal promoter when the insulinoma cells were maintained in 10 mM glucose. We conclude that the proximal promoter of the rat PC gene plays a major role in gluconeogenesis and lipogenesis, whereas the distal promoter is necessary for anaplerosis. Insulin selectively inhibits the expression of the proximal promoter of rat PC
27852	18375	 1166	D-Glucose, anhydrous	Compound	SLC2A1	mRNA	-1	1	10409302	MCGT1 cells [overexpressing GLUT1] grown in normal (8 mM) or elevated (20 mM) glucose had elevated abundance of AR [aldose reductase], PKCalpha, and the native GLUT1 transcripts compared with control cells.
28977	18375	  872	D-Glucose, anhydrous	Compound	ELOVL4	mRNA	0	1	12482854	Lipogenesis is hormonally regulated by insulin, and the ability of this hormone to stimulate lipogenesis is mediated by SREPBP-1c. Only the initial condensation reaction catalyzed by LCE is regulated by insulin The mRNA levels of the identified genes responsible for these reactions follow a similar pattern of regulation. The condensing enzyme, LCE, is suppressed in livers of fasted mice and increased in livers from mice that were fasted (low insulin) and refed a high carbohydrate diet(high insulin).
32053	18375	 1139	D-Glucose, anhydrous	Compound	ELOVL5	mRNA	0	1	12482854	Lipogenesis is hormonally regulated by insulin, and the ability of this hormone to stimulate lipogenesis is mediated by SREPBP-1c. Only the initial condensation reaction catalyzed by LCE is regulated by insulin The mRNA levels of the identified genes responsible for these reactions follow a similar pattern of regulation. The condensing enzyme, LCE, is suppressed in livers of fasted mice and increased in livers from mice that were fasted (low insulin) and refed a high carbohydrate diet(high insulin).
 3917	18375	16026	D-Glucose, anhydrous	Compound	CBL	mRNA	0	-1	12644458	Furthermore, high glucose down-regulated the expression of CAP and Cbl, and insulin-stimulated Cbl phosphorylation, components of an insulin signaling cascade previously characterized in adipocytes.
43543	18375	17125	D-Glucose, anhydrous	Compound	PER2	mRNA	0	-1	12213820	glucose-induced down-regulation of Per1 and Per2 expression.
45191	18375	12952	D-Glucose, anhydrous	Compound	ELOVL6	mRNA	0	1	12482854	Lipogenesis is hormonally regulated by insulin, and the ability of this hormone to stimulate lipogenesis is mediated by SREPBP-1c. Only the initial condensation reaction catalyzed by LCE is regulated by insulin The mRNA levels of the identified genes responsible for these reactions follow a similar pattern of regulation. The condensing enzyme, LCE, is suppressed in livers of fasted mice and increased in livers from mice that were fasted (low insulin) and refed a high carbohydrate diet(high insulin).
45555	18375	 8788	D-Glucose, anhydrous	Compound	GPAM	mRNA	0	1	12413942	Glucose and insulin are anabolic signals which upregulate the transcriptions of a series of lipogenic enzymes to convert excess carbohydrate into triglycerides for efficient energy storage. These enzymes include ATP-citrate lyase (ACL), acetyl-coenzyme A carboxylase (ACC), fatty acid synthase (FAS), and glycerol-3-phosphate acyltransferase (G3PA).
47225	18375	 2052	D-Glucose, anhydrous	Compound	ATF3	mRNA	0	1	15199129	ATF3 is induced in beta cells by signals relevant to beta-cell destruction: proinflammatory cytokines, nitric oxide, and high concentrations of glucose and palmitate.
48621	18375	19172	D-Glucose, anhydrous	Compound	ACLY	mRNA	0	1	12413942	Glucose and insulin are anabolic signals which upregulate the transcriptions of a series of lipogenic enzymes to convert excess carbohydrate into triglycerides for efficient energy storage. These enzymes include ATP-citrate lyase (ACL), acetyl-coenzyme A carboxylase (ACC), fatty acid synthase (FAS), and glycerol-3-phosphate acyltransferase (G3PA).
50044	18375	15807	D-Glucose, anhydrous	Compound	HLCS	mRNA	0	1	12413942	Glucose and insulin are anabolic signals which upregulate the transcriptions of a series of lipogenic enzymes to convert excess carbohydrate into triglycerides for efficient energy storage. These enzymes include ATP-citrate lyase (ACL), acetyl-coenzyme A carboxylase (ACC), fatty acid synthase (FAS), and glycerol-3-phosphate acyltransferase (G3PA).
53058	18375	16278	D-Glucose, anhydrous	Compound	ID2	mRNA	0	1	16234270	the effect of glucose requires glutamine (ii) the effect of glucose is mimicked by low levels of glucosamine, (iii) the glucose effect is inhibited by azaserine, an inhibitor of glutamine:fructose-6-phosphate amidotransferase (GFAT)
54003	18375	19665	D-Glucose, anhydrous	Compound	CHGB	mRNA	0	-1	12438089	in the absence of anx7 signaling system, the cells in the adrenal gland are unable to discriminate between the fed and the fasted states in control chromaffin cells, fasting is accompanied by an increased expression of structural genes for chromaffin cell contents, including chromogranin A and B, and DbetaH the anx7 heterozygous mutation results in sustained expression of these nutritionally sensitive genes
54307	18375	 3230	D-Glucose, anhydrous	Compound	ATP2B1	mRNA	0	-1	12682074	Glucose (11.1 and 22.2 mm) induced a parallel decrease in PMCA transcription, expression, and activity. In contrast the sugar induced a parallel increase in NCX transcription, expression, and activity.
54419	18375	14349	D-Glucose, anhydrous	Compound	ELOVL3	mRNA	0	1	12482854	Lipogenesis is hormonally regulated by insulin, and the ability of this hormone to stimulate lipogenesis is mediated by SREPBP-1c. Only the initial condensation reaction catalyzed by LCE is regulated by insulin The mRNA levels of the identified genes responsible for these reactions follow a similar pattern of regulation. The condensing enzyme, LCE, is suppressed in livers of fasted mice and increased in livers from mice that were fasted (low insulin) and refed a high carbohydrate diet(high insulin).
55741	18375	 2223	D-Glucose, anhydrous	Compound	HES1	mRNA	0	1	12213820	Ananalysis with high density oligonucleotide microarrays identified >100glucose-regulated genes. We found among others immediately up-regulated genes encoding transcriptional regulators TIEG1, VDUP1, and HES1, in addition to cooperatively regulated genes that are associated with cholesterol biosynthesisand cell cycle.
57508	18375	 5731	D-Glucose, anhydrous	Compound	ACOX1	mRNA	0	-1	10967113	Chronic elevated glucose reduces the expression levels of the PPAR target genes, uncoupling protein 2 and acyl-CoA oxidase
61787	18375	 1730	D-Glucose, anhydrous	Compound	KLF10	mRNA	1	1	12213820	Ananalysis with high density oligonucleotide microarrays identified >100glucose-regulated genes. We found among others immediately up-regulated genes encoding transcriptional regulators TIEG1, VDUP1, and HES1, in addition to cooperatively regulated genes that are associated with cholesterol biosynthesisand cell cycle.
62382	18375	 5774	D-Glucose, anhydrous	Compound	Slc8a1	mRNA	0	1	12682074	Glucose (11.1 and 22.2 mm) induced a parallel decrease in PMCA transcription, expression, and activity. In contrast the sugar induced a parallel increase in NCX transcription, expression, and activity.
64433	18375	19975	D-Glucose, anhydrous	Compound	ELOVL2	mRNA	0	1	12482854	Lipogenesis is hormonally regulated by insulin, and the ability of this hormone to stimulate lipogenesis is mediated by SREPBP-1c. Only the initial condensation reaction catalyzed by LCE is regulated by insulin The mRNA levels of the identified genes responsible for these reactions follow a similar pattern of regulation. The condensing enzyme, LCE, is suppressed in livers of fasted mice and increased in livers from mice that were fasted (low insulin) and refed a high carbohydrate diet(high insulin).
65636	18375	 6557	D-Glucose, anhydrous	Compound	ALAS1	mRNA	0	-1	 9169013	In rat hepatocytes, phenobarbital increases ALA-S gene transcription and dibutyryl cAMP potentiates this induction, whereas insulin and glucose have the opposite effect.
 6612	18375	 6596	D-Glucose, anhydrous	Compound	CHGA	mRNA	0	-1	12438089	in the absence of anx7 signaling system, the cells in the adrenal gland are unable to discriminate between the fed and the fasted states in control chromaffin cells, fasting is accompanied by an increased expression of structural genes for chromaffin cell contents, including chromogranin A and B, and DbetaH the anx7 heterozygous mutation results in sustained expression of these nutritionally sensitive genes
 6772	18375	 8280	D-Glucose, anhydrous	Compound	DGAT1	mRNA	1	1	12413942	In the current study, we report that glucose preferentially enhances DGAT1 mRNA expression, whereas insulin specifically increases the level of DGAT2 mRNA.
 6872	18375	 2204	D-Glucose, anhydrous	Compound	COL1A1	mRNA	0	1	16162162	Increased type I collagen mRNA and protein levels were also observed in HSCs at high glucose concentrations
 7278	18375	16053	D-Glucose, anhydrous	Compound	PKLR	mRNA	-1	1	 9708898	AICAR was also found to inhibit activation of the L-PK gene promoter by glucose in transiently transfected hepatoma cells.
12286	17925	 2091	ceramide	Compound	HERC1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
14570	17925	15022	ceramide	Compound	PCGF3	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
14791	17925	 6467	ceramide	Compound	GTF2IP1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 1602	17925	 9722	ceramide	Compound	CEBPA	mRNA	0	-1	12071851	The addition of exogenous N-acetylsphingosine (C2-ceramide) or increasing endogenous ceramide levels inhibited the expression of C/EBPalpha and PPARgamma, and blocked adipocyte development.
   17	17925	 3609	ceramide	Compound	RGS14	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
17013	17925	 3722	ceramide	Compound	PPARG	mRNA	0	-1	12071851	The addition of exogenous N-acetylsphingosine (C2-ceramide) or increasing endogenous ceramide levels inhibited the expression of C/EBPalpha and PPARgamma, and blocked adipocyte development.
 1712	17925	12783	ceramide	Compound	VSNL1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
17149	17925	   22	ceramide	Compound	SV2A	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
17210	17925	13854	ceramide	Compound	GABRB3	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
17617	17925	17493	ceramide	Compound	AMT	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
17630	17925	 3161	ceramide	Compound	PHYHIP	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
17939	17925	 2644	ceramide	Compound	ATXN10	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
19133	17925	17862	ceramide	Compound	MAP1B	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
19215	17925	14145	ceramide	Compound	EDC4	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
19435	17925	11849	ceramide	Compound	HN1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
19780	17925	 9339	ceramide	Compound	KIF3C	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
20100	17925	18361	ceramide	Compound	PIGN	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
20840	17925	 8087	ceramide	Compound	SLC4A4	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
20895	17925	  125	ceramide	Compound	TMEM50A	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 2243	17925	 5419	ceramide	Compound	TNF	mRNA	0	1	12473262	We studied the ability of ceramide to stimulate TNF-alpha production by human PBMCs and the mechanism of action of GSTM on ceramide and LPS induced TNF-alpha production.
22689	17925	11485	ceramide	Compound	EEF1G	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
23526	17925	14950	ceramide	Compound	MICU1	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 2361	17925	  996	ceramide	Compound	CA10	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
24842	17925	 5863	ceramide	Compound	MYC	mRNA	0	-1	10200487	Ceramide-induced downregulation of the c-myc promoter was restored in SAOS2 _1 cells in which a functional Rb gene was reintroduced.
25138	17925	 5138	ceramide	Compound	NCOA6	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
25413	17925	17324	ceramide	Compound	GOT2	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
25702	17925	 7174	ceramide	Compound	ANKRD6	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
26680	17925	18713	ceramide	Compound	SCARB1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
26708	17925	11502	ceramide	Compound	LMNB1	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
28347	17925	14168	ceramide	Compound	ANKH	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
30012	17925	20039	ceramide	Compound	MTMR2	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
30266	17925	 8249	ceramide	Compound	BECN1	mRNA	0	1	14970205	In addition, C(2)-ceramide stimulated the expression of the autophagy gene product beclin1.
36164	17925	19828	ceramide	Compound	LPHN2	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
36167	17925	   54	ceramide	Compound	DOCK3	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
37333	17925	 6266	ceramide	Compound	C3orf18	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
37357	17925	10070	ceramide	Compound	USP11	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
37463	17925	 1084	ceramide	Compound	ALDOC	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
38315	17925	13912	ceramide	Compound	MSL3	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
38810	17925	10290	ceramide	Compound	FOXM1	mRNA	1	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
38938	17925	15870	ceramide	Compound	SLC6A8	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
39369	17925	18612	ceramide	Compound	SOD2	mRNA	-1	1	 9535218	We found that MnSOD protein expression and mRNA production were markedly enhanced after 4 h exposure to oxLDL, C2-ceramide, H2O2, or TNF-a (Fig. 1A, B). Similar results were obtained when p53 protein and mRNA levels of stimulated cells were analyzed (Fig. 2A, B)
39432	17925	14790	ceramide	Compound	MAP3K5	mRNA	0	1	11029458	Cells differentiate in response to various extracellular stimuli. This cellular response requires intracellular signaling pathways. The mitogen-activated protein (MAP) kinase cascade is a core signal transduction pathway that determines the fate of many kinds of cell. MAP kinase kinase kinase activates MAP kinase kinase, which in turn activates MAP kinase. Apoptosis signal-regulating kinase (ASK1) was identified as a MAP kinase kinase kinase involved in the stress-induced apoptosis-signaling cascade that activates the SEK1-JNK and MKK3/MKK6-p38 MAP kinase cascades. Expression of the constitutively active form of ASK1 (ASK1-DeltaN) in keratinocytes induced significant morphological changes and differentiation markers, transglutaminase-1, loricrin, and involucrin. A transient increase in p21(Cip1/WAF1) reduced DNA synthesis, and cell cycle analysis verified the differentiation. p38 MAP kinase inhibitors, SB202190 and SB203580, abolished the induction of differentiation markers, transglutaminase-1, loricrin, and involucrin. In turn, the induction of differentiation with ceramide in keratinocytes caused an increase in ASK1 expression and activity. Furthermore, normal human skin expresses ASK1 protein in the upper epidermis, implicating ASK1 in in vivo keratinocyte differentiation. We propose that the ASK1-p38 MAP kinase cascade is a new intracellular regulator of keratinocyte differentiation.
40080	17925	17902	ceramide	Compound	RAN	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
40228	17925	10383	ceramide	Compound	TFCP2	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 4144	17925	 3346	ceramide	Compound	TMOD3	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
42222	17925	18105	ceramide	Compound	EIF2C1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
42240	17925	 2947	ceramide	Compound	TBPL1	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
42631	17925	 3992	ceramide	Compound	SCN3B	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
  427	17925	 9988	ceramide	Compound	BAZ2B	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
42772	17925	 8355	ceramide	Compound	AGFG1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
42793	17925	 3026	ceramide	Compound	SYT13	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
43249	17925	 5318	ceramide	Compound	ADH5	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
43985	17925	19931	ceramide	Compound	PUM2	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
45244	17925	20087	ceramide	Compound	GPM6A	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
45855	17925	 1194	ceramide	Compound	PPAP2B	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
46460	17925	 3085	ceramide	Compound	FOSB	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
47193	17925	10706	ceramide	Compound	SCN1A	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 4736	17925	 7009	ceramide	Compound	SREBF1	mRNA	0	-1	14505487	Ceramide prevents insulin-dependent induction of GCK and SREBP1 mRNAs
47640	17925	 7106	ceramide	Compound	CD300A	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
48909	17925	 7703	ceramide	Compound	CHERP	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
49100	17925	13844	ceramide	Compound	HSP90B1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
49213	17925	10305	ceramide	Compound	LASP1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
49224	17925	19702	ceramide	Compound	OLFM1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
49487	17925	 8723	ceramide	Compound	KIF22	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
50202	17925	 2197	ceramide	Compound	ME3	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
50333	17925	11248	ceramide	Compound	CDC42SE2	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
50897	17925	11675	ceramide	Compound	MBTPS1	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
53376	17925	 2375	ceramide	Compound	MEST	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
53507	17925	12521	ceramide	Compound	VAPB	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
54379	17925	  991	ceramide	Compound	INS	mRNA	0	1	12771145	Inhibition of de Novo Ceramide Synthesis Prevents Palmitate Impairment of Insulin Gene Expression
54649	17925	 8187	ceramide	Compound	KLC1	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
54904	17925	 5546	ceramide	Compound	SLC6A1	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
55147	17925	16495	ceramide	Compound	FKBP9	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
55198	17925	12317	ceramide	Compound	RPL32	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
56074	17925	 7298	ceramide	Compound	EHD3	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
56805	17925	17972	ceramide	Compound	NR2C2	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
59672	17925	 7590	ceramide	Compound	GCK	mRNA	0	-1	14505487	Ceramide prevents insulin-dependent induction of GCK and SREBP1 mRNAs
59821	17925	 3795	ceramide	Compound	SDC2	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
60390	17925	11397	ceramide	Compound	HNRNPC	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
61504	17925	11419	ceramide	Compound	CYP3A4	mRNA	0	-1	12419308	Treatment with the cell-permeable ceramide analog C(6)-ceramide to the cells significantly decreased the expression of CYP3A4. By contrast, C(6)-dihydroceramide, a biologically inactive analog of C(6)-ceramide, did not affect CYP3A4 expression. We found that bacterial sphingomyelinase (SMase) and tumor necrosis factor-alpha (TNF), which are known to increase intracellular ceramide levels, also markedly suppressed the synthesis of CYP3A4.
63981	17925	 9271	ceramide	Compound	PRMT2	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
66293	17925	17074	ceramide	Compound	GLIS2	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 6638	17925	 9055	ceramide	Compound	MANBAL	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 7193	17925	15753	ceramide	Compound	NCAN	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 7474	17925	19396	ceramide	Compound	C3	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 7981	17925	19657	ceramide	Compound	ICMT	mRNA	0	-1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 8551	17925	12696	ceramide	Compound	PNOC	mRNA	0	1	12395108	Modified assertion
 8769	17925	10044	ceramide	Compound	EHMT2	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 8771	17925	14135	ceramide	Compound	SRPRB	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 9304	17925	14218	ceramide	Compound	SLC7A11	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
 9405	17925	13666	ceramide	Compound	FKBP1A	mRNA	0	1	12186649	Table 3  Known genes differentially expressed in ceramide-dependent apoptosis with no identified direct interaction with the ceramide-dependent apoptosis process
10093	 4436	 7502	serum leptin	Compound	STAR	mRNA	0	-1	11459771	leptin significantly inhibits the expression of steroidogenic acute regulatory protein in primary cultures of rat adrenocortical cells. This inhibition was observed at both the protein and mRNA levels.
13427	 4436	 6451	serum leptin	Compound	LEPR	mRNA	0	-1	14769942	Hyperleptinemia induced using adenovirus on epididymal white fat tissue led to the downregulation of Lepr (the full length leptin receptor) from 1 +/- 0.25 on day 0 to 0.65 +/- 0.15 on day 7, 0.88 +/- 0.10 on day 10 and 0.64 +/- 0.18 on day 14 of hyperleptinemia
13668	 4436	 1438	serum leptin	Compound	VEGFA	mRNA	0	1	11152449	_ Ariadne: In contrast, leptin induced  VEGF mRNA expression in pre-adipocytes (Fig. 5 ). [Expression]
 3618	 4436	 9855	serum leptin	Compound	DGAT2	mRNA	1	-1	15550388	intracerebroventricular infusion of leptin reduced DGAT2 expression in WAT of Irs2-/- mice and ob/ob mice
47133	 4436	19344	serum leptin	Compound	SPARC	mRNA	0	-1	14769942	Hyperleptinemia induced using adenovirus on epididymal white fat tissue led to the downregulation of Sparc from 1 +/- 0.24 on day 0 to 0.70 +/- 0.17 on day 7 and 0.14 +/- 0.on day 10 of hyperleptinemia
48622	 4436	19172	serum leptin	Compound	ACLY	mRNA	0	-1	10095788	We have also found that leptin similarly suppresses the transcription of the ATP citrate-lyase gene in the cells ( unpublished results)
55698	 4436	15411	serum leptin	Compound	INSIG1	mRNA	0	-1	14769942	Hyperleptinemia induced using adenovirus on epididymal white fat tissue exhibited the regulation of Insig-1 gene expression by leptin from 1 +/- 0.15 on day 0, 0.68 +/- 0.09 on day 7, 0.54 +/- 0.18 on day 10 of hyperleptinisation.
58712	 4436	 3051	serum leptin	Compound	PTPN1	mRNA	0	1	14976221	liver PTP1B protein abundance was increased by leptin _ See next evidence lines for clarification of \abundance.\
65443	 4436	19519	serum leptin	Compound	CPT1A	mRNA	-1	1	10998055	Ariadne: Furthermore, in the same cell system, leptin has been reported to upregulate the expression of acyl-CoA oxidase (ACO), carnitine palmitoyl transferase-1 (CPT1), and peroxisome proliferator- activated receptor-alpha (PPAR-alpha) [ 15 ], and to increase glucose  decarboxylation [ 14 ] and lipolysis [ 13 , 15 , 17 , 18 ].
 6560	 4436	 5466	serum leptin	Compound	ACACB	mRNA	0	1	14769942	Hyperleptinemia induced using adenovirus on epididymal white fat tissue led to the up regulation of the lipogenic enzyme Acacb (Acetyl CoA carboxylase-beta) mRNA 8 folds.
65934	 4436	 2631	serum leptin	Compound	PPARGC1A	mRNA	0	1	11108270	Four days after induction of hyperleptinemia (>30 ng/ml) in Wistar rats, by adenovirus gene transfer, PGC-1 mRNA in BAT was 2.3-fold and UCP-1, 4-fold above controls.
 7314	 4436	16458	serum leptin	Compound	UCP1	mRNA	0	1	11108270	Four days after induction of hyperleptinemia (>30 ng/ml) in Wistar rats, by adenovirus gene transfer, PGC-1 mRNA in BAT was 2.3-fold and UCP-1, 4-fold above controls.
  263	 3454	15355	NKX2-1	Protein	NAPSA	mRNA	0	1	14766755	Importantly, expression of napsin was shown to be regulated by TTF-1, a phosphorylated member of the Nkx2 family of homeodomain-containing transcription factors that also regulates the lung-specific expression of SP-B ( 24 ).
33393	 3454	11976	NKX2-1	Protein	PDK4	mRNA	0	1	16960125	Table 4
34770	 3454	19508	NKX2-1	Protein	BMP2	mRNA	0	1	14960358	both hBmp4 promoters include specific cis-active elements that bind to and mediate transcriptional regulation by NKX2.1
36146	 3454	 3179	NKX2-1	Protein	SFTPA2	mRNA	0	1	11713256	We found that CBP and SRC-1 acted synergistically with TTF-1 to increase SP-A2 promoter activity, and that adenoviral E1A, a specific inhibitor of CBP/p300, blocked the stimulatory effects of TTF-1 and SRC-1 , suggesting a role of endogenous CBP/p300.
48208	 3454	 1302	NKX2-1	Protein	ATP8A1	mRNA	-1	1	16960125	Table 4
51410	 3454	11635	NKX2-1	Protein	DHCR24	mRNA	1	1	16960125	Table 4
 5987	 3454	17357	NKX2-1	Protein	ICAM4	mRNA	1	1	16960125	Table 4
60940	 3454	 5734	NKX2-1	Protein	SCGB1A1	mRNA	0	1	12161423	In the presence of C/ EBPalpha, Nkx2.1 stimulated the CCSP promoter already at 50 ng of Nkx2.1  expression plasmid (Fig. 2 B ).
61218	 3454	 5969	NKX2-1	Protein	GAS1	mRNA	-1	1	16960125	Table 4
45376	  208	14987	NADH	Compound	BCL2	mRNA	1	1	12918120	NADH could not only eliminate the apoptosis induced by X-ray irradiation, but also up-regulate expression of bcl-2 protein and down-regulate expression of p53, bax, fas and fasL proteins (P<0.05). At the same time, NADH could reduce level of intracellular ROS in radiated L02 cells
51683	  208	  219	NADH	Compound	FASLG	mRNA	-1	-1	12918120	NADH could not only eliminate the apoptosis induced by X-ray irradiation, but also up-regulate expression of bcl-2 protein and down-regulate expression of p53, bax, fas and fasL proteins (P<0.05). At the same time, NADH could reduce level of intracellular ROS in radiated L02 cells
12107	 3989	  377	aldosterone	Compound	Col3a1	mRNA	0	1	14993121	Aldosterone provoked expression of hypertrophic markers (NPPA, NPPB, and ACTA1) in rat cardiac myocytes by phosphorylation of protein kinase D (PKD) and expression of collagens (COL1A1, COL1A2, and COL3A1) and transforming growth factor-beta1 in rat cardiac fibroblasts by upregulation of phosphoinositide 3-kinase (PI3K)-p100delta. Inhibition of PKD and PI3K-p110delta abrogated the hypertrophic and profibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolactone
13460	 3989	16612	aldosterone	Compound	MMP13	mRNA	0	1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
13632	 3989	 1438	aldosterone	Compound	VEGFA	mRNA	0	1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
16042	 3989	 1471	aldosterone	Compound	COL1A2	mRNA	-1	1	14993121	Aldosterone provoked expression of hypertrophic markers (NPPA, NPPB, and ACTA1) in rat cardiac myocytes by phosphorylation of protein kinase D (PKD) and expression of collagens (COL1A1, COL1A2, and COL3A1) and transforming growth factor-beta1 in rat cardiac fibroblasts by upregulation of phosphoinositide 3-kinase (PI3K)-p100delta. Inhibition of PKD and PI3K-p110delta abrogated the hypertrophic and profibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolactone
17005	 3989	 3722	aldosterone	Compound	PPARG	mRNA	0	1	10913039	The expression of early adipogenic gene markers, such as lipoprotein lipase, peroxisome proliferator-activated receptor-gamma, and adipocyte-specific fatty acid binding protein 2, was enhanced by aldosterone, confirming activation of the differentiation process.
17866	 3989	18271	aldosterone	Compound	ACTA1	mRNA	0	1	14993121	Aldosterone provoked expression of hypertrophic markers (NPPA, NPPB, and ACTA1) in rat cardiac myocytes by phosphorylation of protein kinase D (PKD) and expression of collagens (COL1A1, COL1A2, and COL3A1) and transforming growth factor-beta1 in rat cardiac fibroblasts by upregulation of phosphoinositide 3-kinase (PI3K)-p100delta. Inhibition of PKD and PI3K-p110delta abrogated the hypertrophic and profibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolactone
19679	 3989	16486	aldosterone	Compound	SPP1	mRNA	1	1	16156509	upregulation of cardiac MCP-1 and osteopontin by aldosterone
20658	 3989	 5708	aldosterone	Compound	KITLG	mRNA	0	1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
21292	 3989	 6069	aldosterone	Compound	MMP12	mRNA	0	-1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
25045	 3989	11217	aldosterone	Compound	NPPA	mRNA	0	1	14993121	Aldosterone provoked expression of hypertrophic markers (NPPA, NPPB, and ACTA1) in rat cardiac myocytes by phosphorylation of protein kinase D (PKD) and expression of collagens (COL1A1, COL1A2, and COL3A1) and transforming growth factor-beta1 in rat cardiac fibroblasts by upregulation of phosphoinositide 3-kinase (PI3K)-p100delta. Inhibition of PKD and PI3K-p110delta abrogated the hypertrophic and profibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolactone
  284	 3989	  279	aldosterone	Compound	HIPK1	mRNA	-1	1	12770840	Table 3. Transcripts upregulated by aldosterone
28639	 3989	 4395	aldosterone	Compound	FLT3	mRNA	0	1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
34717	 3989	 2278	aldosterone	Compound	NPPB	mRNA	0	1	14993121	Aldosterone provoked expression of hypertrophic markers (NPPA, NPPB, and ACTA1) in rat cardiac myocytes by phosphorylation of protein kinase D (PKD) and expression of collagens (COL1A1, COL1A2, and COL3A1) and transforming growth factor-beta1 in rat cardiac fibroblasts by upregulation of phosphoinositide 3-kinase (PI3K)-p100delta. Inhibition of PKD and PI3K-p110delta abrogated the hypertrophic and profibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolactone
40798	 3989	13739	aldosterone	Compound	CTGF	mRNA	0	1	15608389	Upon aldosterone treatment, CTGF expression was significantly increased in a dose and time-dependent manner
42053	 3989	13115	aldosterone	Compound	EGR1	mRNA	-1	1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
43499	 3989	10899	aldosterone	Compound	TGFB1	mRNA	0	1	14993121	Aldosterone provoked expression of hypertrophic markers (NPPA, NPPB, and ACTA1) in rat cardiac myocytes by phosphorylation of protein kinase D (PKD) and expression of collagens (COL1A1, COL1A2, and COL3A1) and transforming growth factor-beta1 in rat cardiac fibroblasts by upregulation of phosphoinositide 3-kinase (PI3K)-p100delta. Inhibition of PKD and PI3K-p110delta abrogated the hypertrophic and profibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolactone
43608	 3989	 2451	aldosterone	Compound	YWHAG	mRNA	-1	1	12770840	Table 3. Transcripts upregulated by aldosterone
45797	 3989	 4835	aldosterone	Compound	PPARA	mRNA	0	1	12969137	Long-term treatment (>4 hours) with aldosterone induced the mRNA expression of pparalpha and puralpha.
48284	 3989	 7237	aldosterone	Compound	INSR	mRNA	0	-1	12125101	an inhibition of insulin receptor (IR) mRNA levels and insulin binding by aldosterone this inhibition of the insulin response by aldosterone is mediated by a downregulation of the levels of mineralocorticoid receptors (MRs) (50% decrease) and their mRNA (50% decrease)
51995	 3989	13202	aldosterone	Compound	ITGB7	mRNA	0	-1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
56887	 3989	11653	aldosterone	Compound	FABP2	mRNA	0	1	10913039	The expression of early adipogenic gene markers, such as lipoprotein lipase, peroxisome proliferator-activated receptor-gamma, and adipocyte-specific fatty acid binding protein 2, was enhanced by aldosterone, confirming activation of the differentiation process.
57781	 3989	 9065	aldosterone	Compound	KLF3	mRNA	1	1	12770840	Table 3. Transcripts upregulated by aldosterone
63109	 3989	14810	aldosterone	Compound	CD83	mRNA	0	-1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
63298	 3989	13118	aldosterone	Compound	ASB4	mRNA	0	-1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
65479	 3989	16219	aldosterone	Compound	PROCR	mRNA	0	1	18555797	Transactivated genes in HBMEC exposed to aldosterone (107 M) for 6 h by gene array
 6868	 3989	 2204	aldosterone	Compound	COL1A1	mRNA	0	1	14993121	Aldosterone provoked expression of hypertrophic markers (NPPA, NPPB, and ACTA1) in rat cardiac myocytes by phosphorylation of protein kinase D (PKD) and expression of collagens (COL1A1, COL1A2, and COL3A1) and transforming growth factor-beta1 in rat cardiac fibroblasts by upregulation of phosphoinositide 3-kinase (PI3K)-p100delta. Inhibition of PKD and PI3K-p110delta abrogated the hypertrophic and profibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolactone
 9839	 3989	18112	aldosterone	Compound	Zfp60	mRNA	1	-1	12770840	Table 2. Transcripts downregulated by aldosterone
20343	 1859	 2815	PIAS2	Protein	TP53	mRNA	0	1	18923429	In contrast, P53 mRNA levels were significantly lower in cells depleted of Miz1; therefore, the decrease in p53 protein levels observed in Miz1-depleted cells may reflect a role of Miz1 in P53 transcription, stabilization of the p53 protein or both
29847	 1859	18163	PIAS2	Protein	CDKN1C	mRNA	0	1	14560010	expression of p57Kip2, another target gene of Miz1 is absent in Miz1(-/-) embryos.
36130	 1859	14678	PIAS2	Protein	SLC11A1	mRNA	0	1	12904288	We next tested the Nramp1 promoter in U937 cells. As seen in Fig. 3B, transfected Miz-1 activated this promoter, whereas IRF-8 alone had no effect.
45372	 1859	14987	PIAS2	Protein	BCL2	mRNA	1	1	17082179	Here we report that MIZ-1 activates the transcription of BCL2.
62937	 9134	 7195	U2AF1	Protein	GADD45A	mRNA	-1	1	16855028	U2AF is a heterodimeric splicing factor composed of a large (U2AF(65)) and a small (U2AF(35)) subunit. In humans, alternative splicing generates two U2AF(35) variants, U2AF(35)a and U2AF(35)b. Here, we used RNA interference to specifically ablate the expression of each isoform in HeLa cells. Our results show that knockdown of the major U2AF(35)a isoform reduced cell viability and impaired mitotic progression, leading to accumulation of cells in prometaphase. Microarray analysis revealed that knockdown of U2AF(35)a affected the expression level of approximately 500 mRNAs, from which 90% were underrepresented relative to the control. Among mRNAs underrepresented in U2AF(35)a-depleted cells we identified an essential cell cycle gene, Cdc27, for which there was an increase in the ratio between unspliced and spliced RNA and a significant reduction in protein level. Furthermore, we show that depletion of either U2AF(35)a or U2AF(35)b altered the ratios of alternatively spliced isoforms of Cdc25B and Cdc25C transcripts. Taken together our results demonstrate that U2AF(35)a is essential for HeLa cell division and suggest a novel role for both U2AF(35) protein isoforms as regulators of alternative splicing of a specific subset of genes.
11039	12233	 8037	Hydrocortisone	Compound	KLF6	mRNA	1	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits     (SC only)  criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
12409	12233	 2742	Hydrocortisone	Compound	APEX1	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
12800	12233	17369	Hydrocortisone	Compound	IL6	mRNA	0	-1	17901074	Concurrently, cortisol (0.01 approximately 1 microM) decreased rather than increased proinflammatory cytokine mRNA levels, including interleukin 1 beta (IL1B), interleukin 6 (IL6), and tumor necrosis factor alpha (TNF), in a dose-dependent manner in human amnion fibroblasts.
13816	12233	17250	Hydrocortisone	Compound	PTGS2	mRNA	0	1	19797430	Using cultured human amnion fibroblasts, we found that the induction of COX-2 mRNA expression by cortisol was a glucocorticoid receptor (GR)-dependent process requiring ongoing transcription. Upon transfection of a COX-2 promoter-driven reporter gene into the amnion fibroblasts, cortisol stimulated the COX-2 promoter activity. This was abolished by mutagenesis of a cAMP response element (CRE) at -53 to approximately -59bp as well as by cotransfection of a plasmid expressing dominant-negative CRE-binding protein (CREB). The phosphorylation level of CREB-1 was significantly increased by cortisol treatment of the amnion fibroblasts.Chromatin immunoprecipitation (ChIP) assay revealed that the binding of CREB-1 to the CRE of the COX-2 promoter was increased by cortisol treatment of the amnion fibroblasts.
14116	12233	14961	Hydrocortisone	Compound	CEBPD	mRNA	0	1	12960086	In the presence of cortisol, NotchIC induced the formation of mature adipocytes and enhanced the effect of cortisol on adipsin, peroxisome proliferator-activated receptor-gamma2 and CCAAT enhancer binding protein alpha and delta mRNA levels.
14828	12233	10938	Hydrocortisone	Compound	H2AFY	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 1607	12233	 9722	Hydrocortisone	Compound	CEBPA	mRNA	0	1	12960086	In the presence of cortisol, NotchIC induced the formation of mature adipocytes and enhanced the effect of cortisol on adipsin, peroxisome proliferator-activated receptor-gamma2 and CCAAT enhancer binding protein alpha and delta mRNA levels.
16119	12233	 8326	Hydrocortisone	Compound	CDC6	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
17007	12233	 3722	Hydrocortisone	Compound	PPARG	mRNA	0	1	12960086	In the presence of cortisol, NotchIC induced the formation of mature adipocytes and enhanced the effect of cortisol on adipsin, peroxisome proliferator-activated receptor-gamma2 and CCAAT enhancer binding protein alpha and delta mRNA levels.
18387	12233	 8976	Hydrocortisone	Compound	NOTCH2	mRNA	0	1	12960086	Notch 1 and 2 mRNAs are expressed by osteoblasts and induced by cortisol
19448	12233	 6094	Hydrocortisone	Compound	RAD9A	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 2257	12233	 5419	Hydrocortisone	Compound	TNF	mRNA	0	-1	17901074	Concurrently, cortisol (0.01 approximately 1 microM) decreased rather than increased proinflammatory cytokine mRNA levels, including interleukin 1 beta (IL1B), interleukin 6 (IL6), and tumor necrosis factor alpha (TNF), in a dose-dependent manner in human amnion fibroblasts.
23399	12233	 9226	Hydrocortisone	Compound	CITED2	mRNA	1	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits (OM only) -criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
28289	12233	 6449	Hydrocortisone	Compound	CFLAR	mRNA	1	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits     (SC only)  criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
33403	12233	11976	Hydrocortisone	Compound	PDK4	mRNA	0	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits (SC and OM) - criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
35172	12233	17804	Hydrocortisone	Compound	NOTCH1	mRNA	0	1	12960086	Notch 1 and 2 mRNAs are expressed by osteoblasts and induced by cortisol
39408	12233	 5243	Hydrocortisone	Compound	SESN1	mRNA	-1	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
39811	12233	 7769	Hydrocortisone	Compound	FOXO1	mRNA	-1	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits (OM only) -criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
40050	12233	 8242	Hydrocortisone	Compound	GTSE1	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
41371	12233	15861	Hydrocortisone	Compound	RPRM	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
41796	12233	  621	Hydrocortisone	Compound	MLH1	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
42627	12233	 6875	Hydrocortisone	Compound	CHEK1	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
44018	12233	16725	Hydrocortisone	Compound	ERCC6	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
44099	12233	17959	Hydrocortisone	Compound	RAD52	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
44274	12233	13802	Hydrocortisone	Compound	CDC25A	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
45670	12233	18679	Hydrocortisone	Compound	H2AFZ	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
45846	12233	 1214	Hydrocortisone	Compound	ATM	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
46640	12233	 3471	Hydrocortisone	Compound	IL1B	mRNA	0	-1	17901074	Concurrently, cortisol (0.01 approximately 1 microM) decreased rather than increased proinflammatory cytokine mRNA levels, including interleukin 1 beta (IL1B), interleukin 6 (IL6), and tumor necrosis factor alpha (TNF), in a dose-dependent manner in human amnion fibroblasts.
48163	12233	 3148	Hydrocortisone	Compound	ERCC8	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
49691	12233	 6430	Hydrocortisone	Compound	MDM2	mRNA	1	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
52990	12233	19009	Hydrocortisone	Compound	TSC22D3	mRNA	1	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits (SC and OM) - criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
53523	12233	15594	Hydrocortisone	Compound	CDC25C	mRNA	0	-1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
56130	12233	10811	Hydrocortisone	Compound	FN1	mRNA	-1	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits (OM only) -criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
60066	12233	12976	Hydrocortisone	Compound	IL8	mRNA	0	-1	16707595	Dexamethasone significantly down-regulated VEGF and IL-8 gene expression by 50% (P < 0.001) and 89% (P < 0.001), respectively, and decreased VEGF and IL-8 protein production by 55% (P < 0.001) and 74% (P < 0.001), respectively, under normoxic condition.Similarly, hydrocortisone down-regulated VEGF and IL-8 gene expression.
61216	12233	 5969	Hydrocortisone	Compound	GAS1	mRNA	-1	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits (OM only) -criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
64190	12233	 6765	Hydrocortisone	Compound	C10orf10	mRNA	0	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits (SC and OM) - criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
 6469	12233	12489	Hydrocortisone	Compound	ERCC5	mRNA	-1	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 7364	12233	17327	Hydrocortisone	Compound	RAD1	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
 8339	12233	 6202	Hydrocortisone	Compound	BTG1	mRNA	-1	1	17032748	from full text - Table 3 Overview of the genes that were significantly increased after 24 h 100 nM cortisol treatment (F) compared to control (ctr) in subcutaneous (SC) omental (OM) preadipocytes or both fat deposits     (SC only)  criteria: (1) genes with absent call in control and treated cell arrays were deleted; (2) genes with difference call of no change were deleted; (3) genes with absolute signal below 100 were eliminated; (4) genes with signal log ratio (SLR) below 1 for I (increase) or above K1.0 for D (decrease)were deleted(arbitrary cut-off point of twofold change) and (5) expressed sequence tags (ESTs) and hypothetical protein entries were not analysed.
 8926	12233	15240	Hydrocortisone	Compound	PTPRCAP	mRNA	0	1	17459596	from full text - Table 2 Genes modulated by at least one or more stress hormone as shown by gene arrays.  Note - statistics donpt look rigorous here (only the mean +/- SD of 2 experiments is shown), but Ipm taking the ones in bold that were verified using receptor antagonists
33136	   29	 7360	TAF4B	Protein	RARG	mRNA	1	1	15774719	Several genes known to be important to meiosis and spermatogenesis are also expressed at reduced levels in the Taf4b-null testis at post-natal day 8, a time when the number of spermatogonia is significantly reduced (Fig. 4B). These include genes involved in retinoic acid signaling that are known to impact male fertility (Livera et al. 2002). Retinoic acid receptor gamma, which has been shown to control expression of Stra8 (Chiba et al. 1997), is expressed at lower levels in Taf4b-null testis (Fig. 6C). Other retinoic acid signaling molecules, including cellular retinoic acid-binding protein (Crabp) and retinol-binding protein (Rbp), are reduced in Taf4b-null testis as well (Fig. 6C).
61469	   29	10292	TAF4B	Protein	INHA	mRNA	0	1	16473943	reporter constructs containing native ovary-selective promoters driving the expression of the luciferase reporter gene were transfected into the f-TAF4b and control flag cells. As shown in Fig. 2  A, the activities of the inhibin-alpha (Inha) and -betaA (Inhba) subunit promoters were significantly induced. In addition, the inhibit-betaB (Inhbb), the cyclin D2 (Ccnd2) and follistatin (Fst) promoters were also induced in f-TAF4b cells compared with a control TAF4b-independent promoter, the ubiquitin-activating enzyme E1-like (Ube1L) promoter (Fig. 2  A).
 9400	   29	 6870	TAF4B	Protein	INHBB	mRNA	0	1	16473943	reporter constructs containing native ovary-selective promoters driving the expression of the luciferase reporter gene were transfected into the f-TAF4b and control flag cells. As shown in Fig. 2  A, the activities of the inhibin-alpha (Inha) and -betaA (Inhba) subunit promoters were significantly induced. In addition, the inhibit-betaB (Inhbb), the cyclin D2 (Ccnd2) and follistatin (Fst) promoters were also induced in f-TAF4b cells compared with a control TAF4b-independent promoter, the ubiquitin-activating enzyme E1-like (Ube1L) promoter (Fig. 2  A).
11034	11712	 8037	thapsigargin	Compound	KLF6	mRNA	1	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
16256	11712	15838	thapsigargin	Compound	PER1	mRNA	0	1	11959112	Thapsigargin-induced mPer1 and mPer2 mRNA expressions took distinct signaling pathways from protein kinase C and cAMP, but were partially inhibited by inhibitors of MEK1 and p38 mitogen-activated protein kinase, respectively
16930	11712	 4135	thapsigargin	Compound	TRPC1	mRNA	0	1	16529812	Using real-time PCR and Western blot techniques, we show that the expression of TRPC1, TRPC3 and TRPV6 proteins increases after a prolonged (24-48 h) depletion of the stores with thapsigargin.
20111	11712	 6640	thapsigargin	Compound	GLT8D1	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
20276	11712	19571	thapsigargin	Compound	CXCL2	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
21762	11712	 5208	thapsigargin	Compound	RCAN1	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
23925	11712	 5783	thapsigargin	Compound	CEBPB	mRNA	0	1	15102854	transcription from the human C/EBPbeta gene is induced in response to endoplasmic reticulum stress, such as glucose deprivation, or treatment of cells with tunicamycin or thapsigargin.
30079	11712	 6134	thapsigargin	Compound	GEM	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
34200	11712	12935	thapsigargin	Compound	TRPC3	mRNA	0	1	16529812	Using real-time PCR and Western blot techniques, we show that the expression of TRPC1, TRPC3 and TRPV6 proteins increases after a prolonged (24-48 h) depletion of the stores with thapsigargin.
36612	11712	 1407	thapsigargin	Compound	DUSP4	mRNA	0	-1	11591707	the inhibitory effect of thapsigargin on MKP-2 protein expression previously identified
40266	11712	16388	thapsigargin	Compound	GFAP	mRNA	0	1	10604659	intracellular Ca2+ pump inhibitors, thapsigargin (TG) irreversibly and 2,5-ditert-butyl-hydroquinone (DBHQ) reversibly depleted the Ca(2+)-store accompanied with the induction of G0/G1 arrest, an increase in glial fibrillary acidic protein (GFAP) expression
43549	11712	17125	thapsigargin	Compound	PER2	mRNA	0	1	11959112	Thapsigargin-induced mPer1 and mPer2 mRNA expressions took distinct signaling pathways from protein kinase C and cAMP, but were partially inhibited by inhibitors of MEK1 and p38 mitogen-activated protein kinase, respectively
47205	11712	 2052	thapsigargin	Compound	ATF3	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
48069	11712	11629	thapsigargin	Compound	FOS	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
50214	11712	  842	thapsigargin	Compound	TRPV6	mRNA	0	1	16529812	Using real-time PCR and Western blot techniques, we show that the expression of TRPC1, TRPC3 and TRPV6 proteins increases after a prolonged (24-48 h) depletion of the stores with thapsigargin.
51954	11712	 1178	thapsigargin	Compound	NR4A1	mRNA	0	1	11385620	The TG-induced Nur77 expression is also inhibited by overexpression of Cabin1, an endogenous inhibitor of calcineurin and a corepressor of the transcription factor MEF2, suggesting that MEF2 activation is required for Nur77 expression
52867	11712	 5973	thapsigargin	Compound	PAWR	mRNA	0	1	12242017	Similar to the endogenous par-4 gene, par-4 expression could be induced upon apoptotic insult with thapsigargin following introduction of the promoter DNA into human A375 cells. Also, increased levels of the atypical protein kinase C, zetaPKC, was shown to negatively regulate expression from the ectopic par-4 promoter.
53307	11712	 9562	thapsigargin	Compound	PLK2	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
56156	11712	10811	thapsigargin	Compound	FN1	mRNA	-1	-1	 7756462	Thapsigargin, an agent that mobilizes Ca2+ from internal stores, suppressed basal and progesterone-induced fibronectin production in the absence and presence of cyanoketone.
 5685	11712	18424	thapsigargin	Compound	DUSP1	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
58308	11712	 5913	thapsigargin	Compound	CYR61	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
65697	11712	10219	thapsigargin	Compound	CREB3L1	mRNA	0	1	15665855	Intriguingly, OASIS was induced at the transcriptional level during ER stress in astrocytes of the central nervous system, but not in other cell types examined.
66262	11712	17275	thapsigargin	Compound	TM4SF1	mRNA	0	1	16461377	Table 1. Genes regulated by thapsigargin according to microarray analysis in human VSMCs  Gene ID  Gene Name  Cluster  Fold Change DUSP1 (MKP-1)  MAP kinase phosphatase 1*  Hs.171695  1.975 DSCR1  Down syndrome critical region  Hs.282326  1.778 CYR61  Cysteine-rich protein 61*  Hs.8867  1.718 FN1  Fibronectin 1*  Hs.203717  1.667 GLT8D1  Glycosyltransferase 8 domain-containing 1  Hs.297304  1.563 KLF6  Kruppel-like factor 6  Hs.285313  1.559 PLK2  Pol-like kinase 2*  Hs.398157  1.553 CXCL2  Chemokine (C-X-C motif) ligand*  Hs.75765  1.538 TM4SF1  Transmembrane 4L six family member  Hs.351316  1.533 GEM  GTP-binding protein*  Hs.345139  1.53 FOS  v-fos FBJ murine osteosarcoma viral oncogene homology*  Hs.25647  1.52 ATF3  Activating transcription factor 3*  Hs.460  1.515 Genes significantly changed by ?1.5-fold when treated for 30 min with 100 nM thapsigargin compared with no treatment. In the case of multiple probe sets, exemplar is represented. VSMCs, vascular smooth muscle cells.  * Ca3+/cAMP response element (CRE)-containing consensus.
10030	 7352	 7330	FOXO3	Protein	Csf2rb2	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
10757	 7352	 8674	FOXO3	Protein	SLC3A1	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
11033	 7352	 8037	FOXO3	Protein	KLF6	mRNA	1	1	20123982	Supplemental Table I: Genes involved in leukocyte, macrophage and lymphocyte differentiation that are induced by FoxO3.A3.ER and FoxO3.A3.ER.H212R as identified by Functional Annotation Clustering.  Affymetrix HG-U133 Plus 2.0 arrays according to the manufacturer?s instructions (Affymetrix, Santa Clara, CA).A Custom CDF Version 11 with Entrez-based gene definitions was used to annotate the arrays (28). Raw fluorescence intensity values were normalized, applying quantile normalization. Differential gene expression was analyzed based on log linear mixed model analysis of variance (29) using the commercial software package SAS JMP7 Genomics, version 3.1 from SAS (SAS Institute, Cary, NC). A false positive rate of   0.05 with Holm correction was taken as level of significance. To be significantly regulated, only genes with a -fold change of 1.5 and a p value less than or equal to the threshold estimated by the Holm multiple testing algorithm, as compared with the empty vector without 4OHT, were considered. Additionally, genes with a significantly different regulation between FOXO3.A3.ER and FOXO3.A3.ER.H212R according to Holm correction and a 2-fold differential regulation between FOXO3.A3.ER and FOXO3.A3.ER.H212R were resorted from the co-regulated group to FOXO3.A3.ER or FOXO3.A3.ER.H212R, respectively.
11300	 7352	11173	FOXO3	Protein	ARG1	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
 1304	 7352	 7836	FOXO3	Protein	CD55	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
13247	 7352	 1186	FOXO3	Protein	UBR5	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
13267	 7352	19257	FOXO3	Protein	UCN3	mRNA	-1	1	14563822	Modified assertion
14125	 7352	18264	FOXO3	Protein	OGT	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
14139	 7352	 4864	FOXO3	Protein	HBP1	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
14531	 7352	 8287	FOXO3	Protein	ATP7A	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
16481	 7352	18083	FOXO3	Protein	BNIP3	mRNA	-1	1	11964479	Table 1. Identification of FOXO3a target genes by transcriptional profiling.
16864	 7352	18255	FOXO3	Protein	VCL	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
17799	 7352	 5117	FOXO3	Protein	SAT1	mRNA	1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
18055	 7352	11889	FOXO3	Protein	DEDD	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
19897	 7352	14849	FOXO3	Protein	TGFB2	mRNA	-1	1	12011061	Modified assertion
19918	 7352	17834	FOXO3	Protein	CCNG2	mRNA	-1	1	11964479	Table 1. Identification of FOXO3a target genes by transcriptional profiling.
20661	 7352	19541	FOXO3	Protein	MXD3	mRNA	0	1	17452451	We then analyzed expression of all four Mad/Mxd family  members, Mad1, Mxi1 (also termed Mad2), Mad3, and Mad4,  in DL23 and parental DLD1 cells. Activation of FOXO3a.A3-ER  by 4-OHT resulted in a two- to fourfold increase in mRNA  abundance of all Mad/Mxd family members in DL23 cells,  while the same treatment had no effect in parental cells (Fig.  3A).
21909	 7352	 3995	FOXO3	Protein	ESR1	mRNA	-1	1	15367686	expression of ERalpha was correlated with active FOXO3a levels. Ectopic FOXO3a expression induced ERalpha protein levels and promoter activity, while a dominant negative FOXO3a decreased ERalpha levels.
  228	 7352	19043	FOXO3	Protein	PINK1	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
22839	 7352	16335	FOXO3	Protein	PGGT1B	mRNA	0	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
23391	 7352	 9226	FOXO3	Protein	CITED2	mRNA	1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
25048	 7352	17353	FOXO3	Protein	GRIA3	mRNA	1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
 2505	 7352	11815	FOXO3	Protein	PNRC1	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
25052	 7352	16134	FOXO3	Protein	BC005685	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
25302	 7352	13534	FOXO3	Protein	CCNE2	mRNA	-1	-1	15241468	Indeed, induction of multiple target genes of Myc, including cyclin D2, cdk4, odc, cyclin E2 (B Amati, personal communication), jvt-1 and cad, was strongly inhibited by FoxO3a(A3) (Figure 5A). _  [NC] jvt-1 should be jtv-1
25358	 7352	16061	FOXO3	Protein	KIT	mRNA	0	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
27419	 7352	17966	FOXO3	Protein	MXI1	mRNA	0	1	17452451	Induction of Mxi1 by FOXO3a was also observed in a mammary epithelial cell line (MCF-10A) expressing the FOXO3a.A3-ER fusion protein (clone M11, Figure S3 and S5B).
27645	 7352	12781	FOXO3	Protein	AR	mRNA	1	1	16061480	Here we provide the first linkage by the identification of Forkhead transcription factor FOXO3a, the PI3K/Akt downstream substrate, as a positive regulator for the induction of AR gene expression.
 2817	 7352	 7073	FOXO3	Protein	FXYD3	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
 2829	 7352	  931	FOXO3	Protein	TP53INP1	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
28291	 7352	 6449	FOXO3	Protein	CFLAR	mRNA	1	-1	14551207	Transduction of a nonphosphorylatable, constitutively active mutant of FOXO3a (TM-FOXO3a) led to the down-regulation of FLIP levels.
  283	 7352	  279	FOXO3	Protein	HIPK1	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
28863	 7352	 2111	FOXO3	Protein	ULK1	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
28972	 7352	16957	FOXO3	Protein	ASAH1	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
29518	 7352	18773	FOXO3	Protein	GRB14	mRNA	1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
29648	 7352	13006	FOXO3	Protein	HMGCS2	mRNA	0	1	12027802	FKHRL1, a member of the forkhead in rhabdosarcoma (FKHR) subclass of the Fox family of transcription factors, stimulates transcription from transfected 3-hydroxy-3-methylglutaryl-CoA synthase promoter-luciferase reporter constructs, and that this stimulation is repressed by insulin.
30167	 7352	 2666	FOXO3	Protein	TCF12	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
  309	 7352	19342	FOXO3	Protein	C5orf63	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
32948	 7352	11686	FOXO3	Protein	GTF2I	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
33400	 7352	11976	FOXO3	Protein	PDK4	mRNA	0	1	15047604	Modified assertion
34479	 7352	13882	FOXO3	Protein	DNAJC12	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
34791	 7352	17308	FOXO3	Protein	LGMN	mRNA	-1	1	11964479	Table 1. Identification of FOXO3a target genes by transcriptional profiling.
35234	 7352	 5296	FOXO3	Protein	PLAU	mRNA	1	-1	18239069	In this paper we refine our analysis through the use of FOXO3a chromatin immunoprecipitation (ChIP) microarrays. ChIP microarray results reveal urokinase plasminogen activator (uPA) as a putative novel target of FOXO3a in breast epithelial and breast cancer cell lines. We further show that uPA down-regulation after GC treatment requires serum and GC regulated kinase-1-mediated inactivation of FOXO3a activity. ChIP and luciferase assays confirm that FOXO3a can both occupy and transactivate the uPA promoter.
35569	 7352	 5489	FOXO3	Protein	DAAM1	mRNA	1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
35606	 7352	 1571	FOXO3	Protein	RBL2	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
36558	 7352	 4029	FOXO3	Protein	TLE4	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
36665	 7352	11314	FOXO3	Protein	PCK2	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
37432	 7352	 5336	FOXO3	Protein	SFT2D2	mRNA	1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
38883	 7352	17325	FOXO3	Protein	MXD1	mRNA	-1	1	17452451	We then analyzed expression of all four Mad/Mxd family  members, Mad1, Mxi1 (also termed Mad2), Mad3, and Mad4,  in DL23 and parental DLD1 cells. Activation of FOXO3a.A3-ER  by 4-OHT resulted in a two- to fourfold increase in mRNA  abundance of all Mad/Mxd family members in DL23 cells,  while the same treatment had no effect in parental cells (Fig.  3A).
39121	 7352	16360	FOXO3	Protein	DCP1A	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
39224	 7352	 7376	FOXO3	Protein	TNFSF10	mRNA	-1	1	15668399	Activated FOXO proteins also trigger apoptosis in many cancer cell lines through regulation of a number of proapoptotic proteins, including Fas ligand, TRAIL, and Bim.
39380	 7352	18612	FOXO3	Protein	SOD2	mRNA	-1	1	12239572	By contrast, it is unknown how quiescent cells that lack PKB activity are protected against cell death induced by reactive oxygen species.
39412	 7352	 5243	FOXO3	Protein	SESN1	mRNA	-1	1	11964479	Table 1. Identification of FOXO3a target genes by transcriptional profiling.
39578	 7352	13744	FOXO3	Protein	CDKN1B	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
39809	 7352	 7769	FOXO3	Protein	FOXO1	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
40923	 7352	13617	FOXO3	Protein	SMAD4	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
 4095	 7352	 9978	FOXO3	Protein	GNAI2	mRNA	1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
40976	 7352	 4582	FOXO3	Protein	NOS3	mRNA	1	-1	16100571	Whereas angiopoietin 2 (Ang2) was exclusively regulated by Foxo1, eNOS, which is essential for postnatal neovascularization, was regulated by Foxo1 and Foxo3a. Consistent with these findings, constitutively active Foxo1 and Foxo3a repressed eNOS protein expression and bound to the eNOS promoter.
41804	 7352	 4001	FOXO3	Protein	PGM2L1	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
44957	 7352	14932	FOXO3	Protein	CR2	mRNA	0	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
45049	 7352	 5538	FOXO3	Protein	NF2	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
46034	 7352	12530	FOXO3	Protein	HPGD	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
46081	 7352	 3845	FOXO3	Protein	HSCB	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
46375	 7352	16465	FOXO3	Protein	CAD	mRNA	1	-1	15241468	Indeed, induction of multiple target genes of Myc, including cyclin D2, cdk4, odc, cyclin E2 (B Amati, personal communication), jvt-1 and cad, was strongly inhibited by FoxO3a(A3) (Figure 5A). _  [NC] jvt-1 should be jtv-1
47795	 7352	 6938	FOXO3	Protein	CTSE	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
47899	 7352	12849	FOXO3	Protein	BNIP3L	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
48188	 7352	 6706	FOXO3	Protein	EXT1	mRNA	-1	1	11964479	Table 1. Identification of FOXO3a target genes by transcriptional profiling.
48209	 7352	 1302	FOXO3	Protein	ATP8A1	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
48589	 7352	 3024	FOXO3	Protein	FLJ13224	mRNA	0	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
48784	 7352	17731	FOXO3	Protein	DCN	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
50180	 7352	 7603	FOXO3	Protein	AMPD2	mRNA	0	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
 5036	 7352	11796	FOXO3	Protein	CPEB4	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
51049	 7352	13884	FOXO3	Protein	CDKN1A	mRNA	1	1	15917664	FOXO proteins intervene in the cell cycle by activating the cyclin-dependent kinase (CDK) inhibitors p27kip1 and p21 cip1.
51494	 7352	15841	FOXO3	Protein	FBXO32	mRNA	-1	1	15109499	we show that in cultured myotubes undergoing atrophy, the activity of the PI3K/AKT pathway decreases, leading to activation of Foxo transcription factors and atrogin-1 induction.
51546	 7352	 2679	FOXO3	Protein	CCPG1	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
51664	 7352	  219	FOXO3	Protein	FASLG	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
51699	 7352	12817	FOXO3	Protein	VOPP1	mRNA	0	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
51726	 7352	14357	FOXO3	Protein	TCP11L2	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
52998	 7352	19009	FOXO3	Protein	TSC22D3	mRNA	1	1	15031210	IL-2 deprivation leads to expression of GILZ in T lymphocytes. We then characterized the human gilz promoter and showed that FoxO3 (Forkhead box class O3) binding to the Forkhead responsive elements identified in the promoter is necessary for induction of gilz expression upon IL-2 withdrawal
53610	 7352	18628	FOXO3	Protein	TMX1	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
53790	 7352	16877	FOXO3	Protein	SIRPA	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
53880	 7352	  441	FOXO3	Protein	ATP1B3	mRNA	1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
53887	 7352	 6691	FOXO3	Protein	UNCX	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
53893	 7352	14838	FOXO3	Protein	NKIRAS2	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
55088	 7352	 4733	FOXO3	Protein	PPM1D	mRNA	-1	1	11964479	Table 1. Identification of FOXO3a target genes by transcriptional profiling.
55807	 7352	10718	FOXO3	Protein	TNFAIP8	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
56097	 7352	 8304	FOXO3	Protein	OSBPL9	mRNA	1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
56671	 7352	 6613	FOXO3	Protein	GLCCI1	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
57376	 7352	10331	FOXO3	Protein	XPO7	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
58378	 7352	 6053	FOXO3	Protein	CAT	mRNA	-1	1	15917664	Transcriptional control by FOXO also extends to the regulation of pro-apoptotic genes Bim and Fas Ligand and to the stress response genes like GADD45, Mn superoxide dismutase and catalase.
58558	 7352	  497	FOXO3	Protein	SIRT1	mRNA	-1	1	15604409	Knockdown of Foxo3a expression inhibited the starvation-induced increase in SIRT1 expression.  Stimulation of SIRT1 transcription by Foxo3a was mediated through two p53 binding sites present in the SIRT1 promoter, and a nutrient-sensitive physical interaction was observed between Foxo3a and p53.  SIRT1 expression was not induced in starved p53-deficient mice.
58829	 7352	 9550	FOXO3	Protein	CDK4	mRNA	1	-1	20123982	TABLE 3 Genes involved in proliferation and cell cycle regulation that are repressed by FOXO3.A3.ER and FOXO3.A3.ER.H212R as identified by functional annotation clustering.  Affymetrix HG-U133 Plus 2.0 arrays according to the manufacturer?s instructions (Affymetrix, Santa Clara, CA).A Custom CDF Version 11 with Entrez-based gene definitions was used to annotate the arrays (28). Raw fluorescence intensity values were normalized, applying quantile normalization. Differential gene expression was analyzed based on log linear mixed model analysis of variance (29) using the commercial software package SAS JMP7 Genomics, version 3.1 from SAS (SAS Institute, Cary, NC). A false positive rate of   0.05 with Holm correction was taken as level of significance. To be significantly regulated, only genes with a -fold change of 1.5 and a p value less than or equal to the threshold estimated by the Holm multiple testing algorithm, as compared with the empty vector without 4OHT, were considered. Additionally, genes with a significantly different regulation between FOXO3.A3.ER and FOXO3.A3.ER.H212R according to Holm correction and a 2-fold differential regulation between FOXO3.A3.ER and FOXO3.A3.ER.H212R were resorted from the co-regulated group to FOXO3.A3.ER or FOXO3.A3.ER.H212R, respectively.
58903	 7352	10064	FOXO3	Protein	SELP	mRNA	-1	1	11964479	The signaling pathway from phosphoinositide 3-kinase to the protein kinase Akt controls organismal life-span in invertebrates and cell survival and proliferation in mammals by inhibiting the activity of members of the FOXO family of transcription factors. Table 1. Identification of FOXO3a target genes by transcriptional profiling.
59926	 7352	13264	FOXO3	Protein	TRIM63	mRNA	-1	1	15292521	the FOXO transcription factors and muscle atrophy the FOXO family of transcription factors was reported to regulate MAFbx and MuRF1 transcription and to influence muscle atrophy
61259	 7352	 1552	FOXO3	Protein	ODC1	mRNA	1	-1	15241468	Indeed, induction of multiple target genes of Myc, including cyclin D2, cdk4, odc, cyclin E2 (B Amati, personal communication), jvt-1 and cad, was strongly inhibited by FoxO3a(A3) (Figure 5A). _  [NC] jvt-1 should be jtv-1
62374	 7352	 9848	FOXO3	Protein	SLC12A6	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
62913	 7352	 8521	FOXO3	Protein	CBLB	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
62919	 7352	 7195	FOXO3	Protein	GADD45A	mRNA	-1	1	11964479	Table 1. Identification of FOXO3a target genes by transcriptional profiling.
63116	 7352	13881	FOXO3	Protein	JAK1	mRNA	-1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
63229	 7352	  460	FOXO3	Protein	SEPP1	mRNA	1	1	11964479	Table 1. Identification of FOXO3a target genes by transcriptional profiling.
63872	 7352	12543	FOXO3	Protein	IGFBP1	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
64186	 7352	 6765	FOXO3	Protein	C10orf10	mRNA	0	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
65444	 7352	19519	FOXO3	Protein	CPT1A	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
 6545	 7352	 5374	FOXO3	Protein	MXD4	mRNA	-1	1	17452451	We then analyzed expression of all four Mad/Mxd family  members, Mad1, Mxi1 (also termed Mad2), Mad3, and Mad4,  in DL23 and parental DLD1 cells. Activation of FOXO3a.A3-ER  by 4-OHT resulted in a two- to fourfold increase in mRNA  abundance of all Mad/Mxd family members in DL23 cells,  while the same treatment had no effect in parental cells (Fig.  3A).
65574	 7352	10022	FOXO3	Protein	LIMK2	mRNA	-1	1	17353275	TABLE 2. Foxo3a-upregulated, Epo/SCF-downregulated genes (cluster A) SCF = KITLG
66084	 7352	16821	FOXO3	Protein	DST	mRNA	1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
 8310	 7352	10425	FOXO3	Protein	PNPLA6	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
 8333	 7352	 6202	FOXO3	Protein	BTG1	mRNA	-1	1	14734530	We identified B cell translocation gene 1 (BTG1)/antiproliferative protein 2 as a FoxO3a target gene in erythroid progenitors. Promoter studies indicated BTG1 as a direct target of FoxO3a.
 8882	 7352	13511	FOXO3	Protein	NCEH1	mRNA	-1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
 9538	 7352	20162	FOXO3	Protein	SATB1	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
 9838	 7352	18112	FOXO3	Protein	Zfp60	mRNA	1	1	17353275	TABLE 3. Foxo3a-upregulated genes not regulated by Epo/SCF (cluster D)
40957	12614	 4582	Agtr1b	Protein	NOS3	mRNA	1	1	11044228	The expressions of eNOS in cortical microvascular endothelium and DDAH in kidney are enhanced by Ang II acting on AT(1) receptors. The expression of nNOS in the macula densa is enhanced by salt restriction independent of Ang II or AT(1) receptors.
44068	12614	15206	Agtr1b	Protein	ATP2A2	mRNA	0	-1	16324756	Moreover, SERCA2 mRNA and protein expression were both down-regulated in myopathic hearts and restored to normal by candesartan treatment, significantly
58683	12614	18695	Agtr1b	Protein	MYOCD	mRNA	0	1	15016729	Results showed that Ang II increased myocardin mRNA expression as well as SM alpha-actin mRNA expression via the Ang II type 1 receptor in cultured rat aortic SMCs.
59694	12614	10088	Agtr1b	Protein	Acta2	mRNA	0	1	15016729	Results showed that Ang II increased myocardin mRNA expression as well as SM alpha-actin mRNA expression via the Ang II type 1 receptor in cultured rat aortic SMCs.
24593	 2488	18840	ZBTB17	Protein	GK	mRNA	0	1	14704274	list of potential MIZ-1 targets (SPTBN1, IER3, LDLR, SERPINE1, JAG1, GK, and SLC38A1)
25165	 2488	12328	ZBTB17	Protein	SLC38A1	mRNA	0	1	14704274	list of potential MIZ-1 targets (SPTBN1, IER3, LDLR, SERPINE1, JAG1, GK, and SLC38A1)
34348	 2488	 2401	ZBTB17	Protein	LDLR	mRNA	0	1	11545736	The myc-interacting zinc finger protein (MIZ-1) associates with microtubules, can bind directly to the LDLR promoter, and can activate LDLR transcription.
 4934	 2488	10424	ZBTB17	Protein	JAG1	mRNA	0	1	14704274	list of potential MIZ-1 targets (SPTBN1, IER3, LDLR, SERPINE1, JAG1, GK, and SLC38A1)
51009	 2488	13884	ZBTB17	Protein	CDKN1A	mRNA	1	1	12545156	Modified assertion
55772	 2488	18155	ZBTB17	Protein	IER3	mRNA	0	1	14704274	list of potential MIZ-1 targets (SPTBN1, IER3, LDLR, SERPINE1, JAG1, GK, and SLC38A1)
59768	 2488	13414	ZBTB17	Protein	SERPINE1	mRNA	0	1	14704274	list of potential MIZ-1 targets (SPTBN1, IER3, LDLR, SERPINE1, JAG1, GK, and SLC38A1)
64326	 2488	11057	ZBTB17	Protein	ITGA2	mRNA	0	1	11545736	MIZ-1 also binds to the promoter and activates transcription of other T113242-induced genes such as alpha(2) integrin.
 6543	 2488	 5374	ZBTB17	Protein	MXD4	mRNA	-1	1	12418961	Modified assertion
 9550	 2488	 4860	ZBTB17	Protein	SPTBN1	mRNA	0	1	14704274	list of potential MIZ-1 targets (SPTBN1, IER3, LDLR, SERPINE1, JAG1, GK, and SLC38A1)
11032	13399	 8037	lipopolysaccharide	Compound	KLF6	mRNA	1	1	16495566	Complete list of significantly regulated genes 4 hours following intramammary LPS using the following cutoff criteria: P < 0.05 and change ?1.7-fold
11841	13399	16365	lipopolysaccharide	Compound	IL1A	mRNA	0	1	16207706	Lipopolysaccharide (LPS) activation of murine RAW 264.7 macrophages influences the expression of multiple genes through transcriptional and post-transcriptional mechanisms. We observed a 5-fold increase in CstF-64 expression following LPS treatment of RAW macrophages. The increase in CstF-64 protein was specific in that several other factors involved in 3p-end processing were not affected by LPS stimulation. Activation of RAW macrophages with LPS caused an increase in proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites that occurred concomitant with the increase in CstF-64 expression. Furthermore, forced overexpression of the CstF-64 protein also induced alternative poly(A) site selection on the reporter minigene. Microarray analysis performed on CstF-64 overexpressing RAW macrophages revealed that elevated levels of CstF-64 altered the expression of 51 genes, 14 of which showed similar changes in gene expression with LPS stimulation. Sequence analysis of the 3p-untranslated regions of these 51 genes revealed that over 45% possess multiple putative poly(A) sites. Two of these 51 genes demonstrated alternative polyadenylation under both LPS-stimulating and CstF-64-overexpressing conditions. We concluded that the physiologically increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the changes in expression and alternative polyadenylation of a number of genes, thus identifying another level of gene regulation that occurs in macrophages activated with LPS.
12424	13399	15036	lipopolysaccharide	Compound	SEPHS2	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
13088	13399	 7202	lipopolysaccharide	Compound	LTA	mRNA	0	1	15226448	TABLE 1. LPS and IKKg target gene profiling in murine pre-B cells
15476	13399	18775	lipopolysaccharide	Compound	PFKFB3	mRNA	0	1	10077634	By contrast, Northern blot analysis of human monocytes stimulated with LPS showed that this particular PFK-2 gene was rapidly induced (and therefore was designated iPFK-2)
17652	13399	 9333	lipopolysaccharide	Compound	RACGAP1	mRNA	0	-1	16207706	Lipopolysaccharide (LPS) activation of murine RAW 264.7 macrophages influences the expression of multiple genes through transcriptional and post-transcriptional mechanisms. We observed a 5-fold increase in CstF-64 expression following LPS treatment of RAW macrophages. The increase in CstF-64 protein was specific in that several other factors involved in 3p-end processing were not affected by LPS stimulation. Activation of RAW macrophages with LPS caused an increase in proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites that occurred concomitant with the increase in CstF-64 expression. Furthermore, forced overexpression of the CstF-64 protein also induced alternative poly(A) site selection on the reporter minigene. Microarray analysis performed on CstF-64 overexpressing RAW macrophages revealed that elevated levels of CstF-64 altered the expression of 51 genes, 14 of which showed similar changes in gene expression with LPS stimulation. Sequence analysis of the 3p-untranslated regions of these 51 genes revealed that over 45% possess multiple putative poly(A) sites. Two of these 51 genes demonstrated alternative polyadenylation under both LPS-stimulating and CstF-64-overexpressing conditions. We concluded that the physiologically increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the changes in expression and alternative polyadenylation of a number of genes, thus identifying another level of gene regulation that occurs in macrophages activated with LPS.
18277	13399	16928	lipopolysaccharide	Compound	MEFV	mRNA	0	1	10807793	Modified assertion
19695	13399	16486	lipopolysaccharide	Compound	SPP1	mRNA	1	1	11145688	Osteopontin (OPN), a secreted acidic phosphoprotein that binds to a cell surface RGD integrin-binding motif, was found to be differentially expressed in the presence of NO...Northern blot and nuclear run-on analyses demonstrated that OPN mRNA levels and gene transcription were significantly increased in the presence of LPS-induced NO synthesis.
20264	13399	19571	lipopolysaccharide	Compound	CXCL2	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
20602	13399	12621	lipopolysaccharide	Compound	ANXA7	mRNA	-1	1	11943771	Of the LPS-regulated proteins identified by peptide mass fingerprinting for which probes were present on the oligonucleotide microarray... Similarly, CAP1, Rho-GAP1, and ficolin 1 were down-regulated at both the mRNA transcript and protein levels
21353	13399	10792	lipopolysaccharide	Compound	PON1	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
21907	13399	 3995	lipopolysaccharide	Compound	ESR1	mRNA	-1	1	12057914	Time-course studies identified early, intermediate, and late genes that were commonly up-regulated by all three stimuli. These genes included: phosphodiesterase 1C, cAMP-dependent protein kinase, iNOS, beta-NGF, proenkephalin B and orphanin, corticotrophin-releasing factor (CRF) R, estrogen R, PAI2, and protease inhibitor 17, NFkB p105, c-fos, fos-B, basic transcription factors, and cytoskeleton and motility proteins.
22662	13399	 7012	lipopolysaccharide	Compound	DMBT1	mRNA	0	1	15084757	See Supplemental Tables 1-7. Average Signal Intensity Relative to V-treated Signal Intensity. All changes are greater than or equal to 1.5.
23886	13399	 5783	lipopolysaccharide	Compound	CEBPB	mRNA	0	1	10594926	lipopolysaccharides (LPS), IL-1beta, and TNFalpha induce the expression of the c/ebpbeta and -delta genes in mouse primary astrocytes.
25647	13399	 4935	lipopolysaccharide	Compound	CXCR7	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
25920	13399	16091	lipopolysaccharide	Compound	CD59	mRNA	0	-1	10480555	In the present study, we demonstrated, by the reverse transcription-polymerase chain reaction method, the mRNA expression of complement components (C3, C4, and C5) and membrane regulators (decay-accelerating factor, membrane cofactor protein, Crry, and CD59) in cultured SMCs derived from the rat carotid artery. The expression of C9 mRNA was also induced upon stimulation by interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha) and/or lipopolysaccharide (LPS). Northern blot analysis showed that the mRNA expression of C3, C4, DAF and Crry was up-regulated, but that of CD59 was down-regulated by IFN-gamma, TNF-alpha and/or LPS alone or by synergy.
26374	13399	10421	lipopolysaccharide	Compound	PLD1	mRNA	0	1	11485559	Lipopolysaccharide and pathogen-derived agonists (Candida albicans, arabinoside-terminated lipoarabinomannan and Gram-positive bacteria, but not mannose-capped lipoarabinomannan or double-stranded RNA) strongly induced PLD1 expression at both the mRNA and protein levels.
28602	13399	 3297	lipopolysaccharide	Compound	TIMP1	mRNA	0	1	11343254	See Figure 1: Toxicogenomic patterns of gene expression. All changes correspond to the LPS, 6 hour timepoint and are greater than or equal to 2.
28908	13399	14639	lipopolysaccharide	Compound	CAMK2D	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
29482	13399	 4277	lipopolysaccharide	Compound	MCM7	mRNA	0	-1	16207706	Lipopolysaccharide (LPS) activation of murine RAW 264.7 macrophages influences the expression of multiple genes through transcriptional and post-transcriptional mechanisms. We observed a 5-fold increase in CstF-64 expression following LPS treatment of RAW macrophages. The increase in CstF-64 protein was specific in that several other factors involved in 3p-end processing were not affected by LPS stimulation. Activation of RAW macrophages with LPS caused an increase in proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites that occurred concomitant with the increase in CstF-64 expression. Furthermore, forced overexpression of the CstF-64 protein also induced alternative poly(A) site selection on the reporter minigene. Microarray analysis performed on CstF-64 overexpressing RAW macrophages revealed that elevated levels of CstF-64 altered the expression of 51 genes, 14 of which showed similar changes in gene expression with LPS stimulation. Sequence analysis of the 3p-untranslated regions of these 51 genes revealed that over 45% possess multiple putative poly(A) sites. Two of these 51 genes demonstrated alternative polyadenylation under both LPS-stimulating and CstF-64-overexpressing conditions. We concluded that the physiologically increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the changes in expression and alternative polyadenylation of a number of genes, thus identifying another level of gene regulation that occurs in macrophages activated with LPS.
29693	13399	 6312	lipopolysaccharide	Compound	PREB	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
 3031	13399	13473	lipopolysaccharide	Compound	HBEGF	mRNA	0	1	16207706	Lipopolysaccharide (LPS) activation of murine RAW 264.7 macrophages influences the expression of multiple genes through transcriptional and post-transcriptional mechanisms. We observed a 5-fold increase in CstF-64 expression following LPS treatment of RAW macrophages. The increase in CstF-64 protein was specific in that several other factors involved in 3p-end processing were not affected by LPS stimulation. Activation of RAW macrophages with LPS caused an increase in proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites that occurred concomitant with the increase in CstF-64 expression. Furthermore, forced overexpression of the CstF-64 protein also induced alternative poly(A) site selection on the reporter minigene. Microarray analysis performed on CstF-64 overexpressing RAW macrophages revealed that elevated levels of CstF-64 altered the expression of 51 genes, 14 of which showed similar changes in gene expression with LPS stimulation. Sequence analysis of the 3p-untranslated regions of these 51 genes revealed that over 45% possess multiple putative poly(A) sites. Two of these 51 genes demonstrated alternative polyadenylation under both LPS-stimulating and CstF-64-overexpressing conditions. We concluded that the physiologically increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the changes in expression and alternative polyadenylation of a number of genes, thus identifying another level of gene regulation that occurs in macrophages activated with LPS.
31909	13399	 7289	lipopolysaccharide	Compound	MX2	mRNA	0	1	16207706	Lipopolysaccharide (LPS) activation of murine RAW 264.7 macrophages influences the expression of multiple genes through transcriptional and post-transcriptional mechanisms. We observed a 5-fold increase in CstF-64 expression following LPS treatment of RAW macrophages. The increase in CstF-64 protein was specific in that several other factors involved in 3p-end processing were not affected by LPS stimulation. Activation of RAW macrophages with LPS caused an increase in proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites that occurred concomitant with the increase in CstF-64 expression. Furthermore, forced overexpression of the CstF-64 protein also induced alternative poly(A) site selection on the reporter minigene. Microarray analysis performed on CstF-64 overexpressing RAW macrophages revealed that elevated levels of CstF-64 altered the expression of 51 genes, 14 of which showed similar changes in gene expression with LPS stimulation. Sequence analysis of the 3p-untranslated regions of these 51 genes revealed that over 45% possess multiple putative poly(A) sites. Two of these 51 genes demonstrated alternative polyadenylation under both LPS-stimulating and CstF-64-overexpressing conditions. We concluded that the physiologically increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the changes in expression and alternative polyadenylation of a number of genes, thus identifying another level of gene regulation that occurs in macrophages activated with LPS.
33120	13399	12179	lipopolysaccharide	Compound	FST	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
34028	13399	14883	lipopolysaccharide	Compound	IL1R1	mRNA	0	1	15994259	Figure 1 Gene expression in peripheral blood neutrophils stimulated by several mediators in vitro. (RT-PCR)  Peripheral blood neutrophils were incubated with several physiological stimuli for 3 hours in vitro at 37?C (TNFa, 100 U/ml; GM-CSF, 0.1 nM; IL-8, 10 nM; fMLP, 1 mM; LPS, 10 ng/ml). Expression of indicated genes was measured by real time RT-PCR.
34766	13399	19508	lipopolysaccharide	Compound	BMP2	mRNA	0	-1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
35173	13399	17804	lipopolysaccharide	Compound	NOTCH1	mRNA	0	1	15226448	TABLE 1. LPS and IKKg target gene profiling in murine pre-B cells
35344	13399	10066	lipopolysaccharide	Compound	DIO3	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
36336	13399	 1868	lipopolysaccharide	Compound	PDGFC	mRNA	0	-1	17400552	_Supplemental Table 1. Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond similarly to HA and LPS._
36404	13399	 4537	lipopolysaccharide	Compound	MSR1	mRNA	0	1	16207706	Lipopolysaccharide (LPS) activation of murine RAW 264.7 macrophages influences the expression of multiple genes through transcriptional and post-transcriptional mechanisms. We observed a 5-fold increase in CstF-64 expression following LPS treatment of RAW macrophages. The increase in CstF-64 protein was specific in that several other factors involved in 3p-end processing were not affected by LPS stimulation. Activation of RAW macrophages with LPS caused an increase in proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites that occurred concomitant with the increase in CstF-64 expression. Furthermore, forced overexpression of the CstF-64 protein also induced alternative poly(A) site selection on the reporter minigene. Microarray analysis performed on CstF-64 overexpressing RAW macrophages revealed that elevated levels of CstF-64 altered the expression of 51 genes, 14 of which showed similar changes in gene expression with LPS stimulation. Sequence analysis of the 3p-untranslated regions of these 51 genes revealed that over 45% possess multiple putative poly(A) sites. Two of these 51 genes demonstrated alternative polyadenylation under both LPS-stimulating and CstF-64-overexpressing conditions. We concluded that the physiologically increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the changes in expression and alternative polyadenylation of a number of genes, thus identifying another level of gene regulation that occurs in macrophages activated with LPS.
37275	13399	 8901	lipopolysaccharide	Compound	IL12B	mRNA	0	1	15153525	CCR7, IL-12B, IFN-b1, SERPINB2, TUBB2, and NR4A3 was augmented by exposure to LPS and inhibited by concomitant IL-10
38131	13399	 5870	lipopolysaccharide	Compound	HRH1	mRNA	0	-1	14575147	When expressions of histamine H1 (H1R) and H2 (H2R) receptors in DC were analyzed by RT-PCR, both receptors were down-regulated after LPS or TNF-alpha
 3966	13399	11950	lipopolysaccharide	Compound	PLRG1	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
39789	13399	18172	lipopolysaccharide	Compound	FBXO31	mRNA	0	-1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
41982	13399	12560	lipopolysaccharide	Compound	IL10RB	mRNA	0	1	15226448	TABLE 1. LPS and IKKg target gene profiling in murine pre-B cells
42208	13399	12440	lipopolysaccharide	Compound	SAA1	mRNA	0	1	16717027	TABLE 2 Genes up- or downregulated more than 10-fold in the LPS group
42666	13399	 2600	lipopolysaccharide	Compound	PYCARD	mRNA	0	1	14634131	Moreover, LPS and TNF induce increases in ASC mRNA and protein expression in cells of myeloid/monocytic origin,
42786	13399	14047	lipopolysaccharide	Compound	RPSA	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
42814	13399	 3879	lipopolysaccharide	Compound	FAS	mRNA	0	1	16207706	Lipopolysaccharide (LPS) activation of murine RAW 264.7 macrophages influences the expression of multiple genes through transcriptional and post-transcriptional mechanisms. We observed a 5-fold increase in CstF-64 expression following LPS treatment of RAW macrophages. The increase in CstF-64 protein was specific in that several other factors involved in 3p-end processing were not affected by LPS stimulation. Activation of RAW macrophages with LPS caused an increase in proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites that occurred concomitant with the increase in CstF-64 expression. Furthermore, forced overexpression of the CstF-64 protein also induced alternative poly(A) site selection on the reporter minigene. Microarray analysis performed on CstF-64 overexpressing RAW macrophages revealed that elevated levels of CstF-64 altered the expression of 51 genes, 14 of which showed similar changes in gene expression with LPS stimulation. Sequence analysis of the 3p-untranslated regions of these 51 genes revealed that over 45% possess multiple putative poly(A) sites. Two of these 51 genes demonstrated alternative polyadenylation under both LPS-stimulating and CstF-64-overexpressing conditions. We concluded that the physiologically increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the changes in expression and alternative polyadenylation of a number of genes, thus identifying another level of gene regulation that occurs in macrophages activated with LPS.
 4307	13399	19709	lipopolysaccharide	Compound	RGS2	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
43248	13399	 5318	lipopolysaccharide	Compound	ADH5	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
43727	13399	19003	lipopolysaccharide	Compound	BLVRA	mRNA	0	1	16287987	As will be discussed below, reduction of biliverdin, a kinase inhibitor, is an important aspect of regulatory activity of BVR. BVR is the product of a single-copy gene that, in the rat, is 17,025 bp in length and consists of seven exons and six introns (38) (GenBank). The human BVR gene has eight exons, with the initiation codon in exon 2. Exon 5 includes the most strongly conserved motif, which is found in every oxidoreductase (30). In the rat, the ~1.6-kb transcript is expressed sparingly in organs such as the testis and the thymus but abundantly in others such as the kidney, spleen, liver, and brain. The promoter region of the human and rat genes contain consensus sequence elements (38) associated with regulation of transcriptional activity, embryonic gene expression, and response to hyperthermia (12, 39). In addition to hyperthermia, cytokines and LPS induce BVR transcription (33).
44553	13399	 3462	lipopolysaccharide	Compound	NR1H4	mRNA	0	-1	12519762	we show that LPS significantly decreases farnesoid X receptor (FXR) mRNA in mouse liver
45355	13399	14987	lipopolysaccharide	Compound	BCL2	mRNA	1	1	12509443	The human monocytic cell line THP-1 treated with lipopolysaccharide (LPS) was used as a reproducible cellular model system Below are proteins upregulated by LPS
45877	13399	 9262	lipopolysaccharide	Compound	CYP1A1	mRNA	0	-1	17588258	Both TNF-alpha and LPS repressed the beta-naphthoflavone (betaNF)-mediated induction of Cyp1a1 and Nqo1 at mRNA and activity levels. The downregulation of Cyp1a1, but not Nqo1, was significantly prevented by L-NIL, a Nos2 inhibitor.
45961	13399	12319	lipopolysaccharide	Compound	CAST	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
46480	13399	19036	lipopolysaccharide	Compound	EPHA2	mRNA	0	1	15226448	TABLE 1. LPS and IKKg target gene profiling in murine pre-B cells
47718	13399	12513	lipopolysaccharide	Compound	Tnfaip6	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
 4786	13399	12369	lipopolysaccharide	Compound	HRH2	mRNA	0	-1	14575147	When expressions of histamine H1 (H1R) and H2 (H2R) receptors in DC were analyzed by RT-PCR, both receptors were down-regulated after LPS or TNF-alpha
48151	13399	12541	lipopolysaccharide	Compound	UPP1	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
48189	13399	 6706	lipopolysaccharide	Compound	EXT1	mRNA	-1	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
48678	13399	 9174	lipopolysaccharide	Compound	CXCR6	mRNA	0	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
49911	13399	16285	lipopolysaccharide	Compound	FLOT1	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
50243	13399	 9472	lipopolysaccharide	Compound	ATP1B1	mRNA	0	-1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
50863	13399	  727	lipopolysaccharide	Compound	KIF20A	mRNA	0	-1	16207706	Lipopolysaccharide (LPS) activation of murine RAW 264.7 macrophages influences the expression of multiple genes through transcriptional and post-transcriptional mechanisms. We observed a 5-fold increase in CstF-64 expression following LPS treatment of RAW macrophages. The increase in CstF-64 protein was specific in that several other factors involved in 3p-end processing were not affected by LPS stimulation. Activation of RAW macrophages with LPS caused an increase in proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites that occurred concomitant with the increase in CstF-64 expression. Furthermore, forced overexpression of the CstF-64 protein also induced alternative poly(A) site selection on the reporter minigene. Microarray analysis performed on CstF-64 overexpressing RAW macrophages revealed that elevated levels of CstF-64 altered the expression of 51 genes, 14 of which showed similar changes in gene expression with LPS stimulation. Sequence analysis of the 3p-untranslated regions of these 51 genes revealed that over 45% possess multiple putative poly(A) sites. Two of these 51 genes demonstrated alternative polyadenylation under both LPS-stimulating and CstF-64-overexpressing conditions. We concluded that the physiologically increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the changes in expression and alternative polyadenylation of a number of genes, thus identifying another level of gene regulation that occurs in macrophages activated with LPS.
51153	13399	 8629	lipopolysaccharide	Compound	SLC38A2	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
52546	13399	 9092	lipopolysaccharide	Compound	CXCL6	mRNA	0	1	11577090	Five late LPS-activated chemokine genes (SCYB11, BLC, IP-10, GCP2, and MCP-2) listed in Fig. 3 show diminished up-regulation in cells pretreated with OxLDL.
52773	13399	10375	lipopolysaccharide	Compound	CD24	mRNA	1	-1	10673382	Lipopolysaccharide also triggers the repression of these genes.
53291	13399	 6651	lipopolysaccharide	Compound	CISH	mRNA	0	1	11014223	Both GH and lipopolysaccharide induced the three SOCS messenger RNAs (mRNAs) (SOCS-3, CIS, and SOCS-2) in vivo
53978	13399	11581	lipopolysaccharide	Compound	ITGB1	mRNA	1	1	12847265	Gene array experiments indicated that GM-CSF selectively restored a variety of dexamethasone-suppressed, LPS-inducible genes relevant for innate immunity.
56148	13399	10811	lipopolysaccharide	Compound	FN1	mRNA	-1	1	 8267042	Production of fetal fibronectin was increased by lipopolysaccharide, interleukin-1 beta, and tumor necrosis factor-alpha.
56802	13399	14826	lipopolysaccharide	Compound	IFNAR2	mRNA	0	1	15226448	TABLE 1. LPS and IKKg target gene profiling in murine pre-B cells
56846	13399	20050	lipopolysaccharide	Compound	PDIA3	mRNA	0	1	11274420	LPS induces an increase in all components of the MHC class I pathway including the transporter for antigen presentation (TAP), tapasin and ERp57, and the immunoproteasome subunits LMP2 and LMP7
59920	13399	13264	lipopolysaccharide	Compound	TRIM63	mRNA	-1	1	12782319	LPS (750 microg/100 g body weight) induces MafBx and Murf mRNA (respectively, 23-fold and 33-fold after 12 h; P<0.001). A transient induction of tumor necrosis factor-alpha mRNA (21-fold; P<0.001 at 3 h) and a decrease of insulin like growth factor-I mRNA
60109	13399	  631	lipopolysaccharide	Compound	NDUFA2	mRNA	0	1	12831455	stimulation of THP-1 cells with LPS and IFN-gamma up-regulate mCD14, TLR4, MD-2 and MyD88 expression by these cells, which might be involved in synergistic IL-8 production by the cells.
60893	13399	17954	lipopolysaccharide	Compound	ITPKC	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
62116	13399	18081	lipopolysaccharide	Compound	ACOT9	mRNA	0	1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
62173	13399	14097	lipopolysaccharide	Compound	BCL10	mRNA	0	1	15226448	TABLE 1. LPS and IKKg target gene profiling in murine pre-B cells
 6235	13399	12449	lipopolysaccharide	Compound	TLR2	mRNA	0	1	11160251	Here we show that LPS, TNF-alpha, or IFN-gamma induce TLR2 expression in both human dermal microvessel EC and HUVEC.
63126	13399	 4890	lipopolysaccharide	Compound	DEFB106B	mRNA	0	1	17400552	TABLE 1 Microarray analysis of MH-S macrophage response to HA and LPS: genes that respond differently to HA and LPS
63477	13399	 1595	lipopolysaccharide	Compound	EBI3	mRNA	0	1	15226448	TABLE 1. LPS and IKKg target gene profiling in murine pre-B cells
63967	13399	 5950	lipopolysaccharide	Compound	CCL7	mRNA	0	-1	12065483	See Tables 2 and 3: Expression changes in hepatocytes stimulated with LPS. All changes are greater than or equal to 1.5.
64361	13399	 6353	lipopolysaccharide	Compound	IRS2	mRNA	0	1	16415329	from full text - TABLE 5 LPS-Induced Gene Expression Altered by RAN, but Not FAM Cotreatment
 6476	13399	17143	lipopolysaccharide	Compound	POU2F2	mRNA	0	1	15226448	TABLE 1. LPS and IKKg target gene profiling in murine pre-B cells
 7462	13399	19396	lipopolysaccharide	Compound	C3	mRNA	0	1	10480555	Northern blot analysis showed that the mRNA expression of C3, C4, DAF and Crry was up-regulated, but that of CD59 was down-regulated by IFN-gamma, TNF-alpha and/or LPS alone or by synergy.
 8326	13399	 6202	lipopolysaccharide	Compound	BTG1	mRNA	-1	1	16495566	Complete list of significantly regulated genes 4 hours following intramammary LPS using the following cutoff criteria: P < 0.05 and change ?1.7-fold
 9071	13399	 4970	lipopolysaccharide	Compound	KLF4	mRNA	0	1	16169848	Herein, we identify Kruppel-like factor 4 (KLF4) as being markedly induced in response to IFN-gamma, LPS, or tumor necrosis factor-alpha and decreased by TGF-beta1 in macrophages.
11705	19090	11709	palmitic acid	Compound	UCP2	mRNA	0	1	18458149	UCP-2 has been shown to play a key role in lipotoxicity of pancreatic ?-cells through dissociation of fatty acid oxidation and ATP production (supplemental Fig. 2B) (9?12). UCP-2 promoter was also reported as an SREBP target (11,12). This key regulator of lipotoxicity was up-regulated by by palmitate at both mRNA and protein levels (supplemental Fig. 2A; Fig. 2D).
21340	19090	13132	palmitic acid	Compound	PC	mRNA	1	-1	11916915	pyruvate carboxylase and mitochondrial glycerol 3-phosphate dehydrogenase were downregulated, whereas lactate dehydrogenase and fructose 1,6-bisphosphatases were induced.
25620	19090	11207	palmitic acid	Compound	SYTL4	mRNA	0	1	18458149	Granuphilin was an effector of Rab27a, and its overexpression was reported to inhibit exocytosis of insulin granules (3537). We recently reported that granuphilin promoter was a direct target of SREBP-1c and that the SREBP-1c/granuphilin pathway was a potential mechanism for impairment GSIS in diabetes, leading to ?-cell lipotoxicity (38). This key molecule of lipotoxicity was upregulated by palmitate and suppressed by palmitate-EPA at both mRNA and protein levels (supplemental Fig. 2A; Fig. 2D).
42828	19090	 3879	palmitic acid	Compound	FAS	mRNA	0	1	18458149	SREBP-1c mRNA was highly induced by palmitate and completely suppressed by EPA but not SREBP-1a mRNA (Fig. 2A). These changes in SREBP-1c mRNA were associated with those in both membrane and nuclear forms of SREBP-1c protein (Fig. 2D). In accordance, its target genes, such as fatty acid synthase, stearoy-CoA desaturase 1, and elongation of long-chain fatty acids family number 6 showed were all up-regulated by palmitate
45193	19090	12952	palmitic acid	Compound	ELOVL6	mRNA	0	1	18458149	SREBP-1c mRNA was highly induced by palmitate and completely suppressed by EPA but not SREBP-1a mRNA (Fig. 2A). These changes in SREBP-1c mRNA were associated with those in both membrane and nuclear forms of SREBP-1c protein (Fig. 2D). In accordance, its target genes, such as fatty acid synthase, stearoy-CoA desaturase 1, and elongation of long-chain fatty acids family number 6 showed were all up-regulated by palmitate
45375	19090	14987	palmitic acid	Compound	BCL2	mRNA	1	-1	12606514	In addition, palmitic acid decreased Bcl-2 expression and induced release of cytochrome c from the mitochondria into the cytosol, which was prevented by fumonisin B1 and by oleic acid.
47209	19090	 2052	palmitic acid	Compound	ATF3	mRNA	0	1	15199129	ATF3 is induced in beta cells by signals relevant to beta-cell destruction: proinflammatory cytokines, nitric oxide, and high concentrations of glucose and palmitate.
51003	19090	13884	palmitic acid	Compound	CDKN1A	mRNA	1	-1	18523653	Palmitic acid, as well as stearic acid and myristic acid, compromised the induction of p21 and Bax expression
54382	19090	  991	palmitic acid	Compound	INS	mRNA	0	-1	12771145	Palmitate Decreases Glucose-stimulated Rat Insulin Promoter  Activity
57373	19090	10643	palmitic acid	Compound	Scd1	mRNA	0	1	18458149	SREBP-1c mRNA was highly induced by palmitate and completely suppressed by EPA but not SREBP-1a mRNA (Fig. 2A). These changes in SREBP-1c mRNA were associated with those in both membrane and nuclear forms of SREBP-1c protein (Fig. 2D). In accordance, its target genes, such as fatty acid synthase, stearoy-CoA desaturase 1, and elongation of long-chain fatty acids family number 6 showed were all up-regulated by palmitate
64360	19090	 6353	palmitic acid	Compound	IRS2	mRNA	0	-1	18458149	We recently reported that SREBP directly suppressed hepatic IRS-2 expression and caused insulin resistance in the liver (25). In accordance with changes in SREBP-1c in islets, IRS-2 was strongly suppressed by palmitate and was partially restored by addition of EPA, implicating a role for SREBP-1cmediated IRS-2 repression in the palmitate-EPAmediated changes in ?-cell physiology
12763	15054	10864	bortezomib	Compound	CHAC1	mRNA	0	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
23589	15054	 4571	bortezomib	Compound	GADD45B	mRNA	0	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
26480	15054	 7394	bortezomib	Compound	BAG3	mRNA	0	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
33565	15054	 6421	bortezomib	Compound	HSPA6	mRNA	0	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
37542	15054	 6614	bortezomib	Compound	HSPA1B	mRNA	0	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
39947	15054	 6114	bortezomib	Compound	NFKBIA	mRNA	1	-1	17895889	From table 1 of full text: bortezomib suppressed constitutive NF-kappaB activation via I-kappaB stabilisation in three ATL cell lines (TaY, MT-2 and MT-4). An oligonucleotide DNA microarray analysis of TaY cells revealed upregulation of genes encoding heat shock proteins (HSPA1A, STIP1, HSPA1B, and HSPCA), genes related to protein folding (CDC37 and ANAPC5), Fas-associated factor 1(FAF1) and an oxidative stress-related gene, heme oxygenase-1(HMOX-1), known to be a target gene of hypoxia-inducible gene-1 alpha (HIF-1 alpha).
40768	15054	16298	bortezomib	Compound	RPL27A	mRNA	0	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
41286	15054	 6882	bortezomib	Compound	PMAIP1	mRNA	0	1	18042711	Here, we show that the induction of NOXA by bortezomib is directly dependent on the oncogene c-MYC.
45367	15054	14987	bortezomib	Compound	BCL2	mRNA	1	-1	17895889	From table 1 of full text: bortezomib suppressed constitutive NF-kappaB activation via I-kappaB stabilisation in three ATL cell lines (TaY, MT-2 and MT-4). An oligonucleotide DNA microarray analysis of TaY cells revealed upregulation of genes encoding heat shock proteins (HSPA1A, STIP1, HSPA1B, and HSPCA), genes related to protein folding (CDC37 and ANAPC5), Fas-associated factor 1(FAF1) and an oxidative stress-related gene, heme oxygenase-1(HMOX-1), known to be a target gene of hypoxia-inducible gene-1 alpha (HIF-1 alpha).
49495	15054	10600	bortezomib	Compound	CXCL1	mRNA	0	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
 5102	15054	 2649	bortezomib	Compound	DNAJB1	mRNA	0	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
53542	15054	 8374	bortezomib	Compound	SNCA	mRNA	-1	-1	17895889	From table 1 of full text: bortezomib suppressed constitutive NF-kappaB activation via I-kappaB stabilisation in three ATL cell lines (TaY, MT-2 and MT-4). An oligonucleotide DNA microarray analysis of TaY cells revealed upregulation of genes encoding heat shock proteins (HSPA1A, STIP1, HSPA1B, and HSPCA), genes related to protein folding (CDC37 and ANAPC5), Fas-associated factor 1(FAF1) and an oxidative stress-related gene, heme oxygenase-1(HMOX-1), known to be a target gene of hypoxia-inducible gene-1 alpha (HIF-1 alpha).
55418	15054	16991	bortezomib	Compound	PPP1R15A	mRNA	1	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
63393	15054	19092	bortezomib	Compound	RPS11	mRNA	0	1	15509775	From table 1 in full text:  proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells
13590	 3590	 1438	homocysteine	Compound	VEGFA	mRNA	0	1	14747470	the expression of wt ATF4 increased VEGF mRNA levels in the control cells and had little effect on VEGF levels in DL-homocysteine-treated and glutamine-starved cells. In contrast, the expression ATF4 DN greatly inhibited VEGF expression under all conditions, including anoxia.
28292	 3590	 6449	homocysteine	Compound	CFLAR	mRNA	1	-1	15117910	These data suggest that upregulation of Fas expression and downregulation of FLIP is a mechanism through which Hcy induces EC apoptosis
29077	 3590	  620	homocysteine	Compound	PHLDA1	mRNA	0	1	12738777	We report here that homocysteine induces the expression of T-cell death associated gene 51 (TDAG51), a member of thepleckstrin homology-related domain family, in cultured human vascular endothelial cells. This effect was observed for other ER stress-inducing agents, including DTT and tunicamycin.
32005	 3590	 4292	homocysteine	Compound	DDIT3	mRNA	0	1	14747470	The expression of GADD153 was also up-regulated 4.5 fold by DL-homocysteine, 1.9 fold by L-homocysteine thiolactone, and 3.8 fold by DTT.
42807	 3590	 3879	homocysteine	Compound	FAS	mRNA	0	1	15117910	These data suggest that upregulation of Fas expression and downregulation of FLIP is a mechanism through which Hcy induces EC apoptosis
62965	 3590	 7195	homocysteine	Compound	GADD45A	mRNA	-1	1	10419887	Table 1. Identification of Homocysteine-Respondent Genes Using cDNA Microarrays in Primary HUVECs Exposed to 5 mmol/L Homocysteine for 4 hours (18 hours timepoint is not curtaed)
12264	 8800	 8413	TGFB Family	Protein	FBN1	mRNA	0	1	11012893	mRNA expression of fibrillin-1, emilin, and elastin was strong in quiescent mesangial cells; their gene expression was further up-regulated by transforming growth factor-beta1, while it was transiently reduced when cells were exposed to mitogenic 10% fetal calf serum and platelet-derived growth factor
13897	 8800	17250	TGFB Family	Protein	PTGS2	mRNA	0	1	10678579	COX-2 is inducible by oncogenes ras and scr, interleukin-1, hypoxia, benzo[a]pyrene, ultraviolet light, epidermal growth factor, transforming growth factor beta, and tumor necrosis factor alpha.
20045	 8800	 2164	TGFB Family	Protein	NET1	mRNA	0	1	11278519	NET1 gene was induced upon TGF-beta treatment in several cell types
20665	 8800	 9140	TGFB Family	Protein	TGFBR1	mRNA	0	1	12044009	Beta Catenin
20774	 8800	 4461	TGFB Family	Protein	ACTA2	mRNA	0	1	16794588	Conversion of fibroblasts into myofibroblasts is induced by transforming growth factor-beta1 (TGF-beta1) and is hallmarked by the neo-expression of alpha-smooth muscle actin (alpha-SMA), a commonly used myofibroblast marker.
20907	 8800	14760	TGFB Family	Protein	PALLD	mRNA	0	1	16794588	% Expression of the 4Ig isoform is strongly induced in fibroblast stress fibers upon TGF-beta1 treatment preceding alpha-SMA upregulation. TGF-beta1 induced upregulation of palladin is mediated both by Smad and mitogen-activated protein kinase pathways.
  244	 8800	 4377	TGFB Family	Protein	MSTN	mRNA	0	1	16885393	Treatment with TGF-beta and/or overexpression of SMAD2, -3, or -4 also resulted in a significant increase in myostatin promoter activity.
24562	 8800	 2720	TGFB Family	Protein	TAGLN	mRNA	-1	1	16690609	We show here that TGFbeta treatment increased transcriptional activation of SM22alpha, a smooth muscle-specific promoter, in airway smooth muscle cells, and we demonstrate that this effect stems in part from TGFbeta-induced enhancement of serum response factor (SRF) DNA binding and transcription
28709	 8800	10035	TGFB Family	Protein	STK16	mRNA	0	1	10947953	Interestingly, this factor had the structural features of a Ser/Thr kinase and actually exhibited protein kinase activity. TSF1 mRNA as well as its protein level were stimulated by TGF-beta treatment.
 3627	 8800	 5009	TGFB Family	Protein	AHR	mRNA	0	-1	11259615	Previous studies showed that TGF-beta down-regulates aryl hydrocarbon (AhR) expression in human lung carcinoma cells A549.
37383	 8800	 9189	TGFB Family	Protein	MMP2	mRNA	0	1	17258390	transforming growth factor (TGF)-beta up-regulates matrix metalloproteinase (MMP)-2 leading to the induction of oncogenic signaling in preneoplastic MCF10A human breast epithelial cells.
42812	 8800	 3879	TGFB Family	Protein	FAS	mRNA	0	-1	10640741	The cytokine TGF-beta inhibits basal expression of Fas as well as cytokine-mediated Fas expression by microglia
42869	 8800	11585	TGFB Family	Protein	ELN	mRNA	0	1	11012893	mRNA expression of fibrillin-1, emilin, and elastin was strong in quiescent mesangial cells; their gene expression was further up-regulated by transforming growth factor-beta1, while it was transiently reduced when cells were exposed to mitogenic 10% fetal calf serum and platelet-derived growth factor
46031	 8800	12530	TGFB Family	Protein	HPGD	mRNA	-1	1	15574495	In interrogating the mechanism for 15-PGDH expression loss in colon cancer, we determined that colonic 15-PGDH expression is directly controlled and strongly induced by activation of the TGF-beta tumor suppressor pathway.
46236	 8800	 9584	TGFB Family	Protein	EMILIN1	mRNA	0	1	11012893	mRNA expression of fibrillin-1, emilin, and elastin was strong in quiescent mesangial cells; their gene expression was further up-regulated by transforming growth factor-beta1, while it was transiently reduced when cells were exposed to mitogenic 10% fetal calf serum and platelet-derived growth factor
49891	 8800	15228	TGFB Family	Protein	TIMP3	mRNA	0	1	15468069	activation of ERK-MAPK pathway and Sp1 transcription factor play a pivotal role in the induction of TIMP-3 by TGF-beta in chondrocytes
57584	 8800	18423	TGFB Family	Protein	MIXL1	mRNA	0	1	17568773	Foxh1 and Smads bind the Mixl1 promoter and mediate the TGFbeta-dependent induction of Mixl1. (A, C, F, G, I) HepG2 cells were transiently transfected with the Mixl1-luc reporter, Foxh1 and Smads (S2, S3, S4), Cripto, ActRIB or ActRII, as indicated. Error bars represent standard deviation of the mean. (B, D, E, H) EMSA. A 248-bp Mixl1 promoter fragment containing a wild-type or mutated Foxh1-binding site was incubated with bacterially expressed proteins (B, E) or crude extracts from COS-1 cells transiently transfected with the indicated DNA (D, H). Protein?DNA complexes were visualized by autoradiography. For supershift assays (D, H), anti-myc (M), anti-Flag (F), and anti-Smad4 (S4) antibodies were added to the reactions.Co-expression of Foxh1 with the Mixl1-luc reporter yielded strong TGFbeta-dependent activation of the Mixl1-luc reporter (Figure 1A). Direct binding of Foxh1 to the Mixl1 promoter fragment was confirmed by electrophoretic mobility shift assays (EMSA) using bacterially expressed Foxh1 (Figure 1B). Moreover, Smad2 and Smad4 enhanced both the basal and TGFbeta-induced Foxh1-dependent activation of the Mixl1-luc reporter (Figure 1C).
65608	 8800	16485	TGFB Family	Protein	ABCC6	mRNA	0	1	16374464	Testing of selected cytokines revealed that transforming growth factor (TGF)-beta upregulated, while tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma downregulated the promoter activity in HepG2 cells.
  117	14548	 8755	MAPK p38 Family	Protein	GDF15	mRNA	0	1	18413810	VES treatment induced nuclear translocation and activation of p38 kinase. Pretreatment with p38 kinase inhibitor blocked the VES-induced increase in NAG-1 protein and mRNA levels, whereas an inhibition of protein kinase C, Akt, c-Jun NH(2)-terminal kinase, or MEK activity had no effect on VES-induced NAG-1 levels.
13485	14548	 4693	MAPK p38 Family	Protein	SLC8A1	mRNA	0	1	12502566	ERK and p38 play a role in alpha-adrenergic-stimulated NCX1 upregulation, and (3) p38 activation alone is sufficient for NCX1 upregulation.
24552	14548	 9992	MAPK p38 Family	Protein	MTTP	mRNA	0	1	12716735	These results indicated that MAPKp38 stimulates MTP promoter activity
38886	14548	17325	MAPK p38 Family	Protein	MXD1	mRNA	-1	1	11943771	Of the LPS-regulated proteins identified by peptide mass fingerprinting for which probes were present on the oligonucleotide microarray... Similarly, CAP1, Rho-GAP1, and ficolin 1 were down-regulated at both the mRNA transcript and protein levels
40746	14548	 2915	MAPK p38 Family	Protein	ISG15	mRNA	-1	1	11943771	Of the LPS-regulated proteins identified by peptide mass fingerprinting for which probes were present on the oligonucleotide microarray... Similarly, CAP1, Rho-GAP1, and ficolin 1 were down-regulated at both the mRNA transcript and protein levels
56646	14548	16427	MAPK p38 Family	Protein	EFNA1	mRNA	0	1	11278471	Chemical inhibition of p38 MAPK and SAPK/JNK activation blocks TNF  -alpha-induced ephrin A1 expression.
 7651	14548	 7875	MAPK p38 Family	Protein	IFIT3	mRNA	1	1	11943771	Of the LPS-regulated proteins identified by peptide mass fingerprinting for which probes were present on the oligonucleotide microarray... Similarly, CAP1, Rho-GAP1, and ficolin 1 were down-regulated at both the mRNA transcript and protein levels
  825	14548	 1146	MAPK p38 Family	Protein	GCLC	mRNA	0	1	15485876	IL-1 beta up-regulated GCLC expression (10 ng/ml IL-1 beta, 3.76 +/- 0.86; 100 ng/ml IL-1 beta, 4.22 +/- 0.68-fold control) via the p38 form of mitogen-activated protein kinase and NF kappa B and also increased reactive oxygen species levels (10 ng/ml IL-1 beta, 5.41 +/- 1.8-fold control).
12739	 6866	13434	FOXO4	Protein	HIF1A	mRNA	0	-1	12761217	Modified assertion
13608	 6866	 1438	FOXO4	Protein	VEGFA	mRNA	0	-1	12761217	Modified assertion
19593	 6866	 5712	FOXO4	Protein	BCL6	mRNA	0	1	11777915	An analysis of genes regulated by AFX demonstrated that BCL-6, a transcriptional repressor, is up-regulated approximately 4-7-fold.
23759	 6866	 6636	FOXO4	Protein	BCL2L1	mRNA	0	-1	18391973	FOXO4 indirectly suppresses the expression of the prosurvival Bcl-2 family member Bcl- XL by regulating expression of the transcriptional repressor Bcl-6 (Tang et al., 2002).
 2781	 6866	  908	FOXO4	Protein	MMP9	mRNA	0	1	17242183	In this study, we show that FoxO4 activates transcription of the MMP9 gene in response to tumor necrosis factor alpha (TNF-alpha) signaling.
27859	 6866	 1166	FOXO4	Protein	SLC2A1	mRNA	-1	-1	12761217	Modified assertion
29822	 6866	  252	FOXO4	Protein	BCL2L11	mRNA	0	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
35609	 6866	 1571	FOXO4	Protein	RBL2	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
 3625	 6866	 5009	FOXO4	Protein	AHR	mRNA	0	1	12761217	Modified assertion
36663	 6866	11314	FOXO4	Protein	PCK2	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
38872	 6866	 9451	FOXO4	Protein	RPL7	mRNA	0	1	12761217	Modified assertion
39234	 6866	 7376	FOXO4	Protein	TNFSF10	mRNA	-1	1	15668399	Activated FOXO proteins also trigger apoptosis in many cancer cell lines through regulation of a number of proapoptotic proteins, including Fas ligand, TRAIL, and Bim.
51048	 6866	13884	FOXO4	Protein	CDKN1A	mRNA	1	1	15917664	FOXO proteins intervene in the cell cycle by activating the cyclin-dependent kinase (CDK) inhibitors p27kip1 and p21 cip1.
51679	 6866	  219	FOXO4	Protein	FASLG	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
57402	 6866	 3336	FOXO4	Protein	CCND2	mRNA	0	-1	15917664	They also repress transcription of cyclin D1 and D2, which results in an attenuation of CDK4 activity and reduced phosphorylation of Rb protein, and hence increased binding activity of E2F family members to Rb.
58368	 6866	 6053	FOXO4	Protein	CAT	mRNA	-1	1	15917664	Transcriptional control by FOXO also extends to the regulation of pro-apoptotic genes Bim and Fas Ligand and to the stress response genes like GADD45, Mn superoxide dismutase and catalase.
63880	 6866	12543	FOXO4	Protein	IGFBP1	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
  136	 5953	12396	POU3F3	Protein	UMOD	mRNA	0	1	12925600	In addition, the expression of a number of TAL-specific genes was reduced in the Brn1+/- kidney, including Umod, Nkcc2/Slc12a1, Bsnd, Kcnj1 and Ptger3. These results suggest that Brn1 is essential for both the development and function of the nephron in the kidney
22099	 5953	16698	POU3F3	Protein	SLC12A1	mRNA	0	1	12925600	the expression of a number of TAL-specific genes was reduced in the Brn1+/- kidney, including Umod, Nkcc2/Slc12a1, Bsnd, Kcnj1 and Ptger3.
27865	 5953	 1166	POU3F3	Protein	SLC2A1	mRNA	-1	1	12925600	In addition, the expression of a number of TAL-specific genes was reduced in the Brn1+/- kidney, including Umod, Nkcc2/Slc12a1, Bsnd, Kcnj1 and Ptger3. These results suggest that Brn1 is essential for both the development and function of the nephron in the kidney
27977	 5953	 5531	POU3F3	Protein	KCNJ1	mRNA	0	1	12925600	In addition, the expression of a number of TAL-specific genes was reduced in the Brn1+/- kidney, including Umod, Nkcc2/Slc12a1, Bsnd, Kcnj1 and Ptger3. These results suggest that Brn1 is essential for both the development and function of the nephron in the kidney
28023	 5953	 4300	POU3F3	Protein	BSND	mRNA	0	1	12925600	In addition, the expression of a number of TAL-specific genes was reduced in the Brn1+/- kidney, including Umod, Nkcc2/Slc12a1, Bsnd, Kcnj1 and Ptger3. These results suggest that Brn1 is essential for both the development and function of the nephron in the kidney
54936	 5953	 4452	POU3F3	Protein	PTGER3	mRNA	0	1	12925600	In addition, the expression of a number of TAL-specific genes was reduced in the Brn1+/- kidney, including Umod, Nkcc2/Slc12a1, Bsnd, Kcnj1 and Ptger3. These results suggest that Brn1 is essential for both the development and function of the nephron in the kidney
59645	 5953	19255	POU3F3	Protein	EGR2	mRNA	0	1	15713637	Brn-1 efficiently induced Krox-20 expression as a prerequisite for myelination.
21496	15872	 7854	CASQ1	Protein	SLC25A4	mRNA	0	-1	12127059	Several genes are downregulated at 13 weeks, including SR Ca2+-ATPase (SERCA2) and adenine nucleotide translocase 1 (Ant1) genes.
26854	15872	12195	CASQ1	Protein	MFAP5	mRNA	0	1	12127059	Cardiac ankyrin repeat protein (CARP), glutathione peroxidase (Gpx1), and genes which participate in the formation of extracellular matrix including decorin, TSC-36, Magp2, Osf2, and SPARC are upregulated in CSQ mouse hearts at 7 and 13 weeks of age compared to those of non-transgenic littermates.
36635	15872	18136	CASQ1	Protein	FSTL1	mRNA	0	1	12127059	Cardiac ankyrin repeat protein (CARP), glutathione peroxidase (Gpx1), and genes which participate in the formation of extracellular matrix including decorin, TSC-36, Magp2, Osf2, and SPARC are upregulated in CSQ mouse hearts at 7 and 13 weeks of age compared to those of non-transgenic littermates.
44078	15872	15206	CASQ1	Protein	ATP2A2	mRNA	0	-1	12127059	Several genes are downregulated at 13 weeks, including SR Ca2+-ATPase (SERCA2) and adenine nucleotide translocase 1 (Ant1) genes.
46448	15872	13874	CASQ1	Protein	GPX1	mRNA	0	1	12127059	Calsequestrin (CSQ) is the major Ca2+ binding protein of the cardiac sarcoplasmic reticulum (SR). Transgenic mice overexpressing CSQ at the age of 7 weeks exhibit concentric cardiac hypertrophy, and by 13 weeks the condition progresses to dilated cardiomyopathy. The present study used a differential display analysis to identify genes whose expressions are modulated in the CSQ-overexpressing mouse hearts to provide information on the mechanism of transition from concentric cardiac hypertrophy to failure. Cardiac ankyrin repeat protein (CARP), glutathione peroxidase (Gpx1), and genes which participate in the formation of extracellular matrix including decorin, TSC-36, Magp2, Osf2, and SPARC are upregulated in CSQ mouse hearts at 7 and 13 weeks of age compared to those of non-transgenic littermates. In addition, two novel genes without sequence similarities to any known genes are upregulated in CSQ-overexpressing mouse hearts. Several genes are downregulated at 13 weeks, including SR Ca2+-ATPase (SERCA2) and adenine nucleotide translocase 1 (Ant1) genes. Further, a functionally yet unknown gene (NM_026586) previously identified in the mouse wolffian duct is dramatically downregulated in CSQ mice with dilated hearts. Thus, CARP, Gpx1, and genes encoding extracellular matrix proteins may participate in the development of cardiac hypertrophy and fibrosis, and changes in SERCA2, Ant1, and NM_026586 mRNA expression may be involved in transition from concentric to dilated cardiac hypertrophy.
47125	15872	19344	CASQ1	Protein	SPARC	mRNA	0	1	12127059	Cardiac ankyrin repeat protein (CARP), glutathione peroxidase (Gpx1), and genes which participate in the formation of extracellular matrix including decorin, TSC-36, Magp2, Osf2, and SPARC are upregulated in CSQ mouse hearts at 7 and 13 weeks of age compared to those of non-transgenic littermates.
48778	15872	17731	CASQ1	Protein	DCN	mRNA	-1	1	12127059	Cardiac ankyrin repeat protein (CARP), glutathione peroxidase (Gpx1), and genes which participate in the formation of extracellular matrix including decorin, TSC-36, Magp2, Osf2, and SPARC are upregulated in CSQ mouse hearts at 7 and 13 weeks of age compared to those of non-transgenic littermates.
54157	15872	15639	CASQ1	Protein	ANKRD1	mRNA	0	1	12127059	Calsequestrin (CSQ) is the major Ca2+ binding protein of the cardiac sarcoplasmic reticulum (SR). Transgenic mice overexpressing CSQ at the age of 7 weeks exhibit concentric cardiac hypertrophy, and by 13 weeks the condition progresses to dilated cardiomyopathy. The present study used a differential display analysis to identify genes whose expressions are modulated in the CSQ-overexpressing mouse hearts to provide information on the mechanism of transition from concentric cardiac hypertrophy to failure. Cardiac ankyrin repeat protein (CARP), glutathione peroxidase (Gpx1), and genes which participate in the formation of extracellular matrix including decorin, TSC-36, Magp2, Osf2, and SPARC are upregulated in CSQ mouse hearts at 7 and 13 weeks of age compared to those of non-transgenic littermates. In addition, two novel genes without sequence similarities to any known genes are upregulated in CSQ-overexpressing mouse hearts. Several genes are downregulated at 13 weeks, including SR Ca2+-ATPase (SERCA2) and adenine nucleotide translocase 1 (Ant1) genes. Further, a functionally yet unknown gene (NM_026586) previously identified in the mouse wolffian duct is dramatically downregulated in CSQ mice with dilated hearts. Thus, CARP, Gpx1, and genes encoding extracellular matrix proteins may participate in the development of cardiac hypertrophy and fibrosis, and changes in SERCA2, Ant1, and NM_026586 mRNA expression may be involved in transition from concentric to dilated cardiac hypertrophy.
 1195	20048	 2235	Ciglitazone	Compound	APOE	mRNA	0	1	15339912	Systemic treatment with pioglitazone increased systemic insulin sensitivity and increased apoE mRNA levels in adipose tissue by 2-3-fold. Treatment of cultured 3T3-L1 adipocytes with ciglitazone increased apoE mRNA levels by 2-4-fold in a dose-dependent manner and increased apoE secretion from cells.
20317	20048	 2815	Ciglitazone	Compound	TP53	mRNA	0	1	14960510	Screening by cDNA microarray showed that PPARgamma ligand treatment was associated with upregulation of bad and p53, and downregulation of bcl-2, bcl-xl, and cyclin E1 in MKN45 cells, which was confirmed by quantitative real time PCR.
21308	20048	18117	Ciglitazone	Compound	NOX4	mRNA	0	-1	15590897	Treatment with 15d-PGJ2 or ciglitazone also reduced relative mRNA levels of the NADPH oxidase subunits, nox-1, gp91phox (nox-2), and nox-4, as measured using real-time PCR analysis.
23762	20048	 6636	Ciglitazone	Compound	BCL2L1	mRNA	0	-1	14960510	Screening by cDNA microarray showed that PPARgamma ligand treatment was associated with upregulation of bad and p53, and downregulation of bcl-2, bcl-xl, and cyclin E1 in MKN45 cells, which was confirmed by quantitative real time PCR.
42878	20048	10970	Ciglitazone	Compound	NOX1	mRNA	0	-1	15590897	Treatment with 15d-PGJ2 or ciglitazone also reduced relative mRNA levels of the NADPH oxidase subunits, nox-1, gp91phox (nox-2), and nox-4, as measured using real-time PCR analysis.
44164	20048	 6531	Ciglitazone	Compound	CCNE1	mRNA	0	-1	14960510	Screening by cDNA microarray showed that PPARgamma ligand treatment was associated with upregulation of bad and p53, and downregulation of bcl-2, bcl-xl, and cyclin E1 in MKN45 cells, which was confirmed by quantitative real time PCR.
45363	20048	14987	Ciglitazone	Compound	BCL2	mRNA	1	-1	14960510	Screening by cDNA microarray showed that PPARgamma ligand treatment was associated with upregulation of bad and p53, and downregulation of bcl-2, bcl-xl, and cyclin E1 in MKN45 cells, which was confirmed by quantitative real time PCR.
 4971	20048	12073	Ciglitazone	Compound	IRF1	mRNA	0	1	14656743	Using Northern and Western blot analyses, we documented that PPARgamma ligands, including ciglitazone, troglitazone, and GW7845, significantly increased IRF-1 expression in VSMCs
51850	20048	 2831	Ciglitazone	Compound	BAD	mRNA	0	1	14960510	Screening by cDNA microarray showed that PPARgamma ligand treatment was associated with upregulation of bad and p53, and downregulation of bcl-2, bcl-xl, and cyclin E1 in MKN45 cells, which was confirmed by quantitative real time PCR.
  587	20048	  897	Ciglitazone	Compound	CYBB	mRNA	0	-1	15590897	Treatment with 15d-PGJ2 or ciglitazone also reduced relative mRNA levels of the NADPH oxidase subunits, nox-1, gp91phox (nox-2), and nox-4, as measured using real-time PCR analysis.
62308	20048	11938	Ciglitazone	Compound	DGKA	mRNA	0	1	15117825	The increased DGK{alpha} mRNA levels were quantified by real-time PCR analysis, showing {approx}5-fold to 8-fold increases in the mRNA levels after the treatment with PPAR{gamma} agonists (Figure 5B). .......To verify whether these PPAR{gamma} agonists effects are mediated by the receptors, we used a dominant-negative PPAR{gamma} mutant, PPAR{gamma}L468A/E471A, which has been shown to effectively silence the PPAR{gamma}-dependent gene transcriptions.
 7826	20048	 1292	Ciglitazone	Compound	SOD1	mRNA	0	1	15590897	PPAR-gamma ligands also stimulated both activity and expression of Cu/Zn-SOD in HUVEC.
20833	 5947	12908	lapatinib	Compound	ENO1	mRNA	1	-1	17513611	Figure 5. Cluster analysis of genes differentially expressed by lapatinib.
21838	 5947	 7428	lapatinib	Compound	DHFR	mRNA	0	-1	19529774	From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells (SNU216 gastric cancer cell line). Figure 2. Lapatinib downregulates fluoropyrimidine-target genes. The expressions of representative nucleotide synthesis-related genes [E2F-1, TS, TK1 (thymidine kinase 1), DHFR(dihydrofolate reductase), RRM2 (ribonucleotide reductase M2 polypeptide), DUT (DUTP pyrophosphatase), NME1 (nuclear diphosphate kinase 1)] were reduced as the result of gefitinib or lapatinib treatment in TKI-sensitive cells.
25967	 5947	15317	lapatinib	Compound	PGK1	mRNA	1	-1	17513611	Figure 5. Cluster analysis of genes differentially expressed by lapatinib.
28936	 5947	 5576	lapatinib	Compound	DUT	mRNA	0	-1	19529774	From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells (SNU216 gastric cancer cell line). Figure 2. Lapatinib downregulates fluoropyrimidine-target genes. The expressions of representative nucleotide synthesis-related genes [E2F-1, TS, TK1 (thymidine kinase 1), DHFR(dihydrofolate reductase), RRM2 (ribonucleotide reductase M2 polypeptide), DUT (DUTP pyrophosphatase), NME1 (nuclear diphosphate kinase 1)] were reduced as the result of gefitinib or lapatinib treatment in TKI-sensitive cells.
29781	 5947	16604	lapatinib	Compound	TYMS	mRNA	0	-1	19529774	From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells (SNU216 gastric cancer cell line). Figure 2. Lapatinib downregulates fluoropyrimidine-target genes. The expressions of representative nucleotide synthesis-related genes [E2F-1, TS, TK1 (thymidine kinase 1), DHFR(dihydrofolate reductase), RRM2 (ribonucleotide reductase M2 polypeptide), DUT (DUTP pyrophosphatase), NME1 (nuclear diphosphate kinase 1)] were reduced as the result of gefitinib or lapatinib treatment in TKI-sensitive cells.
38737	 5947	18764	lapatinib	Compound	AKT1	mRNA	1	-1	17513611	Table 2. Lapatinib-induced change in expression of genes in the ERB/AKT pathway at 12 h
51417	 5947	11635	lapatinib	Compound	DHCR24	mRNA	1	-1	17513611	Figure 5. Cluster analysis of genes differentially expressed by lapatinib.
 5257	 5947	 5378	lapatinib	Compound	NME1	mRNA	0	-1	19529774	From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells (SNU216 gastric cancer cell line). Figure 2. Lapatinib downregulates fluoropyrimidine-target genes. The expressions of representative nucleotide synthesis-related genes [E2F-1, TS, TK1 (thymidine kinase 1), DHFR(dihydrofolate reductase), RRM2 (ribonucleotide reductase M2 polypeptide), DUT (DUTP pyrophosphatase), NME1 (nuclear diphosphate kinase 1)] were reduced as the result of gefitinib or lapatinib treatment in TKI-sensitive cells.
58824	 5947	 9550	lapatinib	Compound	CDK4	mRNA	1	-1	17513611	Figure 5. Cluster analysis of genes differentially expressed by lapatinib.
14002	 1190	14600	okadaic acid	Compound	EIF1	mRNA	0	1	10754390	The three sequences corresponded to a human gene homologous to the yeast translation initiation factor Sui-1, a cAMP-regulated phosphoprotein, ARPP-16/19, and a novel gene designated O48. ARPP only responded to OA
19674	 1190	16486	okadaic acid	Compound	SPP1	mRNA	1	1	12210726	Okadaic acid stimulated osteopontin mRNA expression in several cell lines within 3 h, and the increase in osteopontin mRNA was sustained for 24 h.
25894	 1190	19027	okadaic acid	Compound	HMOX1	mRNA	0	1	12042071	Okadaic acid also induced heme oxygenase-1 mRNA in both cell lines, but the magnitude of induction was only twofold, and was rapid and transient
45059	 1190	15257	okadaic acid	Compound	FBXO6	mRNA	0	-1	12383498	Expression of FBG2 was strongly inhibited in hepatoma cells by okadaic acid.
45374	 1190	14987	okadaic acid	Compound	BCL2	mRNA	1	-1	 9762907	increase in the rate of degradation of bcl-2 mRNA. Therefore, OA induces down-regulation of bcl-2 expression via destabilization of its transcript
47836	 1190	10326	okadaic acid	Compound	CCND3	mRNA	0	-1	10361118	Okadaic acid, which inhibits protein phosphatase 1 (PP1) and shifts Sp1 to a phosphorylated form, decreases cyclin D3 gene expression and suppresses Mpl ligand induction.
51078	 1190	13884	okadaic acid	Compound	CDKN1A	mRNA	1	1	 8557703	These results suggest that phorbol ester and okadaic acid activate transcription of the WAF1/CIP1 promoter through a complex of proteins that includes Sp1 and basal transcription factors.
56228	 1190	15199	okadaic acid	Compound	BDNF	mRNA	0	1	10718305	Our results demonstrate that salicyclic acid, cGMP analog, okadaic acid, IBMX, dipyridamole and glutamate significantly enhance BDNF production in DA neuronal cells.
57322	 1190	 4298	okadaic acid	Compound	JUNB	mRNA	0	1	11311563	The shellfish toxin, okadaic acid (OA), is a potent tumor promoter that induces expression of the proto-oncogene junB in mouse keratinocyte 308 cells. Here we show, through deletion analysis of the junB promoter
62828	 1190	  127	okadaic acid	Compound	UHRF1	mRNA	0	1	12612445	Expression of the NP95 gene, which was previously found to be the gene of a murine nuclear protein associated with cell proliferation, was increased in the cultures treated by 12-O-tetradecanoylphorbol-13-acetate (TPA), okadaic acid, and orthovanadate.
65638	 1190	 6557	okadaic acid	Compound	ALAS1	mRNA	0	1	12042071	Okadaic acid was found to induce ALA synthase mRNA in a concentration-dependent fashion in both Huh-7 and HepG2 cells
 3440	 7022	10915	HNRNPU	Protein	BAX	mRNA	0	1	15096513	Because HeLa cells express significant amounts of p73 ( 42 ), we tested whether co-expression of hnRNP U had an effect on the ability of YAP to stimulate the expression of Bax.
62941	 7022	 7195	HNRNPU	Protein	GADD45A	mRNA	-1	1	17174306	In the present study, we show that hnRNP-U specifically enhances the expression of tumor necrosis factor alpha mRNA by increasing its stability, possibly through binding to the 3p untranslated region. We also show that hnRNP-U enhances the expression of several other genes as well, including GADD45A, HEXIM1, HOXA2, IER3, NHLH2, and ZFY, by binding to and stabilizing these mRNAs.
21684	 3500	 2572	KLF11	Protein	CAV1	mRNA	0	-1	15531587	Through a combination of RNA interference, chromatin immunoprecipitation assays, electrophoretic mobility shift assays, and reporter assays, we demonstrate that in the presence of cholesterol, KLF11 acts as a dominant repressor of the caveolin-1 gene.
32796	 3500	 9711	KLF11	Protein	HBE1	mRNA	0	1	10207080	Transfection of K562 cells with FKLF cDNA enhanced the expression of the endogenous epsilon- and gamma-globin genes, suggesting an in vivo role of FKLF in fetal and embryonic globin gene expression. Our results indicate that the protein potentially encoded by the FKLF cDNA acts as a transcriptional activator of embryonic and fetal beta-like globin genes {investigation of promoter bindining sequences was performed}
34795	 3500	14828	KLF11	Protein	HBG1	mRNA	0	1	10207080	Transfection of K562 cells with FKLF cDNA enhanced the expression of the endogenous epsilon- and gamma-globin genes, suggesting an in vivo role of FKLF in fetal and embryonic globin gene expression. Our results indicate that the protein potentially encoded by the FKLF cDNA acts as a transcriptional activator of embryonic and fetal beta-like globin genes {investigation of promoter bindining sequences was performed}
51310	 3500	17260	KLF11	Protein	MAOB	mRNA	0	1	15024015	Here, we show that cotransfection with transforming growth factor (TGF)-beta-inducible early gene (TIEG)2 increased MAO B gene expression at promoter, mRNA, protein, and catalytic activity levels in both SH-SY5Y and HepG2 cells. Mutation of the CACCC element increased the MAO B promoter activity, and cotransfection with TIEG2 further increased the promoter activity, suggesting that CACCC was a repressor element. This increase was reduced when the proximal Sp1 overlapping sites was mutated. Similar interactions were found with Sp3. These results showed that TIEG2 and Sp3 were repressors at the CACCC element but were activators at proximal Sp1 overlapping sites of MAO B. Gel-shift and chromatin immunoprecipitation assays showed that TIEG2 and Sp3 bound directly to CACCC element and the proximal Sp1 sites in both synthetic oligonucleotides and natural MAO B core promoter. TIEG2 had a higher affinity to Sp1 sites than CACCC element, whereas Sp3 had an equal affinity to both elements. Thus, TIEG2 was an activator, but Sp3 had no effect on MAO B gene expression.
54381	 3500	  991	KLF11	Protein	INS	mRNA	0	-1	17479246	Cotransfections of INS-1E and beta-TC3 beta cells with a human (h)KLF11 expression plasmid and an hInsP-driven reporter plasmid resulted in a substantial dose-dependent and glucose-independent inhibition of proinsulin promoter activity. 5p-deletion of hInsP demonstrated that hKLF11 acts via DNA sequences upstream of -173 and requires the beta cell-specific transcription machinery, since hKLF11-mediated inhibition of promoter activity was abolished in HEK293 cells. Besides a previously described GC box, we further identified a CACCC box within the hInsP, both putative KLF11-binding motifs. Electrophoretic mobility shift analysis (EMSA) verified binding of in vitro translated hKLF11 to the GC box, but neither hKLF11-induced inhibition nor basal hInsP activity was altered by mutation or 5p-deletion of the GC box.
62011	 3500	 2608	KLF11	Protein	HBB	mRNA	1	1	10207080	Transfection of K562 cells with FKLF cDNA enhanced the expression of the endogenous epsilon- and gamma-globin genes, suggesting an in vivo role of FKLF in fetal and embryonic globin gene expression. Our results indicate that the protein potentially encoded by the FKLF cDNA acts as a transcriptional activator of embryonic and fetal beta-like globin genes {investigation of promoter bindining sequences was performed}
24576	11926	 2720	HOXD3	Protein	TAGLN	mRNA	-1	1	11850808	Table 1 - Gene regulated by overexpressing HOXD3 in A549 lung cancer cell lines by more than 1.6 fold.
28229	11926	 7832	HOXD3	Protein	THBS1	mRNA	-1	1	11850808	Modified assertion
35226	11926	 5296	HOXD3	Protein	PLAU	mRNA	1	1	14610084	We show here that alpha5beta1 expression, and hence function, during angiogenesis is regulated by the transcription factor Hox D3, a homeobox gene that also controls the expression of endothelial cell integrin alphavbeta3 and urokinase-type plasminogen activator. Hox D3 expression in endothelial cells enhances integrin alpha5 protein and message expression, whereas Hox D3 antisense inhibits its expression. Hox D3 promotes alpha5 expression during angiogenesis in vivo, whereas inhibition of alpha5 expression by Hox D3 antisense suppresses angiogenesis.
45741	11926	19032	HOXD3	Protein	ACTN4	mRNA	1	1	11850808	Table 1 - Gene regulated by overexpressing HOXD3 in A549 lung cancer cell lines by more than 1.6 fold.
52765	11926	10375	HOXD3	Protein	CD24	mRNA	1	1	11850808	Table 1 - Gene regulated by overexpressing HOXD3 in A549 lung cancer cell lines by more than 1.6 fold.
10104	14980	 7502	Dinoprostone	Compound	STAR	mRNA	0	1	12933667	PGE(2) caused a rapid increase in StAR expression
12752	14980	13434	Dinoprostone	Compound	HIF1A	mRNA	0	1	12401798	Modified assertion
13822	14980	17250	Dinoprostone	Compound	PTGS2	mRNA	0	1	15336550	from full text - Table 4 PGE2- and AE1-329-induced genes not altered upon differentiation treatment
14445	14980	13598	Dinoprostone	Compound	CD14	mRNA	0	1	10799905	Protein kinase A inhibitor, N-[2-(p-bromocinnamylamino)ethyl]-5- isoquinolinesulfonamide (H-89), but not protein kinase C inhibitor 3-(1-[3- (dimethylamino)propyl]-1H- indol-3-yl)-4-(1H-indol-3-yl)-1H-py rrole-2,5-dione (GF109203X), abolished the stimulated expression of CD14.
23891	14980	 5783	Dinoprostone	Compound	CEBPB	mRNA	0	1	15299028	We initially showed that prostaglandin E2 (PGE2) rapidly enhances C/EBPbeta mRNA and protein expression, and in this study we identified a 3p-proximal region of the C/EBPbeta promoter containing a 541-bp upstream sequence that could account for this effect.
25799	14980	19027	Dinoprostone	Compound	HMOX1	mRNA	0	-1	12869663	Furthermore, it has been reported that the HO-1 gene is further down-regulated by angiotensin II via calcium-signaling (Ishizaka and Griendling, 1997), interferon- (Takahashi et al., 1999), prostaglandin E2 (Tetsuka et al., 1995), transforming growth factor- (Pellacani et al., 1998), and IL-10 (Immenschuh et al., 1999).
35244	14980	 5296	Dinoprostone	Compound	PLAU	mRNA	1	1	11196203	On treatment of HRG (30 ng/ml) and PGE2(50 micromolar/ml) on FET cells resulted in upregulation of the levels of uPA mRNA, but expresssion was modulated differentially by PGE2 and HRG.
37412	14980	15242	Dinoprostone	Compound	ATF4	mRNA	0	-1	11043924	CREB1 protein of human T lymphocytes was significantly modulated by a brief treatment of 5 to 10 min with PGE2. On the contrary, vitamin E appeared to be ineffective on the CREB1 behavior, while it abolished the PGE2-induced modulation of this protein. The CREB2 protein expression was also affected by PGE2 treatment, but a longer period of incubation (>20 min) was needed to observe these changes. Vitamin E showed a strong enhancing effect on CREB2 that was partially reversed by the subsequent treatment with PGE2
41458	14980	17720	Dinoprostone	Compound	CYP19A1	mRNA	0	1	14668813	aromatase seems to be expressed predominantly in the fibroblasts under the stimulatory influence of IL6 and IL11 and TNFalpha released by inflammatory cells, and prostaglandin E2 in breast cancer cells and inflammatory cells
45344	14980	14987	Dinoprostone	Compound	BCL2	mRNA	1	1	10678579	COX-2 synthesizes prostaglandin E2 (PGE2) which stimulates bcl-2 and inhibits apoptosis, and induces interleukin-6 (IL-6) which enhances haptoglobin synthesis. PGE2 is associated with tumor metastases, IL-6 with cancer cell invasion, and haptoglobin with implantation and angiogenesis
45474	14980	18399	Dinoprostone	Compound	ST3GAL3	mRNA	0	1	11888937	Treatment with a COX-2 inhibitor, celecoxib... beta 3Gal-T5 and ST3Gal III and IV expression was inhibited by celecoxib and was enhanced by prostaglandin E(2) treatment.
50931	14980	 6827	Dinoprostone	Compound	AREG	mRNA	0	1	14500348	In addition, PGE(2), in collaboration with transforming growth factor-alpha or K-Ras oncogene, synergistically induced AR expression and activated receptor tyrosine kinase-dependent signaling pathways
51330	14980	 1360	Dinoprostone	Compound	ST3GAL4	mRNA	0	1	11888937	Treatment with a COX-2 inhibitor, celecoxib... beta 3Gal-T5 and ST3Gal III and IV expression was inhibited by celecoxib and was enhanced by prostaglandin E(2) treatment.
54500	14980	 7132	Dinoprostone	Compound	FOSL2	mRNA	0	1	15299028	prostaglandin E2 (PGE2) rapidly enhances C/EBPbeta mRNA and protein expression
54748	14980	13603	Dinoprostone	Compound	PTGS1	mRNA	0	1	15336550	from full text - Table 4 PGE2- and AE1-329-induced genes not altered upon differentiation treatment
 5592	14980	 4642	Dinoprostone	Compound	HP	mRNA	0	1	10678579	COX-2 synthesizes prostaglandin E2 (PGE2) which stimulates bcl-2 and inhibits apoptosis, and induces interleukin-6 (IL-6) which enhances haptoglobin synthesis. PGE2 is associated with tumor metastases, IL-6 with cancer cell invasion, and haptoglobin with implantation and angiogenesis
60751	14980	19795	Dinoprostone	Compound	CREB1	mRNA	0	-1	11043924	CREB1 protein of human T lymphocytes was significantly modulated by a brief treatment of 5 to 10 min with PGE2. On the contrary, vitamin E appeared to be ineffective on the CREB1 behavior, while it abolished the PGE2-induced modulation of this protein. The CREB2 protein expression was also affected by PGE2 treatment, but a longer period of incubation (>20 min) was needed to observe these changes. Vitamin E showed a strong enhancing effect on CREB2 that was partially reversed by the subsequent treatment with PGE2
 6096	14980	 2479	Dinoprostone	Compound	B3GALT5	mRNA	0	1	11888937	Treatment with a COX-2 inhibitor, celecoxib... beta 3Gal-T5 and ST3Gal III and IV expression was inhibited by celecoxib and was enhanced by prostaglandin E(2) treatment.
 8320	14980	 6202	Dinoprostone	Compound	BTG1	mRNA	-1	1	 9203975	B-cell translocation gene-1 (BTG1), a recently cloned antiproliferative gene. A two-to threefold increase in macrophage BTG1 expression was observed after PGE2 treatment. PGE1 and platelet-activating factor also enhanced BTG1 expression
24877	19288	 5863	PIAS2	Protein	MYC	mRNA	0	1	14560010	Modified assertion
51006	19288	13884	PIAS2	Protein	CDKN1A	mRNA	1	1	12408820	Miz-1 binds to the p21Cip1 core promoter in vivo and is required for upregulation of p21Cip1 upon UV irradiation.
10091	 3477	 7502	Activin	Compound	STAR	mRNA	0	1	14592955	The mRNA levels of steroidogenic acute regulatory protein or P450 steroid side-chain cleavage enzyme, the rate-limiting steps of adrenocortical steroidogenesis, were enhanced by activin and BMP-6. Activin and BMP-6 also activated the transcription of steroidogenic acute regulatory protein as well as the late-step steriodogenic enzyme CYP11B2
28247	 3477	 7832	Activin	Compound	THBS1	mRNA	-1	1	 7698241	Among members of the TGF beta family, TGF beta 1 and TGF beta 2 and to a lesser extent activin could stimulate thrombospondin-1 and CISP/thrombospondin-2 synthesis, whereas inhibin and Mllerian inhibiting substance were inactive.
36702	 3477	 4105	Activin	Compound	CYP11B2	mRNA	0	1	14592955	The mRNA levels of steroidogenic acute regulatory protein or P450 steroid side-chain cleavage enzyme, the rate-limiting steps of adrenocortical steroidogenesis, were enhanced by activin and BMP-6. Activin and BMP-6 also activated the transcription of steroidogenic acute regulatory protein as well as the late-step steriodogenic enzyme CYP11B2
49789	 3477	16228	Activin	Compound	TGIF1	mRNA	0	1	12593671	Subsequent reverse-transcription PCR assays indicated that TGF-beta1 and activin were able to induce a rapid and transient increase in the level of TGIF in both HuT78 and HepG2 hepatoma cells
51015	 3477	13884	Activin	Compound	CDKN1A	mRNA	1	1	 9618481	This region also mediates the transcriptional activation of the p21 promoter by members of the Smad family of proteins, which play important role in the transduction of extracellular signals such as transforming growth factor beta, activin, etc.
54027	 3477	11837	Activin	Compound	CYP11A1	mRNA	0	1	14592955	The mRNA levels of steroidogenic acute regulatory protein or P450 steroid side-chain cleavage enzyme, the rate-limiting steps of adrenocortical steroidogenesis, were enhanced by activin and BMP-6. Activin and BMP-6 also activated the transcription of steroidogenic acute regulatory protein as well as the late-step steriodogenic enzyme CYP11B2
61793	 3477	 1730	Activin	Compound	KLF10	mRNA	1	1	10861837	The BMP-2 (16-fold), BMP-4 (4-fold), and activin (1-3-fold) also induced TIEG mRNA levels
17435	 7006	14361	CLN5	Protein	CXCL12	mRNA	-1	-1	15459177	Table 1. Genes regulated >2-fold in the Cln5-/- mice (3- and 4.5-month-old) upregulated
48774	 7006	17731	CLN5	Protein	DCN	mRNA	-1	-1	15459177	Table 1. Genes regulated >2-fold in the Cln5-/- mice (3- and 4.5-month-old) upregulated
60904	 7006	15700	CLN5	Protein	PRDX2	mRNA	1	1	15459177	downregulated
62010	 7006	 2608	CLN5	Protein	HBB	mRNA	1	-1	15459177	Table 1. Genes regulated >2-fold in the Cln5-/- mice (3- and 4.5-month-old) upregulated
53888	14221	 6691	MESP2	Protein	UNCX	mRNA	-1	-1	16728472	We have analyzed the enhancer region of Epha4, which is responsible for its expression in the anterior PSM, and identified an E-box containing region. Subsequent transgenic and transient luciferase analyses successfully determined that the presence of repeated E-box sequences is a minimum essential requirement for the expression in the anterior PSM. We also show that Mesp2 directly binds to the enhancer sequence of Epha4. Furthermore, the forced expression of Mesp2 in somitic cells results in the activation of Epha4 and repression of the caudal gene Uncx4.1
16068	 1591	 1471	HNRNPK	Protein	COL1A2	mRNA	-1	1	15514164	Reporter gene cell transfection experiments and RNA stability assays show that hnRNPs A1, E1, and K stimulate collagen expression by stabilizing mRNAs We report identification of three mRNA-binding proteins, heterogeneous nuclear ribonucleoprote (hnRNP) A1, E1, and K, as positive effectors of collagen synthesis acting at the post-transcriptional level by interaction with the 3p-untranslated regions (3p-UTRs) of COL1A1, 1A2, and 3A1 mRNAs
24871	 1591	 5863	HNRNPK	Protein	MYC	mRNA	0	1	11121407	Finally, overexpression of hnRNP K in breast cancer cells significantly increased target c-myc promoter activity and c-Myc protein, hnRNP K protein levels, and enhanced breast cancer cell proliferation and growth in an anchorage-independent manner.
33384	 1591	20013	HNRNPK	Protein	SPN	mRNA	0	-1	12411317	We have determined that heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and Pur(alpha) act together to mediate repression of the CD43 promoter during K562 activation.
34936	 1591	 8301	HNRNPK	Protein	SELL	mRNA	0	1	11801644	Fig. 4 A shows that KJ1-26 + CD4 + T cells from the Ld-nOVA recipients expressed lower levels of CD62L and CD45RB and a higher level of CD44 than KJ1-26 + CD4 + T cells from the nontransgenic recipients.
51066	 1591	13884	HNRNPK	Protein	CDKN1A	mRNA	1	-1	15671036	hnRNP K also specifically binds to CU-rich sequences in p21 mRNA 3p-UTR and represses its translation in both nonneuronal and neuronal cells. Further, using RNA interference experiments, we show that the Hu-p21 pathway contributes to the regulation of neurite outgrowth and proliferation in N1E-115 cells, and this pathway is antagonized by hnRNP K.
55236	 1591	12981	HNRNPK	Protein	COL3A1	mRNA	-1	1	15514164	Reporter gene cell transfection experiments and RNA stability assays show that hnRNPs A1, E1, and K stimulate collagen expression by stabilizing mRNAs We report identification of three mRNA-binding proteins, heterogeneous nuclear ribonucleoprote (hnRNP) A1, E1, and K, as positive effectors of collagen synthesis acting at the post-transcriptional level by interaction with the 3p-untranslated regions (3p-UTRs) of COL1A1, 1A2, and 3A1 mRNAs
59448	 1591	16803	HNRNPK	Protein	ALOX15	mRNA	0	-1	12004072	Ariadne: HnRNP K and hnRNP E1 silence the translation of  15-lipoxygenase mRNA by inhibiting 80 S ribosome assembly ( 23 ). [Regulation]
 6897	 1591	 2204	HNRNPK	Protein	COL1A1	mRNA	0	1	15514164	Reporter gene cell transfection experiments and RNA stability assays show that hnRNPs A1, E1, and K stimulate collagen expression by stabilizing mRNAs We report identification of three mRNA-binding proteins, heterogeneous nuclear ribonucleoprote (hnRNP) A1, E1, and K, as positive effectors of collagen synthesis acting at the post-transcriptional level by interaction with the 3p-untranslated regions (3p-UTRs) of COL1A1, 1A2, and 3A1 mRNAs
13855	16004	17250	NGF	Protein	PTGS2	mRNA	0	1	11266466	Similarly, NGF increased  the expression of the NF B target gene COX-2 in the presence of the proteasome  inhibitor lactacystin ( Fig 7 b).
14422	16004	16809	NGF	Protein	SRF	mRNA	0	1	10990459	Modified assertion
14553	16004	 1512	NGF	Protein	RARB	mRNA	0	1	11158236	These results suggest that the RARbeta2 gene could be in a basal repressed state and NGF could increase RARbeta2 transcription by inducing the release of some inhibitory factors from the INR.
15065	16004	11367	NGF	Protein	BHLHE41	mRNA	0	1	15970569	From full text table 4: Reagents regulating expression of the BHLHB2 and BHLHB3 genes
17171	16004	 8822	NGF	Protein	MAG	mRNA	0	1	10221670	Nerve growth factor (NGF) upregulated expression of the MAG binding molecule in a dose dependent manner.
17231	16004	15016	NGF	Protein	APP	mRNA	0	1	11359873	These results  demonstrate that NGF increases APP gene expression at transcriptional level.
18108	16004	17519	NGF	Protein	FGF2	mRNA	0	1	10409634	Moreover, FGF-2 expression  is modulated by NGF , and FGF-2 is detected at the cell surface.
21318	16004	11773	NGF	Protein	CHN1	mRNA	0	1	15447672	alpha chimaerin which has 91% homology to human alpha2 chimaerin, was also up-regulated following exposure to BDNF figure shows NGF also induces
21698	16004	 2572	NGF	Protein	CAV1	mRNA	0	1	12679365	Nerve Growth Factor Blocks the Glucose- induced Down-regulation of Caveolin-1 Expression in Schwann Cells via p75  Neurotrophin Receptor Signaling * Wenbin Tan , Shefali Rouen , Kristin M.
 2278	16004	 5419	NGF	Protein	TNF	mRNA	0	1	11404390	The induction of TNF-alpha production by NGF was blocked by K252a, an inhibitor of the TrkA receptor.
23308	16004	 7455	NGF	Protein	CTSB	mRNA	0	1	10390549	Basic FGF and NGF treatment of macrophages and microglia significantly increased the levels of cathepsin S, B, and L mRNAs
24339	16004	18209	NGF	Protein	MMP3	mRNA	0	1	10734128	NAB2 overexpression blocked NGF-dependent differentiation and prevented NGF induction of TGF-beta1, MMP3 and p21waf1
24994	16004	 4764	NGF	Protein	ISL1	mRNA	0	1	11502362	Modified assertion
25080	16004	12377	NGF	Protein	OSM	mRNA	0	1	12871977	NGF also specifically induces the expression of  neuropoietic cytokines, such as LIF and OSM, raising the possibility of an  autocrine mode of action in PC12 cells during neuronal differentiation.
  253	16004	16516	NGF	Protein	ZC3H15	mRNA	0	1	15150441	Additionally, we demonstrate here that p48ZnF is up-regulated in rat neuronal PC12 cells upon stimulation with the neurotrophic factor NGF (50 ng/ml).
25792	16004	19027	NGF	Protein	HMOX1	mRNA	0	1	12578834	NGF induces HO-1 expression.
26373	16004	10421	NGF	Protein	PLD1	mRNA	0	1	10327185	However, when the cells were treated with NGF, rPLD1a and rPLD1b mRNAs, but not rPLD2 mRNA, increased within 2 days and remained elevated up to 5 days.
 2768	16004	  908	NGF	Protein	MMP9	mRNA	0	1	11698409	This suggests that, in addition to its potent  chemotactic activity, NGF could also potentially regulate MMP-9 expression in  smooth muscle cells.
27963	16004	19309	NGF	Protein	PLAUR	mRNA	0	1	10627600	Both an antisense oligonucleotide for the UPAR mRNA and an antibody directed against UPAR protein block NGF-induced morphological and biochemical differentiation of PC12 cells; NGF-induced UPAR expression is required for subsequent NGF-driven differentiation.
28113	16004	17708	NGF	Protein	FOSL1	mRNA	0	1	19013137	Table 1 - Relative expression data of and references to replicated NGF-responsive IEGs (immediate early genes) - bw
 2851	16004	 7254	NGF	Protein	MAP3K11	mRNA	0	1	11438570	These results demonstrate that MLK3 can induce neuronal apoptosis in the presence of NGF and that its kinase activity is required for its proapoptotic effect.
28952	16004	 3794	NGF	Protein	RAB40A	mRNA	0	1	11158236	These results suggest that the  RAR..2 gene could be in a basal repressed state and NGF could increase RAR..2  transcription by inducing the release of some inhibitory factors from the INR.
29237	16004	18120	NGF	Protein	NGFR	mRNA	0	1	11000524	NGF also induced the expression of the p75 NGF receptor.
29826	16004	  252	NGF	Protein	BCL2L11	mRNA	0	-1	12388545	We report here that nerve growth factor (NGF) leads to both a slow down-regulation of Bim expression in neuronal PC12 cells and rapid Bim phosphorylation.
 3171	16004	16645	NGF	Protein	CCND1	mRNA	0	1	16611639	NGF-induced cyclin D1 expression
36039	16004	18535	NGF	Protein	KCTD11	mRNA	0	1	12186855	We report here the identification of a novel gene, REN, upregulated by neurogenic signals (retinoic acid, EGF, and NGF) in pluripotent embryonal stem (ES) cells and neural progenitor cell lines in association with neurotypic differentiation.
 3704	16004	14578	NGF	Protein	TNFRSF12A	mRNA	0	1	14573547	Fn14 expression in PC12 cells is also upregulated by nerve growth factor treatment.
38326	16004	16635	NGF	Protein	NRG1	mRNA	0	-1	10532805	In PC12 cells, nerve growth factor induces neuronal differentiation and repressed expression of nrg-1.
39314	16004	11174	NGF	Protein	CX3CL1	mRNA	0	1	10415068	Only NGF  slightly increased fractalkine message expression in hypothalamic neurons.
39387	16004	18612	NGF	Protein	SOD2	mRNA	-1	1	12609977	Cells exposed to NGF show a late decrease in the intracellular  content of ROS when compared with untreated cells and increased expression of  the mitochondrial antioxidant enzyme manganese superoxide dismutase, a general  inhibitor of cell death.
41023	16004	13794	NGF	Protein	HIST1H2BO	mRNA	0	1	10477751	Note that both panels are reprobes of the same blot. d, In vitro Akt activation using histone H2B as a substrate in lysates of sympathetic neurons treated for 15 min with increasing concentrations of NGF (ng/ml) or KCl (mM).
42072	16004	13115	NGF	Protein	EGR1	mRNA	-1	1	10842166	Interestingly, the transcription of egr1 in PC12 cells is also activated by  both NGF ( 23 ) and by TPA ( 24 ) with typical immediate early kinetics.
42219	16004	10155	NGF	Protein	CACNA1C	mRNA	1	-1	15155748	TABLE I  Sema 3A regulates gene expression in PC12 cells and hippocampal neurons (PC12+SEMA3A and PC12+NGF columns)
42897	16004	 7577	NGF	Protein	HSP90AA1	mRNA	0	1	14699958	We show that both ATP and NGF upregulate the expression of the stress-induced heat shock protein HSP70 and HSP90
43509	16004	10899	NGF	Protein	TGFB1	mRNA	0	1	10734128	NAB2 overexpression blocked NGF-dependent differentiation and prevented NGF induction of TGF-beta1, MMP3 and p21waf1
44674	16004	12342	NGF	Protein	PTEN	mRNA	0	1	10662831	NGF-treated PC12 cells were reported  previously to express PTEN mRNA (Li and Sun, 1997 ).
45366	16004	14987	NGF	Protein	BCL2	mRNA	1	1	 8910334	NGF markedly increased bcl-2 expression but had little or no effect on the other genes studied.
47615	16004	11030	NGF	Protein	CDK5R1	mRNA	0	1	11331872	Here we show that NGF induces strong, sustained expression of p35, the neuron-specific activator of cyclin-dependent kinase 5 (Cdk5), through activation of the ERK pathway.
51019	16004	13884	NGF	Protein	CDKN1A	mRNA	1	1	10734128	NAB2 overexpression blocked NGF-dependent differentiation and prevented NGF induction of TGF-beta1, MMP3 and p21waf1
51605	16004	 5673	NGF	Protein	ID1	mRNA	0	1	15361847	NGF-induced Id1 expression
51952	16004	 1178	NGF	Protein	NR4A1	mRNA	0	1	11559707	Other diverse signals, such as membrane depolarization  and nerve growth factor, also increase Nur77 expression.
52352	16004	  520	NGF	Protein	ITGA1	mRNA	0	1	11501763	In PC12 wt cells, alpha1 integrin expression is upregulated by EGF and NGF.
54004	16004	19665	NGF	Protein	CHGB	mRNA	0	1	11014221	In acute  (16- to 18-h) NGF exposure experiments (endogenous gene in Fig. 3 ; transfected  promoter in Fig. 7B ), NGF activated chromogranin B expression.
54498	16004	 7132	NGF	Protein	FOSL2	mRNA	0	1	11150315	In contrast, NGF elicits a more  sustained ERK phosphorylation and induces expression of c-fos , Fra-1, and Fra- 2.
55813	16004	13472	NGF	Protein	NTRK3	mRNA	0	-1	14672914	NGF action is inhibited by K252a, a carbazole alkaloid, which has been shown to inhibit trkA, trkB and trkC phosphorylation ( 24 ).
55877	16004	 5857	NGF	Protein	BHLHE40	mRNA	0	1	15970569	From full text table 4: Reagents regulating expression of the BHLHB2 and BHLHB3 genes
56227	16004	15199	NGF	Protein	BDNF	mRNA	0	1	10217270	As both  nerve growth factor and neurotrophin-3 are known to affect the development of a  variety of neurons expressing the brain-derived neurotrophic factor ( bdnf )  gene, this assay was used to determine levels in tissues isolated from newborn  mice carrying a null mutation in the nerve growth factor ( ngf ) or the  neurotrophin-3 ( nt3 ) gene.
56718	16004	13868	NGF	Protein	CHN2	mRNA	0	1	15447672	An increase in the expression of beta chimaerin mRNA by the BDNF treatment was found during the observation period, Expression of beta chimaerin mRNA is induced transiently by NGF as well as BDNF
58369	16004	 6053	NGF	Protein	CAT	mRNA	-1	1	12578834	It has also been shown that NGF may modulate the canonical antioxidant  machinery of ROS detoxification by increasing the expression of catalase and  glutathione peroxidase activities ( 39 , 40 ).
60317	16004	 7889	NGF	Protein	LNPEP	mRNA	0	1	11389728	When PC12 cells were differentiated into neuronal cells by nerve growth factor (NGF), a significant increase in the expression level of P-LAP in the cell was observed.
 6130	16004	10255	NGF	Protein	KLK3	mRNA	0	1	10628752	Effect of NGF on the Expression of PSA Continuous exposure of LNCaP cells to NGF markedly enhanced the expression of PSA, a typical marker of cellular differentiation in prostatic epithelial cells.
 6185	16004	19806	NGF	Protein	PRPH	mRNA	0	1	11573983	NGF treatment markedly stimulated expression of peripherin, alpha-tubulin, and tau mRNAs in both PCER and PCCON cells.
62657	16004	 1326	NGF	Protein	GRIN1	mRNA	0	1	11571288	NGF-increased NR1 promoter activity may involve a complicated mechanism of Sp1 phosphorylation and possible transcription factor exchange.
62732	16004	 8349	NGF	Protein	TXN	mRNA	0	1	12533610	In this study, we showed that NGF induces TRX expression at protein and mRNA levels.
 6614	16004	 6596	NGF	Protein	CHGA	mRNA	0	1	10197763	Chemical blockade of the nerve growth factor receptor TrkA or the mitogen-activated protein kinase pathway component MEK substantially diminished nerve growth factor-induced expression of chromogranin A.Nerve growth factor activated chromogranin A gene expression 7.6-fold in PC12 pheochromocytoma cells, and similarly activated PC12-transfected mouse, rat or human chromogranin A promoter/reporter constructs.
  690	16004	10952	NGF	Protein	TRPV1	mRNA	0	1	12095983	Among several mRNAs, NGF can induce transcription of VR1 in dissociated  cultures of adult DRG , as well as VR1 protein levels in undamaged DRG neurons  after partial nerve injury ( 32 , 33 ).
 9798	16004	13302	NGF	Protein	NTF3	mRNA	0	1	15260993	Interestingly, final target-derived NGF promotes expression of the p75 neurotrophin receptor, in turn causing a reduction in the sensitivity of axons to intermediate target-derived NT-3.
 2469	 2983	17889	trans10,cis12-Octadecadienoate	Compound	SLC2A4	mRNA	1	-1	14519781	trans-10, cis-12 dose dependently decreased insulin stimulated glucose uptake, trans-10, cis-12 CLA, but not cis-9, trans-11 CLA, decreased the expression of the insulin-stimulated glucose transporter 4 (GLUT4) and acetyl-CoA carboxylase (ACC)
65430	 2983	19519	trans10,cis12-Octadecadienoate	Compound	CPT1A	mRNA	-1	1	16868072	A combined histological and microarray analysis of the white adipose tissue (WAT) of mice fed trans-10, cis-12 conjugated linoleic acid (t10c12 CLA) was performed to better define functional responses. Mice fed t10c12 CLA for 14 days lost 85% of WAT mass, 95% of adipocyte lipid droplet volume, and 15% or 47% of the number of adipocytes and total cells, respectively. Microarray profiling of replicated pools (n = 2 per day x diet) of control and treated mice (n = 140) at seven time points after 1 to 17 days of t10c12 CLA feeding found between 2798 and 4318 transcript levels changed by 2-fold or more. Transcript levels for genes involved in glucose and fatty acid import or biosynthesis were significantly reduced. Highly expressed transcripts for lipases were only moderately reduced suggesting lipolysis and fatty acid export continued to occur. Increased levels of mRNAs for two key thermogenesis proteins, uncoupling protein 1 (UCP1) and carnitine palmitoyltransferase 1, may have increased energy expenditures. Significant reductions of mRNAs for major adipocyte regulatory factors, including PPARgamma, SREBP1, CAAT/enhancer binding proteinalpha, and Lipin 1 were correlated with the reduced transcript levels for key metabolic pathways in the WAT. A prolific inflammation response was indicated by the 2- to 100-fold induction of many cytokine transcripts, including those for IL-6, IL1beta, TNF ligands, and CXC family members, and an increased density of macrophages. The combination of cell loss, increased energy expenditure, and transport of lipids out of the adipocytes may account for the cumulative mass loss observed.
19647	10791	16486	Mapk JNK Family	Protein	SPP1	mRNA	1	1	15121739	FGF-1-induced OPN expression was blocked by inhibitors of JNK or MEK1/2 but not of PI3K, p70S6K, or p38MAPK
 3128	15900	16645	lysophosphatidic acid	Compound	CCND1	mRNA	0	1	12759391	LPA stimulated cyclin D1 promoter activity (3.0-fold, 95% confidence interval [CI] = 2.7-fold to 3.3-fold).
40823	15900	13739	lysophosphatidic acid	Compound	CTGF	mRNA	0	1	11487529	Incubation of the cells with simvastatin or lovastatin time-dependently and reversibly changed cell morphology and the actin cytoskeleton with maximal effects observed after about 18 h. Within the same time period, statins reduced the basal expression of CTGF and interfered with CTGF induction by lysophosphatidic acid (LPA) or transforming growth factor beta.
45382	15900	14987	lysophosphatidic acid	Compound	BCL2	mRNA	1	1	12684213	LPA prevented translocation of Bax from cytosol to mitochondria and increased the expression of the antiapoptotic Bcl-2 mRNA and protein.
51277	15900	 1631	lysophosphatidic acid	Compound	AKAP12	mRNA	0	1	12372401	platelet-derived growth factor-BB (PDGF-BB), lysophosphatidic acid (LPA), and eicosapentaenoic acid (EPA) potently modulate SSeCKS gene expression in cultured smooth muscle (RASM) cells
63103	15900	14810	lysophosphatidic acid	Compound	CD83	mRNA	0	1	15454113	Moreover, PA and TNF-alpha-induced expression of CD83 was slightly increased by propranolol
 7444	15900	11420	lysophosphatidic acid	Compound	MIF	mRNA	0	1	12964047	Ariadne: We found that LPA enhanced the expression of MIF mRNA in a dose-dependent manner in vitro.
55352	10404	 4481	HOXB1	Protein	COL5A2	mRNA	1	1	10748126	DNA binding assays and cell transfection experiments revealed that the bipartite core sequence of FPB (5p-ATCAATCA-3p) binds the PBX1/2, PREP1, and HOXB1 proteins, and this in turn leads to promoter transactivation.
10613	17341	 4100	TP53	Protein	SERPINB5	mRNA	0	1	17700520	With regard to Maspin, ATF-2 and p53 directly bind to different sites in the Maspin promoter to independently activate its transcription.
11766	17341	 9867	TP53	Protein	MAPK1	mRNA	0	1	15383658	By contrast, serum- and glucocorticoid-inducible kinase 1 (SGK1) was significantly induced in a p53-dependent manner after DNA damage, and this induction was through extracellular signal-regulated kinase 1/2-mediated posttranslational regulation.
 1273	17341	18332	TP53	Protein	NDRG1	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
13120	17341	 4471	TP53	Protein	PTPN22	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
13939	17341	18671	TP53	Protein	TPP1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
13994	17341	 6389	TP53	Protein	LYL1	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
14684	17341	18841	TP53	Protein	HSPB11	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
16261	17341	15838	TP53	Protein	PER1	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
16594	17341	10839	TP53	Protein	SLC6A6	mRNA	0	-1	12163498	Expression of TauT was decreased after activation of p53
16961	17341	 5610	TP53	Protein	Fcgbp	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
16980	17341	15429	TP53	Protein	WNT10A	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
17292	17341	14807	TP53	Protein	CANX	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
17324	17341	 9108	TP53	Protein	CYP1B1	mRNA	0	1	12214277	Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes.
17503	17341	   42	TP53	Protein	GSN	mRNA	0	1	12214277	Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes.
17798	17341	 5117	TP53	Protein	SAT1	mRNA	1	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
19488	17341	16140	TP53	Protein	ELF5	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
19655	17341	16486	TP53	Protein	SPP1	mRNA	1	1	11807984	Furthermore, we found that Opn expression was upregulated by DNA damage-induced Tp53 activity and by adenovirus-mediated transfer of the human TP53 gene. In addition, a luciferase assay showed that the Opn gene has a functional Tp53-responsive element in its promoter region, and a chromatin immunoprecipitation assay confirmed interaction between the Opn promoter and Tp53 protein in vivo.
19920	17341	17834	TP53	Protein	CCNG2	mRNA	-1	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
20214	17341	11450	TP53	Protein	FZD7	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
20321	17341	 2815	TP53	Protein	TP53	mRNA	0	1	16368933	Downregulated in p53-
21949	17341	19286	TP53	Protein	XRCC5	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
21954	17341	 7521	TP53	Protein	C22orf25	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
22851	17341	10789	TP53	Protein	DSTN	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
23007	17341	 8664	TP53	Protein	TRAFD1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
23462	17341	 7072	TP53	Protein	HTR1B	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
24371	17341	17534	TP53	Protein	PTPRJ	mRNA	0	1	10914555	Increased protein tyrosine phosphatase activity as well as mRNA levels of PTPbeta2 and PTPepsilon could be observed by wildtype p53 overexpression.
 2442	17341	 2984	TP53	Protein	CUBN	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
24942	17341	  887	TP53	Protein	MAPK3	mRNA	0	1	15383658	By contrast, serum- and glucocorticoid-inducible kinase 1 (SGK1) was significantly induced in a p53-dependent manner after DNA damage, and this induction was through extracellular signal-regulated kinase 1/2-mediated posttranslational regulation.
26399	17341	15574	TP53	Protein	MAN2B1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
26403	17341	13160	TP53	Protein	GPN3	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
  267	17341	 5737	TP53	Protein	Expi	mRNA	0	1	12214277	Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes.
 2828	17341	  931	TP53	Protein	TP53INP1	mRNA	-1	1	12067065	That hypothesis is consistent with the presence of a functional p53-response element within the promoter region of the mouse SIP gene and confirmed by the induction of SIP mRNA expression in mouse embryo fibroblasts upon activation of a p53-dependent pathway by transfection with rasV12 or rasV12/E1A
28869	17341	 2111	TP53	Protein	ULK1	mRNA	-1	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
29891	17341	 2612	TP53	Protein	Agtr1b	mRNA	0	1	11375343	In diabetic WTM, p53 was increased in myocytes, and this activation of p53 was characterized by upregulation of Bax, angiotensinogen, Ang type 1 (AT(1)) receptors, and Ang II.
30355	17341	17778	TP53	Protein	CALML5	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
 3152	17341	16645	TP53	Protein	CCND1	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
31914	17341	 8021	TP53	Protein	E4F1	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
32101	17341	 8057	TP53	Protein	Ly6a	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
32546	17341	 5239	TP53	Protein	CITED1	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
32832	17341	12649	TP53	Protein	ETS1	mRNA	1	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
34077	17341	  439	TP53	Protein	IGFBP4	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
 3441	17341	10915	TP53	Protein	BAX	mRNA	0	1	11375343	In diabetic WTM, p53 was increased in myocytes, and this activation of p53 was characterized by upregulation of Bax, angiotensinogen, Ang type 1 (AT(1)) receptors, and Ang II.
34433	17341	12755	TP53	Protein	SMYD1	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
34840	17341	14732	TP53	Protein	S100A3	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
35138	17341	 1449	TP53	Protein	BARX1	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
35167	17341	17804	TP53	Protein	NOTCH1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
 3542	17341	 3594	TP53	Protein	CKS2	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
35515	17341	 6249	TP53	Protein	S100A10	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
 3558	17341	11752	TP53	Protein	WNT4	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
36084	17341	19195	TP53	Protein	DFNA5	mRNA	0	1	16897187	expression of the DFNA5 gene was strongly induced by exogenous and endogenous p53
36564	17341	 8855	TP53	Protein	RAD51B	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
 3727	17341	18834	TP53	Protein	IRS3P	mRNA	0	-1	12089352	The mIRS-3 promoter is inhibited by wild-type p53, and this effect is completely abolished by cotransfection of a dominant negative p53.
37487	17341	13065	TP53	Protein	RASD1	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
38202	17341	13507	TP53	Protein	Hist1h2ao	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
38337	17341	 1872	TP53	Protein	BTG2	mRNA	0	1	16368933	Downregulated in p53-
38885	17341	17325	TP53	Protein	MXD1	mRNA	-1	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
 3907	17341	12631	TP53	Protein	AK1	mRNA	0	1	10557075	AK1beta,was specifically induced upon activation of wt p53 in Val5 cells
40046	17341	 8242	TP53	Protein	GTSE1	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
41287	17341	 6882	TP53	Protein	PMAIP1	mRNA	0	1	12968018	Compound mutant cells also show increased levels of p53 and induction of Noxa, a death effector p53 target gene, suggesting that cell death is potentially mediated by reactive oxygen species activation of p53.
41372	17341	15861	TP53	Protein	RPRM	mRNA	0	1	12036908	we found that expression of the Reprimo gene was significantly increased in normal uteri of p53(wt/wt) mice
42307	17341	 8050	TP53	Protein	INVS	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
42466	17341	13544	TP53	Protein	AGTR1	mRNA	0	1	11375343	In diabetic WTM, p53 was increased in myocytes, and this activation of p53 was characterized by upregulation of Bax, angiotensinogen, Ang type 1 (AT(1)) receptors, and Ang II.
42534	17341	 8883	TP53	Protein	HIST1H2BN	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
42632	17341	 3992	TP53	Protein	SCN3B	mRNA	0	1	16368933	Downregulated in p53-
42688	17341	17469	TP53	Protein	CD200	mRNA	0	1	14644999	We define CD200 as a p53-target gene and identify both p53- and caspase-dependent pathways that control CD200 expression during apoptosis.
42844	17341	 3879	TP53	Protein	FAS	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
43547	17341	17125	TP53	Protein	PER2	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
43807	17341	 3144	TP53	Protein	Erv4	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
43955	17341	 4591	TP53	Protein	S100A4	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
44482	17341	17358	TP53	Protein	CBX1	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
44582	17341	18040	TP53	Protein	NCOA2	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
45126	17341	17119	TP53	Protein	PTPRVP	mRNA	0	1	16107883	Here we report the identification of a new direct p53 target, Ptprv (or ESP), encoding a transmembrane tyrosine phosphatase. Ptprv transcription is dramatically and preferentially increased in cultured cells undergoing p53-dependent cell cycle arrest, but not in cells undergoing p53-mediated apoptosis.
45410	17341	 6411	TP53	Protein	APOBEC1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
46288	17341	10963	TP53	Protein	ANXA1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
46479	17341	19036	TP53	Protein	EPHA2	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
 4654	17341	 1136	TP53	Protein	BMP6	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
48194	17341	19258	TP53	Protein	ING4	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
 4836	17341	 4355	TP53	Protein	BBC3	mRNA	0	1	16407291	In search of the molecular link between ER stress and the mitochondrial apoptotic pathway, we have discovered that in MEFs, ER stress selectively activates BH3-only proteins PUMA and NOXA at the transcript level through the tumor suppressor gene p53. In p53(-/-) MEFs, ER stress-induced apoptosis is partially suppressed.
48540	17341	 6629	TP53	Protein	RIN2	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
48790	17341	12786	TP53	Protein	ANKFY1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
49210	17341	 4945	TP53	Protein	SOX5	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
49544	17341	14497	TP53	Protein	AGT	mRNA	0	1	11375343	In diabetic WTM, p53 was increased in myocytes, and this activation of p53 was characterized by upregulation of Bax, angiotensinogen, Ang type 1 (AT(1)) receptors, and Ang II.
49561	17341	17809	TP53	Protein	LRPAP1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
49678	17341	 6430	TP53	Protein	MDM2	mRNA	1	1	16368933	Downregulated in p53-
50158	17341	 8530	TP53	Protein	PRKCZ	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
50907	17341	  795	TP53	Protein	MAZ	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
51022	17341	13884	TP53	Protein	CDKN1A	mRNA	1	1	14985341	This activation of the p53 pathway leads to the elevation of p21 mRNA expression, which can be considered an indicator of p53 activity,
51258	17341	16115	TP53	Protein	GMNN	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
51931	17341	 5004	TP53	Protein	PIK3R2	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
52155	17341	 3503	TP53	Protein	MAP4	mRNA	0	-1	10521394	Consistent with this finding, we report that p53 physically associates in vivo with HDACs. This interaction is not direct but, rather, is mediated by the corepressor mSin3a. Both wild-type p53 and mSin3a, but not mutant p53, can be found bound to the Map4 promoter at times when this promoter preferentially associates with deacetylated histones in vivo.
52446	17341	11626	TP53	Protein	CELSR2	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
52758	17341	20220	TP53	Protein	BUB1	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
53645	17341	15005	TP53	Protein	DRD3	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
53787	17341	15752	TP53	Protein	DFFA	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
54359	17341	12644	TP53	Protein	TOB1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
54411	17341	 1906	TP53	Protein	CBX2	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
55307	17341	12311	TP53	Protein	TCTE3	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
55750	17341	 4958	TP53	Protein	ARHGDIG	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
55833	17341	10766	TP53	Protein	CIDEB	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
55896	17341	 4539	TP53	Protein	KIAA0247	mRNA	0	1	16368933	Downregulated in p53-
57338	17341	 4298	TP53	Protein	JUNB	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
58247	17341	 9196	TP53	Protein	CKAP2	mRNA	0	1	16061649	DNA damage induces human and mouse CKAP2 expression in a p53-dependent manner and p53 activates the Ckap2 promoter.
58264	17341	20025	TP53	Protein	RNF39	mRNA	0	1	16382142	Microarray studies performed with an NIH 3T3 cell line engineered to express an inducible Arf gene identified numerous p19Arf-responsive genes that were temporally regulated in either a p53-dependent or -independent manner (33). Among these, the Hzf gene (gene identifier 7305176) encoding a previously described \hematopoietic zinc finger\ (Hzf) protein (23) was rapidly induced with kinetics similar to that of the bona fide p53-regulated target gene, Mdm2. The failure of exogenously expressed p19Arf to increase Hzf mRNA levels in p53-null MEFs indicated that Hzf expression is p53 dependent.
58559	17341	  497	TP53	Protein	SIRT1	mRNA	-1	1	15604409	Knockdown of Foxo3a expression inhibited the starvation-induced increase in SIRT1 expression.  Stimulation of SIRT1 transcription by Foxo3a was mediated through two p53 binding sites present in the SIRT1 promoter, and a nutrient-sensitive physical interaction was observed between Foxo3a and p53.  SIRT1 expression was not induced in starved p53-deficient mice.
59307	17341	 3188	TP53	Protein	PIGF	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
59736	17341	 5494	TP53	Protein	LPIN1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
60096	17341	 2167	TP53	Protein	PTPRE	mRNA	0	1	10914555	Increased protein tyrosine phosphatase activity as well as mRNA levels of PTPbeta2 and PTPepsilon could be observed by wildtype p53 overexpression.
61559	17341	 2095	TP53	Protein	DDIT4	mRNA	0	1	16368933	Downregulated in p53-
61756	17341	 7962	TP53	Protein	RRAD	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
62198	17341	17946	TP53	Protein	MAD2L1	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
 6222	17341	15440	TP53	Protein	RAMP2	mRNA	0	1	12214277	Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes.
62244	17341	17162	TP53	Protein	ANGPTL2	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
62304	17341	11343	TP53	Protein	CXCR5	mRNA	0	-1	16254190	Table 3. Alteration of Gene Expression Specially Associated with p53 and H-ras Status in Skin Tumorigenesis upregulated
62691	17341	10055	TP53	Protein	COL19A1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
62762	17341	 5282	TP53	Protein	PERP	mRNA	0	1	19011633	Bach1 repressed the p53-mediated activation of the Perp promoter (Fig. 7c).
62938	17341	 7195	TP53	Protein	GADD45A	mRNA	-1	1	 1423616	Finally, IR induction of the human GADD45 gene, an induction that is also defective in AT cells, was dependent on wild-type p53 function. Wild-type but not mutant p53 bound strongly to a conserved element in the GADD45 gene, and a p53-containing nuclear factor, which bound this element, was detected in extracts from irradiated cells.
63205	17341	 2769	TP53	Protein	LGR5	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
64009	17341	 1012	TP53	Protein	PSRC1	mRNA	0	1	10618717	Actinomycin D, but not cycloheximide, inhibited the p53 dependent DDA3 induction, suggesting that the activation is through transcriptional regulation and does not require de novo protein synthesis.
 6415	17341	 5554	TP53	Protein	MST1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
64474	17341	15063	TP53	Protein	ASS1	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
 6468	17341	12489	TP53	Protein	ERCC5	mRNA	-1	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
65680	17341	  562	TP53	Protein	MAPK12	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
66129	17341	 1058	TP53	Protein	SLC25A17	mRNA	0	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
66266	17341	17073	TP53	Protein	ARL2	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
 6917	17341	 8725	TP53	Protein	NCOA1	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
 7130	17341	14713	TP53	Protein	FOXA1	mRNA	0	1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
 8319	17341	 6202	TP53	Protein	BTG1	mRNA	-1	1	11423996	The list contains genes from LTR6 cells that showed over threefold induction [in response to a temperature induction of p53 in LTR7 cells upon shifting from 37 degrees to 32 degrees - BCD] in at least three time points compared to M1 cells at 2 h at 32 degrees C. The ratios of gene expression at di?erent time points (2, 6, 9 and 12 h at 328C) are shown. [ Note that this experiment compares cells shifted to 32 degrees C for up to 12 hours to a control that is shifted to 32 degrees for only 2 hours - BCD ]
  893	17341	18314	TP53	Protein	STMN1	mRNA	0	-1	10521394	Consistent with this finding, we report that p53 physically associates in vivo with HDACs. This interaction is not direct but, rather, is mediated by the corepressor mSin3a. Both wild-type p53 and mSin3a, but not mutant p53, can be found bound to the Map4 promoter at times when this promoter preferentially associates with deacetylated histones in vivo.
 9879	17341	 7501	TP53	Protein	ADORA2B	mRNA	0	-1	16254190	Table 1. Alteration of Gene Expression Specially Associated with p53 Status in Skin Tumorigenesis _[JL] TP53 dominant negative
13887	 5230	17250	RAS Family	Protein	PTGS2	mRNA	0	1	10678579	COX-2 is inducible by oncogenes ras and scr, interleukin-1, hypoxia, benzo[a]pyrene, ultraviolet light, epidermal growth factor, transforming growth factor beta, and tumor necrosis factor alpha.
17497	 5230	   42	RAS Family	Protein	GSN	mRNA	0	-1	15213223	We demonstrated that silencing of gelsolin expression by small interfering RNA sensitized cells to butyrate-induced apoptosis through amplification of the activation of caspase-9 and caspase-7. These data therefore demonstrate that gelsolin protects cells from butyrate-induced apoptosis and suggest that Ras promotes apoptosis, at least in part, through its ability to down-regulate the expression of gelsolin.
19663	 5230	16486	RAS Family	Protein	SPP1	mRNA	1	1	15857938	high levels of Bcr-Abl activate a signaling cascade involving the sequential activation of Ras, phosphatidylinositol-3 kinase, atypical protein kinase C, Raf-1, and mitogen-activated protein kinase kinase, leading to the ultimate expression of OPN.
26400	 5230	15574	RAS Family	Protein	MAN2B1	mRNA	0	1	12878600	A significant increase of alpha-D-mannosidase (up to 16-fold increase) activity, and a parallel increase of alpha-D-mannosidase transcript in fibroblasts overexpressing Ras with respect to those infected with the empty vector was observed.
27459	 5230	 5919	RAS Family	Protein	MMP1	mRNA	0	1	11259407	The human interstitial collagenase (MMP-1) promoter has been also shown to be a Ras-responsive promoter by virtue of the presence of ETS and AP-1 cis-elements, which act synergistically to activate Ras-dependent transcription of the gene (15, 16). Similarly to what was observed previously with the synthetic ORE reporter, ESE-3 was able to repress the -1200 to +63 collagenase promoter response to Ras (Fig. 6B). In both cases, expression of ETS-2 resulted in enhanced expression of the reporter in these cells
 2751	 5230	  908	RAS Family	Protein	MMP9	mRNA	0	-1	10515879	By contrast, G-protein inhibition by pertussis toxin, or transfection with a dominant negative mutant of Ha-Ras strongly increased fibronectin-induced MMP-2 and MMP-9. Inhibition of PI3 kinase, MAPkinase (MEK1), or p38 MAPkinase by wortmannin, PD 98059, or SB 202190, respectively, strongly promoted fibronectin-induced MMP2 and MMP-9
27833	 5230	12681	RAS Family	Protein	AFP	mRNA	0	-1	10365819	Levels of AFP mRNA but not albumin mRNA were elevated by simvastatin in a dose-dependent manner (1-10 micromol/l).
36232	 5230	 9322	RAS Family	Protein	FGF1	mRNA	0	1	10849427	These results link signaling pathways previously shown to be associated with cell proliferation (18) and cytoskeletal organization (29, 30) to growth factor gene activation and identify a cis element in FGF1 promoter 1D that can be defined as an SRE. This SRE is comprised of Ets and CArG sites. These sites are targets of regulation by divergent signaling pathways; Ets site target of Ras, Rac1, and Cdc42 regulation; and the CArG site target of de novo protein synthesis-independent cascade.
37361	 5230	 9189	RAS Family	Protein	MMP2	mRNA	0	-1	10515879	Modified assertion
44677	 5230	12342	RAS Family	Protein	PTEN	mRNA	0	-1	18794886	Overexpression of mutant Ras promotes a MAPK-dependent repression of PTEN transcription (Vasudevan et al., 2007).
46695	 5230	 6666	RAS Family	Protein	CDON	mRNA	0	-1	12720294	Expression of Cdo and Boc in myoblast cell lines is downregulated by the ras oncogene,
47829	 5230	10326	RAS Family	Protein	CCND3	mRNA	0	1	11779872	Dominant negative RAS-pOPRSVI construct transfected K562 cells were cultured with IPTG for 24 hours, the inducible expression of DN-RAS by IPTG involved in downregulation of CyclinD3, suggesting that RAS induces the Upregulation of CyclinD3.
50268	 5230	 8565	RAS Family	Protein	ARF6	mRNA	0	1	12509462	The sentence from ResnetDB These data suggest that Src, Raf, and H-Ras oncoproteins stimulate elevated ARF6 expression is translated to the assertions Activation of ARF6 (Homo sapiens) Gene Expression by Oncogene Activation of ARF6 (Homo sapiens) Gene Expression by RAF1 (Homo sapiens) Protein
51307	 5230	17260	RAS Family	Protein	MAOB	mRNA	0	1	11956220	Co-transfection of the MAO B promoter with dominant negative forms of Ras, Raf-1, MEKK1, MEK1, MEK3, MEK7, ERK2, JNK1, and p38/RK inhibit the PMA-dependent activation of the MAO B promoter
52870	 5230	 5973	RAS Family	Protein	PAWR	mRNA	0	-1	10514481	Oncogenic Ras induces the transcription activity of NF-kappaB that confers cell survival. Oncogenic Ras also down-modulates the expression of Par-4, a transcriptional repressor protein, that is essential but not sufficient on its own to induce apoptosis. Here we show that reintroduction of Par-4 by transient transfection leads to apoptosis in cells expressing oncogenic Ras but not in those that lack oncogenic Ras expression. Par-4 abrogates oncogenic Ras-inducible NF-kappaB transcription activity
54125	 5230	 5356	RAS Family	Protein	BOC	mRNA	0	-1	12720294	Expression of Cdo and Boc in myoblast cell lines is downregulated by the ras oncogene,
57397	 5230	 3336	RAS Family	Protein	CCND2	mRNA	0	1	11779872	Modified assertion
13408	13131	10696	GRP	Protein	JUN	mRNA	0	1	10912998	A rapid induction of c-jun and jun-B gene expression was noted after BBS treatment
 2794	13131	  908	GRP	Protein	MMP9	mRNA	0	1	12372334	Modified assertion
39966	13131	 6114	GRP	Protein	NFKBIA	mRNA	1	-1	12839933	Modified assertion
57331	13131	 4298	GRP	Protein	JUNB	mRNA	0	1	10912998	A rapid induction of c-jun and jun-B gene expression was noted after BBS treatment
13431	15558	17918	taurocholic acid	Compound	BRF1	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
13797	15558	18311	taurocholic acid	Compound	FDX1	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
23913	15558	 5783	taurocholic acid	Compound	CEBPB	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
27618	15558	18263	taurocholic acid	Compound	EZR	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
36185	15558	  340	taurocholic acid	Compound	SDC1	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
42078	15558	13115	taurocholic acid	Compound	EGR1	mRNA	-1	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
42802	15558	 7101	taurocholic acid	Compound	LXN	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
46439	15558	10422	taurocholic acid	Compound	RHOA	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
47222	15558	 2052	taurocholic acid	Compound	ATF3	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
49024	15558	 9347	taurocholic acid	Compound	Vegp1	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
51947	15558	 1178	taurocholic acid	Compound	NR4A1	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
 5647	15558	18424	taurocholic acid	Compound	DUSP1	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
56651	15558	16427	taurocholic acid	Compound	EFNA1	mRNA	0	1	12709512	Novel genes identified in the current study included ATF3, BRF1, C/EBPbeta, CGRP, EGR-1, ephrinA1, villin2, ferredoxin, latexin, lipocalin, MKP-1, NGFI-B, RhoA, tissue factor (TF), and syndecan.
10190	 1682	   85	TCF3	Protein	NR0B2	mRNA	0	1	16275121	Small heterodimer partner (SHP; NR0B2), an exceptional member of the mammalian nuclear receptor family, directly modulates the activities of conventional nuclear receptors by acting as an inducible and tissue-specific corepressor. Recent progress in dissecting underlying molecular mechanisms, identifying target factors and target genes, and uncovering physiological functions points to the regulatory involvement of SHP in diverse metabolic and intracellular pathways that awaits future clarification. In this review, we carry out a comprehensive survey of all published data and discuss our current understanding of molecular mechanisms and physiological consequences governing SHP action.
51070	 1682	13884	TCF3	Protein	CDKN1A	mRNA	1	1	12493738	Transfection with epicardin/capsulin/Pod-1 small interfering RNA abolished the epicardin/capsulin/Pod-1-mediated suppression of E12-dependent activation of the p21 promoter.
51552	 1682	17867	TCF3	Protein	ADSSL1	mRNA	0	1	10318837	Finally, we report that several different cardiac transcription factors trans-activate the 1.9HSCAT construct... Adss1 appears to be one of the first target genes identified for the bHLH factors Hand1 and Hand2. the combinations utilizing all of the transcription factors, Nkx 2.5, GATA 4, MEF2C, E12, and Hand1 or Hand2, result in a substantial 35-65-fold enhancement of reporter expression
61331	 1682	12305	TCF3	Protein	Epb4.2	mRNA	0	1	14560005	We show here that a nuclear complex containing TAL1, its DNA-binding partner E47, zinc finger transcription factor GATA-1, LIM domain protein LMO2, and LIM domain-binding protein Ldb1 transactivates the protein 4.2 (P4.2) gene through two E box GATA elements in its proximal promoter.
 2477	 7252	17889	FOXO1	Protein	SLC2A4	mRNA	1	-1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
36110	 7252	18165	FOXO1	Protein	ADRB3	mRNA	0	-1	18162510	Knockdown of endogenous FoxO1 increased gene expression levels of Ppargc1a, Ppargc1b, Ucp1, and Adrb3 significantly and increased UCP-1 protein expression in the presence of isoproterenol (Fig. 6D and E). Pparg gene expression in shRNA-transfected cells increased significantly, and Eif4ebp1 gene expression levels were not changed compared with scrambled controltransfected cells (Fig. 6E).
36733	 7252	 4528	FOXO1	Protein	PKM2	mRNA	0	-1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
44451	 7252	13271	FOXO1	Protein	CCL2	mRNA	0	1	19026986	We found that Foxo1 increased the expression of CCAAT/enhancer binding protein (C/EBPbeta, a positive regulator of monocyte chemoattractant protein (MCP)-1 and interleukin (IL)-6 genes, through directly binding to its promoter. Furthermore, knockdown of Foxo1 as well as C/EBPbeta inhibits TNF-alpha-induced expression of MCP-1 and IL-6 in 3T3-L1 adipocytes.
 4732	 7252	 7009	FOXO1	Protein	SREBF1	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
56866	 7252	 2025	FOXO1	Protein	KCNJ8	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
 8363	 7252	13252	FOXO1	Protein	ABCC9	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
 9194	 7252	 8408	FOXO1	Protein	PPARGC1B	mRNA	0	-1	18162510	Knockdown of endogenous FoxO1 increased gene expression levels of Ppargc1a, Ppargc1b, Ucp1, and Adrb3 significantly and increased UCP-1 protein expression in the presence of isoproterenol (Fig. 6D and E). Pparg gene expression in shRNA-transfected cells increased significantly, and Eif4ebp1 gene expression levels were not changed compared with scrambled controltransfected cells (Fig. 6E).
 9507	 7252	16430	FOXO1	Protein	MLYCD	mRNA	0	1	18202312	Figure 2. Fox-induced expression of KATP channel subunit and metabolic genes in the HL-1 mouse atrial cell line.
11155	14262	 9789	ICI D1694	Compound	HSPE1	mRNA	0	1	12907638	Genes that were consistently found to be up-regulated were spermine/spermidine acetyl transferase (SSAT), annexin II, thymosin-beta-10, chaperonin-10==HSPE1, and MAT-8 ==(FXYD3). Treatment of MCF-7 cells with the antifolate tomudex and DNA-damaging agent oxaliplatin also resulted in up-regulation of each of these targets.
17797	14262	 5117	ICI D1694	Compound	SAT1	mRNA	1	1	12907638	Genes that were consistently found to be up-regulated were spermine/spermidine acetyl transferase (SSAT), annexin II, thymosin-beta-10, chaperonin-10==HSPE1, and MAT-8 ==(FXYD3). Treatment of MCF-7 cells with the antifolate tomudex and DNA-damaging agent oxaliplatin also resulted in up-regulation of each of these targets.
 2816	14262	 7073	ICI D1694	Compound	FXYD3	mRNA	-1	1	12907638	Genes that were consistently found to be up-regulated were spermine/spermidine acetyl transferase (SSAT), annexin II, thymosin-beta-10, chaperonin-10==HSPE1, and MAT-8 ==(FXYD3). Treatment of MCF-7 cells with the antifolate tomudex and DNA-damaging agent oxaliplatin also resulted in up-regulation of each of these targets.
33471	14262	15078	ICI D1694	Compound	TMSB10	mRNA	0	1	12907638	Genes that were consistently found to be up-regulated were spermine/spermidine acetyl transferase (SSAT), annexin II, thymosin-beta-10, chaperonin-10==HSPE1, and MAT-8 ==(FXYD3). Treatment of MCF-7 cells with the antifolate tomudex and DNA-damaging agent oxaliplatin also resulted in up-regulation of each of these targets.
41353	14262	 4976	ICI D1694	Compound	ANXA2	mRNA	0	1	12907638	Genes that were consistently found to be up-regulated were spermine/spermidine acetyl transferase (SSAT), annexin II, thymosin-beta-10, chaperonin-10==HSPE1, and MAT-8 ==(FXYD3). Treatment of MCF-7 cells with the antifolate tomudex and DNA-damaging agent oxaliplatin also resulted in up-regulation of each of these targets.
20543	 4971	 6218	Very Low Density LipoProtein	Compound	VCAM1	mRNA	0	1	12606719	We found that LPL treatment reversed tumor necrosis factor alpha and very low-density lipoprotein (VLDL)-stimulated endothelial vascular cell adhesion molecule 1 (VCAM1) induction and VCAM1 promoter responses
42086	 4971	13115	Very Low Density LipoProtein	Compound	EGR1	mRNA	-1	1	 8484785	To demonstrate whether these intracellular responses are only specific to LDL we examined the effects of high- and very low density lipoprotein (HDL and VLDL) on [Ca2+]i and expression of Egr-1 mRNA. The present results show that all lipoproteins induce expression of Egr-1 mRNA and elevation in [Ca2+]i in VSMCs.
38734	 9473	18764	finasteride	Compound	AKT1	mRNA	1	-1	12012013	Finasteride inhibited Akt-1 and MAPK expression while expression of PTEN was significantly increased only at 100 mg dose.
10669	10197	 3198	calcitriol	Compound	TFRC	mRNA	-1	-1	 9135559	In addition, calcitriol suppressed the expression of CD71 Ag on monocytes.
11568	10197	14350	calcitriol	Compound	OCLN	mRNA	0	1	11470825	Modified assertion
11902	10197	16736	calcitriol	Compound	FOXQ1	mRNA	0	1	12648525	and 1 up-regulated, fork head transcription factor Hfh-1L
 1312	10197	 7836	calcitriol	Compound	CD55	mRNA	-1	-1	12199786	Downregulated genes at both time-points were: IL2RA, CMYC, NPM, DEK, AF4, FLI1, htlf, MNDA, BCR, IKAROS, BPI and NFAT4. Upregulated genes at both time-points were IL1B, CD14 and MCL1. CD55, CD58, IRF2, CREB1, ATF4, RAC1, TIAR, KIAA0053, BAT2, BTK, RCK, EV12B and EDN were downregulated at 24 h, while SPI1, MKK3, BTG1 and IL8 were upregulated. At 72 h the upregulated genes were IL1RA, IL2RG, CXCR4, SCYA1, SCYA3, SCYA4, SCYA5, SCYA22, ANX2, CD83 and UPAR
13354	10197	10696	calcitriol	Compound	JUN	mRNA	0	1	16618766	Here, we show that functional AP-1 is required for 1,25-dihydroxyvitamin D3 (1,25D)-induced monocytic differentiation, and that the composition of the AP-1 protein complex that binds TRE, its cognate DNA element, changes as cells differentiate. In HL60 cells in an early stage of differentiation, the principal AP-1 components detected by gel shift analysis include c-jun, ATF-2, fos-B, fra-1, and fra-2.
13520	10197	 3789	calcitriol	Compound	IGF1	mRNA	0	1	12697689	In betaTC3 cells, vitamin D3 at 10 nanoM concentration induced the expression of IGF-1 mRNA which was not observed in control condition.
14110	10197	14961	calcitriol	Compound	CEBPD	mRNA	0	1	11668178	Expression of both C/EBPbeta and C/EBPdelta increases from the growth to maturation developmental stages and, like the bone-specific osteocalcin (OC) gene, is also stimulated 3-6-fold by vitamin D(3)
 1610	10197	 9722	calcitriol	Compound	CEBPA	mRNA	0	1	11668178	Expression of both C/EBPbeta and C/EBPdelta increases from the growth to maturation developmental stages and, like the bone-specific osteocalcin (OC) gene, is also stimulated 3-6-fold by vitamin D(3)
17851	10197	 1203	calcitriol	Compound	NACA	mRNA	0	-1	12648525	Using differential display analysis, we identified eight down-modulated clones in exposed cells: 26S proteasome non-ATPase subunit Pad1, ubiquitin-conjugating enzyme Ube2i, extracellular proteinase inhibitor Expi or Wdnm1, cytochrome-c oxidase Cox7c, microtubule-associated protein-1 light chain-3 (Map1lc3), nascent-associated complex alpha Naca, transforming acidic coiled-coil Tacc3, stearoyl-CoA desaturase (Scd), keratin 6 alpha,
19652	10197	16486	calcitriol	Compound	SPP1	mRNA	1	1	 8070379	Treatment of JB6 Cl41.5a cells with calcitriol and the transcriptional inhibitor actinomycin-D (2-250 ng/ml) indicated that calcitriol-induced accumulation of steady state OPN mRNA and secretion of OPN protein were dose dependently inhibited by actinomycin-D.
23351	10197	 8655	calcitriol	Compound	CDH1	mRNA	0	1	11470825	Modified assertion
23385	10197	 4614	calcitriol	Compound	CSF1	mRNA	0	1	14567913	Basal and 1,25-dihydroxyvitamin D3-stimulated M-CSF expression in cultured calvarial osteoblasts derived from TSHR null or heterozygote mice was not elevated compared with wild-type littermates. In fact, basal RANK-L expression was reduced in TSH-R-/- mice. This indicated that loss of the TSHR did not elevate osteoclast formation through increased M-CSF expression.
23404	10197	 9226	calcitriol	Compound	CITED2	mRNA	1	1	14633706	Fourteen of 17 candidate genes studied were validated as 1 alpha, 25(OH)(2)D(3) target genes by Northern and Western blotting or immunocytochemistry. They included c-JUN, JUNB, JUND, FREAC-1/FoxF1, ZNF-44/KOX7, plectin, filamin, keratin-13, G(0)S2, and the putative tumor suppressors NES-1 and protease M.
24179	10197	 9854	calcitriol	Compound	PLAT	mRNA	0	1	10544252	1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] was found to stimulate t-PA gene expression in ROS17/2.8 osteosarcoma cells.
24807	10197	 5863	calcitriol	Compound	MYC	mRNA	0	-1	11470825	Also, 1a,25(OH)2D3 inhibited expression of b-catenin?TCF-4-responsive genes, c-myc, peroxisome proliferator-activated receptor g, Tcf-1, and CD44, whereas it induced expression of ZO-1.
25438	10197	 7198	calcitriol	Compound	TACC3	mRNA	0	-1	12648525	Using differential display analysis, we identified eight down-modulated clones in exposed cells: 26S proteasome non-ATPase subunit Pad1, ubiquitin-conjugating enzyme Ube2i, extracellular proteinase inhibitor Expi or Wdnm1, cytochrome-c oxidase Cox7c, microtubule-associated protein-1 light chain-3 (Map1lc3), nascent-associated complex alpha Naca, transforming acidic coiled-coil Tacc3, stearoyl-CoA desaturase (Scd), keratin 6 alpha,
 2584	10197	  326	calcitriol	Compound	TXNIP	mRNA	0	1	12821938	Vitamin D(3) upregulated protein 1 (VDUP1) is a 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) upregulated protein, and it is induced by various stresses.
  268	10197	 5737	calcitriol	Compound	Expi	mRNA	0	-1	12648525	Using differential display analysis, we identified eight down-modulated clones in exposed cells: 26S proteasome non-ATPase subunit Pad1, ubiquitin-conjugating enzyme Ube2i, extracellular proteinase inhibitor Expi or Wdnm1, cytochrome-c oxidase Cox7c, microtubule-associated protein-1 light chain-3 (Map1lc3), nascent-associated complex alpha Naca, transforming acidic coiled-coil Tacc3, stearoyl-CoA desaturase (Scd), keratin 6 alpha,
28357	10197	18287	calcitriol	Compound	ABCC3	mRNA	0	1	15824121	Functional analysis of a murine Mrp3 promoter reporter construct revealed vitamin D receptor (VDR)-dependent activation by 1,25-dihydroxyvitamin D(3) (VD3), 9-cis-retinoic acid (RA), and the cholestatic secondary bile acid, lithocholic acid (LCA).
29646	10197	13006	calcitriol	Compound	HMGCS2	mRNA	0	-1	14633706	Downregulated genes from table 3.
33076	10197	 8982	calcitriol	Compound	CES1	mRNA	0	1	10446999	To monitor the ability of ATRA and VD to activate the genetic program underlying monocytic differentiation in the M2 cellular context, we have investigated the expression of VD-responsive genes (Fig. 8) such as HMSE-1, CD14, and hOC by RT-PCR and the expression of genes controlled by a functional VDRE, such as p21waf-1 (51) , or RARE, such as E3 (52) , IRF-1 (53) and p21waf-1 (68) , by Northern blot analysis after different times of ATRA or VD treatment. Fig. 8 shows that both ATRA and VD treatment of Kasumi-1 cells causes a rapid induction of HMSE-1, CD14, and hOC expression, demonstrating VDR involvement in ATRA-dependent monocytic differentiation of M2-type blast cells.
 3448	10197	10915	calcitriol	Compound	BAX	mRNA	0	1	12697689	Vitamin D3 at 10 nanoM concentration significantly increased Bax expression in betaTC3 cells.
35871	10197	19603	calcitriol	Compound	ATF2	mRNA	1	1	16618766	Here, we show that functional AP-1 is required for 1,25-dihydroxyvitamin D3 (1,25D)-induced monocytic differentiation, and that the composition of the AP-1 protein complex that binds TRE, its cognate DNA element, changes as cells differentiate. In HL60 cells in an early stage of differentiation, the principal AP-1 components detected by gel shift analysis include c-jun, ATF-2, fos-B, fra-1, and fra-2.
38814	10197	10290	calcitriol	Compound	FOXM1	mRNA	1	-1	16144839	TABLE ONE Identification of genes downregulated by 1,25(OH)2D3 treatment and their expression profile
39972	10197	13740	calcitriol	Compound	BGLAP	mRNA	0	1	11668178	Expression of both C/EBPbeta and C/EBPdelta increases from the growth to maturation developmental stages and, like the bone-specific osteocalcin (OC) gene, is also stimulated 3-6-fold by vitamin D(3)
41101	10197	11896	calcitriol	Compound	MCM5	mRNA	1	-1	16144839	TABLE ONE Identification of genes downregulated by 1,25(OH)2D3 treatment and their expression profile
42620	10197	19799	calcitriol	Compound	SMC2	mRNA	1	-1	16144839	TABLE ONE Identification of genes downregulated by 1,25(OH)2D3 treatment and their expression profile
44762	10197	 4862	calcitriol	Compound	PDGFA	mRNA	-1	1	14708943	1,25-(OH)2D3 was validated as a regulator of the endogenous PDGF-A gene by the vitamin D-stimulated upregulation of PDGF-A mRNA
 4576	10197	17424	calcitriol	Compound	COX7C	mRNA	0	-1	12648525	Using differential display analysis, we identified eight down-modulated clones in exposed cells: 26S proteasome non-ATPase subunit Pad1, ubiquitin-conjugating enzyme Ube2i, extracellular proteinase inhibitor Expi or Wdnm1, cytochrome-c oxidase Cox7c, microtubule-associated protein-1 light chain-3 (Map1lc3), nascent-associated complex alpha Naca, transforming acidic coiled-coil Tacc3, stearoyl-CoA desaturase (Scd), keratin 6 alpha,
46463	10197	 3085	calcitriol	Compound	FOSB	mRNA	0	1	16618766	Here, we show that functional AP-1 is required for 1,25-dihydroxyvitamin D3 (1,25D)-induced monocytic differentiation, and that the composition of the AP-1 protein complex that binds TRE, its cognate DNA element, changes as cells differentiate. In HL60 cells in an early stage of differentiation, the principal AP-1 components detected by gel shift analysis include c-jun, ATF-2, fos-B, fra-1, and fra-2.
 4721	10197	18600	calcitriol	Compound	ITGAM	mRNA	0	1	10587349	1alpha,25-dihydroxyvitamin D(3) (D(3)) promotes the maturation of myeloid cells and surface expressions of CD14 and CD11b, markers of cell differentiation in response to D(3).
 4800	10197	14082	calcitriol	Compound	Gm5414	mRNA	0	-1	12648525	Using differential display analysis, we identified eight down-modulated clones in exposed cells: 26S proteasome non-ATPase subunit Pad1, ubiquitin-conjugating enzyme Ube2i, extracellular proteinase inhibitor Expi or Wdnm1, cytochrome-c oxidase Cox7c, microtubule-associated protein-1 light chain-3 (Map1lc3), nascent-associated complex alpha Naca, transforming acidic coiled-coil Tacc3, stearoyl-CoA desaturase (Scd), keratin 6 alpha,
48143	10197	 7307	calcitriol	Compound	PSMD14	mRNA	0	-1	12648525	Using differential display analysis, we identified eight down-modulated clones in exposed cells: 26S proteasome non-ATPase subunit Pad1, ubiquitin-conjugating enzyme Ube2i, extracellular proteinase inhibitor Expi or Wdnm1, cytochrome-c oxidase Cox7c, microtubule-associated protein-1 light chain-3 (Map1lc3), nascent-associated complex alpha Naca, transforming acidic coiled-coil Tacc3, stearoyl-CoA desaturase (Scd), keratin 6 alpha,
51217	10197	19545	calcitriol	Compound	PRDM2	mRNA	0	1	11591891	Selective expression of PRDM2 was also induced by 12-O-tetradecanoyl-phorbol-13-acetate in the U937 and HL60 cell lines and by 1,25-dihydroxyvitamin D(3) only in HL60 cells. Tetradecanoylphorbol acetate is a synonym for 12-O-tetradecanoyl-phorbol-13-acetate Calcitriol is a synonym for 1,25-dihydroxyvitamin D(3)
52423	10197	 1446	calcitriol	Compound	CASR	mRNA	0	1	12036954	Human thyroid C-cell (TT) and kidney proximal tubule cell (HKC) CASR gene transcription increased approximately 2-fold at 8 and 12 h after 1,25(OH)2D3 treatment.
54288	10197	  255	calcitriol	Compound	UBE2I	mRNA	0	-1	12648525	Using differential display analysis, we identified eight down-modulated clones in exposed cells: 26S proteasome non-ATPase subunit Pad1, ubiquitin-conjugating enzyme Ube2i, extracellular proteinase inhibitor Expi or Wdnm1, cytochrome-c oxidase Cox7c, microtubule-associated protein-1 light chain-3 (Map1lc3), nascent-associated complex alpha Naca, transforming acidic coiled-coil Tacc3, stearoyl-CoA desaturase (Scd), keratin 6 alpha,
54899	10197	 6515	calcitriol	Compound	MAP1LC3B	mRNA	0	-1	12648525	Using differential display analysis, we identified eight down-modulated clones in exposed cells: 26S proteasome non-ATPase subunit Pad1, ubiquitin-conjugating enzyme Ube2i, extracellular proteinase inhibitor Expi or Wdnm1, cytochrome-c oxidase Cox7c, microtubule-associated protein-1 light chain-3 (Map1lc3), nascent-associated complex alpha Naca, transforming acidic coiled-coil Tacc3, stearoyl-CoA desaturase (Scd), keratin 6 alpha,
55373	10197	14526	calcitriol	Compound	BAALC	mRNA	0	1	16514668	BAALC expression can also be induced by other bone forming factors including PGE(2) and 1,25 dihydroxy vitamin D(3). We determined that BAALC is regulated by PTH predominantly through the cAMP/PKA pathway. Finally, we demonstrate in MC3T3-E1 osteoblastic cells that BAALC overexpression regulates markers of osteoblast differentiation, including downregulating alkaline phosphatase and osteocalcin expression while inducing osteopontin expression.
57361	10197	10643	calcitriol	Compound	Scd1	mRNA	0	-1	12648525	Using differential display analysis, we identified eight down-modulated clones in exposed cells: 26S proteasome non-ATPase subunit Pad1, ubiquitin-conjugating enzyme Ube2i, extracellular proteinase inhibitor Expi or Wdnm1, cytochrome-c oxidase Cox7c, microtubule-associated protein-1 light chain-3 (Map1lc3), nascent-associated complex alpha Naca, transforming acidic coiled-coil Tacc3, stearoyl-CoA desaturase (Scd), keratin 6 alpha,
61266	10197	 1552	calcitriol	Compound	ODC1	mRNA	1	-1	16144839	TABLE ONE Identification of genes downregulated by 1,25(OH)2D3 treatment and their expression profile
63001	10197	 9210	calcitriol	Compound	SGK1	mRNA	0	1	15665527	Renal calcium reabsorption involves the epithelial calcium channel ECaC1 (TRPV5) which is tightly regulated by 1,25(OH)2D3. As shown recently, TRPV5 is activated by the serum and glucocorticoid inducible kinase SGK1, a kinase transcriptionally upregulated by 1,25(OH)2D3.
63166	10197	  688	calcitriol	Compound	TJP2	mRNA	0	1	11470825	Modified assertion
 6425	10197	19228	calcitriol	Compound	VDR	mRNA	0	1	15664452	VDR gene exhibit basal promoter activity in T47D breast cancer cells which is enhanced by 1,25(OH)(2)D(3), estrogen and the phytoestrogen resveratrol. Deletion constructs and site-directed mutagenesis were used to map three distinct GC-rich Sp1 consensus sites that independently mediate the effects of estrogen, resveratrol, and 1,25(OH)(2)D(3) on VDR promoter activity.
65558	10197	14743	calcitriol	Compound	IGF2	mRNA	0	-1	12697689	In betaTC3 cells, vitamin D3 downregulated the expression of 2 IGF-II mRNA isoforms.
 8338	10197	 6202	calcitriol	Compound	BTG1	mRNA	-1	1	12199786	Downregulated genes at both time-points were: IL2RA, CMYC, NPM, DEK, AF4, FLI1, htlf, MNDA, BCR, IKAROS, BPI and NFAT4. Upregulated genes at both time-points were IL1B, CD14 and MCL1. CD55, CD58, IRF2, CREB1, ATF4, RAC1, TIAR, KIAA0053, BAT2, BTK, RCK, EV12B and EDN were downregulated at 24 h, while SPI1, MKK3, BTG1 and IL8 were upregulated. At 72 h the upregulated genes were IL1RA, IL2RG, CXCR4, SCYA1, SCYA3, SCYA4, SCYA5, SCYA22, ANX2, CD83 and UPAR
13230	 9077	  724	Oxidopamine	Compound	CARS	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
13285	 9077	11025	Oxidopamine	Compound	SEC23A	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
14438	 9077	 6233	Oxidopamine	Compound	CLCN3	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
15121	 9077	 3612	Oxidopamine	Compound	SLC1A4	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
19843	 9077	13642	Oxidopamine	Compound	DNAJB9	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
21918	 9077	 3995	Oxidopamine	Compound	ESR1	mRNA	-1	1	12486162	striking increase in the expression of transcripts associated with the cellular response to ER stress ER stress- and protein folding-related genes identified from SAGE analysis of 6-OHDA-treated neuronal PC12 cells
22335	 9077	 3844	Oxidopamine	Compound	Sec61g	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
23884	 9077	 5783	Oxidopamine	Compound	CEBPB	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
25010	 9077	 9245	Oxidopamine	Compound	CLIC4	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
25912	 9077	17410	Oxidopamine	Compound	HERPUD1	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
26478	 9077	 7394	Oxidopamine	Compound	BAG3	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
27406	 9077	17529	Oxidopamine	Compound	XBP1	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
30157	 9077	  123	Oxidopamine	Compound	SLC7A5	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
35519	 9077	 6249	Oxidopamine	Compound	S100A10	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
36845	 9077	 7294	Oxidopamine	Compound	TXNRD1	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
37414	 9077	15242	Oxidopamine	Compound	ATF4	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
 4524	 9077	 6120	Oxidopamine	Compound	POR	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
48985	 9077	18262	Oxidopamine	Compound	PSMD4	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
50973	 9077	 6232	Oxidopamine	Compound	GTPBP2	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
51917	 9077	16691	Oxidopamine	Compound	SQSTM1	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
54016	 9077	18156	Oxidopamine	Compound	EIF4EBP1	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
55412	 9077	16991	Oxidopamine	Compound	PPP1R15A	mRNA	1	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
58362	 9077	  209	Oxidopamine	Compound	CEBPG	mRNA	0	1	15890008	Notably, stress-induced transcription factors such as ATF3, ATF4, CHOP, and C/EBP beta were robustly up-regulated, yet exhibited unique kinetic patterns. Genes involved in the synthesis and modification of proteins (various tRNA synthetases), protein degradation (e.g., ubiquitin, Herpud1, Sqstm1), and oxidative stress (Hmox1, Por) could be subgrouped into distinct kinetic profiles as well.
64160	 9077	19660	Oxidopamine	Compound	SEC23B	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
 7817	 9077	19318	Oxidopamine	Compound	WARS	mRNA	0	1	12598533	Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line.  Data taken from table 1 and table 2.  Fold change >= 1.5.
16362	 4632	10564	Enzastaurin Hydrochloride	Compound	ADD3	mRNA	-1	-1	18759374	Table 1. Differentially expressed genes in KMS-26 enzastaurin-treated cells
17444	 4632	14361	Enzastaurin Hydrochloride	Compound	CXCL12	mRNA	-1	1	18759374	Table 1. Differentially expressed genes in KMS-26 enzastaurin-treated cells
20200	 4632	  335	Enzastaurin Hydrochloride	Compound	MSMO1	mRNA	0	1	18701488	Table S2. Other responsive genes are deregulated by enzastaurin in U251, as detected by Anova and Ingenuity Pathway Analysis software, shown in Tables S2 and S3 respectively. U251 cells were treated in triplicates with 10?M enzastaurin for 4 hours. The initial gene expression analysis data files (CEL files) were generated using Affymetrix GeneChip Operating Software (GCOS) version 1.2. CEL files were processed as described earlier (11). p-value 0.001 and 1.5-fold change were applied as thresholds to select up- or down- regulated probes.
23319	 4632	 7455	Enzastaurin Hydrochloride	Compound	CTSB	mRNA	0	1	18759374	Table 1. Differentially expressed genes in KMS-26 enzastaurin-treated cells
24813	 4632	 5863	Enzastaurin Hydrochloride	Compound	MYC	mRNA	0	-1	18701488	Table S2. Other responsive genes are deregulated by enzastaurin in U251, as detected by Anova and Ingenuity Pathway Analysis software, shown in Tables S2 and S3 respectively. U251 cells were treated in triplicates with 10?M enzastaurin for 18 hours. The initial gene expression analysis data files (CEL files) were generated using Affymetrix GeneChip Operating Software (GCOS) version 1.2. CEL files were processed as described earlier (11). p-value 0.001 and 1.5-fold change were applied as thresholds to select up- or down- regulated probes.
27409	 4632	17966	Enzastaurin Hydrochloride	Compound	MXI1	mRNA	0	-1	18759374	Table 1. Differentially expressed genes in KMS-26 enzastaurin-treated cells
28661	 4632	 9792	Enzastaurin Hydrochloride	Compound	BTN3A2	mRNA	0	-1	18701488	Table S2. Other responsive genes are deregulated by enzastaurin in U251, as detected by Anova and Ingenuity Pathway Analysis software, shown in Tables S2 and S3 respectively. U251 cells were treated in triplicates with 10?M enzastaurin for 18 hours. The initial gene expression analysis data files (CEL files) were generated using Affymetrix GeneChip Operating Software (GCOS) version 1.2. CEL files were processed as described earlier (11). p-value 0.001 and 1.5-fold change were applied as thresholds to select up- or down- regulated probes.
29075	 4632	  620	Enzastaurin Hydrochloride	Compound	PHLDA1	mRNA	0	1	18701488	Table S2. Other responsive genes are deregulated by enzastaurin in U251, as detected by Anova and Ingenuity Pathway Analysis software, shown in Tables S2 and S3 respectively. U251 cells were treated in triplicates with 10?M enzastaurin for 18 hours. The initial gene expression analysis data files (CEL files) were generated using Affymetrix GeneChip Operating Software (GCOS) version 1.2. CEL files were processed as described earlier (11). p-value 0.001 and 1.5-fold change were applied as thresholds to select up- or down- regulated probes.
34792	 4632	17308	Enzastaurin Hydrochloride	Compound	LGMN	mRNA	-1	1	18759374	Table 1. Differentially expressed genes in KMS-26 enzastaurin-treated cells
38973	 4632	14353	Enzastaurin Hydrochloride	Compound	ADM	mRNA	0	-1	18701488	Table S2. Other responsive genes are deregulated by enzastaurin in U251, as detected by Anova and Ingenuity Pathway Analysis software, shown in Tables S2 and S3 respectively. U251 cells were treated in triplicates with 10?M enzastaurin for 4 hours. The initial gene expression analysis data files (CEL files) were generated using Affymetrix GeneChip Operating Software (GCOS) version 1.2. CEL files were processed as described earlier (11). p-value 0.001 and 1.5-fold change were applied as thresholds to select up- or down- regulated probes.
56149	 4632	10811	Enzastaurin Hydrochloride	Compound	FN1	mRNA	-1	1	18701488	Table S2. Other responsive genes are deregulated by enzastaurin in U251, as detected by Anova and Ingenuity Pathway Analysis software, shown in Tables S2 and S3 respectively. U251 cells were treated in triplicates with 10?M enzastaurin for 18 hours. The initial gene expression analysis data files (CEL files) were generated using Affymetrix GeneChip Operating Software (GCOS) version 1.2. CEL files were processed as described earlier (11). p-value 0.001 and 1.5-fold change were applied as thresholds to select up- or down- regulated probes.
59731	 4632	 9276	Enzastaurin Hydrochloride	Compound	NEU1	mRNA	0	1	18701488	Table S2. Other responsive genes are deregulated by enzastaurin in U251, as detected by Anova and Ingenuity Pathway Analysis software, shown in Tables S2 and S3 respectively. U251 cells were treated in triplicates with 10?M enzastaurin for 18 hours. The initial gene expression analysis data files (CEL files) were generated using Affymetrix GeneChip Operating Software (GCOS) version 1.2. CEL files were processed as described earlier (11). p-value 0.001 and 1.5-fold change were applied as thresholds to select up- or down- regulated probes.
62044	 4632	14329	Enzastaurin Hydrochloride	Compound	TRAF5	mRNA	-1	1	18759374	Table 1. Differentially expressed genes in KMS-26 enzastaurin-treated cells
62917	 4632	 7195	Enzastaurin Hydrochloride	Compound	GADD45A	mRNA	-1	1	18759374	Table 1. Differentially expressed genes in KMS-26 enzastaurin-treated cells
 6824	 4632	17987	Enzastaurin Hydrochloride	Compound	MARCKS	mRNA	0	-1	18701488	Table S2. Other responsive genes are deregulated by enzastaurin in U251, as detected by Anova and Ingenuity Pathway Analysis software, shown in Tables S2 and S3 respectively. U251 cells were treated in triplicates with 10?M enzastaurin for 18 hours. The initial gene expression analysis data files (CEL files) were generated using Affymetrix GeneChip Operating Software (GCOS) version 1.2. CEL files were processed as described earlier (11). p-value 0.001 and 1.5-fold change were applied as thresholds to select up- or down- regulated probes.
11120	19476	16521	AGT	Protein	TNFRSF11B	mRNA	0	1	12067713	Platelet-derived growth factor (PDGF), basic fibroblast growth factor, angiotensin II, tumor necrosis factor alpha and interleukin-1beta upregulated OPG expression in VSMC.
11242	19476	19608	AGT	Protein	LEP	mRNA	0	1	12042422	Further, we  demonstrated that Ang II increases leptin expression in cultured adipocytes (6  ).
12747	19476	13434	AGT	Protein	HIF1A	mRNA	0	1	12379645	We show that, in contrast to hypoxia, the induction of HIF-1alpha by Ang II in VSMC is dependent on active transcription and ongoing translation. We demonstrate that stimulation of VSMC by Ang II strongly increases HIF-1alpha gene expression. The activation of diacylglycerol-sensitive protein kinase C (PKC) plays a major role in the increase of HIF-1alpha gene transcription.
13827	19476	17250	AGT	Protein	PTGS2	mRNA	0	1	15525649	from full text - The increases in the levels of COX-2 mRNA in response to Ang II were significantly reduced in the presence of losartan
16847	19476	 5958	AGT	Protein	POSTN	mRNA	0	1	15121739	hypoxia-responsive growth factors fibroblast growth factor-1 (FGF-1) and angiotensin II (ANG II) caused dose- and time-dependent increases in PN and OPN expression in PASMCs
  193	19476	16874	AGT	Protein	PIK3R1	mRNA	0	1	15662030	PI3-kinase p85alpha, p110alpha, and p110delta mRNA was 1.5- to 2-fold higher in the paraventricular nucleus (PVN) of spontaneously hypertensive rats (SHR) compared with their controls, Wistar Kyoto rats (WKY). The increase in p85alpha/p110delta was attenuated in SHR treated with captopril, an angiotensin (Ang)-converting enzyme inhibitor, from in utero to 6 months of age.
19639	19476	16486	AGT	Protein	SPP1	mRNA	1	1	14732733	Ang II is a potent stimulus to vascular expression of PAI-1 and OPN, as well as inflammation and oxidation (Figure 2).28,3234
25486	19476	11591	AGT	Protein	NR4A3	mRNA	0	1	10875239	We demonstrate here that Nor1 is expressed in the pituitary gland and adrenal cortex, and that ACTH and angiotensin II (AngII) treatment of adrenal fasciculata cells induces Nor1 expression.
25882	19476	19027	AGT	Protein	HMOX1	mRNA	0	-1	12869663	Furthermore, it has been reported that the HO-1 gene is further down-regulated by angiotensin II via calcium-signaling (Ishizaka and Griendling, 1997), interferon- (Takahashi et al., 1999), prostaglandin E2 (Tetsuka et al., 1995), transforming growth factor- (Pellacani et al., 1998), and IL-10 (Immenschuh et al., 1999).
28249	19476	 7832	AGT	Protein	THBS1	mRNA	-1	1	16310163	Both glucose and angiotensin II (Ang II) upregulate thrombospondin-1 (TSP1), a major activator of latent TGF-beta, and stimulate increased TGF-beta activity
 2899	19476	 4252	AGT	Protein	ABCA1	mRNA	0	-1	16224068	Ang II inhibits macrophage expression of the ATP-binding cassette transporter A1 (ABCA1), a key regulator of reverse cholesterol transport.
32838	19476	12649	AGT	Protein	ETS1	mRNA	1	1	18337545	Mesangial cells stimulated with ANG II (10(-7) M) exhibited a significant increase in ETS-1 expression
32898	19476	20114	AGT	Protein	ENPEP	mRNA	0	1	12915695	Ang II also enhanced APA mRNA and cell surface expression in BeWo cells analyzed by Northern blotting, flow cytometry, and enzyme activity assay.
 3438	19476	10915	AGT	Protein	BAX	mRNA	0	1	12060599	ANG II also upregulated the expression of Fas, FasL, and Bax and downregulated the expression of Bcl-2 in GECs
39346	19476	 7862	AGT	Protein	CYBA	mRNA	0	1	12426214	Stimulation of Human umbilical vein endothelial cells with        100 nanoM/L of Angiotensin II causes a time and concentration dependent upregulation of p22-phox, p47 phox, p67-phox mRNA subunits of NADPH oxidase. Maximum induction was seen at 7 hours.
40003	19476	13078	AGT	Protein	NCF2	mRNA	0	1	12426214	Stimulation of Human umbilical vein endothelial cells with        100 nanoM/L of Angiotensin II causes a time and concentration dependent upregulation of p22-phox, p47 phox, p67-phox mRNA subunits of NADPH oxidase. Maximum induction was seen at 7 hours.
40972	19476	 4582	AGT	Protein	NOS3	mRNA	1	-1	11882622	Both eNOS and iNOS expression seemed to increase during perindopril treatment.
42091	19476	13115	AGT	Protein	EGR1	mRNA	-1	1	10506481	100 nmol/L Angiotensin II,  induced EGR-1 expression was greater in newborn VSMCs (5.8-fold stimulation over basal) than in adult VSMCs (2.5-fold stimulation).
42830	19476	 3879	AGT	Protein	FAS	mRNA	0	1	10600897	We have also determined that Ang II positively regulates transcription  of the FAS and ob genes in 3T3-L1 and human adipocytes.
44422	19476	13271	AGT	Protein	CCL2	mRNA	0	1	12626661	Angiotensin II has been demonstrated, at least in animal models, to stimulate MCP-1 expression
44771	19476	 4862	AGT	Protein	PDGFA	mRNA	-1	1	11152368	These findings suggest that increased generation of Ang II is associated with enhanced expression of TGF-beta1, PDGF A-chain, and bFGF
45359	19476	14987	AGT	Protein	BCL2	mRNA	1	-1	12060599	ANG II also upregulated the expression of Fas, FasL, and Bax and downregulated the expression of Bcl-2 in GECs
46197	19476	12269	AGT	Protein	PRRX1	mRNA	0	1	15016729	Prx1, a homeodomain protein whose expression was increased by Ang II, also increased SM alpha-actin gene transcription in part via CArG elements, and siRNA specific for Prx1 markedly decreased basal and Ang II-induced SM alpha-actin transcription.
 4659	19476	 1136	AGT	Protein	BMP6	mRNA	0	-1	14592955	Ang II reduced the expression levels of BMP-6 but increased that of activin betaB
48015	19476	11629	AGT	Protein	FOS	mRNA	0	1	16870827	ANG II-mediated MAPK activation is followed by an increase in c-fos  (activated by ERK) and c-jun (activated by JNK) gene expression, as well as increased AP-1 activity. AP-1 is a transcription factor complex (formed from dimerization of c-Jun and c-Fos) and ultimately influences cell differentiation, migration, and adhesion by binding to gene promoter sequences (191).
51673	19476	  219	AGT	Protein	FASLG	mRNA	-1	1	12060599	ANG II also upregulated the expression of Fas, FasL, and Bax and downregulated the expression of Bcl-2 in GECs
53009	19476	19009	AGT	Protein	TSC22D3	mRNA	1	-1	16445697	Conversely, in downregulated clones, there were several signal molecules, such as CGI-121, protein phosphatase type 2A (PP2A), tspan-2 and Sam68. We also found the transcriptional repressors, such as glucocorticoid-induced leucine zipper (GILZ) and inhibitor of DNA binding 3 (Id3), and genes associated with deposition of fibrous matrix, such as procollagen C-proteinase enhancer protein (PCPE)
54121	19476	  822	AGT	Protein	PIK3CD	mRNA	0	1	15662030	PI3-kinase p85alpha, p110alpha, and p110delta mRNA was 1.5- to 2-fold higher in the paraventricular nucleus (PVN) of spontaneously hypertensive rats (SHR) compared with their controls, Wistar Kyoto rats (WKY). The increase in p85alpha/p110delta was attenuated in SHR treated with captopril, an angiotensin (Ang)-converting enzyme inhibitor, from in utero to 6 months of age.
55729	19476	17792	AGT	Protein	PIK3CA	mRNA	0	1	15662030	PI3-kinase p85alpha, p110alpha, and p110delta mRNA was 1.5- to 2-fold higher in the paraventricular nucleus (PVN) of spontaneously hypertensive rats (SHR) compared with their controls, Wistar Kyoto rats (WKY). The increase in p85alpha/p110delta was attenuated in SHR treated with captopril, an angiotensin (Ang)-converting enzyme inhibitor, from in utero to 6 months of age.
56170	19476	10811	AGT	Protein	FN1	mRNA	-1	1	18337545	By utilizing short interfering RNAs against ETS-1, we have also determined that ETS-1 is required to induce the production of fibronectin in response to ANG II.
58682	19476	18695	AGT	Protein	MYOCD	mRNA	0	1	15016729	Results showed that Ang II increased myocardin mRNA expression as well as SM alpha-actin mRNA expression via the Ang II type 1 receptor in cultured rat aortic SMCs.
59692	19476	10088	AGT	Protein	Acta2	mRNA	0	1	15016729	Results showed that Ang II increased myocardin mRNA expression as well as SM alpha-actin mRNA expression via the Ang II type 1 receptor in cultured rat aortic SMCs.
62948	19476	 7195	AGT	Protein	GADD45A	mRNA	-1	1	15375197	_------------------------------------------------------------------------------- Eleven genes were found to be upregulated by ANG II. These encode the proteins for ferredoxin, Nor1, Nurr1, c6orf37, CAT-1, A20, MBLL, M-Ras, RhoB, GADD45alpha, and a novel protein designated FLJ45273.
 7419	19476	14623	AGT	Protein	OLR1	mRNA	0	1	16484599	In vitro and in vivo studies have shown that LOX-1 expression is upregulated by oxLDL. Angiotensin II (Ang II), which participates in atherogenesis, also upregulates the expression of LOX-1.
 9397	19476	 6870	AGT	Protein	INHBB	mRNA	0	1	14592955	Ang II reduced the expression levels of BMP-6 but increased that of activin betaB
14054	11661	10458	MYOCD	Protein	MYH11	mRNA	0	1	15256479	Modified assertion
19125	11661	12812	MYOCD	Protein	CALD1	mRNA	0	1	12756293	Myocardin also induced expression of SM22, SM-calponin, h-caldesmon, SM myosin light chain kinase, SM gamma-actin, and SM-MHC proteins, which are markers of smooth muscle ( Fig. 1 A ).
20769	11661	 4461	MYOCD	Protein	ACTA2	mRNA	0	1	12640126	Most importantly, forced expression of myocardin activated expression of the SM22 alpha, smooth muscle alpha-actin, and calponin-h1 genes in undifferentiated mouse ES cells.
24559	11661	 2720	MYOCD	Protein	TAGLN	mRNA	-1	1	12640126	_ Ariadne: Myocardin transactivates  the SMC-restricted SM22 promoter in non-SMCs. [Expression]
30196	11661	 7949	MYOCD	Protein	ACTG2	mRNA	0	1	12756293	Myocardin also induced expression of SM22, SM-calponin, h-caldesmon, SM myosin light chain kinase, SM gamma-actin, and SM-MHC proteins, which are markers of smooth muscle ( Fig. 1 A ).
34751	11661	18969	MYOCD	Protein	MYLK	mRNA	0	1	12756293	Myocardin also induced expression of SM22, SM-calponin, h-caldesmon, SM myosin light chain kinase, SM gamma-actin, and SM-MHC proteins, which are markers of smooth muscle ( Fig. 1 A ).
45027	11661	 1183	MYOCD	Protein	CNN1	mRNA	0	1	12640126	Most importantly, forced expression of myocardin activated expression of the SM22 alpha, smooth muscle alpha-actin, and calponin-h1 genes in undifferentiated mouse ES cells.
 9404	11661	17664	MYOCD	Protein	NKX2-5	mRNA	0	1	14645532	Modified assertion
10049	 2580	 7928	PRKCB	Protein	TGFBR2	mRNA	0	-1	15774796	In murine colon cancer models, elevated expression of PKCBII elevates cyclooxygenase-2 expression and represses TBRII expression to increase susceptibility to colon cancer.130
19634	 2580	16486	PRKCB	Protein	SPP1	mRNA	1	1	16528250	increases in OPN gene expression in diabetic rat RPTs and IRPTCs are mediated, at least in part, via reactive oxygen species generation, intrarenal rennin-angiotensin system activation, TGF-beta1 expression, and PKC-beta1 signaling.
28045	 2580	 4068	PRKCB	Protein	AMY1B	mRNA	0	1	11025443	The combination of specific inhibitors of PKC and MEK1 inhibits the amylase promoter. Inhibitors of the calcium-dependent PKC isoforms alpha, beta, and gamma decrease the promoter activity;
31916	 2580	 3761	PRKCB	Protein	AMY1A	mRNA	0	1	11025443	The combination of specific inhibitors of PKC and MEK1 inhibits the amylase promoter. Inhibitors of the calcium-dependent PKC isoforms alpha, beta, and gamma decrease the promoter activity;
50588	 2580	 7090	PRKCB	Protein	AMY1C	mRNA	0	1	11025443	The combination of specific inhibitors of PKC and MEK1 inhibits the amylase promoter. Inhibitors of the calcium-dependent PKC isoforms alpha, beta, and gamma decrease the promoter activity;
14097	 7748	14961	NOTCH1	Protein	CEBPD	mRNA	0	1	12960086	In the presence of cortisol, NotchIC induced the formation of mature adipocytes and enhanced the effect of cortisol on adipsin, peroxisome proliferator-activated receptor-gamma2 and CCAAT enhancer binding protein alpha and delta mRNA levels.
 1612	 7748	 9722	NOTCH1	Protein	CEBPA	mRNA	0	1	12960086	In the presence of cortisol, NotchIC induced the formation of mature adipocytes and enhanced the effect of cortisol on adipsin, peroxisome proliferator-activated receptor-gamma2 and CCAAT enhancer binding protein alpha and delta mRNA levels.
17876	 7748	17868	NOTCH1	Protein	HEY2	mRNA	0	1	11095750	In the present study, we show that the intracellular domain of the Notch1 receptor (Notch1 IC), which is constitutively active, up-regulates HRT2 expression in 10T(1/2) fibroblasts.
19467	 7748	 3815	NOTCH1	Protein	LOR	mRNA	0	-1	14570040	Notch1 function in mouse skin. Representation of mammalian skin with several layers of differentiating cells, and some proteins that are expressed in specific cellular layers. After differentiation signals are received, Notch1 induces expression of involucrin, keratin-1 (K1) and the cell-cycle inhibitor Waf1, and prevents the onset of fillagrin and loricrin expression until the cell is at later stages of differentiation. Both ?-catenin-mediated Wnt signalling and Gli2-mediated Sonic-hedgehog signalling are normally repressed in the murine epidermis by Notch1. In Notch1-ablated skin, re-activation of Wnt and Sonic-hedgehog pathways result in the development of basal-cell-carcinoma-like tumours in the mouse.
21249	 7748	15637	NOTCH1	Protein	LIPA	mRNA	0	1	11161219	LIN-12/NOTCH up-regulates lip-1 transcription in P5.p and P7.p where LIP-1 inactivates the MAP kinase to inhibit primary fate specification.
28730	 7748	 3434	NOTCH1	Protein	IVL	mRNA	0	1	14570040	Notch1 function in mouse skin. Representation of mammalian skin with several layers of differentiating cells, and some proteins that are expressed in specific cellular layers. After differentiation signals are received, Notch1 induces expression of involucrin, keratin-1 (K1) and the cell-cycle inhibitor Waf1, and prevents the onset of fillagrin and loricrin expression until the cell is at later stages of differentiation. Both ?-catenin-mediated Wnt signalling and Gli2-mediated Sonic-hedgehog signalling are normally repressed in the murine epidermis by Notch1. In Notch1-ablated skin, re-activation of Wnt and Sonic-hedgehog pathways result in the development of basal-cell-carcinoma-like tumours in the mouse.
32063	 7748	 9588	NOTCH1	Protein	CFD	mRNA	0	1	12960086	In the presence of cortisol, NotchIC induced the formation of mature adipocytes and enhanced the effect of cortisol on adipsin, peroxisome proliferator-activated receptor-gamma2 and CCAAT enhancer binding protein alpha and delta mRNA levels.
35007	 7748	 7998	NOTCH1	Protein	ERBB2	mRNA	0	1	12853432	When P6 cerebellar glia transfected with plasmids encoding the erbB2-Luciferase reporter, measured level of luciferase activity in glia alone or in glia after the addition of neurons indicated that neuronal contact induced a 2-fold increase in erbB2 promoter activity. The erbB2 promoter activity was completely abolished by cotranfection with dominant-negative Notch1 (OCDN1). Constitutively active Notch1 (FCDN1) expression induced a 1.75 +/- 0.23-fold ( p < 0.007) increase of erbB2 protein in glia. These results suggest that Notch1 upregulated erbB2 expression.
36262	 7748	 1611	NOTCH1	Protein	HEY1	mRNA	0	1	12453432	Furthermore, both EC network formation and expression of activated notch 1 or notch 4 induce expression of the bHLH transcription factor HESR-1 and downregulate the known HESR-1 target VEGFR-2 (KDR).
37998	 7748	  871	NOTCH1	Protein	ADAM17	mRNA	0	1	12629177	NOTCH1 activation, indicated by tumor necrosis factor alpha-converting enzyme, TACE [Adam17], and presenilin-mediated processing, also increased
50994	 7748	13884	NOTCH1	Protein	CDKN1A	mRNA	1	1	14570040	Notch1 function in mouse skin. Representation of mammalian skin with several layers of differentiating cells, and some proteins that are expressed in specific cellular layers. After differentiation signals are received, Notch1 induces expression of involucrin, keratin-1 (K1) and the cell-cycle inhibitor Waf1, and prevents the onset of fillagrin and loricrin expression until the cell is at later stages of differentiation. Both ?-catenin-mediated Wnt signalling and Gli2-mediated Sonic-hedgehog signalling are normally repressed in the murine epidermis by Notch1. In Notch1-ablated skin, re-activation of Wnt and Sonic-hedgehog pathways result in the development of basal-cell-carcinoma-like tumours in the mouse.
54414	 7748	 4758	NOTCH1	Protein	GATA3	mRNA	0	1	17658279	(from text) Notch Regulates Expression of Gata3 and Th2 Differentiation Independently of IL-4(A) Notch is required for GATA-3 expression. (B) Notch ICD induces IL-4-independent Th2 differentiation.
56287	 7748	16157	NOTCH1	Protein	NES	mRNA	0	1	11807030	Reduction in the expression of the intermediate filament protein nestin in the medial aspect of the notch1 mutant cerebellar primordium was observed when compared with control wildtype littermates.
60865	 7748	17451	NOTCH1	Protein	GATA2	mRNA	0	1	15689374	Taken together, these data strongly suggest that activation of Gata2 expression by Notch1/RBPjkappa is a crucial event for the onset of definitive hematopoiesis in the embryo.
61441	 7748	 8420	NOTCH1	Protein	Bglap2	mRNA	0	-1	12960086	In the presence of bone morphogenetic protein-2 (BMP-2), ST-2 cells differentiated toward osteoblasts forming mineralized nodules, and Notch 1 opposed this effect and decreased the expression of osteocalcin, type I collagen, and alkaline phosphatase transcripts and Delta2Delta FosB protein.
62135	 7748	 1645	NOTCH1	Protein	KRT1	mRNA	0	1	14570040	Notch1 function in mouse skin. Representation of mammalian skin with several layers of differentiating cells, and some proteins that are expressed in specific cellular layers. After differentiation signals are received, Notch1 induces expression of involucrin, keratin-1 (K1) and the cell-cycle inhibitor Waf1, and prevents the onset of fillagrin and loricrin expression until the cell is at later stages of differentiation. Both ?-catenin-mediated Wnt signalling and Gli2-mediated Sonic-hedgehog signalling are normally repressed in the murine epidermis by Notch1. In Notch1-ablated skin, re-activation of Wnt and Sonic-hedgehog pathways result in the development of basal-cell-carcinoma-like tumours in the mouse.
65858	 7748	 3533	NOTCH1	Protein	TRIB2	mRNA	0	1	17671232	Second, the enhanced expression of TRIB2, which we identify here as a direct target of the T-cell commitment factor NOTCH1, suggested aberrantly activated Notch signaling.
 9533	 7748	18566	NOTCH1	Protein	SMARCC1	mRNA	0	-1	11504912	Therefore,  activated Notch1 appears to down-regulate the expression of SRG3 protein in the  thymus.
17290	 9124	14807	vitamin E	Compound	CANX	mRNA	0	1	16908007	The expression levels of 3 genes, namely, cyclophilin A, calnexin, and N-acetylglucosaminyltransferase 3, out of 6 candidates were significantly increased in the kidney after 4 weeks of an alpha-tocopherol-supplemented diet.
19958	 9124	 5757	vitamin E	Compound	ADIPOQ	mRNA	0	1	19833717	Adiponectin mRNA and protein secretion were also increased by vitamin E (alpha- and gamma-tocopherol) in 3T3-L1 cells
21300	 9124	18667	vitamin E	Compound	MGAT3	mRNA	0	1	16908007	The expression levels of 3 genes, namely, cyclophilin A, calnexin, and N-acetylglucosaminyltransferase 3, out of 6 candidates were significantly increased in the kidney after 4 weeks of an alpha-tocopherol-supplemented diet.
37425	 9124	15242	vitamin E	Compound	ATF4	mRNA	0	1	11043924	CREB1 protein of human T lymphocytes was significantly modulated by a brief treatment of 5 to 10 min with PGE2. On the contrary, vitamin E appeared to be ineffective on the CREB1 behavior, while it abolished the PGE2-induced modulation of this protein. The CREB2 protein expression was also affected by PGE2 treatment, but a longer period of incubation (>20 min) was needed to observe these changes. Vitamin E showed a strong enhancing effect on CREB2 that was partially reversed by the subsequent treatment with PGE2
39590	 9124	15445	vitamin E	Compound	PPIA	mRNA	0	1	16908007	The expression levels of 3 genes, namely, cyclophilin A, calnexin, and N-acetylglucosaminyltransferase 3, out of 6 candidates were significantly increased in the kidney after 4 weeks of an alpha-tocopherol-supplemented diet.
  501	 9124	16088	vitamin E	Compound	GPX4	mRNA	1	-1	14642406	Interleukin-1beta (IL-1beta) increased GPx4 mRNA, protein and activity whereas TNFalpha at 1 ng/ml increased activity while at 3 ng/ml it reduced activity and mRNA. Conversely, alpha-tocopherol reduced mRNA levels without affecting activity.
53545	 9124	 8374	vitamin E	Compound	SNCA	mRNA	-1	1	17654050	Four weeks-old mice were randomly assigned to one of the experimental diets: vitamin E low, 5 mg (n = 3), adequate, 15 mg (n = 6), or high, 132 mg (n = 6). Following 3 months of Vitamin E diet - Pieces of liver were taken and used for Microarray analysis.
60746	 9124	19795	vitamin E	Compound	CREB1	mRNA	0	1	11043924	CREB1 protein of human T lymphocytes was significantly modulated by a brief treatment of 5 to 10 min with PGE2. On the contrary, vitamin E appeared to be ineffective on the CREB1 behavior, while it abolished the PGE2-induced modulation of this protein. The CREB2 protein expression was also affected by PGE2 treatment, but a longer period of incubation (>20 min) was needed to observe these changes. Vitamin E showed a strong enhancing effect on CREB2 that was partially reversed by the subsequent treatment with PGE2
64317	 9124	 9066	vitamin E	Compound	LMO2	mRNA	1	1	17654050	Four weeks-old mice were randomly assigned to one of the experimental diets: vitamin E low, 5 mg (n = 3), adequate, 15 mg (n = 6), or high, 132 mg (n = 6). Following 3 months of Vitamin E diet - Pieces of liver were taken and used for Microarray analysis.
10109	15076	 7502	PRKC Family	Protein	STAR	mRNA	0	1	15666812	Ang II-stimulated StAR transcription in H295R cells is dependent upon both influx of external Ca2+ and tyrosine kinase signaling and is enhanced by protein kinase C and mitogen-activated protein kinase (ERK1/2) activation. In particular, Janus tyrosine kinase-2 (Jak2) activation was increased with Ang-II treatment of H295R cells
10651	15076	 3198	PRKC Family	Protein	TFRC	mRNA	-1	-1	 7781766	Treatment of HL-60 cells with phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, or dibutyryl-cyclic AMP (dbcAMP), a protein kinase A (PKA) activator, resulted in a 90% decrease in the level of TfR mRNA
11567	15076	14350	PRKC Family	Protein	OCLN	mRNA	0	1	15622522	Activation of PKC by the phorbol ester TPA induced ZO-1 and occludin transcription, whereas PKC inhibition lead to decreased expression levels.
11767	15076	 9867	PRKC Family	Protein	MAPK1	mRNA	0	1	15760920	we identified two intracellular signaling molecules protein kinase C (PKC) and extracellular signal-related kinase (ERK). They mediated both the phorbol myristate acetate (PMA) downregulation of DMBT1 expression
11783	15076	 2258	PRKC Family	Protein	PLIN3	mRNA	0	1	12631276	PP17b synthesis in HeLa cells, which was significantly inhibited by protein kinase C (PKC) inhibitor This data shows that PP17b is a neutral lipid droplet-associated protein, and its expression is regulated by PKC- and PKA-dependent pathways.
12439	15076	20232	PRKC Family	Protein	NEUROD1	mRNA	0	1	10507539	Activation of PKC resulted in marked induction of NeuroD mRNA and NeuroD protein. NeuroD mRNA induction was inhibited by calphostin C, an inhibitor of PKC
 1263	15076	18332	PRKC Family	Protein	NDRG1	mRNA	0	1	10395947	These antibodies revealed a protein with the expected 43 kDa molecular mass, up-regulated by phorbol ester, retinoids and 1,25-(OH)2 vitamin D3 in U937 cells.
12745	15076	13434	PRKC Family	Protein	HIF1A	mRNA	0	1	12379645	We show that, in contrast to hypoxia, the induction of HIF-1alpha by Ang II in VSMC is dependent on active transcription and ongoing translation. We demonstrate that stimulation of VSMC by Ang II strongly increases HIF-1alpha gene expression. The activation of diacylglycerol-sensitive protein kinase C (PKC) plays a major role in the increase of HIF-1alpha gene transcription.
13356	15076	10696	PRKC Family	Protein	JUN	mRNA	0	1	11956220	PMA transiently increases egr-1 and c-jun gene expression. Mutation studies show that Egr-1 and c-Jun transactivate the MAO B promoter and increase endogenous MAO B transcripts
16066	15076	 1471	PRKC Family	Protein	COL1A2	mRNA	-1	1	10799556	_ Ariadne: On the other hand,  previous studies have shown that acetaldehyde induces the levels of c-Jun  through a PKC-dependent mechanism and enhances murine alpha2(I) collagen  promoter mediated by PKC activation ( 46 , 47 ). [Expression]
16508	15076	13088	PRKC Family	Protein	CLEC2D	mRNA	0	1	11455585	In this study the expression of C-type lectins during the early activation of PMA-stimulated peripheral blood lymphocytes was examined. To investigate the influence of de novo protein synthesis on activation-dependent expression of C-type lectins, cells were cultured in presence of cycloheximide (CHX) and mRNA levels were analyzed by semi-quantitative reverse transcription-polymerase chain reaction. Upregulated levels of CD69, AICL, and LLT1, but less pronounced changes of CD161/NKR-P1A and CD94 mRNA were found at early time points of cellular activation.
20325	15076	 2815	PRKC Family	Protein	TP53	mRNA	0	1	10801075	The biological activity of u-PA, t-PA, as well as that of limiting concentration of FCS (1%), was mediated by PTK and PKC.
22072	15076	10299	PRKC Family	Protein	CLEC2B	mRNA	0	1	11455585	In this study the expression of C-type lectins during the early activation of PMA-stimulated peripheral blood lymphocytes was examined. To investigate the influence of de novo protein synthesis on activation-dependent expression of C-type lectins, cells were cultured in presence of cycloheximide (CHX) and mRNA levels were analyzed by semi-quantitative reverse transcription-polymerase chain reaction. Upregulated levels of CD69, AICL, and LLT1, but less pronounced changes of CD161/NKR-P1A and CD94 mRNA were found at early time points of cellular activation.
22660	15076	 7012	PRKC Family	Protein	DMBT1	mRNA	0	1	15760920	we identified two intracellular signaling molecules protein kinase C (PKC) and extracellular signal-related kinase (ERK). They mediated both the phorbol myristate acetate (PMA) downregulation of DMBT1 expression
23753	15076	 6636	PRKC Family	Protein	BCL2L1	mRNA	0	-1	12430000	Moreover, we found that the changes in expression of flavo-protein, JKTBP and bcl-xL induced by TPA were blocked by treatment with protein kinase C (PKC) or mitogen-activated protein (MAP) kinase inhibitors that prevent TPA-induced differentiation of TSU-Pr1 cells.
24839	15076	 5863	PRKC Family	Protein	MYC	mRNA	0	1	10801075	The biological activity of u-PA, t-PA, as well as that of limiting concentration of FCS (1%), was mediated by PTK and PKC.
24937	15076	  887	PRKC Family	Protein	MAPK3	mRNA	0	1	15760920	we identified two intracellular signaling molecules protein kinase C (PKC) and extracellular signal-related kinase (ERK). They mediated both the phorbol myristate acetate (PMA) downregulation of DMBT1 expression
25497	15076	11591	PRKC Family	Protein	NR4A3	mRNA	0	1	12564761	The levels of Nurr1, NGFI-B and NOR-1 mRNA were elevated markedly in NTera2 teratocarcinoma-derived neurons (NTera2-N), a model of differentiated human neurons, following a 1.5 or 3 h-exposure to 1 mM dibutyryl cyclic AMP or 100 nm phorbol 12-myristate 13-acetate
25793	15076	19027	PRKC Family	Protein	HMOX1	mRNA	0	1	12869663	Since HO-1 gene expression is strongly induced by agents or conditions that increase oxidative stress, redox signaling plays a crucial role in its regulation. These stimuli include heavy metals, bacterial lipopolysaccharides, hypoxia, hyperoxia, heat shock, ischemia, UV radiation, H2O2, cytokines, nitric oxide, stimuli that deplete cellular glutathione stores, and its substrate heme (Applegate et al., 1991; Shibahara, 1994; Immenschuh and Ramadori, 2000). In addition, several different redox-independent signaling pathways are involved in HO-1 gene regulation (Immenschuh and Ramadori, 2000). These include kinases [e.g., mitogen-activated protein kinases (Elbirt et al., 1998; Oguro et al., 1998), protein kinase C (Alam et al., 1995; Terry et al., 1999)
 2756	15076	  908	PRKC Family	Protein	MMP9	mRNA	0	1	12431981	Enforced MTA1 expression in HT1080 cells reduced basal and 12-myristate 13-acetate-induced 92-kDa type IV collagenase (MMP-9) protein/mRNA levels.
27649	15076	12781	PRKC Family	Protein	AR	mRNA	1	-1	12958311	In chromatin immunoprecipitation assays, we demonstrate a decrease in AR recruitment to the AR-responsive prostate-specific antigen (PSA) promoter following stimulation of PKC. Furthermore, prolonged exposure to indolactam V, a PKC activator, caused a reduction in PSA mRNA expression in prostate cancer LNCaP cells. Finally, we found PKC activation to have a repressive effect on AR and PSA protein expression in androgen-treated LNCaP cells.
29864	15076	10162	PRKC Family	Protein	CDKN2C	mRNA	0	-1	15107819	12-O-tetradecanoylphorbol-13-acetate (TPA), widely used as a protein kinase C (PKC) activator, suppresses the expression of p18(INK4c) through its promoter, accompanied by the induction of human cancer cell growth.
33681	15076	12902	PRKC Family	Protein	SEC16B	mRNA	0	1	12244571	Moreover, the RGPR-p117 mRNA expression in H4-II-E cells was stimulated in the presence of dibutyryl cAMP, PMA, insulin, 17beta-estradiol, or serum in culture medium
35247	15076	 5296	PRKC Family	Protein	PLAU	mRNA	1	1	15180498	Increased expression of PKC in malignant and aggressive breast cancers was recently demonstrated, and PKC activity has been shown to be higher in breast cancers than in normal breast tissue [68, 69]. In addition, high levels of PKC? and -? were correlated with enhanced uPA secretion in highly invasive MDA-MB- 231 breast cancer cells [70]. Furthermore, the introduction of PKC? gene to nonmetastatic MCF-7 breast cancer cells resulted in more aggressive neoplastic phenotype, and the stimulation of PKC activity with phorbol ester, phorbol-12- myristate-13-acetate (PMA), resulted in increases in both invasiveness and uPA expression
 3605	15076	12734	PRKC Family	Protein	MAP2K1	mRNA	0	1	10801075	The biological activity of u-PA, t-PA, as well as that of limiting concentration of FCS (1%), was mediated by PTK and PKC.
36397	15076	 4537	PRKC Family	Protein	MSR1	mRNA	0	1	10969071	Furthermore, in MSR gene promoter-driven luciferase reporter assays with TNF, PKC activator increases, but antioxidant N-acetylcysteine, PK inhibitors, and dominant negative constructs decrease luciferase activity in MSR gene promoter-transfected cells
36543	15076	 1434	PRKC Family	Protein	ALOX12	mRNA	0	1	11914583	indicating that PKCdelta played the functional role in mediating the gene activation of 12(S)-lipoxygenase induced by PMA.
36763	15076	 3532	PRKC Family	Protein	NR4A2	mRNA	0	1	12564761	The levels of Nurr1, NGFI-B and NOR-1 mRNA were elevated markedly in NTera2 teratocarcinoma-derived neurons (NTera2-N), a model of differentiated human neurons, following a 1.5 or 3 h-exposure to 1 mM dibutyryl cyclic AMP or 100 nm phorbol 12-myristate 13-acetate
40986	15076	 4582	PRKC Family	Protein	NOS3	mRNA	1	-1	15919781	it has a variety of effects on gene expression, examples of which are shown in the row of open boxes in Fig. 4.
 4192	15076	 4280	PRKC Family	Protein	PHGDH	mRNA	0	1	10713460	The TPA-induced monocytic differentiation of U937, which also resulted in growth arrest, abruptly downregulated the expression of 3-PGDH. Removal of TPA restored cell growth through the retrodifferentiation process and subsequent expression of 3-PGDH
42082	15076	13115	PRKC Family	Protein	EGR1	mRNA	-1	1	16103054	HGF-induced expression of Egr-1, PDGFA, and VEGF was suppressed by pharmacologic and siRNA inhibitors of mitogen-activated protein kinase kinase 1/2 (MEK1/2) and protein kinase C (PKC) pathways.
42683	15076	18771	PRKC Family	Protein	KLRD1	mRNA	0	1	11455585	Conversely, CHX blocked CD94 mRNA expression in PMA-stimulated cells, demonstrating that this process is dependent on new protein synthesis.
 4315	15076	19709	PRKC Family	Protein	RGS2	mRNA	0	1	11322774	RGS2 mRNA levels were increased in differentiated cells by heat shock, carbachol, and activation of protein kinase C.
44760	15076	 4862	PRKC Family	Protein	PDGFA	mRNA	-1	1	10508235	In mesangial cells, TPA induces the synthesis of a nuclear protein, PDGF-A gene binding protein-1, which binds to the sequence -102 to -82 relative to the transcription start site (45). Elements located at nucleotides -223 to -135 and -71 to -55 have been shown to be important for serum-induced and TPA-induced expression of PDGF-A, respectively (242, 461).
46043	15076	12530	PRKC Family	Protein	HPGD	mRNA	-1	1	10650939	PGDH promoter was strongly induced by phorbol ester
48003	15076	11629	PRKC Family	Protein	FOS	mRNA	0	1	11956220	c-fos gene expression was increased by PMA but not involved in MAO B gene transcription
49295	15076	 2099	PRKC Family	Protein	CD69	mRNA	0	1	11455585	In this study the expression of C-type lectins during the early activation of PMA-stimulated peripheral blood lymphocytes was examined. To investigate the influence of de novo protein synthesis on activation-dependent expression of C-type lectins, cells were cultured in presence of cycloheximide (CHX) and mRNA levels were analyzed by semi-quantitative reverse transcription-polymerase chain reaction. Upregulated levels of CD69, AICL, and LLT1, but less pronounced changes of CD161/NKR-P1A and CD94 mRNA were found at early time points of cellular activation.
50079	15076	 2931	PRKC Family	Protein	CFI	mRNA	0	1	10630630	The production of CFI by Hep G2 cells was enhanced in a dose- and time-dependent fashion by 12-O-tetradecanoyl-1,2-phorbol 13-acetate (TPA), a potent PKC activator. 4Alpha-phorbol didecanoate, an inactive phorbol ester, had no effect on CFI synthesis. The TPA-dependent increase in CFI secretion was correlated with an increase in CFI mRNA levels. These results indicate that TPA regulation of CFI gene requires PKC signalling and is mediated by via a TPA response element (TRE) in the CFI promoter region located at -136/-130
50943	15076	 6827	PRKC Family	Protein	AREG	mRNA	0	1	15072547	Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines
50987	15076	13884	PRKC Family	Protein	CDKN1A	mRNA	1	1	10801075	The biological activity of u-PA, t-PA, as well as that of limiting concentration of FCS (1%), was mediated by PTK and PKC.
51308	15076	17260	PRKC Family	Protein	MAOB	mRNA	0	1	11956220	In this study, we have shown that phorbol 12-myristate 13-acetate (PMA) increases human MAO B, but not MAO A, gene expression.
51601	15076	 5673	PRKC Family	Protein	ID1	mRNA	0	1	12947323	In the TPC-1 cell line, stimulation by TSH and serum up-regulated Id-1 mRNA expression 1.5- and 4.0-fold, respectively. Activation of the mitogen intracellular protein kinase A and protein kinase C signaling pathways also up-regulated Id-1 mRNA expression
51920	15076	 9802	PRKC Family	Protein	IL6ST	mRNA	0	1	10613356	We found that the expression of gp130 was dramatically induced at both the mRNA and protein levels by the two megakaryocytic inducers sodium butyrate (NaBut) and PMA.
51941	15076	 1178	PRKC Family	Protein	NR4A1	mRNA	0	1	12564761	The levels of Nurr1, NGFI-B and NOR-1 mRNA were elevated markedly in NTera2 teratocarcinoma-derived neurons (NTera2-N), a model of differentiated human neurons, following a 1.5 or 3 h-exposure to 1 mM dibutyryl cyclic AMP or 100 nm phorbol 12-myristate 13-acetate
53859	15076	 2903	PRKC Family	Protein	SLC1A2	mRNA	0	1	10804201	PACAP induced expression of GLAST  via activation of PKA-dependent signaling pathways only, but it affected the  expression of GLT-1 via both PKA and PKC-dependent signaling pathways.
54015	15076	18156	PRKC Family	Protein	EIF4EBP1	mRNA	0	-1	12618431	we show that the expression of 4E-BP1 protein and transcript decreases in hematopoietic cell lines cultivated in the presence of phorbol 12-myristate 13-acetate (PMA)
56133	15076	10811	PRKC Family	Protein	FN1	mRNA	-1	1	11343241	These effects were completely prevented by calphostin C, a protein kinase C inhibitor.
  590	15076	  897	PRKC Family	Protein	CYBB	mRNA	0	1	15067074	IFN-gamma induces the serine/threonine phosphorylation of PU.1 in cultured monocytes ... This phosphorylation, as well as the IFN-gamma-induced PU.1 binding and gp91(phox) protein synthesis, is slightly affected by the casein kinase II inhibitor, daidzein, but is abrogated by the protein kinase C (PKC) -alpha and -beta inhibitor, Go6976
59450	15076	16803	PRKC Family	Protein	ALOX15	mRNA	0	1	14757756	PKCdelta, a member of the novel protein kinase C (PKC) subclass, was rapidly phosphorylated and activated upon exposure to IL-13. Treatment of cells with rottlerin, a PKCdelta inhibitor, blocked IL-13-induced 15-LO mRNA and protein expression
 6132	15076	10255	PRKC Family	Protein	KLK3	mRNA	0	-1	12958311	In chromatin immunoprecipitation assays, we demonstrate a decrease in AR recruitment to the AR-responsive prostate-specific antigen (PSA) promoter following stimulation of PKC. Furthermore, prolonged exposure to indolactam V, a PKC activator, caused a reduction in PSA mRNA expression in prostate cancer LNCaP cells. Finally, we found PKC activation to have a repressive effect on AR and PSA protein expression in androgen-treated LNCaP cells.
61348	15076	15502	PRKC Family	Protein	ETS2	mRNA	0	1	12646185	this activity was enhanced by protein kinase C activator, phorbol 12-myristate 13-acetate (PMA), in an ETS consensus-dependent manner, while PMA could also enhance the expression level of ETS2 Endogenous expression of GM-CSF mRNA was increased by ETS2 transfection and the increased expression was further enhanced by PMA
62128	15076	17405	PRKC Family	Protein	PAK1	mRNA	0	1	12531429	Protein kinase C stimulated the activation of p21-activated kinase (PAK), as well. However, it also stimulated the selective and transient down-regulation of PAK1
62418	15076	11013	PRKC Family	Protein	IBSP	mRNA	0	1	11108282	In contrast, the activation of PKC promotes BSP gene expression.
64290	15076	17081	PRKC Family	Protein	LGALS3	mRNA	0	1	12788225	PMA-induced galectin-3 overexpression was blocked by: protein kinase C inhibitors staurosporine, calphostin C, and apigenin; tyrosine-specific protein kinase inhibitors genistein and tyrphostin A25; PD 98059, a selective inhibitor of mitogen-activated protein kinase (MAPK) kinase 1 (MEK1 or MKK1); and SB 203580, a specific inhibitor of p38 MAPK
 6475	15076	17143	PRKC Family	Protein	POU2F2	mRNA	0	1	15024018	We showed that CD86 stimulation increased the nuclear localization of NF-kappaB1 (p50) and phosphorylated RelA (p65) and increased Oct-2 expression and binding to the 3p-IgH enhancer, in a protein kinase C-dependent manner
66150	15076	 3724	PRKC Family	Protein	TNFSF13B	mRNA	0	-1	10331498	TALL-1 expression is dramatically down-regulated by phorbol myristate acetate/ionomycin.
 7261	15076	15475	PRKC Family	Protein	FGFBP1	mRNA	0	1	12670924	In these cells, FGF-BP was up-regulated by treatment with epidermal growth factor (EGF), dependent on protein kinase C and p38 mitogen-activated protein kinase signaling.
 7356	15076	 5400	PRKC Family	Protein	HNRPDL	mRNA	0	1	12430000	Moreover, we found that the changes in expression of flavo-protein, JKTBP and bcl-xL induced by TPA were blocked by treatment with protein kinase C (PKC) or mitogen-activated protein (MAP) kinase inhibitors that prevent TPA-induced differentiation of TSU-Pr1 cells.
  873	15076	12322	PRKC Family	Protein	TJP1	mRNA	0	1	15622522	Activation of PKC by the phorbol ester TPA induced ZO-1 and occludin transcription, whereas PKC inhibition lead to decreased expression levels.
 8795	15076	 1900	PRKC Family	Protein	PRDX1	mRNA	0	1	12960165	Phorbol ester-dependent activation of peroxiredoxin I gene expression via a protein kinase C, Ras, p38 mitogen-activated protein kinase signaling pathway. The data indicate that a protein kinase C, Ras, MEKK1, p38 MAPK signaling pathway plays a major role for the transcriptional up-regulation of Prx I gene expression.
10632	 5447	19362	IRF7	Protein	IFNA7	mRNA	0	1	10938111	Modified assertion
11342	 5447	14652	IRF7	Protein	ZNF217	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
11654	 5447	16413	IRF7	Protein	HMGCS1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
12246	 5447	 8440	IRF7	Protein	ATP5A1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
12479	 5447	   93	IRF7	Protein	BTF3P13	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
13909	 5447	 1706	IRF7	Protein	RAB2A	mRNA	-1	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
13979	 5447	 9482	IRF7	Protein	TMPO	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
14145	 5447	 3138	IRF7	Protein	USP9X	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
 1430	 5447	11536	IRF7	Protein	PCBP1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
16030	 5447	15914	IRF7	Protein	TOP2A	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
16323	 5447	19811	IRF7	Protein	MFAP1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
 1673	 5447	17075	IRF7	Protein	MAT2A	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
17823	 5447	18046	IRF7	Protein	RAF1	mRNA	-1	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
18069	 5447	11867	IRF7	Protein	RRAGD	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
19335	 5447	16719	IRF7	Protein	DNAJA1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
19884	 5447	 5366	IRF7	Protein	CD80	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
21256	 5447	15637	IRF7	Protein	LIPA	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
21772	 5447	 2026	IRF7	Protein	HIST1H4D	mRNA	0	1	11278666	Modified assertion
23281	 5447	 1572	IRF7	Protein	SNX3	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
23413	 5447	 4465	IRF7	Protein	RP2	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
23643	 5447	17594	IRF7	Protein	CCNG1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
 2367	 5447	12406	IRF7	Protein	STAT3	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
23774	 5447	 6636	IRF7	Protein	BCL2L1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
24096	 5447	11801	IRF7	Protein	PPP1R2	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
26768	 5447	 4058	IRF7	Protein	PRKAR1A	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
27417	 5447	17966	IRF7	Protein	MXI1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
27799	 5447	16845	IRF7	Protein	CD22	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
27955	 5447	13525	IRF7	Protein	GLUD2	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
   30	 5447	 3258	IRF7	Protein	FGFR4	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
32736	 5447	 3909	IRF7	Protein	NFE2L2	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
37545	 5447	 6614	IRF7	Protein	HSPA1B	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
38153	 5447	 1322	IRF7	Protein	GTF2B	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
38414	 5447	 5267	IRF7	Protein	TIMM17A	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
38928	 5447	 8219	IRF7	Protein	RFC1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
39320	 5447	 9758	IRF7	Protein	PSEN1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
39871	 5447	17098	IRF7	Protein	TSG101	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
40077	 5447	17902	IRF7	Protein	RAN	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
41291	 5447	 6882	IRF7	Protein	PMAIP1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
41952	 5447	13280	IRF7	Protein	SCAMP1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
42252	 5447	 5633	IRF7	Protein	AMD1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
42704	 5447	 8026	IRF7	Protein	IRF8	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
44180	 5447	10908	IRF7	Protein	NFIL3	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
44778	 5447	 7900	IRF7	Protein	TAB2	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
45075	 5447	18755	IRF7	Protein	TOP1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
45714	 5447	 1590	IRF7	Protein	RSAD2	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
45948	 5447	  938	IRF7	Protein	PLK4	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
46059	 5447	15021	IRF7	Protein	CALR	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
47562	 5447	11595	IRF7	Protein	TMBIM6	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
49340	 5447	 3050	IRF7	Protein	UBE2D1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
49526	 5447	10212	IRF7	Protein	IFNA4	mRNA	0	1	11884139	Modified assertion
50229	 5447	13634	IRF7	Protein	QKI	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
53073	 5447	16278	IRF7	Protein	ID2	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
53281	 5447	 4829	IRF7	Protein	IFNB1	mRNA	0	1	15229469	Subsequently, both IRF3 and IRF7 are involved in the production of delayed-type IFNs (IFN-a/b), thereby amplifying the expression of IFNs69.
53362	 5447	10278	IRF7	Protein	VAMP1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
53605	 5447	 3651	IRF7	Protein	SDCBP	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
54362	 5447	12644	IRF7	Protein	TOB1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
54537	 5447	10710	IRF7	Protein	MAPK9	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
55684	 5447	19511	IRF7	Protein	PAK2	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
55712	 5447	15411	IRF7	Protein	INSIG1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
56359	 5447	 4754	IRF7	Protein	PLSCR1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
56407	 5447	11761	IRF7	Protein	MSH2	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
57279	 5447	15849	IRF7	Protein	IFNA14	mRNA	0	1	10938111	Modified assertion
58597	 5447	10493	IRF7	Protein	PSMA3	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
59805	 5447	13414	IRF7	Protein	SERPINE1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
60181	 5447	10658	IRF7	Protein	CCNC	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
60414	 5447	 5024	IRF7	Protein	CCL5	mRNA	0	1	10799898	Modified assertion
61234	 5447	  885	IRF7	Protein	MS4A1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
61922	 5447	 7040	IRF7	Protein	SC5DL	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
 6257	 5447	12740	IRF7	Protein	ZNF267	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
63900	 5447	12604	IRF7	Protein	ARF4	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
65664	 5447	 3488	IRF7	Protein	MAX	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
65683	 5447	 9275	IRF7	Protein	TWF1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
65867	 5447	15444	IRF7	Protein	HIST1H2BL	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
 7665	 5447	  953	IRF7	Protein	ELF1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
 8036	 5447	19377	IRF7	Protein	MYD88	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
 9337	 5447	 8814	IRF7	Protein	CDK1	mRNA	0	1	15308637	TABLE IV  Selected genes up-regulated by IRF-7
24805	19567	 5863	PIK3 Family	Protein	MYC	mRNA	0	1	11483613	Pi3k inhibitor LY294002 inhibited Epo induced upregulation of Myc expression.
35462	19567	18531	PIK3 Family	Protein	ICAM1	mRNA	0	1	11705740	Activation of NFkB by TNF-alpha induces the mRNA expression of ICAM-1. Pretreatment of hepatocytes with LY294002, a PI3K specific inhibitor reduced the TNF-alpha induced expression of ICAM-1. This suggests that TNF-alpha induced transcriptional activation of NFkB was mediated by PI3K.
35598	19567	15442	PIK3 Family	Protein	BIRC2	mRNA	0	1	15065019	The authors found that survivin and cIAP1 mRNA as well as protein expression were decreased after PI3K inhibition.
48106	19567	13471	PIK3 Family	Protein	BIRC5	mRNA	0	1	15065019	The authors found that survivin and cIAP1 mRNA as well as protein expression were decreased after PI3K inhibition.
50186	19567	 8138	PIK3 Family	Protein	NRP1	mRNA	-1	1	12910515	EGF (100 ng/ml for 24 hours) induced upregulation of NRP1 was inhibited by the pretreatment of cells with 200 nM wortmannin (PI3K inhibitor) suggesting that, EGF mediates its action through PI3K activation. EGF stimulated the NRP1 expression in a concentration dependent manner with maximum effect at 100 ng/ml.
50993	19567	13884	PIK3 Family	Protein	CDKN1A	mRNA	1	-1	11404460	Activation of the phosphatidylinositol-3-OH kinase/Akt pathway results in the suppression of AR target genes, such as p21, and the decrease of androgen/AR-mediated apoptosis, which may involve the inhibition of interaction between AR and AR coregulators.
 6135	19567	10255	PIK3 Family	Protein	KLK3	mRNA	0	-1	11971763	PSA mRNA levels were measured after exposure of LNCaP cells to LY294002 (PI3K inhibitor), LY294002 strongly inhibited the DHT induced overexpression of PSA mRNA levels.
10185	11425	   85	HNF1A	Protein	NR0B2	mRNA	0	-1	11679424	The expression of small heterodimer partner (Shp-1), an orphan receptor that can heterodimerize with Hnf-4alpha and inhibit its transcriptional activity, was also reduced in Hnf-1alpha(-/-) islets.
10657	11425	 3198	HNF1A	Protein	TFRC	mRNA	-1	1	14988562	The transcriptional regulatory networks that specify and maintain human tissue diversity are largely uncharted. To gain insight into this circuitry, we used chromatin immunoprecipitation combined with promoter microarrays to identify systematically the genes occupied by the transcriptional regulators HNF1alpha, HNF4alpha, and HNF6, together with RNA polymerase II, in human liver and pancreatic islets. We identified tissue-specific regulatory circuits formed by HNF1alpha, HNF4alpha, and HNF6 with other transcription factors, revealing how these factors function as master regulators of hepatocyte and islet transcription. Our results suggest how misregulation of HNF4alpha can contribute to type 2 diabetes.
11694	11425	11709	HNF1A	Protein	UCP2	mRNA	0	1	10944108	In addition to reduced expression of the genes encoding insulin, glucose transporter-2, L-pyruvate kinase, aldolase B and 3-hydroxy-3-methylglutaryl coenzyme A reductase, induction of HNF1 alpha-P291fsinsC also significantly inhibits expression of mitochondrial 2-oxoglutarate dehydrogenase (OGDH) E1 subunit mRNA and protein. OGDH enzyme activity and [(14)C]pyruvate oxidation were also reduced. In contrast, the mRNA and protein levels of mitochondrial uncoupling protein-2 were dramatically increased by HNF1 alpha-P291fsinsC induction.
12438	11425	20232	HNF1A	Protein	NEUROD1	mRNA	0	-1	11679424	We found decreased steady-state mRNA levels of genes encoding glucose transporter 2 (Glut2), neutral and basic amino acid transporter, liver pyruvate kinase (L-Pk), and insulin in Hnf-1alpha(-/-) mice. In addition, we determined that the expression of several islet-enriched transcription factors, including Pdx-1, Hnf-4alpha, and Neuro-D1/Beta-2, was reduced in Hnf-1alpha(-/-) mice. These changes in pancreatic islet mRNA levels were already apparent in newborn animals, suggesting that loss of Hnf-1alpha function rather than chronic hyperglycemia is the primary cause of the altered gene expression. This expression profile was pancreatic islet-specific and distinct from hepatocytes...
 1701	11425	 3707	HNF1A	Protein	HNF4A	mRNA	0	-1	11679424	We found decreased steady-state mRNA levels of genes encoding glucose transporter 2 (Glut2), neutral and basic amino acid transporter, liver pyruvate kinase (L-Pk), and insulin in Hnf-1alpha(-/-) mice. In addition, we determined that the expression of several islet-enriched transcription factors, including Pdx-1, Hnf-4alpha, and Neuro-D1/Beta-2, was reduced in Hnf-1alpha(-/-) mice. These changes in pancreatic islet mRNA levels were already apparent in newborn animals, suggesting that loss of Hnf-1alpha function rather than chronic hyperglycemia is the primary cause of the altered gene expression. This expression profile was pancreatic islet-specific and distinct from hepatocytes...
19314	11425	 1981	HNF1A	Protein	ST6GAL1	mRNA	1	1	12878221	The nt-156 to -1 region contains HNF1 recognition element. Mutation of the HNF1 site reduced luciferase activity by about 80% compared with the wild-type construct, suggesting that HNF1 site is involved in the transcription of Form 1 mRNA in colon cancer cells.
19649	11425	16486	HNF1A	Protein	SPP1	mRNA	1	1	15557322	Vitamin D receptor (16), estrogen receptor {alpha} (17), Smad (18), Cbfa (19), and Ets-1 (20) have been shown to regulate OPN expression in osteoclasts, whereas metastasis-associated transcription factor (21), Tcf-1, Ets-1, Ets-2, polyomavirus enhancer A-binding protein-3, c-Jun (22) and acute myeloid leukemia-1 (23) are involved in OPN expression in cancer cells.
20041	11425	16107	HNF1A	Protein	PRODH2	mRNA	0	1	15581617	In addition, the expression of PO was also diminished in the liver derived from HNF1alpha-null mice.
21232	11425	15906	HNF1A	Protein	PAX4	mRNA	0	1	11825903	Modified assertion
22961	11425	 1915	HNF1A	Protein	ONECUT1	mRNA	0	1	11679424	Modified assertion
24502	11425	10666	HNF1A	Protein	SLC17A1	mRNA	0	1	12367519	We show that Npt1 and Npt4 genes were expressed at reduced levels in the kidneys of HNF1alpha -/- mice,
26742	11425	  293	HNF1A	Protein	HNF1B	mRNA	0	-1	11679424	Modified assertion
27842	11425	  477	HNF1A	Protein	PDX1	mRNA	0	1	11679424	Modified assertion
27880	11425	 1166	HNF1A	Protein	SLC2A1	mRNA	-1	-1	11679424	Modified assertion
28925	11425	14164	HNF1A	Protein	Cyp2c11	mRNA	0	1	11562369	trans-Activation of the intact CYP2C11 promoter (1.8-kilobase 5p-flank) was strongly induced by the liver nuclear factors HNF1alpha and HNF3beta but, unexpectedly, was inhibited by GH-activated STAT5b.
 3070	11425	17401	HNF1A	Protein	HMGCR	mRNA	0	-1	10944108	In addition to reduced expression of the genes encoding insulin, glucose transporter-2, L-pyruvate kinase, aldolase B and 3-hydroxy-3-methylglutaryl coenzyme A reductase, induction of HNF1 alpha-P291fsinsC also significantly inhibits expression of mitochondrial 2-oxoglutarate dehydrogenase (OGDH) E1 subunit mRNA and protein. OGDH enzyme activity and [(14)C]pyruvate oxidation were also reduced. In contrast, the mRNA and protein levels of mitochondrial uncoupling protein-2 were dramatically increased by HNF1 alpha-P291fsinsC induction.
32267	11425	15297	HNF1A	Protein	ALDOB	mRNA	0	-1	10944108	In addition to reduced expression of the genes encoding insulin, glucose transporter-2, L-pyruvate kinase, aldolase B and 3-hydroxy-3-methylglutaryl coenzyme A reductase, induction of HNF1 alpha-P291fsinsC also significantly inhibits expression of mitochondrial 2-oxoglutarate dehydrogenase (OGDH) E1 subunit mRNA and protein. OGDH enzyme activity and [(14)C]pyruvate oxidation were also reduced. In contrast, the mRNA and protein levels of mitochondrial uncoupling protein-2 were dramatically increased by HNF1 alpha-P291fsinsC induction.
34985	11425	 3622	HNF1A	Protein	CELA1	mRNA	0	1	12529398	Modified assertion
35075	11425	 3950	HNF1A	Protein	UGT2B17	mRNA	0	1	11191885	In HepG2 cells, HNF1alpha bound to this region and activated the UGT2B17 promoter
35255	11425	 4038	HNF1A	Protein	PAH	mRNA	0	1	11675021	DNA fragments corresponding to the two upstream hypersensitive sites of both genes have enhancer activity that depends upon the liver-enriched transcription factor binding sites for hepatocyte nuclear factor (HNF) 1 and/or CCAAT/enhancer binding protein (C/EBP).
35414	11425	18294	HNF1A	Protein	SRC	mRNA	0	1	10978326	Modified assertion
35566	11425	  376	HNF1A	Protein	SLC17A3	mRNA	0	1	12367519	We show that Npt1 and Npt4 genes were expressed at reduced levels in the kidneys of HNF1alpha -/- mice,
35873	11425	19603	HNF1A	Protein	ATF2	mRNA	1	1	14988562	The transcriptional regulatory networks that specify and maintain human tissue diversity are largely uncharted. To gain insight into this circuitry, we used chromatin immunoprecipitation combined with promoter microarrays to identify systematically the genes occupied by the transcriptional regulators HNF1alpha, HNF4alpha, and HNF6, together with RNA polymerase II, in human liver and pancreatic islets. We identified tissue-specific regulatory circuits formed by HNF1alpha, HNF4alpha, and HNF6 with other transcription factors, revealing how these factors function as master regulators of hepatocyte and islet transcription. Our results suggest how misregulation of HNF4alpha can contribute to type 2 diabetes.
 4347	11425	12348	HNF1A	Protein	SLC10A1	mRNA	0	1	16275121	Small heterodimer partner (SHP; NR0B2), an exceptional member of the mammalian nuclear receptor family, directly modulates the activities of conventional nuclear receptors by acting as an inducible and tissue-specific corepressor. Recent progress in dissecting underlying molecular mechanisms, identifying target factors and target genes, and uncovering physiological functions points to the regulatory involvement of SHP in diverse metabolic and intracellular pathways that awaits future clarification. In this review, we carry out a comprehensive survey of all published data and discuss our current understanding of molecular mechanisms and physiological consequences governing SHP action.
49168	11425	 9409	HNF1A	Protein	SLC22A8	mRNA	0	1	16793932	Transactivation assays revealed that HNF1alpha and HNF1beta markedly increased hOAT3 promoter activity, where the transactivation potency of HNF1beta was lower than that of HNF1alpha.
52301	11425	13636	HNF1A	Protein	SLC4A2	mRNA	0	1	18188457	Dual luciferase assay of PLC/PRF/5 cells transiently transfected with construct I-b1 mutated at the HNF1 site (construct I-b1[HNF1]mut; Figure 5) indicated that abrogation of the HNF1 element results in low promoter activity, with no response to the combination of UDCA and dexamethasone or to either of these compounds alone (Figure 11A). The fact that baseline transcriptional activity of construct I-b1[HNF1]mut was also markedly attenuated compared with that of the wild-type construct (4.5-fold; Figure 11A) suggested that an HNF1-bound transcription factor forms part of the baseline transcription machinery of AE2 {SLC4A2}alternate promoter in intact liver cells. ChIP assays against HNF1alpha in nuclear extracts from PLC/PRF/5 cells (with and without treatments) further supported such a view.
57826	11425	 4921	HNF1A	Protein	PCBD1	mRNA	0	1	11679424	Modified assertion
 6084	11425	 6701	HNF1A	Protein	OGDH	mRNA	0	-1	10944108	In addition to reduced expression of the genes encoding insulin, glucose transporter-2, L-pyruvate kinase, aldolase B and 3-hydroxy-3-methylglutaryl coenzyme A reductase, induction of HNF1 alpha-P291fsinsC also significantly inhibits expression of mitochondrial 2-oxoglutarate dehydrogenase (OGDH) E1 subunit mRNA and protein. OGDH enzyme activity and [(14)C]pyruvate oxidation were also reduced. In contrast, the mRNA and protein levels of mitochondrial uncoupling protein-2 were dramatically increased by HNF1 alpha-P291fsinsC induction.
 6099	11425	 2479	HNF1A	Protein	B3GALT5	mRNA	0	1	12855703	Four factors, Cdx1, Cdx2, HNF1alpha, and HNF1beta, could bind to GCE and transcriptionally activate the beta3Gal-T5 gene.
 6127	11425	 9018	HNF1A	Protein	IAPP	mRNA	0	1	14615061	These results indicate that amylin is positively regulated by cAMP and PKA through the transcription factors HNF-1 and NFY.
61591	11425	 2859	HNF1A	Protein	UROD	mRNA	0	1	14988562	The transcriptional regulatory networks that specify and maintain human tissue diversity are largely uncharted. To gain insight into this circuitry, we used chromatin immunoprecipitation combined with promoter microarrays to identify systematically the genes occupied by the transcriptional regulators HNF1alpha, HNF4alpha, and HNF6, together with RNA polymerase II, in human liver and pancreatic islets. We identified tissue-specific regulatory circuits formed by HNF1alpha, HNF4alpha, and HNF6 with other transcription factors, revealing how these factors function as master regulators of hepatocyte and islet transcription. Our results suggest how misregulation of HNF4alpha can contribute to type 2 diabetes.
63882	11425	12543	HNF1A	Protein	IGFBP1	mRNA	-1	1	14988562	The transcriptional regulatory networks that specify and maintain human tissue diversity are largely uncharted. To gain insight into this circuitry, we used chromatin immunoprecipitation combined with promoter microarrays to identify systematically the genes occupied by the transcriptional regulators HNF1alpha, HNF4alpha, and HNF6, together with RNA polymerase II, in human liver and pancreatic islets. We identified tissue-specific regulatory circuits formed by HNF1alpha, HNF4alpha, and HNF6 with other transcription factors, revealing how these factors function as master regulators of hepatocyte and islet transcription. Our results suggest how misregulation of HNF4alpha can contribute to type 2 diabetes.
 7276	11425	16053	HNF1A	Protein	PKLR	mRNA	-1	-1	11679424	Modified assertion
 8156	11425	17697	HNF1A	Protein	SLC2A2	mRNA	0	-1	11679424	Modified assertion
 9863	11425	18727	HNF1A	Protein	Ins1	mRNA	0	-1	11679424	We found decreased steady-state mRNA levels of genes encoding glucose transporter 2 (Glut2), neutral and basic amino acid transporter, liver pyruvate kinase (L-Pk), and insulin in Hnf-1alpha(-/-) mice. In addition, we determined that the expression of several islet-enriched transcription factors, including Pdx-1, Hnf-4alpha, and Neuro-D1/Beta-2, was reduced in Hnf-1alpha(-/-) mice. These changes in pancreatic islet mRNA levels were already apparent in newborn animals, suggesting that loss of Hnf-1alpha function rather than chronic hyperglycemia is the primary cause of the altered gene expression. This expression profile was pancreatic islet-specific and distinct from hepatocytes...
11695	 1704	11709	FOXA2	Protein	UCP2	mRNA	0	1	12865419	Foxa-2 and Pref-1 expression can be enhanced in primary preadipocytes by growth hormone
11748	 1704	18708	FOXA2	Protein	PEX11A	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
12128	 1704	19506	FOXA2	Protein	ACADM	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
12137	 1704	 6967	FOXA2	Protein	ECH1	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
12346	 1704	15924	FOXA2	Protein	HDC	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
 1301	 1704	 7836	FOXA2	Protein	CD55	mRNA	-1	-1	15452354	B: genes upregulated in foxa2 deletion
13277	 1704	18903	FOXA2	Protein	FOXA2	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
 1397	 1704	 2480	FOXA2	Protein	TST	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
14297	 1704	16808	FOXA2	Protein	ACSL1	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
14477	 1704	18103	FOXA2	Protein	LPL	mRNA	0	1	12865419	Foxa-2 and Pref-1 expression can be enhanced in primary preadipocytes by growth hormone
14529	 1704	10686	FOXA2	Protein	LRP4	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
  157	 1704	 1554	FOXA2	Protein	PLA2G1B	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
16111	 1704	 5511	FOXA2	Protein	Acaa1b	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
16192	 1704	10739	FOXA2	Protein	ARG2	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
16857	 1704	 9894	FOXA2	Protein	FOXA3	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
 1700	 1704	 3707	FOXA2	Protein	HNF4A	mRNA	0	-1	11875061	induction of Foxa2 causes pronounced decreases in the HNF4alpha and HNF1alpha mRNA levels.
17048	 1704	 3722	FOXA2	Protein	PPARG	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
17770	 1704	14685	FOXA2	Protein	SFTPA1B	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
17790	 1704	 1815	FOXA2	Protein	SFTPB	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
17889	 1704	 2286	FOXA2	Protein	G6PC	mRNA	0	1	16275121	Small heterodimer partner (SHP; NR0B2), an exceptional member of the mammalian nuclear receptor family, directly modulates the activities of conventional nuclear receptors by acting as an inducible and tissue-specific corepressor. Recent progress in dissecting underlying molecular mechanisms, identifying target factors and target genes, and uncovering physiological functions points to the regulatory involvement of SHP in diverse metabolic and intracellular pathways that awaits future clarification. In this review, we carry out a comprehensive survey of all published data and discuss our current understanding of molecular mechanisms and physiological consequences governing SHP action.
19132	 1704	17862	FOXA2	Protein	MAP1B	mRNA	0	1	12642491	Engrailed and Foxa2 interact physiologically in a dose-dependent manner: Foxa2 antagonizes the Engrailed-driven regulation of the MAP1B promoter, and vice versa...Direct interaction was confirmed by pull-down experiments
19580	 1704	14545	FOXA2	Protein	BBOX1	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
20184	 1704	  188	FOXA2	Protein	CYP7A1	mRNA	0	1	16275121	Small heterodimer partner (SHP; NR0B2), an exceptional member of the mammalian nuclear receptor family, directly modulates the activities of conventional nuclear receptors by acting as an inducible and tissue-specific corepressor. Recent progress in dissecting underlying molecular mechanisms, identifying target factors and target genes, and uncovering physiological functions points to the regulatory involvement of SHP in diverse metabolic and intracellular pathways that awaits future clarification. In this review, we carry out a comprehensive survey of all published data and discuss our current understanding of molecular mechanisms and physiological consequences governing SHP action.
20820	 1704	 7064	FOXA2	Protein	Cyp2a2	mRNA	0	-1	15539409	CYP2A2 promoter activity was inhibited approximately 85% by transfection of HNF3beta or HNF6, both of which are more highly expressed in female than male liver and can strongly trans-activate the female-specific CYP2C12 promoter.
21175	 1704	 2919	FOXA2	Protein	SLC6A14	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
21356	 1704	10792	FOXA2	Protein	PON1	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
24327	 1704	11223	FOXA2	Protein	AQP5	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
24590	 1704	18840	FOXA2	Protein	GK	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
 2495	 1704	17889	FOXA2	Protein	SLC2A4	mRNA	1	1	12865419	Foxa-2 and Pref-1 expression can be enhanced in primary preadipocytes by growth hormone
25197	 1704	17044	FOXA2	Protein	CERS6	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
26614	 1704	10457	FOXA2	Protein	TAT	mRNA	0	1	16098831	Foxa2 occupied its binding sites in all three target genes... Therefore, the decreased activation of the PEPCK, TAT, and IGFBP-1 genes in Foxa2-deficient hepatocytes that we observed solely in the fasted state (Figure 2) indicates that Foxa2 is essential to the transcriptional response to food deprivation.
27431	 1704	16610	FOXA2	Protein	Lyz2	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
28924	 1704	14164	FOXA2	Protein	Cyp2c11	mRNA	0	1	11562369	trans-Activation of the intact CYP2C11 promoter (1.8-kilobase 5p-flank) was strongly induced by the liver nuclear factors HNF1alpha and HNF3beta but, unexpectedly, was inhibited by GH-activated STAT5b.
28968	 1704	 6303	FOXA2	Protein	C5	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
 2944	 1704	10520	FOXA2	Protein	TBX1	mRNA	0	1	12533514	Modified assertion
29619	 1704	12496	FOXA2	Protein	Gstm5	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
32365	 1704	 3118	FOXA2	Protein	ACACA	mRNA	0	-1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
33610	 1704	13183	FOXA2	Protein	HADH	mRNA	0	1	15314688	We utilized expression profiling to identify additional targets of Foxa2. Strikingly, one of these genes, Hadhsc, encodes short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase, deficiency of which has been shown to cause PHHI in humans. Hadhsc is a direct target of Foxa2, as demonstrated by cotransfection as well as in vivo chromatin immunoprecipitation experiments using isolated islets.
33717	 1704	 1040	FOXA2	Protein	CD36	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
33734	 1704	 7880	FOXA2	Protein	ABCC8	mRNA	0	-1	11875061	induction of DN-Foxa2 also reduces the expression of beta-cell K(ATP) channel subunits Sur1 and Kir6.2 by 70%.
34139	 1704	18523	FOXA2	Protein	Plscr2	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
35377	 1704	 8508	FOXA2	Protein	SULT1A1	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
35830	 1704	 9034	FOXA2	Protein	ITGA7	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
36736	 1704	 4528	FOXA2	Protein	PKM2	mRNA	0	1	12865419	Foxa-2 and Pref-1 expression can be enhanced in primary preadipocytes by growth hormone
36801	 1704	 2958	FOXA2	Protein	DECR2	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
36912	 1704	 4187	FOXA2	Protein	PPP1R3C	mRNA	0	1	16627590	Using luciferase reporter constructs, we demonstrate that FoxA2 transactivates the PTG promoter in H4IIE hepatoma cells.
 3781	 1704	16600	FOXA2	Protein	GJA1	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
37968	 1704	  560	FOXA2	Protein	Retnla	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
40860	 1704	19641	FOXA2	Protein	CHI3L1	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
40926	 1704	 9420	FOXA2	Protein	NR5A2	mRNA	0	1	11595170	Modified assertion
41984	 1704	13676	FOXA2	Protein	SHH	mRNA	0	1	17088430	beta1 integrins were found to drive the expression of Hedgehogs in intestinal epithelial cells in an HNF-3beta (Foxa2)-dependent fashion.
42767	 1704	19447	FOXA2	Protein	SOD3	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
43041	 1704	 2912	FOXA2	Protein	NMU	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
43257	 1704	12473	FOXA2	Protein	PIK3AP1	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
44067	 1704	15206	FOXA2	Protein	ATP2A2	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
44148	 1704	 8923	FOXA2	Protein	PNLIPRP1	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
44193	 1704	17791	FOXA2	Protein	SFTPD	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
44216	 1704	17671	FOXA2	Protein	KCNJ11	mRNA	0	-1	11875061	induction of DN-Foxa2 also reduces the expression of beta-cell K(ATP) channel subunits Sur1 and Kir6.2 by 70%.
45131	 1704	 6977	FOXA2	Protein	HK1	mRNA	0	-1	11875061	loss of Foxa2 function leads to up-regulation of hexokinase (HK) I and II and glucokinase (HK-IV) mRNA expression.
46373	 1704	 4142	FOXA2	Protein	CALCA	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
46774	 1704	 7004	FOXA2	Protein	CROT	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
47337	 1704	 5211	FOXA2	Protein	VSIG2	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
 4795	 1704	19463	FOXA2	Protein	ABCA3	mRNA	0	1	17890326	FOXA2, C/EBPalpha, GATA-6, TTF-1, and NFATc3 increased the activity of the Abca3 luciferase construct in a dose-dependent manner.
48254	 1704	20148	FOXA2	Protein	SLC25A20	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
48286	 1704	 7237	FOXA2	Protein	INSR	mRNA	0	1	12865419	Foxa-2 and Pref-1 expression can be enhanced in primary preadipocytes by growth hormone
48916	 1704	11904	FOXA2	Protein	GRPEL2	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
49364	 1704	18288	FOXA2	Protein	UCP3	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
49592	 1704	 6248	FOXA2	Protein	PIK3C2G	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
51169	 1704	11839	FOXA2	Protein	PCK1	mRNA	0	1	16098831	Foxa2 occupied its binding sites in all three target genes... Therefore, the decreased activation of the PEPCK, TAT, and IGFBP-1 genes in Foxa2-deficient hepatocytes that we observed solely in the fasted state (Figure 2) indicates that Foxa2 is essential to the transcriptional response to food deprivation.
51534	 1704	15480	FOXA2	Protein	AACS	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
51818	 1704	 8032	FOXA2	Protein	HMGN3	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
52331	 1704	 4014	FOXA2	Protein	CDH16	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
53244	 1704	13017	FOXA2	Protein	MAFA	mRNA	0	1	16847327	FoxA2, Nkx2.2, and PDX-1 regulate islet beta-cell-specific mafA expression.....Important regulators of beta-cell formation and function, PDX-1, FoxA2, and Nkx2.2, were shown to specifically bind to region 3 in vivo using the chromatin immunoprecipitation assay. Mutational and functional analyses demonstrated that FoxA2 (bp -7943 to -7910), Nkx2.2 (bp -7771 to -7746), and PDX-1 (bp -8087 to -8063) mediated region 3 activation.
53997	 1704	 1137	FOXA2	Protein	GJB6	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
54371	 1704	  991	FOXA2	Protein	INS	mRNA	0	-1	11875061	The expression of insulin and islet amyloid polypeptide is markedly suppressed after induction of Foxa2, while the glucagon mRNA levels are significantly increased.
54764	 1704	 4990	FOXA2	Protein	IDE	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
55754	 1704	 8156	FOXA2	Protein	CLDN8	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
56737	 1704	18995	FOXA2	Protein	FASN	mRNA	0	-1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
57181	 1704	15520	FOXA2	Protein	Zfp52	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
57266	 1704	 8148	FOXA2	Protein	GCG	mRNA	0	1	11875061	The expression of insulin and islet amyloid polypeptide is markedly suppressed after induction of Foxa2, while the glucagon mRNA levels are significantly increased.
57370	 1704	10643	FOXA2	Protein	Scd1	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
57505	 1704	 5731	FOXA2	Protein	ACOX1	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
57758	 1704	 8036	FOXA2	Protein	CRAT	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
58151	 1704	 6758	FOXA2	Protein	TTR	mRNA	0	1	11763995	Modified assertion
58685	 1704	 1833	FOXA2	Protein	HK2	mRNA	0	1	12865419	Foxa-2 and Pref-1 expression can be enhanced in primary preadipocytes by growth hormone
 5885	 1704	14250	FOXA2	Protein	MGLL	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
58871	 1704	14677	FOXA2	Protein	ACADVL	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
59675	 1704	 7590	FOXA2	Protein	GCK	mRNA	0	-1	11875061	loss of Foxa2 function leads to up-regulation of hexokinase (HK) I and II and glucokinase (HK-IV) mRNA expression.
60091	 1704	 1244	FOXA2	Protein	HNF1A	mRNA	0	-1	11875061	induction of Foxa2 causes pronounced decreases in the HNF4alpha and HNF1alpha mRNA levels.
60885	 1704	10386	FOXA2	Protein	DLK1	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
 6125	 1704	 9018	FOXA2	Protein	IAPP	mRNA	0	-1	11875061	The expression of insulin and islet amyloid polypeptide is markedly suppressed after induction of Foxa2, while the glucagon mRNA levels are significantly increased.
 6143	 1704	 2057	FOXA2	Protein	FABP5	mRNA	0	-1	15452354	B: genes upregulated in foxa2 deletion
62385	 1704	19583	FOXA2	Protein	RAB3C	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
62646	 1704	 1171	FOXA2	Protein	FABP1	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
63047	 1704	 2839	FOXA2	Protein	SFN	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
63226	 1704	  460	FOXA2	Protein	SEPP1	mRNA	1	1	 9687017	Within the 1116 bp upstream of exon 1 four hepatic nuclear factor 3beta (HNF3beta) binding motifs were found, which is in line with liver-specific expression of selenoprotein P.
63624	 1704	12014	FOXA2	Protein	Li	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
 6388	 1704	12701	FOXA2	Protein	SLCO1B3	mRNA	0	-1	14739090	In transfected Huh7 cells, OATP8 promoter activity was inhibited by 70% when HNF3beta was cotransfected.An HNF3beta binding site was located at nt -39/-23 by EMSA.
63892	 1704	12543	FOXA2	Protein	IGFBP1	mRNA	-1	1	16098831	Foxa2 occupied its binding sites in all three target genes... Therefore, the decreased activation of the PEPCK, TAT, and IGFBP-1 genes in Foxa2-deficient hepatocytes that we observed solely in the fasted state (Figure 2) indicates that Foxa2 is essential to the transcriptional response to food deprivation.
 6400	 1704	 3125	FOXA2	Protein	LIPE	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
64366	 1704	 6353	FOXA2	Protein	IRS2	mRNA	0	1	12865419	Foxa-2 and Pref-1 expression can be enhanced in primary preadipocytes by growth hormone
65442	 1704	19519	FOXA2	Protein	CPT1A	mRNA	-1	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
65642	 1704	 6557	FOXA2	Protein	ALAS1	mRNA	0	1	15123725	hepatic nuclear factor 3 (HNF3) and nuclear factor 1 (NF1) are necessary for an appropriate expression of the ALAS gene. Insulin overrides the HNF3beta or HNF3beta plus NF1-mediated stimulation of ALAS transcriptional activity. Electrophoretic mobility shift assay and Southwestern blotting indicate that HNF3 binds to the ALAS promoter We propose a model in which insulin exerts its negative effect through the disturbance of HNF3beta binding or transactivation potential
66060	 1704	 5646	FOXA2	Protein	MT1A	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
66140	 1704	 2115	FOXA2	Protein	LIPC	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
 6923	 1704	 8507	FOXA2	Protein	ACOT4	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
 7069	 1704	13164	FOXA2	Protein	PAX3	mRNA	0	-1	14701752	Modified assertion
 7274	 1704	16053	FOXA2	Protein	PKLR	mRNA	-1	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
 7472	 1704	19396	FOXA2	Protein	C3	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
 7763	 1704	 6883	FOXA2	Protein	ANPEP	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
 8151	 1704	17697	FOXA2	Protein	SLC2A2	mRNA	0	-1	11875061	The mRNA levels of GLUT2 and glucokinase are drastically decreased after induction of Foxa2.
 8300	 1704	 6070	FOXA2	Protein	ACP5	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
 9031	 1704	 7248	FOXA2	Protein	LIPG	mRNA	0	1	15616563	Pharmacological intervention to inhibit phosphorylation of Foxa2 may be an effective treatment for type 2 diabetes.
 9884	 1704	12555	FOXA2	Protein	LDHB	mRNA	0	1	15452354	table 4: gene expressions altered in foxa2 deletion A: genes downregulated in foxa2 deletion
10604	16539	 6270	SMARCE1	Protein	BRCA2	mRNA	0	1	16769725	We then analyzed the effect of BAF57 depletion on the expression of endogenous ER target genes, monitoring mRNA levels by quantitative reverse transcription-PCR (QRT-PCR). The mRNA expression levels of a number of well characterized ER target genes (pS2, cathepsin D, progesterone receptor, BRCA1, BRCA2, and bcl-2) increased in ZR-75-1 cells in response to treatment with 17beta-estradiol (E2) for 24 h, as shown in Fig. 1C. The E2-dependent activation of all of these genes was markedly impaired by transfection with siBAF57 (Fig. 1C), indicating that BAF57 is important for the transcriptional activity of endogenous ER.
21370	16539	13892	SMARCE1	Protein	CTSD	mRNA	0	1	16769725	We then analyzed the effect of BAF57 depletion on the expression of endogenous ER target genes, monitoring mRNA levels by quantitative reverse transcription-PCR (QRT-PCR). The mRNA expression levels of a number of well characterized ER target genes (pS2, cathepsin D, progesterone receptor, BRCA1, BRCA2, and bcl-2) increased in ZR-75-1 cells in response to treatment with 17beta-estradiol (E2) for 24 h, as shown in Fig. 1C. The E2-dependent activation of all of these genes was markedly impaired by transfection with siBAF57 (Fig. 1C), indicating that BAF57 is important for the transcriptional activity of endogenous ER.
36026	16539	 7956	SMARCE1	Protein	BRCA1	mRNA	0	1	16769725	We then analyzed the effect of BAF57 depletion on the expression of endogenous ER target genes, monitoring mRNA levels by quantitative reverse transcription-PCR (QRT-PCR). The mRNA expression levels of a number of well characterized ER target genes (pS2, cathepsin D, progesterone receptor, BRCA1, BRCA2, and bcl-2) increased in ZR-75-1 cells in response to treatment with 17beta-estradiol (E2) for 24 h, as shown in Fig. 1C. The E2-dependent activation of all of these genes was markedly impaired by transfection with siBAF57 (Fig. 1C), indicating that BAF57 is important for the transcriptional activity of endogenous ER.
44167	16539	 6531	SMARCE1	Protein	CCNE1	mRNA	0	-1	14559996	Here we show that the type II arginine-specific methyltransferase PRMT5, which is involved in cyclin E repression, can be found in association with Brg1 and hBrm-based hSWI/SNF complexes.
45351	16539	14987	SMARCE1	Protein	BCL2	mRNA	1	1	16769725	We then analyzed the effect of BAF57 depletion on the expression of endogenous ER target genes, monitoring mRNA levels by quantitative reverse transcription-PCR (QRT-PCR). The mRNA expression levels of a number of well characterized ER target genes (pS2, cathepsin D, progesterone receptor, BRCA1, BRCA2, and bcl-2) increased in ZR-75-1 cells in response to treatment with 17beta-estradiol (E2) for 24 h, as shown in Fig. 1C. The E2-dependent activation of all of these genes was markedly impaired by transfection with siBAF57 (Fig. 1C), indicating that BAF57 is important for the transcriptional activity of endogenous ER.
48048	16539	11629	SMARCE1	Protein	FOS	mRNA	0	1	16769725	Transfection of siBAF57 completely abolished the increase in c-fos expression observed in mock-transfected cells treated with E2 for 1 h (Fig. 4B). These results indicate that BAF57 plays a crucial role in the transcription of c-fos proto-oncogene.
55160	16539	17653	SMARCE1	Protein	TFF1	mRNA	0	1	16769725	We then analyzed the effect of BAF57 depletion on the expression of endogenous ER target genes, monitoring mRNA levels by quantitative reverse transcription-PCR (QRT-PCR). The mRNA expression levels of a number of well characterized ER target genes (pS2, cathepsin D, progesterone receptor, BRCA1, BRCA2, and bcl-2) increased in ZR-75-1 cells in response to treatment with 17beta-estradiol (E2) for 24 h, as shown in Fig. 1C. The E2-dependent activation of all of these genes was markedly impaired by transfection with siBAF57 (Fig. 1C), indicating that BAF57 is important for the transcriptional activity of endogenous ER.
58405	16539	15117	SMARCE1	Protein	PGR	mRNA	0	1	16769725	We then analyzed the effect of BAF57 depletion on the expression of endogenous ER target genes, monitoring mRNA levels by quantitative reverse transcription-PCR (QRT-PCR). The mRNA expression levels of a number of well characterized ER target genes (pS2, cathepsin D, progesterone receptor, BRCA1, BRCA2, and bcl-2) increased in ZR-75-1 cells in response to treatment with 17beta-estradiol (E2) for 24 h, as shown in Fig. 1C. The E2-dependent activation of all of these genes was markedly impaired by transfection with siBAF57 (Fig. 1C), indicating that BAF57 is important for the transcriptional activity of endogenous ER.
29019	12525	   46	XIAP	Protein	SSB	mRNA	0	1	11445534	Similarly, Holcik and colleagues found that the La autoantigen stimulated the IRES in X-linked inhibitor of apoptosis mRNA (Holcik and Korneluk 2000 ).
32883	12525	11449	XIAP	Protein	CASP9	mRNA	1	-1	10930419	XIAP had no detectable effect on ara-C-induced release of mitochondrial cytochrome c and attenuated cleavage of procaspase-9.
  154	18200	 1973	MAPK JNK Family	Protein	LSM5	mRNA	0	1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
16338	18200	19219	MAPK JNK Family	Protein	IER2	mRNA	0	-1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
20623	18200	19120	MAPK JNK Family	Protein	HSPA5	mRNA	0	-1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
22716	18200	13867	MAPK JNK Family	Protein	HIPK3	mRNA	0	1	14766760	Consequently, we have used the recently described specific JNK inhibitor SP600125 and RNA interference to inhibit endogenous JNK activity in the prostate carcinoma cell line DU 145. We demonstrated that endogenous JNK activity increased the expression of a kinase, HIPK3, that has previously been implicated in multidrug resistance in a number of tumors.
22983	18200	 4678	MAPK JNK Family	Protein	ERRFI1	mRNA	0	1	10749885	Induction of gene 33 requires the stress-activated protein kinases (SAPKs)/c-Jun NH(2)-terminal kinases. This expression pattern suggests that gene 33 is a potential marker for diabetic nephropathy and other pathologic responses to persistent sublethal stress.
25179	18200	 6840	MAPK JNK Family	Protein	HMGA1	mRNA	0	1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
27825	18200	 1168	MAPK JNK Family	Protein	SHFM1	mRNA	0	1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
28254	18200	 7832	MAPK JNK Family	Protein	THBS1	mRNA	-1	1	16650813	IL-18-enhanced TSP-1 expression was blocked by SP600125, a c-Jun N-terminal kinase (JNK) specific inhibitor
32007	18200	 4292	MAPK JNK Family	Protein	DDIT3	mRNA	0	-1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
 4546	18200	15684	MAPK JNK Family	Protein	LGALS3BP	mRNA	0	-1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
 4558	18200	14819	MAPK JNK Family	Protein	LMNA	mRNA	0	1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
46116	18200	16240	MAPK JNK Family	Protein	ITGB4	mRNA	0	1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
48908	18200	 7703	MAPK JNK Family	Protein	CHERP	mRNA	0	-1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
51081	18200	13884	MAPK JNK Family	Protein	CDKN1A	mRNA	1	1	15753078	These results implicate galectin-8 as a modulator of cellular growth through up-regulation of p21. This process involves activation of JNK, which enhances the synthesis of p21, combined with the activation of PKB, which inhibits p21 degradation
54279	18200	 6594	MAPK JNK Family	Protein	TCN2	mRNA	0	1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
55411	18200	16991	MAPK JNK Family	Protein	PPP1R15A	mRNA	1	-1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
57335	18200	 4298	MAPK JNK Family	Protein	JUNB	mRNA	0	-1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
62959	18200	 7195	MAPK JNK Family	Protein	GADD45A	mRNA	-1	-1	12036942	Northern analysis of the apoptosis-associated genes Gadd34 and Gadd45 verified their higher expression in JNK2AS-treated cells (Fig. 4C)Citation , and the mRNA levels of Gadd153, another gene whose expression is often up-regulated by conditions that induce Gadd34 and Gadd45, were also elevated. The induction of the Gadd genes suggested that JNK2AS-treated cells were under stress and prompted us to examine the expression of two other stress-regulated genes: (a) Grp78, a molecular chaperone involved in protein folding; and (b) the cyclin-dependent kinase inhibitor p21Cip1/Waf1, which we had found previously to be up-regulated in other JNK2AS-treated cells (17 , 18) . Both genes were markedly up-regulated in JNK2AS-treated cells (Fig. 4C)Citation , suggesting that depletion of JNK2 in PC3 cells facilitates the induction of several independent stress-signaling pathways. Activation of the JNK pathway is important for the phosphorylation and activation of protein components of AP-1 transcription factor complexes (1, 2, 3, 4 , 5, 6, 7 , 28) , suggesting that genes regulated by AP-1-dependent transcription could be negatively affected by JNKAS treatment. Indeed, we detected reduced expression of several AP-1-regulated genes, including lamin A-C (29) , and integrin b-4 (Ref. 30 ; Fig. 4DCitation ). Among other genes whose lower expression after JNK2AS treatment was verified by Northern blotting were HMG-I(Y), a protein highly expressed in prostate cancer (31) and recently identified as a myc-regulated oncogene (32) , Lsm5 (33) , transcobalamin, and DSS1 (Ref. 34 ; Fig. 4Citation D, and data not shown). Importantly, although most JNK2AS-altered genes appeared to be specific for treatment with this oligonucleotide, some gene expression changes were also seen in the JNK1AS- and JNKScr-treated groups, indicating that a more global response to the uptake of oligonucleotides (Fig. 4E)Citation was elicited. Within this group were two IFN-inducible genes, ISGF-3 and ISG15, suggesting that application of phosphorothioate oligonucleotides could induce IFN-dependent responses.
 7900	18200	19902	MAPK JNK Family	Protein	ACHE	mRNA	0	1	18385943	We show that H(2)O(2) increases acetylcholinesterase (AChE) expression via transcriptional activation through c-Jun N-terminal kinase (JNK)
16478	 2819	18083	hydroquinone	Compound	BNIP3	mRNA	-1	-1	15452088	down
32888	 2819	11449	hydroquinone	Compound	CASP9	mRNA	1	-1	15452088	down
23410	 3345	 9226	GK	Protein	CITED2	mRNA	1	-1	17406644	To define GKps role in insulin resistance, we examined gene expression in brown adipose tissue in a glycerol kinase knockout (KO) mouse model using microarray analysis {on 3 day old mice}. Global gene expression profiles of KO mice were distinct from wild type with 668 differentially expressed genes {in brown adipose tissue}. Expression changes >1.5-fold and p<0.05.
27863	 3345	 1166	GK	Protein	SLC2A1	mRNA	-1	-1	17406644	To define GKps role in insulin resistance, we examined gene expression in brown adipose tissue in a glycerol kinase knockout (KO) mouse model using microarray analysis {on 3 day old mice}. Global gene expression profiles of KO mice were distinct from wild type with 668 differentially expressed genes {in brown adipose tissue}. Expression changes >1.5-fold and p<0.05.
 3620	 3345	 9855	GK	Protein	DGAT2	mRNA	1	1	17406644	To define GKps role in insulin resistance, we examined gene expression in brown adipose tissue in a glycerol kinase knockout (KO) mouse model using microarray analysis {on 3 day old mice}. Global gene expression profiles of KO mice were distinct from wild type with 668 differentially expressed genes {in brown adipose tissue}. Expression changes >1.5-fold and p<0.05.
46042	 3345	12530	GK	Protein	HPGD	mRNA	-1	-1	17406644	To define GKps role in insulin resistance, we examined gene expression in brown adipose tissue in a glycerol kinase knockout (KO) mouse model using microarray analysis {on 3 day old mice}. Global gene expression profiles of KO mice were distinct from wild type with 668 differentially expressed genes {in brown adipose tissue}. Expression changes >1.5-fold and p<0.05.
56670	 3345	 6613	GK	Protein	GLCCI1	mRNA	-1	-1	17406644	To define GKps role in insulin resistance, we examined gene expression in brown adipose tissue in a glycerol kinase knockout (KO) mouse model using microarray analysis {on 3 day old mice}. Global gene expression profiles of KO mice were distinct from wild type with 668 differentially expressed genes {in brown adipose tissue}. Expression changes >1.5-fold and p<0.05.
66226	 3345	 6460	GK	Protein	FAM198B	mRNA	-1	1	17406644	To define GKps role in insulin resistance, we examined gene expression in brown adipose tissue in a glycerol kinase knockout (KO) mouse model using microarray analysis {on 3 day old mice}. Global gene expression profiles of KO mice were distinct from wild type with 668 differentially expressed genes {in brown adipose tissue}. Expression changes >1.5-fold and p<0.05.
 7974	 3345	17931	GK	Protein	MAPK6	mRNA	1	1	17406644	To define GKps role in insulin resistance, we examined gene expression in brown adipose tissue in a glycerol kinase knockout (KO) mouse model using microarray analysis {on 3 day old mice}. Global gene expression profiles of KO mice were distinct from wild type with 668 differentially expressed genes {in brown adipose tissue}. Expression changes >1.5-fold and p<0.05.
10010	 8197	 4597	KLF1	Protein	UBE2C	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
10019	 8197	19515	KLF1	Protein	UBAC1	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
10658	 8197	 3198	KLF1	Protein	TFRC	mRNA	-1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
10670	 8197	 8061	KLF1	Protein	TRAPPC2	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
10762	 8197	 5030	KLF1	Protein	TLN1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
11035	 8197	 8037	KLF1	Protein	KLF6	mRNA	1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 1140	 8197	15597	KLF1	Protein	DLGAP5	mRNA	0	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
11549	 8197	 7885	KLF1	Protein	ISG20	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
11760	 8197	11155	KLF1	Protein	HEMGN	mRNA	-1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
12033	 8197	16866	KLF1	Protein	FN3K	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
12521	 8197	 3012	KLF1	Protein	CPOX	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
13571	 8197	19840	KLF1	Protein	GNG2	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
 1368	 8197	19956	KLF1	Protein	UBE2E1	mRNA	1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
14007	 8197	 6824	KLF1	Protein	AHSP	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
14520	 8197	16425	KLF1	Protein	ZBTB22	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
16345	 8197	17741	KLF1	Protein	RUNX1T1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
16412	 8197	15032	KLF1	Protein	Gypa	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
16450	 8197	 9361	KLF1	Protein	DYDC1	mRNA	-1	-1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
16480	 8197	18083	KLF1	Protein	BNIP3	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
16960	 8197	 7696	KLF1	Protein	Rrp7a	mRNA	0	1	15923635	up
17431	 8197	 8509	KLF1	Protein	SF1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
17773	 8197	16517	KLF1	Protein	KRT15	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
19230	 8197	10312	KLF1	Protein	CNTNAP2	mRNA	1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
19783	 8197	12310	KLF1	Protein	4933401L05Rik	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
20233	 8197	18504	KLF1	Protein	EDN2	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
20832	 8197	12908	KLF1	Protein	ENO1	mRNA	1	1	15923635	up
21331	 8197	13132	KLF1	Protein	PC	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
21664	 8197	 4615	KLF1	Protein	NR0B1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
21963	 8197	15307	KLF1	Protein	Hbb-b1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
23317	 8197	 7455	KLF1	Protein	CTSB	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
23506	 8197	19977	KLF1	Protein	CNOT7	mRNA	0	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
23668	 8197	16820	KLF1	Protein	3110040M04Rik	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
23681	 8197	 3777	KLF1	Protein	Hbb-y	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
23727	 8197	12255	KLF1	Protein	SLC3A2	mRNA	0	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
23877	 8197	 6703	KLF1	Protein	GKAP1	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
23937	 8197	 2061	KLF1	Protein	NFE2	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
24437	 8197	19848	KLF1	Protein	KCNK4	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
24669	 8197	14908	KLF1	Protein	Hbb-bh1	mRNA	0	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
 2478	 8197	17889	KLF1	Protein	SLC2A4	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
24891	 8197	19122	KLF1	Protein	PTP4A3	mRNA	-1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
25079	 8197	 6601	KLF1	Protein	Hba-x	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
25204	 8197	 3475	KLF1	Protein	CCT6B	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
25963	 8197	15317	KLF1	Protein	PGK1	mRNA	1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
26408	 8197	 6397	KLF1	Protein	CEP55	mRNA	1	-1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
26483	 8197	19253	KLF1	Protein	TMCC2	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
26653	 8197	 6333	KLF1	Protein	SPOCK1	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
 2682	 8197	12660	KLF1	Protein	PPOX	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 2700	 8197	12731	KLF1	Protein	UBQLN1	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
27850	 8197	 1166	KLF1	Protein	SLC2A1	mRNA	-1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
27892	 8197	 6761	KLF1	Protein	CECR2	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
 2825	 8197	10913	KLF1	Protein	GYPC	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
28252	 8197	 7832	KLF1	Protein	THBS1	mRNA	-1	1	15923635	up
28349	 8197	 1676	KLF1	Protein	SUN1	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
28860	 8197	17518	KLF1	Protein	ANXA6	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
28877	 8197	18216	KLF1	Protein	CA1	mRNA	-1	1	15923635	up
29531	 8197	10272	KLF1	Protein	SLC43A1	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
29862	 8197	 3745	KLF1	Protein	HTRA2	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
32478	 8197	 7354	KLF1	Protein	BLVRB	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
32892	 8197	14012	KLF1	Protein	SRXN1	mRNA	0	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
33131	 8197	 1254	KLF1	Protein	ATAD3A	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
33137	 8197	 7360	KLF1	Protein	RARG	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
33200	 8197	13446	KLF1	Protein	FHOD3	mRNA	0	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
33676	 8197	19528	KLF1	Protein	RHOD	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
33937	 8197	17033	KLF1	Protein	Cd59a	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
34199	 8197	 7386	KLF1	Protein	1700011M02Rik	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
34586	 8197	13084	KLF1	Protein	CABLES1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 3468	 8197	19920	KLF1	Protein	CDK19	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
34821	 8197	 9634	KLF1	Protein	OR51B2	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
35608	 8197	 1571	KLF1	Protein	RBL2	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
35817	 8197	12034	KLF1	Protein	UROS	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
36161	 8197	11189	KLF1	Protein	Lcn5	mRNA	-1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
 3619	 8197	 9855	KLF1	Protein	DGAT2	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
36744	 8197	 4528	KLF1	Protein	PKM2	mRNA	0	1	15923635	up
37293	 8197	19646	KLF1	Protein	ANXA8L2	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
38931	 8197	  337	KLF1	Protein	IL3	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
39445	 8197	18369	KLF1	Protein	TAF3	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
39959	 8197	 6114	KLF1	Protein	NFKBIA	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
40609	 8197	 1112	KLF1	Protein	6720484C15Rik	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
40753	 8197	 2915	KLF1	Protein	ISG15	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
40783	 8197	 7849	KLF1	Protein	KLF9	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 4094	 8197	 9978	KLF1	Protein	GNAI2	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
 4146	 8197	 7778	KLF1	Protein	NXPH4	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
41500	 8197	16471	KLF1	Protein	RELN	mRNA	-1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 4172	 8197	 6566	KLF1	Protein	Epb4.9	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
42218	 8197	10155	KLF1	Protein	CACNA1C	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
42622	 8197	19799	KLF1	Protein	SMC2	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
43320	 8197	19610	KLF1	Protein	SPTA1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
43777	 8197	16606	KLF1	Protein	SAP30	mRNA	0	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
43805	 8197	11318	KLF1	Protein	MAP2K5	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
44314	 8197	 4930	KLF1	Protein	ERMAP	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
44689	 8197	 3194	KLF1	Protein	4933421O10Rik	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
45163	 8197	19899	KLF1	Protein	SLC22A16	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
45696	 8197	 8412	KLF1	Protein	LGALS1	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
46763	 8197	12458	KLF1	Protein	SAMSN1	mRNA	1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
46820	 8197	 5594	KLF1	Protein	TRIM59	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
47022	 8197	 5926	KLF1	Protein	OTUD6B	mRNA	-1	-1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
47250	 8197	17970	KLF1	Protein	EFNA2	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
47591	 8197	19487	KLF1	Protein	CTNND1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
47711	 8197	  295	KLF1	Protein	KCNN4	mRNA	0	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
 4832	 8197	 6386	KLF1	Protein	HMOX2	mRNA	1	1	15923635	up
48552	 8197	11183	KLF1	Protein	ANO9	mRNA	1	-1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
48596	 8197	13622	KLF1	Protein	4930518C09Rik	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
49176	 8197	 2975	KLF1	Protein	PARVG	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
  498	 8197	16088	KLF1	Protein	GPX4	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
 5032	 8197	 4899	KLF1	Protein	DARC	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
51415	 8197	11635	KLF1	Protein	DHCR24	mRNA	1	1	15923635	up
51656	 8197	14103	KLF1	Protein	PGAM1	mRNA	1	1	15923635	up
52621	 8197	  183	KLF1	Protein	MGST3	mRNA	0	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
52764	 8197	10375	KLF1	Protein	CD24	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
52857	 8197	12924	KLF1	Protein	HOXB3	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
53532	 8197	15124	KLF1	Protein	FANCD2	mRNA	-1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
53544	 8197	 8374	KLF1	Protein	SNCA	mRNA	-1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 5407	 8197	 2117	KLF1	Protein	1190001M18Rik	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
54110	 8197	 9035	KLF1	Protein	TSPO	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
54789	 8197	 9800	KLF1	Protein	ZBTB7A	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
54918	 8197	12609	KLF1	Protein	HMBS	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
55416	 8197	16991	KLF1	Protein	PPP1R15A	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
55490	 8197	 9154	KLF1	Protein	MSI2	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
56470	 8197	  121	KLF1	Protein	F2R	mRNA	-1	1	15923635	up
57221	 8197	13524	KLF1	Protein	Daf2	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
57377	 8197	17981	KLF1	Protein	FECH	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
57782	 8197	 9065	KLF1	Protein	KLF3	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
57817	 8197	11093	KLF1	Protein	ETNK1	mRNA	1	1	15923635	up
58177	 8197	 2846	KLF1	Protein	ESRP2	mRNA	-1	-1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
 5847	 8197	 1659	KLF1	Protein	GLIPR2	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
59625	 8197	17722	KLF1	Protein	ARRB1	mRNA	0	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
 5986	 8197	17357	KLF1	Protein	ICAM4	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
60453	 8197	10649	KLF1	Protein	ACVRL1	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
60584	 8197	19275	KLF1	Protein	MTSS1	mRNA	1	1	15923635	up
60907	 8197	15700	KLF1	Protein	PRDX2	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
61589	 8197	 2859	KLF1	Protein	UROD	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
61786	 8197	 1730	KLF1	Protein	KLF10	mRNA	1	1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
62008	 8197	 2608	KLF1	Protein	HBB	mRNA	1	1	11287616	The erythroid cell-specific transcription factor erythroid Kruppel-like factor (EKLF) is an important activator of beta-globin gene expression.
62045	 8197	14329	KLF1	Protein	TRAF5	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
62183	 8197	16399	KLF1	Protein	BRK1	mRNA	1	1	15923635	up
62217	 8197	 8131	KLF1	Protein	RARA	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
63434	 8197	 6972	KLF1	Protein	TATDN3	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
63808	 8197	 3825	KLF1	Protein	SLC22A4	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
64319	 8197	 9066	KLF1	Protein	LMO2	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
65484	 8197	 7048	KLF1	Protein	HERC2	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
65492	 8197	11697	KLF1	Protein	Zfy1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
65517	 8197	 2685	KLF1	Protein	ROBO3	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
65620	 8197	 6557	KLF1	Protein	ALAS1	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
65871	 8197	 5698	KLF1	Protein	KLF8	mRNA	1	1	18687676	Here we show that Bklf or Klf3 (Basic Kr??ppel-like factor) represses the Klf8 (Kr??ppel-like Factor 8) gene in vivo. Conversely, Eklf or Klf1 (Erythroid Kr??ppel-like factor) activates the Klf8 gene. Klf8 is driven by two promoters, both of which contain multiple CACCC sites. Klf3 can repress Klf1-mediated activation of both promoters
65907	 8197	 5005	KLF1	Protein	GMPR	mRNA	1	1	15923635	up
66179	 8197	 4110	KLF1	Protein	RHD	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
66224	 8197	 6460	KLF1	Protein	FAM198B	mRNA	-1	-1	16380451	See Table 3. ELKF-dependent genes in the fetal liver.
66364	 8197	 7914	KLF1	Protein	ANXA5	mRNA	0	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 6773	 8197	 8280	KLF1	Protein	DGAT1	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
  679	 8197	 4116	KLF1	Protein	GLI3	mRNA	0	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 6921	 8197	19936	KLF1	Protein	TMED8	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 7127	 8197	20140	KLF1	Protein	KEL	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
 7141	 8197	12795	KLF1	Protein	TUFT1	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 7234	 8197	16823	KLF1	Protein	ALAS2	mRNA	1	1	10773455	Putative binding sites for the erythroid-specific nuclear factors GATA-1, NF-E2, and EKLF were identified within the first 300bp region of the mouse ALAS2 5p-flanking region
 7277	 8197	16053	KLF1	Protein	PKLR	mRNA	-1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 7654	 8197	 7875	KLF1	Protein	IFIT3	mRNA	1	1	15923635	TABLE 1. Genes that are differentially expressed in the absence of EKLF down
 7780	 8197	16231	KLF1	Protein	CD47	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
  861	 8197	  759	KLF1	Protein	ST3GAL6	mRNA	-1	-1	16380451	Table 3. EKLF-dependent genes in the fetal liver
 9000	 8197	20218	KLF1	Protein	KLHDC3	mRNA	-1	1	15923635	up
 9586	 8197	 6338	KLF1	Protein	3110006O06Rik	mRNA	1	1	16380451	Table 3. EKLF-dependent genes in the fetal liver
10089	 2109	 7502	TP63	Protein	STAR	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
10614	 2109	 4100	TP63	Protein	SERPINB5	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 1109	 2109	  231	TP63	Protein	SMARCD3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
11341	 2109	12918	TP63	Protein	S100A2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
  115	 2109	 8755	TP63	Protein	GDF15	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
11755	 2109	 3530	TP63	Protein	DYRK2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
11907	 2109	12994	TP63	Protein	DDR1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
12890	 2109	 5762	TP63	Protein	DHRS3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
13200	 2109	  264	TP63	Protein	MN1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
  142	 2109	  440	TP63	Protein	POU3F1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
14288	 2109	 2461	TP63	Protein	AHNAK2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
14889	 2109	14770	TP63	Protein	RHOB	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
16603	 2109	17445	TP63	Protein	COL13A1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 1711	 2109	12783	TP63	Protein	VSNL1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
17636	 2109	15680	TP63	Protein	BIK	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
17970	 2109	  467	TP63	Protein	ALDH1A3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
  183	 2109	15417	TP63	Protein	TP53I3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
19367	 2109	15659	TP63	Protein	CDH3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
19817	 2109	17054	TP63	Protein	PPL	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
20394	 2109	11175	TP63	Protein	GAMT	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
20397	 2109	 1252	TP63	Protein	GPRC5B	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
20751	 2109	 6161	TP63	Protein	MFHAS1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
20763	 2109	 4461	TP63	Protein	ACTA2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
21140	 2109	18938	TP63	Protein	T	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
21257	 2109	15957	TP63	Protein	PTPN3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
21712	 2109	 3547	TP63	Protein	ITGB2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 2335	 2109	 8319	TP63	Protein	C1orf21	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
24153	 2109	10547	TP63	Protein	LCAT	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
24177	 2109	 9854	TP63	Protein	PLAT	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 2419	 2109	 6662	TP63	Protein	FGFR2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
25405	 2109	 5754	TP63	Protein	HSD17B1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
25406	 2109	 7264	TP63	Protein	EVPL	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
26634	 2109	 7434	TP63	Protein	GPX2	mRNA	0	1	16446369	Here, we found that GPX2, which encodes a glutathione peroxidase, is up-regulated by p63 but not p53. Accordingly, a unique responsive element was found in the promoter of the GPX2 gene that can be activated and bound by p63 but not p53.
26648	 2109	17632	TP63	Protein	NRCAM	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
28016	 2109	13496	TP63	Protein	TSPAN4	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
28047	 2109	15719	TP63	Protein	CD70	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
28285	 2109	 6449	TP63	Protein	CFLAR	mRNA	1	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
28808	 2109	18525	TP63	Protein	JAG2	mRNA	0	1	11641404	We found that the Jagged1 (JAG1) and Jagged2 (JAG2) genes, encoding ligands for the Notch receptors, are up-regulated by p63 and p73.
29233	 2109	18120	TP63	Protein	NGFR	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
30083	 2109	13156	TP63	Protein	ARL4C	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
31981	 2109	14994	TP63	Protein	IGFBP7	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
32957	 2109	 4891	TP63	Protein	LAMP3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
33108	 2109	 5703	TP63	Protein	ITGA2B	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
33198	 2109	15802	TP63	Protein	TOB2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
34068	 2109	16017	TP63	Protein	TNNC2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
34799	 2109	18651	TP63	Protein	INPP5D	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
34949	 2109	 4739	TP63	Protein	PDLIM7	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
35474	 2109	18531	TP63	Protein	ICAM1	mRNA	0	1	15126418	In vitro studies using two human TEC lines demonstrated that p63 was capable of up-regulating intercellular adhesion molecule-1 (ICAM-1) and enhancing the production of IL-6 and IL-8.
 3564	 2109	11752	TP63	Protein	WNT4	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
36183	 2109	  340	TP63	Protein	SDC1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
36237	 2109	 9322	TP63	Protein	FGF1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
36506	 2109	11438	TP63	Protein	DFFB	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
37294	 2109	19646	TP63	Protein	ANXA8L2	mRNA	1	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 3791	 2109	16001	TP63	Protein	CEL	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
38817	 2109	18626	TP63	Protein	MAST4	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
38878	 2109	11848	TP63	Protein	ZP3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
39311	 2109	11174	TP63	Protein	CX3CL1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
39753	 2109	13618	TP63	Protein	NEFM	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
41943	 2109	12326	TP63	Protein	SP110	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
42497	 2109	10258	TP63	Protein	STX6	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
42504	 2109	 5033	TP63	Protein	KIAA0284	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
43046	 2109	20205	TP63	Protein	RAP1GAP	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
43095	 2109	18619	TP63	Protein	PRICKLE3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
43319	 2109	 2544	TP63	Protein	CRIP2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
43620	 2109	 3234	TP63	Protein	PRODH	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
43791	 2109	  555	TP63	Protein	PDPN	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
44262	 2109	20106	TP63	Protein	NPTXR	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
44597	 2109	19711	TP63	Protein	GRIN2C	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
45635	 2109	 9324	TP63	Protein	MYOM2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 4761	 2109	15325	TP63	Protein	CSPG4	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
47634	 2109	18430	TP63	Protein	AXL	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
47935	 2109	 2629	TP63	Protein	SEPT5	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 4838	 2109	 4355	TP63	Protein	BBC3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
48559	 2109	14316	TP63	Protein	MERTK	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
48568	 2109	18949	TP63	Protein	IL4R	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 4935	 2109	10424	TP63	Protein	JAG1	mRNA	0	1	11641404	We found that the Jagged1 (JAG1) and Jagged2 (JAG2) genes, encoding ligands for the Notch receptors, are up-regulated by p63 and p73.
 4958	 2109	12073	TP63	Protein	IRF1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
49679	 2109	 6430	TP63	Protein	MDM2	mRNA	1	1	12374749	Here, we describe the identification of an HMG1-like protein SSRP1 as a co-activator of p63. Over expression of wild-type, but not deletion mutant, SSRP1 remarkably enhanced p63gamma-dependent luciferase activity, G(1) arrest, apoptosis and expression of endogenous PIG3, p21(Waf1/cip1) and MDM2 in human p53-deficient lung carcinoma H1299 cells and mouse embryonic fibroblasts.
49834	 2109	 8218	TP63	Protein	GAS2L1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
51060	 2109	13884	TP63	Protein	CDKN1A	mRNA	1	1	16007146	e show that the interaction of p63 with PML increases the levels of p63 in cultured cells as well as its ability to transactivate the p53-responsive elements of the GADD45, p21 and bax promoters.
51860	 2109	 8337	TP63	Protein	PTX3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
52590	 2109	 2944	TP63	Protein	RALGPS1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
52652	 2109	  695	TP63	Protein	FDXR	mRNA	0	1	12370809	Here, we identified FDXR as a target gene of the p53 family, that is, p53, p63, and p73. We found that FDXR can be induced by DNA damage in cells in a p53-dependent manner and by a mutated form of p53 that is competent in inducing apoptosis. In addition, we identified a p53 response element located within the FDXR promoter that is responsive to wild-type p53, p63alpha, p63gamma, p73alpha, and p73beta.
52675	 2109	10310	TP63	Protein	GLS2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
53030	 2109	  391	TP63	Protein	NT5E	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
53045	 2109	 2506	TP63	Protein	ARID5A	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
53615	 2109	14381	TP63	Protein	KCNK3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
53635	 2109	 8671	TP63	Protein	RHOC	mRNA	-1	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
55259	 2109	 6598	TP63	Protein	AMPH	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
55343	 2109	13713	TP63	Protein	CDC42EP4	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
55511	 2109	11893	TP63	Protein	C11orf9	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
56181	 2109	18720	TP63	Protein	AHNAK	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
56261	 2109	11760	TP63	Protein	SECTM1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
56305	 2109	 7679	TP63	Protein	COL17A1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
56613	 2109	18149	TP63	Protein	FOXF1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
56650	 2109	16427	TP63	Protein	EFNA1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
57323	 2109	 4298	TP63	Protein	JUNB	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
57766	 2109	 9560	TP63	Protein	C4A	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
58032	 2109	11288	TP63	Protein	SORL1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
58068	 2109	18882	TP63	Protein	CTNNBIP1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
58275	 2109	12117	TP63	Protein	GGT1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
59313	 2109	   89	TP63	Protein	TRIOBP	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
59620	 2109	17598	TP63	Protein	TAP1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
59725	 2109	20041	TP63	Protein	SNCG	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
60861	 2109	17451	TP63	Protein	GATA2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
60892	 2109	17954	TP63	Protein	ITPKC	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
61330	 2109	 5615	TP63	Protein	NOTCH3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 6271	 2109	17147	TP63	Protein	FEZ1	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
62942	 2109	 7195	TP63	Protein	GADD45A	mRNA	-1	1	16007146	e show that the interaction of p63 with PML increases the levels of p63 in cultured cells as well as its ability to transactivate the p53-responsive elements of the GADD45, p21 and bax promoters.
63051	 2109	 2839	TP63	Protein	SFN	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
63250	 2109	11940	TP63	Protein	DSCR3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
63357	 2109	11721	TP63	Protein	PGF	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
64180	 2109	17556	TP63	Protein	FXYD2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
64194	 2109	 6765	TP63	Protein	C10orf10	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
64379	 2109	10877	TP63	Protein	PTGES	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 6446	 2109	19359	TP63	Protein	GAS6	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 6465	 2109	 1404	TP63	Protein	ABCB6	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
65448	 2109	 5899	TP63	Protein	IPO13	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
65481	 2109	16219	TP63	Protein	PROCR	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
65579	 2109	 4268	TP63	Protein	HSPG2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
66088	 2109	16821	TP63	Protein	DST	mRNA	1	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 6812	 2109	 7782	TP63	Protein	EPHB3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 6981	 2109	 9498	TP63	Protein	PLLP	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 7859	 2109	 6724	TP63	Protein	FUS	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 8188	 2109	14870	TP63	Protein	SRGAP3	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
  846	 2109	12082	TP63	Protein	ADRB2	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 8573	 2109	19313	TP63	Protein	GRN	mRNA	0	1	15988020	By using oligonucleotide expression microarray analysis and analyzing the promoters of p63-induced genes, we have identified novel p63-specific response elements (p63-REs) in the promoter regions of EVPL and SMARCD3. _ TABLE 1. List of genes induced over fourfold by TAp63y in 293 inducible cells
 9341	 2109	 8814	TP63	Protein	CDK1	mRNA	0	-1	11593387	Modified assertion
10567	  814	 4762	TFAP2A	Protein	BOK	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
12016	  814	13964	TFAP2A	Protein	PLTP	mRNA	0	1	11573953	Phospholipid transfer protein (PLTP) plays an important role in the metabolism of plasma high density lipoprotein. The mouse gene encoding PLTP and its promoter region has been cloned in our laboratory. The present study was conducted to functionally analyze the transcriptional regulation of the mouse PLTP gene. The results indicated that DNA sequences between -245 and -69 were responsible for the full promoter activity and binding motifs for transcription factor Sp1 and AP-2 within this functional promoter region were synergistically essential for the basal transcription. The transcriptional activity of this gene was significantly increased by chenodeoxycholic acid and fenofibrate, suggesting that transcription factor farnesoid X-activated receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) are likely involved in the transcriptional regulation. DNA sequence analysis suggests that DNA sequences from -407 to -395 and from -393 to -381 are homologous to the recognition motifs of FXR, and those from -859 to -847 and from -309 to -297 are similar to the potential binding motif for PPAR. These findings provide a molecular basis for further investigation of the physiological function and regulation of the PLTP gene in mice.
16463	  814	 3961	TFAP2A	Protein	EPHA7	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
17095	  814	20096	TFAP2A	Protein	RPL18	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
19752	  814	17245	TFAP2A	Protein	STX7	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
20749	  814	12091	TFAP2A	Protein	FXYD4	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
21328	  814	 2251	TFAP2A	Protein	BCMO1	mRNA	0	1	12759335	mouse Bcm gene and determination of its genomic organization, analysis of the 2 kb 5p-flanking region showed several putative transcription factor binding sites including TATA box, a peroxisome proliferator response element (PPRE), AP2, and bHLH...peroxisome proliferator activated receptor (PPAR) gamma (PPARgamma) specifically binds to this element...the PPRE element confers peroxisome proliferator responsiveness via the PPARgamma and retinoid X receptor-alpha heterodimer.
  219	  814	16238	TFAP2A	Protein	PSAP	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
21942	  814	 5932	TFAP2A	Protein	RCHY1	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
24401	  814	  678	TFAP2A	Protein	GRPEL1	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
24770	  814	 6016	TFAP2A	Protein	RPLP0	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
32102	  814	 8057	TFAP2A	Protein	Ly6a	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
33283	  814	11730	TFAP2A	Protein	BRPF1	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
33410	  814	13601	TFAP2A	Protein	BLCAP	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
39551	  814	 2556	TFAP2A	Protein	MCTS1	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
41074	  814	11216	TFAP2A	Protein	ST3GAL5	mRNA	0	1	15890474	Sp1 and AP2 enhance the basal activity of the TATA-less mouse GM3-synthase promoter.
41086	  814	11896	TFAP2A	Protein	MCM5	mRNA	1	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
45210	  814	17757	TFAP2A	Protein	PABPN1	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
45942	  814	14984	TFAP2A	Protein	RPL6	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
46289	  814	10963	TFAP2A	Protein	ANXA1	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
46628	  814	 8117	TFAP2A	Protein	UBA52	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
47566	  814	11595	TFAP2A	Protein	TMBIM6	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
49221	  814	 5739	TFAP2A	Protein	OLFML3	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
50779	  814	12393	TFAP2A	Protein	GPX3	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
51059	  814	13884	TFAP2A	Protein	CDKN1A	mRNA	1	1	 9473523	AP-2 activates expression of positive and negative growth regulators including erbB-2 and p21 WAF1/CIP1.
 5377	  814	 6553	TFAP2A	Protein	SNAP23	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
54942	  814	13891	TFAP2A	Protein	C18orf32	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
55880	  814	 5857	TFAP2A	Protein	BHLHE40	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
60686	  814	12361	TFAP2A	Protein	PITX2	mRNA	0	1	15475956	Cited2(-/-) mice lack expression of the Nodal target genes Pitx2c, Nodal and Ebaf in the left lateral plate mesoderm, where they are required for establishing laterality and cardiovascular development. CITED2 and TFAP2 were detected at the Pitx2c promoter in embryonic hearts, and they activate Pitx2c transcription in transient transfection assays
62281	  814	 7185	TFAP2A	Protein	ILKAP	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
63192	  814	 1376	TFAP2A	Protein	PSMC2	mRNA	0	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
63224	  814	  460	TFAP2A	Protein	SEPP1	mRNA	1	1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
 6324	  814	 2632	TFAP2A	Protein	Prl8a2	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
 7204	  814	 9120	TFAP2A	Protein	RPS5	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
 8801	  814	 1900	TFAP2A	Protein	PRDX1	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
 9065	  814	 4970	TFAP2A	Protein	KLF4	mRNA	0	-1	11741941	By using a subtractive cloning approach, we identified a set of genes repressed by AP-2 alpha Clones found in the screen for genes induced and repressed are shown.
16853	 6509	19220	HOXC8	Protein	MSLN	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
18091	 6509	  284	HOXC8	Protein	CXCL10	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
19363	 6509	15995	HOXC8	Protein	Ly6f	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
19662	 6509	16486	HOXC8	Protein	SPP1	mRNA	1	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
20776	 6509	 4461	HOXC8	Protein	ACTA2	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
24573	 6509	 2720	HOXC8	Protein	TAGLN	mRNA	-1	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
24920	 6509	 8988	HOXC8	Protein	ADAM19	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
28889	 6509	 8621	HOXC8	Protein	NQO1	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
32103	 6509	 8057	HOXC8	Protein	Ly6a	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
35336	 6509	 9354	HOXC8	Protein	PLAGL1	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
 3600	 6509	11498	HOXC8	Protein	FZD2	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
39462	 6509	16138	HOXC8	Protein	SRD5A2	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
39478	 6509	14512	HOXC8	Protein	KRT19	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
39501	 6509	12420	HOXC8	Protein	FAM43A	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
44459	 6509	13271	HOXC8	Protein	CCL2	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
45028	 6509	 1183	HOXC8	Protein	CNN1	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
45197	 6509	 4005	HOXC8	Protein	CDH11	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
46400	 6509	 8012	HOXC8	Protein	EMB	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
47968	 6509	18673	HOXC8	Protein	SLC16A1	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
48546	 6509	 8745	HOXC8	Protein	HES2	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
49115	 6509	  532	HOXC8	Protein	ELMO1	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
51137	 6509	17647	HOXC8	Protein	Eif2s3y	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
51660	 6509	14103	HOXC8	Protein	PGAM1	mRNA	1	1	12974468	Although Hox genes are known to mediate developmental decisions involved in pattern formation during embryogenesis, it is still not well understood what Hox regulates. In order to analyze Hoxc8 downstream target genes, a stable cell line overexpressing Hoxc8 was established using F9 murine teratocarcinoma cells, proteom samples were analyzed by 2-DE, and compared with controls. The protein spots having differences more than 4 fold in intensity were selected, analyzed by MALDI-TOF, and grouped in terms of putative function; cytoskeleton and motility (vimentin, gamma-actin, tropomyosin, and tubulin beta-5 chain); folding, modification and degradation of protein (GRP78, proteasome subunit alpha type 5, 26S proteasome regulatory subunit p27 protein, and PDIR); metabolism (ATP synthase beta subunit, Pgam1, and CAII); transcription/translation factors and general nucleic acid binding proteins (RbAp46, PCNA, eEF-1-beta, and nucleophosmin). Although it may not be significant, 50% of the genes were located on chromosomes 2 and 3, suggesting the possibility of a non-random distribution of Hox downstream genes. Almost 50% of the genes analyzed showed some relation with Hox protein directly or indirectly; i.e., tubulin beta 5, EF-1 beta and PCNA have been reported to contain putative Hox binding regulatory sites and genes like vimentin, pgam1 and nucleophosmin to be regulated by RA, a potent modulator of Hox expression. These results altogether imply that proteom analysis could be a possible tool for the analysis of the potent Hox realizator genes, which provides a new insight into the function of Hox on pattern formation during embryogenesis.
53421	 6509	10145	HOXC8	Protein	HOXC6	mRNA	0	-1	12829790	Ariadne: It is likely that HOXC6 expression is increased in these experiments because  HOXC8 represses HOXC6
54153	 6509	15639	HOXC8	Protein	ANKRD1	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
 5613	 6509	14864	HOXC8	Protein	GREM2	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
 6024	 6509	12258	HOXC8	Protein	PMP22	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
60952	 6509	19999	HOXC8	Protein	NCAM1	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
61220	 6509	 5969	HOXC8	Protein	GAS1	mRNA	-1	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
63040	 6509	 6905	HOXC8	Protein	Ly6c1	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
63942	 6509	16893	HOXC8	Protein	SERPINF1	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
63971	 6509	 5950	HOXC8	Protein	CCL7	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
64468	 6509	15063	HOXC8	Protein	ASS1	mRNA	0	-1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
66090	 6509	16821	HOXC8	Protein	DST	mRNA	1	1	10504454	It is, in particular, noteworthy that En2, which represses the BPAG1e promoter in human keratinocytes, has the opposite activating effect in fibroblasts and neuroepithelial cells. Hoxc-8 and Hoxa-5, also repressors in keratinocytes, activate BPAG1e promoter activity in COS-7 and CHP-100 cells, respectively.
 7683	 6509	13893	HOXC8	Protein	IL1R2	mRNA	0	1	15699330	Table 2. Table of genes deregulated by overexpression of Hoxc8 in C57BL6J MEF cell lines
42923	16044	15885	GABPB2	Protein	ACTB	mRNA	1	1	 9512469	Double-point mutant analysis indicated a major role for the NRF2/GABP site in the enhancer capacity of this element in brown fat cells. It is proposed that NRF2/GABP plays a pivotal role in the co-ordinated enhancement of OXPHOS gene expression associated with mitochondrial biogenesis in brown adipocyte differentiation.
10102	16420	 7502	progesterone	Compound	STAR	mRNA	0	-1	14630719	Progesterone, dexamethasone, and estradiol also inhibited StAR mRNA expression
10707	16420	 8772	progesterone	Compound	SLC1A5	mRNA	0	-1	15845616	downregulated
11191	16420	12191	progesterone	Compound	BASP1	mRNA	0	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
11280	16420	16177	progesterone	Compound	EMP1	mRNA	0	-1	15845616	downregulated
12115	16420	 3493	progesterone	Compound	Clca3	mRNA	0	-1	15845616	downregulated
12417	16420	14299	progesterone	Compound	MT1X	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
12738	16420	13434	progesterone	Compound	HIF1A	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
13478	16420	11457	progesterone	Compound	KCNK1	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
14086	16420	14961	progesterone	Compound	CEBPD	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
14296	16420	16808	progesterone	Compound	ACSL1	mRNA	0	-1	15845616	downregulated
14695	16420	14183	progesterone	Compound	ATP1A1	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
14712	16420	 6105	progesterone	Compound	IL13RA2	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
14732	16420	 1917	progesterone	Compound	STOM	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
15486	16420	18775	progesterone	Compound	PFKFB3	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
15504	16420	 2075	progesterone	Compound	HSD11B2	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
16943	16420	19193	progesterone	Compound	MT2A	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
16983	16420	 2821	progesterone	Compound	SLC16A2	mRNA	0	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
17556	16420	17756	progesterone	Compound	RCN1	mRNA	0	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
17925	16420	  661	progesterone	Compound	UGCG	mRNA	0	-1	15845616	downregulated
18099	16420	12982	progesterone	Compound	ATP6V1B2	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
19595	16420	 5712	progesterone	Compound	BCL6	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
19955	16420	 5757	progesterone	Compound	ADIPOQ	mRNA	0	-1	15845616	downregulated
20242	16420	 9277	progesterone	Compound	CD1D	mRNA	0	-1	15845616	downregulated
21748	16420	16093	progesterone	Compound	C18orf1	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
 2177	16420	 4631	progesterone	Compound	CALB1	mRNA	0	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
21906	16420	 3995	progesterone	Compound	ESR1	mRNA	-1	1	15329476	Treatment with progesterone (P4) resulted in the induction of CaBP-9k mRNA, and a co-treatment with estrogen (E2) plus P4 evoked a synergic effect on its mRNA level in this tissue. translation of CaBP-9k protein was enhanced by E2, while no difference was observed at the transcriptional level. E2 stimulated the expression levels of ERalpha and PR mRNAs and P4 inhibited the expression of these transcripts at an early time point (12 h) and increased them at 24 and 48 h
23020	16420	14746	progesterone	Compound	RAB11FIP5	mRNA	0	-1	15845616	downregulated
23924	16420	 5783	progesterone	Compound	CEBPB	mRNA	0	-1	15845616	downregulated
 2413	16420	 6662	progesterone	Compound	FGFR2	mRNA	0	-1	15845616	downregulated
27295	16420	 4800	progesterone	Compound	CTSF	mRNA	0	-1	15845616	downregulated
 2777	16420	  908	progesterone	Compound	MMP9	mRNA	0	-1	15520195	Zymographic analysis revealed that Pg drastically inhibited matrix metalloproteinase-9
27808	16420	13773	progesterone	Compound	PIP5K1B	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
28346	16420	14168	progesterone	Compound	ANKH	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
28759	16420	19012	progesterone	Compound	EFNB2	mRNA	0	-1	15845616	downregulated
 2892	16420	 9955	progesterone	Compound	TIAM1	mRNA	0	-1	15845616	downregulated
 2950	16420	 2015	progesterone	Compound	BMP2K	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
30077	16420	18445	progesterone	Compound	PLA2G7	mRNA	0	-1	15845616	downregulated
30085	16420	13156	progesterone	Compound	ARL4C	mRNA	0	-1	15845616	downregulated
 3143	16420	16645	progesterone	Compound	CCND1	mRNA	0	-1	12021176	The information below is from table 3 [SH]
33625	16420	 6887	progesterone	Compound	RBP4	mRNA	0	-1	15845616	downregulated
34453	16420	18225	progesterone	Compound	NCAPH	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
34744	16420	 3135	progesterone	Compound	NPL	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
  352	16420	 2541	progesterone	Compound	ZBTB16	mRNA	0	1	12970399	induction of PLZF mRNA in primary cultures of human endometrial stromal cells and myometrial smooth muscle cells (SMC) in response to progesterone. Surprisingly, dexamethasone was a more potent inducer of PLZF expression than progesterone
35233	16420	 5296	progesterone	Compound	PLAU	mRNA	1	-1	14519645	Table 1 Progesterone-regulated genes in the PRAB-36 cell line
35306	16420	13085	progesterone	Compound	HMGA2	mRNA	-1	-1	15845616	downregulated
36128	16420	19126	progesterone	Compound	FAM3C	mRNA	0	-1	15845616	downregulated
36833	16420	 8934	progesterone	Compound	PPM1B	mRNA	0	-1	15845616	downregulated
39189	16420	 5234	progesterone	Compound	PDK3	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
 3928	16420	18724	progesterone	Compound	KRT7	mRNA	0	-1	15845616	downregulated
39435	16420	 3880	progesterone	Compound	INMT	mRNA	0	-1	15845616	downregulated
39459	16420	 5113	progesterone	Compound	PLIN4	mRNA	0	-1	15845616	downregulated
40247	16420	11058	progesterone	Compound	LTF	mRNA	0	-1	15845616	downregulated
 4086	16420	 1959	progesterone	Compound	BCAT1	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
40951	16420	 4582	progesterone	Compound	NOS3	mRNA	1	1	14588184	Modified assertion
 4106	16420	 7628	progesterone	Compound	P4HA2	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
42282	16420	16433	progesterone	Compound	CD44	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
42329	16420	   74	progesterone	Compound	GGTA1P	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
42457	16420	13544	progesterone	Compound	AGTR1	mRNA	0	1	16675453	For example, Ang II (8), cAMP stimulating agents (9), and estrogens (10, 11) decrease rat AT1AR expression by stimulating rat AT1AR mRNA decay. In contrast, insulin (12), low density lipoprotein (13), and progesterone (11) up-regulate receptor expression by decreasing AT1AR mRNA decay rates. Additionally, rat AT1AR expression is regulated by translational mechanisms via cytosolic proteins that interact with the 5p-UTR of the receptor mRNA (10, 1418).
42580	16420	15039	progesterone	Compound	P2RX4	mRNA	0	-1	12021176	The information below is from table 3 [SH]
44162	16420	 6531	progesterone	Compound	CCNE1	mRNA	0	1	NA	Progesterone modulates the mammary epithelial cell cycle both by inducing the synthesis of cyclinE and CDC25A phosphatase and by triggering the degradation of p27Kip1
45296	16420	   33	progesterone	Compound	TACSTD2	mRNA	0	-1	15845616	downregulated
45557	16420	 8788	progesterone	Compound	GPAM	mRNA	0	-1	15845616	downregulated
45695	16420	 8412	progesterone	Compound	LGALS1	mRNA	0	1	 9291476	Galectin-1 gene expression increased from 12 hr and stayed at a high level until 48 hr after progesterone treatment.
45762	16420	13308	progesterone	Compound	HOXA11	mRNA	0	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
46370	16420	 4142	progesterone	Compound	CALCA	mRNA	0	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
46397	16420	 8012	progesterone	Compound	EMB	mRNA	0	-1	15845616	downregulated
46616	16420	11865	progesterone	Compound	CA2	mRNA	0	-1	15845616	downregulated
48118	16420	13471	progesterone	Compound	BIRC5	mRNA	0	-1	10705995	mRNA levels of survivin and the metastatic variant CD44 v7-v10 were also down- regulated.
49381	16420	10569	progesterone	Compound	GPSM2	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
50928	16420	 6827	progesterone	Compound	AREG	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
51297	16420	13755	progesterone	Compound	PNKD	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
51462	16420	15451	progesterone	Compound	CKMT1B	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
51602	16420	 5673	progesterone	Compound	ID1	mRNA	0	-1	15520195	Pg was able to counterbalance the stimulatory effect of estrogen or serum on proliferation and on expression level of Id-1, which generally stimulates cell proliferation and inhibits differentiation.
52367	16420	14057	progesterone	Compound	CYP2E1	mRNA	0	-1	15845616	downregulated
52376	16420	 5697	progesterone	Compound	PDLIM1	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
53975	16420	11581	progesterone	Compound	ITGB1	mRNA	1	1	14519645	Table 1 Progesterone-regulated genes in the PRAB-36 cell line
 5444	16420	10230	progesterone	Compound	F3	mRNA	0	-1	15845616	downregulated
55357	16420	 4481	progesterone	Compound	COL5A2	mRNA	1	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
55867	16420	 5857	progesterone	Compound	BHLHE40	mRNA	0	-1	15845616	downregulated
56132	16420	10811	progesterone	Compound	FN1	mRNA	-1	1	11861043	Modified assertion
56175	16420	17528	progesterone	Compound	HOPX	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
56273	16420	 5196	progesterone	Compound	GJB2	mRNA	0	-1	15845616	downregulated
56467	16420	  121	progesterone	Compound	F2R	mRNA	-1	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
56593	16420	20113	progesterone	Compound	CP	mRNA	0	-1	15845616	downregulated
56648	16420	16427	progesterone	Compound	EFNA1	mRNA	0	-1	15845616	downregulated
56697	16420	14237	progesterone	Compound	WFDC2	mRNA	0	-1	15845616	downregulated
57191	16420	11966	progesterone	Compound	TSPAN8	mRNA	0	-1	15845616	downregulated
57202	16420	15910	progesterone	Compound	TGFBI	mRNA	0	-1	15845616	downregulated
57368	16420	10643	progesterone	Compound	Scd1	mRNA	0	-1	15845616	downregulated
57466	16420	 6644	progesterone	Compound	HUNK	mRNA	0	1	11003847	Modified assertion
57746	16420	 5786	progesterone	Compound	TGFB3	mRNA	0	1	11861043	Modified assertion
58002	16420	16330	progesterone	Compound	CLDN5	mRNA	0	-1	15845616	downregulated
58260	16420	 5398	progesterone	Compound	FUT9	mRNA	0	-1	15845616	downregulated
59427	16420	 2652	progesterone	Compound	ADAMDEC1	mRNA	0	-1	15845616	downregulated
59562	16420	12930	progesterone	Compound	OXTR	mRNA	0	-1	10333543	Modified assertion
59647	16420	19255	progesterone	Compound	EGR2	mRNA	0	1	11750070	PROG triggered a quick (visible as soon as 15 min), strong (6 to 18-fold) and transient (1-2 h) stimulation of Egr-1, Egr-2, Egr-3 and Fos B genes expression
59739	16420	 5494	progesterone	Compound	LPIN1	mRNA	0	-1	15845616	downregulated
59857	16420	  254	progesterone	Compound	RBP1	mRNA	0	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
60305	16420	16684	progesterone	Compound	CYP26A1	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
60395	16420	10103	progesterone	Compound	PRR15L	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
60866	16420	17451	progesterone	Compound	GATA2	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
61449	16420	11512	progesterone	Compound	PRNP	mRNA	0	-1	15845616	downregulated
61544	16420	 6777	progesterone	Compound	XDH	mRNA	0	-1	15845616	downregulated
62119	16420	 2407	progesterone	Compound	FAM65B	mRNA	0	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
62640	16420	16911	progesterone	Compound	LIFR	mRNA	0	-1	15845616	downregulated
62678	16420	 6280	progesterone	Compound	GABARAPL1	mRNA	0	-1	15845616	downregulated
62882	16420	13448	progesterone	Compound	CA3	mRNA	0	-1	15845616	downregulated
63202	16420	 2769	progesterone	Compound	LGR5	mRNA	0	-1	15845616	downregulated
63267	16420	17277	progesterone	Compound	G6PD	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
63887	16420	12543	progesterone	Compound	IGFBP1	mRNA	-1	1	 7523316	Modified assertion
64159	16420	19660	progesterone	Compound	SEC23B	mRNA	0	1	15845616	TABLE 4. The list of genes significantly increased and decreased uterine genes by chronic P4 treatment upregulated
65901	16420	 7341	progesterone	Compound	SMPDL3A	mRNA	0	-1	15845616	downregulated
 7172	16420	17272	progesterone	Compound	Klk1	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
 8043	16420	 3371	progesterone	Compound	Klk1b5	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
  878	16420	 6958	progesterone	Compound	ZDHHC3	mRNA	0	1	15845616	TABLE 3. The list of uterine genes significantly increased and decreased by acute P4 treatment upregulated
 8840	16420	17568	progesterone	Compound	NBL1	mRNA	0	-1	15845616	downregulated
 9067	16420	 4970	progesterone	Compound	KLF4	mRNA	0	1	16157482	Progesterone (P4) is an essential reproductive steroid hormone required for many aspects of female reproductive physiology. Progestins are compounds that demonstrate progesterone-like activity and are used in oral contraception, hormone therapy, and treatment of some reproductive disorders, but differ widely in their chemical structures, potency, and pharmacokinetics. While numerous studies have assessed progestins on specific endpoints, little is known about the activation of global gene expression by progestins. We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines. Excluding drospirenone, one or more of the progestins-regulated 329 genes, with 30 genes regulated by at least 2.0-fold by all progestins in the T47Dco cells. The synthetic progestins show a high degree of similarity in their transcriptional responses, and each progestin regulates between 77 and 91% of the genes regulated by P4. Independent quantitative RT-PCR analysis confirmed a similar regulation for S100P, PPL, IL20RA, NET1, ATP1A1, HIG2, and CXCL12 (SDF-1) by all seven progestins. Attempts to find differentially regulated genes by any progestin compared to all other treatments failed, suggesting any differences are quantitative, not qualitative. This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action.
10661	17311	 3198	angiotensin II	Compound	TFRC	mRNA	-1	1	15126644	from free full text Table
19687	17311	16486	angiotensin II	Compound	SPP1	mRNA	1	1	14597759	Angiotensin II infusion resulted in significant increase of osteopontin mRNA. A 2.8 fold increase was observed.
  229	17311	19043	angiotensin II	Compound	PINK1	mRNA	-1	-1	15126644	from free full text Table
23312	17311	 7455	angiotensin II	Compound	CTSB	mRNA	0	1	15242839	Table 2. Differentially expressed genes identified by SAGE
23680	17311	 3777	angiotensin II	Compound	Hbb-y	mRNA	1	1	15242839	Table 2. Differentially expressed genes identified by SAGE
28253	17311	 7832	angiotensin II	Compound	THBS1	mRNA	-1	1	15126644	from free full text Table
32837	17311	12649	angiotensin II	Compound	ETS1	mRNA	1	1	16138193	Ets-1 expression was assessed by quantitative RT-PCR. Ets-1 expression was significantly increased in the aorta as a result of Ang II infusion (Figure ?(Figure1A).1A).  Figure 1 In vivo induction of Ets-1 in response to Ang II and altered vascular remodeling in Ets1?/? mice. (B) Immunohistochemical analysis of Ets-1 expression after infusion of Ang II for 2 weeks in C57BL/6 mice compared with sham-treated controls. L, lumen. Original magnification, 200.
51088	17311	13884	angiotensin II	Compound	CDKN1A	mRNA	1	1	16908765	Northern blot analysis revealed that aortic expression of p21 was markedly elevated by treatment with Ang II (Figure 3C).
52767	17311	10375	angiotensin II	Compound	CD24	mRNA	1	1	15126644	from free full text Table
55232	17311	12981	angiotensin II	Compound	COL3A1	mRNA	-1	1	15242839	Table 2. Differentially expressed genes identified by SAGE
55573	17311	 9732	angiotensin II	Compound	KLF5	mRNA	0	1	12101409	angiotensin II induced expression of KLF5, which in turn activated platelet-derived growth factor-A (PDGF-A) and transforming growth factor-beta (TGF-beta) expression.
56147	17311	10811	angiotensin II	Compound	FN1	mRNA	-1	1	15242839	Table 2. Differentially expressed genes identified by SAGE
12255	12283	 3207	phenylalanine	Compound	MPO	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
13453	12283	16612	phenylalanine	Compound	MMP13	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
16047	12283	 1471	phenylalanine	Compound	COL1A2	mRNA	-1	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
16789	12283	20225	phenylalanine	Compound	Lyz1	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
17949	12283	 8261	phenylalanine	Compound	MS4A3	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
  256	12283	 3441	phenylalanine	Compound	Ngp	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
26425	12283	 7766	phenylalanine	Compound	Igha	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
38167	12283	 1765	phenylalanine	Compound	CELA2A	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
48572	12283	11797	phenylalanine	Compound	CAMP	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
 6904	12283	 2204	phenylalanine	Compound	COL1A1	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
  699	12283	 6565	phenylalanine	Compound	Bglap-rs1	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
 8123	12283	 4659	phenylalanine	Compound	Mrgpra1	mRNA	0	1	16150627	Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair...Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin alpha heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3).
10107	 8464	 7502	Calcium	Compound	STAR	mRNA	0	1	15666812	Ang II-stimulated StAR transcription in H295R cells is dependent upon both influx of external Ca2+ and tyrosine kinase signaling and is enhanced by protein kinase C and mitogen-activated protein kinase (ERK1/2) activation. In particular, Janus tyrosine kinase-2 (Jak2) activation was increased with Ang-II treatment of H295R cells
14444	 8464	13598	Calcium	Compound	CD14	mRNA	0	1	11034352	Because LPS stimulation upregulates CD14 and TLR4 expression, it was necessary to control for the possibility that these newly expressed molecules were associated with one another independent of LPS stimulation. Although the calcium ionophore A23187 increased the expression of CD14 and TLR4, they did not exhibit energy transfer. However, following A23187 treatment, LPS promoted physical proximity between CD14 and TLR4. Therefore, we suggest that a close interaction between CD14 and TLR4 participates in LPS signaling, leading to nuclear translocation of NF-kappaB.
17708	 8464	10918	Calcium	Compound	AMIGO2	mRNA	0	1	12843293	Overexpression of Ali1 in cerebellar granule neurons inhibited apoptosis that was induced by the medium containing 5 mm KCl. The addition of anti-Ali1 antiserum or the soluble putative extracellular Ali1 domain to the 25 mm KCl-supported culture inhibited the survival of the granule neuron
19691	 8464	16486	Calcium	Compound	SPP1	mRNA	1	1	11703581	Parathyroid hormone, vitamin D(3), calcium, phosphate and some cytokines increase OPN expression in vitro or in vivo, whereas female sex hormones and angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists decrease OPN expression in some renal damage states.
20425	 8464	12150	Calcium	Compound	SDF2L1	mRNA	0	1	11162531	In a murine hepatocellular carcinoma cell line, Sdf2l1 was strongly induced by tunicamycin and a calcium ionophore, A23187, and weakly induced by heat stress but was not induced by cycloheximide.
22048	 8464	16639	Calcium	Compound	ANGPT2	mRNA	0	1	11139469	Ang II significantly induced Ang2 mRNA accumulations without affecting Ang1 or Tie2 expression, which was inhibited by protein kinase C inhibitors and by intracellular Ca(2+) chelating agents.
25466	 8464	 5701	Calcium	Compound	ID3	mRNA	0	1	12087069	GKLF induction by H-Fe is mediated through hydroxyl radicals, p38MAP kinase-, calcium-, and protein synthesis-dependent pathways.
27639	 8464	12781	Calcium	Compound	AR	mRNA	1	-1	 7720667	Cycloheximide and actinomycin D were unable to change the calcium-mediated decrease in AR mRNA, ruling out the necessity for de novo protein synthesis or a change in mRNA stability.
28728	 8464	 3434	Calcium	Compound	IVL	mRNA	0	1	11500521	Modified assertion
 3192	 8464	16645	Calcium	Compound	CCND1	mRNA	0	1	10604659	Ca(2+)-store depletion caused an increased expression of p21 and p27 proteins (cyclin-dependent kinase inhibitors), with unchanged mutant p53 protein of C6 cells but reduced amounts of the cell cycle regulators: cyclin-dependent kinase 2 (CDK2), cdc2, cyclin C, cyclin D1, cyclin D3 and proliferating cell nuclear antigen (PCNA) in a time-dependent manner
34480	 8464	 3920	Calcium	Compound	DHX32	mRNA	0	1	16414036	Ionomycin treatment alone was sufficient to upregulate the expression of DHX32 mRNA isoform transcribed from the proximal promoter.
39571	 8464	13744	Calcium	Compound	CDKN1B	mRNA	-1	-1	10604659	Ca(2+)-store depletion caused an increased expression of p21 and p27 proteins (cyclin-dependent kinase inhibitors), with unchanged mutant p53 protein of C6 cells but reduced amounts of the cell cycle regulators: cyclin-dependent kinase 2 (CDK2), cdc2, cyclin C, cyclin D1, cyclin D3 and proliferating cell nuclear antigen (PCNA) in a time-dependent manner
40261	 8464	16388	Calcium	Compound	GFAP	mRNA	0	-1	10604659	intracellular Ca2+ pump inhibitors, thapsigargin (TG) irreversibly and 2,5-ditert-butyl-hydroquinone (DBHQ) reversibly depleted the Ca(2+)-store accompanied with the induction of G0/G1 arrest, an increase in glial fibrillary acidic protein (GFAP) expression
42797	 8464	17953	Calcium	Compound	S100A7	mRNA	0	1	15740587	both S100A7 and S100A9 were shown to be induced in normal primary keratinocytes (HEKn), when differentiation was promoted by high extracellular calcium, loss of contact with extracellular matrix and confluent conditions,
42936	 8464	15885	Calcium	Compound	ACTB	mRNA	1	1	 8183567	Transcription of the cytoskeletal beta-actin gene is rapidly induced by phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore, A23187, in cultured H4IIE hepatoma (H4) cells.
44235	 8464	 9200	Calcium	Compound	PCNA	mRNA	0	1	10604659	Ca(2+)-store depletion caused an increased expression of p21 and p27 proteins (cyclin-dependent kinase inhibitors), with unchanged mutant p53 protein of C6 cells but reduced amounts of the cell cycle regulators: cyclin-dependent kinase 2 (CDK2), cdc2, cyclin C, cyclin D1, cyclin D3 and proliferating cell nuclear antigen (PCNA) in a time-dependent manner
44495	 8464	10804	Calcium	Compound	CYCS	mRNA	-1	1	12205177	Increases in sarcoplasm Ca2+ concentrations are associated with increases in Ca2+-calmodulin-dependent protein kinase activity (Ojuka et al. 2002), which have been shown to increase PGC-1 and cytochrome c protein expression (Wu et al. 2002).
45240	 8464	12221	Calcium	Compound	MMP19	mRNA	0	-1	12937269	basal keratinocytes constitutively expresses MMP-19, down-regulated the expression of MMP-19 at high calcium concentrations
47815	 8464	10326	Calcium	Compound	CCND3	mRNA	0	1	10604659	Ca(2+)-store depletion caused an increased expression of p21 and p27 proteins (cyclin-dependent kinase inhibitors), with unchanged mutant p53 protein of C6 cells but reduced amounts of the cell cycle regulators: cyclin-dependent kinase 2 (CDK2), cdc2, cyclin C, cyclin D1, cyclin D3 and proliferating cell nuclear antigen (PCNA) in a time-dependent manner
48520	 8464	 2627	Calcium	Compound	CDK2	mRNA	0	1	10604659	Ca(2+)-store depletion caused an increased expression of p21 and p27 proteins (cyclin-dependent kinase inhibitors), with unchanged mutant p53 protein of C6 cells but reduced amounts of the cell cycle regulators: cyclin-dependent kinase 2 (CDK2), cdc2, cyclin C, cyclin D1, cyclin D3 and proliferating cell nuclear antigen (PCNA) in a time-dependent manner
50051	 8464	 6917	Calcium	Compound	CCK	mRNA	0	1	11713982	Recent studies have examined the signaling pathways, transcription factors and regulatory elements involved in cAMP, fibroblast growth factor-2, and calcium-induced CCK gene transcription in neuronal cells.
51094	 8464	13884	Calcium	Compound	CDKN1A	mRNA	1	-1	10604659	Ca(2+)-store depletion caused an increased expression of p21 and p27 proteins (cyclin-dependent kinase inhibitors), with unchanged mutant p53 protein of C6 cells but reduced amounts of the cell cycle regulators: cyclin-dependent kinase 2 (CDK2), cdc2, cyclin C, cyclin D1, cyclin D3 and proliferating cell nuclear antigen (PCNA) in a time-dependent manner
54169	 8464	11214	Calcium	Compound	PRDX5	mRNA	0	1	12522579	By reverse Northern analysis, 13 genes were scored as overexpressed in these HaCaT cells. Northern blot analysis was used to confirm differential gene expression. Six genes, keratin 1, plasminogen activator inhibitor type 2 (PAI-2), ferritin H, peroxiredoxin 5 (PRDX5), insulin-like growth factor binding protein-3 (IGFBP-3), and one EST gene, were differentially expressed in HaCaT cells cultured in the presence of a high calcium concentration.
56234	 8464	15199	Calcium	Compound	BDNF	mRNA	0	1	11775072	The expression of brain-derived neurotrophic factor (BDNF) mRNA is induced by neuronal activity through increased intracellular calcium.
56240	 8464	11111	Calcium	Compound	MT1G	mRNA	0	1	15735762	E2Fs 1-5 could bind to the hMT1G promoter in a chromatin immunoprecipitation assay. VEGF stimulation led to an increased binding of E2Fs 1-3 to the endogenous hMT1G promoter; Induction of the hMT1G promoter upon exposure to heavy metals such as Zn and Cd is mediated by the MRE.
 5869	 8464	 6797	Calcium	Compound	NRN1	mRNA	0	1	14664806	We report that cpg15 is an immediate-early gene induced by Ca(2+) influx through NMDA receptors and L-type voltage-sensitive calcium channels.
58885	 8464	 5635	Calcium	Compound	SERPINB2	mRNA	0	1	12522579	By reverse Northern analysis, 13 genes were scored as overexpressed in these HaCaT cells. Northern blot analysis was used to confirm differential gene expression. Six genes, keratin 1, plasminogen activator inhibitor type 2 (PAI-2), ferritin H, peroxiredoxin 5 (PRDX5), insulin-like growth factor binding protein-3 (IGFBP-3), and one EST gene, were differentially expressed in HaCaT cells cultured in the presence of a high calcium concentration.
60175	 8464	10658	Calcium	Compound	CCNC	mRNA	0	1	10604659	Ca(2+)-store depletion caused an increased expression of p21 and p27 proteins (cyclin-dependent kinase inhibitors), with unchanged mutant p53 protein of C6 cells but reduced amounts of the cell cycle regulators: cyclin-dependent kinase 2 (CDK2), cdc2, cyclin C, cyclin D1, cyclin D3 and proliferating cell nuclear antigen (PCNA) in a time-dependent manner
60919	 8464	 5794	Calcium	Compound	PTH	mRNA	0	-1	14633989	An increase in extracellular calcium enhances the level of acetylated APE1 which acts as a repressor for the PTH promoter
62134	 8464	 1645	Calcium	Compound	KRT1	mRNA	0	1	12522579	By reverse Northern analysis, 13 genes were scored as overexpressed in these HaCaT cells. Northern blot analysis was used to confirm differential gene expression. Six genes, keratin 1, plasminogen activator inhibitor type 2 (PAI-2), ferritin H, peroxiredoxin 5 (PRDX5), insulin-like growth factor binding protein-3 (IGFBP-3), and one EST gene, were differentially expressed in HaCaT cells cultured in the presence of a high calcium concentration.
62610	 8464	 4925	Calcium	Compound	IGFBP3	mRNA	0	1	12522579	By reverse Northern analysis, 13 genes were scored as overexpressed in these HaCaT cells. Northern blot analysis was used to confirm differential gene expression. Six genes, keratin 1, plasminogen activator inhibitor type 2 (PAI-2), ferritin H, peroxiredoxin 5 (PRDX5), insulin-like growth factor binding protein-3 (IGFBP-3), and one EST gene, were differentially expressed in HaCaT cells cultured in the presence of a high calcium concentration.
62829	 8464	  127	Calcium	Compound	UHRF1	mRNA	0	-1	15964557	ICBP90 expression was strongly decreased after TCR triggering concomitantly to cyclin D3 and topoisomerase IIalpha expression decreases. Cell stimulation with PMA and/or calcium ionophore A23187 down-regulated ICBP90 expression.
66195	 8464	16011	Calcium	Compound	GPC1	mRNA	0	-1	12135485	FSH, through its second messengers (increase in intracellular cAMP and intracellular calcium), downregulated the glypican-1 mRNA expression in Sertoli cells from 20-day-old rats.
 7693	 8464	 2455	Calcium	Compound	MYH2	mRNA	0	1	12235157	Downstream mediators of these effects are the activities of the MEF-2 and NFAT transcription factors, whose binding sites in the MyHC IIa promoter are required for calcium-induced activation of the MyHC IIa promoter.
 7905	 8464	19902	Calcium	Compound	ACHE	mRNA	0	1	12805285	_ Ariadne: In confirmation of the linkage of P2Y1 receptor activation in the muscle cells to PKC ( Fig. 1 A ), the application of PKC inhibitors staurosporine (Sp) and chelerythrine chloride (ChCl) significantly reduced the P2Y1 receptor-mediated AChE gene activation. [Regulation] The pathway to activation of the AChE gene was shown to involve protein kinase C and intracellular Ca 2+ release.
 9343	 8464	 8814	Calcium	Compound	CDK1	mRNA	0	1	10604659	Ca(2+)-store depletion caused an increased expression of p21 and p27 proteins (cyclin-dependent kinase inhibitors), with unchanged mutant p53 protein of C6 cells but reduced amounts of the cell cycle regulators: cyclin-dependent kinase 2 (CDK2), cdc2, cyclin C, cyclin D1, cyclin D3 and proliferating cell nuclear antigen (PCNA) in a time-dependent manner
 9460	 8464	 5556	Calcium	Compound	SP1	mRNA	0	1	11864971	Substantially elevated levels of nuclear Sp1 was observed in keratinocytes stimulated with Ca2+.
13454	   73	16612	TAF4	Protein	MMP13	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
19718	   73	16486	TAF4	Protein	SPP1	mRNA	1	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
20168	   73	18631	TAF4	Protein	TAF13	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
23789	   73	 6636	TAF4	Protein	BCL2L1	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
25433	   73	19185	TAF4	Protein	FIGF	mRNA	0	1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
28223	   73	 7832	TAF4	Protein	THBS1	mRNA	-1	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
 3034	   73	13473	TAF4	Protein	HBEGF	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
36335	   73	 1868	TAF4	Protein	PDGFC	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
37368	   73	 9189	TAF4	Protein	MMP2	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
40812	   73	13739	TAF4	Protein	CTGF	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
43487	   73	10899	TAF4	Protein	TGFB1	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
45196	   73	 4005	TAF4	Protein	CDH11	mRNA	0	1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
47986	   73	 4684	TAF4	Protein	IFIT1	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
53057	   73	16278	TAF4	Protein	ID2	mRNA	0	1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
60969	   73	 2450	TAF4	Protein	ITGA6	mRNA	-1	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
62631	   73	  844	TAF4	Protein	VAV3	mRNA	0	-1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
 6445	   73	19359	TAF4	Protein	GAS6	mRNA	0	1	16015375	Figure 5 Changes in gene expression in taf4-/- cells
14969	12370	 3861	Oxidized Low Density LipoProtein	Compound	TIMP2	mRNA	0	-1	17084825	In addition, oxLDL modulates gene expression in macrophage-derived foam cells [24]. Pro-inflammatory genes such as interleukin-8 (IL-8) are upregulated whereas tissue inhibitors of metalloproteinases (TIMPs) are downregulated. Furthermore,
16868	12370	18255	Oxidized Low Density LipoProtein	Compound	VCL	mRNA	-1	1	12716483	In order to gain a more comprehensive overview of the response of endothelial cells to ox-LDL, we determined the expression profile of selected families of genes known to play a role in molecular models of atherosclerosis. The f indings obtained by the cDNA arrays were confirmed by using reverse transcriptionpolymerase chain reaction (RT-PCR) as an independent technique. TABLE 2. GENES DIFFERENTIALLY EXPRESSED BY HUVEC
17217	12370	16024	Oxidized Low Density LipoProtein	Compound	CD5L	mRNA	0	1	12897189	The regulation of AIM via LXR/RXR suggested that incorporation of oxLDL that yields oxysterols, the native ligands of LXR, may also upregulate AIM expression in macrophages.  As expected, incubation of macrophages with oxLDL, but not native LDL, resulted in a significant increase of AIM (cd5l) mRNA.
19651	12370	16486	Oxidized Low Density LipoProtein	Compound	SPP1	mRNA	1	1	17343848	Table 2 Differential gene expression analysis identified by Oligo Atherosclerosis Microarrays
20835	12370	12908	Oxidized Low Density LipoProtein	Compound	ENO1	mRNA	1	-1	12324707	RDA was used to study differential gene expression in macrophage-like cells (PMA-stimulated THP-1 cells) and foam-cell-like cells (PMA-stimulated and oxLDL-exposed THP-1 cells). A modified solid-phase representational difference analysis (RDA) protocol was used [7] in combination with DNA microarray analysis and reverse transcriptase PCR (RT-PCR) for evaluation. Array analysis was performed using a scanner (GMS418 Array Scanner, Genetic MicroSystems, USA) and the GenePixPro 3.0 software (Axon Instruments, USA). For data the level of significance was set to a 2-fold relative difference between samples after background subtraction.
 2225	12370	 5419	Oxidized Low Density LipoProtein	Compound	TNF	mRNA	0	1	21281677	OxLDL bound to the mouse reporter cell line RAW-Blue induced TNF-?? and RANTES mRNA and protein expression.
 2490	12370	17889	Oxidized Low Density LipoProtein	Compound	SLC2A4	mRNA	1	1	12716483	In order to gain a more comprehensive overview of the response of endothelial cells to ox-LDL, we determined the expression profile of selected families of genes known to play a role in molecular models of atherosclerosis. The f indings obtained by the cDNA arrays were confirmed by using reverse transcriptionpolymerase chain reaction (RT-PCR) as an independent technique. TABLE 2. GENES DIFFERENTIALLY EXPRESSED BY HUVEC
25489	12370	11591	Oxidized Low Density LipoProtein	Compound	NR4A3	mRNA	0	1	16945922	NOR1 expression is induced by oxidized low density lipoprotein in macrophages (27)
 2898	12370	 4252	Oxidized Low Density LipoProtein	Compound	ABCA1	mRNA	0	1	19494317	We tested this hypothesis and, as shown in Fig. 8, lack of macrophage CXCL16 significantly decreased oxLDL-induced up-regulation of ABCA1 (Fig. 8A), ABCG1 (Fig. 8B), and apoE (Fig. 8C) mRNA.
32893	12370	14012	Oxidized Low Density LipoProtein	Compound	SRXN1	mRNA	0	1	18597759	Table 4 -Genes uniquely regulated by oxLDL.
36759	12370	 3532	Oxidized Low Density LipoProtein	Compound	NR4A2	mRNA	0	1	15964844	Treatment of macrophages with lipopolysaccharide (LPS), cytokines, or oxidized lipids triggers the transcriptional induction of Nur77 (NR4A1), Nurr1 (NR4A2), and NOR1 (NR4A3) expression.
38932	12370	  337	Oxidized Low Density LipoProtein	Compound	IL3	mRNA	1	1	17343848	Table 2 Differential gene expression analysis identified by Oligo Atherosclerosis Microarrays
39938	12370	 6114	Oxidized Low Density LipoProtein	Compound	NFKBIA	mRNA	1	1	16083882	Table 3: Genes differentially expressed by macrophages from FH subjects TX+ compared to TX- in response to oxLDL stimulation. 6 FH patients TX and with oxLDL addition (pool TX/oxLDL+); 8 FH patients TX+ and with oxLDL addition (pool TX+/oxLDL+) were prepared. Overall, 9036 probe sets (40.6%) were expressed in macrophages from FH patients TX+ (identified as present by MAS 5.0 software), and 9886 probe sets (44.4%) in macrophages from FH patients TX. Using the MAS 5.0 software criteria for statistical significance, 310 probe sets were identified as increased and 799 probe sets as decreased, in macrophages from FH patients TX+, defining the pool FH TX/oxLDL+ as baseline. We filtered genes according to criteria described in Section 2 to identify genes that are likely to be differentially expressed in macrophages from FH patients TX+ after oxLDL incubation. Thirty seven probe sets met these criteria (Table 3): 33 upregulated and 4 downregulated, and corresponded to 29 genes and 1 EST: 26 genes upregulated, and 1 EST and 3 genes downregulated.  Significance level was defined as P < 0.05. Fold change was computed using the one-step Tukeys Biweight method. All fold change values >1.9. __Genes that are regulated by oxLDL treatment in patients with tendon xanthomas have been modeled.  The absence of this regulation in the absence of TX was not captured. - AV__
 4096	12370	 9978	Oxidized Low Density LipoProtein	Compound	GNAI2	mRNA	1	-1	12324707	RDA was used to study differential gene expression in macrophage-like cells (PMA-stimulated THP-1 cells) and foam-cell-like cells (PMA-stimulated and oxLDL-exposed THP-1 cells). A modified solid-phase representational difference analysis (RDA) protocol was used [7] in combination with DNA microarray analysis and reverse transcriptase PCR (RT-PCR) for evaluation. Array analysis was performed using a scanner (GMS418 Array Scanner, Genetic MicroSystems, USA) and the GenePixPro 3.0 software (Axon Instruments, USA). For data the level of significance was set to a 2-fold relative difference between samples after background subtraction.
44756	12370	 4862	Oxidized Low Density LipoProtein	Compound	PDGFA	mRNA	-1	1	 1510670	Exposure of human smooth muscle cells with LDL (100 micro g cholesterol/mL) caused a 4-8 fold increase in PDGF-A levels. The maximal level was found after 8 hour of LDL-incubation. However, addition of BHT, an antioxidant, caused no significant increase in PDGFA mRNA, indicating that oxidative modification of LDL is required for modulating PDGFA transcript levels.
45384	12370	14987	Oxidized Low Density LipoProtein	Compound	BCL2	mRNA	1	1	17343848	Table 2 Differential gene expression analysis identified by Oligo Atherosclerosis Microarrays
  454	12370	14844	Oxidized Low Density LipoProtein	Compound	ACTG1	mRNA	-1	-1	12324707	RDA was used to study differential gene expression in macrophage-like cells (PMA-stimulated THP-1 cells) and foam-cell-like cells (PMA-stimulated and oxLDL-exposed THP-1 cells). A modified solid-phase representational difference analysis (RDA) protocol was used [7] in combination with DNA microarray analysis and reverse transcriptase PCR (RT-PCR) for evaluation. Array analysis was performed using a scanner (GMS418 Array Scanner, Genetic MicroSystems, USA) and the GenePixPro 3.0 software (Axon Instruments, USA). For data the level of significance was set to a 2-fold relative difference between samples after background subtraction.
49879	12370	15228	Oxidized Low Density LipoProtein	Compound	TIMP3	mRNA	0	-1	17084825	In addition, oxLDL modulates gene expression in macrophage-derived foam cells [24]. Pro-inflammatory genes such as interleukin-8 (IL-8) are upregulated whereas tissue inhibitors of metalloproteinases (TIMPs) are downregulated. Furthermore,
50189	12370	 8138	Oxidized Low Density LipoProtein	Compound	NRP1	mRNA	-1	1	12716483	In order to gain a more comprehensive overview of the response of endothelial cells to ox-LDL, we determined the expression profile of selected families of genes known to play a role in molecular models of atherosclerosis. The f indings obtained by the cDNA arrays were confirmed by using reverse transcriptionpolymerase chain reaction (RT-PCR) as an independent technique. TABLE 2. GENES DIFFERENTIALLY EXPRESSED BY HUVEC
57253	12370	 3616	Oxidized Low Density LipoProtein	Compound	CD40	mRNA	0	1	12637341	incubation of HCAECs with ox-LDL (20 to 80 ?g/mL) increased the expression of CD40 (mRNA and protein) in a concentration- and time-dependent manner (Figure 1). Incubation of HCAECs with ox-LDL (20 to 80 ?g/mL) also increased the expression of CD40L (mRNA and protein) in a concentration- and time-dependent manner (Figure 2).
60031	12370	12976	Oxidized Low Density LipoProtein	Compound	IL8	mRNA	0	1	17084825	In addition, oxLDL modulates gene expression in macrophage-derived foam cells [24]. Pro-inflammatory genes such as interleukin-8 (IL-8) are upregulated whereas tissue inhibitors of metalloproteinases (TIMPs) are downregulated. Furthermore,
62210	12370	 8131	Oxidized Low Density LipoProtein	Compound	RARA	mRNA	0	1	17000557	Macrophages obtained from healthy blood donors were treated with native and oxidized LDL for 3 days and altered gene expression was detected using the cDNA microarray method. The genes that showed at least a 2-fold up- or down-regulation according to the ratio of time-matched oxidized lipoprotein to native lipoprotein-treated cells were selected for statistical analysis.
64284	12370	17081	Oxidized Low Density LipoProtein	Compound	LGALS3	mRNA	0	1	12788225	Murine resident peritoneal macrophages loaded with acetylated low-density lipoprotein (AcLDL) or oxidized LDL (OxLDL) showed increased galectin-3 protein and mRNA
66358	12370	 7914	Oxidized Low Density LipoProtein	Compound	ANXA5	mRNA	0	1	17000557	Macrophages obtained from healthy blood donors were treated with native and oxidized LDL for 3 days and altered gene expression was detected using the cDNA microarray method. The genes that showed at least a 2-fold up- or down-regulation according to the ratio of time-matched oxidized lipoprotein to native lipoprotein-treated cells were selected for statistical analysis.
 6778	12370	 2988	Oxidized Low Density LipoProtein	Compound	TLR4	mRNA	0	1	11748108	Furthermore, basal TLR-4 mRNA expression by human monocyte-derived macrophages was upregulated by ox-LDL in vitro.
 7445	12370	11420	Oxidized Low Density LipoProtein	Compound	MIF	mRNA	0	1	12829188	Ariadne: Ox-VLDL was found to induce interleukin-15 (2.10+/-0.48) and macrophage migration inhibitory factor (3.19+/-0.07) expression.
  839	12370	 1146	Oxidized Low Density LipoProtein	Compound	GCLC	mRNA	0	1	20185790	Furthermore, mRNAs encoding ATF4 and classic electrophilic genes GCLM and GCLC were upregulated by oxidized (but not native) low-density lipoprotein (Supplemental Figure IIA through IIC), and this elevation was suppressed by siRNA NRF2 (Figure 2C).
11320	15552	11102	reactive oxygen species	Compound	SELE	mRNA	0	1	12869663	The hereby generated CO has now been postulated to take over the role of NO under oxidative conditions (Foresti and Motterlini, 1999).  Pro-inflammatory mediators, like TNF- and heme, activate the transcription factors NF-B, AP-1, and SP-1 signaling pathways via the formation of ROS, which may result in the transcriptional activation of several genes involved in inflammation, such as ICAM-1, VCAM-1, and selectins (Lavrovsky et al., 1994; Shono et al., 1996).
 1321	15552	19951	reactive oxygen species	Compound	HAMP	mRNA	0	-1	17349976	ROS levels were significantly elevated in hypoxic HepG2 cells, and anti-oxidants prevented the hypoxic down-regulation of hepcidin. Conversely, a prooxidant, H(2)O(2), suppressed hepcidin expression in these cells even in normoxia.
16058	15552	 1471	reactive oxygen species	Compound	COL1A2	mRNA	-1	1	10770928	The ability of ethanol and arachidonic acid (AA), as inducers of oxidative stress and key factors in alcoholic liver disease, to up-regulate alpha 2 collagen type I (COL1A2) gene expression was studied in a hepatic stellate cell line overexpressing the ethanol-inducible cytochrome P450 2E1 (CYP2E1) (E5 cells). A time- and dose-dependent induction in COL1A2 mRNA by ethanol or AA was observed that was prevented by diallylsulfide, a CYP2E1 inhibitor.
16210	15552	 2348	reactive oxygen species	Compound	THBS2	mRNA	0	1	12861025	Moreover, TSP2 induction by Rac(V12) is dependent upon reactive oxygen species (ROS) production, as gp91ds-tat peptide, an inhibitor of NADPH oxidase, and the flavoprotein inhibitor diphenylene iodinium (DPI) block TSP2 synthesis.
19672	15552	16486	reactive oxygen species	Compound	SPP1	mRNA	1	1	16528250	increases in OPN gene expression in diabetic rat RPTs and IRPTCs are mediated, at least in part, via reactive oxygen species generation, intrarenal rennin-angiotensin system activation, TGF-beta1 expression, and PKC-beta1 signaling.
20546	15552	 6218	reactive oxygen species	Compound	VCAM1	mRNA	0	1	12869663	The hereby generated CO has now been postulated to take over the role of NO under oxidative conditions (Foresti and Motterlini, 1999).  Pro-inflammatory mediators, like TNF- and heme, activate the transcription factors NF-B, AP-1, and SP-1 signaling pathways via the formation of ROS, which may result in the transcriptional activation of several genes involved in inflammation, such as ICAM-1, VCAM-1, and selectins (Lavrovsky et al., 1994; Shono et al., 1996).
21357	15552	10792	reactive oxygen species	Compound	PON1	mRNA	0	-1	15607899	PON1 expression is downregulated by oxidative stress. In contrast, more recent studies have shown that PON2 expression is upregulated in response to oxidative stress-inducing agents
 2554	15552	  326	reactive oxygen species	Compound	TXNIP	mRNA	0	1	14766217	The vitamin D3 up-regulated protein 1 (VDUP1) is identified as interacting protein with thioredoxin (TRX) and functions as a natural antagonist of TRX. Its expression is regulated by various stresses including ROS, UV, and heat shock
27443	15552	 5919	reactive oxygen species	Compound	MMP1	mRNA	0	1	12119354	We show here the transient activation of the small GTPase Rac, followed by a rise in reactive oxygen species (ROS), as necessary early steps in a signal transduction cascade that lead to NFkappaB activation and collagenase-1 (CL-1)/matrix metalloproteinase-1 production after integrin-mediated cell shape changes.
29264	15552	15496	reactive oxygen species	Compound	GAPDH	mRNA	0	1	11295360	Microsequencing analysis revealed that these HPRPs corresponded to at least six pairs of proteins. Of these, four pairs of HPRPs were thioredoxin peroxidase I (TPx I), TPx II, TPx III, and the product of human ORF06, all of which belong to the peroxiredoxin (Prx) family and all of which are involved in the elimination of hydroperoxides. The other two pairs corresponded to heat shock protein 27 (HSP27) and glyceraldehyde-3-phosphate dehydrogenase (G3PDH), respectively.
29566	15552	13348	reactive oxygen species	Compound	VIM	mRNA	0	1	15124904	We analyzed the profiles of newly synthesized proteins by GA with 2-dimensional gel electrophoresis and MALDI-TOF MS and found that two families of proteins were expressed by GA. One was similar to the protein family synthesized by heat shock (Hsp70, Hsp73, Hsp65, Hsp90, vimentin, tubulin, Ras homolog); and the other was a family of protein specific to GA (calreticulin, annexin III, thioredoxin peroxidase).
33074	15552	17390	reactive oxygen species	Compound	DUSP2	mRNA	0	1	12673251	PAC1 transcription is induced in response to serum deprivation and oxidative stress, which results in p53-dependent apoptosis
33601	15552	 3700	reactive oxygen species	Compound	EPHX1	mRNA	0	1	16710476	Notably, the transcription factor nuclear factor (erythroid derived 2) like 2 (Nfe2l2), as well as numerous oxidative stress response genes (Aldh1a1, Aldh1a7, Adh1, Ephx1, Ephx2), glutathione-S-transferase isotypes (Gsta1, Gsta3, Gstm6, Mgst1, Gstm2, Gstm3), and glutamate-cysteine ligase (Gclc), a regulator of glutathione metabolism (31), showed significant overexpression in the Met KO hepatocytes
35132	15552	  372	reactive oxygen species	Compound	ADH1A	mRNA	0	1	16710476	Notably, the transcription factor nuclear factor (erythroid derived 2) like 2 (Nfe2l2), as well as numerous oxidative stress response genes (Aldh1a1, Aldh1a7, Adh1, Ephx1, Ephx2), glutathione-S-transferase isotypes (Gsta1, Gsta3, Gstm6, Mgst1, Gstm2, Gstm3), and glutamate-cysteine ligase (Gclc), a regulator of glutathione metabolism (31), showed significant overexpression in the Met KO hepatocytes
35242	15552	 5296	reactive oxygen species	Compound	PLAU	mRNA	1	1	11519039	Ariadne: Here, we provide evidence that ROS-generating anthracycline antibiotics, including doxorubicin and aclarubicin, upregulate uPA expression in 2 human malignant cell lines, RC-K8 and H69 small-cell lung-carcinoma cells.
36226	15552	 8092	reactive oxygen species	Compound	ANXA3	mRNA	0	1	15124904	We analyzed the profiles of newly synthesized proteins by GA with 2-dimensional gel electrophoresis and MALDI-TOF MS and found that two families of proteins were expressed by GA. One was similar to the protein family synthesized by heat shock (Hsp70, Hsp73, Hsp65, Hsp90, vimentin, tubulin, Ras homolog); and the other was a family of protein specific to GA (calreticulin, annexin III, thioredoxin peroxidase).
37541	15552	 6614	reactive oxygen species	Compound	HSPA1B	mRNA	0	1	15124904	We analyzed the profiles of newly synthesized proteins by GA with 2-dimensional gel electrophoresis and MALDI-TOF MS and found that two families of proteins were expressed by GA. One was similar to the protein family synthesized by heat shock (Hsp70, Hsp73, Hsp65, Hsp90, vimentin, tubulin, Ras homolog); and the other was a family of protein specific to GA (calreticulin, annexin III, thioredoxin peroxidase).
39364	15552	18612	reactive oxygen species	Compound	SOD2	mRNA	-1	1	16424123	No alterations were seen in either aortic Mn SOD, Cu/Zn SOD, or biliverdin reductase protein levels, all proteins upregulated by oxidative stress (31-34)
40043	15552	 2507	reactive oxygen species	Compound	SAFB	mRNA	0	1	11295360	Microsequencing analysis revealed that these HPRPs corresponded to at least six pairs of proteins. Of these, four pairs of HPRPs were thioredoxin peroxidase I (TPx I), TPx II, TPx III, and the product of human ORF06, all of which belong to the peroxiredoxin (Prx) family and all of which are involved in the elimination of hydroperoxides. The other two pairs corresponded to heat shock protein 27 (HSP27) and glyceraldehyde-3-phosphate dehydrogenase (G3PDH), respectively.
41013	15552	 3809	reactive oxygen species	Compound	HSPA8	mRNA	0	1	15124904	We analyzed the profiles of newly synthesized proteins by GA with 2-dimensional gel electrophoresis and MALDI-TOF MS and found that two families of proteins were expressed by GA. One was similar to the protein family synthesized by heat shock (Hsp70, Hsp73, Hsp65, Hsp90, vimentin, tubulin, Ras homolog); and the other was a family of protein specific to GA (calreticulin, annexin III, thioredoxin peroxidase).
42822	15552	 3879	reactive oxygen species	Compound	FAS	mRNA	0	1	10711676	tBH treatment of hRPE cells resulted in increased expression of FasL and Fas. Glutathione and NAC completely abrogated tBH-induced increase in FasL and Fas expression
42889	15552	 7577	reactive oxygen species	Compound	HSP90AA1	mRNA	0	1	11231909	H 2 O 2 stimulated  expression of both HSP70 (Figure 5 ) and HSP90 (data not shown)
 4309	15552	19709	reactive oxygen species	Compound	RGS2	mRNA	0	1	11488592	H2O2 increased RGS2 mRNA levels time- and concentration-dependently
46056	15552	15021	reactive oxygen species	Compound	CALR	mRNA	0	1	15124904	We analyzed the profiles of newly synthesized proteins by GA with 2-dimensional gel electrophoresis and MALDI-TOF MS and found that two families of proteins were expressed by GA. One was similar to the protein family synthesized by heat shock (Hsp70, Hsp73, Hsp65, Hsp90, vimentin, tubulin, Ras homolog); and the other was a family of protein specific to GA (calreticulin, annexin III, thioredoxin peroxidase).
 4974	15552	12073	reactive oxygen species	Compound	IRF1	mRNA	0	1	19443641	Taken together, these data suggest that IRF-1 gene activation by reactive oxygen species is an early signal that promotes inflammation after ischemic renal injury.
50133	15552	 6224	reactive oxygen species	Compound	PRDX6	mRNA	0	1	12851211	These data indicate that the antioxidant enzyme 1-cysPrx is induced in lung cells by oxidative stress.
51208	15552	12831	reactive oxygen species	Compound	EPHX2	mRNA	0	1	16710476	Notably, the transcription factor nuclear factor (erythroid derived 2) like 2 (Nfe2l2), as well as numerous oxidative stress response genes (Aldh1a1, Aldh1a7, Adh1, Ephx1, Ephx2), glutathione-S-transferase isotypes (Gsta1, Gsta3, Gstm6, Mgst1, Gstm2, Gstm3), and glutamate-cysteine ligase (Gclc), a regulator of glutathione metabolism (31), showed significant overexpression in the Met KO hepatocytes
51221	15552	 6941	reactive oxygen species	Compound	TFAM	mRNA	0	1	16230352	In mitochondria-rich rat hepatoma cells that overexpress NRF-1, basal and oxidant-induced increases were found in Tfam expression and mtDNA content.
51478	15552	 7810	reactive oxygen species	Compound	ALDH1A1	mRNA	0	1	16710476	Notably, the transcription factor nuclear factor (erythroid derived 2) like 2 (Nfe2l2), as well as numerous oxidative stress response genes (Aldh1a1, Aldh1a7, Adh1, Ephx1, Ephx2), glutathione-S-transferase isotypes (Gsta1, Gsta3, Gstm6, Mgst1, Gstm2, Gstm3), and glutamate-cysteine ligase (Gclc), a regulator of glutathione metabolism (31), showed significant overexpression in the Met KO hepatocytes
51681	15552	  219	reactive oxygen species	Compound	FASLG	mRNA	-1	1	12488132	Following exposure to 50-150 microM H2O2 levels of mRNA and protein for Fas and, to a lesser degree, Fas-L were increased and intestinal epithelial cells underwent apoptosis
53420	15552	16035	reactive oxygen species	Compound	IDH2	mRNA	0	1	11278619	IDPm is induced by ROS and that decreased expression of IDPm markedly elevates the ROS generation, DNA fragmentation, lipid peroxidation, and concurrent mitochondrial damage with a significant reduction in ATP level.
56135	15552	10811	reactive oxygen species	Compound	FN1	mRNA	-1	1	15086456	_ Ariadne: The present data demonstrate that high glucose increases cellular ROS in HPMC through activation of PKC, NADPH oxidase, and mitochondrial metabolism and that ROS, thus generated, up-regulate fibronectin expression by HPMC. [Expression]
57993	15552	18530	reactive oxygen species	Compound	PSIP1	mRNA	0	1	16403949	Lens epithelium-derived growth factor (LEDGF)/p75, a transcriptional protein, is inducible by oxidative stress and protects cells from various stresses by upregulating stress-responsive genes.
58379	15552	 6053	reactive oxygen species	Compound	CAT	mRNA	-1	1	 8762051	Because H2O2 is considered to play a major role in reperfusion injury to the heart, this study was undertaken to examine if H2O2 alters the expression of these enzymes in the rat neonatal myocytes. The results suggest that H2O2-induced expression of catalase was in part due to transcriptional activation.
58898	15552	10064	reactive oxygen species	Compound	SELP	mRNA	-1	1	11457873	In cultured endothelial cells, activation of GC-A augmented H2O2-induced P-selectin expression.
60052	15552	12976	reactive oxygen species	Compound	IL8	mRNA	0	1	17220369	We preincubated cells with a ROS scavenger, nPG (100 M); this preincubation significantly reduced PMA-induced IL-8 gene expression (Fig. 5B)
60901	15552	15700	reactive oxygen species	Compound	PRDX2	mRNA	1	1	11295360	Microsequencing analysis revealed that these HPRPs corresponded to at least six pairs of proteins. Of these, four pairs of HPRPs were thioredoxin peroxidase I (TPx I), TPx II, TPx III, and the product of human ORF06, all of which belong to the peroxiredoxin (Prx) family and all of which are involved in the elimination of hydroperoxides. The other two pairs corresponded to heat shock protein 27 (HSP27) and glyceraldehyde-3-phosphate dehydrogenase (G3PDH), respectively.
 6472	15552	12489	reactive oxygen species	Compound	ERCC5	mRNA	-1	1	17207589	Exposure of human pulmonary epithelial cells (A549) to non-toxic doses of 100muM H(2)O(2) indeed showed a 2 to 4.5-fold increase in expression of XPA, XPC, ERCC4, and ERCC5, whereas the expression of ERCC1 was 5-fold decreased.
66070	15552	 5646	reactive oxygen species	Compound	MT1A	mRNA	0	1	11230134	The proximal promoter of the mouse MT-I gene has two binding sites for USF (Carthew et al., 1987; Li et al., 1998). One site overlaps an antioxidant response element (ARE; Dalton et al., 1994). This composite element (USF/ARE) participates in oxidant induction of MT gene expression by stress and cadmium (Dalton et al., 1994; Li et al., 1998) and can regulate basal expression of the gene in cultured cells (Carthew et al., 1987; Dalton et al., 1994).
 8330	15552	 6202	reactive oxygen species	Compound	BTG1	mRNA	-1	1	16274887	oxidative stress caused by sulfur amino acid deficiency (SD) induces B cell translocation gene-1 (Btg-1), which belongs to the Apro family, in hepatocytes.
 8896	15552	14725	reactive oxygen species	Compound	PON2	mRNA	0	1	15607899	PON1 expression is downregulated by oxidative stress. In contrast, more recent studies have shown that PON2 expression is upregulated in response to oxidative stress-inducing agents
11249	 1802	19608	LPIN1	Protein	LEP	mRNA	0	1	10884287	leptin mRNA levels are reduced to 10% of normal in fld mice
14471	 1802	18103	LPIN1	Protein	LPL	mRNA	0	1	10884287	The lack of lipid accumulation in fld/fld adipose tissue could be attributed, in part, to a failure to induce expression of lipoprotein lipase and enzymes involved in fatty acid synthesis, such as fatty acid synthase and acetyl-CoA carboxylase.
 1614	 1802	 9722	LPIN1	Protein	CEBPA	mRNA	0	1	15123608	fld mice exhibited 2 fold reductions in expression of ... PPARG and CEBPA and in ... aP2.  The expression of DGAT was reduced 3 fold in fld tissue
17039	 1802	 3722	LPIN1	Protein	PPARG	mRNA	0	1	15123608	fld mice exhibited 2 fold reductions in expression of ... PPARG and CEBPA and in ... aP2.  The expression of DGAT was reduced 3 fold in fld tissue
31917	 1802	17812	LPIN1	Protein	APOA2	mRNA	0	-1	10884287	Preliminary studies to examine levels of apolipoproteins A-I, A-II, A-IV and E revealed slightly higher apo A-I and apo A-II levels in plasma of fld mice
32064	 1802	 9588	LPIN1	Protein	CFD	mRNA	0	1	10884287	As expected, mRNA levels for LPL were reduced in fld white adipose tissue, as were those of adipsin.  We also found that uncoupling protein 1 mRNA in brown adipose tissue from fld mice was reduced.
32358	 1802	 3118	LPIN1	Protein	ACACA	mRNA	0	1	10884287	The lack of lipid accumulation in fld/fld adipose tissue could be attributed, in part, to a failure to induce expression of lipoprotein lipase and enzymes involved in fatty acid synthesis, such as fatty acid synthase and acetyl-CoA carboxylase.
45316	 1802	17025	LPIN1	Protein	APOA1	mRNA	0	-1	10884287	Preliminary studies to examine levels of apolipoproteins A-I, A-II, A-IV and E revealed slightly higher apo A-I and apo A-II levels in plasma of fld mice
50893	 1802	16714	LPIN1	Protein	FABP4	mRNA	0	1	15123608	fld mice exhibited 2 fold reductions in expression of ... PPARG and CEBPA and in ... aP2.  The expression of DGAT was reduced 3 fold in fld tissue
56760	 1802	18995	LPIN1	Protein	FASN	mRNA	0	1	10884287	The lack of lipid accumulation in fld/fld adipose tissue could be attributed, in part, to a failure to induce expression of lipoprotein lipase and enzymes involved in fatty acid synthesis, such as fatty acid synthase and acetyl-CoA carboxylase.
 6403	 1802	 3125	LPIN1	Protein	LIPE	mRNA	0	1	10884287	hormone-sensitive lipase activity was found to be reduced 50% in fld compared to wild type tissue
 6559	 1802	 5466	LPIN1	Protein	ACACB	mRNA	0	1	10884287	The lack of lipid accumulation in fld/fld adipose tissue could be attributed, in part, to a failure to induce expression of lipoprotein lipase and enzymes involved in fatty acid synthesis, such as fatty acid synthase and acetyl-CoA carboxylase.
 6774	 1802	 8280	LPIN1	Protein	DGAT1	mRNA	1	1	15123608	fld mice exhibited 2 fold reductions in expression of ... PPARG and CEBPA and in ... aP2.  The expression of DGAT was reduced 3 fold in fld tissue
 7349	 1802	16458	LPIN1	Protein	UCP1	mRNA	0	1	10884287	As expected, mRNA levels for LPL were reduced in fld white adipose tissue, as were those of adipsin.  We also found that uncoupling protein 1 mRNA in brown adipose tissue from fld mice was reduced.
12523	12069	 3012	HIST1H1A	Protein	CPOX	mRNA	1	1	15039436	downregulated
14126	12069	18264	HIST1H1A	Protein	OGT	mRNA	-1	1	15039436	downregulated
48874	12069	 5601	HIST1H1A	Protein	DUSP16	mRNA	-1	1	15039436	downregulated
52777	11020	10375	PLOD1	Protein	CD24	mRNA	1	-1	15067357	In contrast, increase in tumor rejection antigen (gp96) 1 and decrease in connective tissue growth factor (CTGF), transforming growth factor-beta 1 induced transcript 1 (TGFB1Il), pim-1 oncogene (PIM1), v-maf musculoaponeurotic fibrosarcoma oncogene homologue (MAF) and CD24 antigen
13344	10499	10696	BLVRA	Protein	JUN	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
13900	10499	17250	BLVRA	Protein	PTGS2	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
23766	10499	 6636	BLVRA	Protein	BCL2L1	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
34467	10499	 9258	BLVRA	Protein	CDKN2B	mRNA	0	-1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
35586	10499	 6993	BLVRA	Protein	PRKCA	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
35599	10499	15442	BLVRA	Protein	BIRC2	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
39583	10499	13744	BLVRA	Protein	CDKN1B	mRNA	-1	-1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
41457	10499	17720	BLVRA	Protein	CYP19A1	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
42907	10499	 7577	BLVRA	Protein	HSP90AA1	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
45368	10499	14987	BLVRA	Protein	BCL2	mRNA	1	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
51396	10499	 3328	BLVRA	Protein	HSF1	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
55315	10499	14620	BLVRA	Protein	HHIP	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
59483	10499	 7094	BLVRA	Protein	EGFR	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
59535	10499	 5657	BLVRA	Protein	PECAM1	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
  597	10499	 8858	BLVRA	Protein	CSN2	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
62963	10499	 7195	BLVRA	Protein	GADD45A	mRNA	-1	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
63512	10499	 6708	BLVRA	Protein	WISP3	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
 6728	10499	10999	BLVRA	Protein	HSPB1	mRNA	0	1	14988408	In vitro translated hBVR and nuclear extract containing hBVR in gel mobility-shift assay bound to AP-1 sites in the ATF-2 promoter region and to an oligonucleotide containing the CRE site. Both bindings could be competed out by excess unlabeled probe; in the presence of hBVR antibody, they displayed shifted bands. Co-transfection of hBVR with ATF-2 or c-jun promoters caused a severalfold increase in luciferase activity. hBVR modulation of ATF-2 and HO-1 expression suggests it has a potential role in regulation of AP-1 and cAMP-regulated genes and a role in cell signaling.
13094	 3036	13485	wortmannin	Compound	ABCC1	mRNA	0	-1	17215852	Furthermore, incubation of AML blasts with wortmannin, a PI3K pharmacological inhibitor, resulted in lower levels of phosphorylated Akt, downregulated MRP1 expression, and decreased Rhodamine 123 extrusion in an in vitro functional dye efflux assay.
20333	 3036	 2815	wortmannin	Compound	TP53	mRNA	0	1	17215852	We also demonstrate that wortmannin-dependent PI3K/Akt inhibition upregulated p53 protein levels in most AML cases, and this correlated with diminished MRP1 expression and enhanced phosphorylation of murine double minute 2 (MDM2).
26843	 3036	17395	wortmannin	Compound	RAD21	mRNA	0	-1	11243849	In addition, wortmannin, a DNA-dependent protein kinase (DNA-PK) inhibitor, decreased the level of hHR21(SP) mRNA, indicating that DNA-PK might be involved in the regulation of hHR21(SP).
29005	 3036	11331	wortmannin	Compound	RAD51	mRNA	0	-1	19671683	blocking the activations of ERK1/2 and AKT by MKK1/2 inhibitor (U0126) and phosphoinositide 3-kinase inhibitor (wortmannin) suppressed the expression of Rad51 and enhanced the erlotinib-induced cell death in erlotinib-resistant cells
37393	 3036	 9189	wortmannin	Compound	MMP2	mRNA	0	-1	12697668	In addition, phosphatidylinositol 3p-kinase inhibitor, LY294002 or wortmannin, strongly inhibited R1881-induced pro-MMP-2 expression.
49651	 3036	 1632	wortmannin	Compound	SFTPC	mRNA	0	-1	10353697	In contrast to MAPK, FGF-2-induced SP-C expression was partially inhibited by PI 3-kinase inhibitor wortmannin.
51672	 3036	  219	wortmannin	Compound	FASLG	mRNA	-1	1	11756562	Here we report that FasL is not expressed by normal VSMC, but its expression is upregulated by stresses that induce apoptosis, including serum deprivation, exposure to the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor wortmannin, and ablation of Akt signaling.
54179	 3036	 6350	wortmannin	Compound	CA9	mRNA	0	-1	12154057	The PI3K inhibitors LY294002 and wortmannin inhibited CAIX expression in dense cultures in a dose-dependent manner, specifically targeting the CA9 promoter (-173/+31 region) that was transactivated by constitutively active p110 PI3K subunit.
10014	 6475	 4597	AKT Family	Protein	UBE2C	mRNA	1	1	15504738	The expression of active mAKT1 blocked the down-regulation of CKS2, HEC, UBE2C, and ZWINT genes (cell cycle-related, Fig. 7B); of RFC4 and TYMS genes (DNA replication and repair-related, Fig. 7B); and of HMGB2 and HIST1H4C  genes (chromatin-related, Fig. 7, B and C) induced by the anti-HER2 antibody.
13594	 6475	 1438	AKT Family	Protein	VEGFA	mRNA	0	1	11507052	Transfection of the dominant negative Akt-K178A vector led to a 75% reduction in VEGF promoter activity in Hct116 cells and 60% in LoVo cells.
  190	 6475	16874	AKT Family	Protein	PIK3R1	mRNA	0	1	10567366	In addition, overexpression of a constitutively active protein kinase B increased p85alphaPI 3-K mRNA levels. These results indicate that the phosphatidylinositol 3-kinase/PKB/p70S6 kinase pathway is required for the stimulation by insulin of p85alphaPI 3-K gene expression in human muscle cells.
21908	 6475	 3995	AKT Family	Protein	ESR1	mRNA	-1	-1	11108261	Modified assertion
24873	 6475	 5863	AKT Family	Protein	MYC	mRNA	0	-1	11773597	AKT activation resulted in the repression of c-myc, early growth response 1 (EGR1), transforming growth factor beta receptor III (TGF-betar III), and thrombospondin-1 (THBS1).
25622	 6475	14852	AKT Family	Protein	HIST1H4C	mRNA	0	1	15504738	The expression of active mAKT1 blocked the down-regulation of CKS2, HEC, UBE2C, and ZWINT genes (cell cycle-related, Fig. 7B); of RFC4 and TYMS genes (DNA replication and repair-related, Fig. 7B); and of HMGB2 and HIST1H4C  genes (chromatin-related, Fig. 7, B and C) induced by the anti-HER2 antibody.
27648	 6475	12781	AKT Family	Protein	AR	mRNA	1	-1	16472761	Moreover, LY294002, but not PD98059, inhibited the PSA and AR suppression effect by EGF in concurrence with the suppression of phosphorylation levels of Akt.
27812	 6475	 2395	AKT Family	Protein	EP300	mRNA	0	1	15224190	In addition, Akt interacts with the coactivator and the activity of Akt is required to maintain the steady-state level of p300.
28230	 6475	 7832	AKT Family	Protein	THBS1	mRNA	-1	-1	11773597	AKT activation resulted in the repression of c-myc, early growth response 1 (EGR1), transforming growth factor beta receptor III (TGF-betar III), and thrombospondin-1 (THBS1).
28286	 6475	 6449	AKT Family	Protein	CFLAR	mRNA	1	1	14551207	The serine/threonine kinase Akt/PKB was recently reported to promote FLIP expression in endothelial and tumor cells.
28716	 6475	 4097	AKT Family	Protein	ZWINT	mRNA	0	1	15504738	The expression of active mAKT1 blocked the down-regulation of CKS2, HEC, UBE2C, and ZWINT genes (cell cycle-related, Fig. 7B); of RFC4 and TYMS genes (DNA replication and repair-related, Fig. 7B); and of HMGB2 and HIST1H4C  genes (chromatin-related, Fig. 7, B and C) induced by the anti-HER2 antibody.
29081	 6475	  620	AKT Family	Protein	PHLDA1	mRNA	0	1	11773597	platelet-derived growth factor-beta (PDGFbeta)-regulated genes; only T-cell death-associated gene 51 (TDAG51) was induced in both cases.
29779	 6475	16604	AKT Family	Protein	TYMS	mRNA	0	1	15504738	The expression of active mAKT1 blocked the down-regulation of CKS2, HEC, UBE2C, and ZWINT genes (cell cycle-related, Fig. 7B); of RFC4 and TYMS genes (DNA replication and repair-related, Fig. 7B); and of HMGB2 and HIST1H4C  genes (chromatin-related, Fig. 7, B and C) induced by the anti-HER2 antibody.
34023	 6475	14883	AKT Family	Protein	IL1R1	mRNA	0	1	15030977	The IL-1R1 induction was found to be PI3K/Akt-dependent but NF-kappaB-independent.
 3429	 6475	10915	AKT Family	Protein	BAX	mRNA	0	-1	12535517	AKT promoted YAP localization to the cytoplasm, resulting in loss from the nucleus, where it functions as a coactivator of transcription factors, including p73 ({601990}). p73-mediated induction of BAX ({600040}) expression following DNA damage required YAP function and was attenuated by AKT phosphorylation of YAP.
 3538	 6475	 3594	AKT Family	Protein	CKS2	mRNA	0	1	15504738	The expression of active mAKT1 blocked the down-regulation of CKS2, HEC, UBE2C, and ZWINT genes (cell cycle-related, Fig. 7B); of RFC4 and TYMS genes (DNA replication and repair-related, Fig. 7B); and of HMGB2 and HIST1H4C  genes (chromatin-related, Fig. 7, B and C) induced by the anti-HER2 antibody.
36080	 6475	12045	AKT Family	Protein	TGFBR3	mRNA	0	-1	11773597	AKT activation resulted in the repression of c-myc, early growth response 1 (EGR1), transforming growth factor beta receptor III (TGF-betar III), and thrombospondin-1 (THBS1).
36389	 6475	 4537	AKT Family	Protein	MSR1	mRNA	0	1	11597931	We also demonstrated that the constitutively active form of Akt enhanced activity of the SRA promoter but that the dominant-negative mutant of Akt completely abolished the expression of SRA after treatment with Gas6.
36679	 6475	19540	AKT Family	Protein	RFC4	mRNA	0	1	15504738	The expression of active mAKT1 blocked the down-regulation of CKS2, HEC, UBE2C, and ZWINT genes (cell cycle-related, Fig. 7B); of RFC4 and TYMS genes (DNA replication and repair-related, Fig. 7B); and of HMGB2 and HIST1H4C  genes (chromatin-related, Fig. 7, B and C) induced by the anti-HER2 antibody.
 4157	 6475	 9655	AKT Family	Protein	NDC80	mRNA	0	1	15504738	The expression of active mAKT1 blocked the down-regulation of CKS2, HEC, UBE2C, and ZWINT genes (cell cycle-related, Fig. 7B); of RFC4 and TYMS genes (DNA replication and repair-related, Fig. 7B); and of HMGB2 and HIST1H4C  genes (chromatin-related, Fig. 7, B and C) induced by the anti-HER2 antibody.
42105	 6475	13115	AKT Family	Protein	EGR1	mRNA	-1	-1	11773597	AKT activation resulted in the repression of c-myc, early growth response 1 (EGR1), transforming growth factor beta receptor III (TGF-betar III), and thrombospondin-1 (THBS1).
42846	 6475	 3879	AKT Family	Protein	FAS	mRNA	0	-1	10919669	The myrAkt-expressing cells continued to proliferate, even in the absence of hormones, and they were resistant to programmed cell death induced by starvation. These effects were paralleled by the induction of the G1 cyclins D3 and E and by the inhibition of induction of the proapoptotic Fas, Fas ligand, and BAD genes in starved cells.
45093	 6475	  738	AKT Family	Protein	IGF1R	mRNA	0	1	15208677	Modified assertion
45272	 6475	 8651	AKT Family	Protein	IGFBP2	mRNA	0	1	17372210	To further investigate this link, we determined that IGFBP-2 expression is negatively regulated by PTEN and positively regulated by phosphatidylinositol 3-kinase (PI3K) and Akt activation.
45378	 6475	14987	AKT Family	Protein	BCL2	mRNA	1	1	18245266	Overexpression of DN Akt blocked or reduced HGF-induced increase in Bcl-2, Egr-1, c-fos, ornithine decarboxylase, and COX-2 expression detected by the microarray (data not shown).
51671	 6475	  219	AKT Family	Protein	FASLG	mRNA	-1	-1	10919669	The myrAkt-expressing cells continued to proliferate, even in the absence of hormones, and they were resistant to programmed cell death induced by starvation. These effects were paralleled by the induction of the G1 cyclins D3 and E and by the inhibition of induction of the proapoptotic Fas, Fas ligand, and BAD genes in starved cells.
51846	 6475	 2831	AKT Family	Protein	BAD	mRNA	0	-1	10919669	The myrAkt-expressing cells continued to proliferate, even in the absence of hormones, and they were resistant to programmed cell death induced by starvation. These effects were paralleled by the induction of the G1 cyclins D3 and E and by the inhibition of induction of the proapoptotic Fas, Fas ligand, and BAD genes in starved cells.
58555	 6475	  497	AKT Family	Protein	SIRT1	mRNA	-1	1	17318262	Overexpression of Akt led to upregulation of VEGF, increased production of superoxide ROS, and the switch to a more pronounced glycolytic metabolism ...  and ...  Second, Akt can induce expression of the ROS-generating enzyme NOX4....  From Full text...  We further demonstrated that Akt induced genes associated with resistance to ROS, including Sirt1 and rictor, and activation of the AP-1 subunit JunD....  ....And...  Treatment of this spontaneous melanoma with the Akt inhibitor resulted in significant decreases in 3 genes that may account for this resistance. Sirt1 is a deacetylase that attenuates p53 in the presence of oxidative stress; rictor is a rapamycin-insensitive member of the mammalian target of rapamycin complex; and VEGF is likely the major angiogenic factor in melanoma. Inhibition of Akt led to significant and reproducible decreases in the mRNA levels of all 3 genes.  .... Note: if they didnt not use an inhibitor to verify AKT action, I coded to expression of AKT.  If they used an inhibitor to verify action,  coded to kaof (AKT)
59745	 6475	13414	AKT Family	Protein	SERPINE1	mRNA	0	1	12745435	Hence, we conclude that the induction of PAI-1 gene expression is cell adhesion dependent and is through PI-3 kinase and Akt activation.
61260	 6475	 1552	AKT Family	Protein	ODC1	mRNA	1	1	18245266	Overexpression of DN Akt blocked or reduced HGF-induced increase in Bcl-2, Egr-1, c-fos, ornithine decarboxylase, and COX-2 expression detected by the microarray (data not shown).
61413	 6475	17154	AKT Family	Protein	HMGB2	mRNA	0	1	15504738	The expression of active mAKT1 blocked the down-regulation of CKS2, HEC, UBE2C, and ZWINT genes (cell cycle-related, Fig. 7B); of RFC4 and TYMS genes (DNA replication and repair-related, Fig. 7B); and of HMGB2 and HIST1H4C  genes (chromatin-related, Fig. 7, B and C) induced by the anti-HER2 antibody.
65930	 6475	 2631	AKT Family	Protein	PPARGC1A	mRNA	0	-1	12606503	Reporter assays demonstrate that insulin suppresses the basal PGC-1 promoter activity and that coexpression of protein kinase (PK)-B mimics the effect of insulin in HepG2 cells.
11719	19586	 2959	SALL4	Protein	TNFRSF10D	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
12571	19586	 8389	SALL4	Protein	DAD1	mRNA	0	1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
13086	19586	13086	SALL4	Protein	TRO	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
13087	19586	 7202	SALL4	Protein	LTA	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
17094	19586	 1418	SALL4	Protein	CARD9	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
20345	19586	 2815	SALL4	Protein	TP53	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
20633	19586	 2132	SALL4	Protein	XIAP	mRNA	0	1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
 2223	19586	 5419	SALL4	Protein	TNF	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
24014	19586	18873	SALL4	Protein	BIRC7	mRNA	0	1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
33653	19586	 7821	SALL4	Protein	FASTK	mRNA	0	1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
 4064	19586	 8836	SALL4	Protein	FKBP8	mRNA	0	1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
44682	19586	12342	SALL4	Protein	PTEN	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
45373	19586	14987	SALL4	Protein	BCL2	mRNA	1	1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
47226	19586	 2052	SALL4	Protein	ATF3	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
47565	19586	11595	SALL4	Protein	TMBIM6	mRNA	0	1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
48494	19586	10084	SALL4	Protein	GDNF	mRNA	0	1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
53289	19586	 6651	SALL4	Protein	CISH	mRNA	0	1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
53324	19586	13563	SALL4	Protein	MAP3K12	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
54214	19586	 4651	SALL4	Protein	MDM4	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
55484	19586	15563	SALL4	Protein	PDCD4	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
58419	19586	 6144	SALL4	Protein	DAPK3	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
58974	19586	 6885	SALL4	Protein	ABL1	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
60156	19586	 2356	SALL4	Protein	STK17A	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
61245	19586	11652	SALL4	Protein	CUL3	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
 8199	19586	 4440	SALL4	Protein	CARD11	mRNA	0	-1	18487508	These genes include 38 important apoptosis- inducing genes (TNF, TP53, PTEN, CARD9, CARD11, CYCS, LTA) and apoptosis-inhibiting genes (Bmi-1, BCL2, XIAP, DAD1, TEGT). Real-time PCR has shown that expression levels of these genes changed significantly after SALL4 knockdown, which ubiquitously led to cell apoptosis Q-RT-PCR shows differentially regulated expression levels of apoptotic genes in SALL4 knockdown NB4 cells.Human acute promyelocytic leukemia NB4 cells
11060	19184	18226	LY 294002	Compound	PPP1R12B	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
13519	19184	 3789	LY 294002	Compound	IGF1	mRNA	0	-1	15809062	PTEN overexpression resulted in a significant decrease in the expression of IGF-I, -II, and IGF-IR. PTEN regulates IGFBP-3 at the transcriptional level PI3 kinase inhibitor, LY294002, upregulates IGFBP-3 expression but downregulates IGF-I and IGF-II, indicating that PTEN controls IGFBP-3 and IGFs by an Akt-dependent pathway.
  164	19184	11767	LY 294002	Compound	PCDH11Y	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
20632	19184	 2132	LY 294002	Compound	XIAP	mRNA	0	-1	12393602	Corresponding to enhanced apoptosis, LY294002 down-regulated expression of the antiapoptotic proteins X-linked inhibitor of apoptosis protein (XIAP)
34654	19184	16763	LY 294002	Compound	PSORS1C1	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
38821	19184	14027	LY 294002	Compound	COL5A1	mRNA	-1	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.;MCF-7 breast cancer cell line, RPS6KB1-suppressed
43068	19184	16235	LY 294002	Compound	VTCN1	mRNA	0	-1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.;MCF-7 breast cancer cell line, RPS6KB1-suppressed
43236	19184	 7078	LY 294002	Compound	PCDH10	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
45044	19184	10427	LY 294002	Compound	FAM5C	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.;MCF-7 breast cancer cell line, RPS6KB1-suppressed
52736	19184	13227	LY 294002	Compound	SOX15	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.;MCF-7 breast cancer cell line, RPS6KB1-suppressed
62592	19184	 4925	LY 294002	Compound	IGFBP3	mRNA	0	1	15809062	PTEN overexpression resulted in a significant decrease in the expression of IGF-I, -II, and IGF-IR. PTEN regulates IGFBP-3 at the transcriptional level PI3 kinase inhibitor, LY294002, upregulates IGFBP-3 expression but downregulates IGF-I and IGF-II, indicating that PTEN controls IGFBP-3 and IGFs by an Akt-dependent pathway.
63132	19184	19932	LY 294002	Compound	RELB	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.;MCF-7 breast cancer cell line, RPS6KB1-suppressed
65561	19184	14743	LY 294002	Compound	IGF2	mRNA	0	-1	15809062	PTEN overexpression resulted in a significant decrease in the expression of IGF-I, -II, and IGF-IR. PTEN regulates IGFBP-3 at the transcriptional level PI3 kinase inhibitor, LY294002, upregulates IGFBP-3 expression but downregulates IGF-I and IGF-II, indicating that PTEN controls IGFBP-3 and IGFs by an Akt-dependent pathway.
65879	19184	 6103	LY 294002	Compound	CECR1	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
  857	19184	  759	LY 294002	Compound	ST3GAL6	mRNA	-1	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
 9612	19184	17078	LY 294002	Compound	B2M	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
 9899	19184	 4451	LY 294002	Compound	ARL11	mRNA	0	1	18652687	Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.; BT-474 breast cancer cell line, RPS6KB1-suppressed
13063	 7615	14711	ZFPM1	Protein	MS4A2	mRNA	0	-1	16522818	Although the activity of the beta-chain promoter, which was upregulated by coexpression of GATA-1, was significantly suppressed by coexpression of FOG-1 in the simian kidney CV-1 cells (beta-chain(-), GATA-1(-), and FOG-1(-)), the transactivation of the beta-chain promoter by the GATA-1 mutant V205G, which cannot bind FOG-1, was not affected by coexpression of FOG-1.
21914	 7615	 3995	ZFPM1	Protein	ESR1	mRNA	-1	1	17310981	. Importantly, the levels of several genes linked to the control of cancerous transformation in the breast (Esr1, Prg and Foxa1) are significantly reduced upon Fog2 excision
21962	 7615	15307	ZFPM1	Protein	Hbb-b1	mRNA	1	1	 9230307	Northern blot analysis was consistent with these results, revealing that 624 hr after induction, ?- and ?-globin mRNAs were induced to levels 3- to 4-fold higher in FOG- infected G1ER cells compared to control infected cells ( Figure 6C).
23700	 7615	 8837	ZFPM1	Protein	IL5	mRNA	0	-1	11714753	We show that FOG-1 can repress GATA-3-dependent activation of the IL-5 promoter in T cells.
23938	 7615	 2061	ZFPM1	Protein	NFE2	mRNA	1	1	 9230307	Figure 5. Synergistic Activation of Transcription by FOG and GATA-1 from p45 NF-E2 Regulatory Sequences
 5150	 7615	12350	ZFPM1	Protein	GYPA	mRNA	0	-1	14749362	In the context of the GPA promoter, our  transactivation assay revealed that FOG coexpression drastically reduced GPA  promoter activation by SCL and its partners (Fig. 8B ).
27509	 7624	  245	Notch Family	Protein	HES5	mRNA	0	1	14500836	RBP-Jkappa binding to its target sequence is important not only for Notch signaling, but also for BMP2 signaling, to activate the Hes-5 gene promoter.
28761	 7624	19012	Notch Family	Protein	EFNB2	mRNA	0	1	15875024	The current model of arterial-venous identity proposes that binding of vascular endothelial growth factor to its heterodimeric receptor--Flk1 and neuropilin 1 (NP-1; also called Nrp1)--activates the Notch signalling pathway in the endothelium, causing induction of ephrin B2 expression and suppression of ephrin receptor B4 expression
36263	 7624	 1611	Notch Family	Protein	HEY1	mRNA	0	1	14500836	In this paper, we show that BMP2 enhances Notch-induced transcriptional activation of Hes-5 and Hesr-1 in mouse neuroepithelial cells.
51021	 7624	13884	Notch Family	Protein	CDKN1A	mRNA	1	1	14570040	When Notch-IC is present, however, it competes with the inhibitory proteins to bind to CSL. Notch1-IC also directly stimulates expression of the cell-cycle regulator Waf1 (also known as Cip1 and p21) in primary mouse keratinocytes25. The increase in Waf1 concentration causes proliferating keratinocytes to withdraw from the cell cycle and helps to initiate terminal differentiation.
62285	 7624	16368	Notch Family	Protein	EPHB4	mRNA	0	-1	15875024	The current model of arterial-venous identity proposes that binding of vascular endothelial growth factor to its heterodimeric receptor--Flk1 and neuropilin 1 (NP-1; also called Nrp1)--activates the Notch signalling pathway in the endothelium, causing induction of ephrin B2 expression and suppression of ephrin receptor B4 expression
40964	 6930	 4582	MEOX2	Protein	NOS3	mRNA	1	1	15735029	Table 1. Genes regulated by Gax expression upregulated
45353	 6930	14987	MEOX2	Protein	BCL2	mRNA	1	-1	 9649428	Forced Gax expression led to Bcl-2 down-regulation and Bax up-regulation
51083	 6930	13884	MEOX2	Protein	CDKN1A	mRNA	1	1	12842453	Gax strongly inhibited HUVEC proliferation and mitogen-stimulated 3H-thymidine uptake. p21 expression in HUVECs transduced with Gax was increased up to 5-fold as measured by Northern blot, and p21 promoter activity was activated by 4- to 5-fold. Tube formation on Matrigel was strongly inhibited by Gax expression
 7208	 6930	 6110	MEOX2	Protein	NKX3-2	mRNA	0	1	15024065	Bapx1 expression in the sclerotome is lost in the absence of both Meox proteins
11255	18032	19608	Thiazolidinedione	Compound	LEP	mRNA	0	-1	15936183	TZDs reduce leptin mRNA levels in adipocytes
12784	18032	17369	Thiazolidinedione	Compound	IL6	mRNA	0	-1	15936183	A decreased IL-6 mRNA synthesis and secretion was found in 3T3-L1 cells treated with TZDs
14499	18032	18103	Thiazolidinedione	Compound	LPL	mRNA	0	1	10098492	Nuclear hormone receptor ligands such as thiazolidinediones [peroxisome proliferator-activated receptors (PPARs)] or hydrocortisone (glucocorticoid receptor) induce LPL transcription, whereas proinflammatory cytokines, such as tumor necrosis factor-, are inhibitory
19632	18032	16486	Thiazolidinedione	Compound	SPP1	mRNA	1	-1	NA	PMA-induced OPN expression was significantly decreased by troglitazone (Tro) and other PPARgamma ligands. is translated to Inhibition of SPP1 (Homo sapiens) Gene Expression by Troglitazone
19940	18032	 5757	Thiazolidinedione	Compound	ADIPOQ	mRNA	0	1	15936183	PPARG2 is required for gene transcription of adiponectin.  TZDs induce this transcription
20566	18032	13134	Thiazolidinedione	Compound	SORBS1	mRNA	0	1	15936183	Also, the expression of genes involved in glycerol-3-phosphate synthesis, such as PEPCK, glycerol-3-phosphate dehydrogenase as well as the c-cbl-associated protein was enhanced (after TZD treatment)
21536	18032	17505	Thiazolidinedione	Compound	LGALS12	mRNA	0	1	12370119	Galectin-12 has recently been shown to be a predominantly adipocyte-expressed protein which is stimulated by insulin-sensitizing thiazolidinediones and possesses apoptosis-inducing activity.
21685	18032	 2572	Thiazolidinedione	Compound	CAV1	mRNA	0	1	12813462	Caveolin-1 protein was strongly upregulated by the glitazones in HT-29 cells
21913	18032	 3995	Thiazolidinedione	Compound	ESR1	mRNA	-1	1	15734868	Effect of TZDs on gene expression. TZD treatment of the eight patients with type 2 diabetes (Table 1) was associated with a statistically significant twofold or greater increase in the expression (by microarray) of 107 gene sequences and a twofold or greater decrease in the expression of six gene sequences (online appendix [available at http://diabetes.diabetesjournals.org]).
 2226	18032	 5419	Thiazolidinedione	Compound	TNF	mRNA	0	-1	15936183	Studies of the effects of TZD have shown suppressed activation of the TNF-a promoter and reduced TNF-a mRNA expression
 2497	18032	17889	Thiazolidinedione	Compound	SLC2A4	mRNA	1	1	15936183	TZD treatment increased the expression of the insulin-responsive glucose transporter GLUT4
25050	18032	17353	Thiazolidinedione	Compound	GRIA3	mRNA	1	1	15734868	Effect of TZDs on gene expression. TZD treatment of the eight patients with type 2 diabetes (Table 1) was associated with a statistically significant twofold or greater increase in the expression (by microarray) of 107 gene sequences and a twofold or greater decrease in the expression of six gene sequences (online appendix [available at http://diabetes.diabetesjournals.org]).
33395	18032	11976	Thiazolidinedione	Compound	PDK4	mRNA	0	-1	14625542	Thus, animals lacking functional PPAR-gamma in skeletal muscle do not show TZD-induced skeletal muscle insulin sensitization. During the glucose clamp studies, we also measured circulating FFA levels (Fig. 5b) and HGP (Fig. 5c); because the effects of both TZDs were the same in the MKO animals (Fig. 5b), the data were combined. Basal FFA levels were elevated and poorly suppressed by insulin in the untreated MKO animals, whereas TZD administration decreased basal FFA levels below control values and enhanced the suppressive effects of insulin. In the untreated MKO animals, HGP was slightly elevated in the basal state, and the suppressive effects of insulin were significantly (P = 0.019) attenuated (Fig. 5c). After TZD treatment, basal HGP was decreased and the suppressive effects of insulin were restored (P = 0.006). TZDs also led to an increase of 2.9-fold (P = 0.0001) in intrahepatic triglyceride content, consistent with findings in other TZD-treated mouse models of insulin resistance38. Thus, TZDs exert their expected effects in adipose tissue and liver, but not muscle, in MKO animals.  Plasma glucose, insulin, triglyceride and FFA levels were all decreased in vivo in the TZD-treated animals (Table 1). Thus, despite the fact that TZD treatment did not improve insulin sensitization in skeletal muscle, most of the other symptoms of Syndrome X were ameliorated, highlighting the importance of adipose tissue and liver as target organs for TZDs.  Protein and gene expression measurements Using quantitative PCR to measure mRNA expression of selected genes in skeletal muscle, we found that PPAR-alpha mRNA and AMPK protein levels were unchanged in MKO animals compared with controls, and were unaffected by TZD treatment (data not shown). Pyruvate dehydrogenase kinase-4 (PDK-4) and uncoupling protein-3 (UCP-3) mRNA levels were also comparable in MKO mice compared with controls (data not shown), but TZD administration caused a significant 85% decrease in UCP-3 and a 60% decrease in PDK-4 mRNA in all groups (P = 0.0003 and 0.02, respectively).
36557	18032	 4029	Thiazolidinedione	Compound	TLE4	mRNA	-1	1	15734868	Effect of TZDs on gene expression. TZD treatment of the eight patients with type 2 diabetes (Table 1) was associated with a statistically significant twofold or greater increase in the expression (by microarray) of 107 gene sequences and a twofold or greater decrease in the expression of six gene sequences (online appendix [available at http://diabetes.diabetesjournals.org]).
36667	18032	11314	Thiazolidinedione	Compound	PCK2	mRNA	-1	1	15936183	Also, the expression of genes involved in glycerol-3-phosphate synthesis, such as PEPCK, glycerol-3-phosphate dehydrogenase as well as the c-cbl-associated protein was enhanced (after TZD treatment)
39808	18032	 7769	Thiazolidinedione	Compound	FOXO1	mRNA	-1	1	15734868	Effect of TZDs on gene expression. TZD treatment of the eight patients with type 2 diabetes (Table 1) was associated with a statistically significant twofold or greater increase in the expression (by microarray) of 107 gene sequences and a twofold or greater decrease in the expression of six gene sequences (online appendix [available at http://diabetes.diabetesjournals.org]).
43609	18032	 2451	Thiazolidinedione	Compound	YWHAG	mRNA	-1	1	15734868	Effect of TZDs on gene expression. TZD treatment of the eight patients with type 2 diabetes (Table 1) was associated with a statistically significant twofold or greater increase in the expression (by microarray) of 107 gene sequences and a twofold or greater decrease in the expression of six gene sequences (online appendix [available at http://diabetes.diabetesjournals.org]).
44499	18032	10804	Thiazolidinedione	Compound	CYCS	mRNA	-1	1	15734868	Effect of TZDs on gene expression. TZD treatment of the eight patients with type 2 diabetes (Table 1) was associated with a statistically significant twofold or greater increase in the expression (by microarray) of 107 gene sequences and a twofold or greater decrease in the expression of six gene sequences (online appendix [available at http://diabetes.diabetesjournals.org]).
48840	18032	 9823	Thiazolidinedione	Compound	HSD11B1	mRNA	0	-1	11278270	In adipocytes, the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) converts inactive cortisone into the active glucocorticoid cortisol and thereby plays an important role in regulating the actions of corticosteroids in adipose tissue. Here, we show that both TZD and non-TZD PPARgamma agonists markedly reduced 11beta-HSD-1 gene expression in 3T3-L1 adipocytes.
49360	18032	18288	Thiazolidinedione	Compound	UCP3	mRNA	0	-1	14625542	Thus, animals lacking functional PPAR-gamma in skeletal muscle do not show TZD-induced skeletal muscle insulin sensitization. During the glucose clamp studies, we also measured circulating FFA levels (Fig. 5b) and HGP (Fig. 5c); because the effects of both TZDs were the same in the MKO animals (Fig. 5b), the data were combined. Basal FFA levels were elevated and poorly suppressed by insulin in the untreated MKO animals, whereas TZD administration decreased basal FFA levels below control values and enhanced the suppressive effects of insulin. In the untreated MKO animals, HGP was slightly elevated in the basal state, and the suppressive effects of insulin were significantly (P = 0.019) attenuated (Fig. 5c). After TZD treatment, basal HGP was decreased and the suppressive effects of insulin were restored (P = 0.006). TZDs also led to an increase of 2.9-fold (P = 0.0001) in intrahepatic triglyceride content, consistent with findings in other TZD-treated mouse models of insulin resistance38. Thus, TZDs exert their expected effects in adipose tissue and liver, but not muscle, in MKO animals.  Plasma glucose, insulin, triglyceride and FFA levels were all decreased in vivo in the TZD-treated animals (Table 1). Thus, despite the fact that TZD treatment did not improve insulin sensitization in skeletal muscle, most of the other symptoms of Syndrome X were ameliorated, highlighting the importance of adipose tissue and liver as target organs for TZDs.  Protein and gene expression measurements Using quantitative PCR to measure mRNA expression of selected genes in skeletal muscle, we found that PPAR-alpha mRNA and AMPK protein levels were unchanged in MKO animals compared with controls, and were unaffected by TZD treatment (data not shown). Pyruvate dehydrogenase kinase-4 (PDK-4) and uncoupling protein-3 (UCP-3) mRNA levels were also comparable in MKO mice compared with controls (data not shown), but TZD administration caused a significant 85% decrease in UCP-3 and a 60% decrease in PDK-4 mRNA in all groups (P = 0.0003 and 0.02, respectively).
51071	18032	13884	Thiazolidinedione	Compound	CDKN1A	mRNA	1	1	NA	Troglitazone treatment increased expression of two cyclin-dependent kinase inhibitors, p21(WAF1/CIP1) and p16(INK4), and reduced cyclin D1 expression, consistent with G1 arrest. is translated to Activation of CDKN2A (Homo sapiens) Gene Expression by Troglitazone
53064	18032	16278	Thiazolidinedione	Compound	ID2	mRNA	0	-1	12613669	Taken together, our data suggest that TZDs repress Id2 expression through a PPARgamma-independent pathway
55395	18032	12303	Thiazolidinedione	Compound	SOCS3	mRNA	0	1	12584205	15d-PGJ(2) and rosiglitazone rapidly induce the transcription of suppressor of cytokine signaling (SOCS) 1 and 3, which in turn inhibit JAK activity in activated glial cells.
60131	18032	 4430	Thiazolidinedione	Compound	SOCS1	mRNA	0	1	12584205	15d-PGJ(2) and rosiglitazone rapidly induce the transcription of suppressor of cytokine signaling (SOCS) 1 and 3, which in turn inhibit JAK activity in activated glial cells.
61267	18032	 1552	Thiazolidinedione	Compound	ODC1	mRNA	1	1	15734868	Effect of TZDs on gene expression. TZD treatment of the eight patients with type 2 diabetes (Table 1) was associated with a statistically significant twofold or greater increase in the expression (by microarray) of 107 gene sequences and a twofold or greater decrease in the expression of six gene sequences (online appendix [available at http://diabetes.diabetesjournals.org]).
61791	18032	 1730	Thiazolidinedione	Compound	KLF10	mRNA	1	1	15734868	Effect of TZDs on gene expression. TZD treatment of the eight patients with type 2 diabetes (Table 1) was associated with a statistically significant twofold or greater increase in the expression (by microarray) of 107 gene sequences and a twofold or greater decrease in the expression of six gene sequences (online appendix [available at http://diabetes.diabetesjournals.org]).
63999	18032	 3679	Thiazolidinedione	Compound	GPD1	mRNA	0	1	15936183	Also, the expression of genes involved in glycerol-3-phosphate synthesis, such as PEPCK, glycerol-3-phosphate dehydrogenase as well as the c-cbl-associated protein was enhanced (after TZD treatment)
12856	 2385	17369	KLF7	Protein	IL6	mRNA	0	1	16339272	In human adipocytes overexpressing KLF7, the expression of adiponectin and leptin was decreased compared with that in control cells, whereas expression of IL-6 was increased.
18037	 2385	10676	KLF7	Protein	STMN2	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
19943	 2385	 5757	KLF7	Protein	ADIPOQ	mRNA	0	-1	16339272	In human adipocytes overexpressing KLF7, the expression of adiponectin and leptin was decreased compared with that in control cells, whereas expression of IL-6 was increased.
20134	 2385	  241	KLF7	Protein	STMN3	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
20378	 2385	15736	KLF7	Protein	CLGN	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
22551	 2385	11978	KLF7	Protein	UCHL1	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
25356	 2385	 3017	KLF7	Protein	INA	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
26484	 2385	19253	KLF7	Protein	TMCC2	mRNA	1	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
33733	 2385	 7880	KLF7	Protein	ABCC8	mRNA	0	-1	16339272	In the insulin-secreting cell line (HIT-T15 cells), the expression and glucose-induced secretion of insulin were significantly suppressed in KLF7-overexpressed cells compared with control cells, accompanied by the reduction in the expression of glucose transporter 2, sulfonylurea receptor 1, Kir6.2, and pancreatic-duodenal homeobox factor 1.
34374	 2385	 5335	KLF7	Protein	CCL27	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
38267	 2385	 5392	KLF7	Protein	UNC13A	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
41383	 2385	 2186	KLF7	Protein	WDR17	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
44000	 2385	 3080	KLF7	Protein	CDHR1	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
44217	 2385	17671	KLF7	Protein	KCNJ11	mRNA	0	-1	16339272	In the insulin-secreting cell line (HIT-T15 cells), the expression and glucose-induced secretion of insulin were significantly suppressed in KLF7-overexpressed cells compared with control cells, accompanied by the reduction in the expression of glucose transporter 2, sulfonylurea receptor 1, Kir6.2, and pancreatic-duodenal homeobox factor 1.
44296	 2385	19907	KLF7	Protein	MAP3K7	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
44298	 2385	 5682	KLF7	Protein	SYP	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
47645	 2385	14557	KLF7	Protein	APLP1	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
 4816	 2385	 4107	KLF7	Protein	FLRT3	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
49279	 2385	18788	KLF7	Protein	GRAMD1C	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
51572	 2385	 6898	KLF7	Protein	SEPT6	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
  566	 2385	 1295	KLF7	Protein	CLSTN2	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
58689	 2385	 1833	KLF7	Protein	HK2	mRNA	0	-1	16339272	We also found that the overexpression of KLF7 resulted in the decrease of hexokinase 2 expression in smooth muscle cells, and of glucose transporter 2 expression in the HepG2 cells.
59597	 2385	 8232	KLF7	Protein	UMODL1	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
61761	 2385	15901	KLF7	Protein	ADCY3	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
 6187	 2385	19806	KLF7	Protein	PRPH	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
62988	 2385	14462	KLF7	Protein	CACNA1B	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
65688	 2385	14693	KLF7	Protein	SYT1	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
 6662	 2385	 3355	KLF7	Protein	NDRG4	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
 6978	 2385	17412	KLF7	Protein	MEGF11	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
 6983	 2385	16745	KLF7	Protein	MLLT11	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
 8153	 2385	17697	KLF7	Protein	SLC2A2	mRNA	0	-1	16339272	In the insulin-secreting cell line (HIT-T15 cells), the expression and glucose-induced secretion of insulin were significantly suppressed in KLF7-overexpressed cells compared with control cells, accompanied by the reduction in the expression of glucose transporter 2, sulfonylurea receptor 1, Kir6.2, and pancreatic-duodenal homeobox factor 1.
 9871	 2385	 1115	KLF7	Protein	NXNL2	mRNA	0	1	17123745	Here we extended this genetic evidence by establishing the transcriptional profile of differentiating olfactory sensory neurons (OSNs) in Klf7(-/-) mice, and by identifying relevant genes that are directly regulated by KLF7
11303	19590	11173	coumarin	Compound	ARG1	mRNA	-1	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
 1396	19590	 2480	coumarin	Compound	TST	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
14428	19590	12289	coumarin	Compound	MAT1A	mRNA	0	1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
19834	19590	13642	coumarin	Compound	DNAJB9	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
20209	19590	  335	coumarin	Compound	MSMO1	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
25768	19590	   19	coumarin	Compound	CYP1A2	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
26726	19590	11941	coumarin	Compound	BHMT	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
29469	19590	 2468	coumarin	Compound	ACAA2	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
 2969	19590	  884	coumarin	Compound	AZGP1	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
33290	19590	 4788	coumarin	Compound	SLC27A2	mRNA	0	1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
33501	19590	13127	coumarin	Compound	FGG	mRNA	0	1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
34483	19590	 9183	coumarin	Compound	SELENBP1	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
34644	19590	 4847	coumarin	Compound	THRSP	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
39294	19590	17682	coumarin	Compound	ACO1	mRNA	0	1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
40775	19590	 8137	coumarin	Compound	ABCB11	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
44834	19590	19354	coumarin	Compound	ECI1	mRNA	0	1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
46272	19590	15281	coumarin	Compound	CTH	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
46446	19590	13874	coumarin	Compound	GPX1	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
 4764	19590	 5109	coumarin	Compound	AKR1D1	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
48625	19590	19172	coumarin	Compound	ACLY	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
56744	19590	18995	coumarin	Compound	FASN	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
59381	19590	 8563	coumarin	Compound	SULT1B1	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (LIVER)
61501	19590	11419	coumarin	Compound	CYP3A4	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
62372	19590	16104	coumarin	Compound	Serpina3m	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
63123	19590	 5848	coumarin	Compound	Lrp3	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
64117	19590	17677	coumarin	Compound	CDO1	mRNA	0	-1	16963487	Coumarin was used as a model compound because its toxicity depends on bioactivation by P450 enzymes. TABLE 3 Genes significantly changed by coumarin in at least two systems: in vivo, in the standard, or in the modified model (HEPATOCYTE)
11337	11106	12387	HDAC Family	Protein	MYB	mRNA	0	1	17628529	We next sought to identify a set of genes whose expression was inhibited by both FR235222 and oxamflatin in a pattern similar to that of their transcriptional inhibition of GATA-1. Using GeneSpring software, this analysis identified 80 genes having a good correlation (R > 0.98) with the repression of GATA-1 gene (Fig. 3 and supplementary data).
19914	11106	17834	HDAC Family	Protein	CCNG2	mRNA	-1	-1	16608856	Following estradiol treatment of cells, chromatin immunoprecipitation analyses reveal recruitment of ER to the cyclin G2 regulatory region, dismissal of RNA polymerase II, and recruitment of a complex containing N-CoR and histone deacetylases, leading to a hypoacetylated chromatin state.
23941	11106	 2061	HDAC Family	Protein	NFE2	mRNA	1	1	17628529	We next sought to identify a set of genes whose expression was inhibited by both FR235222 and oxamflatin in a pattern similar to that of their transcriptional inhibition of GATA-1. Using GeneSpring software, this analysis identified 80 genes having a good correlation (R > 0.98) with the repression of GATA-1 gene (Fig. 3 and supplementary data).
46029	11106	12530	HDAC Family	Protein	HPGD	mRNA	-1	1	17628529	We next sought to identify a set of genes whose expression was inhibited by both FR235222 and oxamflatin in a pattern similar to that of their transcriptional inhibition of GATA-1. Using GeneSpring software, this analysis identified 80 genes having a good correlation (R > 0.98) with the repression of GATA-1 gene (Fig. 3 and supplementary data).
55647	11106	19007	HDAC Family	Protein	STAT5B	mRNA	0	1	17628529	We next sought to identify a set of genes whose expression was inhibited by both FR235222 and oxamflatin in a pattern similar to that of their transcriptional inhibition of GATA-1. Using GeneSpring software, this analysis identified 80 genes having a good correlation (R > 0.98) with the repression of GATA-1 gene (Fig. 3 and supplementary data).
56473	11106	  121	HDAC Family	Protein	F2R	mRNA	-1	1	17628529	We next sought to identify a set of genes whose expression was inhibited by both FR235222 and oxamflatin in a pattern similar to that of their transcriptional inhibition of GATA-1. Using GeneSpring software, this analysis identified 80 genes having a good correlation (R > 0.98) with the repression of GATA-1 gene (Fig. 3 and supplementary data).
11965	 3356	11518	atorvastatin	Compound	ACOX2	mRNA	0	1	12065722	liver PPARalpha, acyl-CoA oxidase, and carnitine palmitoyltransferase I mRNA levels (1.9-, 1.25-, and 3.4-fold, respectively) and hepatic fatty acid beta-oxidation activity (1.25-fold) were increased by atorvastatin at 30 mg/kg. Furthermore, hepatic triglyceride content (45%) and plasma nonesterified fatty acids (NEFAs) (49%) were reduced.
 1302	 3356	 7836	atorvastatin	Compound	CD55	mRNA	-1	1	NA	Background Complement-mediated vascular injury is important in the pathophysiology of atherosclerosis and myocardial infarction. As recent evidence shows that the statins, HMGCoA reductase inhibitors, have beneficial effects on endothelial cell (EC) function independent of lipid-lowering, we explored the hypothesis that statins modulate vascular EC resistance to complement through upregulation of complement-inhibitory proteins. Methods/Results Human umbilical vein EC (HUVEC) were treated with atorvastatin or simvastatin and expression of decay-accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 was measured by flow-cytometry. A dose-dependent increase in DAF expression of upto 4 fold was seen 24-48h post-treatment. CD59 expression was increased by 50% whilst MCP was unchanged. Similar results were obtained with human aortic EC. Statin-induced upregulation of DAF required increased steady-state mRNA and de novo protein synthesis. Inclusion of L-mevalonate, or geranylgeranyl pyrophosphate, reversed the effect on DAF expression, confirming the role of HMGCoA reductase inhibition and suggesting that DAF expression is negatively regulated by geranylgeranylation. Neither farnesyl pyrophosphate nor squalene inhibited statin-induced DAF expression suggesting the effect is independent of cholesterol lowering. We found that statin-induced DAF expression is mediated by activation of PKC? and inhibition of RhoA and is independent of PI-3K and nitric oxide activity. The increase of DAF following statin treatment is functionally relevant, resulting in marked reduction in C3 deposition and complement-mediated EC lysis inhibitable by anti-DAF mAb 1H4 (p < 0.05). Conclusions These observations provide evidence for a novel cytoprotective action of the statins on vascular endothelium, independent of the effect on lipids, and resulting in enhanced protection against complement-mediated injury. Modulation of complement regulatory protein expression by statins may contribute to the early beneficial effects of statins in reducing morbidity and mortality associated with atherosclerosis.
21092	 3356	13403	atorvastatin	Compound	ACOX3	mRNA	0	1	12065722	liver PPARalpha, acyl-CoA oxidase, and carnitine palmitoyltransferase I mRNA levels (1.9-, 1.25-, and 3.4-fold, respectively) and hepatic fatty acid beta-oxidation activity (1.25-fold) were increased by atorvastatin at 30 mg/kg. Furthermore, hepatic triglyceride content (45%) and plasma nonesterified fatty acids (NEFAs) (49%) were reduced.
 2912	 3356	 4252	atorvastatin	Compound	ABCA1	mRNA	0	-1	17466310	We determined the lowest effective concentrations for three commonly prescribed statins (atorvastatin, simvastatin, rosuvastatin) and a newly-available statin (pitavastatin) (Fig. 5AD). All four statins produced a clear reduction in ABCA1 and ABCG1 mRNA expression in THP-1 macrophages at concentrations of 50?100 nM. These effects were also seen in HMDMs at 100nM and higher (Fig. 5E),
40980	 3356	 4582	atorvastatin	Compound	NOS3	mRNA	1	1	11408394	Moreover, atorvastatin caused an upregulation of ecNOS mRNA expression (138+/-7% of control) and an enhanced ecNOS activity in the vessel wall (209+/-46% of control).
45792	 3356	 4835	atorvastatin	Compound	PPARA	mRNA	0	1	12065722	liver PPARalpha, acyl-CoA oxidase, and carnitine palmitoyltransferase I mRNA levels (1.9-, 1.25-, and 3.4-fold, respectively) and hepatic fatty acid beta-oxidation activity (1.25-fold) were increased by atorvastatin at 30 mg/kg. Furthermore, hepatic triglyceride content (45%) and plasma nonesterified fatty acids (NEFAs) (49%) were reduced.
57498	 3356	 5731	atorvastatin	Compound	ACOX1	mRNA	0	1	12065722	liver PPARalpha, acyl-CoA oxidase, and carnitine palmitoyltransferase I mRNA levels (1.9-, 1.25-, and 3.4-fold, respectively) and hepatic fatty acid beta-oxidation activity (1.25-fold) were increased by atorvastatin at 30 mg/kg. Furthermore, hepatic triglyceride content (45%) and plasma nonesterified fatty acids (NEFAs) (49%) were reduced.
58900	 3356	10064	atorvastatin	Compound	SELP	mRNA	-1	-1	12130721	Pretreatment of HCAECs with simvastatin or atorvastatin (1 and 10 microM) reduced ox-LDL-induced expression of LOX-1 as well as adhesion molecules
59316	 3356	 3216	atorvastatin	Compound	ABCG1	mRNA	0	-1	17466310	Compactin, and a commonly prescribed statin, atorvastatin (also used by Argmann et al. [19]), were employed. ABCA1 and ABCG1 mRNA expression tended to be decreased by both statins, in PMA and PDBu differentiated macrophages (Fig. 4AD).
65439	 3356	19519	atorvastatin	Compound	CPT1A	mRNA	-1	1	12065722	liver PPARalpha, acyl-CoA oxidase, and carnitine palmitoyltransferase I mRNA levels (1.9-, 1.25-, and 3.4-fold, respectively) and hepatic fatty acid beta-oxidation activity (1.25-fold) were increased by atorvastatin at 30 mg/kg. Furthermore, hepatic triglyceride content (45%) and plasma nonesterified fatty acids (NEFAs) (49%) were reduced.
10029	15405	 7330	Dietary Lipid	Compound	Csf2rb2	mRNA	-1	1	16129712	OBJECTIVE: To examine the effect of a high-fat diet on gene expression in adipose tissues and to determine induction kinetics of adipose monocyte chemoattractant protein-1 and -3 (MCP-1 and MCP-3) in diet-induced obesity (DIO) and the effect of a lack of MCP-1 signaling on DIO susceptibility and macrophage recruitment into adipose tissue. RESEARCH METHODS AND PROCEDURES: Obese and lean adipose tissues were profiled for expression changes. The time-course of MCP-1 and MCP-3 expression was examined by reverse transcriptase-polymerase chain reaction. Plasma MCP-1 levels were determined by enzyme-linked immunosorbent assay (ELISA). Chemokine receptor-2 (CCR2) knockout mice were placed on the high-fat diet to determine DIO susceptibility. Macrophage infiltration in adipose tissue was examined by immunohistochemistry with F4/80 antibody. RESULTS: DIO elevated adipose expression of many inflammatory genes, including MCP-1 and MCP-3. Adipose MCP-1 and MCP-3 mRNA levels increased within 7 days of starting a high-fat diet, with elevation of plasma MCP-1 detected after 4 weeks on the diet. The induction of MCP-1 and MCP-3 expression preceded that of tumor necrosis factor-alpha. The elevated plasma MCP-1 concentration in obese mice was partially reversed by treatment with AM251. No change in DIO susceptibility and macrophage accumulation in adipose tissue were observed in CCR2 knockout mice, which lack the MCP-1 receptor CCR2. DISCUSSION: A high-fat diet elevated adipose expression of inflammatory genes, including early induction of MCP-1 and MCP-3, supporting the view that obese adipose tissues contribute to systemic inflammation. However, despite increased MCP-1 in obesity, disruption of MCP-1 signaling did not confer resistance to DIO in mice or reduce adipose tissue macrophage infiltration.
19688	15405	16486	Dietary Lipid	Compound	SPP1	mRNA	1	1	 9804809	Osteopontin (Opn), an osteoblast matrix protein gene also expressed by activated macrophages, was up-regulated in the aorta by these high fat diets
10065	11135	20197	IFNA Family	Protein	ZNRF3	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
13198	11135	11884	IFNA Family	Protein	A4GALT	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
18338	11135	 1722	IFNA Family	Protein	SEC14L3	mRNA	0	-1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
19227	11135	 9523	IFNA Family	Protein	XPNPEP3	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
20740	11135	 9161	IFNA Family	Protein	EMID1	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
21424	11135	 9960	IFNA Family	Protein	CSF2RB	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
22919	11135	13921	IFNA Family	Protein	TLR1	mRNA	0	1	11607792	Exogenously added IFN-alpha upregulated TLR1, TLR2, TLR3, and TLR7 mRNA expression in macrophages, as well as TLR3 mRNA expression in epithelial and endothelial cell lines.
23873	11135	13151	IFNA Family	Protein	APOL3	mRNA	0	1	17202376	Table: IFNA treatment
24858	11135	 5863	IFNA Family	Protein	MYC	mRNA	0	-1	11910354	The down-regulated genes include c-myc and c-Met, the hepatocyte growth factor (HGF) receptor. Down-regulation of c-Met is caused by IFN-alpha suppression of the c-Met promoter through down-regulation of Sp1 binding and results in attenuation of HGF-induced signals and cell proliferation.
25432	11135	12337	IFNA Family	Protein	CLTCL1	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
  258	11135	 3027	IFNA Family	Protein	USP41	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
27287	11135	19002	IFNA Family	Protein	SF3A1	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
33630	11135	 2466	IFNA Family	Protein	IL17RA	mRNA	0	-1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
34465	11135	 4326	IFNA Family	Protein	APOL1	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
35850	11135	 7188	IFNA Family	Protein	IGLL1	mRNA	0	-1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
36301	11135	 8679	IFNA Family	Protein	MET	mRNA	0	-1	11910354	The down-regulated genes include c-myc and c-Met, the hepatocyte growth factor (HGF) receptor. Down-regulation of c-Met is caused by IFN-alpha suppression of the c-Met promoter through down-regulation of Sp1 binding and results in attenuation of HGF-induced signals and cell proliferation.
40601	11135	 9051	IFNA Family	Protein	PRAME	mRNA	0	-1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
41998	11135	11528	IFNA Family	Protein	RBX1	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
42177	11135	16349	IFNA Family	Protein	TBC1D10A	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
42303	11135	10268	IFNA Family	Protein	CABP7	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
43030	11135	16232	IFNA Family	Protein	RTDR1	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
43752	11135	14030	IFNA Family	Protein	TLR7	mRNA	0	1	11607792	Exogenously added IFN-alpha upregulated TLR1, TLR2, TLR3, and TLR7 mRNA expression in macrophages, as well as TLR3 mRNA expression in epithelial and endothelial cell lines.
44104	11135	14347	IFNA Family	Protein	USP18	mRNA	0	1	17202376	Table: IFNA treatment
44543	11135	15832	IFNA Family	Protein	SLC2A11	mRNA	0	-1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
45047	11135	 5538	IFNA Family	Protein	NF2	mRNA	-1	-1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
45254	11135	15994	IFNA Family	Protein	CELSR1	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
45676	11135	 2083	IFNA Family	Protein	EFCAB6	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
 4568	11135	  838	IFNA Family	Protein	MORC2	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
49175	11135	 2975	IFNA Family	Protein	PARVG	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
51449	11135	11366	IFNA Family	Protein	SMC1B	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
51806	11135	 6589	IFNA Family	Protein	BCL2L13	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
52530	11135	14510	IFNA Family	Protein	PNPLA5	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
53358	11135	18618	IFNA Family	Protein	SGSM3	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
53614	11135	17652	IFNA Family	Protein	ASCC2	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
54124	11135	 5087	IFNA Family	Protein	BCR	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
59314	11135	   89	IFNA Family	Protein	TRIOBP	mRNA	0	-1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
 6237	11135	12449	IFNA Family	Protein	TLR2	mRNA	0	1	11607792	Exogenously added IFN-alpha upregulated TLR1, TLR2, TLR3, and TLR7 mRNA expression in macrophages, as well as TLR3 mRNA expression in epithelial and endothelial cell lines.
62630	11135	18685	IFNA Family	Protein	LARGE	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
64375	11135	10877	IFNA Family	Protein	PTGES	mRNA	0	-1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
 6580	11135	 8360	IFNA Family	Protein	TLR3	mRNA	0	1	17202376	Table: IFNA treatment
66114	11135	10240	IFNA Family	Protein	SLC5A1	mRNA	0	-1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
 8139	11135	12288	IFNA Family	Protein	SREBF2	mRNA	0	1	16319195	Table 3. Genes on chromosome 22 exhibiting IFN-sensitive expression changes
 8558	11135	 7488	IFNA Family	Protein	APOL2	mRNA	0	1	17202376	Table: IFNA treatment
16048	 8885	 1471	HNRNPA1	Protein	COL1A2	mRNA	-1	1	15514164	Reporter gene cell transfection experiments and RNA stability assays show that hnRNPs A1, E1, and K stimulate collagen expression by stabilizing mRNAs We report identification of three mRNA-binding proteins, heterogeneous nuclear ribonucleoprote (hnRNP) A1, E1, and K, as positive effectors of collagen synthesis acting at the post-transcriptional level by interaction with the 3p-untranslated regions (3p-UTRs) of COL1A1, 1A2, and 3A1 mRNAs
33502	 8885	13127	HNRNPA1	Protein	FGG	mRNA	0	-1	15671034	Overexpression of hnRNP A1 suppressed basal gamma-fibrinogen transcription.
42287	 8885	16433	HNRNPA1	Protein	CD44	mRNA	0	-1	10958793	Expression of oncogene products reverses hnRNP A1-dependent repression of CD44 v5 exon inclusion without down-regulating hnRNP A1 expression levels.
55240	 8885	12981	HNRNPA1	Protein	COL3A1	mRNA	-1	1	15514164	Reporter gene cell transfection experiments and RNA stability assays show that hnRNPs A1, E1, and K stimulate collagen expression by stabilizing mRNAs We report identification of three mRNA-binding proteins, heterogeneous nuclear ribonucleoprote (hnRNP) A1, E1, and K, as positive effectors of collagen synthesis acting at the post-transcriptional level by interaction with the 3p-untranslated regions (3p-UTRs) of COL1A1, 1A2, and 3A1 mRNAs
 6873	 8885	 2204	HNRNPA1	Protein	COL1A1	mRNA	0	1	15514164	Reporter gene cell transfection experiments and RNA stability assays show that hnRNPs A1, E1, and K stimulate collagen expression by stabilizing mRNAs We report identification of three mRNA-binding proteins, heterogeneous nuclear ribonucleoprote (hnRNP) A1, E1, and K, as positive effectors of collagen synthesis acting at the post-transcriptional level by interaction with the 3p-untranslated regions (3p-UTRs) of COL1A1, 1A2, and 3A1 mRNAs
10046	 6119	 7928	Colforsin	Compound	TGFBR2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 1303	 6119	 7836	Colforsin	Compound	CD55	mRNA	-1	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
13228	 6119	19706	Colforsin	Compound	CDC37	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
13245	 6119	 3136	Colforsin	Compound	COPS7A	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
14091	 6119	14961	Colforsin	Compound	CEBPD	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
16486	 6119	18083	Colforsin	Compound	BNIP3	mRNA	-1	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
17904	 6119	12188	Colforsin	Compound	FAU	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
17981	 6119	11254	Colforsin	Compound	SLC31A2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
19130	 6119	 9770	Colforsin	Compound	CAB39	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
19671	 6119	16486	Colforsin	Compound	SPP1	mRNA	1	-1	10506130	_ sentences for pubmedID=10506130: _ Ariadne: Results showed that forskolin also inhibited the  expression of alkaline phosphatase, bone sialoprotein, osteopontin, and  osteocalcin genes (Fig. 2 C ). [Expression]
19969	 6119	17377	Colforsin	Compound	PTP4A2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
20607	 6119	19120	Colforsin	Compound	HSPA5	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
21186	 6119	 8320	Colforsin	Compound	GATA6	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
21884	 6119	  174	Colforsin	Compound	SLC38A4	mRNA	0	-1	11566196	Treatment with forskolin increased the steady-state levels of ATA1 and ATA2 mRNAs, but decreased that of ATA3 mRNA.
22900	 6119	17923	Colforsin	Compound	RAB3IP	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
23310	 6119	 7455	Colforsin	Compound	CTSB	mRNA	0	1	 2751829	The TSH-induced increase in cathepsin B mRNA concentrations (approximately fivefold over that in untreated cells) was partially mimicked by forskolin (approximately threefold) and ionomycin, while phorbol ester decreased cathepsin B mRNA concentrations. Similar changes were observed for thyroglobulin and actin mRNA concentrations.... These results demonstrate (1) that cathepsin B expression in the thyroid is regulated in parallel with that of thyroglobulin and actin, and (2) that cyclic AMP- and Ca2+-dependent processes stimulate gene expression, while phorbol ester treatment inhibits gene expression in FRTL5 cells.
23896	 6119	 5783	Colforsin	Compound	CEBPB	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
24889	 6119	19122	Colforsin	Compound	PTP4A3	mRNA	-1	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
25167	 6119	12328	Colforsin	Compound	SLC38A1	mRNA	0	1	11566196	Treatment with forskolin increased the steady-state levels of ATA1 and ATA2 mRNAs, but decreased that of ATA3 mRNA.
25467	 6119	 5701	Colforsin	Compound	ID3	mRNA	0	1	10585876	We here demonstrated that there was a dramatic rise of Id2 and Id3 mRNA levels when 3T3-L1 adipocytes or isolated rat fat cells were exposed to lipolytic and anti-lipogenic agents, forskolin and isoproterenol.
26677	 6119	17350	Colforsin	Compound	CXADR	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
27294	 6119	 5962	Colforsin	Compound	RAB3GAP2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 2749	 6119	 9169	Colforsin	Compound	CRIP1	mRNA	0	1	12451123	The LIM domain proteins cysteine-rich protein-1 (CRP1) and CRP2 are expressed in sciatic nerve and induced by forskolin in cultured Schwann cells, but only CRP2 requires pou3f1 for normal expression
28865	 6119	 2111	Colforsin	Compound	ULK1	mRNA	-1	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
30176	 6119	 2353	Colforsin	Compound	Tsc22d1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
32785	 6119	 3630	Colforsin	Compound	PA2G4	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
32881	 6119	11449	Colforsin	Compound	CASP9	mRNA	1	1	15486232	To conduct a genome-wide search for cAMP-responsive genes in KGN cell line, asynchronously growing cells were treated with either vehicle or 25 uM forskolin for 3 h. TABLE 1. List of forskolin-induced genes (2-fold or more)
33007	 6119	17897	Colforsin	Compound	RPL38	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
33635	 6119	11522	Colforsin	Compound	STK36	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
34220	 6119	 5204	Colforsin	Compound	CCNL1	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
 3562	 6119	11752	Colforsin	Compound	WNT4	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
36202	 6119	16669	Colforsin	Compound	HSPD1	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
38002	 6119	  871	Colforsin	Compound	ADAM17	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
38330	 6119	 1872	Colforsin	Compound	BTG2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
38727	 6119	 6609	Colforsin	Compound	ATP6V0E1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
39029	 6119	15612	Colforsin	Compound	ACSL4	mRNA	0	1	10924347	We demonstrate that ACS4 expression in steroidogenic tissues in vivo is induced by adrenocorticotropic hormone (ACTH) and suppressed by glucocorticoid. ACTH also induced ACS4 protein but not its mRNA in Y1 adrenocortical tumor cells, whereas both ACS4 mRNA and protein were increased by dibutyryl cAMP (db-cAMP) and forskolin.
39950	 6119	 6114	Colforsin	Compound	NFKBIA	mRNA	1	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
40720	 6119	15136	Colforsin	Compound	TMED10	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
42059	 6119	13115	Colforsin	Compound	EGR1	mRNA	-1	-1	16223959	TABLE 7  Significantly decreased genes from cell growth, maintenance, and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells
42147	 6119	 6102	Colforsin	Compound	C5orf62	mRNA	0	1	11288140	In addition to a robust induction by NGF and FGF, both of which cause PC12 cells to differentiate, NID67 is strongly induced by forskolin, A23187 and ATP
42428	 6119	 4998	Colforsin	Compound	FPGS	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 4302	 6119	19709	Colforsin	Compound	RGS2	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
43318	 6119	 2544	Colforsin	Compound	CRIP2	mRNA	0	1	12451123	The LIM domain proteins cysteine-rich protein-1 (CRP1) and CRP2 are expressed in sciatic nerve and induced by forskolin in cultured Schwann cells, but only CRP2 requires pou3f1 for normal expression
46296	 6119	15186	Colforsin	Compound	SLC39A1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
47488	 6119	 1303	Colforsin	Compound	TAX1BP1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
50196	 6119	18110	Colforsin	Compound	VDAC1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
50257	 6119	16618	Colforsin	Compound	VDAC3	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
50385	 6119	13860	Colforsin	Compound	GNL2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 5078	 6119	11561	Colforsin	Compound	PSENEN	mRNA	0	1	16449647	Electrophoretic mobility shift assays and chromatin immunoprecipitation analysis showed the binding of CREB to the PEN-2 promoter region both in vitro and in vivo. Activation of the CREB transcriptional factor by forskolin dramatically promoted the expression of PEN-2 mRNA and protein, whereas the other components of the gamma-secretase complex remained unaffected. Forskolin treatment slightly increases the secretion of soluble APPalpha and Abeta without affecting Notch cleavage. These results demonstrate that expression of PEN-2 is regulated by CREB and suggest that the specific control of PEN-2 expression may imply additional physiological functions uniquely assigned to PEN-2
50917	 6119	 6827	Colforsin	Compound	AREG	mRNA	0	1	15284208	Similar effects of AR mRNA induction were seen in T cells treated with cAMP-elevating agents such as prostaglandin E(2) and forskolin as well as with the phosphodiesterase inhibitors rolipram and isobutylmethylxanthine.
51144	 6119	 8629	Colforsin	Compound	SLC38A2	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
51393	 6119	 9681	Colforsin	Compound	KCNAB3	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
51669	 6119	  219	Colforsin	Compound	FASLG	mRNA	-1	-1	 9188860	Forskolin not only inhibited activation-induced cell death and NF-kappa B activation, but also suppressed expression of Fas and Fas ligand (Fas-L)
53052	 6119	16278	Colforsin	Compound	ID2	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
53501	 6119	10752	Colforsin	Compound	VDAC2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
54266	 6119	  322	Colforsin	Compound	GADD45G	mRNA	1	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
54770	 6119	19552	Colforsin	Compound	IQGAP1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
55692	 6119	15411	Colforsin	Compound	INSIG1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
55841	 6119	 3559	Colforsin	Compound	PNPLA2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
55865	 6119	 5857	Colforsin	Compound	BHLHE40	mRNA	0	1	15970569	From full text table 4: Reagents regulating expression of the BHLHB2 and BHLHB3 genes
58531	 6119	15461	Colforsin	Compound	PTPRF	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
60408	 6119	 7842	Colforsin	Compound	ZNF331	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
60446	 6119	 8600	Colforsin	Compound	SCN2B	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
60592	 6119	13475	Colforsin	Compound	INHBA	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
60749	 6119	19795	Colforsin	Compound	CREB1	mRNA	0	1	15340044	Treatment with forskolin, an activator of adenylyl cyclase, restored both CREB-1 and pCREB-1 levels; this resulted in the restoration of CRE-binding, CRE-reporter activity, and CREB-1 and RFC mRNA levels
61237	 6119	 5523	Colforsin	Compound	FOLR1	mRNA	0	1	15340044	Treatment with forskolin, an activator of adenylyl cyclase, restored both CREB-1 and pCREB-1 levels; this resulted in the restoration of CRE-binding, CRE-reporter activity, and CREB-1 and RFC mRNA levels
61551	 6119	 2095	Colforsin	Compound	DDIT4	mRNA	0	1	15753290	Supporting Table 7. The lists of cAMP responsive genes from HEK293T and MIN6 cells, hepatocytes, and pancreatic islets based on gene profiling using Affymetrix arrays. The values are lower bounds of the 90% confidence intervals of fold changes. In other words, if the lower bound value is 1, one can say with 90% probability that the gene expression is increased (fold change  1). Gene expression induced by cAMP treatment (forskolin) is shown in \FSK induction\ columns; inhibition by dominant negative A-CREB is shown in \A-CREB inhibition\ columns.
63121	 6119	13881	Colforsin	Compound	JAK1	mRNA	-1	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
63810	 6119	 5182	Colforsin	Compound	JAK2	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
65429	 6119	19519	Colforsin	Compound	CPT1A	mRNA	-1	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
65753	 6119	 3309	Colforsin	Compound	IGF2R	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
66302	 6119	13248	Colforsin	Compound	TSC22D1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
66309	 6119	 6336	Colforsin	Compound	CDC42	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 7983	 6119	10330	Colforsin	Compound	RGS11	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
  900	 6119	18314	Colforsin	Compound	STMN1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 9024	 6119	10441	Colforsin	Compound	STAT2	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 9499	 6119	13194	Colforsin	Compound	CLK1	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 9675	 6119	18215	Colforsin	Compound	XPR1	mRNA	0	-1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
 9883	 6119	12555	Colforsin	Compound	LDHB	mRNA	0	1	16223959	Table 6a. Significantly increased genes from cell growth, maintenance and signal transduction ontologies following forskolin treatment in WKY and SHR vascular smooth muscle cells.
10576	 9377	18139	FOXO1	Protein	CTSZ	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
10663	 9377	 3198	FOXO1	Protein	TFRC	mRNA	-1	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
11286	 9377	13564	FOXO1	Protein	IDH1	mRNA	0	-1	17107961	Table 2. Glucose metabolism
 1136	 9377	15597	FOXO1	Protein	DLGAP5	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
11824	 9377	15178	FOXO1	Protein	NCAPG	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
 1193	 9377	20175	FOXO1	Protein	Adam1a	mRNA	0	1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
12038	 9377	12088	FOXO1	Protein	RASGRP2	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
12716	 9377	 8296	FOXO1	Protein	DDC	mRNA	0	-1	17107961	Table 4. Neurotransmitter receptors and monoamine synthetic pathway
 1305	 9377	 7836	FOXO1	Protein	CD55	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
13246	 9377	 1186	FOXO1	Protein	UBR5	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
 1365	 9377	19956	FOXO1	Protein	UBE2E1	mRNA	1	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
13926	 9377	 6858	FOXO1	Protein	PPARD	mRNA	0	1	15691844	FoxO1 activation after myotube formation altered the expression of several genes of FA metabolism. Acyl-CoA oxidase and peroxisome proliferator-activated receptor delta mRNA levels increased 2.2-fold and 1.4-fold, respectively, whereas mRNA for acetyl-CoA carboxylase decreased by 50%.
14124	 9377	18264	FOXO1	Protein	OGT	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
14435	 9377	10342	FOXO1	Protein	P2RY14	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
14475	 9377	18103	FOXO1	Protein	LPL	mRNA	0	1	12586369	Lipoprotein lipase (LPL) plays a role in lipid usage in skeletal muscle by hydrolyzing plasma triglycerides into fatty acids, which are further utilized for beta-oxidation. Lipid usage is stimulated during fasting, diabetes mellitus and exercise, concomitant with enhanced LPL expression in skeletal muscle. Here we show that the forkhead type transcription factor FKHR is strongly induced in skeletal muscle in fasting mice, in mice with streptozotocin-induced diabetes and in mice after treadmill running. Ectopic expression of FKHR enhanced LPL gene expression in C2C12 muscle cells in culture. These results implicate FKHR as an important modulator of lipid metabolism in skeletal muscle.
14515	 9377	 9628	FOXO1	Protein	GINS2	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
14637	 9377	 9449	FOXO1	Protein	RBBP6	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
14824	 9377	 3484	FOXO1	Protein	RYBP	mRNA	0	1	16980307	The data revealed the existence of a novel set of VEGF-responsive genes that require FKHR activity for optimal expression in ECs, including bone morphogenic protein 2, cbp/p300-interacting transactivator 2, decay accelerating factor (DAF), vascular cell adhesion molecule-1 (VCAM-1), manganese superoxide dismutase, endothelial-specific molecule-1, RING1 and YY1 binding protein, and matrix metalloproteinase-10 and MGC5618
14868	 9377	15284	FOXO1	Protein	TCF4	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
16019	 9377	15914	FOXO1	Protein	TOP2A	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
16194	 9377	10739	FOXO1	Protein	ARG2	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
17625	 9377	 7579	FOXO1	Protein	ATP6V1A	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
17631	 9377	 2756	FOXO1	Protein	OXR1	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
17703	 9377	15781	FOXO1	Protein	PDP1	mRNA	0	1	17107961	Table 2. Glucose metabolism
17878	 9377	20216	FOXO1	Protein	NUF2	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
19286	 9377	17881	FOXO1	Protein	RAD51AP1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
19436	 9377	11849	FOXO1	Protein	HN1	mRNA	0	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
19866	 9377	19589	FOXO1	Protein	LOX	mRNA	0	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
19921	 9377	17834	FOXO1	Protein	CCNG2	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
19947	 9377	 5757	FOXO1	Protein	ADIPOQ	mRNA	0	1	17090532	Foxo1 up-regulates adiponectin gene transcription
20030	 9377	11153	FOXO1	Protein	TK1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
20459	 9377	10306	FOXO1	Protein	ANGPTL4	mRNA	0	1	16870142	% Adenoviral-mediated overexpression of forkhead transcription factor Foxo1 increased angptl4 mRNA expression,
20494	 9377	 6218	FOXO1	Protein	VCAM1	mRNA	0	1	21177856	Expression of vascular cellular adhesion molecule-1 mRNA, up-regulated by FoxO1 in endothelial cells, was enhanced by siRNA knockdown of PKA-alpha
20738	 9377	12355	FOXO1	Protein	DROSHA	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
20935	 9377	14129	FOXO1	Protein	SQRDL	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
21349	 9377	 3999	FOXO1	Protein	SCAND1	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
  215	 9377	16238	FOXO1	Protein	PSAP	mRNA	0	1	12606579	Table I. FKHR activation augments the expresson of genes involved in myotube fusion
21519	 9377	19739	FOXO1	Protein	FBLN2	mRNA	0	1	12606579	Table I. FKHR activation augments the expresson of genes involved in myotube fusion
21877	 9377	 4637	FOXO1	Protein	ASNS	mRNA	0	-1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
22044	 9377	16639	FOXO1	Protein	ANGPT2	mRNA	0	-1	16100571	Whereas angiopoietin 2 (Ang2) was exclusively regulated by Foxo1, eNOS, which is essential for postnatal neovascularization, was regulated by Foxo1 and Foxo3a. Consistent with these findings, constitutively active Foxo1 and Foxo3a repressed eNOS protein expression and bound to the eNOS promoter.
22070	 9377	10299	FOXO1	Protein	CLEC2B	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
22091	 9377	 9303	FOXO1	Protein	GATM	mRNA	0	-1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
22594	 9377	15547	FOXO1	Protein	GLUL	mRNA	0	-1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
22633	 9377	11627	FOXO1	Protein	TNNT1	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
23397	 9377	 9226	FOXO1	Protein	CITED2	mRNA	1	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
23575	 9377	 5777	FOXO1	Protein	TH1L	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
23785	 9377	 6636	FOXO1	Protein	BCL2L1	mRNA	0	1	10871843	Modified assertion
23933	 9377	 7409	FOXO1	Protein	SIGMAR1	mRNA	0	1	17107961	Table 4. Neurotransmitter receptors and monoamine synthetic pathway
24102	 9377	12973	FOXO1	Protein	ANLN	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
24263	 9377	 4420	FOXO1	Protein	TPM3	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
  246	 9377	 4377	FOXO1	Protein	MSTN	mRNA	0	1	16885393	Moreover, expression of a constitutively active form of FoxO1 increased myostatin mRNA
24768	 9377	18767	FOXO1	Protein	NPTX1	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
25139	 9377	19332	FOXO1	Protein	PHF21A	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
25158	 9377	  130	FOXO1	Protein	TTC13	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
 2527	 9377	 6833	FOXO1	Protein	TPD52L1	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
26410	 9377	 6397	FOXO1	Protein	CEP55	mRNA	1	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
26490	 9377	 4291	FOXO1	Protein	IQGAP3	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
26662	 9377	10152	FOXO1	Protein	MYL3	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
 2681	 9377	19981	FOXO1	Protein	OAZ1	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
27740	 9377	 8731	FOXO1	Protein	RNF24	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
27782	 9377	17622	FOXO1	Protein	COL24A1	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
27800	 9377	17167	FOXO1	Protein	SHCBP1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
27841	 9377	  477	FOXO1	Protein	PDX1	mRNA	0	-1	12488434	Modified assertion
 2822	 9377	 8456	FOXO1	Protein	TMEM47	mRNA	0	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
28846	 9377	 9036	FOXO1	Protein	SOX4	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
28987	 9377	17461	FOXO1	Protein	PRRG4	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
29477	 9377	13291	FOXO1	Protein	Serpina1d	mRNA	0	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
29492	 9377	 6159	FOXO1	Protein	ADARB1	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
29543	 9377	18292	FOXO1	Protein	GNAS	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
29610	 9377	19914	FOXO1	Protein	DEPDC1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
29652	 9377	14803	FOXO1	Protein	ACADSB	mRNA	0	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
29839	 9377	18163	FOXO1	Protein	CDKN1C	mRNA	0	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
29855	 9377	 3884	FOXO1	Protein	TXNDC16	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
29904	 9377	19189	FOXO1	Protein	SRA1	mRNA	0	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
30030	 9377	11215	FOXO1	Protein	MBNL2	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
30075	 9377	18445	FOXO1	Protein	PLA2G7	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
  303	 9377	11658	FOXO1	Protein	IDH3G	mRNA	0	-1	17107961	Table 2. Glucose metabolism
30307	 9377	 8362	FOXO1	Protein	DNAJC8	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
31980	 9377	14994	FOXO1	Protein	IGFBP7	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
32025	 9377	14405	FOXO1	Protein	ABI3BP	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
32180	 9377	 3228	FOXO1	Protein	MCM6	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
32456	 9377	10777	FOXO1	Protein	PFKFB2	mRNA	0	-1	17107961	Table 2. Glucose metabolism
32491	 9377	 4984	FOXO1	Protein	HLX	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
32947	 9377	11686	FOXO1	Protein	GTF2I	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
33404	 9377	11976	FOXO1	Protein	PDK4	mRNA	0	1	14966024	The putative transcriptional activators of PDK isozymes, peroxisome proliferator-activated receptor-alpha (PPAR-alpha) protein, and forkhead homolog in rhabdomyosarcoma (FKHR) mRNA were also measured.
33697	 9377	 1040	FOXO1	Protein	CD36	mRNA	0	1	15691844	The enhanced FA utilization induced by FoxO1 was mediated by a severalfold increase in plasma membrane level of the fatty acid translocase FAT/CD36 and eliminated by cell treatment with the CD36 inhibitor sulfo-N-succinimidyl-oleate.
33961	 9377	14949	FOXO1	Protein	ERBB3	mRNA	-1	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
33968	 9377	19235	FOXO1	Protein	KIAA0664	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
34194	 9377	 8013	FOXO1	Protein	FSTL3	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
34772	 9377	19508	FOXO1	Protein	BMP2	mRNA	0	1	16980307	The data revealed the existence of a novel set of VEGF-responsive genes that require FKHR activity for optimal expression in ECs, including bone morphogenic protein 2, cbp/p300-interacting transactivator 2, decay accelerating factor (DAF), vascular cell adhesion molecule-1 (VCAM-1), manganese superoxide dismutase, endothelial-specific molecule-1, RING1 and YY1 binding protein, and matrix metalloproteinase-10 and MGC5618
35328	 9377	 9354	FOXO1	Protein	PLAGL1	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
35568	 9377	 5489	FOXO1	Protein	DAAM1	mRNA	1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
 3565	 9377	11752	FOXO1	Protein	WNT4	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
36086	 9377	 6375	FOXO1	Protein	DMPK	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
36350	 9377	18497	FOXO1	Protein	PRL	mRNA	0	1	16690806	When FOXO1A was overexpressed in human endometrial stromal cells, expression of IGFBP1, DCN, and PRL increased, whereas levels of TIMP3 and CNR1 decreased
36505	 9377	19613	FOXO1	Protein	PAPLN	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
36610	 9377	 1407	FOXO1	Protein	DUSP4	mRNA	0	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
36628	 9377	18113	FOXO1	Protein	HSDL1	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
36666	 9377	11314	FOXO1	Protein	PCK2	mRNA	-1	1	12228231	DAF-16 and its mammalian homologues, including FKHR (FOXO1), FKHRL1 (FOXO3a), and AFX (FOXO4) interact directly with IRSs from the IGFBP-1 promoter in a sequence-specific fashion in in vitro assays and in cells. In liver-derived cells, FOXO proteins stimulate the activity of promoters for IGFBP-1, glucose-6 phosphatase, and PEPCK. In other cell types, FOXO proteins also stimulate the expression of proteins that inhibit cell cycle progression, including p27Kip, Rb2, and GADD45, and proteins that promote cells death, including Bim and Fas ligand.
37931	 9377	 1985	FOXO1	Protein	DENND4A	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
38032	 9377	19164	FOXO1	Protein	CDCA2	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
38262	 9377	 4888	FOXO1	Protein	PLXDC2	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
38313	 9377	 1849	FOXO1	Protein	SLC25A11	mRNA	0	-1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
38316	 9377	13912	FOXO1	Protein	MSL3	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
38774	 9377	12443	FOXO1	Protein	MMP10	mRNA	0	1	16980307	The data revealed the existence of a novel set of VEGF-responsive genes that require FKHR activity for optimal expression in ECs, including bone morphogenic protein 2, cbp/p300-interacting transactivator 2, decay accelerating factor (DAF), vascular cell adhesion molecule-1 (VCAM-1), manganese superoxide dismutase, endothelial-specific molecule-1, RING1 and YY1 binding protein, and matrix metalloproteinase-10 and MGC5618
38958	 9377	13652	FOXO1	Protein	ESM1	mRNA	0	1	16980307	The data revealed the existence of a novel set of VEGF-responsive genes that require FKHR activity for optimal expression in ECs, including bone morphogenic protein 2, cbp/p300-interacting transactivator 2, decay accelerating factor (DAF), vascular cell adhesion molecule-1 (VCAM-1), manganese superoxide dismutase, endothelial-specific molecule-1, RING1 and YY1 binding protein, and matrix metalloproteinase-10 and MGC5618
39229	 9377	 7376	FOXO1	Protein	TNFSF10	mRNA	-1	1	15668399	Activated FOXO proteins also trigger apoptosis in many cancer cell lines through regulation of a number of proapoptotic proteins, including Fas ligand, TRAIL, and Bim.
39287	 9377	13309	FOXO1	Protein	LITAF	mRNA	0	-1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
39366	 9377	18612	FOXO1	Protein	SOD2	mRNA	-1	1	16980307	The data revealed the existence of a novel set of VEGF-responsive genes that require FKHR activity for optimal expression in ECs, including bone morphogenic protein 2, cbp/p300-interacting transactivator 2, decay accelerating factor (DAF), vascular cell adhesion molecule-1 (VCAM-1), manganese superoxide dismutase, endothelial-specific molecule-1, RING1 and YY1 binding protein, and matrix metalloproteinase-10 and MGC5618
39431	 9377	14790	FOXO1	Protein	MAP3K5	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
39465	 9377	14512	FOXO1	Protein	KRT19	mRNA	0	-1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
39815	 9377	 7769	FOXO1	Protein	FOXO1	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
41091	 9377	11896	FOXO1	Protein	MCM5	mRNA	1	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
 4126	 9377	11322	FOXO1	Protein	ZNF367	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
41425	 9377	 6423	FOXO1	Protein	LUM	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
 4183	 9377	15414	FOXO1	Protein	ANK3	mRNA	0	1	12606579	Table I. FKHR activation augments the expresson of genes involved in myotube fusion
42005	 9377	18956	FOXO1	Protein	KIAA0101	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
42236	 9377	18227	FOXO1	Protein	TNNI1	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
42297	 9377	 9608	FOXO1	Protein	DDB1	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
42795	 9377	 3026	FOXO1	Protein	SYT13	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
43455	 9377	11445	FOXO1	Protein	DMWD	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
44089	 9377	12049	FOXO1	Protein	C5orf13	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
44519	 9377	13400	FOXO1	Protein	TMEM37	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
44578	 9377	11594	FOXO1	Protein	GCHFR	mRNA	0	-1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
44955	 9377	16428	FOXO1	Protein	ABTB2	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
45091	 9377	 1162	FOXO1	Protein	KCNA7	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
45389	 9377	10271	FOXO1	Protein	IFRD2	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
45568	 9377	 2888	FOXO1	Protein	ST6GALNAC2	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
45656	 9377	13538	FOXO1	Protein	KIAA1217	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
45686	 9377	10242	FOXO1	Protein	NUSAP1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
46039	 9377	12530	FOXO1	Protein	HPGD	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
46082	 9377	10588	FOXO1	Protein	SEMA3B	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
46181	 9377	 4563	FOXO1	Protein	GPD2	mRNA	0	-1	17107961	Table 2. Glucose metabolism
46311	 9377	  546	FOXO1	Protein	LEFTY2	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
46708	 9377	  502	FOXO1	Protein	TTK	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
47909	 9377	12849	FOXO1	Protein	BNIP3L	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
47969	 9377	18673	FOXO1	Protein	SLC16A1	mRNA	0	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
48146	 9377	15397	FOXO1	Protein	N6AMT2	mRNA	0	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
48282	 9377	 7237	FOXO1	Protein	INSR	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
48631	 9377	19172	FOXO1	Protein	ACLY	mRNA	0	-1	17107961	Table 2. Glucose metabolism
48636	 9377	 5076	FOXO1	Protein	ASPM	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
48971	 9377	13423	FOXO1	Protein	ATP5E	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
49779	 9377	12772	FOXO1	Protein	NCL	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
49809	 9377	 4701	FOXO1	Protein	FBP1	mRNA	0	-1	17107961	Table 2. Glucose metabolism
49881	 9377	15228	FOXO1	Protein	TIMP3	mRNA	0	-1	16690806	Silencing of FOXO1A using small interfering RNA oligonucleotides decreased IGFBP1 and DCN levels and increased CNR1, TIMP3, and PRL levels
50699	 9377	16305	FOXO1	Protein	CRIPT	mRNA	0	1	17107961	Table 4. Neurotransmitter receptors and monoamine synthetic pathway
51166	 9377	11839	FOXO1	Protein	PCK1	mRNA	0	1	11742412	new data suggest a potential role for the forkhead family of transcription factors through phosphorylation by Akt-related protein kinases39, and the PPARg co-activator PGC-1 (ref. 67).
51267	 9377	11731	FOXO1	Protein	JMJD1C	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
51305	 9377	17260	FOXO1	Protein	MAOB	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
51688	 9377	 5401	FOXO1	Protein	WNT16	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
51872	 9377	17440	FOXO1	Protein	FRAT2	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
52873	 9377	 5973	FOXO1	Protein	PAWR	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
53023	 9377	 5763	FOXO1	Protein	CENPK	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
 5323	 9377	13578	FOXO1	Protein	GUCY1B3	mRNA	0	1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
53276	 9377	 5876	FOXO1	Protein	FOXP1	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
53290	 9377	 6651	FOXO1	Protein	CISH	mRNA	0	-1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
  534	 9377	14107	FOXO1	Protein	AURKB	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
54277	 9377	  322	FOXO1	Protein	GADD45G	mRNA	1	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
54358	 9377	 9098	FOXO1	Protein	LRRC17	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
54550	 9377	 4663	FOXO1	Protein	CKMT2	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
55184	 9377	10517	FOXO1	Protein	SLC11A2	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
55362	 9377	 4481	FOXO1	Protein	COL5A2	mRNA	1	1	12606579	Table I. FKHR activation augments the expresson of genes involved in myotube fusion
55624	 9377	 6008	FOXO1	Protein	PFKM	mRNA	0	-1	17107961	Table 2. Glucose metabolism
55845	 9377	 3559	FOXO1	Protein	PNPLA2	mRNA	0	1	19297333	We show here that the promotor region of the rate-limiting lipolytic enzyme, adipose triglyceride lipase (ATGL), has two FoxO1-binding sites, and co-transfection with wild type and unphosphorylated FoxO1 mutant activates the expression of luciferase driven by the ATGL promotor.
55986	 9377	16973	FOXO1	Protein	Mlxipl	mRNA	0	-1	17107961	Table 2. Glucose metabolism
56224	 9377	 6642	FOXO1	Protein	CENPF	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
56367	 9377	15899	FOXO1	Protein	MB	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
56582	 9377	 5131	FOXO1	Protein	CLU	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
57208	 9377	 9893	FOXO1	Protein	OSGIN2	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
57358	 9377	10643	FOXO1	Protein	Scd1	mRNA	0	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
57388	 9377	 3336	FOXO1	Protein	CCND2	mRNA	0	-1	15917664	They also repress transcription of cyclin D1 and D2, which results in an attenuation of CDK4 activity and reduced phosphorylation of Rb protein, and hence increased binding activity of E2F family members to Rb.
57834	 9377	 3565	FOXO1	Protein	BRIP1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
58013	 9377	19273	FOXO1	Protein	PSAT1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
 5845	 9377	 7683	FOXO1	Protein	HPRT1	mRNA	0	1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
58826	 9377	 9550	FOXO1	Protein	CDK4	mRNA	1	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
58868	 9377	 3110	FOXO1	Protein	OSBPL3	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
59366	 9377	 1017	FOXO1	Protein	STAMBPL1	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
59442	 9377	18714	FOXO1	Protein	FKBP1B	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
59512	 9377	 2671	FOXO1	Protein	RHOU	mRNA	-1	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
 5957	 9377	14109	FOXO1	Protein	TUBB1	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
59921	 9377	13264	FOXO1	Protein	TRIM63	mRNA	-1	1	15550386	mechanism by which IGF-1 inversely regulates these markers, and found that the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway, which we had previously characterized as being critical for hypertrophy, is also required to be active in order for IGF-1-mediated transcriptional changes to occur. We had recently demonstrated that the IGF1/PI3K/Akt pathway can block dexamethasone-induced up-regulation of the atrophy-induced ubiquitin ligases MuRF1 and MAFbx by blocking nuclear translocation of a FOXO transcription factor.
60153	 9377	 2356	FOXO1	Protein	STK17A	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
60457	 9377	18772	FOXO1	Protein	EFEMP1	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
 6112	 9377	16922	FOXO1	Protein	RRM2	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
61393	 9377	19256	FOXO1	Protein	SLC37A4	mRNA	0	-1	17107961	Table 2. Glucose metabolism
61734	 9377	 2349	FOXO1	Protein	SLC16A3	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
61883	 9377	 9387	FOXO1	Protein	DAPK1	mRNA	0	1	12351634	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.
61961	 9377	11046	FOXO1	Protein	FERMT2	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
61977	 9377	12943	FOXO1	Protein	DDX31	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
61989	 9377	 4878	FOXO1	Protein	USP13	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
62561	 9377	10778	FOXO1	Protein	FKBP5	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
62619	 9377	 4925	FOXO1	Protein	IGFBP3	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
62825	 9377	  127	FOXO1	Protein	UHRF1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
62912	 9377	 8521	FOXO1	Protein	CBLB	mRNA	-1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
63156	 9377	 2147	FOXO1	Protein	EXO1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
63203	 9377	 2769	FOXO1	Protein	LGR5	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
63425	 9377	 5861	FOXO1	Protein	SLC43A3	mRNA	0	-1	12150827	Supplemental Table S4. Transcripts found in Class III [transcriptional downregulation]
63642	 9377	 2408	FOXO1	Protein	ALB	mRNA	0	1	15272020	Supplemental information 1 Increased gene expression in the skeletal muscle of FOXO1 mice.
63888	 9377	12543	FOXO1	Protein	IGFBP1	mRNA	-1	1	10358076	Reporter gene studies in HepG2 hepatoma cells show that FKHR stimulates insulin-like growth factor-binding protein-1 promoter activity through an IRS, and introduction of IRSs confers this effect on a heterologous promoter.
64189	 9377	 6765	FOXO1	Protein	C10orf10	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
64467	 9377	15063	FOXO1	Protein	ASS1	mRNA	0	-1	17107961	Table 3. Genes involved in NO synthesis and cytokine signaling
65436	 9377	19519	FOXO1	Protein	CPT1A	mRNA	-1	-1	17107961	Table 2. Glucose metabolism
 6556	 9377	 5466	FOXO1	Protein	ACACB	mRNA	0	1	15691844	FoxO1 activation after myotube formation altered the expression of several genes of FA metabolism. Acyl-CoA oxidase and peroxisome proliferator-activated receptor delta mRNA levels increased 2.2-fold and 1.4-fold, respectively, whereas mRNA for acetyl-CoA carboxylase decreased by 50%.
66087	 9377	16821	FOXO1	Protein	DST	mRNA	1	1	12351634	adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes The following comes from Table I.
 6816	 9377	 4193	FOXO1	Protein	C2orf27A	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
 6919	 9377	 8725	FOXO1	Protein	NCOA1	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
  762	 9377	18034	FOXO1	Protein	MKI67	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
 7877	 9377	12730	FOXO1	Protein	FBXO30	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
  831	 9377	 1146	FOXO1	Protein	GCLC	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
 8323	 9377	 6202	FOXO1	Protein	BTG1	mRNA	-1	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
 8830	 9377	 5001	FOXO1	Protein	EPS8	mRNA	0	1	12150827	Supplemental Table S1. Transcripts found in Class I [activated by FKHR]
 9027	 9377	10441	FOXO1	Protein	STAT2	mRNA	0	1	12150827	Supplemental Table S2. Transcripts found in Class IIa [induced by FKHR] Supplemental Table S3. Transcripts found in Class IIb [induced by FKHR]
   93	 9377	 5975	FOXO1	Protein	MYL2	mRNA	0	-1	15272020	TABLE II - Gene with decreased expression in the skeletal muscle of FOXO1 mice
 9314	 9377	19757	FOXO1	Protein	PCDH20	mRNA	0	1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
 9335	 9377	 8814	FOXO1	Protein	CDK1	mRNA	0	-1	17609436	Table 1 FROM SUPPLEMENT captures information from the abstract.  Table 1. Gene list of the 50 most induced and 50 most repressed genes upon decidualization
10050	 1176	 7928	nicotine	Compound	TGFBR2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
10692	 1176	 1023	nicotine	Compound	COPS3	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
 1113	 1176	19547	nicotine	Compound	CTNNB1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
11463	 1176	17842	nicotine	Compound	LRRC41	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
11496	 1176	12895	nicotine	Compound	CHRNA1	mRNA	0	1	17510389	When HBEC lines were exposed to 100 nmol/L nicotine and then RNA was harvested at 72 and 144 h, a significant increase in the expression levels of CHRNA1, CHRNA5, and CHRNA7 were found at 72 h, with return to baseline levels of expression upon nicotine removal (Fig. 3 ). No significant increase or decrease was found in the levels of expression of other nAChR subunit genes analyzed.
11569	 1176	14350	nicotine	Compound	OCLN	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
12247	 1176	12471	nicotine	Compound	CD58	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
12576	 1176	  770	nicotine	Compound	ATP6V0B	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
13904	 1176	 5443	nicotine	Compound	TARBP2	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
16121	 1176	 8326	nicotine	Compound	CDC6	mRNA	0	1	16862215	It was observed that low levels of E2F1 and high levels of Rb were bound to the cdc6 and cdc25A promoters in quiescent A549 cells. Stimulation with 1 ?M nicotine caused the dissociation of Rb from both the promoters, while there were increased amounts of E2F1 bound to them (Figure 1H, top 2 panels).
16182	 1176	12037	nicotine	Compound	ARL4D	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
17446	 1176	15149	nicotine	Compound	CTBP1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
18399	 1176	12580	nicotine	Compound	NDUFS5	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
20109	 1176	18449	nicotine	Compound	RPS4X	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
20151	 1176	10482	nicotine	Compound	CALM2	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
21326	 1176	 3351	nicotine	Compound	CNTD1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
22372	 1176	10815	nicotine	Compound	CHRNA5	mRNA	0	1	17510389	When HBEC lines were exposed to 100 nmol/L nicotine and then RNA was harvested at 72 and 144 h, a significant increase in the expression levels of CHRNA1, CHRNA5, and CHRNA7 were found at 72 h, with return to baseline levels of expression upon nicotine removal (Fig. 3 ). No significant increase or decrease was found in the levels of expression of other nAChR subunit genes analyzed.
22656	 1176	11587	nicotine	Compound	KCNB1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
23968	 1176	 6252	nicotine	Compound	POU6F1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
25311	 1176	14351	nicotine	Compound	EPHA1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
25354	 1176	 8158	nicotine	Compound	PFDN5	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
25421	 1176	 8220	nicotine	Compound	CYP2J2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
27315	 1176	11758	nicotine	Compound	DRAP1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
27375	 1176	   18	nicotine	Compound	GPAA1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
27474	 1176	 7059	nicotine	Compound	CHRNB4	mRNA	0	1	14764595	Up-regulation induced by 1 mm nicotine ... Only residues belonging to two beta2 segments, 74-89 and 106-115, confer up-regulation to beta4
27507	 1176	14266	nicotine	Compound	CBFB	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
28015	 1176	13496	nicotine	Compound	TSPAN4	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
29789	 1176	12747	nicotine	Compound	MAP2K4	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
32213	 1176	 3727	nicotine	Compound	CBR1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
33040	 1176	14077	nicotine	Compound	HTR2B	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
33095	 1176	11608	nicotine	Compound	EIF3G	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
33164	 1176	 4143	nicotine	Compound	NREP	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
33470	 1176	 1218	nicotine	Compound	ADAM15	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
34438	 1176	13145	nicotine	Compound	APBA1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
34702	 1176	 4009	nicotine	Compound	PIP4K2A	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
34733	 1176	 5535	nicotine	Compound	ZNF74	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
35028	 1176	 1920	nicotine	Compound	ODF2	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
35362	 1176	 8429	nicotine	Compound	METAP2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
36037	 1176	 7956	nicotine	Compound	BRCA1	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
36686	 1176	11277	nicotine	Compound	DCAF7	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
36811	 1176	12717	nicotine	Compound	TFDP2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
 3699	 1176	 5902	nicotine	Compound	CREBBP	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
38742	 1176	 8342	nicotine	Compound	HSF2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
38839	 1176	 2762	nicotine	Compound	CYP4A11	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
39075	 1176	15760	nicotine	Compound	HDHD1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
39318	 1176	 9758	nicotine	Compound	PSEN1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
39533	 1176	13230	nicotine	Compound	TCF3	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
39872	 1176	17098	nicotine	Compound	TSG101	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
40062	 1176	15866	nicotine	Compound	PPM1G	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
40241	 1176	14934	nicotine	Compound	AK2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
40589	 1176	  159	nicotine	Compound	NR3C2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
41087	 1176	11896	nicotine	Compound	MCM5	mRNA	1	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
41769	 1176	 2998	nicotine	Compound	CNN2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
42350	 1176	15033	nicotine	Compound	KRT5	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
42910	 1176	 7577	nicotine	Compound	HSP90AA1	mRNA	0	1	12115584	Nicotine-induced caspase-3 activation and Hsp90 alpha expression, as well as suppression of the induction by GA, were also observed in a xeroderma pigmentosum patient-derived cell line, XP2 OS cells.
43076	 1176	 9356	nicotine	Compound	KLRC4	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
44234	 1176	 9200	nicotine	Compound	PCNA	mRNA	0	1	18495523	Exposure of BEP2D cells to either NNK or NNN increased their proliferative potential, effect which is abolished by a-BGT or Mec. NNK- or NNN-treated BEP2D cells showed multifold increases of PCNA and Bcl-2 genes
44249	 1176	 8813	nicotine	Compound	DAZL	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
44281	 1176	13802	nicotine	Compound	CDC25A	mRNA	0	1	16862215	It was observed that low levels of E2F1 and high levels of Rb were bound to the cdc6 and cdc25A promoters in quiescent A549 cells. Stimulation with 1 ?M nicotine caused the dissociation of Rb from both the promoters, while there were increased amounts of E2F1 bound to them (Figure 1H, top 2 panels).
44659	 1176	15706	nicotine	Compound	SLCO1A2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
45349	 1176	14987	nicotine	Compound	BCL2	mRNA	1	1	18495523	Exposure of BEP2D cells to either NNK or NNN increased their proliferative potential, effect which is abolished by a-BGT or Mec. NNK- or NNN-treated BEP2D cells showed multifold increases of PCNA and Bcl-2 genes
45642	 1176	 3117	nicotine	Compound	USP6NL	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
45981	 1176	 2427	nicotine	Compound	KRT13	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
46699	 1176	 4709	nicotine	Compound	TRIM29	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
46991	 1176	  427	nicotine	Compound	RAD51D	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
 4773	 1176	15277	nicotine	Compound	FDFT1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
47803	 1176	16870	nicotine	Compound	PODXL	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
48109	 1176	13471	nicotine	Compound	BIRC5	mRNA	0	1	16601104	It was first assessed whether the induction of XIAP and survivin occurs at the transcriptional level by semiquantitative RT-PCR by using RNA extracted from quiescent as well as nicotine-stimulated cells (32, 33). As shown in Fig. 3a, expression of XIAP or -actin did not change upon nicotine stimulation whereas survivin levels were significantly up-regulated.
48954	 1176	14133	nicotine	Compound	BLZF1	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
49040	 1176	16903	nicotine	Compound	NR2F6	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
50218	 1176	19778	nicotine	Compound	DGKD	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
 5087	 1176	 1445	nicotine	Compound	RELA	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
50948	 1176	 3271	nicotine	Compound	ATP7B	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
51216	 1176	19545	nicotine	Compound	PRDM2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
52130	 1176	  204	nicotine	Compound	MED7	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
52582	 1176	10969	nicotine	Compound	USO1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
52898	 1176	16792	nicotine	Compound	COL4A2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
53113	 1176	 1786	nicotine	Compound	PRMT5	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
53219	 1176	13710	nicotine	Compound	ATP6V0D1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
53461	 1176	12941	nicotine	Compound	MFSD7	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
53571	 1176	 8105	nicotine	Compound	CDC123	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
53788	 1176	15752	nicotine	Compound	DFFA	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
53872	 1176	 7425	nicotine	Compound	ASPA	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
54186	 1176	 6209	nicotine	Compound	STK38	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
55256	 1176	12794	nicotine	Compound	PAICS	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
55695	 1176	15411	nicotine	Compound	INSIG1	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
56017	 1176	15964	nicotine	Compound	CCNO	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
56124	 1176	10811	nicotine	Compound	FN1	mRNA	-1	1	18495523	The stimulatory effect of nicotine on fibronectin expression was abolished by a-bungarotoxin (a-BGT), an inhibitor of a7-AChR. Of note, nicotine increased the expression of a7-AChR on fibroblasts.
56306	 1176	 7679	nicotine	Compound	COL17A1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
56665	 1176	 9537	nicotine	Compound	CTBS	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
56879	 1176	16842	nicotine	Compound	SPINK2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
57177	 1176	 9019	nicotine	Compound	CTSH	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
59001	 1176	 3425	nicotine	Compound	EVI2B	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
  593	 1176	  897	nicotine	Compound	CYBB	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
60324	 1176	 8682	nicotine	Compound	STAT6	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
62309	 1176	11938	nicotine	Compound	DGKA	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
62756	 1176	 3849	nicotine	Compound	CACNA1D	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
64225	 1176	17883	nicotine	Compound	RANGAP1	mRNA	1	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
65870	 1176	11694	nicotine	Compound	NEDD4	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
  757	 1176	18794	nicotine	Compound	SST	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
 7968	 1176	  985	nicotine	Compound	MRPL4	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
 8019	 1176	17704	nicotine	Compound	BMI1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
  844	 1176	12082	nicotine	Compound	ADRB2	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
 8845	 1176	19611	nicotine	Compound	SKI	mRNA	0	1	11328964	Table 2a. Genes whose expression is  increased by nicotine stimulation
 8930	 1176	13759	nicotine	Compound	IL13RA1	mRNA	0	-1	11328964	Table 2b Genes whose expression is decreased by nicotine stimulation
